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In the intervening 10 years tremendous advances in the field of cardiac computed 
tomography have occurred. We now can legitimately claim that computed tomography 
angiography (CTA) of the coronary arteries is available. In the evaluation of patients 
with suspected coronary artery disease (CAD), many guidelines today consider CTA 
an alternative to stress testing. The use of CTA in primary prevention patients is 
more controversial in considering diagnostic test interpretation in populations with 
a low prevalence to disease. However the nuclear technique most frequently used by 
cardiologists is myocardial perfusion imaging (MPI). The combination of a nuclear 
camera with CTA allows for the attainment of coronary anatomic, cardiac function 
and MPI from one piece of equipment. PET/SPECT cameras can now assess perfusion, 
function, and metabolism. Assessing cardiac viability is now fairly routine with these 
enhancements to cardiac imaging. This issue is full of important information that 
every cardiologist needs to now.
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Preface 
This book brings together contributions from around the world, investigators who are
clinical versus imaging science in their orientation, and representatives from academic 
medical centers and the imaging industry. Each article is written to be accessible to
those with a basic knowledge of coronary imaging but also to be stimulating and
educational to those who are experts and investigators in medical imaging.
This book covers where advances have been dramatic in the past two decades and
shows the major contributions of the imaging scientists and engineers from both 
academia and industry. Patients with know or suspected coronary artery disease who 
are asymptomatic or who have stable symptoms are often evaluated noninvasive.
Functional test, such as stress electrocardiography, stress echocardiography, and stress 
nuclear perfusion imaging, detect and quantity the presence of ischemia based on 
electrical, mechanical, or perfusion abnormalities, indirectly, but nuclear perfusion 
imaging directly, establishing the burden of coronary artery disease. Multidetector CT
(MDCT) has emerged as a tool to evaluate noninvasive the coronary anatomy. MDCT 
has overcome many of its original limitations and now provides ECG-gated 
acquisition with short acquisition time, sub millimeter spatial resolution, allowing
excellent visualization of the coronary arteries. Over the last 15 years, the rate of
technologic advancements leading to improved coronary angiography with MDCT
has rapidly exceeded those of other cardiac imaging modalities. Image quality is
undergoing constant refinement, and the number of uninterpretable coronary studies
has gradually decreased from 20%-40% using for detector, to 15% - 25% with 16-
detector, and is now as low as 3% to 10% with 64-detector systems. 
But this section is also devoted to the current state of myocardial perfusion imaging 
(MPI). MPI is well establishment imaging techniques and is already integral part of the
management of coronary artery disease (CAD), and is included in a number of 
professional guidelines. Coronary angiography, considered the “gold standard” for 
the diagnosis of CAD, often does not provide information about the functional 
significance of coronary stenosis, especially in borderline lesions. Andres Gruentzig
said; when coronary angiography founded coronary narrowing, I would like to have some kind
of diagnostic procedure who gives me functional significance that lesion. MPI is very
important diagnostic tool for the diagnosis culprit lesions, and indicating who patients 
have for cardiovascular intervention (PCI or ACBP). The predominant theme is that
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MPI finding can serve as the gatekeeper for more costly and more risky invasive 
strategies in the evaluation and treatment of patients with coronary artery disease. 
The book Coronary Angiography – Advances in Noninvasive Imaging Approach for 
Evaluation of Coronary Artery Disease includes a series of articles that provide a state‐
of‐the‐art summary of the current clinical applications of cardiac CT, reviews data that 
support the accuracy and the prognostic use of CT coronary angiography and reports 
of the newest technological advances and promising future applications of these 
imaging modalities. Its also provide other diagnostic approach like functional test, 
which finding helps to make decision about invasive strategies with best benefit for 
patients.  
Finally, the next decades should see even greater advances in the field, and such 
breakthroughs will be instrumental in further enhancing the information that can be 
derived from functional testing for the assessment of myocardial blood flow, cardiac 
function, and myocardial viability. 
Readers of Coronary Angiography will enjoy in this book and will find the information 
and expert opinions very useful to their clinical practice. 
 
Branislav Baškot MD PhD Ass Prof  
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Utilization of Functional Tests Prior 
to and Adherence to Guidelines 
on Coronary Angiography 
James T Leung1 and Dominic Y Leung2 
1Sydney Medical School, University of Sydney, 
2Liverpool Hospital, University of New South Wales, 
Australia 
1. Introduction  
Coronary angiography is one of the most commonly performed investigations in clinical 
cardiology and remains the “gold standard” in the anatomical diagnosis of coronary artery 
disease.  It is often required to establish the diagnosis of coronary disease and to provide a 
map of a patient’s coronary artery anatomy prior to percutaneous coronary intervention or 
coronary artery bypass surgery. 
Despite its importance, invasive coronary angiography should not be performed in all 
patients suspected to have coronary artery disease.  Functional tests, such as stress ECG, 
echo or nuclear perfusion imaging, are often recommended as initial tests for many of these 
patients.  These functional tests are widely available and practised.  In addition to their 
diagnostic value, functional tests provide independent and additional prognostic 
information (Marwick et al., 1997).  Furthermore, functional tests are often required to guide 
management of patients with intermediate lesions on invasive coronary angiography.  
According to the Bayesian theorem, the impact of a screening test is most significant in 
patients with intermediate pre-test probability of disease. Furthermore, cost-effectiveness 
analyses often reveal that the use of screening tests in these patients is the most favourable 
approach. Despite the established roles of functional tests and their extensive incorporation 
in best practice guidelines, there is little data on the extent of their use and on how the 
results of such tests are utilised prior to referral to coronary angiography in patients with 
low to intermediate pre-test probabilities of coronary disease.  
Guidelines have proliferated in cardiology in recent years.  Major professional bodies like 
the American College of Cardiology, American Heart Association and the European Society 
of Cardiology have published guidelines on a wide range of cardiovascular disorders and 
cardiovascular investigations.  These guidelines incorporate the latest evidence base and 
provide recommendations, which are intended to improve the quality of patient care and 
clinical outcomes whilst minimising costs.  These recommendations are based on the most 
effective and evidence-based strategies.  The American College of Cardiology and American 
Heart Association have published comprehensive guidelines on the use of coronary 
angiography (Scanlon et al., 1999).  The guidelines were initially published in 1987 and were 
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angiography in clinical scenarios such as patients with known or suspected coronary artery 
disease, stable or unstable angina pectoris, acute coronary syndromes, recurrence of 
symptoms after revascularization, congestive heart failure or other conditions.   
There has been considerable interest in evaluating compliance with guidelines in clinical 
practice. This is particularly pertinent as improved compliance with treatment guidelines is 
associated with better clinical outcomes in patients with acute coronary syndromes (Schiele 
et al., 2005).  Despite the widespread dissemination of the guidelines on coronary 
angiography, the compliance rate with these guidelines in clinical practice and the 
relationship between compliance and results of angiography has not been prospectively 
evaluated. 
As discussed in other chapters, computed tomography (CT) coronary angiography is now 
increasingly being used to evaluate patients with suspected coronary artery disease.  The 
American College of Cardiology, together with other professional bodies, has published 
criteria for the appropriate use of CT coronary angiography (Hendel et al., 2006).  CT 
coronary angiography will increasingly be incorporated into clinical practice as an 
important imaging modality for the evaluation of patients suspected to be suffering from 
coronary artery disease.  An important consideration for clinicians and administrators will 
be the diagnostic value of imaging tests and their cost effectiveness in these patients.  More 
data has recently become available regarding the incremental value of functional testing and 
other imaging modalities like CT coronary angiography in patients with suspected coronary 
artery disease.  In particular, the incremental value of non-invasive testing in risk 
stratification and the prediction of adverse events in these patients will be of interest in 
guiding practice and, more importantly, health care policy.  
2. Utilisation of functional tests prior to coronary angiography 
As discussed earlier, despite their well-documented clinical usefulness, there is little 
information on the pattern of use of functional tests in patients prior to undergoing invasive 
coronary angiography.  In particular, for patients who are subsequently found to have no 
significant coronary artery disease on coronary angiography, it will be interesting to 
examine how and why they ended up having invasive coronary angiography.  It may be 
argued that, for these patients, a “failure” of the investigative algorithms led them to 
undergo an invasive test, which may not have been indicated and should not have been 
performed. These tests should have been avoided as they exposed the patient to needless 
risks and might have been unnecessary monetary, resource and manpower wastes. By 
examining where the process has “failed”, one will hopefully be able to learn how to 
minimise future such “failures”. The purpose of our study was to analyse the patterns of use 
and the results of functional tests in patients found to have normal coronary arteries on 
invasive coronary angiography. 
2.1 The study - methods 
Over a 7 and a half-year period, a total of 6,409 patients underwent 8,069 coronary 
procedures at our hospital. Our hospital is the only tertiary referral centre serving a 
population of about 800,000 people.  Only patients referred for coronary angiography for 
evaluation of coronary artery disease were included in the analysis.  Angiographic studies 
on patients referred for valvular or haemodynamic indications were excluded from the 
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analysis. Patients with documented coronary artery disease referred for coronary 
angioplasty or other percutaneous intervention were also excluded.  Therefore, the study 
included 6,053 patients who underwent a total of 6,830 coronary angiographic procedures.  
Of the 6,830 procedures, 4,610 were for male patients and 2,220 were for female patients.  
The mean age of the patients was 60.9 ± 11 years.  Clinical information, including age and 
gender, referrer details, indications for angiography, type of the study and subsequent 
results, was prospectively collected and entered into a computerised database. 
Coronary angiography was performed according to standard techniques via either the 
femoral, brachial or radial approaches.  Patients with no angiographically detectable disease 
or irregularities in any of the epicardial coronary arteries were considered to have normal 
coronary arteries on angiography.  Patients who had previously undergone coronary artery 
bypass surgery and who were found to have patent bypass grafts on angiography were not 
considered to have normal coronary arteries.   
Patients who were subsequently found to have normal coronary arteries on angiography 
were identified.  The clinical records of these patients were then reviewed. Their clinical 
characteristics and presenting symptoms, including risk factors for coronary artery 
disease, were analysed.  Chest pain as the main presenting symptom was characterized on 
retrospective chart review as typical, atypical or non-anginal/non-specific pain.  Five risk 
factors were considered: diabetes mellitus, cigarette smoking, hypertension, 
hypercholesterolemia and family history of coronary artery disease. Patients’ pre-test 
probabilities of coronary artery disease were estimated from age, gender and presenting 
symptoms (Diamond & Forrester, 1979).  
The types and results of functional tests, if performed for these patients, were recorded and 
analysed.  Results of functional tests including exercise ECG, exercise or pharmacologic 
stress echocardiogram or nuclear myocardial perfusion studies were sought. None of the 
patients had CT coronary angiography as it was not available at the time of the study.  
Functional tests were considered negative if no evidence of inducible ischaemia was 
detected on testing and if the level of the stress was considered adequate.  Functional tests 
were considered inconclusive if there was equivocal evidence of inducible ischaemia or if 
there was no inducible ischaemia at inadequate levels of stress. 
Information on the physicians who referred these patients (referrers) for coronary angiography 
was also recorded. Referrers were classified into cardiologists or other physicians according to 
the field of specialisation.  In particular, for cardiologist referrers, those who performed 
coronary angiography were considered proceduralists whilst cardiologists who do not 
perform angiography were considered non-proceduralists.  
2.2 Results 
2.2.1 Patients 
Seven hundred and fifty six patients undergoing 762 procedures were found to have normal 
epicardial coronary arteries on angiography.  This means that 11.2% of the coronary 
angiograms performed were for patients with normal coronary arteries. The mean age of 
these patients was 54.9 ± 11.5 years with female patients comprising 54.9%.  Clinical 
information was obtainable in all but 4 patients (99.5%).  The mean number of coronary risk 
factors was 1.5 ± 1.  The mean pre-test probability of coronary artery disease was 41.7 ± 30% 
(median 46.1%, inter-quartile range 14.1 - 58.9%).   Three hundred and thirteen patients 
underwent coronary angiography as hospital inpatients while 445 patients underwent 
coronary angiography as a day-only procedure on an outpatient basis. There were no 
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American College of Cardiology, together with other professional bodies, has published 
criteria for the appropriate use of CT coronary angiography (Hendel et al., 2006).  CT 
coronary angiography will increasingly be incorporated into clinical practice as an 
important imaging modality for the evaluation of patients suspected to be suffering from 
coronary artery disease.  An important consideration for clinicians and administrators will 
be the diagnostic value of imaging tests and their cost effectiveness in these patients.  More 
data has recently become available regarding the incremental value of functional testing and 
other imaging modalities like CT coronary angiography in patients with suspected coronary 
artery disease.  In particular, the incremental value of non-invasive testing in risk 
stratification and the prediction of adverse events in these patients will be of interest in 
guiding practice and, more importantly, health care policy.  
2. Utilisation of functional tests prior to coronary angiography 
As discussed earlier, despite their well-documented clinical usefulness, there is little 
information on the pattern of use of functional tests in patients prior to undergoing invasive 
coronary angiography.  In particular, for patients who are subsequently found to have no 
significant coronary artery disease on coronary angiography, it will be interesting to 
examine how and why they ended up having invasive coronary angiography.  It may be 
argued that, for these patients, a “failure” of the investigative algorithms led them to 
undergo an invasive test, which may not have been indicated and should not have been 
performed. These tests should have been avoided as they exposed the patient to needless 
risks and might have been unnecessary monetary, resource and manpower wastes. By 
examining where the process has “failed”, one will hopefully be able to learn how to 
minimise future such “failures”. The purpose of our study was to analyse the patterns of use 
and the results of functional tests in patients found to have normal coronary arteries on 
invasive coronary angiography. 
2.1 The study - methods 
Over a 7 and a half-year period, a total of 6,409 patients underwent 8,069 coronary 
procedures at our hospital. Our hospital is the only tertiary referral centre serving a 
population of about 800,000 people.  Only patients referred for coronary angiography for 
evaluation of coronary artery disease were included in the analysis.  Angiographic studies 
on patients referred for valvular or haemodynamic indications were excluded from the 
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analysis. Patients with documented coronary artery disease referred for coronary 
angioplasty or other percutaneous intervention were also excluded.  Therefore, the study 
included 6,053 patients who underwent a total of 6,830 coronary angiographic procedures.  
Of the 6,830 procedures, 4,610 were for male patients and 2,220 were for female patients.  
The mean age of the patients was 60.9 ± 11 years.  Clinical information, including age and 
gender, referrer details, indications for angiography, type of the study and subsequent 
results, was prospectively collected and entered into a computerised database. 
Coronary angiography was performed according to standard techniques via either the 
femoral, brachial or radial approaches.  Patients with no angiographically detectable disease 
or irregularities in any of the epicardial coronary arteries were considered to have normal 
coronary arteries on angiography.  Patients who had previously undergone coronary artery 
bypass surgery and who were found to have patent bypass grafts on angiography were not 
considered to have normal coronary arteries.   
Patients who were subsequently found to have normal coronary arteries on angiography 
were identified.  The clinical records of these patients were then reviewed. Their clinical 
characteristics and presenting symptoms, including risk factors for coronary artery 
disease, were analysed.  Chest pain as the main presenting symptom was characterized on 
retrospective chart review as typical, atypical or non-anginal/non-specific pain.  Five risk 
factors were considered: diabetes mellitus, cigarette smoking, hypertension, 
hypercholesterolemia and family history of coronary artery disease. Patients’ pre-test 
probabilities of coronary artery disease were estimated from age, gender and presenting 
symptoms (Diamond & Forrester, 1979).  
The types and results of functional tests, if performed for these patients, were recorded and 
analysed.  Results of functional tests including exercise ECG, exercise or pharmacologic 
stress echocardiogram or nuclear myocardial perfusion studies were sought. None of the 
patients had CT coronary angiography as it was not available at the time of the study.  
Functional tests were considered negative if no evidence of inducible ischaemia was 
detected on testing and if the level of the stress was considered adequate.  Functional tests 
were considered inconclusive if there was equivocal evidence of inducible ischaemia or if 
there was no inducible ischaemia at inadequate levels of stress. 
Information on the physicians who referred these patients (referrers) for coronary angiography 
was also recorded. Referrers were classified into cardiologists or other physicians according to 
the field of specialisation.  In particular, for cardiologist referrers, those who performed 
coronary angiography were considered proceduralists whilst cardiologists who do not 
perform angiography were considered non-proceduralists.  
2.2 Results 
2.2.1 Patients 
Seven hundred and fifty six patients undergoing 762 procedures were found to have normal 
epicardial coronary arteries on angiography.  This means that 11.2% of the coronary 
angiograms performed were for patients with normal coronary arteries. The mean age of 
these patients was 54.9 ± 11.5 years with female patients comprising 54.9%.  Clinical 
information was obtainable in all but 4 patients (99.5%).  The mean number of coronary risk 
factors was 1.5 ± 1.  The mean pre-test probability of coronary artery disease was 41.7 ± 30% 
(median 46.1%, inter-quartile range 14.1 - 58.9%).   Three hundred and thirteen patients 
underwent coronary angiography as hospital inpatients while 445 patients underwent 
coronary angiography as a day-only procedure on an outpatient basis. There were no 
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significant differences in gender distribution, number of coronary risk factors and pre-test 
probability of coronary artery disease between patients who underwent coronary 
angiography as inpatients and those who underwent the procedure as day-only patients. 
However, patients who underwent coronary angiography as inpatients were significantly 
younger and more likely to have presented with non-anginal chest pain (Table 1). 
 
Parameters Inpatient procedure(n=313) 
Day-only procedure 
(n=445) p 
Men/Women 149/164 199/246 0.43 
Age (years) 53.6  12.5 55.8  10.8 0.01 
Number of risk factors 1.48  1.1 1.49  1 0.73 
Presenting symptom 
n (%)   <0.001 
Typical angina 62 (19.8%) 99 (22.2%)  
Atypical angina 110 (35.1%) 172 (38.7%)  
Non anginal chest pain 85 (27.2%) 71 (15.9%)  
Dyspnea 23 (7.3%) 48 (10.8%)  
Others 26 (8.3%) 34 (7.6%)  
Asymptomatic 2 (0.6%) 16 (3.6%)  
Pre-test probability of 
coronary disease (%) 39.6  30 43.2  29.8 0.11 
Table 1. Clinical characteristics of patients who were subsequently found to have 
angiographically normal coronary arteries divided according to whether they were hospital 
inpatients or not at the time of angiography. (Reproduced with permission from: Leung DY, 
Lo ST, Liew CT, Wong A, Hopkins AP, Juergens CJ. Utilization of functional tests prior to 
coronary angiography in patients with angiographically normal coronary arteries. 
International Journal of Cardiology 2005; 104(3):326 – 331. Elsevier Limited) 
2.2.2 Utilization of functional tests 
Only 483 of the 758 patients (63.7%) had undergone functional tests as part of the diagnostic 
workup prior to coronary angiography.  Two hundred and fifty three patients (33.4%) 
underwent exercise electrocardiography, 140 underwent stress nuclear perfusion imaging 
(18.5%), 9 underwent stress echocardiography (1.2%) and 81 underwent more than one 
functional test (10.7%).  There were no significant differences in gender distribution, age, 
number of coronary risk factors and pre-test probability of coronary disease between 
patients who had undergone functional tests and those who had not.  However, inpatients 
were significantly less likely to have undergone functional tests prior to angiography 
compared to day-only patients (Table 2). 
Multiple logistic regression analysis identified inpatient status as the only independent 
predictor of undergoing functional tests prior to coronary angiography in these patients (OR 
5.9, 95% confidence interval 5.0 - 7.0, p <0.001).  
Of the 483 patients who underwent functional tests prior to coronary angiography, 
inducible ischaemia was detectable in only 241 patients (49.6%).  Therefore less than half of 
the performed tests were positive. Functional tests were reported negative for inducible 
 
 




(n = 483) 
No functional tests 
(n=275) p 
Men/Women 218/265 130/145 0.57 
Age (years) 55.3  10.7 54.2  12.8 0.2 
Number of coronary risk factors 1.5  1.1 1.45  1.1 0.52 
Pre-test probability of coronary disease (%) 42.5  29 40.2  31 0.32 
Inpatient/day-only patient (n) 126/357 187/88 <0.001 
Table 2. Clinical characteristics of the patients when subdivided according to whether they 
had undergone functional testing prior to coronary angiography. (Reproduced with 
permission from: Leung DY, Lo ST, Liew CT, Wong A, Hopkins AP, Juergens CJ. Utilization 
of functional tests prior to coronary angiography in patients with angiographically normal 
coronary arteries. International Journal of Cardiology 2005; 104(3):326 – 331. Elsevier 
Limited) 
ischaemia for 245 patients.  Of these, 151 patients achieved adequate stress levels whilst in 
91 cases the results were inconclusive.  Of the 151 patients with negative functional tests, 114 
(75.5%) underwent coronary angiography as outpatients and 37 as inpatients.  Only 22 
patients (14.5%) had history of previous admission to hospital with chest pain prior to 
angiography.   
Patients were further divided into 3 subgroups according to their pre-test probability of 
coronary disease: low risk (pre-test probability <20%), intermediate risk (pre-test probability 
20% to <80%) and high risk (pre-test probability ≥ 80%).  There were no significant 
differences in the utilisation and the results of functional tests across the clinical risk 
subgroups for day-only patients (Figure 1, p = 0.2) or for inpatients (Figure 2, p = 0.76).  
However, a higher proportion of day-only patients underwent functional tests prior to 
angiography irrespective of pre-test probability of disease compared to inpatients. 
 
 
Fig. 1. Use and results of functional tests in patients undergoing coronary angiography as a 
day-only procedure. (Reproduced with permission from: Leung DY, Lo ST, Liew CT, Wong 
A, Hopkins AP, Juergens CJ. Utilization of functional tests prior to coronary angiography in 
patients with angiographically normal coronary arteries. International Journal of Cardiology 
2005; 104(3):326 – 331. Elsevier Limited) 
A total of 33 physicians referred these patients to our institution for coronary angiography.  
Twenty (60.6%) were cardiologists and 13 (39.4%) were other physicians.  Patients referred 
by cardiologists were significantly more likely to have undergone functional tests compared 
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Fig. 2. Use and results of functional tests in patients undergoing coronary angiography as 
inpatients. (Reproduced with permission from: Leung DY, Lo ST, Liew CT, Wong A, 
Hopkins AP, Juergens CJ. Utilization of functional tests prior to coronary angiography in 
patients with angiographically normal coronary arteries. International Journal of Cardiology 
2005; 104(3):326 – 331. Elsevier Limited) 
with those referred by other physicians (66% vs 50.8%, p = 0.001).  Of the cardiologists, 9 
were proceduralists and 11 were non-proceduralists. There was no significant difference 
between procedural cardiologists and non-procedural cardiologists in the use of functional 
tests in patients prior to coronary angiography (68% vs 64%, p = 0.28). 
2.3 Discussion 
This study examined the use and results of functional tests in a large consecutive series of 
patients who were subsequently found to have angiographically normal coronary arteries at 
our institution over the study period.  The overall utilisation of functional tests in our 
patients was only modest and a significant proportion of patients either had no functional 
tests done prior to angiography or proceeded directly to coronary angiography despite 
negative functional tests.  Referrer characteristics and patient status, rather than pre-test 
probability of coronary artery disease, appeared to have a greater impact on the use of 
functional tests prior to angiography. 
Functional tests have established and pivotal roles in the investigation and management of 
patients with suspected or confirmed coronary artery disease.  They have a high sensitivity 
and specificity in the non-invasive diagnosis of coronary artery disease in patients with 
suggestive symptoms.  Information like blood pressure, exercise capacity and heart rate 
response to exercise are of further prognostic value.  The addition of cardiac imaging during 
functional tests provides incremental prognostic information (Marwick et al., 1999).  
Therefore, functional tests not only allow diagnosis of coronary artery disease but also allow 
clinicians to risk-stratify patients.  Higher risk patients should be referred onto coronary 
angiography whilst lower risk patients can safely be managed without expensive and 
invasive investigations. In the American College of Cardiology/American Heart Association 
guidelines for coronary angiography, functional tests play a central role (Scanlon et al., 
1999).  
It has been suggested that the diagnostic as well as the follow up costs were lower for those 
who had undergone functional tests prior to coronary angiography, irrespective of the pre-
test probability of coronary disease, without significant differences in the medium term 
outcome (Shaw et al., 1999a).  The cost differences between the two strategies may reflect a 
decreased need for coronary angiography in patients with normal perfusion scan results 
(Shaw et al., 1999b).  Functional tests, therefore, have the potential to accrue cost savings by 
acting as a "gate-keeper" for coronary angiography by excluding those with normal results 
who have no significant coronary disease and excellent short to medium term outcome. 
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According to the Bayesian theorem, the post-test probability of coronary artery disease is 
dependent on the prevalence of the disease in the population being tested.  Impact of 
screening tests is highest in patients with intermediate pre-test probability.  Proceeding to 
coronary angiography without functional tests may be justifiable in patients with high pre-
test probability of coronary artery disease.  In patients with multiple coronary risk factors 
and typical angina, coronary angiography without functional tests may be more appropriate 
as the results of functional tests are less likely to obviate the need for angiography in these 
patients.  Cost-effectiveness analyses by Patterson et al suggested that proceeding straight to 
coronary angiography in patients with high pre-test probability of disease (>80%) may be 
more cost-effective (Patterson et al., 1995).  One would expect that the use of functional tests 
would be higher in patients with low to intermediate pre-test probability of coronary 
disease.  However, the results of the present study showed that this is not the case; the use 
of functional tests in these patients was low (Figures 1 and 2).   The use of functional tests 
was particularly low for hospital inpatients. Inpatients were less likely to have undergone 
functional tests prior to angiography compared with day-only patients across all three 
groups of pre-test probability of coronary disease.   For intermediate risk patients, 83.5% of 
day-only patients compared with only 42.1% of inpatients had undergone functional tests 
prior to angiography.  For low risk patients, 79.7% of day-only patients compared with only 
36.3% of inpatients had undergone functional tests. This cannot be explained by any 
differences in risk factor profiles or pre-test probability of disease.   
There could be a number of possible explanations for these findings.  Hospital inpatients 
may be more likely to be perceived as unstable, which may have made the treating 
physicians reluctant to subject them to functional testing.  Some of our regional referring 
hospitals do not have stress testing facilities and direct referral to our institution for 
coronary angiography might have been an easier solution.  The delay in obtaining stress 
echocardiography or stress perfusion nuclear imaging contrasted with the overriding 
pressure to discharge patients from hospital may make such functional testing less attractive 
to treating physicians.  
Functional tests are neither 100% sensitive nor 100% specific.  In our study, a high 
proportion of patients with negative functional tests with adequate stress still proceeded to 
angiography.  This may have resulted from the suspicion of a false negative functional test, 
frustration on the part of the physicians about the lack of a definitive diagnosis and the 
desire to answer the question "once and for all". However, despite the lack of 100% 
sensitivity, patients with normal stress echocardiograms or stress nuclear perfusion imaging 
had very low cardiac event rates on follow up, in the range of <0.5%/year (Metz et al., 2007).  
Functional tests may also be falsely positive.  However, patient and test characteristics 
associated with false positive functional tests are well described.  Exercise ECG is well 
known to be non-specific in young or middle aged women.  The basal inferior wall changes 
on stress echocardiogram and diaphragmatic and breast attenuation artefacts on stress 
nuclear perfusion imaging are well-described sources of false positive findings.  The recent 
advent of CT coronary angiography may help in ruling out coronary artery disease and its 
use in equivocal or un-interpretable functional tests is considered appropriate. 
The increased use of coronary angiography, regardless of whether it is indicated or not, may 
have more than just an economic impact.  In addition to the increased risks of procedural 
complications, increased diagnostic testing has been shown to result in an increased 
therapeutic intervention rate downstream (VerrilliWelch, 1996; Wennberg et al., 1996).  
While the concern of increased downstream therapeutic intervention is minimal in patients 
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Fig. 2. Use and results of functional tests in patients undergoing coronary angiography as 
inpatients. (Reproduced with permission from: Leung DY, Lo ST, Liew CT, Wong A, 
Hopkins AP, Juergens CJ. Utilization of functional tests prior to coronary angiography in 
patients with angiographically normal coronary arteries. International Journal of Cardiology 
2005; 104(3):326 – 331. Elsevier Limited) 
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with angiographically normal coronary arteries, the risks of procedural complications and 
the increased overall costs of investigations cannot justify indiscriminate use of angiography 
in patients with low to intermediate pre-test probability of disease. 
There are considerable variations in the use of coronary angiography (Pilote et al., 1995), 
which was closely related to the availability of cardiac catheterization facilities (Every et al., 
1993).  With the use of angiography closely related to its availability, there have been 
concerns over the appropriateness of coronary angiography (Bernstein et al., 1999; Chassin 
et al., 1987b).  A significant proportion of coronary angiography was found to be 
"inappropriate" (Gray et al., 1990), with "inappropriate" use of coronary angiography higher 
in high-use sites (Chassin et al., 1987a).  In the study by Chassin et al (Chassin et al., 1987b), 
patients without angina or with atypical angina and who had not undergone exercise testing 
constituted the most common subgroup of inappropriate angiography.  In a random audit 
of 320 patients referred for coronary angiography (Gray et al., 1990), only 53% of the 
patients had undergone functional tests prior to angiography.  In a consecutive series of 
3631 patients referred for coronary angiography, 5% were performed for inappropriate 
indications and another 33% for uncertain indications (Hemingway et al., 2001).  Similarly, 
asymptomatic patients and patients with atypical angina or mild angina who had not 
undergone exercise testing comprised the majority of the inappropriate and uncertain 
indications.  Furthermore, the appropriateness ratings for angiography predicted both the 
angiographic findings of coronary disease, subsequent rates of revascularisation and 
mortality rates after a mean follow-up time of 2.5 years (Hemingway et al., 2001).  
There has been considerable interest in examining the difference in treatment (Borowsky et 
al., 1995), procedural use (Nash et al., 1997), and patient outcome between cardiologists and 
non-cardiologists in patients with coronary artery diseases.  It has been reported that 
cardiologists were more likely than non-cardiologists to recommend "clinically necessary" 
coronary angiography (Borowsky et al., 1995).  Some reports suggested that cardiologists 
were more likely to prescribe medical therapies of proven efficacy in the care of patients 
with myocardial infarction (Ayanian et al., 1994), while others suggested that myocardial 
infarct patients in the care of cardiologists had a lower risk-adjusted mortality rate (Nash et 
al., 1997).  The results of our study suggested that cardiologists were more likely to have 
referred patients with suspected coronary artery disease for functional tests prior to 
angiography and procedural cardiologists were as likely as their non-procedural 
counterparts to utilise functional tests prior to referral for angiography.   
Our study is only a single centre experience and may not reflect experience of other centres.  
We selected only patients with angiographically normal coronary arteries as these patients 
represent a lower clinical risk subgroup where functional tests should have been more 
widely used and clinically relevant.  As a result of the selection, we did not include patients 
who had undergone functional tests but were not referred for angiography.  Furthermore, 
our aim was to document the use of functional tests and not to judge whether referral of low 
to intermediate risk patients without functional tests was "appropriate" or not.    
In conclusion, use of functional tests prior to coronary angiography was only modest and 
was particularly low for hospital inpatients in our large consecutive series of patients with 
angiographically normal coronary arteries.  A significant proportion of patients proceeded 
to coronary angiography despite negative functional tests.  Referrer characteristics and 
hospital inpatient status, rather than pre-test probability of coronary artery disease, 
appeared to have greater impact on utilization of functional tests.   
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3. Adherence to guidelines on coronary angiography 
The American College of Cardiology and The American Heart Association initially 
published their guidelines on the use of invasive coronary angiography in 1987.  An update 
was issued in 1999 (Scanlon et al., 1999).  The guidelines examined the indications for 
coronary angiography in a wide range of commonly encountered clinical situations.  These 
included patients with known or suspected coronary artery disease with minimal or stable 
symptoms, patients with unstable coronary symptoms, patients after myocardial infarction, 
patients after revascularisation, patients with heart failure or with haemodynamic 
instability, patients undergoing non cardiac surgery and patients with valvular or 
congenital heart disease.  These guidelines incorporate the latest available evidence and 
provide guidance to clinicians to the best evidence based practice.  Despite the wide 
dissemination of these guidelines, there is little information on how they are incorporated 
into daily clinical practice and how closely they are adhered to.  It would be interesting to 
find out how compliant clinicians are with these guidelines and how compliance is 
translated into the clinical results.  Furthermore, it will be helpful to identify areas where 
compliance is low so that further efforts may be spent on these problem areas to improve 
compliance. 
3.1 The study - methods 
A total of 802 consecutive patients referred to our cardiac catheterisation laboratory for 
coronary angiography were prospectively enrolled and evaluated over a 5-month period in 
2002.  Clinical history including coronary risk factors, presenting symptoms, 
electrocardiograms and laboratory test results were recorded prospectively.  Chest pain as a 
presenting symptom was assessed and classified as typical angina, atypical angina or non-
anginal chest pain.  Five coronary risk factors were considered: diabetes mellitus, cigarette 
smoking, hypertension, hypercholesterolemia and family history of coronary artery disease.  
Electrocardiographic changes were considered ischaemic if there was horizontal ST segment 
depression or elevation of ≥ 1 mm or if there was symmetrical T wave inversion of ≥ 3 mm 
in ≥ 2 contiguous leads.   
The physicians who referred these patients were classified as cardiologists or general 
physicians according to their primary field of specialisation.  Cardiologists were further sub-
classified into non-invasive or invasive cardiologists according to whether they performed 
coronary angiography.  The type and results of functional tests, if performed, were recorded 
and information on left ventricular function, if available, was also collected.  Functional tests 
were considered positive it there was evidence of inducible ischaemia on testing (ST 
segment deviation of ≥ 1mm on exercise electrocardiography, inducible new segmental wall 
dysfunction on stress echocardiography or reversible perfusion defects on nuclear perfusion 
imaging).   They were considered negative if there was no evidence of inducible ischaemia 
on testing and if the level of the stress was considered adequate for exercise stress (peak 
heart rate ≥ 85% age predicted maximum).  Functional tests were considered inconclusive if 
there was equivocal evidence of inducible ischaemia or if there was no inducible ischaemia 
at inadequate levels of stress for exercise stress.   
Patients with no irregularities detected in any of the epicardial coronary artery on 
angiography were considered to have normal coronary arteries on angiography. Patients 
with less than 50% diameter stenosis in any of the epicardial coronary arteries or its major 
branches were considered to have minor coronary artery disease.  Angiograms on patients 
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who had previously undergone coronary artery bypass surgery and were found to have all 
bypass grafts patent (<50% diameter stenosis) and no ungrafted but stenotic native vessels 
on angiography were not considered to have significant flow limiting stenosis.  
Complications of coronary angiography, if any, were also recorded.   
Compliance with guidelines on coronary angiography was assessed for these 802 patients by 
2 independent assessors, blinded to the results of angiography, according to the American 
College of Cardiology/American Heart Association guidelines on coronary angiography 
(Scanlon et al., 1999).  Referrals were considered compliant with guidelines if they fulfilled 
either the Class I or Class II indications.  Referrals were considered non-compliant (outside 
guidelines) if they fulfilled Class III indications or none of the Class I or II indications.  
Disagreements between the 2 assessors were reconciled with arbitration by an independent 
third assessor.  Intra-observer agreement was assessed with the same assessor evaluating 
compliance on the same 802 patients, 12 months after the initial assessment. Both 
assessments were done with the assessor blinded to the results of the initial assessment and 
coronary angiography.  
3.2 Results 
3.2.1 Patients characteristics 
We evaluated a total of 802 patients (Table 3).  The indications for coronary angiography 
were; assessment of chest pain with known or suspected coronary artery disease in 491 
patients (61.1%), non ST segment elevation myocardial infarction in 127 patients (15.8%), ST 
segment elevation myocardial infarction in 72 patients (9%), congestive heart failure or 
dyspnoea in 70 patients (8.7%), valvular heart disease in 20 patients (2.5%), prior to non 
cardiac surgery in 11 patients (1.5%), arrhythmias in 5 patients and miscellaneous in 6 
patients (0.8%).  Two hundred and thirty six patients (29.4%) had had coronary angiography 
previously.   
One hundred and nineteen patients (14.8%) were referred by general physicians (internists), 
341 (42.5%) by non-invasive cardiologists and 342 (42.6%) by invasive cardiologists.  Cardiac 
Troponin T levels were measured in 354 patients and a significantly higher proportion of 
patients referred by general physicians had raised cardiac Troponin T levels compared to 
those referred by cardiologists (56 of the 69 patients versus 141 of 285 patients, p<0.001)  
3.2.2 Investigations prior to angiography  
All patients had 12-lead electrocardiography before coronary angiography as part of the 
initial diagnostic work-up.  Twelve-lead electrocardiography was normal in 261 patients 
(32.5%), showed non-specific changes in 174 patients (21.7%), was un-interpretable in 30 
patients (3.7%) and showed ischemic changes in 337 patients (42%). 
Left ventricular function was assessed as part of the diagnostic work up before coronary 
angiography with echocardiography in 232 (28.9%) patients and with radionuclide 
ventriculography in another 123 patients (15.3%).  Left ventricular function was assessed in 
a further 37 patients (3.6%) from previous contrast ventriculography.  Left ventricular 
function was not assessed prior to coronary angiography in 410 patients (51.1%).  Inpatients 
were significantly less likely to have their left ventricular function evaluated prior to 
coronary angiography compared with day-only patients (36.9% vs 62.9%, p<0.001).  Of the 
392 patients who had left ventricular function assessment, 149 (38%) had an ejection fraction 
of < 50% and 243 patients had normal function (ejection fraction  50%).  
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Age 62 ± 11 years 
Male / Female (n) 522 / 280 
Average number of coronary risk factors 2.7 ± 1.3 
Medications, n (%)  
Aspirin 642 (80%) 
Beta blockers 542 (67.6%) 
Calcium antagonists 177 (22.1%) 
Nitrates 289 (36%) 
Angiotensin converting enzyme inhibitors 375 (46.8%) 
Statins 547 (68.2%) 
Clopidogrel 111 (13.8%) 
Unfractionated heparin or enoxaparin 220 (27.5%) 
Angiotension receptor blockers 103 (12.8%) 
Inpatient / day only procedure (n) 433 / 369 
Previous coronary artery bypass surgery, n(%) 89 (11.1%) 
Previous percutaneous coronary intervention, n(%) 88 (11%) 
History of myocardial infarction, n(%) 141 (17.6%) 
Acute coronary syndrome during index hospital 
admission (for inpatients), n(%) 
199 (24.8%) 
Renal impairment, n(%) 71 (8.9%) 
Table 3. The baseline clinical characteristics of the 802 patients. (Reproduced with 
permission from: Leung DY, Hallani H, Lo ST, Hopkins AP, Juergens CP. How compliant 
are we with guidelines for coronary angiography in clinical practice? Internal Medicine 
Journal 2007, Oct;37(10):699-704. John Wiley and Sons) 
Serum cardiac Troponin T levels were measured in 347 of the 433 inpatients (80.1%) and 
were elevated to ≥ 0.03 ng/ml in one or more blood samples in 194 patients (44.8%).  
Cardiac Troponin T levels were measured in only 7 of the 369 day-only patients and were 
elevated in 3 patients (0.8%). 
3.2.3 Functional test results 
Functional tests were performed in 262 of the 369 (71%) day-only patients and in only 75 of 
the 433 inpatients (17.3%, p<0.001).  Even after the 197 patients with raised cardiac Troponin 
T levels were excluded from analysis, inpatients were still significantly less likely to have 
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had functional tests prior to coronary angiography compared with day-only patients (28.5% 
vs 71.6%, p<0.001).  Patients with history of percutaneous coronary intervention, coronary 
artery bypass surgery or documented myocardial infarction were significantly less likely to 
have functional tests prior to coronary angiography (79/224, 35.3%) than patients with no 
such history (258/578, 44.6%, p=0.016).  Only 288 of the 491 patients (58.6%) referred for 
assessment of chest pain not associated with either non-ST elevation or ST elevation 
myocardial infarction had functional tests prior to angiography. One hundred and nine 
patients (13.6%) underwent exercise electrocardiography, 41 patients (5.1%) underwent 
exercise echocardiography, 57 (7.1%) underwent exercise nuclear perfusion scan and 130 
patients (16.2%) underwent vasodilator stress nuclear perfusion scan.  Table 4 shows the 
results of functional tests in these 337 patients. 
 
 Positive functional test (n) 
Negative 
functional test (n) 
Total 
(n) 
Adequate stress level  
(For exercise stress, n)* 81 (74) 23 (20) 104 (94) 
Inadequate stress level* 
(For exercise stress, n) 65 (58) 38 (33) 103 (91) 
Vasodilator stress (n) 108 (83) 22 (20) 130 (103) 
Total (n) 254 (215) 83 (73) 337 (288) 
Table 4. Results for functional tests in the 337 patients (The numbers in parentheses are the 
number of patients with assessment of chest pain as indications for coronary angiography in 
each category). (Reproduced with permission from: Leung DY, Hallani H, Lo ST, Hopkins 
AP, Juergens CP. How compliant are we with guidelines for coronary angiography in 
clinical practice? Internal Medicine Journal 2007, Oct;37(10):699-704. John Wiley and Sons) 
3.2.4 Coronary angiography results 
The coronary arteries were angiographically normal in 152 patients (19%) and showed only 
minor disease in another 111 patients (13.8%).  One hundred and sixty six patients (20.7%) 
had single vessel disease, 145 (18.1%) had double vessel disease and 228 (28.4%) had triple 
vessel disease.  Of the 89 patients who had previous coronary artery bypass surgery, 40 
patients (45%) had no significant graft disease.  The overall rate of angiography showing 
either normal or minor diseases was 37.7%. The overall complication rate of coronary 
angiography was low.  There were 51 cases of access site haematoma (6.4%), one case for 
each of pseudo-aneurysm, arterio-venous fistula, neurologic deficit, significant arrhythmia 
and contrast allergy.  No deaths as a result of the angiography were recorded.  
3.2.5 Compliance with guidelines 
Referrals for coronary angiography were considered outside the guidelines for coronary 
angiography in 34.3% and 36.2% as evaluated by the 2 independent assessors.  The 
concordance rate between the 2 independent assessors was 88.2% (kappa 0.74, p<0.001).  
The concordance rate between the 2 independent evaluations by the same assessor was 
97.5% (kappa 0.945, p<0.001). 
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Coronary angiography showed normal coronary arteries or only minor coronary disease in 
a significantly higher proportion of patients when the referrals were outside published 
guidelines compared with referrals within the guidelines (181 of the 264 referrals, 68.4% 
versus 121 of the 538 referrals, 22.6%, p<0.001). 
There were no significant differences in complications of coronary angiography between the 
group where referrals were within guidelines (6.7%) and the group where referrals were 
outside guidelines (7.2%, p = 0.79). 
Table 5 shows the compliance rate for each of the indications of coronary angiography.  The 
compliance rates were high with indications of non-ST elevation and ST elevation 
myocardial infarction, valvular heart disease and arrhythmias.  However, the compliance 
rates were lower with indications of assessment of dyspnoea or heart failure and prior to 
non-cardiac surgery and were particularly low with assessment of chest pain (n = 491, mean 
age 61.3 ± 11 years, 300 men). Two hundred and ninety five of these 491 patients (60%) were 
day-only patients. Only 288 of these 491 (58.7%) had functional tests and only 254 (51.7%) 
had assessment of left ventricular function prior to coronary angiography. 
 
Indication Non-compliant with guidelines n(%) 
Compliant with 
guidelines n(%) Total (n) 
Assessment of Chest 
pain 230 (46.8%) 261 (53.2%) 491 
Non-ST elevation 
myocardial infarction 1 (0.8%) 126 (99.2%) 127 
ST elevation 
myocardial infarction 3 (4.2%) 69 (95.8%) 72 
Dyspnea/heart 
failure 18 (25.7%) 52 (74.3%) 70 
Valvular disease 4 (20%) 16 (80%) 20 
Prior to non cardiac 
surgery 3 (27.3%) 8 (72.7%) 11 
Arrhythmia 1 (20%) 4 (80%) 5 
Others 4 (66.7%) 2 (33.3%) 6 
Total 264 (32.9%) 538 (67.1%) 802 
Table 5. The compliance rates for coronary angiography to the American College of 
Cardiology/American Heart Association guidelines according to the indications for 
angiography. (Reproduced with permission from: Leung DY, Hallani H, Lo ST, Hopkins AP, 
Juergens CP. How compliant are we with guidelines for coronary angiography in clinical 
practice? Internal Medicine Journal 2007, Oct;37(10):699-704. John Wiley and Sons) 
Concentrating on referrals from cardiologists (n=683), referrals from non-invasive 
cardiologists were significantly more likely to be outside published guidelines compared 
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outside guidelines (7.2%, p = 0.79). 
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age 61.3 ± 11 years, 300 men). Two hundred and ninety five of these 491 patients (60%) were 
day-only patients. Only 288 of these 491 (58.7%) had functional tests and only 254 (51.7%) 
had assessment of left ventricular function prior to coronary angiography. 
 
Indication Non-compliant with guidelines n(%) 
Compliant with 
guidelines n(%) Total (n) 
Assessment of Chest 
pain 230 (46.8%) 261 (53.2%) 491 
Non-ST elevation 
myocardial infarction 1 (0.8%) 126 (99.2%) 127 
ST elevation 
myocardial infarction 3 (4.2%) 69 (95.8%) 72 
Dyspnea/heart 
failure 18 (25.7%) 52 (74.3%) 70 
Valvular disease 4 (20%) 16 (80%) 20 
Prior to non cardiac 
surgery 3 (27.3%) 8 (72.7%) 11 
Arrhythmia 1 (20%) 4 (80%) 5 
Others 4 (66.7%) 2 (33.3%) 6 
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Table 5. The compliance rates for coronary angiography to the American College of 
Cardiology/American Heart Association guidelines according to the indications for 
angiography. (Reproduced with permission from: Leung DY, Hallani H, Lo ST, Hopkins AP, 
Juergens CP. How compliant are we with guidelines for coronary angiography in clinical 
practice? Internal Medicine Journal 2007, Oct;37(10):699-704. John Wiley and Sons) 
Concentrating on referrals from cardiologists (n=683), referrals from non-invasive 
cardiologists were significantly more likely to be outside published guidelines compared 
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with referrals from invasive cardiologists (141 of the 341 referrals, 41.3% versus 103 of the 
342 referrals, 30.1%, p = 0.002).  Multivariate logistic regression analysis identified younger 
age (OR 1.04 for every year younger, 95% CI 1.029 – 1.048, p<0.001), female gender (OR 2.67, 
95% CI 2.24 – 3.19, p<0.001), day-only procedure (OR 2.27, 95% CI 1.91 – 2.69, p<0.001) and 
non-invasive cardiologist referrer (OR 1.41, 95% CI 1.19 – 1.67, p = 0.046) to be independent 
predictors of non-compliance with published guidelines.   
When patients with raised cardiac Troponin T (n = 197) were excluded from the multivariate 
analysis, day-only procedure was no longer a significant independent predictor of non-
compliance.  Younger age (OR 1.04 for every year younger, 95% CI 1.03 – 1.05, p<0.001), 
female gender (OR 2.24, 95% CI 1.87 – 2.69, p<0.001) and non-invasive cardiologist referrer 
(OR 1.47, 95% CI 1.29 – 1.67, p = 0.004) remained independent predictors of non-compliance 
with guidelines.   
3.3 Discussion 
In our large consecutive series of patients referred for coronary angiography, we found that 
more than a third of the referrals were outside the American College of 
Cardiology/American Heart Association guidelines for coronary angiography.  The inter-
observer and intra-observer agreement in assessing compliance were high.  The rate of 
coronary angiography showing either normal coronary arteries or only minor diseases was 
significantly higher when the referrals were outside guidelines.  The compliance rate was 
particularly low with indications of assessment of chest pain.  Younger age, female gender, 
day-only procedure and non-invasive cardiologist referrals were independent predictors of 
non-compliance with the guidelines. 
Practice guidelines have proliferated in clinical medicine in the past 2 decades in all major 
fields. The compilation and publication of these practice guidelines represent efforts by 
professional bodies to incorporate an ever-expanding evidence based medicine into best 
clinical practice. A systemic review suggested significant improvement of care after 
introduction of clinical guidelines although the size of the improvement varied considerably 
(GrimshawRussell, 1993). The dissemination and implementation of these guidelines have 
emerged as major challenges. Furthermore, awareness of these guidelines does not 
necessarily equate to compliance. Therefore, the full potential for these guidelines to 
improve health care delivery and clinical outcomes has yet to be completely realized. 
A number of studies have found significant gaps between clinical practice and guidelines in 
a number of areas (Brand et al., 1995; Leape et al., 2003; Vikman et al., 2003).  In a study of 
antithrombotic therapy in atrial fibrillation, a report found that only 47% of the eligible 
patients received warfarin according to published guidelines and 4 patients had a stroke 
during a 12-month follow-up period (Nair et al., 2005).  These 4 patients were not on 
warfarin despite recommendations by the guidelines.  In a random audit of Medicare data 
in 5 US states showed that 30% of percutaneous coronary angioplasties was rated as Class III 
indications according to the 1988 American College of Cardiology/American Heart 
Association guidelines whereas 24% were class III by use of the 1993 guidelines (Leape et al., 
2003).  Similar gaps were found between clinical practice and the European Society of 
Cardiology guidelines for the management of non-ST elevation myocardial infarction 
(Vikman et al., 2003) and only about 50% of patients post myocardial infarction received 
beta blockers as recommended by the guidelines (Brand et al., 1995).  
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Adherence to guidelines has been suggested to lead to an improved clinical outcome. A 
clear relationship was found between extent of guideline implementation and one-year 
mortality in patients with acute myocardial infarction (Schiele et al., 2005). Compliance 
remained an independent predictor of survival even after adjustment for clinical risk. 
Similarly, compliance with the guidelines significantly improved prognosis in acute 
coronary syndrome regardless of risk score (Gulati et al., 2004) and resulted in an 
improved outcome in high risk patients with non ST elevation myocardial infarction 
(Vikman et al., 2004). In evaluating the impact of compliance with guidelines for coronary 
angiography, patient outcome such as survival may not be appropriate. Nevertheless, we 
were able to demonstrate that the rate of coronary angiography showing either normal 
coronary arteries or only minor diseases was significantly lower when the referrals were 
within the guidelines. Rates of normal coronary angiography may be a reasonable 
surrogate for measuring the impact of compliance as a high negative rate has significant 
implications due to inappropriate costs, superfluous resource utilisation and unnecessary 
risks for the patient.   
Little is known about the barriers to compliance with guidelines by physicians. Potential 
barriers may include awareness, familiarity, disagreement with the guidelines, resistance 
to change, and absence of disincentives or penalties for not adhering to recommendations 
on the part of the physicians (Cabana et al., 1999).  In addition to physician factors, our 
study also identified clinical parameters and scenarios that were predictive of non-
compliance with the guidelines.  Younger age and female gender were found to be 
predictors.  One may postulate that physicians may be more aggressive in recommending 
coronary angiography outside guidelines in younger patients as they do not want to 
“miss” significant coronary disease in such patients.  The compulsion for a “definitive” 
diagnosis and fear of litigation in an increasing medico-legal environment may also have 
contributed.  Day-only procedure as a predictor of non-compliance may be explained by 
the fact that patients with acute coronary syndrome with raised cardiac Troponin T levels 
almost always underwent angiography as inpatients.  This is supported by the fact that 
day-only procedure was not an independent predictor when patients with elevated 
Troponin levels were excluded from the multivariate analysis.  In our study, non-invasive 
cardiologists were more likely to refer outside the guidelines for coronary angiography.  
This may be because non-invasive cardiologists are potentially less familiar with the 
guidelines.  Furthermore, in the present study, clinical scenarios of assessment of chest 
pain in patients with suspected or known coronary artery disease appeared to be areas 
where the non-compliance rate was particularly high.  These may be areas in  
which physicians have the most difficulties adhering to the recommendations of the 
guidelines. 
Only a small proportion of patients, especially for inpatients, had functional tests prior to 
coronary angiography. Functional tests, which play an important role in the risk 
stratification of patients with suspected or confirmed coronary artery disease as depicted 
in the published guidelines, were performed in a relatively small proportion of the 
patients in our study.  Our previous study on a different patient population also found a 
low rate of utilisation of functional tests.  Referrer characteristics and inpatient status, 
rather than pre-test probability of coronary disease, appeared to have the greatest impact 
on utilisation of functional tests (Leung et al., 2005).  Non-utilisation of functional tests 
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prior to coronary angiography was a common reason for “inappropriate” referral for 
coronary angiography, as established by previous studies (Chassin et al., 1987b; Gray et 
al., 1990).   
Our study represents the experiences of a single tertiary referral hospital, and hence may 
not be representative of other centres around the world.  However, we feel that our study 
population was representative as our institution is the only cardiac catheterisation 
laboratory in a public hospital tertiary referral centre serving a population of about 
800,000.  The aim of the present study was to evaluate compliance with the American 
College of Cardiology and American Heart Association guidelines for coronary 
angiography and not to judge whether the referrals were appropriate.  Referral outside 
guidelines may be entirely appropriate depending on the patient’s specific clinical 
situation.  These guidelines for coronary angiography were published in 1999.  As the 
evidence base has been evolving and improving, these guidelines may not reflect 
contemporary practice.  Although the rate of angiography showing either normal 
coronary arteries or minor disease was significantly higher when the referrals were 
outside published guidelines, which can have significant cost-effective implications, our 
results do not allow us to perform cost-effectiveness analysis. 
4. Conclusions  
Coronary angiography is one of the most commonly performed cardiac procedures. It 
continues to play an important role in the management of cardiac patients and is 
indispensible in patients considered for coronary revascularisation. It is an invasive 
procedure not without significant risks and, together with its inherent costs, should not be 
carried out or repeated without sufficient justification. Functional tests, including stress 
ECG, stress echo, nuclear perfusion imaging and magnetic resonance imaging are all 
accepted functional tests that provide important diagnostic and prognostic information 
and should form part of the body of investigations in patients suspected to be suffering 
from coronary artery disease. More recently, CT coronary angiography is being used as a 
“ruling out” test and is considered an appropriate indication in certain subsets of patients 
with chest pain. Improvement in the use of these functional tests may lead to better risk 
stratification so that low risk patients may be spared the risks and costs of invasive 
coronary angiography and higher risk patients can have their angiography expedited. We 
identified that the use of functional tests, especially in low to intermediate risk patients, 
was suboptimal and have identified certain problematic areas where their use was very 
low. The ACC and AHA have published guidelines on coronary angiography. Although 
the guidelines were published in 1999, it is still a useful document applicable to clinical 
practice today. There is ample evidence to suggest, in multiple areas of cardiology, that 
adherence to guidelines was associated with improved patient outcomes. In our study, we 
found that the adherence to the guidelines on coronary angiography was only modest in 
certain indications and non-adherence led to a higher rate of normal coronary 
angiography. Attention should be paid to these problem areas to identify the underlying 
reasons for non-compliance so that efforts can be made by both individual physicians and 
professional bodies to improve the rate of compliance so that the full potential of these 
guidelines can be realised.  
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1. Introduction 
Quantitative coronary angiography remains the reference standard for assessing coronary 
anatomy, measuring anatomic severity of the stenotic lesion and assisting in the process of 
intracoronary interventions. Thus, treatment of coronary artery disease (CAD) is performed 
primarily on the basis of anatomic measurements of stenosis severity, although the disease 
severity correlates better with physiologic disturbances which can be revealed by the 
analysis of coronary artery flow and coronary flow reserve (CFR). Direct invasive 
measurements of coronary flow signal using Doppler flow wires and catheters provide a lot 
of information on the pathophysiology of coronary flow dynamics (Chamuleau et al, 2001; 
Bax et al, 2006; Braden, 2006; Werner et al., 2006; Kaul & Jayaweera, 2008; Courtis et al., 
2009). But in clinical practice, these invasive techniques are rarely applied because of the 
time and expense required. Alternative methodology in detecting coronary flow and CFR is 
positron emission tomography which is feasible but expensive and scarcely available (West 
& Kramer, 2009). In fact, a large-scale assessment of such important functional parameters is 
hampered by the lack of a reliable, low-cost, noninvasive method that might be used for this 
purpose (Pellikka, 2004). Some years ago transesophageal echocardiography was proposed 
for evaluation of coronary flow and CFR in man. However, this method demonstrates some 
important limitations: it is semiinvasive, and has optimal feasibility in visualizing the flow 
in only very proximal part of the left anterior descending coronary artery (LAD) (ranging 
from 69% to 97%) and right coronary artery (RCA) (ranging from 66% to 83%) which 
allowes the assessment of transstenotic or prestenotic CFR but not poststenotic CFR 
(Vrublevsky et al., 2001, 2004). Until recently, transthoracic echocardiography (TTE) 
evaluation of the CAD was aimed at the assessment of regional and global left ventricular 
function (Youn & Foster, 2004). Direct transthoracic visualization of the coronary arteries 
was attempted in children and occasionally in adults with coronary artery anomalies, 
arteriovenous fistulas, and aneurysms (Harada et al., 1999; Hiraishi et al, 2000; P.C. 
Frommelt & M.A. Frommelt, 2004). However, with the advent of harmonic imaging, 
contrast agents and high-frequency transducers, direct transthoracic Doppler visualization 
of non-dilated arteries and measurement of coronary artery flow is now relevant in the 
majority of patients. The aims of this review are to outline the technical aspects of coronary 
artery visualization and flow measurements both at rest and with pharmacological stress, to 
demonstrate pathologic coronary artery flow patterns by TTE and to discuss clinical 
implications of TTE for patients with suspected or confirmed CAD.  
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2. How coronary arteries should be visualized by TTE 
2.1 New technical considerations for transthoracic echocardiography evaluation of 
coronary arteries: high-frequency transducers, multi-frequency transducers, 
harmonic imaging and contrast agents  
One of the first reports on TTE visualization of distal LAD as a vessel with a most superficial 
location (3-7 cm from skin) was presented by Fusejima et al., 1987. However, clinical 
application of the method was limited by a low success rate of the LAD assessment because 
adequate signals were available in only 35% of control subjects and 50% of patients with 
cardiac disease. The introduction of high-frequency (7.5-MHz) transducers allowed a more 
frequent visualization of distal LAD (Ross et al., 1990; Kenny & Shapiro, 1992). But a major 
limitation of Doppler evaluation of blood flow in distal LAD associated with a low-intensity 
Doppler signal caused by ultrasound attenuation was overcome with echocontrast agents 
alone. Several reports on echocardiographic contrast enhancement of coronary artery 
images have been published and shown considerable improvement of visualization rate of 
distal LAD. Caiati et al., 1999a, 1999b, during TTE gave a peripheral injection of Levovist, a 
contrast agent consisting of a suspension of galactose microbubbles, and demonstrated 
enhanced coronary color flow Doppler signals. Lambertz et al., 1999, reported the increase 
of visualization rate of mid-distal LAD during high-frequency TTE from 40% without a 
contrast agent to 88% with Levovist. In addition, contrast administration facilitated the 
positioning of the pulsed sample Doppler volume. Okayama et al, 2002, demonstrated a 
success rate of CFR assessment in the LAD in 70% of cases without an echocontrast agent 
and in 97% after a Levovist injection with particular improvement of systolic pattern quality. 
With the routine use of contrast, coronary flow and CFR measurements in the distal LAD 
become feasible in the majority of patients. Several reports gave little information on 
transthoracic visualization of the posterior descending coronary artery (PDA) (Voci et al., 
2002; Tokai et al., 2003). Voci et al., 2002, could estimate coronary blood flow in the PDA in 
76% of patients at rest, but CFR assessment was performed in 54% of patients only because 
of hyperventilation caused by adenosine. Tokai et al., 2003, demonstrated beneficial effect of 
Levovist on coronary blood flow signals in the PDA, with increase of visualization rate from 
30% without a contrast agent to 86% with it.  
High frequency transducers can be most successfully used for scanning the apical area, that 
is for examination of distal LAD or PDA. Unlike distal LAD and PDA, non-distal LAD, 
circumflex artery (Cx) and right coronary artery (RCA) are located too deep for TTE, and 
high-frequency transducers preferred by many investigators can not be used (Boshchenko et 
al., 2008). Standard low-frequency transducers provide a good penetration and seem to be 
the optimal choice for scanning the RCA, Cx and proximal and mid LAD. Unfortunately, as 
standard cardiac low-frequency transducers have lower resolution and lower sensitivity of 
Doppler exam, low success rate of visualization of non-distal coronary arteries was reported 
in earlier studies (Voci & Pizzuto, 2001). In recent years, the advantage of using a 
multifrequency (1.7- to 3.5-MHz) transducer with second tissue harmonics lies in the fact 
that coronary flow imaging and standard TTE can be readily alternated (Pellikka, 2004), and 
it is true for estimating both distal LAD and PDA, and proximal-mid segments of coronary 
vessels. Wideband of low ultrasound frequencies of multifrequency transducers at the exit 
(1.7-3.5 MHz)  provides a good scanning depth which is particularly important for 
visualizing non-distal LAD and PDA, and second tissue harmonics enables to receive 
reflected ultrasonic waves of high-frequency range  (3,5-7 МГц)  at the entrance improving 
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the image quality for both near and far setting zones. According to our data the feasibility of 
LAD and PDA visualization with second harmonics has progressively improved, and 
harmonic imaging facilitated the examination considerably (Table 1).  
 
Authors N of  patients Transducers, contrast agents Success rate, % 
distal  LAD     
Fusejima et al., 1987    high-frequency transducer 35%healthy volunteers  50% CAD patients 
Hozumi et al.,1998a 23 high-frequency transducer 78 
Lambertz et al., 1999 45 high-frequency transducer, contrast agent  80 
Caiati et al., 1999a 56 harmonic, contrast agent 88 
Lethen et al., 2003 33 high-frequency transducer 91 
Boshchenko et al., 2008 150 harmonic 93 
Sicari et al., 2008 1779 harmonic, contrast agent 96 
PDA     
Krzanowski et al., 2000 50 harmonic 33 
Tokai et al., 2003 50 harmonic, contrast agent 86 
Takeuchi et al., 2004 151 harmonic, contrast agent 83 
Otsuka et al., 2005 129 harmonic, contrast agent 97 
Boshchenko et al., 2008 150 harmonic 91 
distal  Cx     
Krzanowski et al., 2000 50 harmonic 0 
Boshchenko et al., 2008 150 harmonic 33 
Table 1. Success rate in visualizing distal coronary arteries by TTE
2.2 Main ultrasonic windows, positions, views by which main coronary arteries can be 
visualized, and hints concerning optimization of ultrasound images of coronary 
arteries such as setting depth, Nyquist limit, Doppler angle, size of the sample volume  
Modern, high quality ultrasound systems are required for success scanning. In most cases 
TTE is performed with the help of Acuson Sequoia 512 (Acuson) or HDI 5000, HDI 5000 
SonoCT and iE33 (Philips). We used Vivid 7 (GE HealthCare) with 1.7-3.5 MHz narrow-
band transducers with second harmonic mode (Boshchenko et al., 2008, 2009).  
After obtaining optimal quality B-mode image, the search for coronary arteries is started with 
color Doppler mapping with or without the use of harmonics. To achieve the best image 
quality the sample size of color Doppler should be kept at minimum. As the Doppler velocities 
of coronary blood flow are low, the velocity range should be set with a low Nyquist limit (15-
20 cm/s), and filters should be decreased. Too low Nyquist limit can be a cause of more color 
Doppler artifacts obscuring the images (<10-13 cm/s), too high Nyquist limit is not able to 
detect low blood flow velocity within coronary arteries (Pellikka, 2004; Korsarz & Stein, 2004; 
Boshchenko et al., 2008, 2009). Some ultrasound systems offer special color maps for coronary 
artery examination including second or third harmonics of B-mode and color Doppler 
mapping, low Nyquist limit, special gain for B-mode and Doppler mode, etc.  
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76% of patients at rest, but CFR assessment was performed in 54% of patients only because 
of hyperventilation caused by adenosine. Tokai et al., 2003, demonstrated beneficial effect of 
Levovist on coronary blood flow signals in the PDA, with increase of visualization rate from 
30% without a contrast agent to 86% with it.  
High frequency transducers can be most successfully used for scanning the apical area, that 
is for examination of distal LAD or PDA. Unlike distal LAD and PDA, non-distal LAD, 
circumflex artery (Cx) and right coronary artery (RCA) are located too deep for TTE, and 
high-frequency transducers preferred by many investigators can not be used (Boshchenko et 
al., 2008). Standard low-frequency transducers provide a good penetration and seem to be 
the optimal choice for scanning the RCA, Cx and proximal and mid LAD. Unfortunately, as 
standard cardiac low-frequency transducers have lower resolution and lower sensitivity of 
Doppler exam, low success rate of visualization of non-distal coronary arteries was reported 
in earlier studies (Voci & Pizzuto, 2001). In recent years, the advantage of using a 
multifrequency (1.7- to 3.5-MHz) transducer with second tissue harmonics lies in the fact 
that coronary flow imaging and standard TTE can be readily alternated (Pellikka, 2004), and 
it is true for estimating both distal LAD and PDA, and proximal-mid segments of coronary 
vessels. Wideband of low ultrasound frequencies of multifrequency transducers at the exit 
(1.7-3.5 MHz)  provides a good scanning depth which is particularly important for 
visualizing non-distal LAD and PDA, and second tissue harmonics enables to receive 
reflected ultrasonic waves of high-frequency range  (3,5-7 МГц)  at the entrance improving 
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the image quality for both near and far setting zones. According to our data the feasibility of 
LAD and PDA visualization with second harmonics has progressively improved, and 
harmonic imaging facilitated the examination considerably (Table 1).  
 
Authors N of  patients Transducers, contrast agents Success rate, % 
distal  LAD     
Fusejima et al., 1987    high-frequency transducer 35%healthy volunteers  50% CAD patients 
Hozumi et al.,1998a 23 high-frequency transducer 78 
Lambertz et al., 1999 45 high-frequency transducer, contrast agent  80 
Caiati et al., 1999a 56 harmonic, contrast agent 88 
Lethen et al., 2003 33 high-frequency transducer 91 
Boshchenko et al., 2008 150 harmonic 93 
Sicari et al., 2008 1779 harmonic, contrast agent 96 
PDA     
Krzanowski et al., 2000 50 harmonic 33 
Tokai et al., 2003 50 harmonic, contrast agent 86 
Takeuchi et al., 2004 151 harmonic, contrast agent 83 
Otsuka et al., 2005 129 harmonic, contrast agent 97 
Boshchenko et al., 2008 150 harmonic 91 
distal  Cx     
Krzanowski et al., 2000 50 harmonic 0 
Boshchenko et al., 2008 150 harmonic 33 
Table 1. Success rate in visualizing distal coronary arteries by TTE
2.2 Main ultrasonic windows, positions, views by which main coronary arteries can be 
visualized, and hints concerning optimization of ultrasound images of coronary 
arteries such as setting depth, Nyquist limit, Doppler angle, size of the sample volume  
Modern, high quality ultrasound systems are required for success scanning. In most cases 
TTE is performed with the help of Acuson Sequoia 512 (Acuson) or HDI 5000, HDI 5000 
SonoCT and iE33 (Philips). We used Vivid 7 (GE HealthCare) with 1.7-3.5 MHz narrow-
band transducers with second harmonic mode (Boshchenko et al., 2008, 2009).  
After obtaining optimal quality B-mode image, the search for coronary arteries is started with 
color Doppler mapping with or without the use of harmonics. To achieve the best image 
quality the sample size of color Doppler should be kept at minimum. As the Doppler velocities 
of coronary blood flow are low, the velocity range should be set with a low Nyquist limit (15-
20 cm/s), and filters should be decreased. Too low Nyquist limit can be a cause of more color 
Doppler artifacts obscuring the images (<10-13 cm/s), too high Nyquist limit is not able to 
detect low blood flow velocity within coronary arteries (Pellikka, 2004; Korsarz & Stein, 2004; 
Boshchenko et al., 2008, 2009). Some ultrasound systems offer special color maps for coronary 
artery examination including second or third harmonics of B-mode and color Doppler 
mapping, low Nyquist limit, special gain for B-mode and Doppler mode, etc.  
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2.2.1 Technique of examination for each segment of main coronary arteries  
There are several windows by which coronary arteries can be visualized with the patients in 
the supine or left decubitus positions (Krzanowski et al., 2000, 2003; Saraste et al., 2005; 
Boshchenko et al., 2008). Standard parasternal short- and long-axis views from second- or 
third intercostal space or low parasternal short- or long-axis views from fourth- or fifth 
intercostal space should be used. Alternatively, a modified apical 2, 3 or 5-chamber view or 
subcostal scanning can be performed. TTE has a very high time resolution, while spatial 
resolution is low due to a small size of scanning windows. So, coronary arteries appear as 
linear intramyocardial color fragmental structures of approximately 0.5-2.5 cm in length and 
2 to 4 mm in diameter. Initially, a short part of arteries can be visualized. Then, by step-by-
step movement of the transducer according to the course of the vessel, a longer fragment of 
arteries can be assessed.  
The scanning depth for the search of proximal and mid coronary artery segments should be 
set at 10-15 cm. The transducer should be placed at the left parasternal position from second 
or third intercostal space and a modified short-axis B-view of great vessels should be 
obtained. The search of the left main coronary artery (LMCA) and proximal LAD can be 
started in B-mode (figure 1A, B) by consecutive clockwise and cranial rotation of the 
transducer, but color Doppler mapping which makes images clearer can also be 
recommended for initial search. The LMCA has approximately 1-3 cm in length, and the 
vessel should be visualized along its entire extension.  
 
 
Fig. 1. Images of the LMCA and proximal LAD (pLAD). The left parasternal position, a 
modified parasternal short axis view of great vessels, Nyquist limit is 20-67 cm/s. A – 
LMCA, B-mode; B – pLAD, B-mode; C – LMCA, Color Doppler mapping; D - bifurcation of 
the LMCA; Color Doppler mapping. 
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The normal anterograde blood flow in the LMCA is identified on color Doppler map as a 
linear structure dawning from left coronary sinus of Valsalva and has a red or blue color 
depending on the placement of the transducer, anatomic features of chest and LMCA origin 
(figure 1C). Bifurcation of the vessel into the LAD and Cx is a marker of LMCA distal board 
(figure 1D). If the origin of the Cx can not be found, the LMCA and proximal LAD should be 
assessed as a common segment. Proximal LAD should be assessed after the LMCA by a 
slight change of the imaging plane in a parasternal or low parasternal short-axis B-view or 
by change of the position in a modified parasternal long-axis view. The origin of the first 
diagonal branch can be used as a distal mark of proximal LAD (fig. 2A). Mid LAD should be 
searched in the low left parasternal position from third- to fifth intercostal spaces and a 
modified short- or long-axis view of the left ventricle in the anterior interventricular groove 
(fig 2B, C). Distal LAD should be assessed from the low left parasternal position to a 
modified apical five-chamber position at  varying levels using different  short- and long-axis 
views in the anterior interventricular groove before, at or after the apex of the left ventricle 
(fig 2D,E). The setting depth should be reduced approximately to 6-10 cm, and the 
transducer may be substituted for a high-frequency one, because the location of distal LAD 
is superficial. The LAD is the best vessel for TTE assessment as there are clear anatomic 
marks for its search and segmentation, such as: anterior interventricular groove, origin of 
the first diagonal branch and papillary muscles. The segment of the LAD from the origin of 
diagonal branch to papillary muscles in the short-axis view should be assessed as its mid 
segment, and the segment of the LAD apical to papillary muscles should be marked as distal 
LAD. Apical window is usually the best one to obtain low Doppler angles for velocity 
measurements in the LAD. The normal anterograde blood flow in the entire LAD before the 
apex is identified as a red linear color signal on color Doppler map, which reflects the 
direction of the flow from base to apex of the left ventricle. 
Unlike the LAD, the scanning depth for the RCA and Cx should be set at 12-15 cm. Proximal 
Cx should be visualized in the left parasternal position and a modified short-axis B-view of 
great vessels with the slight caudal tip of the transducer. The normal anterograde blood flow 
in proximal Cx is identified as a blue linear color signal on color Doppler map, reflecting the 
direction of the flow from the transducer (fig. 3A). There are no clear anatomic marks for the 
distal border of proximal Cx. Visualization of mid and distal segments of the Cx is very 
difficult and possible in a few patients only. Mid and distal Cx should be examined with the 
same position of the transducer as proximal Cx.  As the mid and distal Cx are located in the 
coronary sulcus at the border between the left atrium and left ventricle, the angulation from 
heart basis to apex at the level of papillary muscles is usually required (fig 3B).  The posterior 
papillary muscle can be used as a symbolic border between mid and distal Cx. The first or 
second obtuse marginal branches (OMB) presenting distal parts of the Cx can be assessed from 
fourth- and fifth intercostal spaces in the apical long-axis position in a modified four- or five-
chamber view at either lateral or inferior wall of the left ventricle (fig. 3C).  
Proximal RCA should be examined in the left parasternal position from second- or third 
intercostal spaces in modified short- or long-axis B-views as a structure dawning from right 
coronary sinus of Valsalva and lying along the anterior wall of the aorta (fig. 4A, B). It may 
be relatively easy to visualize proximal RCA in B-mode and Color Doppler mapping but 
pulse-wave Doppler examination is rarely correct because the angle between the direction of 
coronary blood flow and Doppler beam exceeds 60 degrees. The mid and distal RCA should 
be searched using Color Doppler mapping only. The subcostal position, a short-axis B-view 
or a modified apical two-chamber position with cranial angulation of the transducer should 
be used for the search of mid RCA (fig. 4C). Good quality images of the PDA – usually distal 
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2.2.1 Technique of examination for each segment of main coronary arteries  
There are several windows by which coronary arteries can be visualized with the patients in 
the supine or left decubitus positions (Krzanowski et al., 2000, 2003; Saraste et al., 2005; 
Boshchenko et al., 2008). Standard parasternal short- and long-axis views from second- or 
third intercostal space or low parasternal short- or long-axis views from fourth- or fifth 
intercostal space should be used. Alternatively, a modified apical 2, 3 or 5-chamber view or 
subcostal scanning can be performed. TTE has a very high time resolution, while spatial 
resolution is low due to a small size of scanning windows. So, coronary arteries appear as 
linear intramyocardial color fragmental structures of approximately 0.5-2.5 cm in length and 
2 to 4 mm in diameter. Initially, a short part of arteries can be visualized. Then, by step-by-
step movement of the transducer according to the course of the vessel, a longer fragment of 
arteries can be assessed.  
The scanning depth for the search of proximal and mid coronary artery segments should be 
set at 10-15 cm. The transducer should be placed at the left parasternal position from second 
or third intercostal space and a modified short-axis B-view of great vessels should be 
obtained. The search of the left main coronary artery (LMCA) and proximal LAD can be 
started in B-mode (figure 1A, B) by consecutive clockwise and cranial rotation of the 
transducer, but color Doppler mapping which makes images clearer can also be 
recommended for initial search. The LMCA has approximately 1-3 cm in length, and the 
vessel should be visualized along its entire extension.  
 
 
Fig. 1. Images of the LMCA and proximal LAD (pLAD). The left parasternal position, a 
modified parasternal short axis view of great vessels, Nyquist limit is 20-67 cm/s. A – 
LMCA, B-mode; B – pLAD, B-mode; C – LMCA, Color Doppler mapping; D - bifurcation of 
the LMCA; Color Doppler mapping. 
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The normal anterograde blood flow in the LMCA is identified on color Doppler map as a 
linear structure dawning from left coronary sinus of Valsalva and has a red or blue color 
depending on the placement of the transducer, anatomic features of chest and LMCA origin 
(figure 1C). Bifurcation of the vessel into the LAD and Cx is a marker of LMCA distal board 
(figure 1D). If the origin of the Cx can not be found, the LMCA and proximal LAD should be 
assessed as a common segment. Proximal LAD should be assessed after the LMCA by a 
slight change of the imaging plane in a parasternal or low parasternal short-axis B-view or 
by change of the position in a modified parasternal long-axis view. The origin of the first 
diagonal branch can be used as a distal mark of proximal LAD (fig. 2A). Mid LAD should be 
searched in the low left parasternal position from third- to fifth intercostal spaces and a 
modified short- or long-axis view of the left ventricle in the anterior interventricular groove 
(fig 2B, C). Distal LAD should be assessed from the low left parasternal position to a 
modified apical five-chamber position at  varying levels using different  short- and long-axis 
views in the anterior interventricular groove before, at or after the apex of the left ventricle 
(fig 2D,E). The setting depth should be reduced approximately to 6-10 cm, and the 
transducer may be substituted for a high-frequency one, because the location of distal LAD 
is superficial. The LAD is the best vessel for TTE assessment as there are clear anatomic 
marks for its search and segmentation, such as: anterior interventricular groove, origin of 
the first diagonal branch and papillary muscles. The segment of the LAD from the origin of 
diagonal branch to papillary muscles in the short-axis view should be assessed as its mid 
segment, and the segment of the LAD apical to papillary muscles should be marked as distal 
LAD. Apical window is usually the best one to obtain low Doppler angles for velocity 
measurements in the LAD. The normal anterograde blood flow in the entire LAD before the 
apex is identified as a red linear color signal on color Doppler map, which reflects the 
direction of the flow from base to apex of the left ventricle. 
Unlike the LAD, the scanning depth for the RCA and Cx should be set at 12-15 cm. Proximal 
Cx should be visualized in the left parasternal position and a modified short-axis B-view of 
great vessels with the slight caudal tip of the transducer. The normal anterograde blood flow 
in proximal Cx is identified as a blue linear color signal on color Doppler map, reflecting the 
direction of the flow from the transducer (fig. 3A). There are no clear anatomic marks for the 
distal border of proximal Cx. Visualization of mid and distal segments of the Cx is very 
difficult and possible in a few patients only. Mid and distal Cx should be examined with the 
same position of the transducer as proximal Cx.  As the mid and distal Cx are located in the 
coronary sulcus at the border between the left atrium and left ventricle, the angulation from 
heart basis to apex at the level of papillary muscles is usually required (fig 3B).  The posterior 
papillary muscle can be used as a symbolic border between mid and distal Cx. The first or 
second obtuse marginal branches (OMB) presenting distal parts of the Cx can be assessed from 
fourth- and fifth intercostal spaces in the apical long-axis position in a modified four- or five-
chamber view at either lateral or inferior wall of the left ventricle (fig. 3C).  
Proximal RCA should be examined in the left parasternal position from second- or third 
intercostal spaces in modified short- or long-axis B-views as a structure dawning from right 
coronary sinus of Valsalva and lying along the anterior wall of the aorta (fig. 4A, B). It may 
be relatively easy to visualize proximal RCA in B-mode and Color Doppler mapping but 
pulse-wave Doppler examination is rarely correct because the angle between the direction of 
coronary blood flow and Doppler beam exceeds 60 degrees. The mid and distal RCA should 
be searched using Color Doppler mapping only. The subcostal position, a short-axis B-view 
or a modified apical two-chamber position with cranial angulation of the transducer should 
be used for the search of mid RCA (fig. 4C). Good quality images of the PDA – usually distal 
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Fig. 2. Doppler Color images of the LAD. A – distal board of proximal LAD with origin of 
the first diagonal branch (I DB); B – mid LAD (mLAD), the left parasternal position, a 
modified parasternal short axis view of great vessels; C – mLAD, the left parasternal 
position, a modified parasternal long axis view; D – distal LAD (dLAD) before 
circumflexing the cardiac apex, a modified apical five chamber position; E - dLAD after 
circumflexing the apex of the left ventricle. 
RCA – can be obtained from fourth- and fifth intercostal spaces in the apical long-axis 
position in a modified two- or three-chamber view with caudal tip of the transducer in the 
posterior interventricular groove (fig. 4D). There are no anatomic marks for segmentation of 
the entire RCA. The direction of the normal mid RCA and PDA flow is the same as that of 
the normal LAD flow. 
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Fig. 3. Color Doppler images of the Cx, Nyquist limit is 20-33 cm/s. A – proximal Cx (pCx); 
the left parasternal position, a modified parasternal short-axis view of great vessels; B - mid 
Cx (mCx); the left parasternal position, a modified parasternal short-axis view at the level of 
papillary muscles; C – the first obtuse marginal branches (OMB) presenting distal Cx, the 
apical long-axis position, a modified five-chamber view. 
2.2.2 Main pitfalls at visualizing coronary arteries by TTE 
Main pitfalls of assessment of coronary arteries by TTE arise due to partial visualization of 
the vessels and anatomic features of coronary bed (Boshchenko et al., 2008). Certain large 
branches of coronary arteries – the intermediate coronary artery, diagonal and marginal 
branches can occasionally be visualized and confused with main coronary arteries, most 
frequently with the LAD (fig. 5A, B). It is more typical for the occluded main artery in which 
case the branches enlarge and take over its function (Krzanowski et al., 2003). To avoid this 
mistake, the LAD should be searched in the anterior interventricular groove along its entire 
extension with the end points in the LMCA and distal LAD. By moving step-by-step 
towards the aorta or downwards to the left ventricle apex without loosing the LAD sight, 
the LAD can be correctly identified. The diagonal and marginal branches have no 
connections with either the LMCA or distal LAD or both.  
The distinction between various vessels seen at the lateral and inferior walls of the ventricle 
can be challenging (Krzanowski et al., 2003). As first and second OMB is lying parallel and 
close to the PDA, they may be taken for the PDA. If the artery is circumflexing the posterior  
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Fig. 2. Doppler Color images of the LAD. A – distal board of proximal LAD with origin of 
the first diagonal branch (I DB); B – mid LAD (mLAD), the left parasternal position, a 
modified parasternal short axis view of great vessels; C – mLAD, the left parasternal 
position, a modified parasternal long axis view; D – distal LAD (dLAD) before 
circumflexing the cardiac apex, a modified apical five chamber position; E - dLAD after 
circumflexing the apex of the left ventricle. 
RCA – can be obtained from fourth- and fifth intercostal spaces in the apical long-axis 
position in a modified two- or three-chamber view with caudal tip of the transducer in the 
posterior interventricular groove (fig. 4D). There are no anatomic marks for segmentation of 
the entire RCA. The direction of the normal mid RCA and PDA flow is the same as that of 
the normal LAD flow. 
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Fig. 3. Color Doppler images of the Cx, Nyquist limit is 20-33 cm/s. A – proximal Cx (pCx); 
the left parasternal position, a modified parasternal short-axis view of great vessels; B - mid 
Cx (mCx); the left parasternal position, a modified parasternal short-axis view at the level of 
papillary muscles; C – the first obtuse marginal branches (OMB) presenting distal Cx, the 
apical long-axis position, a modified five-chamber view. 
2.2.2 Main pitfalls at visualizing coronary arteries by TTE 
Main pitfalls of assessment of coronary arteries by TTE arise due to partial visualization of 
the vessels and anatomic features of coronary bed (Boshchenko et al., 2008). Certain large 
branches of coronary arteries – the intermediate coronary artery, diagonal and marginal 
branches can occasionally be visualized and confused with main coronary arteries, most 
frequently with the LAD (fig. 5A, B). It is more typical for the occluded main artery in which 
case the branches enlarge and take over its function (Krzanowski et al., 2003). To avoid this 
mistake, the LAD should be searched in the anterior interventricular groove along its entire 
extension with the end points in the LMCA and distal LAD. By moving step-by-step 
towards the aorta or downwards to the left ventricle apex without loosing the LAD sight, 
the LAD can be correctly identified. The diagonal and marginal branches have no 
connections with either the LMCA or distal LAD or both.  
The distinction between various vessels seen at the lateral and inferior walls of the ventricle 
can be challenging (Krzanowski et al., 2003). As first and second OMB is lying parallel and 
close to the PDA, they may be taken for the PDA. If the artery is circumflexing the posterior  
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Fig. 4. Color Doppler images of the RCA. Nyquist limit is 17-20 cm/s. A – proximal RCA 
(pRCA); the left parasternal position, a modified parasternal short-axis view of great vessels; 
B – pRCA; the left parasternal position, a modified parasternal long-axis view. C – mid RCA 
(mRCA); a modified apical two-chamber position with cranial angulation of the transducer; 
D - the PDA as distal RCA, the apical long-axis position, a modified two-chamber view. 
surface of the apex of  the left ventricle, this vessel is detected by coronary angiography as 
the PDA in the majority of cases. On the other hand, if the artery is sending a branch to the 
posterior papillary muscle or lying next to the lateral wall of the left ventricle, this vessel is 
identified by coronary angiography as the OMB. The PDA which is usually a distal RCA 
may arise from the Cx if the left coronary artery is strongly dominant, and this fact may 
result in diagnostic mistakes too. 
In scanning mid or distal LAD, certain extracardiac arteries visualized on color Doppler 
mapping may be confused with the LAD, for example, the left internal thoracic artery 
(LIMA). However, the pulse-wave Doppler assessment allows an accurate distinction 
between them: unlike coronary arterial flow which is biphasic systole-diastolic with 
predominant diastolic phase, the extracardiac arteries show a typical peripheral arterial flow 
with high velocity predominantly systolic flow and very low anterograde or retrograde 
diastolic flow.  
As there are no clear anatomic marks for segmentation of the Cx and RCA, the pitfalls in 
assessing the place of coronary stenoses can be observed. 
Frequently, in coronary artery occlusions and retrograde filling distal to occlusions in 
particular, the mistakes in distinction between coronary artery and concomitant vein may be 
made, i.e. mid cardiac vein may be assessed as the LAD or posterior cardiac vein – as the 
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Fig. 5. Large branches of coronary arteries confused with main coronary arteries: A - the 
intermediate coronary artery, the diameter of which is equal to those of the LAD and Cx; 
pLAD – proximal LAD, pCx – proximal Cx; B – the first diagonal branch (I DB), which is 
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Fig. 4. Color Doppler images of the RCA. Nyquist limit is 17-20 cm/s. A – proximal RCA 
(pRCA); the left parasternal position, a modified parasternal short-axis view of great vessels; 
B – pRCA; the left parasternal position, a modified parasternal long-axis view. C – mid RCA 
(mRCA); a modified apical two-chamber position with cranial angulation of the transducer; 
D - the PDA as distal RCA, the apical long-axis position, a modified two-chamber view. 
surface of the apex of  the left ventricle, this vessel is detected by coronary angiography as 
the PDA in the majority of cases. On the other hand, if the artery is sending a branch to the 
posterior papillary muscle or lying next to the lateral wall of the left ventricle, this vessel is 
identified by coronary angiography as the OMB. The PDA which is usually a distal RCA 
may arise from the Cx if the left coronary artery is strongly dominant, and this fact may 
result in diagnostic mistakes too. 
In scanning mid or distal LAD, certain extracardiac arteries visualized on color Doppler 
mapping may be confused with the LAD, for example, the left internal thoracic artery 
(LIMA). However, the pulse-wave Doppler assessment allows an accurate distinction 
between them: unlike coronary arterial flow which is biphasic systole-diastolic with 
predominant diastolic phase, the extracardiac arteries show a typical peripheral arterial flow 
with high velocity predominantly systolic flow and very low anterograde or retrograde 
diastolic flow.  
As there are no clear anatomic marks for segmentation of the Cx and RCA, the pitfalls in 
assessing the place of coronary stenoses can be observed. 
Frequently, in coronary artery occlusions and retrograde filling distal to occlusions in 
particular, the mistakes in distinction between coronary artery and concomitant vein may be 
made, i.e. mid cardiac vein may be assessed as the LAD or posterior cardiac vein – as the 
 
Transthoracic Echocardiography in the Assessment of Coronary Arteries 29 
Fig. 5. Large branches of coronary arteries confused with main coronary arteries: A - the 
intermediate coronary artery, the diameter of which is equal to those of the LAD and Cx; 
pLAD – proximal LAD, pCx – proximal Cx; B – the first diagonal branch (I DB), which is 
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PDA (fig 6). As veins are larger, located closer to the right ventricle than arteries and 
demonstrate a three-phase predominantly systolic flow with very high respiratory 
variations, it is not very difficult to differentiate between the vessels. Krzanowski et al., 2003 
and Youn & Foster, 2004, observed that a strong signal confusing coronary artery flow may 
 
 
Fig. 6. Distinction between the posterior descending coronary artery (PDA) and concomitant 
posterior cardiac vein (PCV): A – the PDA is slighter, located closer to the left ventricle and 
demonstrates a biphasic predominantly diastolic flow without respiratory variations; B – the 
PCV is larger, located closer to the right ventricle and demonstrates a three-phase 
predominantly systolic flow with high respiratory variations; C- simultaneous image of the 
PDA and PCV. 
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be generated by pericardial fluid, but the flow within the pericardial sac is most pronounced 
in systole while the coronary artery flow is predominantly diastolic. We did not have similar 
difficulties in our practice. 
2.3 Feasibility of transthoracic echocardiography in visualizing coronary arteries  
Feasibility of TTE in visualizing coronary arteries with the addition of harmonics, newer 
transducers, and contrast agents has been reported to be as high as 100% for distal LAD and 
33-97% for the PDA (table 1). Imaging of the entire Cx and proximal and mid RCA has been 
possible with a low rate (table 1, Kenny & Shapiro, 1992; Krzanowski et al., 2000, Watanabe 
et al., 2001; Saraste et al, 2006, etc.). Our data (Boshchenko et al., 2008) of TTE feasibility in 
the assessment of main coronary arteries with both success Color Doppler mapping and 
good quality of pulse-wave Doppler recording presented in tables 2 and 3 agree with the 
data of other authors. TTE demonstrated adequate success rate of color Doppler mapping of 
the LMCA, all LAD segments and PDA, and poor feasibility in detecting other segments of 
main coronary arteries.  
 
Vessel proximal segment mid segment distal segment 
LMCA 70 
LAD 82 83 93 
Cx 35 5 31 
RCA 25 35 95 






or mid or distal) 
two segments (proximal and mid
or proximal and distal or mid 
and distal) 
three segments 
(proximal and mid and 
distal) 
LAD 93 92 68 
Cx 35 0 0 
RCA 95 51 6 
Table 3. Success rate of the detection of one and more segments of each coronary artery by 
TTE (%) (Boshchenko et al, 2008) 
Thus, although this technique requires experience and practice, and only skilled operators 
can be expected to achieve a 90% success rate in visualizing the coronary arteries, it is 
possible to use current technology in a clinical setting. 
2.4 Normal Doppler systole-diastolic coronary flow pattern and coronary blood flow 
velocity at rest  
2.4.1 Pulse-wave Doppler recording of coronary blood flow velocity by TTE 
With pulse-wave Doppler assessment efforts should be directed at maintaining the optimal 
Doppler angle, and size of the sample volume (Hozumi et al., 1998a, 1998b; Caiati et al, 
1999a, 1999b). The angle of incidence between the Doppler beam and flow direction should 
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PDA (fig 6). As veins are larger, located closer to the right ventricle than arteries and 
demonstrate a three-phase predominantly systolic flow with very high respiratory 
variations, it is not very difficult to differentiate between the vessels. Krzanowski et al., 2003 
and Youn & Foster, 2004, observed that a strong signal confusing coronary artery flow may 
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posterior cardiac vein (PCV): A – the PDA is slighter, located closer to the left ventricle and 
demonstrates a biphasic predominantly diastolic flow without respiratory variations; B – the 
PCV is larger, located closer to the right ventricle and demonstrates a three-phase 
predominantly systolic flow with high respiratory variations; C- simultaneous image of the 
PDA and PCV. 
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be generated by pericardial fluid, but the flow within the pericardial sac is most pronounced 
in systole while the coronary artery flow is predominantly diastolic. We did not have similar 
difficulties in our practice. 
2.3 Feasibility of transthoracic echocardiography in visualizing coronary arteries  
Feasibility of TTE in visualizing coronary arteries with the addition of harmonics, newer 
transducers, and contrast agents has been reported to be as high as 100% for distal LAD and 
33-97% for the PDA (table 1). Imaging of the entire Cx and proximal and mid RCA has been 
possible with a low rate (table 1, Kenny & Shapiro, 1992; Krzanowski et al., 2000, Watanabe 
et al., 2001; Saraste et al, 2006, etc.). Our data (Boshchenko et al., 2008) of TTE feasibility in 
the assessment of main coronary arteries with both success Color Doppler mapping and 
good quality of pulse-wave Doppler recording presented in tables 2 and 3 agree with the 
data of other authors. TTE demonstrated adequate success rate of color Doppler mapping of 
the LMCA, all LAD segments and PDA, and poor feasibility in detecting other segments of 
main coronary arteries.  
 
Vessel proximal segment mid segment distal segment 
LMCA 70 
LAD 82 83 93 
Cx 35 5 31 
RCA 25 35 95 






or mid or distal) 
two segments (proximal and mid
or proximal and distal or mid 
and distal) 
three segments 
(proximal and mid and 
distal) 
LAD 93 92 68 
Cx 35 0 0 
RCA 95 51 6 
Table 3. Success rate of the detection of one and more segments of each coronary artery by 
TTE (%) (Boshchenko et al, 2008) 
Thus, although this technique requires experience and practice, and only skilled operators 
can be expected to achieve a 90% success rate in visualizing the coronary arteries, it is 
possible to use current technology in a clinical setting. 
2.4 Normal Doppler systole-diastolic coronary flow pattern and coronary blood flow 
velocity at rest  
2.4.1 Pulse-wave Doppler recording of coronary blood flow velocity by TTE 
With pulse-wave Doppler assessment efforts should be directed at maintaining the optimal 
Doppler angle, and size of the sample volume (Hozumi et al., 1998a, 1998b; Caiati et al, 
1999a, 1999b). The angle of incidence between the Doppler beam and flow direction should 
Coronary Angiography 
– Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 32
be minimized, less than 30 degrees being optimal for coronary artery. The sample volume or 
gate should be reduced (1.5-3.0 mm) and positioned within the coronary artery (Pellikka, 
2004). We usually use a 2-3 mm gate for pulse-wave Doppler, a 3 mm gate for proximal 
segments and a smaller gate (2 mm) for distal segments. 
2.4.2 Normal Doppler systole-diastolic coronary flow pattern in coronary arteries  
According to coronary physiology, most coronary flow occurs during diastole with a 
smaller systolic component (fig. 7) (Gould et al, 1974; Bax, 2006). So, coronary blood flow on 
pulse-wave Doppler image is presented as continuous, biphasic systole-diastolic flow with 
predominant diastolic phase and low velocities. 
2.4.3 Normal Doppler coronary flow velocities at rest 
Transthoracic measurements of coronary flow velocity are proved to be highly reproducible 
and correlate with invasive measurements and measurements with positron emission 
tomography (Hozumi et al., 1998a; Caiati et al, 1999a, 1999b, Lethen et al., 2003; Ueno et al., 
2002b). The measurements can include assessment of peak velocity, time velocity integral, 
and mean velocity in systole and diastole (fig. 8). But, in evaluating coronary flow, most 
investigators measure the diastolic component, and peak diastolic blood flow velocity is 
assessed most frequently as an easily and quickly estimated characteristic. The duration of 
diastolic and systolic flow is another potential measure (Crowley & Shapiro, 1998; Hozumi 
et al., 2000; Daimon et al., 2005; Youn et al., 2005). 
 
 
Fig. 7. Doppler examination in the PDA: A – laminar flow in the PDA is presented by red 
linear structure on color Doppler map; B - velocity pattern registered by pulse-wave 
Doppler; s – systolic phase, d – diastolic phase. 
In previous works, control subjects with normal coronary angiograms and normal left 
ventricular systolic function showed that the peak diastolic velocity in distal LAD was 
21.27.9 cm/s and the duration of diastolic coronary artery flow was 58.56.4% of the R-R 
interval at rest within the range of physiologic heart rates (60-100 b/m) (Youn et al, 2002). In 
studies including the participants without significant LAD stenosis, the peak diastolic 
velocity in distal LAD was ranging from 218 cm/s to 289 cm/s (Hozumi et al, 1998a, 
1998b; Youn et al, 2002; Pizzuto et al, 2004). In our study (Boshchenko et al., 2008) with 
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Fig. 8. Scheme of normal coronary blood flow pattern;  Vps and Vpd – systolic and diastolic 
peak coronary flow velocities, VTIs and VTId – systolic and diastolic time velocity integrals, 
ATs  and ATd – acceleration time in systole and diastole. 
healthy volunteers the coronary flow characteristics were comparable in the conforming 
segments of the LAD, Cx and RCA, and coronary flow velocities showed a non-significant 
decrease from proximal segments to distal segments of coronary arteries (tab. 4). But the 
limits of normal distal LAD flow at rest have not yet been largely settled due to the 
multitude of variables affecting the baseline coronary flow velocity. 
 
 
Characteristics  proximal LAD (n=17) mid LAD (n=16) distal LAD (n=17) 
Vps , cm/s 17 (15-21) 14 (12-16) 14 (13-15) 
Vms , cm/s 13 (12-16) 11 (9-12) 11 (9-12) 
VTIs , cm  3.7 (3.2-4.9)  3.3 (2.7-3.7)  2.8 (2.2-3.6)  
ATs, ms 118 (107-126) 111 (89-118) 111 (96-111) 
Vpd , cm/s 28 (22-35)  25 (22-30)  25 (21-27)  
Vmd , cm/s 22 (16-27) 19 (16-22) 19 (16-20) 
VTId , cm  10.9 (7.9-13.8)  10.6 (8.8-13.5)  10.4 (8.6-11.9)  
ATd, ms 204 (126-244) 200 (155-222) 156 (133-171) 
Table 4. Coronary blood flow in the LAD (mediana (range)). Vps and Vpd – systolic and 
diastolic peak coronary flow velocity, Vms and Vmd – systolic and diastolic mean coronary 
flow velocity, VTIs and VTId – systolic and diastolic time velocity integrals, ATs  and ATd – 
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3. Detection of coronary artery stenosis and occlusion by TTE at rest 
In adults, TTE is successfully attempted for detection of coronary artery anomalies, 
arteriovenous fistulas, and coronary aneurysms (Harada et al., 1999; Hiraishi et al., 2000; 
P.C. Frommelt & M.A. Frommelt, 2004). Thus, the overall sensitivity and specificity of TTE 
for accurate identification of coronary aneurysms are 95% and 99%, respectively (Hiraishi et 
al, 2000). Unlike aneurysms, direct visualization of atherosclerotic plaques in non-dilated or 
mild-dilated coronary arteries with the help of TTE is rather an exception. Accordingly, TTE 
can not assess correctly the structure and length of atherosclerotic plaques.  Unlike 
computed tomography, TTE as well as coronary angiography detects coronary stenoses 
basing not on visualizing atherosclerotic plaque per se but revealing stenosis of coronary 
artery lumen in the site of the plaque. But coronary angiography examines anatomy of the 
entire coronary tree by assessing multipositional images of coronary artery lumen, while 
TTE assesses primarily the function of coronary vessels by detecting stenosis as focal zones 
with acceleration and turbulence of coronary blood flow. 
3.1 Direct detection of atherosclerotic plaques and assessment of coronary artery 
wall thickness  
Direct detection of atherosclerotic plaques is rarely possible. It is reliable only in case of a 
major proximal plaque with acoustic shadow due to calcium (fig. 9).  Maxted et al, 1998, 
tried to search for coronary artery stents in proximal and mid LAD, using increased 
echogenicity, markedly thickened walls of the artery in the stent site, and a stented lumen 
 
 
Fig. 9. The cascade proximal plaques with calcium in proximal LAD. B-mode. 
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with relatively straight edges and a diameter approximately equal to that of the deployed 
stent. Stents were determined in 10 of 13 cases, but examinations were time consuming, each 
taking approximately 60 minutes to obtain, process, and review the images. Despite our 
optimism with this technology, we realize that this method for direct assessment of the 
plaques and stents per se has several limitations. 
On the other hand, intravascular ultrasound and epicardial echocardiography studies have 
demonstrated that coronary atherosclerosis is a diffuse pathological process and before 
CAD is clinical evident, >90% of the coronary artery tree is atherosclerotic. So, coronary 
artery wall structure, artery lumen diameter and their qualitative or quantitative changes 
can be predictors of coronary artery stenosis and direct markers of coronary vasomotor 
function (Voci & Pizzuto, 2001). High-frequency TTE using a 7.5 or 10 MHz transducer can 
be used to correctly and accurately measure the wall thickness and diameter of distal LAD 
and to detect their changes (Kenny et al., 1990; Perry et al., 208a, 2008b). Takeuchi et al, 2006, 
demonstrated that wall thickness and external diameter of the LAD enlarged with the 
increase of the number of CAD risk factors, and wall thickness of the LAD >0.72 mm was a 
predictor of LAD stenosis with 74% sensitivity and 87% specificity. Perry et al, 2008a, found 
the wall thicknesses and external diameters of the LAD in patients with CAD to be 
significantly larger than those in normal volunteers, indicating atherosclerotic buildup. TTE 
can detect vasodilating effects of nitroglycerin and salbutamol on the LAD, correlating with 
peripheral vascular reactivity to these vasodilators (Perry et al, 2008b). So, TTE is a probably 
useful tool for noninvasive assessment of coronary vasoreactivity and provides a chance to 
be a surrogate marker of coronary stenosis (Perry et al, 2008а, 2008b). 
3.2 Main Doppler principles of the detection of coronary stenosis by TTE  
The detection of coronary stenosis by TTE should be performed basing on Doppler methods 
– color Doppler mapping and pulse-wave Doppler recoding.  
3.2.1 Focal aliasing and flow acceleration in the site of a significant stenosis  
First, Color Doppler mapping should be used for stenoses search. Even at low Nyquist 
limits (13-18 cm/s), the color Doppler flow pattern in the normal coronary artery is 
uniformly consistent with laminar flow. The focal flow acceleration and turbulence may be 
detected as aliasing zone on color Doppler map and can assist in localizing the stenosis site 
(Krzanowski et al, 2000; Hozumi et al., 2000; Takeuchi et al., 2001; Saraste et al., 2005). 
Second, Doppler velocity patterns should be registered by pulse-wave Doppler.  If Doppler 
color mapping shows a color laminar flow, Doppler velocity patterns should be obtained in 
the site with the best signal on color Doppler map. If a local increase of the velocity appears 
on Doppler colour flow map as a localized area of aliased and disturbed signal, Doppler 
velocity patterns should be obtained in the site of alising (fig. 10). 
Third, coronary blood flow should be measured. Velocities of coronary blood flow in the 
stenosis site are increased compared with non-stenosis sites (both prestenotic and 
poststenotic) (Hozumi et al., 2000, Okayama et al., 2008). Some authors have shown 
redistribution of coronary flow in LAD stenosis with the increase of systolic wave due to 
stenosis and decrease of diastolic-to-systolic velocity ratio in the poststenotic site (Crowley 
& Shapiro, 1998; Daimon et al., 2005). There are transthoracic quantitative diagnostic 
markers of coronary artery stenosis >50%, offered by Krzanowski et al, 2000, and 
Anjaneyulu et al., 2008, based on the measurement of peak diastolic velocity in the stenosis 
site. The peak diastolic velocity >1.5 m/s has demonstrated 85% sensitivity and 88%  
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with relatively straight edges and a diameter approximately equal to that of the deployed 
stent. Stents were determined in 10 of 13 cases, but examinations were time consuming, each 
taking approximately 60 minutes to obtain, process, and review the images. Despite our 
optimism with this technology, we realize that this method for direct assessment of the 
plaques and stents per se has several limitations. 
On the other hand, intravascular ultrasound and epicardial echocardiography studies have 
demonstrated that coronary atherosclerosis is a diffuse pathological process and before 
CAD is clinical evident, >90% of the coronary artery tree is atherosclerotic. So, coronary 
artery wall structure, artery lumen diameter and their qualitative or quantitative changes 
can be predictors of coronary artery stenosis and direct markers of coronary vasomotor 
function (Voci & Pizzuto, 2001). High-frequency TTE using a 7.5 or 10 MHz transducer can 
be used to correctly and accurately measure the wall thickness and diameter of distal LAD 
and to detect their changes (Kenny et al., 1990; Perry et al., 208a, 2008b). Takeuchi et al, 2006, 
demonstrated that wall thickness and external diameter of the LAD enlarged with the 
increase of the number of CAD risk factors, and wall thickness of the LAD >0.72 mm was a 
predictor of LAD stenosis with 74% sensitivity and 87% specificity. Perry et al, 2008a, found 
the wall thicknesses and external diameters of the LAD in patients with CAD to be 
significantly larger than those in normal volunteers, indicating atherosclerotic buildup. TTE 
can detect vasodilating effects of nitroglycerin and salbutamol on the LAD, correlating with 
peripheral vascular reactivity to these vasodilators (Perry et al, 2008b). So, TTE is a probably 
useful tool for noninvasive assessment of coronary vasoreactivity and provides a chance to 
be a surrogate marker of coronary stenosis (Perry et al, 2008а, 2008b). 
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The detection of coronary stenosis by TTE should be performed basing on Doppler methods 
– color Doppler mapping and pulse-wave Doppler recoding.  
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Fig. 10. Examples of Color Doppler flow mapping of distal RCA presented by PDA: upper 
panel – patient C. without RCA stenosis: artery color flow map is red indicating low velocity 
with peak diastolic flow velocity (Vpd) equal to 25 cm/s; lower panel – patient S. with 75% 
stenosis of mid RCA: Changes in the color flow map for color aliasing in the stenosis site 
and distal to it with Vpd acceleration up to 80 cm/s. 
specificity diastolic velocity >1.5 m/s has demonstrated 85% sensitivity and 88% specificity 
in the detection of LMCA stenosis>50% (Anjaneyulu et al., 2008). Krzanowski et al., 2000, 
and Saraste et al., 2005, showed that a local peak diastolic flow velocity >2.0 m/s could be 
used as a sign of diameter reduction>50% for all three main coronary arteries. It seems 
attractive and easy to detect coronary stenoses basing on the search of the aliasing zone and 
the measurement of peak diastolic flow velocity only, but both methods are semi-
quantitative and, unfortunately, inaccurate. As previously reported, laminar peak diastolic 
velocity in the coronary artery is from 0.21 ± 0.08 m/s (Youn et al., 2002, Hozumi et al., 1998) 
to 0.28 ± 0.09 m/s (Pizzuto F., 2004), and the velocity will not exceed 1 m/s even in case of 
its 3-4-fold increase in the stenosis site. So, local peak diastolic flow velocity >2.0 m/s is a 
highly specific, but low sensitive marker of coronary artery stenosis. On the other hand, 
some other reasons, such as reologic factors, heart rate, etc. can cause disturbed Doppler 
signal, hence local aliasing may be a highly sensitive but low specific sign of coronary 
stenosis. So, Hozumi et al, 2000, have observed localized aliasing by color flow mapping in 
100% of patients with LAD restenosis >50% after percutaneous transluminal coronary 
d
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angioplasty (PTCA), and 56% of patients without restenosis. Finally, both markers are 
strongly dependent on different hemodynamic factors (perfusion pressure, heart rate, blood 
pressure, myocardial mass, etc.) and technical setting (depth of scanning, quality of pulse-
wave Doppler pattern, angle of incidence between the Doppler beam and flow direction, 
etc).  So, most authors have supposed that the ratio of stenotic-to-prestenotic diastolic 
velocity is more correct and allows an exclusion or minimization of hemodynamic influence.  
3.2.2 The ratio of stenotic to prestenotic blood flow velocity  
To measure the stenotic to prestenotic velocity ratio, the localized color aliasing 
corresponding to local flow acceleration should be searched first to obtain coronary flow 
velocity in the stenosis site. When localized aliasing is detected, the sample volume of pulse-
wave Doppler should be set at the aliasing and Doppler velocity pattern should be recorded. 
Then, the sample volume should be slightly moved from the aliasing to the prestenosis site 
and spectral Doppler recording should be made again (fig. 11).  
 
 
Fig. 11. 70% stenosis in mid LAD. Left panel – prestenosis site; right panel – stenosis site; 
Vpd – peak diastolic blood flow velocity. The stenotic to prestenotic flow velocity ratio is 
60/22 = 2.72 (>2.0).  
Krzanowski et al., 2000, and Saraste et al., 2005, determined the stenotic-to-prestenotic peak 
blood flow velocity ratio over than 2.0 to be a sign of >50% stenosis  with 62-100% sensitivity 
and 92-100% specificity for the LAD, 63% sensitivity and 96% specificity for the RCA, and 
38% sensitivity and 99% specificity for the Cx. The same sensitivity (86%) and specificity 
(93%) were demonstrated by Hozumi et al., 2000, for the ratio of prestenotic-to-stenotic 
mean diastolic velocity <0.45 in the detection of LAD restenosis after PTCA.  ТТЕ with the 
use of both a local peak diastolic flow velocity >2.0 m/s and stenotic-to-prestenotic peak 
blood flow velocity ratio >2.0 permitted to reveal 48% of all LAD stenoses, 30% of all Cx 
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stenoses and 14% of all RCA stenoses (Krzanowski et al., 2000). Like the assessment of peak 
diastolic velocity this approach is easy, semi-quantitative and, though to a lesser extent, 
dependent on hemodynamic factors too. On the other hand, it is known that volume blood 
flow velocity in the prestenosis site is equal to that in the stenosis one, and, assuming the 
constant artery diameter and measuring diastolic time velocity integrals in both stenosis and 
prestenosis sites, the vessel % stenosis can be calculated according to a modified continuity 
equation. The feasibility of this approach for transesophageal echocardiography was 
demonstrated by Isaaz et al, 1998 (as cited in Vrublevsky et al., 2001). We use this concept 
for TTE. Diastolic time velocity integral (VTId) is measured in stenosis and prestenosis sites, 
and the stenosis % area is calculated as: stenosis, % = 100  (1 - prestenotic VTId / stenotic 
VTId) (fig.12). The sensitivity and specificity of >50% stenosis identification by a modified 
continuity equation in the LAD are 72% and 96%, in the Cx - 40% and 94%, and in the RCA – 
50% and 93%, respectively, for the segments which are successfully visualized (Boshchenko 
et al., 2008). The data on all segments, successfully visualized and unvisualized, are shown 



















1 0 0 1 - 100 - 97 
LAD (n=300) 55 39 8 24 56 96 79 89 
Cx (n=300) 28 6 4 26 7 94 33 70 
RCA (n=300) 47 21 9 35 26 93 57 78 
Table 5. Diagnostic accuracy of Doppler TTE in the detection of >50% stenosis in main 
coronary arteries (Boshchenko et al., 2008). 
Thus, TTE is highly specific for identification of coronary stenosis >50%, but, being low 
sensitive for Cx and RCA stenosis, may be helpful as a screening tool for LMCA and LAD 
stenosis >50%, limiting the use of groundless catheterization.   
3.3 Main Doppler principles of the detection of coronary occlusion by TTE  
TTE permits visualizing separate segments of coronary arteries only, and the detection of 
coronary occlusion as well as stenoses by TTE should be performed basing on Doppler 
color-coding of the flow velocity and direction. The first offered TTE sign of coronary artery 
occlusion was the absence of coronary blood flow on color Doppler map, and it 
demonstrated very low feasibility of the method (Krzanowski et al., 2000) because it was 
difficult to differentiate between real absence of coronary flow due to occlusion and absence 
of visualization of coronary artery due to TTE limitations. So, at present, TTE does not seem 
to be a suitable method for the assessment of acute coronary occlusions. But transthoracic 
color-Doppler ultrasound can be useful after acute myocardial infarction for the detection of 
an open LAD, reflecting adequate myocardial reperfusion basing on anterograde flow in the 
LAD alone or together with perforators (Voci et al, 2002).   
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Fig. 12. Calculation of stenosis % area of proximal LAD according a modified continuity 
equation by TTE. A - scheme of calculation by TTE; B - example of Doppler flow patterns in 
patient with 35% stenosis according to coronary angiography data; C - Doppler flow 
patterns in patient with 60% stenosis; D - Doppler flow patterns in patient with 80% 
stenosis; VTId – diastolic time velocity integral  
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difficult to differentiate between real absence of coronary flow due to occlusion and absence 
of visualization of coronary artery due to TTE limitations. So, at present, TTE does not seem 
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Unlike acute occlusion, chronic total coronary occlusion (CTO) of over 1-month duration leads 
to the formation of stable collateral coronary pathways (Werner & Figulla, 2002; Braden, 2006; 
Werner et al., 2006). Recently, feasibility of TTE for the CTO identification of the LAD and 
RCA has been established. Watanabe et al., 2001, proposed the inversion of the coronary blood 
flow in the epicardial collateral vessels on color Doppler map to be a main ultrasound sign of 
CTO. It has been established that retrograde flow in distal LAD is a good marker of LAD 
occlusion with 88% sensitivity  and 100% specificity (Hirata et al., 2004) and retrograde flow in 
the PDA is a good marker of RCA occlusion with 67% sensitivity and 100% specificity (Otsuka 
et al., 2005). But Pizzuto et al., 2006, doubted such a high sensitivity of TTE in the detection of 
LAD occlusion having revealed a retrograde flow in distal LAD in only 43% of patients with 
CTO and normal anterograde flow in more than half patients (55%). Angiography data 
demonstrate that in LAD and RCA occlusions, besides collateral flow distal to the occluded 
region through the connections on the epicardial surface, 63-86% of patients have 
intramyocardial collateral channels lying usually in the interventricular septum. According to 
these findings an additional examination of the retrograde flow in the septal branches of the 
LAD and RCA has demonstrated the increase of TTE sensitivity in the CTO detection from 88 
to 96% for the LAD (Hirata et al., 2004) and from 67 to 80% for the RCA (Otsuka et al., 2005, 
Saraste et al., 2005).  
According to our data (Boshchenko et al., 2009), the sensitivity and specificity of retrograde 
flow for identification of the occluded LAD by TTE in distal LAD alone were 77% and 97%, 
and those in both distal LAD and septal branches of the LAD - 85% and 97%, respectively. 
The sensitivity and specificity of retrograde flow for identification of the occluded RCA by 
TTE in the PDA alone were 77% and 98%, and those in both the PDA and septal branches of 
the RCA - 88% and 98%, respectively. Basing on these data the following order of TTE 
detection of LAD and RCA occlusion could be offered. First, potential epicardial collateral 
vessels should be examined. The retrograde flow in distal LAD will be a highly specific 
marker of LAD occlusion, and the retrograde flow in the PDA will be a sign of RCA 
occlusion, respectively. In this case, the examination can be stopped. Second, if the flow in 
distal LAD and RCA is anterograde,  the septal (intramyocardial) collateral pathways of the 
LAD and RCA should be examined additionally, because 8% of patients with LAD CTO and 
11% of patients with RCA CTO demonstrate an inversion of the flow direction in the septal 
branches only (Boshchenko et al, 2009) (fig. 13). Unlike the LAD and RCA, low success rate 
of visualization of the Cx does not allow the use of TTE for CTO detection. 
TTE detection of CTO is based on the identification of coronary blood flow direction alone 
without the assessment of the rest Doppler coronary flow velocities and, thus, it does not 
depend on the hemodynamic conditions of the patients and does not require 
discontinuation of the therapy including antianginal, hypotensive, and antiarrhythmic 
drugs. So, TTE can be used in unstable patients, patients with life-threatening rhythm and 
conductance disturbances. TTE can be rather an attractive non-invasive method with little 
time consumption and good specificity in standardized approach, answering the principal 
question – whether the LAD or RCA is chronically opened or closed. The length and 
accurate site of CTO can not be assessed by TTE.  
4. Noninvasive assessment of coronary flow reserve in main coronary 
arteries by TTE  
Over the last two decades it has been demonstrated that measurements of coronary flow 
reserve (CFR) are a diagnostic approach providing a lot of additional information on the 
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Fig. 13. Patient B. Proximal occlusion of the right coronary artery (RCA). Examples of the 
retrograde coronary blood flow in septal branch of the RCA and in the PDA 
(intramyocardial and epicardial collateral flow, respectively). 
function of coronary artery and assisting in the decision-making process of cardiac 
interventions. Reserve of coronary blood flow is defined as the ability of coronary flow 
volume to increase under maximal coronary hyperemia when compared with coronary flow 
volume at rest. Coronary flow velocity correlates well with flow volume, and measurements 
of the ratio of hyperemic-to-rest coronary flow velocity can substitute direct measurements 
of the ratio of hyperemic-to-rest flow volume. At present, intracoronary Doppler with 
adenosine or papaverine infusion remains to be the reference standard for the assessment of 
coronary flow velocity reserve (CFVR) in vivo. In normal coronary bed, microvascular flow 
at rest is low-optimal for the maintenance of wall perfusion, and it increases at stress due to 
maximal peripheral vasodilatation according to myocardial demand; normal epicardial 
coronary artery with a high degree of elasticity under these conditions demonstrates a high 
CFVR. In agreement with experimental and intracoronary wire studies (Gould et al., 1974; 
Gould & Lipscomb, 1974), three main mechanisms, alone or in combination, may explain 
why coronary flow does not increase or even decreases during adenosine infusion in 
stenosis. First, in mild, moderate or tight severe stenoses, CFVR reflects the state of 
microcirculation to a greater degree. Epicardial stenoses induce increased resistance to flow, 
and microvascular resistant vessels already are dilated maximally at rest to maintain the 
basal flow. Therefore, a hyperemic stimulus results in a smaller increment of poststenotic 
flow, and the change of flow or the ratio of hyperemic-to-rest flow are less, and CFVR distal 
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CFVR. In agreement with experimental and intracoronary wire studies (Gould et al., 1974; 
Gould & Lipscomb, 1974), three main mechanisms, alone or in combination, may explain 
why coronary flow does not increase or even decreases during adenosine infusion in 
stenosis. First, in mild, moderate or tight severe stenoses, CFVR reflects the state of 
microcirculation to a greater degree. Epicardial stenoses induce increased resistance to flow, 
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to the stenosis site is reduced. Second, in incompletely calcified severe coronary stenosis, the 
coronary artery preserves some degree of elasticity and may collapse during adenosine 
infusion allowing a decrease in intraluminal tense pressure, which is induced by flow 
acceleration in the stenosis site. This collapse may translate distally into a damped flow 
producing at times a coronary steal effect. Third, prestenotic collaterals may be opened at 
stress, causing coronary redistribution from the critically hypoperfused bed to less stenotic 
regions. So, CFVR should be measured in the most distal part of the epicardial artery for 
assessing its function along the entire length. 
TTE is a good method for detection of distal flow in the LAD and PDA (usually distal RCA), 
and it has the main advantage among other noninvasive technologies being valid for easy, 
fast, direct assessment of distal CFVR. That is particularly important in cases of repeated 
monitoring of stenosis progressive changes.  Hozumi et al, 1998a, 1998b, performed the first 
validation of TTE comparing CFVR in the LAD with simultaneous intracoronary Doppler 
guide wire assessment. TTE reflected invasive measurement of coronary flow velocity and 
CFVR accurately, and the agreement between the two methods was 0.97 for averaged 
diastolic and systolic peak velocities, 0.98 for diastolic peak velocity and 0.97 for CFVR. A 
very good correlation was observed between TTE and intracoronary Doppler guide wire not 
only for the LAD (Caiati et al., 1999a, 1998b; Lethen et al., 2003) but for the PDA as well 
(Ueno et al., 2002b). The correlation ranging from 0.79 to 0.97 has been reported for 
noninvasive techniques compared with invasive ones in cases of decision-making process 
(Hozumi et al., 1998a, 1998b; Caiati et al., 1999a, 1998b) and intracoronary intervention 
(Lethen et al., 2003). Thus, TTE can be used as a possible substitute of the invasive method 
for correct clinical measurement of CFVR, particularly in the LAD.    
4.1 Comparison and choice of optimal stress agents for transthoracic measurement 
of CFR 
A variety of agents can be used as vasodilators to examine CFVR by TTE including 
adenosine, dipyridamole and dobutamine with or without additional atropine (Pellikka, 
2004; Korsarz & Stein, 2004). All drugs have potent endothelium-independent vasodilating 
properties, but act by different mechanisms. Dobutamine increases metabolic myocardial 
demand inducing the rise of rate-pressure product, and accordingly contributes to the 
increase of coronary flow. Both adenosine and dipyridamole induce coronary arteriolar 
vasodilatation associated with hyperemic coronary flow as a result of stimulation of 
adenosine A2-receptors on arteriolar smooth-muscle cells causing vasorelaxation.  
As dobutamine stress echocardiography is widely available, it is appropriate to consider a 
combination of CFVR examinations and these tests (Pellikka, 2004). But dobutamine infused 
with the traditional rate of 5-10-20 mcg/kg/min induces a smaller acceleration of the flow 
and lower CFVR than adenosine as a reference standard (Meimoun et al., 2006). Similar 
CFVR values can be obtained with two drugs at peak dobutamine infusion only (with the 
infusion rate of 40 mcg/kg/min). But it is not always possible in patients with positive 
dobutamine stress echocardiography and chest pain. Furthermore, CFVR assessment with 
recording of the LAD or RCA flow velocity at each step is time-consuming and requires an 
average of 25-30 minutes. A number of technical difficulties during TTE with dobutamine 
also must be stressed because a high heart rate and consequently a reduced diastolic filling 
time and increased myocardial contractility can impair good-quality recording of the 
coronary flow pattern. This is particularly true for very high heart rates at peak stress test.  
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Like intracoronary Doppler wire assessment of CFVR, adenosine, a direct coronary 
vasodilator, seems to be a drug of the first choice for TTE. Intravenous adenosine has a short 
half-life (8-10 seconds) inducing rapid onset of vasodilatation and resulting in short 
examination periods. CFVR assessment may be performed at bedside within a few minutes. 
Adenosine should be infused intravenously at the rate of 140 mcg/kg/min for 2 minutes.  
Coronary flow velocities are measured before and immediately after the cessation of 
adenosine infusion. But if simultaneous evaluation of regional function is necessary, 
repeated infusion of adenosine is required, and the effect of ischemic preconditioning can be 
observed. Adenosine may be a cause of adverse effects, attributed to nonselective 
stimulation of the A1-, A2B-, and A3-receptors, because of its lack of specificity for the A2-
receptors. Among these effects, arterial hypotension, dyspnea and chest discomfort are 
frequent and tend to impair LAD flow velocity recording during hyperemia. 
Dipyridamole is an indirect vasodilator, decreasing the cellular uptake of adenosine and 
increasing its endogenous level. Compared with adenosine, the duration of the infusion is 
longer (0.56 mg/kg for 4 minutes or 0.84 mg/kg for 6 minutes) and, depending on the dose 
administered and infusion rate, its effects can last up to 30 minutes allowing a combined 
CFVR and wall motion evaluation. Peak vasodilating activity is obtained 2 to 4 minutes after 
the cessation of dipyridamole infusion. In agreement with the comparative TTE study of 
Lim et al, 2000, dipyridamole with the infusion rate of 0.56 mg/kg may induce lower CFVR 
than adenosine, and CFVR value, achieved with adenosine, can be obtained with 
dipyridamole infusion rate of 0.84 mg/kg only. Adverse effects after dipyridamole infusion 
appear slowly and have a less intensity than those after adenosine, without marked dispnea 
and arterial hypotension. Both adenosine and dipyridamole are contraindicated in patients 
with active asthma or severe chronic obstructive pulmonary disease with wheezing. The 
vasodilative effect of both drugs is reversed by antagonists, such as methylxanthines, which 
compete for the A2 receptor, and therefore, foods and drinks containing xantines (chocolate, 
coffee, tea, colas, etc.) should be avoided for at least 12 hours before testing.   
In summary, adenosine should be a drug of choice for TTE, if CFVR assessment is required 
in one artery only.  If combined evaluation of regional function and CFVR assessment in the 
LAD or both the LAD and PDA are planned, the choice should be made in favor of 
dipyridamole with the infusion rate of 0.84 mg/kg. Dobutamine could be a good alternative 
to adenosine and dipyridamole for CFVR assessment in patients with contraindications to 
both drugs or scheduled dobutamine stress echocardiography. If echocontrast infusion is 
necessary, a separate intravenous line should be made. 
4.2 Cut-off level for normal and pathologic CFVR  
4.2.1 TTE calculation of CFVR  
For CFVR assessment, the correction of angle incidence between the Doppler beam and flow 
direction may be used; however, as evaluation is performed on the basis of ratio values, the 
absolute velocity is of less importance. However, the angle should not change between the 
baseline and hyperemic phases of the test, so the differences in blood flow velocity can still 
be compared. After obtaining the baseline and hyperemic coronary flow velocities, CFVR 
should be expressed as the ratio of coronary flow velocity under maximal vasodilatation to 
coronary flow velocity at rest (fig.14) (Picano et al., 1999; Korcarz & Stein, 2004). 
Various investigators consider that the peak diastolic flow velocity (Vpd),  mean diastolic 
flow velocity (Vmd), and average peak diastolic flow velocity (AVpd) can be used as a 
reference parameter for CFVR assessment. Vpd, being a most easily and quickly measured 
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dipyridamole infusion rate of 0.84 mg/kg only. Adverse effects after dipyridamole infusion 
appear slowly and have a less intensity than those after adenosine, without marked dispnea 
and arterial hypotension. Both adenosine and dipyridamole are contraindicated in patients 
with active asthma or severe chronic obstructive pulmonary disease with wheezing. The 
vasodilative effect of both drugs is reversed by antagonists, such as methylxanthines, which 
compete for the A2 receptor, and therefore, foods and drinks containing xantines (chocolate, 
coffee, tea, colas, etc.) should be avoided for at least 12 hours before testing.   
In summary, adenosine should be a drug of choice for TTE, if CFVR assessment is required 
in one artery only.  If combined evaluation of regional function and CFVR assessment in the 
LAD or both the LAD and PDA are planned, the choice should be made in favor of 
dipyridamole with the infusion rate of 0.84 mg/kg. Dobutamine could be a good alternative 
to adenosine and dipyridamole for CFVR assessment in patients with contraindications to 
both drugs or scheduled dobutamine stress echocardiography. If echocontrast infusion is 
necessary, a separate intravenous line should be made. 
4.2 Cut-off level for normal and pathologic CFVR  
4.2.1 TTE calculation of CFVR  
For CFVR assessment, the correction of angle incidence between the Doppler beam and flow 
direction may be used; however, as evaluation is performed on the basis of ratio values, the 
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baseline and hyperemic phases of the test, so the differences in blood flow velocity can still 
be compared. After obtaining the baseline and hyperemic coronary flow velocities, CFVR 
should be expressed as the ratio of coronary flow velocity under maximal vasodilatation to 
coronary flow velocity at rest (fig.14) (Picano et al., 1999; Korcarz & Stein, 2004). 
Various investigators consider that the peak diastolic flow velocity (Vpd),  mean diastolic 
flow velocity (Vmd), and average peak diastolic flow velocity (AVpd) can be used as a 
reference parameter for CFVR assessment. Vpd, being a most easily and quickly measured 
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Fig. 14. Example of CFVR evaluation in the PDA. Vpd – peak diastolic coronary flow 
velocity.  
index, demonstrates a higher inter- and intra-observed variability of assessment than Vpm 
and AVpd. But CFVR evaluation is based on the ratio values of the same parameters, and 
similar values of CFVR were reported for Vpd and Vmd (Hozumi et al., 1998; Caiati et al., 
1999b). The time required to complete a CFVR test in one artery is around 5–8 minutes 
depending on the investigators’ experience. 
4.2.2 Cut-off level of CFVR for significant stenosis in the LAD and RCA 
Pizzuto et al, 2001, 2003 revealed CFVR value for the LAD ranging from 2.90±0.58 to 
3.050.81 in control group of patients with angiographically normal coronary arteries, and 
similar values for CFVR were found in <50% LAD in-stent restenosis (Lambertz et al., 1999; 
Pizzuto et al, 2003). Later, CFVR in angiographically normal LAD patients with remote CAD 
(presence of previous remote myocardial infarction and wall motion abnormalities) was 
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TTE the cut-off value of CFVR is generally accepted to be 2.0 for predicting significant LAD 
stenosis in patients under decision-making process, after intracoronary intervention, and 
with in-stent restenosis (table 6). The sensitivity and specificity of Doppler TTE 
measurement of CFVR for detecting significant angiographic disease were satisfactory, 
ranging from 77% to 94% and 65% to 100%, respectively, slightly depending on the study 
population, dose of stress medications and cut-off value of diameter % stenosis. In one 
study, CFVR with a cut-off value <2.0 was a significantly better predictor (90%sensitivity, 
96%specificity) of LAD stenosis than multidetector computed tomography (80%sensitivity, 
93%specificity) and improved the diagnostic accuracy of the latter from 90 to 96% (Pizzuto 
et al., 2009). A cut-off value <2.0 was appropriate even for the diagnosis of significant 
stenosis of donor LAD giving collaterals to other arteries (Pizzuto et al., 2004; Iwata et al, 
2006).  
Several investigators studied the accuracy of Doppler TTE measurement of CFVR in the 
PDA to detect stenosis in the RCA, and the same cut-off value of CFVR (<2.0), 
demonstrating sensitivity 84-89% and specificity 83-96%, was accepted for predicting 









Stress agent Sens Specif Population 
Hozumi et al., 1998b  >70% <2.0 Vpd, Vmd adenosine 92% 82% unselected 
Caiati et al., 1999a >70% <2.0 Vpd, Vmd dipyridamole 86% 90% unselected 
Voci et al., 2002 >70% <2.0 Vpd adenosine 89% 100% unselected 
Voci P et al., 2003  >90% <1.0 Vpd adenosine 92% 98% unselected 
Nohtomi Y. et al., 2003 >50% <2.0 Vpd dipyridamole 94% 65% unselected 
Lethen et al., 2003  >70% <2.0 S/D mean 
velocity 
adenosine 89% 90% after PTCA 
Takeuchi et al., 2004 >50% <2.0 AVpd adenosine 91% 75% unselected 
Matsumura et al., 2003 >70% <2.0 Vmd adenosine 90% 93% unselected 
Rigo et al., 2003 >50% <1.9 Vpd dipyridamole 81% 84% unselected 
Okayama et al., 2002 >70% <2.0 AVpd adenosine 94% 88% unselected 
Pizzuto et al., 2003  >70% <2.0 Vpd, Vmd adenosine 91% 95% after stenting 
Lowenstein et al., 2003 >70% <2.0 Vpd dipyridamole 87% 73% unselected 
Hirata et al., 2006 >50% <2.0 Vmd adenosine 77% 100% after PTCA 
Pizzuto et al., 2009  >70% <2.0 Vpd adenosine 90% 96% unselected 
Table 6. Sensitivity and specificity of Doppler TTE measurement of CFVR for detecting 
significant LAD stenosis. Vpd – and Vmd – peak and mean diastolic coronary flow velocities, 
AVpd – average peak diastolic velocity of coronary blood flow, S/D mean velocity – systole-
diastolic mean velocity of coronary blood flow, Sens – sensitivity, Specif – specificity.  
4.2.3 Cut-off value of CFVR for occluded LAD and RCA 
CFVR can be a marker of chronic occluded LAD or RCA function. CFVR is always 
depressed in the collateral dependent vascular area, and the value<2.0 is registered in the 
LAD or PDA distal to the occlusion in all cases (Takeuchi et al., 2005, Pizzuto et al., 2006). 
But TTE is able to reveal patients with CFVR <1.0 reflecting coronary steal effect which 
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Fig. 14. Example of CFVR evaluation in the PDA. Vpd – peak diastolic coronary flow 
velocity.  
index, demonstrates a higher inter- and intra-observed variability of assessment than Vpm 
and AVpd. But CFVR evaluation is based on the ratio values of the same parameters, and 
similar values of CFVR were reported for Vpd and Vmd (Hozumi et al., 1998; Caiati et al., 
1999b). The time required to complete a CFVR test in one artery is around 5–8 minutes 
depending on the investigators’ experience. 
4.2.2 Cut-off level of CFVR for significant stenosis in the LAD and RCA 
Pizzuto et al, 2001, 2003 revealed CFVR value for the LAD ranging from 2.90±0.58 to 
3.050.81 in control group of patients with angiographically normal coronary arteries, and 
similar values for CFVR were found in <50% LAD in-stent restenosis (Lambertz et al., 1999; 
Pizzuto et al, 2003). Later, CFVR in angiographically normal LAD patients with remote CAD 
(presence of previous remote myocardial infarction and wall motion abnormalities) was 
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TTE the cut-off value of CFVR is generally accepted to be 2.0 for predicting significant LAD 
stenosis in patients under decision-making process, after intracoronary intervention, and 
with in-stent restenosis (table 6). The sensitivity and specificity of Doppler TTE 
measurement of CFVR for detecting significant angiographic disease were satisfactory, 
ranging from 77% to 94% and 65% to 100%, respectively, slightly depending on the study 
population, dose of stress medications and cut-off value of diameter % stenosis. In one 
study, CFVR with a cut-off value <2.0 was a significantly better predictor (90%sensitivity, 
96%specificity) of LAD stenosis than multidetector computed tomography (80%sensitivity, 
93%specificity) and improved the diagnostic accuracy of the latter from 90 to 96% (Pizzuto 
et al., 2009). A cut-off value <2.0 was appropriate even for the diagnosis of significant 
stenosis of donor LAD giving collaterals to other arteries (Pizzuto et al., 2004; Iwata et al, 
2006).  
Several investigators studied the accuracy of Doppler TTE measurement of CFVR in the 
PDA to detect stenosis in the RCA, and the same cut-off value of CFVR (<2.0), 
demonstrating sensitivity 84-89% and specificity 83-96%, was accepted for predicting 









Stress agent Sens Specif Population 
Hozumi et al., 1998b  >70% <2.0 Vpd, Vmd adenosine 92% 82% unselected 
Caiati et al., 1999a >70% <2.0 Vpd, Vmd dipyridamole 86% 90% unselected 
Voci et al., 2002 >70% <2.0 Vpd adenosine 89% 100% unselected 
Voci P et al., 2003  >90% <1.0 Vpd adenosine 92% 98% unselected 
Nohtomi Y. et al., 2003 >50% <2.0 Vpd dipyridamole 94% 65% unselected 
Lethen et al., 2003  >70% <2.0 S/D mean 
velocity 
adenosine 89% 90% after PTCA 
Takeuchi et al., 2004 >50% <2.0 AVpd adenosine 91% 75% unselected 
Matsumura et al., 2003 >70% <2.0 Vmd adenosine 90% 93% unselected 
Rigo et al., 2003 >50% <1.9 Vpd dipyridamole 81% 84% unselected 
Okayama et al., 2002 >70% <2.0 AVpd adenosine 94% 88% unselected 
Pizzuto et al., 2003  >70% <2.0 Vpd, Vmd adenosine 91% 95% after stenting 
Lowenstein et al., 2003 >70% <2.0 Vpd dipyridamole 87% 73% unselected 
Hirata et al., 2006 >50% <2.0 Vmd adenosine 77% 100% after PTCA 
Pizzuto et al., 2009  >70% <2.0 Vpd adenosine 90% 96% unselected 
Table 6. Sensitivity and specificity of Doppler TTE measurement of CFVR for detecting 
significant LAD stenosis. Vpd – and Vmd – peak and mean diastolic coronary flow velocities, 
AVpd – average peak diastolic velocity of coronary blood flow, S/D mean velocity – systole-
diastolic mean velocity of coronary blood flow, Sens – sensitivity, Specif – specificity.  
4.2.3 Cut-off value of CFVR for occluded LAD and RCA 
CFVR can be a marker of chronic occluded LAD or RCA function. CFVR is always 
depressed in the collateral dependent vascular area, and the value<2.0 is registered in the 
LAD or PDA distal to the occlusion in all cases (Takeuchi et al., 2005, Pizzuto et al., 2006). 
But TTE is able to reveal patients with CFVR <1.0 reflecting coronary steal effect which 
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develops in 33% to 47% of occluded vessel territories (Takeuchi et al., 2005, Pizzuto et al., 
2006). Coronary steal effect occurs when collateral circulation is poor and the donor artery is 
significant stenotic (Pizzuto et al, 2006; Braden, 2006).  
4.3 CFVR for detecting myocardial ischemia and assisting in the decision-making 
process in patients with chest pain  
Transthoracic CFVR measurement may have incremental predictive value in addition to 
stress echocardiography for detecting CAD in LAD and RCA distribution. In the study by 
Rigo et al., 2003, CFVR<1.9 in the LAD correlated well with stenosis severity and wall-
motion abnormalities. The inverse correlation between CFVR and peak wall motion score 
index in the overall study population was significant (r=0.46: p<0.001), and the concordance 
between the 2 techniques was good (80%) (Rigo et al, 2003). CFVR had excellent sensitivity 
(81-94%) but moderate or good specificity (65-84%) in detecting significant LAD stenosis 
whereas wall motion score index showed lower sensitivity (69-74%) and higher specificity 
(82-95%), and both techniques demonstrated a similar diagnostic accuracy ranging from 82 
to 86% for CFVR and from 81 to 84% for wall motion score index (Rigo et al, 2003; 
Lowenstein et al., 2003; Nohtomi et al., 2003). So, the data for flow and function may be 
complementary in predicting the underlying angiographic findings and increase the 
diagnostic accuracy up to 94%(Nohtomi et al., 2003), because abnormal wall motion may 
confirm and negative CFVR may exclude CAD more accurately. So, CVFR measurement is 
more important in patients with negative stress echocardiography by wall motion criteria. 
Similarly, transthoracic CFVR by Doppler is associated with perfusion abnormalities, as it 
has been shown with exercise single photon emission computed tomography thallium 
imaging. Most patients with abnormal perfusion in the LAD territory had abnormal CFVR 
in the LAD; those with perfusion defect in the RCA territory had abnormal CFVR in the 
PDA; vise versa, patients with normal exercise perfusion had CFVR greater than 2.0.  A 
transthoracic CFVR in the LAD <2.0 provided data consistent with those obtained by single 
photon emission computed tomography for physiologic estimation of stenosis severity with 
94% sensitivity and 100% specificity (Hirata et al., 2006).  Tokai et al., 2003, showed the 
equivalent potential of transthoracic CFVR in the PDA for detecting myocardial ischemia in 
the left ventricular inferior region and RCA stenosis. As has been reported by Fujimoto et al, 
2004,  CFVR in the Cx could be obtained in 72% of patients and CFVR<2.0 had 92% 
sensitivity and 96% specificity for predicting the perfusion defect in the Cx territory.   
In one comparative study (Osorio et al., 2007) with simultaneous CFVR assessment and 
quantitative analysis of myocardial contrast perfusion, CFVR was a much better index for 
detecting LAD stenosis than myocardial blood flow reserve (sensitivity 92% and 84%, 
specificity 94% and 87%, and accuracy 93% and 86% for CFVR and myocardial reserve, 
respectively).  
In summary, CFVR measurement may be a useful tool for detecting myocardial ischemia in 
the LAD distribution and, probably, in the RCA and Cx territory. 
4.4 CFVR in moderate and severe coronary artery stenosis  
Evaluation of patients with angiographic moderate coronary artery stenosis is challenging. 
Neither visual assessment of an angiogram nor quantitative coronary angiography can 
accurately predict the significance of most moderate stenoses (50–70%).  Rest coronary flow 
is preserved until severe narrowing occurs (>80%), but according to the experimental study 
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in mice (Wikstrom et al., 2005), there is a close correlation between CFVR in the left coronary 
artery and coronary minimal lumen diameter of this vessel (r=0.87, p<0.005), and CFVR 
depends on the diameter % stenosis. In clinical studies, the degree of angiographic stenosis 
also is related to CFVR in both the LAD and RCA (Lambertz et al.,1999; Pizzuto et al., 2001; 
Voci et al., 2002, 2003; Sicari et al., 2009). With insignificant LAD stenosis (<50%), CFVR in 
the LAD is normal (Lambertz et al., 1999; Voci et al., 2002), equal to 2.60.6 in subjects with 
totally normal coronary arteries, 2.60.6 in subjects with LAD stenosis of 0-20% and 2.20.5 
in subjects with LAD stenosis of 20-40% (Sicari et al., 2009). In cases with moderate stenosis, 
overall group CFVR is intermediate (from 2.23± 0.20 to 2.330.32); and only in high-grade 
stenosis CFVR is low (from 1.120.49 to 1.64 ± 0.30). But according to individual analysis 
data, CFVR reduction is found upstream in the classical ischemic cascade, and can well 
detect stenosis unable to induce regional wall motion abnormalities during stress echo (see 
4.3). CFVR is often <2.0 when stenosis is still moderate (50%-60%) (fig. 15) mirroring the 
decrease of subendocardial blood flow without total wall perfusion deficit and wall motion 
disturbance. So, demonstrating a higher negative predictive value in the detection of 
ischemia, compared with wall motion score index or nuclear cardiac imaging, CFVR is very 
useful in moderate stenosis to assess its functional significance and to help consider the 
necessity of revascularization (when CFVR<2.0).  
In severe stenosis, CFVR is more preserved in subjects with stenosis of 70-90% than in 
subjects with stenosis greater than 90% (Voci et al., 2003). Pizzuto et al., 2001 and Voci et al., 
2003, found the cut-off value of CFVR <1.0 to be a marker of coronary flow steal effect in 
patients with severe LAD stenosis (>90%) with 92%sensitivity, 98%specificity, and 
97%diagnostic accuracy. This finding is in agreement with the experimental work of Gould 
et al., 1974, who showed that CFVR in over 90% stenosis of the lumen diameter is blunted 
mainly due to either stenosis site collapse or development of coronary steal through 
collateral vessels.  
So, CFVR by Doppler TTE may be a useful tool for: 1) selection of patients with moderate 
stenosis and CFVR<2.0 for revascularization and 2) detection of patients with >90%stenosis 
basing on coronary steal effect (CFVR<1.0). 
4.5 CFVR after intracoronary interventions  
Another important application of TTE is assessment of early efficacy and remote coronary 
restenosis after intracoronary interventions. In the study of Pizzuto et al., 2001, CFVR 
measurement was performed before and within 1 day after LAD stenting. Prestent impaired 
CFVR increased after success stent implantation from 1.450.5 to 2.580.7 in groups with 70-
90% and >90% stenosis, and an absence of CFVR change was revealed only in 3 patients 
with >90%stenosis due to reactive hyperemia, microvascular stunning or post-procedure 
vasoconstriction. Unlike intracoronary Doppler studies with the guide wire or guiding 
catheter, the influence of which on the vascular endothelium and coronary flow dynamics is 
unpredictable and may be a cause of high rate of impaired CFVR after balloon angioplasty 
or stenting (50% and 30%, respectively) even in the absence of any residual angiographic 
stenosis, TTE, being a non-invasive technique, is deprived of this effect, and can more 
accurately reflect changes of coronary flow. 
In the study including 53 patients, coronary angiography and CFVR detection were 
performed 6 months after PTCA of the LAD (Lethen et al., 2003). The investigators observed 
CFVR to significantly differ in the groups with and without restenosis, and CFVR with the 
cut-off value <2.0 demonstrated 89% sensitivity and 90% specificity for predicting  
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develops in 33% to 47% of occluded vessel territories (Takeuchi et al., 2005, Pizzuto et al., 
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4.3 CFVR for detecting myocardial ischemia and assisting in the decision-making 
process in patients with chest pain  
Transthoracic CFVR measurement may have incremental predictive value in addition to 
stress echocardiography for detecting CAD in LAD and RCA distribution. In the study by 
Rigo et al., 2003, CFVR<1.9 in the LAD correlated well with stenosis severity and wall-
motion abnormalities. The inverse correlation between CFVR and peak wall motion score 
index in the overall study population was significant (r=0.46: p<0.001), and the concordance 
between the 2 techniques was good (80%) (Rigo et al, 2003). CFVR had excellent sensitivity 
(81-94%) but moderate or good specificity (65-84%) in detecting significant LAD stenosis 
whereas wall motion score index showed lower sensitivity (69-74%) and higher specificity 
(82-95%), and both techniques demonstrated a similar diagnostic accuracy ranging from 82 
to 86% for CFVR and from 81 to 84% for wall motion score index (Rigo et al, 2003; 
Lowenstein et al., 2003; Nohtomi et al., 2003). So, the data for flow and function may be 
complementary in predicting the underlying angiographic findings and increase the 
diagnostic accuracy up to 94%(Nohtomi et al., 2003), because abnormal wall motion may 
confirm and negative CFVR may exclude CAD more accurately. So, CVFR measurement is 
more important in patients with negative stress echocardiography by wall motion criteria. 
Similarly, transthoracic CFVR by Doppler is associated with perfusion abnormalities, as it 
has been shown with exercise single photon emission computed tomography thallium 
imaging. Most patients with abnormal perfusion in the LAD territory had abnormal CFVR 
in the LAD; those with perfusion defect in the RCA territory had abnormal CFVR in the 
PDA; vise versa, patients with normal exercise perfusion had CFVR greater than 2.0.  A 
transthoracic CFVR in the LAD <2.0 provided data consistent with those obtained by single 
photon emission computed tomography for physiologic estimation of stenosis severity with 
94% sensitivity and 100% specificity (Hirata et al., 2006).  Tokai et al., 2003, showed the 
equivalent potential of transthoracic CFVR in the PDA for detecting myocardial ischemia in 
the left ventricular inferior region and RCA stenosis. As has been reported by Fujimoto et al, 
2004,  CFVR in the Cx could be obtained in 72% of patients and CFVR<2.0 had 92% 
sensitivity and 96% specificity for predicting the perfusion defect in the Cx territory.   
In one comparative study (Osorio et al., 2007) with simultaneous CFVR assessment and 
quantitative analysis of myocardial contrast perfusion, CFVR was a much better index for 
detecting LAD stenosis than myocardial blood flow reserve (sensitivity 92% and 84%, 
specificity 94% and 87%, and accuracy 93% and 86% for CFVR and myocardial reserve, 
respectively).  
In summary, CFVR measurement may be a useful tool for detecting myocardial ischemia in 
the LAD distribution and, probably, in the RCA and Cx territory. 
4.4 CFVR in moderate and severe coronary artery stenosis  
Evaluation of patients with angiographic moderate coronary artery stenosis is challenging. 
Neither visual assessment of an angiogram nor quantitative coronary angiography can 
accurately predict the significance of most moderate stenoses (50–70%).  Rest coronary flow 
is preserved until severe narrowing occurs (>80%), but according to the experimental study 
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in mice (Wikstrom et al., 2005), there is a close correlation between CFVR in the left coronary 
artery and coronary minimal lumen diameter of this vessel (r=0.87, p<0.005), and CFVR 
depends on the diameter % stenosis. In clinical studies, the degree of angiographic stenosis 
also is related to CFVR in both the LAD and RCA (Lambertz et al.,1999; Pizzuto et al., 2001; 
Voci et al., 2002, 2003; Sicari et al., 2009). With insignificant LAD stenosis (<50%), CFVR in 
the LAD is normal (Lambertz et al., 1999; Voci et al., 2002), equal to 2.60.6 in subjects with 
totally normal coronary arteries, 2.60.6 in subjects with LAD stenosis of 0-20% and 2.20.5 
in subjects with LAD stenosis of 20-40% (Sicari et al., 2009). In cases with moderate stenosis, 
overall group CFVR is intermediate (from 2.23± 0.20 to 2.330.32); and only in high-grade 
stenosis CFVR is low (from 1.120.49 to 1.64 ± 0.30). But according to individual analysis 
data, CFVR reduction is found upstream in the classical ischemic cascade, and can well 
detect stenosis unable to induce regional wall motion abnormalities during stress echo (see 
4.3). CFVR is often <2.0 when stenosis is still moderate (50%-60%) (fig. 15) mirroring the 
decrease of subendocardial blood flow without total wall perfusion deficit and wall motion 
disturbance. So, demonstrating a higher negative predictive value in the detection of 
ischemia, compared with wall motion score index or nuclear cardiac imaging, CFVR is very 
useful in moderate stenosis to assess its functional significance and to help consider the 
necessity of revascularization (when CFVR<2.0).  
In severe stenosis, CFVR is more preserved in subjects with stenosis of 70-90% than in 
subjects with stenosis greater than 90% (Voci et al., 2003). Pizzuto et al., 2001 and Voci et al., 
2003, found the cut-off value of CFVR <1.0 to be a marker of coronary flow steal effect in 
patients with severe LAD stenosis (>90%) with 92%sensitivity, 98%specificity, and 
97%diagnostic accuracy. This finding is in agreement with the experimental work of Gould 
et al., 1974, who showed that CFVR in over 90% stenosis of the lumen diameter is blunted 
mainly due to either stenosis site collapse or development of coronary steal through 
collateral vessels.  
So, CFVR by Doppler TTE may be a useful tool for: 1) selection of patients with moderate 
stenosis and CFVR<2.0 for revascularization and 2) detection of patients with >90%stenosis 
basing on coronary steal effect (CFVR<1.0). 
4.5 CFVR after intracoronary interventions  
Another important application of TTE is assessment of early efficacy and remote coronary 
restenosis after intracoronary interventions. In the study of Pizzuto et al., 2001, CFVR 
measurement was performed before and within 1 day after LAD stenting. Prestent impaired 
CFVR increased after success stent implantation from 1.450.5 to 2.580.7 in groups with 70-
90% and >90% stenosis, and an absence of CFVR change was revealed only in 3 patients 
with >90%stenosis due to reactive hyperemia, microvascular stunning or post-procedure 
vasoconstriction. Unlike intracoronary Doppler studies with the guide wire or guiding 
catheter, the influence of which on the vascular endothelium and coronary flow dynamics is 
unpredictable and may be a cause of high rate of impaired CFVR after balloon angioplasty 
or stenting (50% and 30%, respectively) even in the absence of any residual angiographic 
stenosis, TTE, being a non-invasive technique, is deprived of this effect, and can more 
accurately reflect changes of coronary flow. 
In the study including 53 patients, coronary angiography and CFVR detection were 
performed 6 months after PTCA of the LAD (Lethen et al., 2003). The investigators observed 
CFVR to significantly differ in the groups with and without restenosis, and CFVR with the 
cut-off value <2.0 demonstrated 89% sensitivity and 90% specificity for predicting  
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Fig. 15. Examples of CFVR in distal LAD in patients with LAD stenosis are presented. A - 
case with mild proximal LAD stenosis, CFVR is 2.3; B - case with moderate LAD stenosis; 
the basal peak diastolic flow velocity is normal, but it increases less than 2 times after 
dipyridamole, and CFVR is decreased (1.6); C - case with proximal severe LAD stenosis and 
basal poststenotic acceleration of coronary flow with high peak diastolic flow velocity in 
distal LAD at rest; after dipyridamole the increase of peak diastolic flow velocity is slight, 
CFVR is equal to 1.3. 
significant LAD restenosis. Similar studies were carried out after LAD stent, and CFVR with 
the cut-off value <2.0 also demonstrated sensitivity ranging from 77% to 93% and specificity 
ranging from 78% to 100% for predicting LAD restenosis (Ruscazio et al., 2002; Pizzuto et al, 
2003a; Hirata et al., 2006). One of the criticisms of TTE is that assessment has been limited to 
the LAD, but progress is being made in examining other vessels. High success rate of CFVR 
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measurements in the PDA permits to hope for the forthcoming appearance of CFVR studies 
before and after RCA intracoronary interventions. 
Thus, noninvasive CFVR assessment by TTE is a very promising tool in monitoring early 
efficacy of LAD angioplasty or stenting and detecting remote restenosis after LAD 
intracoronary interventions. 
4.6 Factors influencing CFVR 
Besides stenosis, several factors can influence the baseline or hyperemic coronary flow and 
cause decreased CFVR. Elevation of the basal flow can occur with hypertension, 
tachycardia, anemia, thyrotoxicosis, or valvular disease, or after caffeine intake (coffee, tea, 
cola, etc.). The conditions which can decrease the maximum hyperemic flow include not 
only epicardial coronary stenosis but also microvascular disease with impaired structure, 
function, rheology, and lower density of capillaries, polycythemia and elevated left ventricle 
end-diastolic pressure (Baumgart et al., 1998; Hirata et al., 2001; Neishi et al., 2005; de 
Grigorio et al., 2005; Sherrid et al., 2006; Kaul & Jayaweera, 2008). 
4.7 CFVR and prognosis in CAD patients 
According to the data of studies in patients with acute anterior myocardial infarction, CFVR 
is able to reflect an absence of microvascular reperfusion in the presence of a patent 
epicardial coronary artery, and is a negative determinant for myocardial viability (Ueno et 
al., 2002a; Rigo et al., 2004; Meimoun et al., 2009).  Ueno et al., 2002a, reported that CFVR 
measured in open infarct-related LAD on day 1 after success primary angioplasty was a 
good predictor of the recovery of regional left ventricle function at discharge, whereas Rigo 
et al., 2004, found CFVR in the LAD <2.0 to be useful also in predicting an unfavorable long-
term (6-month) outcome. In the study of Meimoun et al., 2009, a cut-off CFVR value of 1.7 
was an independent predictor of both the left ventricle recovery at a 3-month follow-up, and 
in-hospital adverse cardiac events including death, recurrent myocardial infarction, and 
acute heart failure.  
CFVR<2.0 was associated with an unfavorable outcome in an unselected cohort of patients 
with positive and negative stress echocardiograms by wall motion criteria (Rigo et al., 2008), 
in patients with intermediate LAD stenosis (Rigo et al., 2007), and in patients with chest pain 
and normal or near-normal coronary arteries (Sicari et al., 2009). CFVR<1.8 provided 
independent information for prognostic stratification in patients with inducible ischemia 
during stress echocardiography, and it was associated with an increase of event rate (death 
and myocardial infarction) by 46% during 19-month follow-up (Cortigiani et al., 2010). But 
LAD CFVR demonstrated an extremely high additional prognostic value (up to 160%) in 
patients with negative stress echocardiography by wall motion criteria, and a reduced CFVR 
was associated with a less benign long-term outcome (Rigo et al., 2006; Cortigiani et al., 
2010). In the study of Rigo et al., 2006, CFVR<1.92 was the best predictor of future events 
(sensitivity = 77%, specificity = 85%), and the 3-year event-free survival was higher in 
patients with normal CFVR (>1.92) compared with patients with reduced CVFR (98% versus 
64%, P<0.0001). The main reasons for CFVR importance in the prognosis in patients with 
negative stress echocardiography are the following: (1) CFVR can detect moderate coronary 
stenoses inducing no wall motion abnormalities during stress test (see 4.3, 4.4); (2) CFVR can 
be useful for the detection of severe stenosis in patients on antiischemic therapy. When 
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CFVR is equal to 1.3. 
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and normal or near-normal coronary arteries (Sicari et al., 2009). CFVR<1.8 provided 
independent information for prognostic stratification in patients with inducible ischemia 
during stress echocardiography, and it was associated with an increase of event rate (death 
and myocardial infarction) by 46% during 19-month follow-up (Cortigiani et al., 2010). But 
LAD CFVR demonstrated an extremely high additional prognostic value (up to 160%) in 
patients with negative stress echocardiography by wall motion criteria, and a reduced CFVR 
was associated with a less benign long-term outcome (Rigo et al., 2006; Cortigiani et al., 
2010). In the study of Rigo et al., 2006, CFVR<1.92 was the best predictor of future events 
(sensitivity = 77%, specificity = 85%), and the 3-year event-free survival was higher in 
patients with normal CFVR (>1.92) compared with patients with reduced CVFR (98% versus 
64%, P<0.0001). The main reasons for CFVR importance in the prognosis in patients with 
negative stress echocardiography are the following: (1) CFVR can detect moderate coronary 
stenoses inducing no wall motion abnormalities during stress test (see 4.3, 4.4); (2) CFVR can 
be useful for the detection of severe stenosis in patients on antiischemic therapy. When 
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ischemia-dependent wall motion abnormality is the diagnostic end point, concomitant 
antiischemic therapy modifies the prognostic value of stress echocardiography, markedly 
reducing TTE sensitivity; in fact, a positive test result in on therapy patients is more 
prognostically malignant, and a negative test result is less prognostically benign. The flow 
information in patients with known or suspected coronary artery disease is relatively 
unaffected by concomitant antiischemic therapy, and does not influence CFVR significantly. 
In the study with 1779 patients performed by Sicari et al., 2008, the symptoms-free survival 
was higher in patients with normal CFVR (>2.0) and lower in patients with abnormal CFVR 
(87% versus 34%, P =0.0001), and it was comparable to that in patients with normal CFVR 
on and off therapy and in patients with abnormal CFVR on and off therapy; so, antiischemic 
therapy at the time of testing did not modify the prognostic value of Doppler CFVR. (3) 
CFVR can identify severe microvascular disease (Rigo et al., 2006; Cortigiani et al., 2007; 
Sicari et al., 2009). Coronary microvascular dysfunction does not normally induce wall 
motion abnormalities but has been linked to an adverse outcome, which can be accurately 
detected by abnormal CFVR.  So, in a prospective study in 394 patients with 
angiographically normal or near-normal coronary arteries and preserved regional and 
global left ventricular function at baseline and during stress, CFVR <2.0 adds incremental 
value to the prognostic stratification achieved with clinical and angiographic data (Sicari et 
al., 2009), and selects a subgroup of patients with a less benign prognosis. During a median 
follow-up of 51 months, long-term survival estimated for adverse events (death and 
myocardial infarction) showed an extremely better outcome for the patients with a normal 
CFVR compared with those with an abnormal CFVR (96% versus 55%).  
In summary, CFVR provides independent information for prognostic stratification, and a 
reduced CFVR is associated with a less benign long-term outcome in patients with acute 
anterior myocardial infarction, known or suspected CAD with positive and particularly 
negative stress echocardiography by wall motion criteria. CFVR measurement is offered to 
be added to routine stress echocardiography.   
5. Transthoracic visualization of internal thoracic artery grafts and venous 
grafts  
We do not have our own sufficient experience of coronary graft assessment. But in 
published studies TTE visualization of the left internal mammary artery (IMA) graft has 
varied from 70% to 100%, the venous grafts to the LAD could be assessed  in 91%, to the 
RCA – in 96%, to the Cx – in 90% (Chirillo et al., 2001, 2004; Chong et al., 2004). The Nyquist 
limits should be set at 20 cm/s for the IMA grafts and 10-12 cm/s for the venous grafts 
(Youn & Foster, 2004). In the proximal part next to the subclavian artery, patent IMA grafts 
demonstrate a flow pattern with predominant systolic velocity, and next to distal 
anastomosis site the flow pattern has predominant diastolic velocity similar to that of the 
coronary artery. Some researchers made an effort to detect dipyridamole-induced CFVR in 
the IMA and venous grafts. Meyer et al., 2004, compared CFVR in the proximal left IMA 
graft with the help of simultaneous TTE and intracoronary Doppler guide wire assessment. 
TTE reflected invasive measurement of CFVR accurately, and the agreement between the 
two methods was 0.97, and patients with CFVR>2.1 showed patent IMA graft. According to 
the data of Chirillo et al., 2001, 2004, CFVR<1.9 in proximal IMA grafts and CFVR <1.6 in 
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venous grafts demonstrated a higher sensitivity in the detection of 50-100%graft stenoses in 
comparison with wall motion score index. But recently, Pizzuto et al., 2005 have determined 
distal CFVR in the IMA grafts to depend on flow interrelation in the graft and native LAD, 
and to be a better predictor of LAD function than IMA graft patency in the presence of flow 
competition. So, TTE value for identification of graft patency is not yet established, and 
further studies are required.    
6. Conclusion 
In summary, with the advent of harmonic imaging, contrast agents and high-frequency 
transducers, TTE can be used for the diagnosis of coronary narrowing as a noninvasive, 
inexpensive, non-X-ray, high time resolution and widely used in clinical practice method. 
After a period of investigators’ training, detection and measurement of distal LAD and 
RCA flow and CFVR by TTE is feasible in more than 90% of patients and correlates well 
with invasive measurements. Clinical applications of TTE for  direct assessment of 
coronary stenoses and occlusions are limited due to partial artery visualization, and TTE 
can not be accepted as an alternative to coronary angiography. But Doppler TTE in CAD 
patients can be a helpful method providing additional information on the coronary artery 
function for: 
- noninvasive clinical repeated or serial measurements of coronary flow velocity at rest 
after stress which are necessary for understanding the physiology and pathophysiology 
of coronary flow; in this case the LAD can be used as a reference vessel; 
- preliminary identification of coronary stenosis in the LMCA, LAD and PDA; 
- detection of restenosis after percutaneous intracoronary interventions in the LMCA, 
LAD and PDA; 
- diagnosis of reperfusion in the acute phase of myocardial infarction in the LAD 
territory with evaluation of no-reflow after recanalization;  
- identification of chronic occluded LAD and RCA; 
- assessment of endothelial function; 
- measurement of CFVR in the following groups of patients: (1) with suspected or 
confirmed CAD in those who undergo stress echocardiography (dobutamine or 
dipyridamole) for reflecting perfusion, function, prognosis-risk stratification, and 
selection of significant coronary stenosis (CFR<2.0) of the LAD and RCA; (2) with 
intermediate-grade coronary obstruction where the functional assessment of the lesion 
is doubtful, and CFVR can be used in considering pro et contra of coronary 
interventions; (3) with not reliable stress tests due to left bundle-branch block or right 
bundle-branch block because of the high rate of the false-positive results where CVFR 
may be used for noninvasive detection of LAD or RCA stenosis; (4) after coronary 
angioplasty, stent or coronary bypass graft of the LAD and RCA where serial follow-up 
for the assessment of efficacy and early or remote restenosis is required; (5) with 
ongoing drug therapy for serial follow-up, particularly if the drug effect is uncertain; (6) 
with typical or atypical chest pain and angiographically normal coronary arteries where 
microvascular disease is possible (syndrome X, left ventricle hypertrophy, diabetes 
mellitus, etc.); and (7) with acute anterior myocardial infarction for the assessment of 
viability, prognosis and prediction of improvement of the regional left ventricular 
function.  
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ischemia-dependent wall motion abnormality is the diagnostic end point, concomitant 
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was higher in patients with normal CFVR (>2.0) and lower in patients with abnormal CFVR 
(87% versus 34%, P =0.0001), and it was comparable to that in patients with normal CFVR 
on and off therapy and in patients with abnormal CFVR on and off therapy; so, antiischemic 
therapy at the time of testing did not modify the prognostic value of Doppler CFVR. (3) 
CFVR can identify severe microvascular disease (Rigo et al., 2006; Cortigiani et al., 2007; 
Sicari et al., 2009). Coronary microvascular dysfunction does not normally induce wall 
motion abnormalities but has been linked to an adverse outcome, which can be accurately 
detected by abnormal CFVR.  So, in a prospective study in 394 patients with 
angiographically normal or near-normal coronary arteries and preserved regional and 
global left ventricular function at baseline and during stress, CFVR <2.0 adds incremental 
value to the prognostic stratification achieved with clinical and angiographic data (Sicari et 
al., 2009), and selects a subgroup of patients with a less benign prognosis. During a median 
follow-up of 51 months, long-term survival estimated for adverse events (death and 
myocardial infarction) showed an extremely better outcome for the patients with a normal 
CFVR compared with those with an abnormal CFVR (96% versus 55%).  
In summary, CFVR provides independent information for prognostic stratification, and a 
reduced CFVR is associated with a less benign long-term outcome in patients with acute 
anterior myocardial infarction, known or suspected CAD with positive and particularly 
negative stress echocardiography by wall motion criteria. CFVR measurement is offered to 
be added to routine stress echocardiography.   
5. Transthoracic visualization of internal thoracic artery grafts and venous 
grafts  
We do not have our own sufficient experience of coronary graft assessment. But in 
published studies TTE visualization of the left internal mammary artery (IMA) graft has 
varied from 70% to 100%, the venous grafts to the LAD could be assessed  in 91%, to the 
RCA – in 96%, to the Cx – in 90% (Chirillo et al., 2001, 2004; Chong et al., 2004). The Nyquist 
limits should be set at 20 cm/s for the IMA grafts and 10-12 cm/s for the venous grafts 
(Youn & Foster, 2004). In the proximal part next to the subclavian artery, patent IMA grafts 
demonstrate a flow pattern with predominant systolic velocity, and next to distal 
anastomosis site the flow pattern has predominant diastolic velocity similar to that of the 
coronary artery. Some researchers made an effort to detect dipyridamole-induced CFVR in 
the IMA and venous grafts. Meyer et al., 2004, compared CFVR in the proximal left IMA 
graft with the help of simultaneous TTE and intracoronary Doppler guide wire assessment. 
TTE reflected invasive measurement of CFVR accurately, and the agreement between the 
two methods was 0.97, and patients with CFVR>2.1 showed patent IMA graft. According to 
the data of Chirillo et al., 2001, 2004, CFVR<1.9 in proximal IMA grafts and CFVR <1.6 in 
Transthoracic Echocardiography in the Assessment of Coronary Arteries 51 
venous grafts demonstrated a higher sensitivity in the detection of 50-100%graft stenoses in 
comparison with wall motion score index. But recently, Pizzuto et al., 2005 have determined 
distal CFVR in the IMA grafts to depend on flow interrelation in the graft and native LAD, 
and to be a better predictor of LAD function than IMA graft patency in the presence of flow 
competition. So, TTE value for identification of graft patency is not yet established, and 
further studies are required.    
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In summary, with the advent of harmonic imaging, contrast agents and high-frequency 
transducers, TTE can be used for the diagnosis of coronary narrowing as a noninvasive, 
inexpensive, non-X-ray, high time resolution and widely used in clinical practice method. 
After a period of investigators’ training, detection and measurement of distal LAD and 
RCA flow and CFVR by TTE is feasible in more than 90% of patients and correlates well 
with invasive measurements. Clinical applications of TTE for  direct assessment of 
coronary stenoses and occlusions are limited due to partial artery visualization, and TTE 
can not be accepted as an alternative to coronary angiography. But Doppler TTE in CAD 
patients can be a helpful method providing additional information on the coronary artery 
function for: 
- noninvasive clinical repeated or serial measurements of coronary flow velocity at rest 
after stress which are necessary for understanding the physiology and pathophysiology 
of coronary flow; in this case the LAD can be used as a reference vessel; 
- preliminary identification of coronary stenosis in the LMCA, LAD and PDA; 
- detection of restenosis after percutaneous intracoronary interventions in the LMCA, 
LAD and PDA; 
- diagnosis of reperfusion in the acute phase of myocardial infarction in the LAD 
territory with evaluation of no-reflow after recanalization;  
- identification of chronic occluded LAD and RCA; 
- assessment of endothelial function; 
- measurement of CFVR in the following groups of patients: (1) with suspected or 
confirmed CAD in those who undergo stress echocardiography (dobutamine or 
dipyridamole) for reflecting perfusion, function, prognosis-risk stratification, and 
selection of significant coronary stenosis (CFR<2.0) of the LAD and RCA; (2) with 
intermediate-grade coronary obstruction where the functional assessment of the lesion 
is doubtful, and CFVR can be used in considering pro et contra of coronary 
interventions; (3) with not reliable stress tests due to left bundle-branch block or right 
bundle-branch block because of the high rate of the false-positive results where CVFR 
may be used for noninvasive detection of LAD or RCA stenosis; (4) after coronary 
angioplasty, stent or coronary bypass graft of the LAD and RCA where serial follow-up 
for the assessment of efficacy and early or remote restenosis is required; (5) with 
ongoing drug therapy for serial follow-up, particularly if the drug effect is uncertain; (6) 
with typical or atypical chest pain and angiographically normal coronary arteries where 
microvascular disease is possible (syndrome X, left ventricle hypertrophy, diabetes 
mellitus, etc.); and (7) with acute anterior myocardial infarction for the assessment of 
viability, prognosis and prediction of improvement of the regional left ventricular 
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1. Introduction 
Conventional echocardiography is widely used and well documented in evaluation of 
patients with stable and unstable coronary artery disease (Mollema et al., 2009). In 
particular, assessment of left ventricular function, volumes and ejection fraction adds 
important prognostic information in individual patients. In addition, echocardiography may 
detect any concomitant valvular heart disease as well as acute complications in unstable 
coronary syndromes.  Stress echocardiography has through several studies established its 
role in diagnosis of stable coronary artery disease and assessment of myocardial viability 
(Sicari et al., 2008). 
However, introduction of ultrasound contrast agents and contrast specific imaging 
modalities have significantly improved the usefulness of echocardiography in diagnosis and 
assessment of coronary artery disease (Dijkmans et al., 2006). Indications for use of 
ultrasound contrast are implemented in guidelines for assessment of left ventricular 
function at rest and during stress echocardiography (Senior et al., 2009; Mulvagh et al., 
2008). Ultrasound contrast is recommended for assessing left ventricular ejection fraction at 
rest when image quality is suboptimal and for stress echocardiography when the 
endocardial boarder is not visualized in 2 or more left ventricular segments (Senior et al., 
2009; Mulvagh et al., 2008).  
In contrast echocardiography regional myocardial function and perfusion may be assessed 
simultaneously, thereby optimizing the non-invasive diagnostics of coronary artery disease. 
The incremental value of assessing myocardial perfusion in diagnosing coronary artery 
disease is emphasised by the ischemic cascade (Fig. 1), demonstrating that hypoperfusion 
precedes functional impairment, ECG changes, symptoms and myocardial necrosis as 
depicted in Fig.1. (Crossman, 2004; Leong-Poi et al., 2002).  
Diagnosing distribution and extent of myocardial ischemia by contrast echocardiography 
can give information on the total ischemic burden and has become a supplemental tool in 
evaluation of the physiological impact of an angiographic coronary artery stenosis. 
Consequently, myocardial perfusion assessment by contrast echocardiography may also be 
used for risk prediction in patients with known coronary artery disease and in prioritizing 
the need for urgent revascularization among patients with acute coronary syndromes 
(Jeetley et al., 2007; Rinkevich et al., 2005; Lønnebakken  et al., 2011). It has the potential to 
become a future tool to tailor and evaluate the effect of treatment on myocardial perfusion 
in patients with different clinical syndromes of coronary artery disease. Furthermore, 
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contrast echocardiography can be used to identify myocardial ischemia in patients with 
non-obstructive coronary artery disease i.e. microvascular disease which cannot be 












Fig. 1. The ischemic cascade 
2. Methodology 
Contrast echocardiography has several advantages compared to other non-invasive imaging 
techniques like cardiac magnetic resonance imaging and cardiac computer tomography. 
First, it can be performed without the radiation exposure of computer tomography and 
without the potential nephrotoxisity of the gadolinium contrast agent necessary to assess 
myocardial perfusion by magnetic resonance imaging. Second, it can be performed bed-side 
and give immediate answers to important clinical questions in management of patients with 
known or suspected coronary artery disease. Contrast echocardiography requires 
intravenous administration of a second or third generation ultrasound contrast agent during 
contrast specific ultrasound imaging.  
2.1 Ultrasound contrast agents and imaging modalities 
Ultrasound contrast agents consist of microbubbles with an inert gas core surrounded by a 
shell. Due to the microbubble size and stability, they can pass the pulmonary circulation 
without destruction and intravenous administration as bolus dosages or continuous 
infusion can therefore be used (Senior et al., 2009). Importantly, the contrast microbubbles 
act as isolated intravascular tracers and are therefore ideal for perfusion assessment.  Future 
possibility of targeting contrast microbubbles against specific disease processes, including 
inflammation in unstable plaque, activated platelets in thrombus formation or against 
factors involved in angiogenesis may allow even more specific diagnoses (Kaufman & 
Lindner., 2007; Chadderdon & Kaul., 2010). 
Ultrasound contrast agents in coronary artery disease have been shown to be safe, but 
allergic anaphylactic reactions have been observed (Senior et al., 2009; Wei et al., 2008). 
Therefore, patients should be observed closely with continuous recording of heart rhythm 
and frequent measurement of blood pressure during contrast echocardiography and for at 
least 20 minutes after the examination. Emergency equipment should always be available in 
the examination room during contrast echocardiography. Contrast echocardiography has 
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few absolute contraindications, except for known allergy against the contrast agent. 
However, caution and close observation should be performed in patients with unstable 
coronary artery disease or decompensated heart failure. Ultrasound contrast agent should 
also be used with caution in patients with severe pulmonary disease. The gas in the contrast 
microbubbles is excreted through the lungs, and in patients with severe pulmonary disease, 
clearance is delayed, causing increased halftime of the gas in the circulation. In patients with 
mechanical valve prosthesis contrast echocardiography should be avoided due to extensive 
destruction of contrast microbubbles by the prosthesis. An overview of current 
commercially available ultrasound contrast agents is given in Table 1. 
 
Contrast agents Gas core Shel l  
SonoVue Sulphur hexafluoride Phospholipid monolayer 
Lumini ty/Def ini ty Perflutren Phospholipid monolayer 
Optison Perflutren Albumin 
Albunex Air Albumin 
Table 1. Gas core and shell composition in ultrasound contrast agents available for clinical 
use 
Contrast microbubbles have unique acoustic properties when exposed to ultrasound. At very 
low mechanical index, the ultrasound microbubbles have a linear response to the ultrasound 
exposure. At low mechanical index (MI 0.08-0.3) the ultrasound microbubbles start to oscillate 
giving rise to a non-linear response contrasting the linear response of the myocardial tissue at 
low mechanical index. Contrast specific ultrasound imaging modalities remove the linear 
tissue response and enhance the contrast microbubble response. Different techniques may be 
used to emphasis the contrast microbubbles acoustic signals and to filter the tissue signals, the 
main techniques being power modulation, pulse inversion or coherent contrast imaging. 
Low-mechanical index imaging is the most commonly used modality, often combined with 
a high energy ultrasound flash causing microbubble destruction, known as destruction-
replenishment imaging or flash imaging (Fig. 2). By this technique real-time contrast 
echocardiography with simultaneous assessment of myocardial function and perfusion can 
be performed.   
High mechanical index imaging causes microbubble destruction. By high mechanical index 
triggered imaging, myocardial perfusion can be assessed, but myocardial function can not 
be assessed simultaneously using this imaging modality. The advantage of this imaging 
modality is a better reproducibility for quantification of myocardial perfusion. 
2.2 Performance and image interpretation 
Ultrasound contrast may be used to improve endocardial border delineation, a technique 
known as left ventricular opacification (LVO) (Fig.3) (Chahal & Senior, 2010), which has 
been demonstrated to optimize assessment of left ventricular volumes and ejection fraction 
by echocardiography compared to cardiac magnetic resonance imaging, the current gold 
standard (Malm et al., 2006). In patients with poor acoustic windows, left ventricular 
ejection fraction is often underestimated if ultrasound contrast is not used (Kurt et al., 2009; 
Plana et al., 2008). Using ultrasound contrast significantly improves echocardiographic 
reproducibility and accuracy in patients with poor acoustic windows, and use of contrast 
echocardiography in such cases for accurate assessment of left ventricular ejection fraction is  
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replenishment
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(10 heart cyclies)
Contrast microbubble destruction
Allowing assessment of refilling
Contrast microbubble oscillation
Contrast specific ultrasound signals
 
Fig. 2. Destruction replenishment contrast echocardiography, where a high energy 
ultrasound burst causes ultrasound microbubble destruction, followed by low mechanical 
index ultrasound imaging assessing only the non-linear ultrasound refection from 
oscillating contrast microbubbles by contrast specific ultrasound imaging allowing 
assessment of contrast enhancement and hence myocardial perfusion.   
recommended in current guidelines (Senior et al., 2009). Similarly, during stress 
echocardiography, adding ultrasound contrast allows a complete evaluation of wall motion 
in all myocardial regions in almost every patient (Hoffmann et al., 2007).  
In a study of 632 patients with poor acoustic windows, adding ultrasound contrast not only 
avoided the need of further expensive and time consuming examinations but also had direct 
impact on patient’s treatment (Kurt et al., 2009). 
 
 
Fig. 3. Left ventricular opacification (LVO) by contrast echocardiography illustrating the 
improved endocardial border delineation in particular in the apical part of the left ventricle 
in an apical 4-chamber view compared to conventional echocardiography. 
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In myocardial contrast echocardiography (MCE), contrast is not only used for enhanced 
endocardial border delineation, but also for assessment of regional perfusion with high 
spatial and temporal resolution (Fig. 4) (Elhendy & Porter., 2005). MCE has the potential to 
significantly improve non-invasive evaluation of coronary artery disease (Elhendy et al., 
2004; Lønnebakken et al., 2009). Contrasting other non-invasive imaging modalities, MCE 
visualizes the capillary filling in the myocardium and can give information on regional 
myocardial perfusion including subendocardial hypoperfusion, which is the first sign of 
ischemia (Dijkmans et al.,2006). Consequently, MCE increases the sensitivity to detect 
ischemia. In addition, myocardial microvascular integrity can be evaluated and myocardial 
viability assessed. 
Myocardial contrast echocardiography is mainly performed using apical 4-chamber, apical 
2-chamber and apical 3-chamber views. Parasternal imaging is more difficult due to contrast 
attenuation, but additional parasternal long- and short axis images may be useful in 
individual patients, in particular at peak stress. By combining rest-imaging with an exercise 
or pharmacological stress test, myocardial function and perfusion can be evaluated not only 
at rest but also during stress, which is particularly important in diagnosis of stable coronary 
artery disease, evaluation of viability and in evaluating the result after coronary 
revascularization.  Image analysis is performed using a standardized 17-segment left 
ventricular model, in which the different left ventricular segments are assigned to the three 
main coronary arteries using a standardized scheme (Fig. 5) (Lang et al., 2006). However, the 
considerable variation in coronary artery anatomy must be taken into account when 
comparing MCE results to coronary angiography. 
 
 
Fig. 4. Myocardial contrast echocardiography with low mechanical index demonstrating the 
delayed contrast enhancement in the distal septum and apex of the left ventricle (green 
arrows) compared to the proximal septum and lateral wall in an apical 4-chamber view. 
2.2.1 Wall motion scoring 
Myocardial regional function or wall motion is evaluated from active myocardial thickening 
and scored according to current guidelines as normal (1), hypokinetic (2), akinetic (3) or 
dyskinetic (4) (Sicari et al., 2008). In addition, there should be a further increase in wall 
thickening during stress testing to be scored as normal. In viability assessment, an akinetic 
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segment that starts to function at low stress level but ceases to function again at higher stress 
level is indicative of viable myocardium with ischemia, known as the biphasic response, 
typically for stunned or hibernating myocardium. Such findings indicate that the regional 
myocardial function will improve from revascularisation.  Akinetic myocardial segments 
that remain akinetic during stress indicate infarct scarring which will not benefit from 
revascularization. 
 
Panel A Panel B
 
Fig. 5. Left ventricular model for wall motion and perfusion scoring during contrast 
echocardiography and standardized attribution to the main coronary arteries. 
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2.2.2 Perfusion scoring 
Regional perfusion scoring is based on visual evaluation of contrast enhancement in the 
myocardium. At rest the myocardium should be filled with contrast during 5 heart beats, 
while at peak stress the myocardium should be filled in 1-2 heart beats. Delayed 
enhancement is consistent with hypoperfusion or ischemia, while lack of enhancement is 
consistent with myocardial fibrosis of infarct scaring. However, artefacts like contrast 
destruction in the near field may cause false perfusion defects in the apical myocardium, 
while attenuation may cause false perfusion defects in the basal parts. In addition, perfusion 
defects in thin fibrotic myocardium may be underestimated because of shine-through effect.  
In patients with stable coronary artery disease, perfusion scoring by contrast stress 
echocardiography has been demonstrated to identify prognostically important angiographic 
coronary artery disease (multivessel disease and proximal stenosis in the left anterior 
descending artery) significantly better than wall motion scoring (Lønnebakken et al., 2009). 
However, anatomical variations in coronary anatomy as well as collateral circulation and 
coronary artery bypass grafting will influence the perfusion area of the individual coronary 
artery. Therefore, except for stenosis in the proximal left anterior descending artery, the 
anatomic culprit lesion can usually not be identified by MCE.  
2.2.3 Quantification of myocardial perfusion 
Quantification software assessing contrast enhancement from increase in video intensity 
over time has been developed (Agati et al., 2005). From quantitative analysis, typical 
contrast enhancement curves can be obtained for blood flow velocity (β), perfusion rate 











Fig. 6. Contrast enhancement curves: for normally perfused myocardium (red curve), 
ischemic/hypoperfused myocardium and for infarct area (blue curve), respectively. 
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that remain akinetic during stress indicate infarct scarring which will not benefit from 
revascularization. 
 
Panel A Panel B
 
Fig. 5. Left ventricular model for wall motion and perfusion scoring during contrast 
echocardiography and standardized attribution to the main coronary arteries. 
 
Contrast Echocardiography in Coronary Artery Disease 67 
2.2.2 Perfusion scoring 
Regional perfusion scoring is based on visual evaluation of contrast enhancement in the 
myocardium. At rest the myocardium should be filled with contrast during 5 heart beats, 
while at peak stress the myocardium should be filled in 1-2 heart beats. Delayed 
enhancement is consistent with hypoperfusion or ischemia, while lack of enhancement is 
consistent with myocardial fibrosis of infarct scaring. However, artefacts like contrast 
destruction in the near field may cause false perfusion defects in the apical myocardium, 
while attenuation may cause false perfusion defects in the basal parts. In addition, perfusion 
defects in thin fibrotic myocardium may be underestimated because of shine-through effect.  
In patients with stable coronary artery disease, perfusion scoring by contrast stress 
echocardiography has been demonstrated to identify prognostically important angiographic 
coronary artery disease (multivessel disease and proximal stenosis in the left anterior 
descending artery) significantly better than wall motion scoring (Lønnebakken et al., 2009). 
However, anatomical variations in coronary anatomy as well as collateral circulation and 
coronary artery bypass grafting will influence the perfusion area of the individual coronary 
artery. Therefore, except for stenosis in the proximal left anterior descending artery, the 
anatomic culprit lesion can usually not be identified by MCE.  
2.2.3 Quantification of myocardial perfusion 
Quantification software assessing contrast enhancement from increase in video intensity 
over time has been developed (Agati et al., 2005). From quantitative analysis, typical 
contrast enhancement curves can be obtained for blood flow velocity (β), perfusion rate 











Fig. 6. Contrast enhancement curves: for normally perfused myocardium (red curve), 
ischemic/hypoperfused myocardium and for infarct area (blue curve), respectively. 
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myocardium, the blood flow velocity is about 0.5 ml/s and the peak intensity level is 
rapidly reached (Fig.6 red curve). In ischemic myocardium, both the blood flow velocity and 
perfusion rate are reduced, the refilling time is increased while the total blood volume 
remains normal (Fig.6 green curve). This contrasts the reduced total blood volume 
characterizing the myocardial contrast enhancement in infracts scarring and myocardial 
fibrosis (Fig.6 blue curve) (Wei et al., 1998; Toledo et al., 2006).   
Using quantification, it is theoretically possible to compare myocardial perfusion in different 
regions and settings. However, previous studies have demonstrated that it is difficult to 
compare between different patients due to large interindividual variation. In a study of 20 
healthy subjects with normal wall motion and coronary angiography, both considerable 
inter-individual and also inter-regional variability in perfusion parameters were noted, 
suggesting that quantitative perfusion parameters currently are best suited for with-in 
patient repeated assessment, for instance during stress testing (Malm 2005). This was 
confirmed in a follow-up study of patients who underwent quantitative contrast stress 
echocardiography prior to and 9 months after percutaneous coronary revascularization. In 
this study, stress induced perfusion but not absolute perfusion parameters were improved 
in patients with angiographic successful result, while a lack of improvement in stress 
induced perfusion was associated with angiographically confirmed restenosis irrespective of 
patient symptoms (Lønnebakken et al., 2009). However, standardisation and assessment of 
optimal cut-off values for myocardial perfusion has to be derived from larger trials before 
quantification of myocardial perfusion can be used in clinical assessment of coronary artery 
disease (Abdelmoneim  et al., 2009). 
3. Clinical applications 
Contrast echocardiography has documented important clinical impact on diagnosis, risk 
prediction and follow-up of patients with different clinical syndromes of coronary artery 
disease as well as in detection of thrombotic complications in patients with ischemic heart 
disease. In addition assessing the total ischemic burden and viability by contrast 
echocardiography adds prognostic information in individual patients.  
3.1 Stable coronary artery disease 
Diagnosing stable coronary artery disease may be challenging, in particular since atypical 
symptoms are not uncommon. The most used diagnostic test in coronary artery disease, the 
exercise electrocardiogram, is associated with a low accuracy to detect significant angiographic 
coronary artery disease. Invasive coronary angiography is according to current guidelines the 
diagnostic gold standard. However, it is invasive and associated with potential risk for severe 
complications and allergic reactions, and includes radiation exposure. Furthermore, coronary 
angiography does not give information on the functional importance of a coronary stenosis. 
Stress echocardiography has an overall diagnostic sensitivity of 85% and specificity of 90% in 
detecting significant angiographic coronary artery disease from meta-analyses (Senior et al., 
2005; Picano et al., 2008). However, in 33% of patients referred for conventional stress 
echocardiography the image quality does not allow adequate evaluation. By adding 
ultrasound contrast during stress echocardiography almost all patients can be satisfactory 
examined by stress echocardiography and by simultaneous assessment of both myocardial 
function and perfusion (MCE) the sensitivity of detecting significant angiographic coronary 
artery stenosis may be increased to 90% but the specificity is reduced (Senior et al., 2009). 
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In a meta-analysis of 8 studies the sensitivity and specificity of detecting coronary artery 
disease by myocardial contrast stress echocardiography was 83 and 80 %, respectively.  In 
patients with known or suspected coronary artery disease, perfusion was significantly 
better than wall motion analysis in detecting angiographic coronary artery stenosis, in 
particularly at intermediate stress level (Elhendy et al., 2004). In addition, in patients with 
known coronary artery disease awaiting percutaneous coronary intervention, perfusion 
scoring was significantly better than wall motion scoring in identifying patients with 
prognostic significant angiographic coronary artery stenosis, like triple-vessel disease and 
proximal stenosis in the left anterior descending artery (Lønnebakken et al., 2009). Of note 
this could be achieved at intermediate stress level. Failure to achieve adequate stress level 
is an important limitation in assessing coronary artery disease by stress 
electrocardiography or stress echocardiography. It has been demonstrated that using 
contrast stress echocardiography with perfusion assessment (MCE) seems to overcome 
this limitation.  
The weak association between the degree of angiographic coronary artery stenosis and 
quantitative myocardial perfusion by contrast stress echocardiography has been noted in 
several studies (Malm et al., 2006; Peltier et al., 2004; Perez et al., 2004; Lønnebakken et al., 
2009). This may be explained by the fact that many other factors than coronary artery lumen 
diameter reduction is important for myocardial perfusion, including coronary flow 
autoregulation, collateral circulation, stenosis length and serial stenosis in addition to 
hemodynamic condition are important for myocardial perfusion. Although, mainly due to 
anatomic variation in coronary anatomy, contrast stress echocardiography has limited 
power to predict the anatomical localisation of angiographic coronary artery stenosis, the 
method is accurate to predict proximal stenosis in the left anterior descending coronary 
artery and to identify patients with multivessel disease. In addition, assessing the total 
ischemic burden in the individual patient may be clinical important for choosing the optimal 
treatment. It has been demonstrated that only patients with an ischemic burden >20% will 
benefit prognostically from revascularization, otherwise revascularization will only have 
symptomatic effect, suggesting that asymptomatic or low-symptomatic patients will have 
no or little effect and may be equally well off treated medically.  
3.2 Acute coronary syndrome 
Patients with acute coronary syndrome are a heterogeneous group with varying disease 
severity and prognosis, from unstable angina pectoris, non-ST elevation myocardial 
infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). It is well known that 
both short- and long-term prognosis in NSTEMI patients is as severe as STEMI patients, 
although the incidence of acute coronary artery occlusions varies. It has been demonstrated 
that contrast echocardiography can be used for risk assessment in acute coronary syndrome 
patients (Senior et al., 2004; Khang et al., 2005).  
3.2.1 Unstable angina pectoris 
In patients hospitalized with acute chest pain but having normal serum troponin level, 
contrast echocardiography has been shown to be a useful tool to distinguish between 
patients with acute coronary syndrome and non-cardiac chest pain (Jeetley et al., 2007; 
Rinkevich et al., 2005; Kaul et al., 2004). Another study in 957 patients with acute chest pain 
and a non-diagnostic electrocardiogram demonstrated that myocardial perfusion by 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 68
myocardium, the blood flow velocity is about 0.5 ml/s and the peak intensity level is 
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fibrosis (Fig.6 blue curve) (Wei et al., 1998; Toledo et al., 2006).   
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regions and settings. However, previous studies have demonstrated that it is difficult to 
compare between different patients due to large interindividual variation. In a study of 20 
healthy subjects with normal wall motion and coronary angiography, both considerable 
inter-individual and also inter-regional variability in perfusion parameters were noted, 
suggesting that quantitative perfusion parameters currently are best suited for with-in 
patient repeated assessment, for instance during stress testing (Malm 2005). This was 
confirmed in a follow-up study of patients who underwent quantitative contrast stress 
echocardiography prior to and 9 months after percutaneous coronary revascularization. In 
this study, stress induced perfusion but not absolute perfusion parameters were improved 
in patients with angiographic successful result, while a lack of improvement in stress 
induced perfusion was associated with angiographically confirmed restenosis irrespective of 
patient symptoms (Lønnebakken et al., 2009). However, standardisation and assessment of 
optimal cut-off values for myocardial perfusion has to be derived from larger trials before 
quantification of myocardial perfusion can be used in clinical assessment of coronary artery 
disease (Abdelmoneim  et al., 2009). 
3. Clinical applications 
Contrast echocardiography has documented important clinical impact on diagnosis, risk 
prediction and follow-up of patients with different clinical syndromes of coronary artery 
disease as well as in detection of thrombotic complications in patients with ischemic heart 
disease. In addition assessing the total ischemic burden and viability by contrast 
echocardiography adds prognostic information in individual patients.  
3.1 Stable coronary artery disease 
Diagnosing stable coronary artery disease may be challenging, in particular since atypical 
symptoms are not uncommon. The most used diagnostic test in coronary artery disease, the 
exercise electrocardiogram, is associated with a low accuracy to detect significant angiographic 
coronary artery disease. Invasive coronary angiography is according to current guidelines the 
diagnostic gold standard. However, it is invasive and associated with potential risk for severe 
complications and allergic reactions, and includes radiation exposure. Furthermore, coronary 
angiography does not give information on the functional importance of a coronary stenosis. 
Stress echocardiography has an overall diagnostic sensitivity of 85% and specificity of 90% in 
detecting significant angiographic coronary artery disease from meta-analyses (Senior et al., 
2005; Picano et al., 2008). However, in 33% of patients referred for conventional stress 
echocardiography the image quality does not allow adequate evaluation. By adding 
ultrasound contrast during stress echocardiography almost all patients can be satisfactory 
examined by stress echocardiography and by simultaneous assessment of both myocardial 
function and perfusion (MCE) the sensitivity of detecting significant angiographic coronary 
artery stenosis may be increased to 90% but the specificity is reduced (Senior et al., 2009). 
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better than wall motion analysis in detecting angiographic coronary artery stenosis, in 
particularly at intermediate stress level (Elhendy et al., 2004). In addition, in patients with 
known coronary artery disease awaiting percutaneous coronary intervention, perfusion 
scoring was significantly better than wall motion scoring in identifying patients with 
prognostic significant angiographic coronary artery stenosis, like triple-vessel disease and 
proximal stenosis in the left anterior descending artery (Lønnebakken et al., 2009). Of note 
this could be achieved at intermediate stress level. Failure to achieve adequate stress level 
is an important limitation in assessing coronary artery disease by stress 
electrocardiography or stress echocardiography. It has been demonstrated that using 
contrast stress echocardiography with perfusion assessment (MCE) seems to overcome 
this limitation.  
The weak association between the degree of angiographic coronary artery stenosis and 
quantitative myocardial perfusion by contrast stress echocardiography has been noted in 
several studies (Malm et al., 2006; Peltier et al., 2004; Perez et al., 2004; Lønnebakken et al., 
2009). This may be explained by the fact that many other factors than coronary artery lumen 
diameter reduction is important for myocardial perfusion, including coronary flow 
autoregulation, collateral circulation, stenosis length and serial stenosis in addition to 
hemodynamic condition are important for myocardial perfusion. Although, mainly due to 
anatomic variation in coronary anatomy, contrast stress echocardiography has limited 
power to predict the anatomical localisation of angiographic coronary artery stenosis, the 
method is accurate to predict proximal stenosis in the left anterior descending coronary 
artery and to identify patients with multivessel disease. In addition, assessing the total 
ischemic burden in the individual patient may be clinical important for choosing the optimal 
treatment. It has been demonstrated that only patients with an ischemic burden >20% will 
benefit prognostically from revascularization, otherwise revascularization will only have 
symptomatic effect, suggesting that asymptomatic or low-symptomatic patients will have 
no or little effect and may be equally well off treated medically.  
3.2 Acute coronary syndrome 
Patients with acute coronary syndrome are a heterogeneous group with varying disease 
severity and prognosis, from unstable angina pectoris, non-ST elevation myocardial 
infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). It is well known that 
both short- and long-term prognosis in NSTEMI patients is as severe as STEMI patients, 
although the incidence of acute coronary artery occlusions varies. It has been demonstrated 
that contrast echocardiography can be used for risk assessment in acute coronary syndrome 
patients (Senior et al., 2004; Khang et al., 2005).  
3.2.1 Unstable angina pectoris 
In patients hospitalized with acute chest pain but having normal serum troponin level, 
contrast echocardiography has been shown to be a useful tool to distinguish between 
patients with acute coronary syndrome and non-cardiac chest pain (Jeetley et al., 2007; 
Rinkevich et al., 2005; Kaul et al., 2004). Another study in 957 patients with acute chest pain 
and a non-diagnostic electrocardiogram demonstrated that myocardial perfusion by 
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contrast echocardiography was better than other commonly used risk score models like the 
Thrombolysis in Myocardial Infarction (TIMI) risk score (Antman et al., 2000) to 
discriminate between patients with  intermediate or high risk for reinfarction or death (Tong 
et al., 2005). Based on current documentation, advanced echocardiography is underused in 
diagnostics and management of patients with acute chest pain.   
 
Variables in TIM I  risk  score score 
Age ≥65 years 1 
≥3 risk factors of CAD (family history of CAD, hypertension, diabetes, current 
smoking, hypercholesterolemia) 1 
Prior CAD (previous MI, CABG, PCI or known angiographic stenosis ≥50%) 1 
ST-segment depression ≥0.05 mV in ≥2 ECG leads 1 
≥2 episodes of chest pain the last 24 hour 1 
Aspirin the last 7 days or unfractionated heparin the last 24 hour 1 
Elevated serum cardiac markers 1 
Table 2. Thrombolysis In Myocardial Infarction risk score (TIMI). 
3.2.2 Non-ST elevation myocardial infarction 
Current guidelines for management of NSTEMI are diverging, recommending invasive risk 
stratification and revascularization within 12-72 hours in patients at intermediate and high 
risk (Bassand et al., 2007; Smith et al., 2006). In clinical risk assessment, TIMI risk score is 
one of the most recommended and widely used models in NSTEMI patients (Table 2). Of 
note, these clinical risk score models may underestimate angiographic coronary artery 
disease severity, in particular in patients scored as intermediate risk (Volat et al., 2008). In a 
recently published series of 110 patients with NSTEMI, the extent of myocardial ischemia 
assessed by contrast echocardiography was a better predictor of angiographic severe 
coronary artery disease than the TIMI risk score, in particular in identifying patients with 
severe disease like left main stem stenosis, trippel-vessel disease or multi-vessel disease 
including proximal stenosis in the left anterior descending artery and also better than wall 
motion scoring analysis (Fig. 7) (Lønnebakken et al., 2011). In another study in NSTEMI 
patients, about 30% of the patients had an acute occlusion of a main coronary artery despite 
normal electrocardiogram. In this study, deformation analysis by echocardiography has 
proven useful in identifying NSTEMI patients with severe angiographic coronary artery 
disease (Grenne et al., 2010). In particular serial assessment of regional left ventricular strain 
may identify these patients while awaiting coronary angiography and revascularisation. 
Theoretically, detection of these patients by either contrast echocardiography or other 
advanced imaging techniques represents new tools for identification of patients with high 
subclinical ischemic burden that may benefit from earlier revascularization.  
3.2.3 ST elevation myocardial infarction 
In acute STEMI the recommended treatment is immediate coronary angiography and 
revascularization. Contrast echocardiography can assess area at risk and help in diagnosing 
acute myocardial infarction in patients with acute chest pain and a non-diagnostic ECG, 
particularly common in patients with acute occlusion of the circumflex artery (Hayat & 
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Senior., 2008). But contrast echocardiography will not be indicated in pre-catheterization 
evaluation of most patients with STEMI.  
 
 
Fig. 7. Contrast echocardiography in apical 4-chamber, 2-chamber and 3-chamber views 
(upper panels) demonstrating the extensive reduction of myocardial perfusion in a NSTEMI 
patient with angiographic trippel-vessel disease including acute occlusion of the right 
coronary artery and left main stem stenosis (lower panels). 
In spite of successful reopening of the infarct related artery by percutaneous coronary 
intervention, some STEMI patients still develop unexpectedly large myocardial infarctions 
due to the no-reflow phenomenon. The no-reflow phenomenon is caused by impaired 
microcirculation which can be a consequence of peripheral embolization during the 
percutaneous revascularization procedure or revascularisation damage due to inflammation 
and oedema causing microvascular obstruction and subsequent myocardial necrosis. The 
no-reflow phenomenon after revascularization can be diagnosed by MCE (Kaul., 2006). Lack 
of reperfusion after coronary intervention predicts myocardial necrosis, reduced left 
ventricular function, left ventricular remodelling and subsequent development of heart 
failure. Thus, MCE may be used in STEMI patients to identify successful reopening of the 
infarct related artery and to give prognostic information by identifying patients with no-
reflow who need additional treatment in the acute and chronic phase of a STEMI (Dwivedi 
et al., 2008; Niccoli et al., 2009; Galiuto et al., 2010) 
In addition to guide and evaluate treatment, an ongoing study evaluates the effect of 
ultrasound contrast enhanced thrombolysis in acute treatment of STEMI. The ongoing 
Sonolysis trial uses a combination of ultrasound induced contrast microbubbles destruction 
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normal electrocardiogram. In this study, deformation analysis by echocardiography has 
proven useful in identifying NSTEMI patients with severe angiographic coronary artery 
disease (Grenne et al., 2010). In particular serial assessment of regional left ventricular strain 
may identify these patients while awaiting coronary angiography and revascularisation. 
Theoretically, detection of these patients by either contrast echocardiography or other 
advanced imaging techniques represents new tools for identification of patients with high 
subclinical ischemic burden that may benefit from earlier revascularization.  
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In acute STEMI the recommended treatment is immediate coronary angiography and 
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particularly common in patients with acute occlusion of the circumflex artery (Hayat & 
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evaluation of most patients with STEMI.  
 
 
Fig. 7. Contrast echocardiography in apical 4-chamber, 2-chamber and 3-chamber views 
(upper panels) demonstrating the extensive reduction of myocardial perfusion in a NSTEMI 
patient with angiographic trippel-vessel disease including acute occlusion of the right 
coronary artery and left main stem stenosis (lower panels). 
In spite of successful reopening of the infarct related artery by percutaneous coronary 
intervention, some STEMI patients still develop unexpectedly large myocardial infarctions 
due to the no-reflow phenomenon. The no-reflow phenomenon is caused by impaired 
microcirculation which can be a consequence of peripheral embolization during the 
percutaneous revascularization procedure or revascularisation damage due to inflammation 
and oedema causing microvascular obstruction and subsequent myocardial necrosis. The 
no-reflow phenomenon after revascularization can be diagnosed by MCE (Kaul., 2006). Lack 
of reperfusion after coronary intervention predicts myocardial necrosis, reduced left 
ventricular function, left ventricular remodelling and subsequent development of heart 
failure. Thus, MCE may be used in STEMI patients to identify successful reopening of the 
infarct related artery and to give prognostic information by identifying patients with no-
reflow who need additional treatment in the acute and chronic phase of a STEMI (Dwivedi 
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In addition to guide and evaluate treatment, an ongoing study evaluates the effect of 
ultrasound contrast enhanced thrombolysis in acute treatment of STEMI. The ongoing 
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at high mechanical index ultrasound and thrombolysis, where destruction of microbubbles 
causes streaming and thereby improves the effect of thrombolysis in reopening of the infarct 
related artery (Slikkerveer et al., 2008).  
 
 
Fig. 8. Complications in acute myocardial infarction. Myocardial mural thrombus in the 
apex of the left ventricle, with lack of contrast enhancement due to the thrombus avascular 
characteristics (Panel A and B). In comparison, the typical contrast enhancement in a patient 
with pulmonary carcinoma and a myocardial metastasis in the right ventricle (Panel C).  
Development of intraventricular mural thrombus is a feared complication to acute 
myocardial infarction which untreated may lead to severe thromboembolic episodes. A 
magnetic resonance study demonstrated that mural thrombus formation in patients with 
acute coronary syndromes may be more common than previously anticipated (Solheim et 
al., 2010). However, suspected mural thrombus may be ruled out in about 90% of patients 
by contrast echocardiography (Kurt et al., 2009; Hamilton-Craige et al., 2010). Diagnosing a 
mural thrombus with contrast echocardiography is simple and can be performed with a 
single ultrasound contrast bolus injection. A mural thrombus is characterized by a lack of 
contrast enhancement due to its avascular nature (Fig 8 Panel A and B). In contrast, a 
myocardial tumor is characterized by contrast enhancement which is particular high in 
malignant tumores that are highly vascularised structures (Fig.8 panel C).  
In acute myocardial infarction, myocardial rupture is a rare and deadly complication. A 
rupture of the free ventricular wall is usually associated with sudden death, but 
occasionally, epicardial coverage occurs and subsequent formation of a ventricular 
pseudoaneurysm. Ventricular pseudoaneurysms can be difficult to diagnose by 
conventional echocardiography (Fig. 9 left panel), but are easy to recognize after injection of 
an ultrasound contrast agent during imaging (Fig. 9 right panel).  
3.3 Restenosis after revascularization 
In patients undergoing percutaneous coronary intervention with stent implantation, 10-30% 
will develop significant angiographic restenosis in spite of initial successful treatment. 
Restenosis is caused by intimal hyperplasia and is asymptomatic in 50% of patients (Giedd 
& Bergmann., 2004). However, even in asymptomatic patients development of restenosis is 
associated with a poorer prognosis (Pfisterer et al., 1993; Zellweger et al., 2003). Non- 
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Fig. 9. Extracardial contrast enhancement due to a pseudoaneurysm in the lateral wall of the 
left ventricle (right panel) not visible with conventional echocardiography (left panel). 
invasive diagnosis of restenosis can be challenging. Previous SPECT studies have 
demonstrated that normalization of regional myocardial perfusion usually occurs after 
successful revascularization (Manyari et al., 1988; Zhang et al., 2004). In a follow-up study 
using quantitative contrast stress echocardiography in 33 patients with stable angina 
pectoris treated with percutaneous coronary intervention and stent implantation, there was 
no improvement in stress-induced myocardial perfusion during follow-up in patients who 
had developed a significant angiographic restenosis, while the stress-induced perfusion was 
improved in patients with successful revascularisation at 9 months (Lønnebakken et al., 
2009).  
At present, quantitative contrast stress echocardiography is not recommended in routine 
assessment of coronary artery disease due to inter-individual variation and lack of data on 
normal values and cut-off values indicating ischemia for this method. Still, serial assessment 
in individual patients may be useful. 
3.4 Non-obstructive coronary artery disease
Although coronary angiography remains the gold standard for diagnosis of coronary artery 
disease, it should be kept in mind that myocardial ischemia may be present in spite of 
angiographically open epicardial coronary arteries, a condition known as non-obstructive 
ischemic heart disease. This condition cannot be diagnosed using angiography alone, but 
requires additional use of perfusion assessment with cardiac magnetic resonance or MCE.  
In patients with acute coronary syndrome, non-obstructive ischemic heart disease is present 
in 15% of women and 9% of men (Berger et al., 2009). Cardiac magnetic resonance studies in 
NSTEMI patients have demonstrated myocardial infarction in up to 34% of patients with 
normal coronary arteries by coronary angiography.  Clot autolysis and recanalisation of the 
infarct related artery are the main reasons for this finding as well as microvascular disease 
that can not be detected by coronary angiography, the current diagnostic gold standard.  In 
patients with recurrent hospitalisation for chest pain and “normal” coronary arteries by 
coronary angiography additional non-invasive cardiac imaging should be performed. MCE 
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rupture of the free ventricular wall is usually associated with sudden death, but 
occasionally, epicardial coverage occurs and subsequent formation of a ventricular 
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3.3 Restenosis after revascularization 
In patients undergoing percutaneous coronary intervention with stent implantation, 10-30% 
will develop significant angiographic restenosis in spite of initial successful treatment. 
Restenosis is caused by intimal hyperplasia and is asymptomatic in 50% of patients (Giedd 
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Fig. 9. Extracardial contrast enhancement due to a pseudoaneurysm in the lateral wall of the 
left ventricle (right panel) not visible with conventional echocardiography (left panel). 
invasive diagnosis of restenosis can be challenging. Previous SPECT studies have 
demonstrated that normalization of regional myocardial perfusion usually occurs after 
successful revascularization (Manyari et al., 1988; Zhang et al., 2004). In a follow-up study 
using quantitative contrast stress echocardiography in 33 patients with stable angina 
pectoris treated with percutaneous coronary intervention and stent implantation, there was 
no improvement in stress-induced myocardial perfusion during follow-up in patients who 
had developed a significant angiographic restenosis, while the stress-induced perfusion was 
improved in patients with successful revascularisation at 9 months (Lønnebakken et al., 
2009).  
At present, quantitative contrast stress echocardiography is not recommended in routine 
assessment of coronary artery disease due to inter-individual variation and lack of data on 
normal values and cut-off values indicating ischemia for this method. Still, serial assessment 
in individual patients may be useful. 
3.4 Non-obstructive coronary artery disease
Although coronary angiography remains the gold standard for diagnosis of coronary artery 
disease, it should be kept in mind that myocardial ischemia may be present in spite of 
angiographically open epicardial coronary arteries, a condition known as non-obstructive 
ischemic heart disease. This condition cannot be diagnosed using angiography alone, but 
requires additional use of perfusion assessment with cardiac magnetic resonance or MCE.  
In patients with acute coronary syndrome, non-obstructive ischemic heart disease is present 
in 15% of women and 9% of men (Berger et al., 2009). Cardiac magnetic resonance studies in 
NSTEMI patients have demonstrated myocardial infarction in up to 34% of patients with 
normal coronary arteries by coronary angiography.  Clot autolysis and recanalisation of the 
infarct related artery are the main reasons for this finding as well as microvascular disease 
that can not be detected by coronary angiography, the current diagnostic gold standard.  In 
patients with recurrent hospitalisation for chest pain and “normal” coronary arteries by 
coronary angiography additional non-invasive cardiac imaging should be performed. MCE 
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can be used to diagnose myocardial ischemia in such patients and thereby distinguish 
between patients with non-cardiac chest pain and patients with non-obstructive ischemic 
heart disease. Non-obstructive ischemic heart disease most often is caused by microvascular 
disease associated with diabetes mellitus, obesity and hypertension, but also hemodynamic 
changes like increased left ventricular filling pressure and increased arterial stiffness can 
cause reduced myocardial perfusion pressure and hence myocardial ischemia despite 
angiographically normal epicardial coronary arteries (London et al., 2004).  Chronic 
myocardial ischemia in such patients may promote development of myocardial fibrosis and 
secondary structural changes in the left ventricle, finally leading to functional impairment 
and heart failure (Niccoli et al., 2009).   
Another recently recognized condition mainly affecting women is the Takotsubo 
cardiomyopathy, mimicking an acute myocardial infarction. The exact pathophysiological 
mechanism remains unknown in Takotsubo cardiomyopathy, but it involves myocardial 
hypoperfusion that can be diagnosed by contrast echocardiography causing functional 
impairment mainly in the apical part of the left ventricle with the characteristic apical 
ballooning (Fig. 10) (Abdelmoneim et al., 2009). The microvascular involvement is also 
confirmed by early cardiac MRI demonstrating late gadolinium uptake suggesting diffuse 
microcirculation damage (Avegliano et al., 2011).  
 
 
Fig. 10. Takotsubo Cardiomyopathy. Contrast echocardiography in diastole and systole 
illustrating the apical akinesia and ballooning of the left ventricle in an apical 4-chamber 
view, in addition there is a delayed contrast enhancement in the apical segments of the left 
ventricle. The right panel shows the normal coronary angiogram confirming the diagnosis 
Takotsubo cardiomyopathy. 
4. Conclusion 
Contrast echocardiography allows simultaneous assessment of regional myocardial function 
and perfusion, improving non-invasive diagnosis and assessment of coronary artery 
disease. Contrast echocardiography gives information on the physiological impact of the 
coronary artery stenosis, reveals the ischemic burden, detects viable myocardium and may 
 
Contrast Echocardiography in Coronary Artery Disease 75 
act as a supplemental tool to coronary angiography in management of coronary artery 
disease and in follow-up after treatment. In addition, the ability to diagnose myocardial 
ischemia in patients with no-reflow phenomenon or microvascular disease and 
angiographically normal coronary arteries may help distinguishing patients with non-
obstructive ischemic coronary artery disease from patients with non-cardiac chest pain. 
Future studies using targeted contrast microbubbles against specific disease processes may 
further improve diagnosis in ischemic coronary artery disease, and on-going studies explore 
the use of ultrasound contrast agents to potentiate the effect of thrombolysis in acute 
coronary artery occlusions.  
5. References 
Abdelmoneim SS, Dhoble A, Bernier M, Erwin PJ, Korosoglou G, Senior R, Moir S, 
Kowatsch I, Xian-Hong S, Muro T, Dawson D, Vogel R, Wei K, West CP, Montori 
VM, Pellikka PA, Abdel-Kader SS & Mulvagh SL. (2009) Quantitative myocardial 
contrast echocardiography during pharmacological stress for diagnosis of coronary 
artery disease: a systematic review and meta-analysis of diagnostic accuracy 
studies. Eur J Echocardiogr 2009;10(7):813-825 
Abdelmoneim SS, Mankad SV, Bernier M, Dhoble A, Hagen ME, Ness SA, Chandrasekaran 
K, Pellikka PA, Oh JK & Mulvagh SL. (2009). Microvascular function in Takotsubo 
cardiomyopathy with contrast echocardiography: prospective evaluation and 
review of literature. J Am Soc Echocardiogr . 2009;22:1249-55. 
Agati L, Tonti G, Galiuto L, Di Bello V, Funaro S, Madonna MP, Garramone B & Magri T, 
A.M.I.C.I Investigators. (2005). Quantification methods in contrast 
echocardiography. Eur J Echocardiogr 2005;6 Suppl 2:S14-20.  
Antman EM, Cohen M, Bernink PJ, Mc Cabe CH, Horacek T, Papuchis G, Mauntner B, 
Corbalan R, Radley D & Braunwald El. (2000). The TIMI risk score for unstable 
angina/non-ST elevation MI: A method for prognostication and therapeutic 
decision making. JAMA 2000;284:835-42. 
Avegeliano G, Huguet M, Costabel JP, Ronderos R, Bijnens B, Kuschnir P, Thierer J, Tob\on-
Gomez C, Martinez GO & Frangi A. (2011) Morphologic pattern of late gadolinium 
enhancement in takotsubo cardiomyopathy detected by early cardivascular 
magnetic resonance. Clin.Cardiol. 2011; 34:178-82. 
Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, 
Hasdai D, Ohman EM, Wallentin L & Wijns W. (2007) Guidelines for the diagnosis 
and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 
2007;28(13):1598-1660. 
Berger JS, Elliott L, Gallup D, RoeM, Granger CB, Armstrong PW, Simes RJ, White HD, Van 
de Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker 
RC & Douglas PS. (2009) Sex differences in mortality following acute coronary 
syndromes. JAMA 2009; 302:874-82. 
Chadderdon SM & Kaul S. Molecular imaging with contrast enhanced ultrasound. (2010) J
Nucl Cardiol 2010; 17:667-77. 
Chahal NS & Senior R. Clinical applications of left ventricular opacification. (2010) JACC 
Cardiovasc Imaging 2010; 3:188-96. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 74
can be used to diagnose myocardial ischemia in such patients and thereby distinguish 
between patients with non-cardiac chest pain and patients with non-obstructive ischemic 
heart disease. Non-obstructive ischemic heart disease most often is caused by microvascular 
disease associated with diabetes mellitus, obesity and hypertension, but also hemodynamic 
changes like increased left ventricular filling pressure and increased arterial stiffness can 
cause reduced myocardial perfusion pressure and hence myocardial ischemia despite 
angiographically normal epicardial coronary arteries (London et al., 2004).  Chronic 
myocardial ischemia in such patients may promote development of myocardial fibrosis and 
secondary structural changes in the left ventricle, finally leading to functional impairment 
and heart failure (Niccoli et al., 2009).   
Another recently recognized condition mainly affecting women is the Takotsubo 
cardiomyopathy, mimicking an acute myocardial infarction. The exact pathophysiological 
mechanism remains unknown in Takotsubo cardiomyopathy, but it involves myocardial 
hypoperfusion that can be diagnosed by contrast echocardiography causing functional 
impairment mainly in the apical part of the left ventricle with the characteristic apical 
ballooning (Fig. 10) (Abdelmoneim et al., 2009). The microvascular involvement is also 
confirmed by early cardiac MRI demonstrating late gadolinium uptake suggesting diffuse 
microcirculation damage (Avegliano et al., 2011).  
 
 
Fig. 10. Takotsubo Cardiomyopathy. Contrast echocardiography in diastole and systole 
illustrating the apical akinesia and ballooning of the left ventricle in an apical 4-chamber 
view, in addition there is a delayed contrast enhancement in the apical segments of the left 
ventricle. The right panel shows the normal coronary angiogram confirming the diagnosis 
Takotsubo cardiomyopathy. 
4. Conclusion 
Contrast echocardiography allows simultaneous assessment of regional myocardial function 
and perfusion, improving non-invasive diagnosis and assessment of coronary artery 
disease. Contrast echocardiography gives information on the physiological impact of the 
coronary artery stenosis, reveals the ischemic burden, detects viable myocardium and may 
 
Contrast Echocardiography in Coronary Artery Disease 75 
act as a supplemental tool to coronary angiography in management of coronary artery 
disease and in follow-up after treatment. In addition, the ability to diagnose myocardial 
ischemia in patients with no-reflow phenomenon or microvascular disease and 
angiographically normal coronary arteries may help distinguishing patients with non-
obstructive ischemic coronary artery disease from patients with non-cardiac chest pain. 
Future studies using targeted contrast microbubbles against specific disease processes may 
further improve diagnosis in ischemic coronary artery disease, and on-going studies explore 
the use of ultrasound contrast agents to potentiate the effect of thrombolysis in acute 
coronary artery occlusions.  
5. References 
Abdelmoneim SS, Dhoble A, Bernier M, Erwin PJ, Korosoglou G, Senior R, Moir S, 
Kowatsch I, Xian-Hong S, Muro T, Dawson D, Vogel R, Wei K, West CP, Montori 
VM, Pellikka PA, Abdel-Kader SS & Mulvagh SL. (2009) Quantitative myocardial 
contrast echocardiography during pharmacological stress for diagnosis of coronary 
artery disease: a systematic review and meta-analysis of diagnostic accuracy 
studies. Eur J Echocardiogr 2009;10(7):813-825 
Abdelmoneim SS, Mankad SV, Bernier M, Dhoble A, Hagen ME, Ness SA, Chandrasekaran 
K, Pellikka PA, Oh JK & Mulvagh SL. (2009). Microvascular function in Takotsubo 
cardiomyopathy with contrast echocardiography: prospective evaluation and 
review of literature. J Am Soc Echocardiogr . 2009;22:1249-55. 
Agati L, Tonti G, Galiuto L, Di Bello V, Funaro S, Madonna MP, Garramone B & Magri T, 
A.M.I.C.I Investigators. (2005). Quantification methods in contrast 
echocardiography. Eur J Echocardiogr 2005;6 Suppl 2:S14-20.  
Antman EM, Cohen M, Bernink PJ, Mc Cabe CH, Horacek T, Papuchis G, Mauntner B, 
Corbalan R, Radley D & Braunwald El. (2000). The TIMI risk score for unstable 
angina/non-ST elevation MI: A method for prognostication and therapeutic 
decision making. JAMA 2000;284:835-42. 
Avegeliano G, Huguet M, Costabel JP, Ronderos R, Bijnens B, Kuschnir P, Thierer J, Tob\on-
Gomez C, Martinez GO & Frangi A. (2011) Morphologic pattern of late gadolinium 
enhancement in takotsubo cardiomyopathy detected by early cardivascular 
magnetic resonance. Clin.Cardiol. 2011; 34:178-82. 
Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, 
Hasdai D, Ohman EM, Wallentin L & Wijns W. (2007) Guidelines for the diagnosis 
and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 
2007;28(13):1598-1660. 
Berger JS, Elliott L, Gallup D, RoeM, Granger CB, Armstrong PW, Simes RJ, White HD, Van 
de Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker 
RC & Douglas PS. (2009) Sex differences in mortality following acute coronary 
syndromes. JAMA 2009; 302:874-82. 
Chadderdon SM & Kaul S. Molecular imaging with contrast enhanced ultrasound. (2010) J
Nucl Cardiol 2010; 17:667-77. 
Chahal NS & Senior R. Clinical applications of left ventricular opacification. (2010) JACC 
Cardiovasc Imaging 2010; 3:188-96. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 76
Crossman DC. (2004) The pathophysiology of myocardial ischaemia. Heart 2004;90(5):576-
580. 
Dijkmans PA, Senior R, Becher H, Porter TR, Wei K, Visser CA & Kamp O. (2006). 
Myocardial contrast echocardiography evolving as a clinically feasible technique 
for accurate, rapid, and safe assessment of myocardial perfusion: the evidence so 
far. J Am Coll Cardiol 2006;48(11):2168-2177. 
Dwivedi G, Janardhanan R, Hayat SA, Lim TK, Greaves K & Senior R. (2008) Relationship 
between myocardial perfusion with myocardial contrast echocardiography and 
function early after acute myocardial infarction for the prediction of late recovery 
of function. Int J Cardiol 2008. 
Elhendy A, O'Leary EL, Xie F, McGrain AC, Anderson JR & Porter TR. (2004). Comparative 
accuracy of real-time myocardial contrast perfusion imaging and wall motion 
analysis during dobutamine stress echocardiography for the diagnosis of coronary 
artery disease. J Am Coll Cardiol 2004;44(11):2185-2191. 
Elhendy A & Porter TR. (2005) Assessment of myocardial perfusion with real-time 
myocardial contrast echocardiography: methodology and clinical applications. J
Nucl Cardiol 2005;12(5):582-590. 
Galiuto L, Paraggio L, Liuzzo G, de Caterina AR & Crea F. (2010) Predicting the no-reflow 
phenomenon following sucessful percutaneous coronary intervention. Biomark. 
Med. 2010; 4:403-20. 
Giedd KN & Bergmann SR.(2004) Myocardial perfusion imaging following percutaneous 
coronary intervention: the importance of restenosis, disease progression, and 
directed reintervention. J Am Coll Cardiol 2004;43(3):328-336. 
Grenne B, Eek C, Sjøli B, Dahlslett T, Uchto M, Hol PK, Skulstad H, Smiseth OA, Edvardsen 
T & Brunvand H. (2010) Acute coronary occlusion in non-ST-elevation acute 
coronary syndrome: outcome and early identification by strain echocardiography. 
Heart 2010; 96:1550-6. 
Hamilton-Craig C, Boga T, West C, Kelly N, Anscombe R, Burstow D & Platts D. (2010) 
Contrast echocardiography in Australian clinical practise. Heart Lung Circ 2010; 
19:385-94. 
Hayat SA & Senior R. (2008) Myocardial contrast echocardiography in ST elevation 
myocardial infarction: ready for prime time? Eur Heart J 2008; 29:299-314. 
Hoffmann R, Borges AC, Kasprzak JD, von BS, Firschke C, Greis C, Engelhardt M, Becher H 
& Vanoverschelde JL.(2007) Analysis of myocardial perfusion or myocardial 
function for detection of regional myocardial abnormalities. An echocardiographic 
multicenter comparison study using myocardial contrast echocardiography and 2D 
echocardiography. Eur J Echocardiogr 2007;8(6):438-448. 
Jeetley P, Burden L, Greaves K & Senior R. (2007). Prognostic value of myocardial  contrast 
echocardiography in patients presenting to hospital with acute chest pain and 
negative troponin. Am J Cardiol 2007;99(10):1369-1373. 
Kaufmann BA & Lindner JR.(2007) Molecular imaging with targeted contrast ultrasound. 
Curr Opin Biotechnol 2007;18(1):11-16. 
Kaul S, Senior R, Firschke C, Wang XQ, Lindner J, Villanueva FS, Firozan S, Kontos MC, 
Taylor A, Nixon IJ, Watson DD & Harrell FE. (2004) Incremental value of cardiac 
 
Contrast Echocardiography in Coronary Artery Disease 77 
imaging in patients presenting to the emergency department with chest pain and 
without ST-segment elevation: a multicenter study. Am Heart J 2004;148(1):129-136. 
Kaul S. (2006) Evaluating the 'no reflow' phenomenon with myocardial contrast 
echocardiography. Basic Res Cardiol 2006;101(5):391-399. 
Kang DH, Kang SJ, Song JM, Choi KJ, Hong MK, Song JK, Park SW & Park SJ. (2005) 
Efficacy of myocardial contrast echocardiography in the diagnosis and risk 
stratification of acute coronary syndrome. Am J Cardiol 2005;96(11):1498-1502. 
Kurt M, Shaikh KA, Peterson L, Kurrelmeyer KM, Shah G, Nagueh SF, Fromm R, Quinones 
MA & Zoghbi WA. (2009) Impact of contrast echocardiography on evaluation of  
ventricular function and clinical management in a large prospective cohort. J Am 
Coll Cardiol. 2009;3:802-10. 
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, 
Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John SM & Stewart 
W. (2006) Recommendations for chamber quantification. Eur J Echocardiogr 
2006;7(2):79-108. 
Leong-Poi H, Rim SJ, Le DE, Fisher NG, Wei K & Kaul S.(2002) Perfusion versus function: 
the ischemic cascade indemand ischemia: implications of single-vessel versus 
multivessel stenosis. Circulation 2002;105(8):987-992. 
London GM, Marchais SJ, Guerin AP & Pannier B. (2004) Arterial stiffness : pathophysiology 
and clinical impact. Clin Exp Hypertens 2004;26:689-99.
Lønnebakken MT, Bleie Ø, Strand E, Staal EM, Nygård OK & Gerdts E. (2009) Myocardial 
contrast echocardiography in assessment of stable coronary artery disease at 
intermediate dobutamine-induced stress level Echocardiography 2009;26:52-60.
Lønnebakken MT, Staal EM, Bleie Ø, Strand E, Nygård OK & Gerdts E. (2009). Quantitative 
contrast stress echocardiography in assessment of restenosis after percutaneous 
coronary intervention in stable coronary artery disease. Eur J Echocardiogr. 2009; 
10:858-64. 
Lønnebakken MT, Staal EM, Nordrehaug JE & Gerdts E. (2011) Usefulness of contrast 
echocardiography for predicting the severity of angiographic coronary disease in 
non-ST-elevation myocardial infarction. Am J Cardiol 2011, feb 22 (e-pub ahead of 
print) 
Malm S, Frigstad S, Helland F, Oye K, Slordahl S & Skjarpe T. (2005) Quantification of 
resting myocardial blood flow velocity in normal humans using real-time contrast 
echocardiography. A feasibility study. Cardiovasc Ultrasound 2005;3:16. 
Maim S, Frigstad S, Sagberg E, Steen PA & Skjarpe T. (2006)Real.time simultaneous triplan 
contrast echocardiography gives rapid, accurate, and reproducible assessment of 
left ventricular volumes and ejection fraction: a comparison with magnetic 
resonance imaging. J Am Soc Echocardiogr. 2006; 19:1494-501. 
Malm S, Frigstad S, Torp H, Wiseth R & Skjarpe T. (2006) Quantitative adenosine real-time 
myocardial contrast echocardiography for detection of angiographically significant 
coronary artery disease. J Am Soc Echocardiogr 2006;19(4):365-372. 
Manyari DE, Knudtson M, Kloiber R& Roth D. (1988) Sequential thallium-201 myocardial 
perfusion studies after successful percutaneous transluminal coronary artery 
angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. 
Circulation 1988;77(1):86-95. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 76
Crossman DC. (2004) The pathophysiology of myocardial ischaemia. Heart 2004;90(5):576-
580. 
Dijkmans PA, Senior R, Becher H, Porter TR, Wei K, Visser CA & Kamp O. (2006). 
Myocardial contrast echocardiography evolving as a clinically feasible technique 
for accurate, rapid, and safe assessment of myocardial perfusion: the evidence so 
far. J Am Coll Cardiol 2006;48(11):2168-2177. 
Dwivedi G, Janardhanan R, Hayat SA, Lim TK, Greaves K & Senior R. (2008) Relationship 
between myocardial perfusion with myocardial contrast echocardiography and 
function early after acute myocardial infarction for the prediction of late recovery 
of function. Int J Cardiol 2008. 
Elhendy A, O'Leary EL, Xie F, McGrain AC, Anderson JR & Porter TR. (2004). Comparative 
accuracy of real-time myocardial contrast perfusion imaging and wall motion 
analysis during dobutamine stress echocardiography for the diagnosis of coronary 
artery disease. J Am Coll Cardiol 2004;44(11):2185-2191. 
Elhendy A & Porter TR. (2005) Assessment of myocardial perfusion with real-time 
myocardial contrast echocardiography: methodology and clinical applications. J
Nucl Cardiol 2005;12(5):582-590. 
Galiuto L, Paraggio L, Liuzzo G, de Caterina AR & Crea F. (2010) Predicting the no-reflow 
phenomenon following sucessful percutaneous coronary intervention. Biomark. 
Med. 2010; 4:403-20. 
Giedd KN & Bergmann SR.(2004) Myocardial perfusion imaging following percutaneous 
coronary intervention: the importance of restenosis, disease progression, and 
directed reintervention. J Am Coll Cardiol 2004;43(3):328-336. 
Grenne B, Eek C, Sjøli B, Dahlslett T, Uchto M, Hol PK, Skulstad H, Smiseth OA, Edvardsen 
T & Brunvand H. (2010) Acute coronary occlusion in non-ST-elevation acute 
coronary syndrome: outcome and early identification by strain echocardiography. 
Heart 2010; 96:1550-6. 
Hamilton-Craig C, Boga T, West C, Kelly N, Anscombe R, Burstow D & Platts D. (2010) 
Contrast echocardiography in Australian clinical practise. Heart Lung Circ 2010; 
19:385-94. 
Hayat SA & Senior R. (2008) Myocardial contrast echocardiography in ST elevation 
myocardial infarction: ready for prime time? Eur Heart J 2008; 29:299-314. 
Hoffmann R, Borges AC, Kasprzak JD, von BS, Firschke C, Greis C, Engelhardt M, Becher H 
& Vanoverschelde JL.(2007) Analysis of myocardial perfusion or myocardial 
function for detection of regional myocardial abnormalities. An echocardiographic 
multicenter comparison study using myocardial contrast echocardiography and 2D 
echocardiography. Eur J Echocardiogr 2007;8(6):438-448. 
Jeetley P, Burden L, Greaves K & Senior R. (2007). Prognostic value of myocardial  contrast 
echocardiography in patients presenting to hospital with acute chest pain and 
negative troponin. Am J Cardiol 2007;99(10):1369-1373. 
Kaufmann BA & Lindner JR.(2007) Molecular imaging with targeted contrast ultrasound. 
Curr Opin Biotechnol 2007;18(1):11-16. 
Kaul S, Senior R, Firschke C, Wang XQ, Lindner J, Villanueva FS, Firozan S, Kontos MC, 
Taylor A, Nixon IJ, Watson DD & Harrell FE. (2004) Incremental value of cardiac 
 
Contrast Echocardiography in Coronary Artery Disease 77 
imaging in patients presenting to the emergency department with chest pain and 
without ST-segment elevation: a multicenter study. Am Heart J 2004;148(1):129-136. 
Kaul S. (2006) Evaluating the 'no reflow' phenomenon with myocardial contrast 
echocardiography. Basic Res Cardiol 2006;101(5):391-399. 
Kang DH, Kang SJ, Song JM, Choi KJ, Hong MK, Song JK, Park SW & Park SJ. (2005) 
Efficacy of myocardial contrast echocardiography in the diagnosis and risk 
stratification of acute coronary syndrome. Am J Cardiol 2005;96(11):1498-1502. 
Kurt M, Shaikh KA, Peterson L, Kurrelmeyer KM, Shah G, Nagueh SF, Fromm R, Quinones 
MA & Zoghbi WA. (2009) Impact of contrast echocardiography on evaluation of  
ventricular function and clinical management in a large prospective cohort. J Am 
Coll Cardiol. 2009;3:802-10. 
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, 
Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John SM & Stewart 
W. (2006) Recommendations for chamber quantification. Eur J Echocardiogr 
2006;7(2):79-108. 
Leong-Poi H, Rim SJ, Le DE, Fisher NG, Wei K & Kaul S.(2002) Perfusion versus function: 
the ischemic cascade indemand ischemia: implications of single-vessel versus 
multivessel stenosis. Circulation 2002;105(8):987-992. 
London GM, Marchais SJ, Guerin AP & Pannier B. (2004) Arterial stiffness : pathophysiology 
and clinical impact. Clin Exp Hypertens 2004;26:689-99.
Lønnebakken MT, Bleie Ø, Strand E, Staal EM, Nygård OK & Gerdts E. (2009) Myocardial 
contrast echocardiography in assessment of stable coronary artery disease at 
intermediate dobutamine-induced stress level Echocardiography 2009;26:52-60.
Lønnebakken MT, Staal EM, Bleie Ø, Strand E, Nygård OK & Gerdts E. (2009). Quantitative 
contrast stress echocardiography in assessment of restenosis after percutaneous 
coronary intervention in stable coronary artery disease. Eur J Echocardiogr. 2009; 
10:858-64. 
Lønnebakken MT, Staal EM, Nordrehaug JE & Gerdts E. (2011) Usefulness of contrast 
echocardiography for predicting the severity of angiographic coronary disease in 
non-ST-elevation myocardial infarction. Am J Cardiol 2011, feb 22 (e-pub ahead of 
print) 
Malm S, Frigstad S, Helland F, Oye K, Slordahl S & Skjarpe T. (2005) Quantification of 
resting myocardial blood flow velocity in normal humans using real-time contrast 
echocardiography. A feasibility study. Cardiovasc Ultrasound 2005;3:16. 
Maim S, Frigstad S, Sagberg E, Steen PA & Skjarpe T. (2006)Real.time simultaneous triplan 
contrast echocardiography gives rapid, accurate, and reproducible assessment of 
left ventricular volumes and ejection fraction: a comparison with magnetic 
resonance imaging. J Am Soc Echocardiogr. 2006; 19:1494-501. 
Malm S, Frigstad S, Torp H, Wiseth R & Skjarpe T. (2006) Quantitative adenosine real-time 
myocardial contrast echocardiography for detection of angiographically significant 
coronary artery disease. J Am Soc Echocardiogr 2006;19(4):365-372. 
Manyari DE, Knudtson M, Kloiber R& Roth D. (1988) Sequential thallium-201 myocardial 
perfusion studies after successful percutaneous transluminal coronary artery 
angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. 
Circulation 1988;77(1):86-95. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 78
Mollema SA, Nucifora GV, Bax JJ. (2009) Prognostic value of echocardiography after acute 
myocardial infarction. Heart 2009;95(21):1732-1745. 
Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, Burns PN, 
Castello R, Coon PD, Hagen ME, Jollis JG, Kimball TR, Kitzman DW, Kronzon I, 
Labovitz AJ, Lang RM, Mathew J, Moir WS, Nagueh SF, Pearlman AS, Perez JE, 
Porter TR, Rosenbloom J, Strachan GM, Thanigaraj S, Wei K, Woo A, Yu EH & 
Zoghbi WA. (2008) American Society of Echocardiography Consensus Statement on 
the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am 
Soc Echocardiogr 2008;21(11):1179-1201. 
Niccoli G, Burzotta F, Galiuto L & Crea F. (2009) Myocardial no-reflow in humans. J Am Coll 
Cardiol 2009; 54:281-92. 
Peltier M, Vancraeynest D, Pasquet A, Ay T, Roelants V, D'hondt AM, Melin JA & 
Vanoverschelde JL. (2004) Assessment of the physiologic significance of coronary 
disease with dipyridamole real-time myocardial contrast echocardiography. 
Comparison with technetium-99m sestamibi single-photon emission computed 
tomography and quantitative coronary angiography. J Am Coll Cardiol 
2004;43(2):257-264. 
Perez d, I, Rodrigo JL, Almeria C, Perez FM, Serra V & Zamorano JL. (2004) Myocardial 
contrast echocardiography in coronary artery disease. Eur J Echocardiogr 2004;5 
Suppl 2:S11-S16. 
Pfisterer M, Rickenbacher P, Kiowski W, Müller-Brand J & Burkart F. (1993). Silent ischemia 
after percutaneous transluminal coronary angioplasty: incidence and prognostic 
significance. J Am Coll Cardiol 1993;22(5):1446-1454.
Picano E, Molinaro S & Pasanisi E. (2008) The diagnostic accuracy of pharmacological stress 
echocardiography for the assessment of coronary artery disease: a meta-analysis.
Cardiovasc Ultrasound 2008;6:30. 
Plana JC, Mikati IA, Dokainish H, Lakkis N, Abukhalil J, Davis R, Hetzell BC & Zoghbi 
WA.(2008) A randomized cross-over study for evaluation of the effect of image 
optimization with contrast on the diagnostic accuracy of dobutamine 
echocardiography in coronary artery disease The OPTIMIZE Trial. JACC Cardiovasc 
Imaging 2008; 1:145-52. 
Rinkevich D, Kaul S, Wang XQ, Tong KL, Belcik T, Kalvaitis S, Lepper W, Dent JM & Wei K. 
(2005) Regional left ventricular perfusion and function in patients presenting to the 
emergency department with chest pain and no ST-segment elevation. Eur Heart J 
2005;26(16):1606-1611. 
Senior R, Villanueva F & Vannan MA. (2004) Myocardial contrast echocardiography in acute 
coronary syndromes. Cardiol Clin 2004;22(2):253-267 
Senior R, Monaghan M, Becher H, Mayet J & Nihoyannopoulos P. (2005) Stress 
echocardiography for the diagnosis and risk stratification of patients with 
suspected or known coronary artery disease: a critical appraisal. Supported by the 
British Society of Echocardiography. Heart 2005;91(4):427-436. 
Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL & 
Nihoyannopoulos P.(2009). Contrast echocardiography: evidence-based 
recommendations by European Association of Echocardiography. Eur J Echocardiogr 
2009;10(2):194-212. 
 
Contrast Echocardiography in Coronary Artery Disease 79 
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt 
JU & Zamorano JL.  (2008) Stress echocardiography expert consensus statement: 
European Association of Echocardiography (EAE) (a registered branch of the ESC). 
Eur J Echocardiogr. 2008;9(4):415-437. 
Slikkerveer J, Dijkmans PA, Sieswerda GT, Doevendans PA, van Dijk AP, Verheugt FW, 
Porter TR & Kamp O. (2008) Ultrasound enhanced thrombolysis using 
microbubbles infusion in patients with acute ST elevation myocardial infarction: 
rationale and design of the Sonolysis study. Trials 2008; 9:72. 
Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr. Jacobs AK, Kern MJ, King SB, III, Morrison A, 
O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, 
Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, 
Ornato JP, Page RL & Riegel B. (2006). ACC/AHA/SCAI 2005 guideline update for 
percutaneous coronary intervention: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for 
Percutaneous Coronary Intervention). Circulation 2006;113(7):e166-e286. 
Solheim S, Seljeflot I, Lunde K, Bjørnerheim R, Aakhus S, Forfang K & Arnesen H. (2010)  
Fequency of left ventricular thrombus in patients with anterior wall acute 
myocardial infarction treated with percutaneous coronary intervention and dual 
antiplatelet therapy.  Am J Cardiol. 2010;106:1197-200. 
Toledo E, Jacobs LD, Lodato JA, DeCara JM, Coon P, Mor-Avi V & Lang RM. (2006) 
Quantitative diagnosis of stress-induced myocardial ischemia using analysis of 
contrast echocardiographic parametric perfusion images. Eur J Echocardiogr 
2006;7(3):217-225. 
Tong KL, Kaul S, Wang XQ, Rinkevich D, Kalvaitis S, Belcik T, Lepper W, Foster WA & Wei 
K. (2005). Myocardial contrast echocardiography versus Thrombolysis In 
Myocardial Infarction score in patients presenting to the emergency department 
with chest pain and a nondiagnostic electrocardiogram. J Am Coll Cardiol. 2005; 
46:920-7. 
Vorlat A, Claeys MJ, De RH, Gevaert S, Vandekerckhove Y, Dubois P, De MA & Vrints C. 
(2008). TIMI risk score underestimates prognosis in unstable angina/non-ST 
segment elevation myocardial infarction. Acute Card Care 2008;10(1):26-29. 
Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM & Kaul S.(1998). Quantification of 
myocardial blood flow with ultrasound-induced destruction of microbubbles 
administered as a constant venous infusion. Circulation 1998;97(5):473-483. 
Wei K, Mulvagh SL, Carson L, Davidoff R, Gabriel R, Grimm RA, Wilson S, Fane L, Herzog 
CA, Zoghbi WA, Taylor R, Farrar M, Chaudhry FA, Porter TR, Irani W & Lang RM. 
(2008) The safety of deFinity and Optison for ultrasound image enhancement: a 
retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 
2008;21(11):1202-1206. 
Zellweger MJ, Weinbacher M, Zutter AW, Jeger RV, Mueller-Brand J, Kaiser C, Buser PT & 
Pfisterer ME. (2003). Long-term outcome of patients with silent versus symptomatic 
ischemia six months after percutaneous coronary intervention and stenting. J Am 
Coll Cardiol 2003;42(1):33-40. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 78
Mollema SA, Nucifora GV, Bax JJ. (2009) Prognostic value of echocardiography after acute 
myocardial infarction. Heart 2009;95(21):1732-1745. 
Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, Burns PN, 
Castello R, Coon PD, Hagen ME, Jollis JG, Kimball TR, Kitzman DW, Kronzon I, 
Labovitz AJ, Lang RM, Mathew J, Moir WS, Nagueh SF, Pearlman AS, Perez JE, 
Porter TR, Rosenbloom J, Strachan GM, Thanigaraj S, Wei K, Woo A, Yu EH & 
Zoghbi WA. (2008) American Society of Echocardiography Consensus Statement on 
the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am 
Soc Echocardiogr 2008;21(11):1179-1201. 
Niccoli G, Burzotta F, Galiuto L & Crea F. (2009) Myocardial no-reflow in humans. J Am Coll 
Cardiol 2009; 54:281-92. 
Peltier M, Vancraeynest D, Pasquet A, Ay T, Roelants V, D'hondt AM, Melin JA & 
Vanoverschelde JL. (2004) Assessment of the physiologic significance of coronary 
disease with dipyridamole real-time myocardial contrast echocardiography. 
Comparison with technetium-99m sestamibi single-photon emission computed 
tomography and quantitative coronary angiography. J Am Coll Cardiol 
2004;43(2):257-264. 
Perez d, I, Rodrigo JL, Almeria C, Perez FM, Serra V & Zamorano JL. (2004) Myocardial 
contrast echocardiography in coronary artery disease. Eur J Echocardiogr 2004;5 
Suppl 2:S11-S16. 
Pfisterer M, Rickenbacher P, Kiowski W, Müller-Brand J & Burkart F. (1993). Silent ischemia 
after percutaneous transluminal coronary angioplasty: incidence and prognostic 
significance. J Am Coll Cardiol 1993;22(5):1446-1454.
Picano E, Molinaro S & Pasanisi E. (2008) The diagnostic accuracy of pharmacological stress 
echocardiography for the assessment of coronary artery disease: a meta-analysis.
Cardiovasc Ultrasound 2008;6:30. 
Plana JC, Mikati IA, Dokainish H, Lakkis N, Abukhalil J, Davis R, Hetzell BC & Zoghbi 
WA.(2008) A randomized cross-over study for evaluation of the effect of image 
optimization with contrast on the diagnostic accuracy of dobutamine 
echocardiography in coronary artery disease The OPTIMIZE Trial. JACC Cardiovasc 
Imaging 2008; 1:145-52. 
Rinkevich D, Kaul S, Wang XQ, Tong KL, Belcik T, Kalvaitis S, Lepper W, Dent JM & Wei K. 
(2005) Regional left ventricular perfusion and function in patients presenting to the 
emergency department with chest pain and no ST-segment elevation. Eur Heart J 
2005;26(16):1606-1611. 
Senior R, Villanueva F & Vannan MA. (2004) Myocardial contrast echocardiography in acute 
coronary syndromes. Cardiol Clin 2004;22(2):253-267 
Senior R, Monaghan M, Becher H, Mayet J & Nihoyannopoulos P. (2005) Stress 
echocardiography for the diagnosis and risk stratification of patients with 
suspected or known coronary artery disease: a critical appraisal. Supported by the 
British Society of Echocardiography. Heart 2005;91(4):427-436. 
Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL & 
Nihoyannopoulos P.(2009). Contrast echocardiography: evidence-based 
recommendations by European Association of Echocardiography. Eur J Echocardiogr 
2009;10(2):194-212. 
 
Contrast Echocardiography in Coronary Artery Disease 79 
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt 
JU & Zamorano JL.  (2008) Stress echocardiography expert consensus statement: 
European Association of Echocardiography (EAE) (a registered branch of the ESC). 
Eur J Echocardiogr. 2008;9(4):415-437. 
Slikkerveer J, Dijkmans PA, Sieswerda GT, Doevendans PA, van Dijk AP, Verheugt FW, 
Porter TR & Kamp O. (2008) Ultrasound enhanced thrombolysis using 
microbubbles infusion in patients with acute ST elevation myocardial infarction: 
rationale and design of the Sonolysis study. Trials 2008; 9:72. 
Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr. Jacobs AK, Kern MJ, King SB, III, Morrison A, 
O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, 
Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, 
Ornato JP, Page RL & Riegel B. (2006). ACC/AHA/SCAI 2005 guideline update for 
percutaneous coronary intervention: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for 
Percutaneous Coronary Intervention). Circulation 2006;113(7):e166-e286. 
Solheim S, Seljeflot I, Lunde K, Bjørnerheim R, Aakhus S, Forfang K & Arnesen H. (2010)  
Fequency of left ventricular thrombus in patients with anterior wall acute 
myocardial infarction treated with percutaneous coronary intervention and dual 
antiplatelet therapy.  Am J Cardiol. 2010;106:1197-200. 
Toledo E, Jacobs LD, Lodato JA, DeCara JM, Coon P, Mor-Avi V & Lang RM. (2006) 
Quantitative diagnosis of stress-induced myocardial ischemia using analysis of 
contrast echocardiographic parametric perfusion images. Eur J Echocardiogr 
2006;7(3):217-225. 
Tong KL, Kaul S, Wang XQ, Rinkevich D, Kalvaitis S, Belcik T, Lepper W, Foster WA & Wei 
K. (2005). Myocardial contrast echocardiography versus Thrombolysis In 
Myocardial Infarction score in patients presenting to the emergency department 
with chest pain and a nondiagnostic electrocardiogram. J Am Coll Cardiol. 2005; 
46:920-7. 
Vorlat A, Claeys MJ, De RH, Gevaert S, Vandekerckhove Y, Dubois P, De MA & Vrints C. 
(2008). TIMI risk score underestimates prognosis in unstable angina/non-ST 
segment elevation myocardial infarction. Acute Card Care 2008;10(1):26-29. 
Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM & Kaul S.(1998). Quantification of 
myocardial blood flow with ultrasound-induced destruction of microbubbles 
administered as a constant venous infusion. Circulation 1998;97(5):473-483. 
Wei K, Mulvagh SL, Carson L, Davidoff R, Gabriel R, Grimm RA, Wilson S, Fane L, Herzog 
CA, Zoghbi WA, Taylor R, Farrar M, Chaudhry FA, Porter TR, Irani W & Lang RM. 
(2008) The safety of deFinity and Optison for ultrasound image enhancement: a 
retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 
2008;21(11):1202-1206. 
Zellweger MJ, Weinbacher M, Zutter AW, Jeger RV, Mueller-Brand J, Kaiser C, Buser PT & 
Pfisterer ME. (2003). Long-term outcome of patients with silent versus symptomatic 
ischemia six months after percutaneous coronary intervention and stenting. J Am 
Coll Cardiol 2003;42(1):33-40. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 80
Zhang X, Liu X, He ZX, Shi R, Yang M, Gao R, Chen J, Yang Y & Fang W. (2004) Long-term 
prognostic value of exercise 99mTc-MIBI SPET myocardial perfusion imaging in 
patients after percutaneous coronary intervention. Eur J Nucl Med Mol Imaging 
2004;31(5):655-662. 
4
Non-Invasive Imaging in Approaching 
Ischemic Coronary Artery Disease 
Lucia Agoston-Coldea, Teodora Mocan and Silvia Lupu 
The “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, 
Romania 
1. Introduction 
Ischemic coronary artery disease represents one of the major contemporary health problems 
because of its elevated vital risk. Nowadays, atherosclerosis-related cardiovascular disease 
is the most significant non-traumatic mortality factor and the prime “killer” of the 21st 
century. 
Increased morbidity and mortality in coronary artery disease (Rosamond et al., 2008), the 
significant impact on quality of life, negatively affecting the physical, psychological and 
social well-being of the patient (Xie et al., 2008) as well as the high costs of diagnosis and 
treatment for this disease (Rosamond et al., 2008) have lead to developing new imaging 
techniques in order to explore such patients more efficiently.  
Cardiac imaging has developed greatly since the chest radiograph was first used to describe 
the heart’s shape. Nowadays, non-invasive imaging, including echocardiography, Single 
Photon Emission Computer Tomography (SPECT), coronary angiography and, more 
recently, Positron Emission Tomography (PET), multidetector computed tomography 
angiography as well as cardiac magnetic resonance imaging (MRI), represent standard 
procedures in clinical practice (Budoff et al., 2008) (Gaemperli et al., 2008).  
The latter, especially, have a crucial importance in approaching patients with suspected or 
known coronary artery disease, as well as in assessing risk stratification, prognosis and 
reperfusion indications in patients with ischemic coronary artery disease (Mark et al., 2010). 
The purpose of this chapter is to help promote new ways of integrating the non-invasive 
diagnostic imaging in the diagnosis and management of coronary artery disease patients.  
2. The value of non-invasive cardiac imaging in patients with coronary artery 
disease
Epicardial arteries visualization is essential for confirming coronary artery disease and for 
accurately establishing its severity. Over the last 40 years, coronary angiography has been 
the key exploration in assessing coronary artery obstruction, as well as the need for 
reperfusion, despite its invasive character and high costs. Nowadays, invasive coronary 
angiography is still considered the "gold standard" for diagnostic coronary testing, although 
it has a few major disadvantages and limitations (patient exposure to ionizing radiation, 
two-dimensional image acquisition of coronary arteries, inappropriate atherosclerotic 
plaques assessment).  
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16-channel computed tomography coronary angiography has recently become a leading 
procedure in cardiac imaging, as it allows an accurate visualization of the coronary artery 
lumen, as well as an appropriate assessment of stenosis severity; computed tomography 
coronary angiography results can now be used as an essential tool for prognosis assessment 
in patients with coronary heart disease (Mark et al., 2010). 
2.1 The diagnostic value of non-invasive cardiac imaging in patients with coronary 
artery disease 
However, non-invasive imaging techniques (e.g. coronary multidetector computed 
tomography angiography and magnetic resonance imaging angiography), which are 
valuable and comparatively cheaper, can currently be used for studying the coronary artery 
wall. Both contribute to the diagnosis of coronary artery ischemic disease and the image 
quality produced by coronary multidetector computed tomography angiography favorably 
compares to that of coronary angiography. These explorations have their own limitations, 
including poor image acquisition due to cardiac motion or important calcium deposits, but, 
most of the times, good quality images are obtained.  
Coronary multidetector computed tomography angiography allows outer-luminal plaque 
visualization and can assess subsequent luminal stenosis.  As with invasive coronary 
angiography, visual grading of coronary segment narrowing by ranges of stenosis is the 
current standard of practice and has been shown to provide useful clinical information 
relative to invasive coronary angiography (Cheng et al., 2008) (Miller et al., 2008).  
Quantitative coronary multidetector computed tomography angiography is a high accuracy 
procedure which allows noninvasive detection of suspected obstructive coronary artery 
disease; it has been used in some research applications but is not currently a routine part of 
clinical interpretation. This promising technology has potential as an additional diagnostic 
tool, which will most likely complement invasive coronary angiography in routine clinical 
care (Hoffmann et al., 2005).  
In a recent multicenter study, visual and quantitative assessments of stenosis severity by 
coronary multidetector computed tomography angiography were quite similar (Miller et al., 
2008). Technical progress in coronary multidetector computed tomography technology 
(increased number of detectors – 64, prolonged rotation time and, consequently, good 
spatial resolution) a careful patient selection and multi-slice coronary analysis led to a 
current sensitivity of 90-100%, a specificity of 95-100% (Hamon et al., 2006) and a negative 
predictive value of 97-100% (Yang et al., 2010) in coronary artery disease evaluation. The use 
of coronary multidetector computed tomography versus conventional coronary 
angiography and intravascular ultrasound for diagnostic purposes has been assessed in 
several studies and meta-analysis.  
In older studies, in which the computed tomography apparatus had less than 64 detection 
channels, coronary multidetector computed tomography seemed to provide less useful and 
less accurate information than conventional coronary angiography. However, the accuracy 
improved over the years, while the number of detectors continued to increase from 4 to 16 
and then to 64, allowing a more faithful description of a larger number of coronary artery 
segments, previously impossible to visualize.  (Hamon et al., 2007) (Vanhoenacker et al., 
2007) (Janne d’Othec et al., 2008). Later studies affirmed that coronary multidetector 
computed tomography might allow a more accurate atherosclerosis evaluation, despite their 
lower efficacy in assessing stenosis severity.  
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Recently, other studies tried to compare the diagnostic performance of 64-channel computed 
tomography with that of invasive coronary angiography in identifying obstructive coronary 
disease in various populations; the average sensitivity per-patient for identifying obstructive 
coronary artery disease was 98%, with an average per-patient specificity of 88% (Stein et al., 
2008). The mean prevalence of obstructive coronary artery disease in these studies was 61%. 
The negative predictive value for multidetector computed tomography was estimated at 
96%, while the positive predictive value proved to be rather insignificant, with large 
variations within the interval 64% to 100%. 
Recently, most multicenter studies which compared 64-channel coronary multidetector 
computed tomography with conventional angiography have proved that multidetector 
computed tomography angiography had excellent sensitivity and very good negative 
predictive value in detecting coronary artery disease (Mowatt et al. 2008). Nevertheless, the 
positive predictive values are less important, since coronary artery stenosis is often 
overestimated by coronary multidetector computed tomography angiography, when 
compared to coronary angiography. This tends to happen because calcium blooming 
artifacts diminish the signal acquisition accuracy, whilst invasive coronary angiography fails 
to appreciate the extent of positive vessel remodelling by atherosclerosis.  
In the prospective ACCURACY (Assessment by Coronary Computed Tomographic 
Angiography of Individuals Undergoing Invasive Coronary Angiography) study, 230 
patients with typical or atypical chest pain were enrolled, all of which were referred for 
invasive coronary angiography and agreed to have a coronary multidetector computed 
tomography prior to their catheterization (Budoff et al., 2008). After having carefully 
interpreted the data, the sensitivity, specificity, as well as positive and negative predictive 
values for detecting ≥50% or ≥70% stenosis were 95%, 83%, 64%, and 99%, respectively, and 
94%, 83%, 48%, 99%, respectively. In this prospective multicenter trial of chest pain patients 
without known coronary artery disease, 64-multidetector row coronary multidetector 
computed tomography proved a very high diagnostic accuracy in detecting obstructive 
coronary stenosis for both 50% and 70% stenosis thresholds. Moreover, the high (99%) 
negative predictive value of coronary multidetector computed tomography angiography 
pleads for its current use as an effective noninvasive alternative to invasive coronary 
angiography to rule out coronary artery obstructive stenosis. 
The CORE 64 (Coronary Artery Evaluation Using 64-Row Multidetector Computed 
Tomography Angiography) study was conducted in 9 international centers and enrolled 316 
symptomatic patients, aged 40 years or more, with suspected or known coronary disease. 
All patients whose calcium scores were less than 600 were referred for invasive coronary 
angiography, 291 (92%) of which completed coronary multidetector computed tomography 
prior to invasive coronary angiography. Obstructive coronary artery disease was diagnosed 
in 56% of the patients. Quantitative computed tomography angiography showed a 
sensitivity of 85%, a specificity of 90%, a positive predictive value of 91% and a negative 
predictive value of 83% in detecting or ruling out significant (>50%) coronary artery stenosis 
when compared to conventional angiography, thus proving  that it can very accurately 
assess the presence and severity of obstructive coronary artery disease. However, the 
negative and positive predictive values estimated by this study are not significant enough to 
consider completely replacing conventional coronary angiography by multidetector 
computed tomography.   Only two patients in the study group had contrast agent-related 
side effects after computed tomography angiography. (Miller et al., 2008) (Dewey et al., 
2010). One study conducted in the Netherlands showed that multidetector computed 
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tomography has a considerable value in diagnosing obstructive coronary disease, but is 
slightly less valuable for stenosis severity assessment when compared to both conventional 
coronary angiography and intravascular ultrasound. In this study, 100 patients underwent 
coronary multidetector computed tomography angiography followed by both conventional 
coronary angiography and intravascular ultrasound. Only those segments in which 
intravascular ultrasound imaging was performed were included for coronary multidetector 
computed tomography and quantitative coronary angiography analysis. On coronary 
multidetector computed tomography angiography, each segment was evaluated for 
significant stenosis (defined as ≥50% luminal narrowing, as in conventional coronary 
angiography). Secondly, on coronary multidetector computed tomography angiography, 
each segment was evaluated for the presence of atherosclerotic plaques. Atherosclerosis was 
defined on intravascular ultrasound as a plaque burden covering ≥40% from the vessel’s 
cross-sectional area. Multidetector computed tomography angiography correctly ruled out 
significant stenosis in 53 of 53 (100%) patients. However, 19% patients were incorrectly 
diagnosed as having significant lesions on coronary multidetector computed tomography 
angiography, which finally led to 100% sensitivity, 85% specificity, 81% positive and 100% 
negative predictive values. (van Velzen et al., 2011).  
Nowadays, coronary multidetector computed tomography angiography is used to diminish 
the large number of normal coronary angiographies (by 25-30 %) (Blanchard et al., 2002).  
Although coronary multidetector computed tomography angiography results prior to 64-
channel technology were once considered adequate, the current trend in cardiac imaging is 
to ignore such studies, which are only limited to assessing coronary calcium (Otero et al. 
2009). To this day, the incremental diagnostic value of 128 -, 256 - and 320-channel coronary 
multidetector computed tomography systems over 64-channel systems has not been proven. 
(Mark et al., 2010) (Hein et al., 2009). However, non-invasive methods might completely 
replace the expensive and rather unpleasant coronary angiography in the future. 
64-slice coronary angiography can be as effective as conventional coronary angiography in 
patient selection for coronary artery by-pass graft surgery, especially when 3-vessel or left 
main coronary artery disease and its equivalents are present. The overall sensitivity, 
specificity, positive predictive value and negative predictive value of coronary multidetector 
computed tomography angiography for coronary artery bypass graft surgery candidates 
selection were 85.9%, 96.0%, 93.8%, and 90.7%, respectively. (Lee et al., 2011).  
Despite all its advantages, all cases should be thoroughly selected, as coronary multidetector 
computed tomography angiography exposes the patient to a fairly large amount of 
radiation. Since coronary artery disease has become the main cause for mortality in recently 
developed countries, a noninvasive test that would not imply patient exposure to radiation 
is greatly needed.  
In addition to coronary multidetector computed tomography, magnetic resonance imaging 
angiography can also provide accurate data concerning cardiac morphology, as well as 
coronary and cardiac functions (Hoffmann et al., 2008). Over the last 20 years, cardiac 
magnetic resonance imaging techniques have developed greatly, but their current use in 
coronary artery disease assessment is rather limited, despite the high initial expectations. In 
an expert consensus document on “appropriate” indications for cardiac multidetector 
computed tomography (Tayloret al., 2010) and magnetic resonance imaging published in 
2006 (Hendel et al 2006), only coronary multidetector computed tomography angiography is 
recommended as an “adequate” imaging method for coronary artery disease assessment, 
while cardiac magnetic resonance imaging angiography is firmly rejected.  
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As far as spatial resolution and study success rates are concerned, coronary multidetector 
computed tomography angiography is superior to coronary magnetic resonance imaging 
angiography. The latter also has the major disadvantages of long image acquisition times 
and operator dependency, which limit its use to diagnosing congenital abnormal coronary 
artery origin and coronary artery aneurysms in patients with Kawasaki disease (Sakuma et 
al., 2011). 
In a recent study, multidetector computed tomography and magnetic resonance imaging 
angiography were compared. 7516 patients were evaluated by multidetector computed 
tomography, whilst 989 underwent magnetic resonance imaging angiography. Bivariate 
analysis of data yielded a mean sensitivity and specificity of 97.2% and 87.4% for computed 
tomography and 87.1% and 70.3% for magnetic resonance imaging. In other studies which 
only included patients with suspected coronary artery disease, sensitivity and specificity of 
computed tomography were 97.6% and 89.2%. Covariate analysis showed that 16-detector 
row scanners had a greater sensitivity (98.1%) in diagnosing coronary artery disease than 
older-generation scanners (95.6%) (Schuetz et al., 2010).
When using steady-state free precession magnetic resonance imaging angiography, no 
contrast agents are needed; however, the accuracy of this approach has not yet been 
determined in a multicenter trial.  So far, in a patient-based analysis, the sensitivity, 
specificity, positive and negative predictive values of magnetic resonance imaging 
angiography were 88%, 72%, 88%, and 79%, respectively, all significantly lower than for 
multidetector computed tomography. The non–contrast-enhanced whole-heart coronary 
magnetic resonance imaging angiography at 1.5-T can noninvasively detect significant 
coronary artery disease with high sensitivity and moderate specificity. A negative predictive 
value of 88% indicates that whole-heart coronary magnetic resonance imaging angiography 
can rule out coronary artery disease (Kato et al., 2010). 
A single MRI study can provide very useful information regarding ischaemic heart disease. 
This technique allows the assessment of rest function, as well as gadolinium chelate contrast 
evaluation. The latter comprises three postcontrast temporal phases: phase one provides 
information regarding microvascular obstruction, which is the equivalent of the no-reflow 
phenomenon, at rest and during stress; early perfusion is used to evaluate microvascular 
obstruction and to track down thrombi, while late gadolinium enhancement technique 
provides data regarding the presence of myocardial infarction and focal myocardial 
damage. In most cases of acute chest pain, biomarkers and electrocardiographically can 
identify high risk patients; however, in some circumstances, coronary artery disease cannot 
be detected by such methods, thus imposing the evaluation by contrast cardiac MRI; first-
pass perfusion or early enhancement techniques (Nijveldt et al., 2008) can be used for this 
purpose. Ingkanisorn et al, apealed to MRI examination after adenosine stress perfusion to 
investigate patients with typical angina and negative troponin; in such cases, adenosine 
stress results proved to have a 100% sensitivity and 93% specificity and thus a very high 
negative predictive value (Ingkanisorn et al., 2006). Cardiac MRI-measured microvascular 
obstruction is frequently associated with extensive myocardial damage and poor left 
ventricular function and, by consequence, with a poor functional recovery and clinical 
outcome (Rubenstein et al., 2008). 
A multi-center clinical trial proved that delayed-enhancement cardiac magnetic resonance 
imaging can provide solid evidence for the presence of acute and chronic myocardial 
infarction, particularly in patients with negative troponins. Moreover, this type of 
investigation can accurately discriminate between ischemic and non-ischemic myocardial 
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64-slice coronary angiography can be as effective as conventional coronary angiography in 
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specificity, positive predictive value and negative predictive value of coronary multidetector 
computed tomography angiography for coronary artery bypass graft surgery candidates 
selection were 85.9%, 96.0%, 93.8%, and 90.7%, respectively. (Lee et al., 2011).  
Despite all its advantages, all cases should be thoroughly selected, as coronary multidetector 
computed tomography angiography exposes the patient to a fairly large amount of 
radiation. Since coronary artery disease has become the main cause for mortality in recently 
developed countries, a noninvasive test that would not imply patient exposure to radiation 
is greatly needed.  
In addition to coronary multidetector computed tomography, magnetic resonance imaging 
angiography can also provide accurate data concerning cardiac morphology, as well as 
coronary and cardiac functions (Hoffmann et al., 2008). Over the last 20 years, cardiac 
magnetic resonance imaging techniques have developed greatly, but their current use in 
coronary artery disease assessment is rather limited, despite the high initial expectations. In 
an expert consensus document on “appropriate” indications for cardiac multidetector 
computed tomography (Tayloret al., 2010) and magnetic resonance imaging published in 
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coronary artery disease with high sensitivity and moderate specificity. A negative predictive 
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can rule out coronary artery disease (Kato et al., 2010). 
A single MRI study can provide very useful information regarding ischaemic heart disease. 
This technique allows the assessment of rest function, as well as gadolinium chelate contrast 
evaluation. The latter comprises three postcontrast temporal phases: phase one provides 
information regarding microvascular obstruction, which is the equivalent of the no-reflow 
phenomenon, at rest and during stress; early perfusion is used to evaluate microvascular 
obstruction and to track down thrombi, while late gadolinium enhancement technique 
provides data regarding the presence of myocardial infarction and focal myocardial 
damage. In most cases of acute chest pain, biomarkers and electrocardiographically can 
identify high risk patients; however, in some circumstances, coronary artery disease cannot 
be detected by such methods, thus imposing the evaluation by contrast cardiac MRI; first-
pass perfusion or early enhancement techniques (Nijveldt et al., 2008) can be used for this 
purpose. Ingkanisorn et al, apealed to MRI examination after adenosine stress perfusion to 
investigate patients with typical angina and negative troponin; in such cases, adenosine 
stress results proved to have a 100% sensitivity and 93% specificity and thus a very high 
negative predictive value (Ingkanisorn et al., 2006). Cardiac MRI-measured microvascular 
obstruction is frequently associated with extensive myocardial damage and poor left 
ventricular function and, by consequence, with a poor functional recovery and clinical 
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A multi-center clinical trial proved that delayed-enhancement cardiac magnetic resonance 
imaging can provide solid evidence for the presence of acute and chronic myocardial 
infarction, particularly in patients with negative troponins. Moreover, this type of 
investigation can accurately discriminate between ischemic and non-ischemic myocardial 
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injury, which helps identify the correct diagnosis in patients with normal angiographic 
results. This technique is useful even in cases of confirmed coronary artery disease, as it 
allows the examiner to identify details such as microvascular damage, myocardial stunning, 
residual viability or right ventricular infarction. Post-myocardial infarction complications 
such as pericarditis or left ventricular thrombi can also be identified, which can help in 
choosing the right therapy for these patients. MRI evaluation also allows the quantification 
of infarct size by delayed-enhancement techniques and can be a valuable surrogate end 
point for clinical trials, with significant reductions in sample size when compared to other 
methods (Kim et al., 2010). 
Cardiac magnetic resonance imaging can complete or replace echocardiographic findings in 
patients with dilated ischemic cardiomyopathy and can provide useful information 
concerning myocardial perfusion and viability (Maceira et al., 2006). Left ventricular 
dysfunction after myocardial infarction may be due to necrosis, to post infarction stunning 
or hibernation of viable myocardium (Schinkel et al., 2007). Recurrent stunning may lead to 
myocardial hibernation and requires revascularization for function recovery.  
Regional myocardial function can be evaluated by regional kinesis or regional parietal 
thickening assessment using standard or post-apnoea cardiac magnetic resonance imaging 
techniques, in normal conditions or after pharmacologically induced stress (using adenosine 
or dobutamine) (Kuijpers et al., 2004). Stress cardiac magnetic resonance imaging is 
particularly useful for assessing lesions in stable coronary patients who have no indication 
for coronary angiography (Kuijpers et al., 2004).   
By using cine-cardiac magnetic resonance imaging in post-apnoea, major coronary arteries 
images can be obtained, while morphology and tissue analysis of the atherosclerotic plaque 
allows an accurate assessment of its composition and rupture risk. It is possible to evaluate 
the atherosclerotic plaques while using echo-spin sequences with T1, T2 pondering or by 
measuring proton density. However, the low temporal resolution of this technique limits its 
current use. In this case, MRI signal improvement by using contrast agents, especially 
gadofluorine (Sirol et al., 2004), allows a more appropriate examination of the atherosclerotic 
plaque because of its fast and persistent (as long as 24 hours) accumulation in lipid-rich 
atherosclerotic plaques. The gadofluorine-M-enhanced MRI can accurately identify 
atherosclerotic plaque inflammation and neovascularization in animal models of 
atherosclerosis, which can help identify high rupture risk atherosclerotic plaques (Sirol et 
al., 2009).  
Since macrophage activity is an essential factor in atherosclerosis development and 
complications, macrophage imaging can be used as a biomarker for subclinical inflamed 
lesions, allowing risk assessment and therapy guiding. A sufficient T2 signal intensity after 
superparamagnetic phagocytosable nanoparticles administration can help identify inflamed 
plaques and closely monitor early tissue response to adequate therapy (Morishige et al, 
2010). Cardiac magnetic resonance imaging can also highlight neoformation blood vessels in 
the atherosclerotic plaque by using Gadolinium, which binds αvβ3 vessel wall integrin. 
Other contrast agents, with high affinity for lipidic structures, muscular and inflammatory 
cells, can also be used for assessing subclinical coronary artery disease by cardiac magnetic 
resonance imaging (Barkhausen et al., 2003).   
Velocity encoding techniques in post-apnoea can be used to measure the coronary flow with 
the purpose of establishing the coronary flow reserves. Last, but not least, the fast echo-
gradient with phase contrast technique allows perfusion evaluation in normal and stress 
conditions (using vasodilators) and normal or pathological coronary flow velocities. Other 
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technologies are able to provide an accurate image of diseased vessel walls, such as 
intravascular ultrasound, magnetic resonance imaging, and optical coherence tomography 
(Mark et al., 2010). 
Cardiac magnetic resonance imaging allows a fast, radiation-free investigation of the 
myocardial function, perfusion and viability and can provide useful data concerning 
coronary arteries and atherosclerotic plaques. However, precise indications for the use of 
this technique, based on a balanced risk-advantage ratio, are yet to be established.   
2.2 Prognostic value of non-invasive cardiac imaging in patients with coronary artery 
disease 
Coronary calcifications are vascular degenerative phenomena determined by active vascular 
remodeling processes. The calcium burden is an important risk factor for vascular 
remodeling (Schmermund et al., 2001) and plaque instability (Burke et al., 2002). Histo-
pathological studies (Rumberger et al., 1995) have shown a significant relationship between 
calcified areas and the level of arterial atherosclerosis, indicating that coronary calcifications 
are direct markers of coronary artery disease.  
Coronary multidetector computed tomography is a sensitive method for detecting coronary 
artery calcium. Multidetector computed tomography coronary angiography allows a 
pseudo-quantitative assessment of coronary artery calcifications using the Agatston calcium 
score (Corti et al., 2001) as well as calcium mass and volume calculations for certain 
coronary segments (Ulzheimer et al., 2003). Although the latter method proved to have 
higher reproductibility, the Agatston score is more frequently used in clinical practice. The 
prognostic value of coronary calcification assessment by multidetector computed 
tomography coronary angiography has been reported in several studies, but with mixed 
results (Chow et al., 2010) (Carrigan et al., 2009) (Hay et al., 2010).  
Coronary multidetector computed tomography is also important for identifying high risk 
asymptomatic patients, especially if calcium scoring is used (Detrano et al., 1996) and has 
proved to be more accurate than the Framingham score (Greendland et al., 2004) or the 
SCORE method. In asymptomatic patients, low detectable coronary artery calcium scores 
are significantly less reliable in predicting plaque burden due to their association with high 
overall noncalcified coronary artery plaque prevalence and nearly a 10% rate of significantly 
occlusive noncalcified coronary artery plaque (Cheng et al., 2007). In one study, in which 
632 subjects were enrolled, Raggi et al. have demonstrated that elevated coronary artery 
calcium can increase the odds of acute myocardial infarction and cardiac death in 
asymptomatic patients (Raggi et al., 2000). The MESA study also proved that the coronary 
artery calcium score was a better predictor for cardiovascular events in 6772 asymptomatic 
patients, when compared to classic risk factors (Detrano et al., 2008). The target is to 
emphasize risk stratification and primary risk prevention in asymptomatic patients in order 
to decrease cardiovascular mortality and morbidity. The Framingham Risk Score only 
predicts coronary heart disease events moderately well when family history is not included 
as a risk factor. There is a current preoccupation for developing new risk stratification tests 
and establishing new and more accurate risk factors. While the Framingham Risk Score, 
European Systematic Coronary Risk Evaluation Project and European Prospective 
Cardiovascular Munster Study still provide excellent tools for risk factor modification, the 
coronary artery calcium score may bring an additional benefit in risk assessment. There 
have been several studies supporting the role of coronary artery calcium score in predicting 
myocardial infarction and cardiovascular mortality, which proved to be significant for risk 
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stratification in asymptomatic patients presenting in the emergency room (Sharma et al., 
2010).  In CORE study done on 291 patients (5% patients had low, 75% had intermediate, 
and 20% had high pre-test probability of obstructive coronary artery disease) was observed 
that the absence of coronary calcification does not exclude obstructive stenosis or the need 
for revascularization among patients with high enough suspicion of coronary artery disease 
to be referred for coronary angiography, in contrast with the published recommendations 
(Gottlieb et al., 2010).  
Also, the total coronary calcium score measured by multidetector computed tomography 
can be used as an independent prediction factor for major acute coronary events in patients 
with chest pain. A recent study on 263 patients presenting in the emergency room with 
acute chest pain and low-to-intermediate cardiovascular risk, defined by traditional risk 
factors, showed that computed tomography coronary artery calcium assessment is a 
powerful tool for prognosis evaluation. The absence of coronary artery calcium suggests an 
excellent long-term (5-year) prognosis, with no primary or secondary cardiac outcomes 
occurring in study patients at 5-year follow-up (Laudon et al., 2010). However, it has not yet 
been established whether there is a significant correlation between the total coronary 
calcium score and long- term clinical outcomes in patients who underwent percutaneous 
coronary intervention with drug eluting stents. In a recent study on 286 patients with 
coronary artery disease, Jeong showed that the total coronary calcium score measured by 
multidetector computed tomography was highly associated with chronic and significant 
coronary lesions, while the coronary calcium score ≥ 400 predicted lower procedural success 
rate and poor long-term clinical outcomes (Jeong et al., 2010). 
One recently published meta-analysis (Hay et al., 2010) established the prognostic value of 
multidetector computed tomography in 9592 symptomatic patients with suspected coronary 
artery disease, reporting major adverse cardiovascular events such as death, myocardial 
infarction and revascularization. The sensitivity was 0.99 for major adverse cardiovascular 
events after normal multidetector computed tomography findings, with a specificity of 0.41. 
Stratifying by no coronary artery disease, nonobstructive coronary artery disease, or 
obstructive coronary artery disease, there were incrementally increasing adverse events. 
Adverse cardiovascular events among patients with normal multidetector computed 
tomography findings are very rare and comparable to a baseline risk among healthy 
patients. Increasing burden of coronary artery disease on multidetector computed 
tomography is associated with an increasing rate of revascularization necessity, myocardial 
infarction, and death. In predicting the incidence of adverse clinical events, normal findings 
in multidetector computed tomography are comparable to reported values for stress 
myocardial perfusion scan or stress echocardiography. 
The critical analysis of these studies shows that there is a moderate correlation between the 
Agatston score and coronary artery stenosis assessed by coronarography (Detrano et al., 
1996); secondly, the total calcium scoring seems to have a rather low positive predictive 
value, which tends to vary according to sex and age, but a significantly high negative 
predictive value (>95% in asymptomatic patients and 98% in patients presenting with chest 
pain) (McLaughlin et al., 1999). Some of these studies were not adequately powered to 
detect differences in rates of clinical outcomes such as death, myocardial infarction, and 
coronary revascularization. Adequate outcome evaluation studies require the submission of 
large samples and often long periods of follow-up. A recent multidetector computed 
tomography expert consensus statement sponsored by the American College of Cardiology 
and 6 additional medical societies points to the need for continued collection and 
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assessment of prognostic data after multidetector computed tomography (Mark et al., 
2010). 
2.3 Therapeutic value of non-invasive cardiac imaging in patients with coronary artery 
disease 
It is quite difficult to establish whether there is a perfect diagnostic test, since there are quite 
many indirect issues to consider. A diagnostic test can only be considered valuable if it 
provides additional information that can help alter the clinical approach. So far, stress 
testing has not proven useful in such patients. However, some tests were validated by 
clinical trials as useful tools for every day practice. For instance, the choice between early 
emergency revascularization versus elective angiography seemed to favor the latter, as the 
clinical outcome tends to be better (Mark et al., 2010). Although it is reasonable to assume 
that fully validated diagnostic tests that show a direct impact on the clinical outcome are 
better, such level of validation is quite difficult to obtain, since large trial funding is scarce 
and the studies themselves are time consuming. Some statistical models including chi-
square, p values with adjusted hazard ratios or calculation of c-indexes and proportion of 
subjects with reclassified risk have shown that some anatomic imaging tests are more likely 
to provide useful additional information in patients with acute coronary syndromes. 
However, favorable statistical analysis does not imply that a certain diagnostic test should 
alter clinical outcomes more than others and usually does not influence clinical decisions, as 
the test’s value is often overestimated (Mark et al., 2010). 
2.4 Non-invasive cardiac imaging in clinical practice of patients with coronary artery 
disease 
The evolution of atherosclerosis is progressive and clinically silent for a long period of time 
before stable angina is installed, followed by non-stable angina and other acute coronary 
syndromes. The term “acute coronary syndrome” includes unstable angina pectoris, non-
ST-segment elevation myocardial infarction and ST-segment elevation myocardial 
infarction, all of which are life-threatening events (Figure 1). Over the past decades, 
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stratification in asymptomatic patients presenting in the emergency room (Sharma et al., 
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assessment of prognostic data after multidetector computed tomography (Mark et al., 
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Fig. 1. Algorithm of diagnostic in coronary artery disease 
- High risk of coronary artery disease development; in patients >40 years of age, with 
diabetes mellitus, peripheral arterial disease or other coronary risk equivalents; it 
correlates with an absolute or 10-year risk of coronary heart disease >20%. 
Multidetector computed tomography angiography (64-slice scanner) has high sensitivity 
and specificity in patients presenting to the emergency department with atypical chest pain, 
normal cardiac biomarkers and/or non-diagnostic ECG (Hoffmann et al., 2009). 
Symptomatic patients with coronary artery disease are stratified in three classes according 
to the risk of major cardiovascular events development:  
- Low risk for developing cardiovascular events (<10%).
- Intermediate risk for developing cardiovascular events (10% to 90%).
- High risk for developing cardiovascular events (>90%). 
2.4.2 Symptomatic patients with stable angina pectoris 
Several studies have shown that multidetector computed tomography helps assess non-
significant, but possibly unstable atherosclerotic plaques with high risk for rupture and 
embolisation. This is the more important as the negative predictive value of stress tests with 
regard to major cardiovascular events is rather low (Vignaux, 2008). The role of cardiac 
magnetic resonance imaging in such patients is not established (Figure 2).   
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Fig. 3. Algorithm for non-invasive imaging use in detecting coronary artery disease in 
patients with Acute Coronary Syndrome 
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2.4.3 Symptomatic patients with acute coronary syndromes 
Non-invasive imaging techniques should be employed according to the type of coronary 
syndrome (ST-segment elevation myocardial infarction, non- ST-segment elevation 
myocardial infarction or UI) or the possible risk (whether high or low) for developing major 
cardiovascular events (Figure 3).  
2.4.3.1 ST-segment elevation myocardial  infarction patients 
In ST-segment elevation myocardial infarction patients, non-invasive cardiac imaging is 
used only in accordance with the intended moment for revascularization (before of after 
revascularization), with the time passed from the onset of pain until hospitalization (acute 
or recent myocardial infarction) or with invasive coronary angiography results (coronary 
lesions versus normal arteries). In ST-segment elevation myocardial infarction patients 
which present within the first hours from the onset of pain, emergency revascularization is 
required and non-invasive imaging is of no use.   However, non-invasive imaging can prove 
useful in patients with previously revascularized ST-segment elevation myocardial 
infarction for assessing residual ischaemia and establishing the need for late 
revascularization. Multidetector computed tomography is particularly useful if common 
trunk or right coronary artery sinus lesions, non-detected by invasive techniques, are 
suspected or in quantifying lesion length, as well as the vascular bed down-stream in order 
to provide the necessary information pending aorto-cornary by-pass. Cardiac magnetic 
resonance imaging in post-revascularization ST-segment elevation myocardial infarction 
patients is useful for morphology and global and segmentary left ventricle systolic function 
assessment, mechanical complication evaluation, infarctus size, stress and rest myocardial 
perfusion. Cardiac magnetic resonance imaging is particularly efficient in establishing the 
cause of acute coronary syndromes in ST-segment elevation myocardial infarction patients 
with normal coronary arteries, who sometimes have a Tako-Tsubo syndrome or suffer from 
myocarditis. In some cases, coronary multidetector computed tomography can help identify 
intra-stent restenosis or unstable atherosclerotic plaques, as well as coronary artery 
abnormalities that have not been identified during the invasive procedure.  At patients with 
ST-segment elevation myocardial infarction and normal coronaries (Vignaux, 2008), cardiac 
magnetic resonance imaging have an important role in establishment of infarctus diagnosis 
and for excluding Tako-Tsubo syndrome or myocarditis.  
2.4.3.2 Non-ST-segment elevation myocardial  infarction patients 
Myocardial revascularization is not a top priority in patients presenting with non-ST-
segment elevation myocardial infarction, since no major long term benefit has been proven. 
The most appropriate approach is a late (48 hours) angiography. Multidetector computed 
tomography angiography could help select patients at risk who have normal myocardial 
biomarker values and non-diagnostic ECGs and allow the early discharge of subjects with 
normal coronary arteries. (Goldstein et al., 2007) (O'Connor et al, 2010). 
2.4.3.3 Patients wi th unstable angina and atypical  chest pain  
Multidetector computed tomography is very useful in patients with atypical thoracic pain 
and normal cardiac enzymes, as well as in patients with valvular or vascular disease, dilated 
cardiomyopathy, congenital heart disease or left ventricular aneurysms, intracardiac 
thrombi and confirmed coronary artery disease. In addition to that, only 15-25% of 
hospitalized patients presenting with nonspecific acute chest pain prove to have genuine 
acute coronary syndromes (Yoo et al., 2010) 
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Coronary artery disease can also provide additional data when common trunk or right 
coronary ostium stenosis are present, in case of myocardial infarction with normal coronary 
arteries or in patients with confirmed coronary artery disease. Cardiac magnetic resonance 
imaging can be used for confirmation and risk stratification in patients with coronary artery 
disease and for sustaining differential diagnosis with myocarditis or pericarditis.   
3. Conclusion 
Over the last few years, new non-invasive imaging techniques that allow heart exploration 
such as coronary multidetector computed tomography and cardiac magnetic resonance 
imaging have demonstrated their diagnostic and prognostic value, as well as their impact on 
clinical outcomes, when properly used. However, despite convincing evidence concerning 
their high efficiency, sustained by several studies, clinical trials and meta-analyses, there is 
still an acute need for proper algorithms which can be used for basic approach in relation to 
cardiovascular risk and coronary artery disease severity.   
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1. Introduction 
Computed Tomography (CT) scanners essentially consist of a rotating X-ray tube emitting a 
fan-beam of X-rays mounted on a gantry opposite a set of curvilinear detector rows. The X-
ray beam, collimated at source and prior to detection, rotates around the patient who lies on 
a table that passes through the gantry. The gantry may either move sequentially down the 
table (step and shoot) or the table and the gantry move together (helical scanning) thereby 
reducing scan times and improving temporal resolution. 
Early CT scanners, with only one detector and a pencil beam, took approximately 3 minutes 
to complete one 360o rotation around the patient. Fan shaped x-ray beams, increasing the 
number of detectors and the advent of slip-ring technology allow modern CT scanners to 
have speeds in excess of 330ms per rotation (with their absolute mechanical limit being 
between 50 and 200ms) and has allowed cardiac CT to flourish, and in particular allows 
motion free images of the coronary arteries to become a reality. (Kalender, 2000, as cited in 
Nicol & Padley, 2007a). 
The detectors sense and record the attenuation of the X-ray beam for any given point in the 
imaged slice. In Cardiac CT (CCT) images are obtained with slice thicknesses as thin as 
0.4mm. The X-ray attenuation is translated into a numerical value (Hounsfield Units (HU)). 
Multiple attenuation values are obtained from any given point during the rotation of the X-
ray tube. Filtered back projection is then automatically performed to achieve a final 
attenuation value. These values are converted and mapped to form a grey-scale image. 
Magnetic resonance uses a strong static magnetic field to effectively magnetise the protons 
in the body. Radiofrequency pulses are transmitted to excite the protons in the tissue being 
imaged and an echo signal is produced and recorded in the receiver coils and these are used 
to produce an image. Different types of pulse sequences can be used to take advantage of 
the different relaxation characteristics of the tissue to help generate image contrast.  
Typically a 1.5 tesla (T) MRI scanner is used for cardiac MR (CMR) and superior image 
quality is achieved by using higher numbers of receiver channels. 
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2. Technical aspects of CT and MR coronary angiography 
CT and MR coronary angiography (CTCA and MRCA) depend on three main factors – 
spatial resolution, temporal resolution and contrast resolution. 
2.1 Spatial resolution 
Spatial resolution is defined as the ability to distinguish two separate objects in close 
proximity (Fig. 1) (Smith, 1997).  
 
 
Fig. 1. Spatial resolution , expressed as line pairs/mm (lp/mm), is considered the point at 
which the individual strips cannot be readily distinguished by the eye. A line pair gauge 
such as this one is typically used to measure this. Reproduced with permission (Smith, 
1997).  
This is critically important in coronary artery imaging as coronary arteries have small 
luminal diameters, approximately 5mm at the ostia, tapering distally (or within the 
branches) to < 1mm. As CT and MR values for any given point is represented as a voxel (a 
three dimensional pixel), the smaller the voxel, the higher the spatial resolution.  Other 
factors that affect spatial resolution may be fixed or variable. Fixed (non-modifiable) factors 
include scanner capabilities and patient size whilst variable factors include heart rate and 
motion artefact that can, to large extent, be mitigated. 
2.1.1 Fixed factors 
Current CT scanners generate images with isotropic voxel sizes as small as 0.4mm3. 
Importantly, the detector thickness of the scanner determines the z-axis “in-plane” 
resolution which varies between manufacturers from 0.4 to 0.7mm (Nicol & Padley, 2007a). 
As a result of this limitation CTCA can currently only distinguish stenoses to within 30% 
accuracy, compared with 10% on invasive coronary angiography (ICA) with a spatial 
resolution of 0.1-0.2mm. The spatial resolution of MR is typically 1-1.5mm but high 
resolution black blood images may be as low as 0.6mm. 
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2.1.2 Variable factors 
In CT and MR the attenuation or signal values within each voxel are averaged out before 
being displayed on a grey scale image. Slice thickness is also modifiable; the thicker the 
slice, the greater the volume averaged and therefore the lower the spatial resolution. The 
trade-off with higher spatial resolution is increased noise. In both CCT and CMR spatial 
resolution can be improved by reducing the field-of-view, akin to zooming into an image. In 
CT coronary angiography, thin-cuts are obtained with the field of view reduced to just 
larger than the cardiac boundaries (Fig. 2). 
 
 
Fig. 2. The acquired scan is reconstructed to give a wide field-of-view (FOV) to include the 
lungs (a) and a smaller FOV to increase spatial resolution of cardiac structures (b). 
 
 
Fig. 3. Both cardiac and respiratory motion can lead to step artefact. These appear as 
horizontal lines on the sagittal dataset (panel a) and missing sections of the right coronary 
artery (blue arrowheads) on the volume rendered reconstruction (panel b). Respiratory 
rather than cardiac motion artefact can be distinguished by the involvement of the sternum 
(yellow arrowhead) in the former (panel a). (RV=Right Ventricle; Ao=Aorta; PA=Pulmonary 
Artery; LA=Left Atrium; SVC=Superior Vena Cava; LAD=Left Anterior Descending artery.)  
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Motion artefact impairs spatial resolution in both CCT and CMR. A well-prepared and co-
operative patient who is able to comply with the breathing instructions will reduce the 
chance of step artefact (in CCT) (Fig. 3) and blurring (in CMR) due to respiration or 
movement. Reducing the heart rate reduces cardiac motion by increasing the diastolic phase 
during which coronary arteries move least. Arrhythmias, especially if irregular, may make 
prospectively gated studies impossible. 
2.2 Temporal resolution 
Cardiac motion artefact can also be reduced by acquiring images faster. In CCT this is 
achieved by increasing the speed of rotation of the gantry and the pitch of the table. This is 
similar to selecting a faster shutter speed on a camera and enables fast-moving structures 
such as coronary arteries to be captured with minimal blurring.  Standard single source 
scanners with temporal resolution of 165 to 250 ms require heart rates to be <65bpm for 
optimal coronary image quality, and pharmacological rate control, usually with β-blockers, 
is ubiquitous. Dual source CT scanners have reduced the temporal resolution in CCT to 
75ms with each detector array requiring only a quarter scan of data. This has made 
acquisition of CTCA possible at almost any heart rate (Flohr et al., 2006); however image 
quality is still improved at lower heart rates. 
The temporal resolution of CMR is typically 50ms. It is preset by the technician and is not 
constrained by MR hardware as with CT. However, tachycardia does adversely affect image 
quality and lower heart rates are more desirable as the scan time is reduced and more k 
space is filled during each cardiac cycle (Kato et al., 2010). 
2.3 Contrast resolution 
Contrast resolution is the ability to distinguish between objects of different attenuation or 
signal when they are next to each other. In CT the coronary arterial wall and lumen have 
similar attenuation values and administration of intravenous contrast is therefore required. 
Adequate and well-timed opacification enables differentiation of the vessel wall from the 
lumen. Various components of atherosclerotic plaque also have different densities and are 
able to be characterised. This is an advantage of CTCA when compared with the pure 
lumenography of invasive catheter angiography. Coronary calcium can be readily identified 
on an unenhanced CT scan. However lipid-rich soft plaque, that is more prone to rupture 
and vessel remodelling are not visible without contrast administration (Fig. 4).  
In CMR, exogenous contrast agents are usually not required. In 2D black blood sequences, a 
dual inversion recovery prepulse is used to make the blood appear black with persisting 
signal within the walls of the coronary arteries, producing images with reasonable contrast. 
For bright blood sequences, prepulses make the blood appear bright with adjacent tissues 
including myocardium and fat appearing dark. The prepulses used include T2 preparation 
pulses and fat saturation techniques, pre-programmed into the CMR sequence. 
2.4 Patient preparation 
Patient preparation is probably the most vital part of ensuring diagnostically adequate 
studies in both CCT and CMR. The patient selection process should identify those who 
would benefit from CTCA or MRCA and those who would be suitable to have the scan. 
Attention should be paid to patient factors such as excessive body mass index, arrhythmias, 
potential inability to keep still or follow breathing instructions or claustrophobia. If present, 
alternative means of coronary assessment should be considered. 
 




Fig. 4. Eccentric plaque (yellow arrows) can lead to positive remodelling (panel a) where the 
vessel expands to preserve lumen size, however continued plaque accumulation eventually 
leads to stenosis (panel b).  
All patients referred for CCT or CMR should receive a patient information leaflet outlining 
the process of their scan. Patients are usually told to take their usual medications, including 
cardio-active medications, and to avoid consuming caffeine for twelve hours prior to the 
scan. On arrival, baseline observations including a heart rate and blood pressure should be 
taken. Patients should complete a questionnaire about allergies, relevant medical conditions 
and medications.  
For CCT, contraindications to β-blockade and glyceryl trinitrate (GTN) are also ascertained. 
Intravenous access in the right antecubital fossa that allows rapid flow of contrast should be 
sited (18G or 20G cannula). The right side is used as it prevents high density contrast 
traversing the thorax and obscuring the cardiac structures through streak artefact (Nicol et 
al., 2008a). 
For both CT and CMR, ECG electrodes are placed in the appropriate positions on the 
patient’s chest to obtain a good amplitude R wave on the ECG trace. For CCT, where a low 
heart rate is critical, the heart rate is monitored and if just greater than 70 beats per minutes 
(bpm), breathing instructions alone may reduce the heart rate to < 65bpm. If the heart rate 
remains greater than 70bpm, negative chronotropic agents should be considered to reduce 
the heart rate.  
For CCT the commonest drug used to reduce the heart rate is metoprolol. It is cheap, has a 
short half-life and is available in oral and intravenous (IV) forms, both of which are equally 
efficacious. Ideally, patients should be rate controlled prior to attendance at the CT 
department; however, if the heart rate remains high, IV metoprolol can be given 
immediately before acquisition. Ivabridine (Procoralan) can be used as an alternative to β-
blockade in those with contra-indications. Sublingual GTN can be administered to promote 
vasodilatation of the coronary arteries and improve image quality but the patient should be 
warned about headaches as possible side effects (McParland et al., 2010). 
2.5 ECG gating 
Once the patient’s heart rate is optimised, the appropriate CCT or CMR gating protocol is 
selected for the acquisition.  
For CCT gating may be prospective or retrospective depending on the clinical scenario and 
information required.  Cardiac motion is usually least in diastole, usually between 60-80% of 
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Fig. 4. Eccentric plaque (yellow arrows) can lead to positive remodelling (panel a) where the 
vessel expands to preserve lumen size, however continued plaque accumulation eventually 
leads to stenosis (panel b).  
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and medications.  
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heart rate is critical, the heart rate is monitored and if just greater than 70 beats per minutes 
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2.5 ECG gating 
Once the patient’s heart rate is optimised, the appropriate CCT or CMR gating protocol is 
selected for the acquisition.  
For CCT gating may be prospective or retrospective depending on the clinical scenario and 
information required.  Cardiac motion is usually least in diastole, usually between 60-80% of 
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the R-R interval (Fig. 5). However, in patients with heart rates greater than 70bpm, imaging 
the heart in end-systole (35% of the R-R interval) may be better (Hoffmann et al., 2005).  
 
 
Fig. 5. Sample gated ECG where the heart is scanned during 60-80% of the cardiac cycle 
(diastole). This is when cardiac motion is likely to be at its minimum.  
In order to minimise radiation dose, prospective gating (with variable temporal padding) 
is usually preferred if the heart rate is between 55 and 70bpm. However, if the heart rate 
cannot be optimised to less than 70bpm, or is irregular, a retrospectively gated study 
should be considered. Even with retrospective gating, newer scanning algorithms are able 
to limit the higher dose delivered to diastole (dose modulation). However, even with this, 
the retrospectively gated acquisition confers a higher radiation dose to the patient.  
However, as the heart is imaged throughout the whole cardiac cycle, additional 
information on cardiac output, ejection fraction and wall motion analysis can be obtained. 
With increasing experience, it may also be possible to perform diagnostically adequate 
prospectively gated studies in patients with certain arrhythmias as long as the heart rate 
variability is not too extreme. In CMR, prospectively triggered and gated scans are 
acquired. 
3. Acquiring CTCA and MRCA 
3.1 CTCA acquisition 
The CT coronary angiogram is acquired in several steps – topogram, coronary calcium score, 
test bolus and contrast enhanced coronary angiogram. 
3.1.1 Coronary calcium scoring 
The presence of calcium is a surrogate marker for atherosclerosis and an independent risk 
factor of future coronary risk. It is used as an adjunct to conventional risk stratification. To 
obtain a coronary calcium score, an un-enhanced scan is performed from the carina to just 
below the diaphragm. Good contrast resolution with CT enables quantification of the overall 
burden of disease. The usual scoring system is the Agatston calcium score (Agatston et al., 
1990). Software used in coronary calcium scoring automatically detects any structure 
>130HU. The aggregate score of all detected calcium which lies within the coronary arterial 
tree is used to calculate the overall coronary calcium score. 
3.1.2 Contrast administration (test bolus and CTCA) 
Intravenous contrast administration improves the contrast resolution of the coronary 
angiogram and is essential for lumenography. For CTCA a high iodine concentration (300-
370 mg/ml) is required for appropriate opacification. Usually the contrast injection is given 
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as a timed bolus followed by a saline push to concentrate the dye in the left heart and aorta. 
The minimisation of contrast within the right heart and SVC reduces the likelihood of streak 
artefact interfering with the interpretation of the proximal right coronary artery. 
The accuracy of the timing of the bolus may be improved by the use of a test bolus or bolus 
tracking to accurately determine the time taken to achieve peak concentration in the 
ascending aorta prior to full coronary assessment. 
The test-bolus method determines the time to peak concentration of a small bolus of contrast 
in the aortic root. This time plus an additional 3-5 seconds (to allow adequate coronary 
opacification) is then used for the CTCA acquisition. The test bolus allows the patient to be 
aware of the common side effects of flushing and hopefully negates the potential heart rate 
response during the full CTCA contrast administration. Bolus tracking is similar to the test 
bolus but the scan and contrast injections are activated simultaneously. Once the contrast 
opacification in the region of interest reaches a predetermined threshold (usually 100-
150HU), and following a preset delay (usually 5-8 second) to allow for breathing 
instructions or table movement, the full scan is started and the CTCA is acquired. Whilst the 
total radiation dose is slightly less, the timed bolus does not allow much room for error.  
Whilst newer contrast media have an improved allergenic profile, any cardiac CT imaging 
service must be equipped to handle any potential contrast reactions. Patients with contrast 
media allergy may still undergo an un-enhanced coronary calcium score so that some 
information about their coronary risk profile can be obtained.  
3.2 Post processing 
CTCA images are best viewed on dedicated post-processing workstations. The table below 
shows the commonly used post-processing display protocols highlighting their advantages 
and drawbacks (Table 1).  
 
 
Table 1. Comparison of commonly used post-processing display protocols. (Reproduced 
with permission from Nicol & Padley, 2007b). 
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Fig. 6. Axial raw data through the heart showing the right and left coronary ostia (yellow 
and blue arrows respectively).  
 
 
Fig. 7. Sagittal multiplanar reformat showing the closed aortic valve in profile (yellow 
arrow), open mitral valve (blue arrow) and right (blue arrowhead) and left (yellow 
arrowhead) coronary ostia. (LV=Left Ventricle; LA=Left Atrium;Ao=Aorta;dAo=descending 
Aorta).  
 





Fig. 8. Two curved multiplanar reformat images of the right coronary artery. These are 




Fig. 9. Sagittal maximum intensity projection of showing the right (blue arrowhead) and left 
(yellow arrowhead) coronary ostia. (RV=Right Ventricle; Ao=Aorta;dAo=descending Aorta; 
LA=Left Atrium; LVOT=Left Ventricular Outflow Tract). 
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Fig. 10. Volume rendered image demonstrating a left anterior oblique view of the heart. The 
right coronary (yellow arrow), left anterior descending (blue arrow) and left circumflex 
(yellow arrowheads) arteries are clearly seen. (Ao=Aorta).  
3.3 MRCA acquisition technique 
There are two major hurdles to overcome when performing MRCA; respiratory and cardiac 
motion. Two methods are used to acquire MRCA images. These are breath-hold and free-
breathing, coronary MRA. MRCA, as with CTCA, is further hampered by arrhythmias.  
Breath-hold MRCA attempts to suppress respiratory motion by acquiring images in periods 
of apnoea. This technique allows both two-dimensional (2D) sequential images and 
subsequent shorter 3D imaging with first pass intravenous contrast. However, image quality 
is often suboptimal due to limited patient co-operation secondary to fatigue or inability to 
follow instruction adequately. Additionally breath holding is frequently associated with 
cranial drift of the diaphragm (of up to 1cm) (Danias et al., 1998), further limiting the final 
resolution of the images. These limitations may result in registration errors with apparent 
gaps in the coronary arteries that may be misinterpreted as signal voids from stenoses. As a 
result of these limitations free breathing navigator sequences are now most commonly used 
for MRCA. 
Navigator sequences are used to correct for, and reduce the effects of, respiratory motion 
(Fig. 11). The position of the diaphragm is tracked and image data is only acquired at end 
expiration when respiratory motion is minimal or absent. Prospective ECG gating is used to 
correct for cardiac motion and data is only collected when coronary artery motion is known 
to be minimal. As with CTCA, this is usually mid-to-late diastole, however, at higher heart 
rates end-systole may be preferable. The disadvantages of this technique are that scan times 
are long with a full coronary dataset taking between 5 and 15 minutes to acquire (Sakuma et 
al., 2005, 2006). This is due to the fact that this technique is very inefficient with often less 
than 2% of the scan time being used to acquire data when there is neither coronary nor 
respiratory motion. The data acquisition is pre-programmed into the MRCA sequence, 
 
 




Fig. 11. Coronal view of the MRCA sequence showing the right coronary artery 
(arrowheads) as it passes through the AV groove. The left main stem is seen in cross-section 
(arrow) as it passes underneath the right pulmonary artery (RPA). (RV=right ventricle; 
MPA=main pulmonary artery; LA=left atrium). 
although the user must define the time of least coronary motion at the time of acquisition. 
More recently 3D data acquisition during a single breath-hold using steady state free 
precession (SSFP) and parallel imaging has become possible (Deshpande et al., 2001) 
producing high resolution and high quality images with reduced scan times (Jahnke et al., 
2005). Parallel imaging (with under sampling in two rather than one phase encoding 
direction) further reduces scan time but requires large coil arrays (Nehrke et al., 2006; 
Niendorf et al., 2006).  
Newer self-navigated, free-breathing, whole heart MRCA techniques further improve image 
quality due to reduced respiratory and cardiac motion artifact. This technique uses a 
synchronous respiratory signal from the echoes acquired during imaging. The motion 
information is then retrospectively corrected, improving temporal resolution and producing 
stiller images (Stehning et al., 2005). 
4. Clinical application of CTCA and MRCA 
The significant technological improvements in CT imaging have brought CTCA into the 
forefront of coronary artery disease (CAD) assessment. With the improved temporal and 
spatial resolution, CTCA has become a viable alternative to invasive coronary angiography 
(ICA) in patients with low to intermediate likelihood of CAD (Schuijf et al., 2011). ICA 
however remains the most appropriate test in those with a high probability of severe CAD 
that may require intervention.  
More broadly CCT can also be used to assess plaque morphology, and depending on the 
protocol selected, be used to assess cardiac function (wall motion and ejection fraction), 
cardiac chamber volumes, myocardial perfusion and be used to image the pericardium, 
cardiac valves, and pulmonary veins (Nicol et al., 2009). CCT is increasingly used to 
Coronary Angiography 




Fig. 10. Volume rendered image demonstrating a left anterior oblique view of the heart. The 
right coronary (yellow arrow), left anterior descending (blue arrow) and left circumflex 
(yellow arrowheads) arteries are clearly seen. (Ao=Aorta).  
3.3 MRCA acquisition technique 
There are two major hurdles to overcome when performing MRCA; respiratory and cardiac 
motion. Two methods are used to acquire MRCA images. These are breath-hold and free-
breathing, coronary MRA. MRCA, as with CTCA, is further hampered by arrhythmias.  
Breath-hold MRCA attempts to suppress respiratory motion by acquiring images in periods 
of apnoea. This technique allows both two-dimensional (2D) sequential images and 
subsequent shorter 3D imaging with first pass intravenous contrast. However, image quality 
is often suboptimal due to limited patient co-operation secondary to fatigue or inability to 
follow instruction adequately. Additionally breath holding is frequently associated with 
cranial drift of the diaphragm (of up to 1cm) (Danias et al., 1998), further limiting the final 
resolution of the images. These limitations may result in registration errors with apparent 
gaps in the coronary arteries that may be misinterpreted as signal voids from stenoses. As a 
result of these limitations free breathing navigator sequences are now most commonly used 
for MRCA. 
Navigator sequences are used to correct for, and reduce the effects of, respiratory motion 
(Fig. 11). The position of the diaphragm is tracked and image data is only acquired at end 
expiration when respiratory motion is minimal or absent. Prospective ECG gating is used to 
correct for cardiac motion and data is only collected when coronary artery motion is known 
to be minimal. As with CTCA, this is usually mid-to-late diastole, however, at higher heart 
rates end-systole may be preferable. The disadvantages of this technique are that scan times 
are long with a full coronary dataset taking between 5 and 15 minutes to acquire (Sakuma et 
al., 2005, 2006). This is due to the fact that this technique is very inefficient with often less 
than 2% of the scan time being used to acquire data when there is neither coronary nor 
respiratory motion. The data acquisition is pre-programmed into the MRCA sequence, 
 
 




Fig. 11. Coronal view of the MRCA sequence showing the right coronary artery 
(arrowheads) as it passes through the AV groove. The left main stem is seen in cross-section 
(arrow) as it passes underneath the right pulmonary artery (RPA). (RV=right ventricle; 
MPA=main pulmonary artery; LA=left atrium). 
although the user must define the time of least coronary motion at the time of acquisition. 
More recently 3D data acquisition during a single breath-hold using steady state free 
precession (SSFP) and parallel imaging has become possible (Deshpande et al., 2001) 
producing high resolution and high quality images with reduced scan times (Jahnke et al., 
2005). Parallel imaging (with under sampling in two rather than one phase encoding 
direction) further reduces scan time but requires large coil arrays (Nehrke et al., 2006; 
Niendorf et al., 2006).  
Newer self-navigated, free-breathing, whole heart MRCA techniques further improve image 
quality due to reduced respiratory and cardiac motion artifact. This technique uses a 
synchronous respiratory signal from the echoes acquired during imaging. The motion 
information is then retrospectively corrected, improving temporal resolution and producing 
stiller images (Stehning et al., 2005). 
4. Clinical application of CTCA and MRCA 
The significant technological improvements in CT imaging have brought CTCA into the 
forefront of coronary artery disease (CAD) assessment. With the improved temporal and 
spatial resolution, CTCA has become a viable alternative to invasive coronary angiography 
(ICA) in patients with low to intermediate likelihood of CAD (Schuijf et al., 2011). ICA 
however remains the most appropriate test in those with a high probability of severe CAD 
that may require intervention.  
More broadly CCT can also be used to assess plaque morphology, and depending on the 
protocol selected, be used to assess cardiac function (wall motion and ejection fraction), 
cardiac chamber volumes, myocardial perfusion and be used to image the pericardium, 
cardiac valves, and pulmonary veins (Nicol et al., 2009). CCT is increasingly used to 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 
 
110 
examine acquired structural or congenital heart disease (Nicol et al., 2007), aberrant 
coronary vasculature, coronary artery bypass grafts (CABG) (Niemen et al., 2003) and intra-
coronary stents (Gaspar et al., 2005). 
 
 
Fig. 12. Maximum intensity projection image from a navigator coronary MRA sequence 
demonstrating an aberrant circumflex artery (black arrowheads) arising from the right 
coronary artery passing between the aorta (Ao) and the right atrium (RA). Note also the 
resultant artefact (yellow arrowheads) due to cardiac motion. (LA=left atrium). 
MRCA is most commonly used to investigate patients with suspected anomalous coronary 
arteries (Fig. 12) and fistulae, and in children and young adults with suspected coronary 
artery aneurysms such as in patients with Kawasaki's disease. It can potentially be used to 
assess graft patency in CABG; however the presence of surgical clips may limit graft 
visualisation. In patients with poor renal function, MRCA can be used to assess the patency 
of proximal coronary arteries in patients undergoing major cardiac surgery, such as valve 
replacement, as no contrast agent is used. 
4.1 CT and MR coronary angiography 
Unlike ICA that provides a “lumenogram”, a good quality CTCA can demonstrate both the 
lumen and the wall. The real strength of CTCA is its negative predictive value (usually over 
99% cf. ICA), effectively ruling out coronary artery disease in those with a normal study 
(Budoff et al., 2008; Meijboom et al., 2008). The positive predictive value of CTCA is less 
favourable due its comparatively limited spatial resolution. The diagnostic accuracy of 
CTCA is further impaired by the presence of heavy coronary calcification, which may lead 
to the overestimation of stenoses. All coronary stenoses should be viewed from multiple 
angles and appropriate window settings to reduce “blooming” artefact from calcium. If 
contrast is seen passing alongside a calcified lesion in any plane, then the stenosis is unlikely 
to be more than 50% on ICA. CTCA is as effective in determining soft plaque burden as 
intravascular ultrasound (IVUS) (Leber et al., 2006). Clinically this is important due to the 
higher prevalence of soft plaque in those patients with acute coronary syndromes than those 
who have stable angina (Korosoglou et al., 2010; Motoyama et al., 2007). An algorithm for 
the investigation of symptomatic patients based on their pre-test probability is suggested 
(Fig. 13).  
 




Fig. 13. Potential algorithm for sequential imaging of anatomy and function for diagnosis 
and management of coronary artery disease (CAD) based on pre-test probability in 
symptomatic patients. A low to intermediate pre-test probability favours initial evaluation 
of the presence or absence of obstructive stenosis, since the prevalence of obstructive CAD 
will be low. As a consequence only a few patients will have abnormalities that may require 
further testing and revascularisation. (LM = left main coronary artery; 3VD = triple vessel 
disease.) Adapted with permission from Schuijf JD et al., 2011).  
Like CTCA, MRCA is able to demonstrate both the lumen and vessel wall. However CMR 
studies routinely provide additional cardiac anatomy and functional information. 
Compared with CTCA the speed of acquisition and spatial resolution of MRCA has so far 
limited its use clinically. There are important technical differences between CTCA and 
MRCA; in CTCA the right coronary artery is often the most difficult vessel to image due to 
movement artifact, especially in prospectively acquired imaging, but in MRCA the left 
circumflex artery is relatively difficult to image due to its distance from the receiver coil and 
its proximity to the great cardiac vein (Danias et al., 1999). As with CTCA, multiple studies 
have assessed the accuracy of MRCA for the detection of significant CAD. In essence 
MRCA, like CTCA, has a high negative predictive value but variable specificity and positive 
predictive value (Danias et al., 2004; Kato et al., 2010; Kim et al., 2001; Schuetz et al., 2010). 
MRCA is particularly useful in left main coronary and three vessel disease assessment (Kato 
et al., 2010; Kim et al., 2001) (Fig. 14) but overall 1.5T CMRA is comparable with 16 MDCT 
when assessing the entire coronary tree (Kefer et al., 2005). 
Wall thickness and plaque characterisation are significant areas of research in both CTCA 
and MRCA as plaque rupture and myocardial infarction can occur in the absence of 
significant luminal narrowing. In MRCA, T1 weighted 2D and 3D black blood imaging can 
detect atherosclerotic plaque and determine wall thickness and thus positive remodelling 
(Fayad et al., 2000; Kim et al., 2002), whilst CTCA studies have demonstrated that the 
presence of positive remodelling and “spotty” plaque morphology (a predominantly soft 
plaque with some areas of calcification within it) are strongly associated with subsequent 
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Fig. 14. Maximum intensity projection image (a) from a navigator coronary MRA sequence 
demonstrating a normal calibre left anterior descending artery (arrowheads). The second 
image (b) shows non-occlusive, non-calcified plaque (arrow) in the mid left anterior 
descending artery (arrowheads) on this coronary MRA. (Ao=aorta; LV=left ventricle; 
PA=pulmonary artery). 
acute coronary syndrome (Motoyama et al., 2007). MRCA has been used to demonstrate 
positive remodelling in diabetic patients with nephropathy compared with those without 
(Kim et al., 2007) and recent evidence demonstrates that high signal on T1 weighted images 
seen in plaques in the walls of coronary arteries is associated with positive remodelling. This 
suggests MRCA may also be useful for investigating complex plaques non-invasively 
(Kawasaki et al., 2009). Late contrast enhancement of the coronary arterial wall in MRCA 
has been seen in areas of calcific plaque and significant stenotic lesions following recent 
infarcts (Yeon et al., 2007; Ibrahim et al., 2009) and it has been proposed that late contrast 
enhancement may be useful in visualisation of inflammatory activity in atherosclerosis 
associated with acute coronary syndrome. For early CAD assessment, recent studies have 
shown that MRCA can demonstrate endothelial loss of normal vasomotor tone prior to the 
development of any vascular remodelling (Hays et al., 2010).  
4.2 Coronary stent assessment 
Clinically all stents are susceptible to varying degrees of neo-intimal hyperplasia, in-stent re-
stenosis and complete occlusion. The metal in the stents make them easily visible on CT (Fig. 
15) however CTCA analysis of stents must be done cautiously due to “blooming” artefacts 
(Nicol & Padley, 2007b). Blooming is worse with bare metal stents than drug eluting stents 
but CTCA has been shown to be clinically reliable for stents >3mm in diameter and is 
clinically useful in the assessment of left main stem stents (Pugliese et al., 2008). Stents of 
smaller calibre are less easily assessed and caution is advised when attempting to determine 
the severity of stenoses. 
4.3 Coronary artery bypass graft assessment 
The inherent larger calibre of vessel grafts, relative immobility and lack of calcification, 
make them ideally suited to CTCA analysis (Fig. 16). Indeed, the sensitivity and specificity 
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of CTCA in graft patency analysis has been shown to be 95-100% and 94-100% respectively 




Fig. 15. Curved planar reformat of a metal stent extending from the left main stem (blue 





Fig. 16. Volume-rendered images demonstrating quadruple coronary artery bypass grafts. 
There are a vein graft to the right coronary artery (yellow arrow), two vein grafts supplying 
the acute marginal and lateral marginal branches of the LCx (blue arrows) and a left internal 
mammary artery graft supplying the left anterior descending artery (arrowheads). 
However, complete examination of grafts and their patency should include assessment of 
their run-off which may be limited with CT. Limitations of CTCA include blooming artefact 
from surgical clips which can particularly affect distal LIMA anastomosis assessment. CABG 
patients often have significant and heavy calcification, which can also cause blooming 
artefact on CTCA. MRCA can also be used to assess CABG but again surgical clips may 
hinder full assessment.  
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4.4 Functional information 
Whilst CMR remains the gold-standard for cardiac functional analysis, retrospectively gated 
CCT studies allow assessment of global and regional left ventricular function with good 
correlation with both CMR and transthoracic echocardiography (Nicol et al., 2008b). It is 
important to be aware of limitations of CCT however when assessing both global and 
regional wall motion abnormalities especially if not reconstructing 100% of the cardiac cycle. 
Whilst end-systole and end-diastole usually fall at around 35% and 65% respectively there is 
significant inter-patient variation and values from the analysis may not reflect that of CMR 
or echocardiography that routinely utilise the whole cardiac cycle. Importantly, when 
assessing functional CT data regional wall motion abnormalities in the absence of impaired 
systolic wall thickening should also be treated with caution as they may be artefactual 
(Nicol et al., 2008). 
5. Clinical application of CTCA and MRCA in congenital and structural heart 
disease assessment 
Both CCT and CMR are able to demonstrate complex anatomy in congenital cardiac disease. 
CMR remains the gold standard for adult congenital heart disease assessment but the 
increasing availability, speed of acquisition and superior spatial resolution of CCT makes it 
a viable alternative in many clinical situations (Nicol et al., 2007). CMR is generally 
contraindicated in patients with pacemaker and implanted defibrillator devices. 
Unlike CMR, that offers complete cardiothoracic visualisation, CCT is only able to 
demonstrate both the coronary anatomy and the pulmonary arterial trunk with extended 
injection protocols that increase right heart and pulmonary opacification in addition to the 
coronary anatomy (Nicol et al., 2009). CTCA is the gold standard for the full delineation of 
aberrant coronary anatomy, however MRCA is, in most patients, adequate for delineation of 
the clinically important coronary ostia and using dedicated sequences can also sometimes 
produce diagnostic images of the entire coronary tree. As a general rule, MRCA should be 
considered first line if radiation exposure is likely to be higher than acceptable, i.e. in 
children or young females, and MRCA should certainly be considered in those requiring 
regular follow up such as Kawasaki’s disease. 
Increasingly CCT is used for acquired structural heart disease and assessment of valve 
disease using planimetry and assessment of valve function on cine images acquired in 
retrospectively gated studies is gaining clinical acceptance (Chheda et al., 2010). It is 
important to remember however that CCT is unable to assess flow and is therefore inferior 
to both CMR and echocardiography for the assessment of valve gradients. 
Combined cardiac and non-cardiac angiography is now used in the assessment of trans-
catheter aortic valve implantation (TAVI). Assessment of the aortic root size, aortic 
pathology (plaque burden, calcification, vessel tortuosity), access routes (ilio-femoral and 
subclavian arteries), coronary arteries and valve calcification can all be assessed using CT 
angiography (Ewe et al., 2011) (Fig. 17). 
6. Future developments in CT and MR 
6.1 CCT imaging 
There have been significant advances in CT scanner technology over the last decade with 
the advent of increasing numbers of detectors (up to 320) allowing whole heart coverage 
 
 




Fig. 17. Volume rendered images of the aorta obtained as part of the TAVI assessment 
protocol. The level of the aortic root (yellow arrow), right subclavian artery origin (blue 
arrowhead), right carotid artery (yellow arrow head) and left brachiocephalic artery (blue 
arrow) are shown in (a). The tortuosity of the iliofemoral arteries (yellow arrowheads) 
demonstrated in (b), will help with surgical planning.  
without table feed, and fast pitch dual source CT allowing a full cardiac acquisition in a 
fraction of a second with radiation doses routinely <1mSv for a CTCA. 
Future technological advances are likely to remain focused on rapid acquisition of cardiac 
data at low ionizing radiation doses. This may be achieved using a variety of techniques 
such as multi-source, multi-energy CT or inverse geometry CT. 
6.2 Multi-source, multi-energy CT 
By increasing the number of X-ray sources it may be possible to further reduce the temporal 
resolution by two-thirds with the addition of a third source (58ms) or three-quarters with a 
fourth (41ms), however the weight of each additional X-ray source may reduce the overall 
gantry rotation time negating any additional benefit. The use of air bearing systems may 
allow this but the ability to overcome the effects of high centrifugal forces remains a 
significant challenge. 
The major advantage of dual source CT (DSCT) technology is the ability to acquire a 
complete dataset using one-quarter of a gantry rotation time, thereby reducing the temporal 
resolution by half. The second advantage of dual headed CT is the ability to acquire the 
dataset at differing energies (Dual energy CT (DECT)). It is also possible to perform DECT 
on single headed scanners by rapidly alternating kV from a single tube. Either technique 
fundamentally alters the penetration of the X-ray beam and therefore the attenuation by 
tissues. By subtracting one dataset from the other it is possible to, for example to artificially 
“remove” calcium or contrast, potentially spelling the end for non-enhanced CT preceding 
contrast studies. It may also be used to assess myocardial densities at different energies, 
paving the way for potential tissue characterization in infarct or ischaemic myocardium. 
DECT subtraction techniques are currently limited to large calibre vessels such as the aorta 
as the resolution of the current generation of CT scanners is not yet sufficient to apply this to 
the coronary arteries. 
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6.3 Inverse Geometry CT (IGCT) 
IGCT is a novel system under investigation that employs a large array of X-ray sources 
opposite a smaller detector array (Fig. 18). It is anticipated to be able to image a thick 
volume in a single gantry rotation with isotropic resolution. The ability to image a volume is 
primarily determined by the size of the X-ray source array, in much the same way that it is 
determined by the size of the detector array in a conventional CT system. As well as 
demonstrating low wasted radiation (Mazin et al., 2007) (and therefore a much smaller 
radiation requirement), this technique also has the potential to maximise gantry rotation 
time further reducing spatial resolution. 
 
 
Fig. 18. Standard MDCT (a) requires an 18cm detector array when scanning a 10cm region of 
interest (due to cone beam) introducing artefacts at beam edges. Inverse Geometry CT 
(IGCT) (b) uses multiple x-ray sources and only requires a 10cm detector array for a 10cm 
region of interest, reducing detector size and weight, reducing cone beam artefact and 
producing greater signal to noise ratios for reduced radiation exposure.  
Future advances in material technology will also advance CT imaging with flat panel 
technology already under investigation. The use of strong light weight materials may also 
overcome some of the mechanical limitations that prevent faster gantry rotation times today 
and may improve spatial and temporal resolution to nearer that of interventional coronary 
angiography. 
6.4 3T CMR imaging 
At 3T, there is improved signal to noise ratio (SNR) as SNR is proportional to the field 
strength of the static magnetic field (Singerman et al., 1997). 3T results in better spatial and 
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temporal resolution and shorter scanning time. There is a doubling of SNR and a 4-fold 
reduction in scanning time using 3T parallel imaging and spatial harmonics compared with 
1.5T. Additionally, at higher field strengths the prolongation of the T1 values make spin 
labelling techniques more attractive. However triggering is more problematic at higher field 
strengths (3T and 7T) as the enhanced magneto-hydrodynamic effect produces an artifactual 
voltage that is overlaid on the T wave of the ECG. This can result in triggering off the T 
wave (rather than the R wave) making it difficult to reliably identify the time of least 
coronary motion. Using sophisticated R wave detection algorithms this problem can be 
overcome. 
MRCA at 3T has been performed (Stuber et al., 2002) however although the contrast to noise 
ratio is improved, there is no overall improvement in image quality or diagnostic accuracy 
(25). 3T MRCA has been shown to have high sensitivity and specificity for the detection of 
significant (>50%) coronary stenoses (Yang et al., 2009), possibly even being comparable to 
64 MDCT (Hamdan et al., 2011) when using contrast-enhanced methods that rely on double 
dose infusion of contrast media. This is required as gradient-echo sequences are used 
instead of SSFP sequences due to the need to overcome magnetic field inhomogeneity and 
radiofrequency energy deposition at high field strengths (Bi et al., 2007; Liu et al., 2008). It is 
hoped that the use of sophisticated shimming algorithms and adiabetic T2 preparations will 
further improve acquisition at 3T (Nezafat et al., 2006; Schär et al., 2004) in the future. 
7. Future application of CTCA and MRCA 
Both CCT and CMR continue to develop rapidly. The applications for CTCA continue to 
expand and with the development of myocardial perfusion and scar imaging the ability to 
look at the coronary lumen and vessel wall and gain functional information about both the 
blood flow and myocardial function will see this field continue to expand.  
The recent UK NICE guidelines include CTCA within their recommendations for patients 
with chest pain (NICE, 2010) and the ever growing demand for rapid exclusion or 
confirmation of coronary artery disease are likely to see CTCA become a far more 
ubiquitous tool used in almost all hospitals. 
As radiation doses continue to fall and as CTCA research produces outcome and cost 
effectiveness data, the role and utilisation of this rapidly evolving technology is likely to 
increase further. The combination of newer technology has raised the possibility of assessing 
flow; indeed venous and arterial phases of cerebral flow can already be imaged using CT 
and this opens up many possibilities for potential cardiac flow assessment in the future.  
In MRCA, the greater availability of more powerful magnets, increased number of receiver 
coils and more sophisticated algorithms, may reduce imaging time. MRCA may become 
routine in the early detection of coronary artery disease at the positive remodelling stage or 
even earlier. Plaques at risk of rupture may be identified early and intervention undertaken 
before myocardial damage occurs. 
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1. Introduction 
X-ray computed tomography (CT) was first invented in 1972 and its ability to obtain cross 
sectional images has proven to be a major advance in the field of medicine, garnering the 
Nobel Prize in medicine for Sir Godfrey Newbold Hounsfield and Allan McLeod Cormack 
in 1979. Since then, numerous advances have been made with the introduction of high 
quality scanners and new imaging protocols to enhance the quality of the images and 
reduce the amount of radiation. Inherent drawbacks of conventional CT imaging for cardiac 
imaging, such as low temporal resolution and the need for ECG gating, prompted the 
development of electron beam CT (EBCT). Further advances in the scanners have led to the 
introduction of multi detector CT  (MDCT) scanners, which have increased spatial 
resolution and now utilize sequential imaging acquisition modes and other features to 
minimize radiation exposure. MDCT scanners for coronary imaging utilize a minimum of 16 
slice, and now 64 - 320 slice scanners are widely used to get excellent, high-resolution 
images of the heart and the coronary arteries. 
2. Basics of operation 
The coronary CT angiogram (CCTA) is a relatively fast and simple procedure. Adequate 
patient preparation and co-operation are essential for good image acquisition. Beta-blockers 
are routinely given to slow the heart rate (Bluemke et al. 2008) in order to eliminate or 
reduce artifact from motion of the coronary arteries. This chapter deals primarily w ith the 
use of coronary CTA as an alternative to invasive angiography and another chapter 
describes the technical features in more detail. However, in brief, temporal resolution is an 
important limitation and is determined by the speed of the X-ray gantry(Kapoor and 
Thompson 2009). MDCT scanners improve this temporal resolution by acquiring a full CT 
slice in only half a rotation, and recent advances in scanner design have improved the speed 
of rotation and even added second tube sources in order to improve temporal resolution 
even more. The 64-slice MSCT instruments are now considered the minimum standard for 
CT scanners intended for coronary artery imaging. Images are most commonly acquired 
using prospective gating and only during diastole (for example at 70-80% of the R-R 
interval) in order to reduce the radiation dosage (Earls et al. 2008). Both spatial resolution 
and temporal resolution are less with CCTA than conventional invasive coronary 
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introduction of multi detector CT  (MDCT) scanners, which have increased spatial 
resolution and now utilize sequential imaging acquisition modes and other features to 
minimize radiation exposure. MDCT scanners for coronary imaging utilize a minimum of 16 
slice, and now 64 - 320 slice scanners are widely used to get excellent, high-resolution 
images of the heart and the coronary arteries. 
2. Basics of operation 
The coronary CT angiogram (CCTA) is a relatively fast and simple procedure. Adequate 
patient preparation and co-operation are essential for good image acquisition. Beta-blockers 
are routinely given to slow the heart rate (Bluemke et al. 2008) in order to eliminate or 
reduce artifact from motion of the coronary arteries. This chapter deals primarily w ith the 
use of coronary CTA as an alternative to invasive angiography and another chapter 
describes the technical features in more detail. However, in brief, temporal resolution is an 
important limitation and is determined by the speed of the X-ray gantry(Kapoor and 
Thompson 2009). MDCT scanners improve this temporal resolution by acquiring a full CT 
slice in only half a rotation, and recent advances in scanner design have improved the speed 
of rotation and even added second tube sources in order to improve temporal resolution 
even more. The 64-slice MSCT instruments are now considered the minimum standard for 
CT scanners intended for coronary artery imaging. Images are most commonly acquired 
using prospective gating and only during diastole (for example at 70-80% of the R-R 
interval) in order to reduce the radiation dosage (Earls et al. 2008). Both spatial resolution 
and temporal resolution are less with CCTA than conventional invasive coronary 
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angiography and these limitations must be kept in mind when deciding which test to order. 
The maximum spatial resolution of MSCT is 0.4 mm, and is determined by the size of the 
picture elements of the CT detector. Smaller coronary segments frequently are not evaluable 
with CTA and coronary CTA may be unable to distinguish moderate from severe flow 
limiting stenosis, because of these limitations of resolution(Kapoor and Thompson 2009). 
3. Application of coronary calcium scoring 
Non-contrast CT scanning of the coronary arteries is a widely used technique for risk 
stratification and prognosis for individuals without know coronary artery disease. With this 
technique, calcium in the form of calcium hydroxyapatite in the artery wall is imaged and 
quantified in order to provide a rough measure of the presence of coronary atherosclerosis. 
There is a linear relationship between the amount of coronary calcium and coronary 
atherosclerosis, that is, the more coronary calcium the higher the likelihood of coronary 
stenosis(Rumberger et al. 1995), and proportionally prognostic – the higher the calcium 
score the greater the likelihood of coronary events(O'Rourke et al. 2000). Moehlenkamp and 
colleagues recently demonstrated that coronary calcium scoring not only adds prognostic 
value to the Framingham risk model, but also that it’s value is greater than hsCRP 
(Mohlenkamp et al. 2003). A lso the recent randomized Eisner Trial demonstrated that 
coronary calcium testing leads to better downstream control of coronary risk 
factors(Rozanski et al. 2011).  Thus, the ability of coronary calcium scoring to non-invasively 
identify and quantify the amount of coronary calcium is invaluable to diagnose pre-clinical 
CAD and help to aggressively modify the risk factors. It should be emphasized that 
coronary CTA, while a very useful tool, is not a particularly appropriate test for patients 
with chest pain syndromes. CT coronary calcium scoring is performed without the use of 
iodinated x-ray contrast. In order to perform CT coronary angiography, the focus of this 
chapter, x-ray contrast is administered. 
4. CCTA as an alternative to invasive angiography 
While CCTA can sometimes provide images of truly impressive quality, the spatial and 
temporal resolution are significantly inferior to invasive angiography, and CCTA images 
are sometimes degraded by artifacts.  A  recent prospective multicenter-blinded study 
evaluated the diagnostic performance of 64-multidetector row CCTA compared w ith 
invasive coronary angiography (ICA) in patients w ith chest pain w ithout known CAD 
who were referred for non-emergent ICA. The data revealed high diagnostic performance 
at both 50% and 70% stenosis thresholds. In addition, the 99% negative predictive value 
(NPV) of CCTA at the patient and vessel levels establishes it as a highly effective 
noninvasive alternative to ICA for the exclusion of obstructive coronary artery 
stenosis(Budoff et al. 2008). The strength of the CCTA lies in its high negative predictive 
value. A good quality negative CCTA without artifacts can rule out the presence of CAD with a 
great level of confidence. The high negative predictive value has been consistently 
demonstrated(Gopalakrishnan et al. 2008; Mowatt et al. 2008; Stein et al. 2008) and it is 
this population where coronary CTA might well be a substitute for invasive angiography. 
Figure 1 demonstrates a normal high quality coronary CT angiogram and figure 2 
demonstrates one in which the diagnosis of high - grade coronary artery disease was 
made. In general, coronary CTA is much less accurate in the presence of heavy coronary 
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calcification and in patients w ith atrial fibri l lation or other irregular cardiac rhythms. 
Figure 3 is an example of such a non-diagnostic study. Another chapter deals w ith the 
accuracy of CTA in greater detail. 
Fig. 1. CT coronary angiogram of a 39 year old male who complained of chest pain 
(maximum intensity image of the right coronary artery (A and B) and the left coronary 
artery (C) and reformatted image (D). The study was normal giving a high degree of 
confidence that coronary artery disease was not present. 
A lthough coronary CTA has limitations, it is much less invasive than invasive coronary 
angiography and it is an appropriate alternative in selective cases. For example, according to 
the ACCF/ SCCT/ ACR/ ASNC appropriate use criteria for diagnosing CAD, patients who 
present with non-acute symptoms and possibly representing an ischemic equivalent, CCTA 
is considered an appropriate test in those with a low to intermediate probability of CAD 
whose ECG is uninterpretable and who cannot exercise(Taylor et al. 2010). CCTA is also 
considered appropriate in patients with a low to intermediate pre-test probability w ith acute 
symptoms suggestive of acute coronary syndrome (ACS) with a normal ECG and cardiac 
biomarkers(Taylor et al. 2010). However, in patients who have obvious severe cardiac 
ischemia, coronary CTA is not an appropriate alternative to invasive angiography as it w ill 
simply delay interventional therapy and add to the x-ray contrast load prior to the needed 
invasive procedure(Taylor et al. 2010). 
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Fig. 2. Volume rendered (A) and maximum intensity projection (B) CT angiogram images 
from a 48-year-old male demonstrating a high-grade stenosis in the mid segment of the left 
anterior descending coronary artery. The patient had presented with persistent, intermittent 
chest pain and a myocardial perfusion image had been equivocal. 
Fig. 3. Thin maximum intensity projection (MIP) coronary CT angiogram in a 65-year-old 
female patient showing the proximal left coronary artery branches. Heavy coronary calcium 
makes the study non-diagnostic. Image quality is also impaired by insufficient x-ray 
contrast in the aorta and coronary arteries at the time of acquisition. 
Coronary CT Angiography as an Alternative to Invasive Coronary Angiography 127 
Another category of patients in whom CCTA is used as an alternative to invasive 
angiography are those w ith an equivocal or low probabil i ty stress tests whose symptoms 
suggestive of angina persist despite low probabili ty scans. These patients are often 
referred for cardiac catheterization, but CCTA is a less invasive test that can rule out 
obstructive CAD as a cause for their symptoms. The high negative predictive value of 
CCTA allows the clinician to confidently reassure the patient w ithout invasive testing. 
This same rationale applies to  those patients w ith suspected coronary artery disease who 
are scheduled to undergo non-cardiac surgeries. When applied to the appropriate subset 
of patients, i.e. those w ith relatively low pre-test probabili ty of CAD, CCTA can prove to 
be the final test to confidently rule out the presence of CAD and these patients benefit 
from avoiding the higher cost and potential complications of invasive coronary 
angiography. 
4.1 Etiology of cardiomyopathy 
When patients present with a new diagnosis of heart failure /  cardiomyopathy, further 
diagnostic evaluation is warranted. Coronary artery disease is the most common cause of 
cardiomyopathy and differentiating ischemic from non-ischemic etiology has important 
therapeutic and prognostic implications. In particular, since ischemic cardiomyopathy has 
the potential for improvement from revascularization, it is very important that the etiology 
be established. Treatment guidelines for patients with a new diagnosis of cardiomyopathy 
prominently feature the use of invasive coronary angiography, and it is considered the gold 
standard for establishing the diagnosis of cardiomyopathy of coronary artery disease. While 
myocardial perfusion imaging has some value in this population, there are important 
limitations in this group such as lower diagnostic accuracy and difficulty in performing 
stress in some of them. A lso, while regional wall motion abnormalities identified by two 
dimensional echocardiography or radionuclide angiography have been proposed to be 
specific for coronary artery stenosis induced ischemia and infarction(Budoff et al. 1998), 
subsequent studies have shown similar abnormalities with dilated cardiomyopathies, not 
related to coronary artery disease(Andreini et al. 2007). With the use coronary CT 
angiogram, however, a diagnosis either in favor of or against coronary artery disease can be 
made fairly easily. Patients with acute congestive heart failure may not be suitable for CCTA 
immediately because of tachycardia and the need to avoid x-ray contrast. However, once the 
heart failure is compensated, coronary CTA can be performed and the accuracy in this 
setting has been established. One study that demonstrated excellent sensitivity (89%) and 
negative predictive value (99%), suggests that it could be used in patients with a 
cardiomyopathy to identify the etiology(Garcia et al. 2006). A lso, a direct comparison with 
coronary angiography revealed excellent accuracy of the MDCT in correctly diagnosing the 
etiology of cardiomyopathy, ischemic or non-ischemic(Andreini et al. 2009).  There are 
obvious advantages to non-invasively ruling in or out coronary artery disease in this group 
of patients. The ACC/ ASNC/ AHA consider it appropriate to evaluate for CAD in new 
onset HF and no prior diagnosis of CAD and reduced LVEF(Taylor et al. 2010). 
4.2 Utilization prior to electrophysiology procedure 
Atrial fibrillation is a common arrhythmia and is associated with significant morbidity. The 
options available for the treatment of atrial fibrillation, especially in symptomatic 
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cardiomyopathy to identify the etiology(Garcia et al. 2006). A lso, a direct comparison with 
coronary angiography revealed excellent accuracy of the MDCT in correctly diagnosing the 
etiology of cardiomyopathy, ischemic or non-ischemic(Andreini et al. 2009).  There are 
obvious advantages to non-invasively ruling in or out coronary artery disease in this group 
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individuals, include anti-arrhythmia drug therapy, surgery, and catheter based approaches. 
The use of radio frequency ablation to isolate the pulmonary veins is a growing therapy for 
atrial fibrillation and has emerged as an important alternative to conventional treatments. 
The majority of the atrial fibrillation foci appear to arise around the pulmonary veins and 
successful pulmonary vein isolation (PVI) can prove to be a permanent cure for atrial 
fibrillation. Coronary CT angiography is a key diagnostic tool in managing patients being 
considered for PVI(Cronin et al. 2004). For one, the presence of significant coronary artery 
disease has implications for adjunctive medical therapy since Vaughan-Williams class 1C 
drugs such as flecainide are contraindicated in patients with CAD. Coronary CTA can  
diagnose coronary artery disease in these patients. Essential components for a successful 
pulmonary vein isolation procedure include accurate anatomical mapping of the pulmonary 
veins. This is important because the pulmonary vein anatomy is variable, and common ostia 
and extra pulmonary veins are common. The knowledge of this anatomy is helpful to avoid 
pulmonary vein stenosis and necessary to avoid missing potential areas contributing to 
atrial fibrillation(Jongbloed et al. 2005). MDCT provides excellent visualization of the origins 
of the pulmonary veins, the diameter of the ostia, course of the pulmonary veins, presence 
of dual ostia and presence of additional supernumary veins(Schwartzman et al. 2003). The 
distance of the esophagus from the left atrium is also an important parameter that can also 
easily measured. Another important pre-requisite for the procedure is the absence of a left 
atrial appendage thrombus, a finding not uncommon in patients with atrial fibrillation.  CT 
angiography allows for excellent visualization of the entire left atrium and the appendage 
and can be used to identify the presence or absence of a thrombus. Invasive angiography is 
not ordinarily needed in patients being evaluated for pulmonary vein isolation for treatment 
of atrial fibrillation; the exception being those with signs of ischemia who may need 
revascularization as part of the management strategy. 
4.3 Coronary anomalies 
The incidence of coronary anomalies in the general population is about 1%(Yamanaka and 
Hobbs 1990). A coronary anomaly can be defined as a pattern that is not routinely 
encountered in the general population. Coronary anomalies account for about 12% of the 
deaths in U.S high school and college athletes(Van Camp et al. 1995). The American Heart 
Association’s (AHA) committee on sudden death attributed 19% of the deaths in athletes to 
coronary anomalies. Invasive coronary angiography is often used to diagnose coronary 
anomalies and they are routinely found unexpectedly when angiograms are performed for 
other reason, but ICA has inherent limitations to accurately study coronary anomalies 
because of its two dimensional display and the non-visualization of adjacent vascular 
structures. Computed tomography angiography, however, is inherently three dimensional 
and is ideal for providing extensive information about the spatial anatomy of the coronary 
artery, including the origin, course, presence of an intra-myocardial path as well as the 
relationship to the surrounding structures. The sensitivity of the CCTA in diagnosing 
coronary anomalies is nearly 100%(Kacmaz et al. 2008).  Figures 4 and 5 demonstrate the 
superb display of coronary anomalies by CT angiography. Since many patients in whom the 
diagnosis of a coronary anomaly are made young, it is important to pay particular attention 
to keeping the radiation dose low in this group. For example, diagnostic tests to rule out a 
coronary anomaly are frequently ordered in young athletes who have symptoms. The 
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radiation dose with CCTA is heavily dependent on imaging technique and pristine image 
quality is not needed for this indication. Thus, lower than standard tube current and tube 
voltage along with other radiation sparing algorithms should be used for this group of 
patients. In fact, the origins of the coronary arteries can sometimes be seen quite well w ith a 
limited field-of-view, non-contrast CT at a very low radiation dose and such an exam should 
be considered. 
Fig. 4. CT angiogram maximum intensity projection (A), volume rendered (B) and 
reformatted image (C) from a 55 year old female with chest pain and problems during a 
coronary angiogram. The right coronary artery arises from the left coronary cusp (arrow) 
and courses between the aorta and the main pulmonary artery 
4.4 Evaluation of left main coronary artery stent patency 
The conventional treatment of left main coronary artery (LMCA) stenosis is coronary artery 
bypass graft surgery. However recent advances in percutaneous coronary intervention (PCI) 
have prompted utilization of stents to treat LMCA stenosis. The rate of angiographic 
restenosis on follow up studies varies from 22% to 40%(Silvestri et al. 2000; Park et al. 2003), 
although the use of drug eluting stents (DES) has markedly reduced the incidence of in-stent 
restenosis.  However, because of the potential dire consequences of re-stenosis in the left 
main coronary artery, surveillance angiography is usually recommended 2-6 months after 
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individuals, include anti-arrhythmia drug therapy, surgery, and catheter based approaches. 
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Fig. 5. Complex congenital heart disease in a 22-year-old male patient being considered for 
surgical intervention. The patient previously had a modified Fontan operation for a large 
ventricular septal defect and transposition of the great arteries. He developed a giant right 
atrium and very difficult atrial arrhythmia. Oblique maximum intensity projection (A) and 
volume rendered (B) CT coronary angiogram images also demonstrate anomalous coronary 
arteries (arrow) arising from the same coronary cusp to the right and posteriorly to the 
sternum. 
intervention to this segment. Several studies have proposed CCTA as an alternative non-
invasive modality to assess ISR in this patient group.  Blooming artifacts caused by the stent 
struts are a major hindrance in the accurate CTA evaluation of ISR in other vessels(Mahnken 
et al. 2004), (Cademartiri et al. 2007). However LMCA stents tend to be large, usually with a 
diameter greater than 3.5mm. Also the left main segment is less prone to motion artifact on 
CT than other segments, and evaluation of stents in the LMCA is more accurate with CCTA 
than in other locations. One study prospectively evaluated the accuracy of stent patency in 
Fig. 6. Thin MIP oblique projections from a coronary CT angiogram in a patient with a stent 
in the left main coronary artery (arrow). A lthough there is suboptimal image quality related 
to artifact from the metallic struts and coronary calcium in this case, the stent appears to be 
patent. Coronary CT angiography is considered to be accurate in determining the patency of 
large stents, which have been placed in the left main coronary artery segment.  
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the LMCA by CCTA and compared it to conventional coronary angiography and 
intravascular ultrasound(Van Mieghem et al. 2006). In this study of 70 patients the 
sensitivity, specificity, accuracy, positive predictive value and negative predictive value of 
identifying ISR (defined as >50% narrowing) in LMCA stents was 100%, 97%, 98%, 86% and 
100% respectively. The accuracy was lower (83%) for LMCA bifurcation stents. 
Conventional angiography identified 14% of the patients having ISR, which were also 
identified by CCTA. The 2010 appropriateness use criteria (AUC) consider it appropriate to 
use CCTA in asymptomatic patients for the assessment of left main coronary stent with a 
stent diameter greater than 3mm. The accuracy of CCTA in detecting in-stent restenosis 
depends on the type of stent and the complexity of the lesion and these should be taken into 
account before considering this modality for evaluating ISR (figure 6). Coronary CT 
angiography, and even non-contrast gated CT scans, can also be useful as an alternative or 
adjunct to invasive angiography if there is a question of mal-positioning of a left main stent 
(figure 7). 
Fig. 7. Non-contrast CT of the heart demonstrating a mal-positioned stent in the left main 
coronary artery (arrow) that extrudes approximately 5 mm into the aorta. Invasive coronary 
angiography had been planned, but was deferred because of concerns that the stent might 
become dislodged.  
5. Coronary CT angiography as complementary to invasive angiography 
As discussed, coronary CT angiography is less invasive, although has lower resolution than 
invasive angiography. However, it is inherently three - dimensional and therefore provides 
diagnostic content which is different from and which can be complementary to the 
information derived from invasive angiography. 
5.1 Defining coronary anatomy prior to CTO-PCI 
Chronic total occlusions (CTOs) of coronary arteries are complex lesions present in 
approximately 30% of patients undergoing coronary angiography(Grantham et al. 2009).  
CTOs are defined, as lesions present for at least 3 months with grade 0 to 1 Thrombolysis in 
Myocardial Infraction (TIMI) flow on angiography. CCTA is being increasingly used as a 
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non-invasive modality to accurately define the characteristics of the CTO to assist in the 
interventional procedure. 
There are several advantages to performing a CCTA prior to planned revascularization of a 
CTO. The length of the occluded segment, which is an important predictor of success of 
revascularization, can be easily obtained(Mollet et al. 2005). The course of the artery, 
occlusion length, collateral circulation, degree of calcium are important variables that can be 
obtained by CCTA, all of which assist in planning the procedure that translates into shorter 
procedure times. Foreshortening of the vessel and limited visualization of the distal vessel in 
the absence of collateral fil l ing are important shortcomings of invasive coronary 
angiography, which are easily fixed by CCTA. It can also define bends and angles inside the 
occluded segment that prove to be extremely helpful to the operator to navigate the wire 
safely and successfully through the occlusion to the distal vessel. The degree of calcification 
also has an adverse effect on the success of the procedure. One study showed that the 
distribution of calcium within the lumen is an independent predictor of failed percutaneous 
revascularization of CTO(Soon et al. 2007). The ability of CCTA to characterize the 
distribution of calcium within the lesion is important in predicting the likelihood of PCI 
success. Cross-sectional calcification, which can only reliably be detected on CCTA, was 
noted to be more important than the length of calcium deposits in one study(Soon et al. 
2007). CCTA information can be utilized to plan the strategy of CTO-PCI. In the evaluation 
of a CTO, the CT angiogram is able to provide complementary data to that of conventional 
angiography that may be relevant to the success of the CTO recanalization (figure 8). 
Fig. 8. Chronic total occlusion (CTO) of the right coronary artery (arrows) is seen with 
measurements of the occlusion length on MIP images of a coronary CT angiogram. The 
patient subsequently underwent PCI of the CTO. Knowledge of the occlusion length and the 
morphology of the occluded segment were felt to have been helpful in planning the 
interventional procedure. 
5.2 CT angiography for coronary bypass grafts 
Many coronary bypass grafts ultimately fail and the standard of care for assessing patients 
post aorto - coronary bypass has been invasive coronary angiography. Traditionally, this 
method has been used somewhat liberally, as these patients already have known significant 
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CAD and, in the presence of symptoms, a negative non-invasive functional study may not 
be completely reassuring.  CCTA has been shown to be a useful alternative in evaluating by-
pass grafts. The location and patency of grafts can be established with very high accuracy 
and the conduit can be visualized in a three dimensional fashion(Malagutti et al. 2007). 
Stenoses in the proximal anastamotic site and the body of vein grafts are accurately 
displayed with CCTA. However, distal anastomotic sites and especially the coronary artery 
just beyond the anastomosis are sometimes not easily discerned. Current CT technology is 
still l imited in the presence of significant coronary calcifications and these patients often 
have heavy coronary calcifications. Metallic clips also sometimes obscure the distal 
anastomosis site.  When patients are being considered for repeat coronary artery bypass 
surgery, potential injury to patent internal mammary artery bypass grafts can contribute to 
the hazard of the procedure. Sometimes this injury occurs during the median sternotomy if 
the bypass graft is adherent to the posterior sternum and inadvertently cut. This occurrence 
can lead to death or major morbidity. CT angiography can very effectively display the 
course of bypass grafts relative to the sternum and is considered highly appropriate in this 
patient population. It is considered to be a useful tool for planning these operations and 
helpful in avoiding this complication (figure 9). 
Fig. 9. Modified lateral and axial views of coronary CT angiogram MIP images were 
obtained in a patient scheduled for repeat coronary bypass surgery. The previously placed 
left internal mammary artery graft (arrows) is patent and seen to be located immediately 
posterior and to the right of the midline of the sternum. Based on the results of the 
examination, the planned approach to the subsequent sternotomy was modified in order to 
avoid injury to the bypass 
5.3 Coronary aneurysms 
Coronary artery aneurysms and ectasia are characterized by an abnormal dilatation of a 
coronary artery. Morgagni in 1761 first described a coronary artery aneurysm(Falsetti and 
Carrol 1976). Coronary artery aneurysms are defined as coronary artery segments that have 
a diameter that exceeds the diameter of normal adjacent coronary segments or the diameter 
of the patient’s largest coronary vessel by 1.5 times and involves less than 50% of the total 
length of the vessel(Pahlavan and Niroomand 2006). The various etiologies of aneurysms 
include coronary atherosclerosis (50%), followed by congenital (17%) and infectious causes 
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(10%)(Pahlavan and Niroomand 2006). The pathogenesis is related to the underlying cause, 
but a pre-requisite to aneurysm formation is the presence of an abnormal tunica media in 
the vessel wall that results in enlargement and remodeling of an arterial segment(Diaz-
Zamudio et al. 2009). Percutaneous intervention, especially w ith stents, has also been shown 
to be a cause for the development of aneurysms(Aoki et al. 2008). The diagnostic approach 
to coronary aneurysms depends on the clinical scenario, and coronary CT angiography is a 
useful adjunct to diagnose, evaluate, and follow up these coronary artery abnormalities. 
Figures 10-12 demonstrate close agreement between invasive assessment and CT 
angiography in 3 patients with coronary aneurysms and figure 13 demonstrates it in one 
with a saphenous vein graft pseudoaneurysm. While the natural history of these conditions 
is not well described and follow up algorithms are not worked out, coronary aneurysms 
appear to be displayed in accurate detail using CT angiography. 
    
    
Fig. 10. Aneurysmal dilation of the proximal segments of the left anterior descending artery 
in a male patient who had recurrent coronary emboli. The aneurysmal segment is seen on 
oblique maximum intensity projection (A) and volume rendered (B) CT angiogram as well 
as on intravascular ultrasound (C) and right anterior oblique projection invasive coronary 
angiogram (D). The appearance and diameter of the dilated segment agrees closely on the 
three modalities. 
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Fig. 11. Huge right coronary artery aneurysm seen on axial view MIP coronary CT 
angiogram (A) and on invasive coronary angiogram (B). 
Fig. 12. Coronary CT angiogram MIP (A) and MPR (B) views and invasive coronary 
angiogram RAO projection showing aneurysmal dilation of the left anterior descending 
coronary artery. 
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Fig. 13. Saphenous vein bypass graft which developed dissection and contained rupture /  
pseudoaneurysm post percutaneous intervention. The appearances on CT angiogram by 
volume rendered image (A), MPR (B), and oblique MIP (C) agreed closely with those on 
invasive coronary angiogram (D). 
6. Prognostic implications of CCTA 
CCTA has proven to be an excellent technique to diagnose CAD and is increasingly being used 
as a first line modality in low risk populations. Several prior diagnostic techniques used in the 
detection of CAD have proven to provide important prognostic information. CCTA, although 
a relatively newer imaging technique, has also been shown in recent studies to provide 
important prognostic information(Ostrom et al. 2008). In a recent report by Gaemperli and 
colleagues, patients without coronary atherosclerosis on CTA had an excellent prognosis 
where as the risk for cardiac events increased significantly in the presence of coronary plaques 
or obstructive lesions. The event rates in the first year were reported to be 34% and 59%, 
respectively(Gaemperli et al. 2008). There was a strong positive correlation between the extent 
of coronary atherosclerosis (i.e., the number of segments with coronary plaques) and an 
adverse cardiac outcome. The presence of three or more coronary plaques was the cut-off 
providing the highest accuracy to predict future cardiac events. Another study revealed the 
1st-year event rate for patients with abnormal coronary arteries to be 30% compared to 0% in 
patients with normal coronary arteries emphasizing the importance of evaluation of coronary 
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plaque burden(Gaemperli et al. 2008). Recent angiographic and IVUS derived evidence 
suggests that assessing plaque phenotype is important in detecting vulnerable plaque(Stone et 
al. 2011). CCTA’s can be used to evaluate the coronary lumen and vessel wall and provide 
information on obstructive lesions as well as non-stenotic plaques. The burden of 
atherosclerotic disease determined by CCTA was associated with all-cause mortality among 
patients with suspected CAD referred for evaluation in an ambulatory setting(Ostrom et al. 
2008). CTA demonstrating the presence of luminal obstruction or non- obstructive, non-
calcified plaque is a useful noninvasive modality that accurately predicts all-cause mortality 
with incremental benefit over traditional risk factor assessment and CACS. 
7. Other applications of CTA in lieu of invasive angiography 
In addition to the above common conditions, there are other, less frequent states when the 
relatively non-invasive nature of CTA makes it preferable to invasive angiography. For 
example, occasional patients have very challenging arterial access problems for direct 
angiography and noninvasively imaging the coronary arteries or bypass graft anatomy 
might be preferable, even if it would not otherwise be the approach of choice. A lso, other 
patients in whom invasive angiography is risky, such as those with aortic valve endocarditis 
or heavy aortic atherosclerosis, might also benefit from the less invasive alternative. In these 
cases, the potential hazard of the invasive procedure is large enough to alter the decision. 
8. Conclusion 
Coronary CT angiography is an excellent non-invasive diagnostic modality that can be 
utilized to study in detail the coronary anatomy. It can sometimes supplant traditional 
invasive coronary angiography, especially in patients in whom the need for coronary 
intervention is felt to be unlikely. It’s excellent negative predictive value makes it a useful, 
less invasive tool for ruling out coronary artery disease in patients who are at the lower risk 
of the spectrum for the presence of coronary atherosclerosis.  The inherently three 
dimensional nature also makes coronary CT angiography useful for patients with coronary 
anomalies and in selected patients who have already had coronary angiography, such as 
those scheduled to undergo repeat coronary bypass surgery intervention for chronic 
coronary total occlusions, or those with incomplete procedures. While there has been 
considerable improvement in the temporal and spatial resolution of the CCTA, it is still 
inferior to invasive coronary angiography in these aspects and direct invasive angiography 
is usually needed to make detailed revascularization decisions. 
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tomography coronary angiography in patients with dilated cardiomyopathy. J Am 
Coll Cardiol. 49, 20, (May 22. 2007), 2044-2050. 
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Fig. 13. Saphenous vein bypass graft which developed dissection and contained rupture /  
pseudoaneurysm post percutaneous intervention. The appearances on CT angiogram by 
volume rendered image (A), MPR (B), and oblique MIP (C) agreed closely with those on 
invasive coronary angiogram (D). 
6. Prognostic implications of CCTA 
CCTA has proven to be an excellent technique to diagnose CAD and is increasingly being used 
as a first line modality in low risk populations. Several prior diagnostic techniques used in the 
detection of CAD have proven to provide important prognostic information. CCTA, although 
a relatively newer imaging technique, has also been shown in recent studies to provide 
important prognostic information(Ostrom et al. 2008). In a recent report by Gaemperli and 
colleagues, patients without coronary atherosclerosis on CTA had an excellent prognosis 
where as the risk for cardiac events increased significantly in the presence of coronary plaques 
or obstructive lesions. The event rates in the first year were reported to be 34% and 59%, 
respectively(Gaemperli et al. 2008). There was a strong positive correlation between the extent 
of coronary atherosclerosis (i.e., the number of segments with coronary plaques) and an 
adverse cardiac outcome. The presence of three or more coronary plaques was the cut-off 
providing the highest accuracy to predict future cardiac events. Another study revealed the 
1st-year event rate for patients with abnormal coronary arteries to be 30% compared to 0% in 
patients with normal coronary arteries emphasizing the importance of evaluation of coronary 
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plaque burden(Gaemperli et al. 2008). Recent angiographic and IVUS derived evidence 
suggests that assessing plaque phenotype is important in detecting vulnerable plaque(Stone et 
al. 2011). CCTA’s can be used to evaluate the coronary lumen and vessel wall and provide 
information on obstructive lesions as well as non-stenotic plaques. The burden of 
atherosclerotic disease determined by CCTA was associated with all-cause mortality among 
patients with suspected CAD referred for evaluation in an ambulatory setting(Ostrom et al. 
2008). CTA demonstrating the presence of luminal obstruction or non- obstructive, non-
calcified plaque is a useful noninvasive modality that accurately predicts all-cause mortality 
with incremental benefit over traditional risk factor assessment and CACS. 
7. Other applications of CTA in lieu of invasive angiography 
In addition to the above common conditions, there are other, less frequent states when the 
relatively non-invasive nature of CTA makes it preferable to invasive angiography. For 
example, occasional patients have very challenging arterial access problems for direct 
angiography and noninvasively imaging the coronary arteries or bypass graft anatomy 
might be preferable, even if it would not otherwise be the approach of choice. A lso, other 
patients in whom invasive angiography is risky, such as those with aortic valve endocarditis 
or heavy aortic atherosclerosis, might also benefit from the less invasive alternative. In these 
cases, the potential hazard of the invasive procedure is large enough to alter the decision. 
8. Conclusion 
Coronary CT angiography is an excellent non-invasive diagnostic modality that can be 
utilized to study in detail the coronary anatomy. It can sometimes supplant traditional 
invasive coronary angiography, especially in patients in whom the need for coronary 
intervention is felt to be unlikely. It’s excellent negative predictive value makes it a useful, 
less invasive tool for ruling out coronary artery disease in patients who are at the lower risk 
of the spectrum for the presence of coronary atherosclerosis.  The inherently three 
dimensional nature also makes coronary CT angiography useful for patients with coronary 
anomalies and in selected patients who have already had coronary angiography, such as 
those scheduled to undergo repeat coronary bypass surgery intervention for chronic 
coronary total occlusions, or those with incomplete procedures. While there has been 
considerable improvement in the temporal and spatial resolution of the CCTA, it is still 
inferior to invasive coronary angiography in these aspects and direct invasive angiography 
is usually needed to make detailed revascularization decisions. 
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1. Introduction 
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developed countries [1]. CAD is a common and sometimes disabling disorder, although 
medication therapy, percutaneous coronary intervention and coronary artery bypass 
grafting have developed recently. Medical doctors need to prevent from developing acute 
coronary syndrome. The development of non-invasive cardiac imaging tools (particularly, 
cardiac computed tomography, echocardiography and so on) for the diagnostic and 
prognostic assessments of patients is evolving evidence for various treatment strategies. 
Cardiac catheterization is golden standard for the diagnosis of CAD. Although the risk of 
adverse events for invasive coronary angiography is generally considered to be low, 
potential life-threatening complications can arise, including not only coronary artery 
dissection, but also arrhythmia, stroke, hemorrhage, myocardial infarction (MI), and death 
[2]. Non-invasive imaging devices for CAD have been developing, such as 
echocardiography, scintigraphy, computed tomography (CT) and magnetic resonance 
imaging (MRI) and so on. Particularly, the development of cardiac CT is remarkable in the 
last 10 years.  
Prior report suggested a hierarchial model of efficacy to assess the contribution of diagnostic 
imaging to the patient management process. Level 1 is technical quality of the images. Level 
2 is diagnostic accuracy, sensitivity, and specificity associated with interpretation of the 
images. Level 3 is whether the information produces change in the referring physician’s 
diagnostic thinking. Level 4 is efficacy, which concerns effect on the patient management 
plan. Level 5 is effect of the information on patient outcomes. Level 6 is societal costs and 
benefits of a diagnostic imaging technology [3].  
CT imaging was introduced in 1972 [4]. The ability to obtain cross-sectional images of the 
computer-assisted tomography, Sir Geoffrey N. Hounsfield and Allan M. Cormack were 
awarded the Nobel prize in Medicine in 1979.  
Since a 4 detector row cardiac CT angiography was launched in 1998. Cardiac CT has 
experienced rapid improvement of imaging qualities with the ongoing evolution of cardiac 
CT. The diagnostic accuracy of the 64 detector cardiac CT to detect coronary stenoses is 
available. Cardiac CT is useful for the diagnosis and risk stratification of CAD. Cardiac CT 
presently has not been considered a routine replacement for invasive coronary angiography, 
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because the diagnostic accuracy of cardiac CT is not greater than that of invasive coronary 
angiography yet. Invasive coronary angiography is more appropriate than cardiac CT for 
patients with a high pretest likelihood of CAD. Cardiac CT is appropriate for stable patients 
with acute chest pain [5]. A recently published guideline reports several appropriate 
indications for cardiac CT. At First, they are symptomatic patients with intermediate 
likelihood of CAD. Particularly, the patients are indicated in whom stress testing, including 
in electrocardiography, echocardiography, and scintigraphy is not possible because of 
severe aortic stenosis, severe heart failure and aortic dissection etc., or the result of stress 
testing is equivocal or uninterpretable with acute chest pain. Secondly, they are patients 
with acute chest pain and intermediate likelihood of CAD but absence of ECG changes and 
normal myocardial enzyme levels [6]. Cardiac CT is useful for the diagnosis of CAD in 
complete left bundle branch block patients, because the diagnostic accuracy is slight lower 
with stress test of electrocardiography, echocardiography and scintigraphy [7]. 
The best approaches to the care of CAD, improving not only the efficacy and safety of 
treatments, but also the cost. 
We discuss the usefulness of cardiac CT for the risk stratification of CAD. 
2.1 The technique and limitation of cardiac CT imaging 
The clinical value of CT for imaging of the heart has been very limited for the long time. 
Cardiac imaging requires a very high temporal resolution, because the heart is rapid motion. 
Therefore, dedicated scanner designs needed to be developed to increase acquisition speed. 
Furthermore, cardiac CT imaging requires providing contiguous cross-sectional images of 
the heart. Every displayed image must be of the same cardiac phase. Gaps may occur if 
adjacent images depict the heart in different phases of the cardiac cycle. Data acquisition 
must be triggered by the patient’s electrocardiogram (ECG), image reconstruction must be 
synchronized to a function correlated to cardiac motion. The heart is subjected to intrinsic 
motion by cardiac contraction and to motion by breathing. CT imaging of the complete heart 
has to be performed within one single breath-hold. 
Recently, the number of detectors expands from 64 to 320. With a detector width of 0.5 mm, 
this will be able to be coverage of about 160 mm. It can be obtained in one rotation and can 
be performed during one heartbeat [8-10]. This will decrease the length of the necessary 
breath-hold, decrease the amount of contrast agents to achieve intravascular enhancement 
during scan, and may be useful in patients with an inconstant heart rate or arrhythmia. 
2.2 Atherosclerosis of the coronary artery  
Cardiac CT has several potential applications for patients with CAD. Cardiac CT can 
demonstrate the morphological features of CAD and estimate ventricular function, 
perfusion. Recently, the visualization of coronary artery has been developing with coronary 
artery calcium (CAC), coronary artery stenosis.  
The pathology of coronary artery is important in order to understand the image of cardiac 
CT, taking into account the pathology of coronary artery. CAC is a surrogate marker for 
coronary atherosclerotic plaque. In the coronary arteries, calcifications occur almost 
exclusively in the context of atherosclerotic changes [11,12]. In the most patients with acute 
coronary syndromes, CAC can be detected, and the amount of calcium in these patients is 
substantially greater than in matched control subjects without CAD [13]. With the exception 
of patients in the renal failure, nonatherosclerotic calcification of the coronary artery wall is 
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rare. The amount of CAC correlates moderately with the extent of atherosclerotic plaque 
burden in a coronary artery [11,12]. On the other hand, not every atherosclerotic coronary 
plaque is calcified. The presence or absence of CAC is not closely associated with an 
individual atherosclerotic plaque to rupture. And CAC is not associated with stability or 
instability of an individual plaque [12]. Plaques with healed ruptures almost invariably 
contain calcium, whereas plaque erosions are frequently not calcified.  
Although there is a quantitative relationship between CAC and coronary plaque burden, 
there is only a weak correlation between the amount of CAC and the angiographic severity 
of coronary artery stenoses [11]. Cardiac CT has several potential applications for patients 
with coronary artery disease. Cardiac CT can demonstrate the morphological features of 
coronary artery disease and estimate ventricular function, perfusion. Recently, the 
visualization of coronary artery has been developing with CAC, coronary artery stenoses. 
Non-enhanced CT studies of the heart are almost exclusively performed to assess calcified 
structures within the heart and CAC. 
The absence of detectable CAC rules out the presence of significant coronary artery stenoses 
with high negative predictive value [11].  
2.3 Coronary calcium in cardiac CT 
Non-enhanced CT studies of the heart are almost exclusively performed to assess calcified 
structures within the heart and coronary arteries. 
Cardiac CT detects and quantifies the amount of CAC. It is a marker of atherosclerotic 
disease burden. Calcification does not occur in a normal coronary artery wall, it therefore 
indicates the presence of atherosclerosis, but is not specific for coronary artery stenoses. 
CAC scores predict the total atherosclerotic plaque burden. 
However, the absence of detectable CAC rules out the presence of significant coronary 
artery stenoses with high negative predictive value [11]. Although these findings are 
consistent with the concept that the calcified plaque burden parallels the overall plaque 
burden, CAC testing is not appropriate as an alternative for angiographic disease detection, 
because of the modest relationship between CAC and coronary artery stenoses [14]. Because 
even coronary atherosclerotic plaque burden is not necessarily associated with significant 
coronary artery stenoses, even the detection of large amounts of calcium does not imply the 
presence of the significant stenoses. The CAC detection could be as a marker for CAD 
prognosis in asymptomatic patients. The presence and severity of CAC has independent 
and incremental value in the estimation of death or nonfatal MI [15]. CAC is important in 
the risk stratification, and noncalcified atherosclerosis is also important. Some studies 
against intravascular ultrasound have reported a sensitivity of 91% and 95% to detect 
calcified and 78% and 58% for noncalcified lesions by 16 slice CT [16,17] and increased the 
sensitivity to detect noncalcified lesions to 83% by 64 slice CT [18]. Because of the high CT 
attenuation of calcified lesions, their differentiation from fibrous and lipid-rich lesions is 
easy. Noncalcified plaque is consisted of lipid-rich plaques and fibrous plaques. Lipid-rich 
plaque (less than 50 HU) is lower CT Hounsfield attenuation numbers than fibrous plaques 
(50 to 120 HU) and calcified plaque (more than 121 HU) [17,19]. Patients with acute coronary 
syndromes were found to have a higher prevalence of noncalcified as compared with 
calcified plaque than stable coronary artery disease [20]. 
We show the algorithm to diagnose ischemic heart disease with cardiac CT in American 
Heart Association guideline and Japanese Circulation Society guideline. 
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Fig. 1. Detection of CAD in symptomatic patients without known heart disease symptomatic 
acute presentation [21]. The stratification of pretest probability of CAD are shown in Table 1. 
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Diagnostic impact of coronary calcium 
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Fig. 2. Use of CTangiography in the setting of prior test results [6]. 
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Age Sex Angina Pectoris Angina Pectoris Chest pain Asymptom
<39 Men Intermediate Intermediate Low Very low
Women Intermediate Very low Very low Very low
40-49 Men High Intermediate Intermediate Low
Women Intermediate Low Very low Very low
50-59 Men High Intermediate Intermediate Low
Women Intermediate Intermediate Low Very low
>60 Men High Intermediate Intermediate Low
Women High Intermediate Intermediate Low  
1) Very low pretest probability: Less than 5% pretest probability of CAD 
2) Low pretest probability: Between 5% and 10% pretest probability of CAD 
3) Intermediate pretest probability: Between 10% and 90% pretest probability of CAD 
4) High pretest probability: More than 90% pretest probability of CAD 
Table 1. Pretest Probability of CAD by Age, Sex, and Symptom [22] 
 
Suspected CAD patients with chest symptom, or 
abnormal results of rest electrocardiogram and echocardiogram. 
The patients can be performed exercise electrocardiogram 
with sufficient stress exercise.The patients’ ischemic heart disease 








unable to diagnose ischemia
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Fig. 3. Algorithm to diagnose stable angina pectoris for the patients who are able to exercise 
(revised Japanese Circulation Society Guideline 2009, Circulation Journal Vol 73, Suppl. 
Ⅲ,1019-1089, 2009). 
The Duke’s treadmill score (Bruce protocol) is calculated as follows: 
- duration of exercise in minutes - (5 x the maximal ST segment deviation  
- during or after exercise, in millimeters) – (4 x the treadmill angina index).  
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- The angina index has a value of 0::if the patient had nonlimiting angina,  
- 1: if exercise angina occurred, and 2: if angina was the reason the patient stopped 
exercising. The score had a range from -25 (highest risk) to +15 (lowest risk). 
The outpatients had treadmill scores indicating low risk (≥ +5) and their four-year survival rate 
was 99% (average annual mortality rate, 0.25%). The outpatients had scores indicating high 
risk (< -10) and their four-year survival rate was 79% (average annual mortality rate, 5.0%)[23].  
 
Suspected CAD patients with chest symptom, 
electrocardiogram and echocardiogram who are not able to exercise.
Sufficient hospital conditiona) and patient conditionb)
for cardiac CT.
Drug Stress SPECTc)Cardiac CT
normal



















Fig. 4. Algorithm to diagnose stable angina pectoris for the patients who are not able to 
exercise (revised Japanese Circulation Society Guideline 2009,Circulation Journal Vol 73, 
Suppl. Ⅲ,1019-1089, 2009). 
a. Hospital condition for cardiac CT 
1. The staffs have sufficient experience on cardiac CT. 
2. The hospital equips with cardiac CT which is better than 64 slice. 
3. The staffs are able to show good images and work the proper reporting system. 
4. The staffs understood the feature of each CAG and cardiac CT.  
5. The staffs try to make the protocol for lowering the radiation exposure. 
b. Patient condition for cardiac CT 
1. The staffs are careful of the risk of radiation exposure in women which is less than 
50 years old. 
2. It is difficult to diagnose in the patients with many calcified coronary arteries, for 
example, the patients with hemodialysis, and the elderly patients. 
3. Serum creatinin is less than 2.0 mg/dL. 
4. The eGFR is more than 60 mL/min/1.73m2. 
5. Diabetes mellitus nephropathy patients, including to microalbuminuria are not 
recommended 
6. The contrast alergy patients are not recommended. 
7. Asthma patients are not recommended. 
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c. Stress SPECT 
1. The stress test is recommend exercise stress, rather than drug stress.  
2. The diagnosis is recommended 17 or 20 segment method to diagnose the area and 
degree of ischemia. 
3. The staff confirm whether the patients have contraindication of the stress drug. 
4. Echocardiogram and perfusion MRI can be alternative stress test depending on the 
facilities. 
5. Less than 50% count of maximum count in the defect area is more than moderate 
ischemia. 
6. The count between 50% and 70% count of maximum count in the defect area is 
mild ischemia. 
7. More than 70% count of maximum count is normal myocardium. 
2.4 Visualization of the coronary artery lumen in cardiac CT 
Cardiac CT can be applied for visualization of the coronary artery lumen after intravenous 
injection of a contrast agent. The administration of beta blockers before the cardiac CT scan 
and the use of sublingual nitroglycerin can achieve coronary vasodilation and maximize 
image quality. Studies for the diagnosis of coronary artery stenoses using 64 slice CT 
scanning with invasive coronary angiography report sensitivities and specificities of 87-99% 
and 86-97%, respectively, and importantly, a negative predictive value of 98-100% [24-27]. 
Cardiac CT could be an efficient initial triage tool in patients with acute chest pain with low 
to intermediate risk, because of the high sensitivity and negative predictive value. In the 
symptomatic population, there is lack of study that shows an improved prognostic power of 
cardiac CT over other modalities including coronary artery calcium scores and carotid 
intima media thickness [28]. The clinical use of cardiac CT to detect plaque for purposes of 
risk stratification asymptomatic individuals has not recommended yet, although the clinical 
use of risk stratification in asymptomatic high risk individuals has been reported repeatedly 
[29-31]. 
Patency and occlusion of bypass grafts can be established with sensitivity and specificity of 
nearly 100% in cardiac CT, because of the large size and limited mobility of these structures 
[14,32,33]. But, the limitations are the detection of stenoses at the site of anastomosis to the 
coronary artery and in the peripheral run-off coronary artery. Metallic clips and severe 
coronary calcium lead to reduced sensitivity and specificity in post CABG patients. Before 
re-operative coronary surgery, cardiac CT can be used to define the relationship of sternal 
wires to cardiac and graft structures for the purpose of planning surgical reentry techniques. 
Cardiac CT with volume rendering images is useful to patients with known or suspected 
congenital coronary artery anomalies. Cardiac CT can classify the origin and the complex 
course of anomalous coronary arteries [34,35]. 
Although artifacts caused by metal and partial volume effects limit the evaluation of in-stent 
restenosis with 64-slice CT, high accuracy, approximately 90%, can be obtained in stents 
3mm or greater in diameter [36,37]. 
3. Conclusion 
Cardiac CT is a rapidly developing and advancing technology. The increase of radiation will 
reduce artifact, improve coronary artery visualization, although an excess of radiation 
exposure leads to cancer. Cardiac CT is useful in the non-invasive diagnosis of coronary 
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- The angina index has a value of 0::if the patient had nonlimiting angina,  
- 1: if exercise angina occurred, and 2: if angina was the reason the patient stopped 
exercising. The score had a range from -25 (highest risk) to +15 (lowest risk). 
The outpatients had treadmill scores indicating low risk (≥ +5) and their four-year survival rate 
was 99% (average annual mortality rate, 0.25%). The outpatients had scores indicating high 
risk (< -10) and their four-year survival rate was 79% (average annual mortality rate, 5.0%)[23].  
 
Suspected CAD patients with chest symptom, 
electrocardiogram and echocardiogram who are not able to exercise.
Sufficient hospital conditiona) and patient conditionb)
for cardiac CT.
Drug Stress SPECTc)Cardiac CT
normal



















Fig. 4. Algorithm to diagnose stable angina pectoris for the patients who are not able to 
exercise (revised Japanese Circulation Society Guideline 2009,Circulation Journal Vol 73, 
Suppl. Ⅲ,1019-1089, 2009). 
a. Hospital condition for cardiac CT 
1. The staffs have sufficient experience on cardiac CT. 
2. The hospital equips with cardiac CT which is better than 64 slice. 
3. The staffs are able to show good images and work the proper reporting system. 
4. The staffs understood the feature of each CAG and cardiac CT.  
5. The staffs try to make the protocol for lowering the radiation exposure. 
b. Patient condition for cardiac CT 
1. The staffs are careful of the risk of radiation exposure in women which is less than 
50 years old. 
2. It is difficult to diagnose in the patients with many calcified coronary arteries, for 
example, the patients with hemodialysis, and the elderly patients. 
3. Serum creatinin is less than 2.0 mg/dL. 
4. The eGFR is more than 60 mL/min/1.73m2. 
5. Diabetes mellitus nephropathy patients, including to microalbuminuria are not 
recommended 
6. The contrast alergy patients are not recommended. 
7. Asthma patients are not recommended. 
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c. Stress SPECT 
1. The stress test is recommend exercise stress, rather than drug stress.  
2. The diagnosis is recommended 17 or 20 segment method to diagnose the area and 
degree of ischemia. 
3. The staff confirm whether the patients have contraindication of the stress drug. 
4. Echocardiogram and perfusion MRI can be alternative stress test depending on the 
facilities. 
5. Less than 50% count of maximum count in the defect area is more than moderate 
ischemia. 
6. The count between 50% and 70% count of maximum count in the defect area is 
mild ischemia. 
7. More than 70% count of maximum count is normal myocardium. 
2.4 Visualization of the coronary artery lumen in cardiac CT 
Cardiac CT can be applied for visualization of the coronary artery lumen after intravenous 
injection of a contrast agent. The administration of beta blockers before the cardiac CT scan 
and the use of sublingual nitroglycerin can achieve coronary vasodilation and maximize 
image quality. Studies for the diagnosis of coronary artery stenoses using 64 slice CT 
scanning with invasive coronary angiography report sensitivities and specificities of 87-99% 
and 86-97%, respectively, and importantly, a negative predictive value of 98-100% [24-27]. 
Cardiac CT could be an efficient initial triage tool in patients with acute chest pain with low 
to intermediate risk, because of the high sensitivity and negative predictive value. In the 
symptomatic population, there is lack of study that shows an improved prognostic power of 
cardiac CT over other modalities including coronary artery calcium scores and carotid 
intima media thickness [28]. The clinical use of cardiac CT to detect plaque for purposes of 
risk stratification asymptomatic individuals has not recommended yet, although the clinical 
use of risk stratification in asymptomatic high risk individuals has been reported repeatedly 
[29-31]. 
Patency and occlusion of bypass grafts can be established with sensitivity and specificity of 
nearly 100% in cardiac CT, because of the large size and limited mobility of these structures 
[14,32,33]. But, the limitations are the detection of stenoses at the site of anastomosis to the 
coronary artery and in the peripheral run-off coronary artery. Metallic clips and severe 
coronary calcium lead to reduced sensitivity and specificity in post CABG patients. Before 
re-operative coronary surgery, cardiac CT can be used to define the relationship of sternal 
wires to cardiac and graft structures for the purpose of planning surgical reentry techniques. 
Cardiac CT with volume rendering images is useful to patients with known or suspected 
congenital coronary artery anomalies. Cardiac CT can classify the origin and the complex 
course of anomalous coronary arteries [34,35]. 
Although artifacts caused by metal and partial volume effects limit the evaluation of in-stent 
restenosis with 64-slice CT, high accuracy, approximately 90%, can be obtained in stents 
3mm or greater in diameter [36,37]. 
3. Conclusion 
Cardiac CT is a rapidly developing and advancing technology. The increase of radiation will 
reduce artifact, improve coronary artery visualization, although an excess of radiation 
exposure leads to cancer. Cardiac CT is useful in the non-invasive diagnosis of coronary 
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artery disease for the stable and acute chest pain patients, especially who cannot be 
sufficiently evaluated by electrocardiography, echocardiography, scintigraphy or cardiac 
MRI. 
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1. Introduction
Whereas in the past computed tomography (CT) of the coronary arteries could detect only 
calcifications, recently multislice computed tomography (MSCT) has been already accepted 
as an efficient noninvasive tool for the detection of coronary artery stenosis, providing good 
sensitivity, specificity, and very high negative predictive value. However, it must be 
recognized that these good results are obtained when technically inadequate scans or 
patients with rapid heart rates, arrhythmia, or severe calcification were excluded. Therefore, 
for patients who already have a clinical indication for coronary angiography by MSCT in a 
real world, it would be a clinically important advantage if the same MSCT data could be 
used to gain additional information about the coronary artery disease (CAD). It has been 
reported that MSCT enables the analysis of the coronary plaques, left ventricular (LV) 
function, left atrial volume, myocardial enhancement, aortic valve, and the thoracic aorta, 
besides the assessment of the coronary stenosis. In this chapter, we focus on the additional 
information obtained simultaneously from the same data for coronary angiography by 
MSCT.
2. Assessment of myocardial contrast enhancement concomitantly with an 
assessment of coronary stenosis 
MSCT has reached a spatial and temporal resolution that is high enough to visualize not 
only coronary arteries but also infracted and non-infarcted myocardium (Paul et al., 2003). 
Nevertheless, coronary arteries with severely calcified plaques can still be difficult to 
evaluate by MSCT angiography (Leschka et al., 2005) because blooming artifacts and beam 
hardening effects can lead to misinterpretation of the luminal area. 
Here, we analyzed first-pass myocardial enhancement by 64-MSCT, evaluated its use for 
detecting significant stenosis and compared the results with quantitative coronary 
angiography (QCA) (Yoshida et al., 2009). In our study, myocardial contrast enhancement is 
quantified by deriving the signal density (SD) from the Hounsfied units (HU) values of the 
CT images. Data from 70 patients with single-vessel disease who underwent 64-MSCT 
followed by catheter-based coronary angiography were analyzed. After an evaluation of 
coronary stenosis, early- and late-diastolic (at 60% and 90% of the RR interval, respectively) 
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1. Introduction
Whereas in the past computed tomography (CT) of the coronary arteries could detect only 
calcifications, recently multislice computed tomography (MSCT) has been already accepted 
as an efficient noninvasive tool for the detection of coronary artery stenosis, providing good 
sensitivity, specificity, and very high negative predictive value. However, it must be 
recognized that these good results are obtained when technically inadequate scans or 
patients with rapid heart rates, arrhythmia, or severe calcification were excluded. Therefore, 
for patients who already have a clinical indication for coronary angiography by MSCT in a 
real world, it would be a clinically important advantage if the same MSCT data could be 
used to gain additional information about the coronary artery disease (CAD). It has been 
reported that MSCT enables the analysis of the coronary plaques, left ventricular (LV) 
function, left atrial volume, myocardial enhancement, aortic valve, and the thoracic aorta, 
besides the assessment of the coronary stenosis. In this chapter, we focus on the additional 
information obtained simultaneously from the same data for coronary angiography by 
MSCT.
2. Assessment of myocardial contrast enhancement concomitantly with an 
assessment of coronary stenosis 
MSCT has reached a spatial and temporal resolution that is high enough to visualize not 
only coronary arteries but also infracted and non-infarcted myocardium (Paul et al., 2003). 
Nevertheless, coronary arteries with severely calcified plaques can still be difficult to 
evaluate by MSCT angiography (Leschka et al., 2005) because blooming artifacts and beam 
hardening effects can lead to misinterpretation of the luminal area. 
Here, we analyzed first-pass myocardial enhancement by 64-MSCT, evaluated its use for 
detecting significant stenosis and compared the results with quantitative coronary 
angiography (QCA) (Yoshida et al., 2009). In our study, myocardial contrast enhancement is 
quantified by deriving the signal density (SD) from the Hounsfied units (HU) values of the 
CT images. Data from 70 patients with single-vessel disease who underwent 64-MSCT 
followed by catheter-based coronary angiography were analyzed. After an evaluation of 
coronary stenosis, early- and late-diastolic (at 60% and 90% of the RR interval, respectively) 
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short-axis images at 3 levels of the LV (basal, mid and apical), were analyzed. The SD in 
segments of the LV wall supplied by coronaries with and without stenosis was assessed. In 
this study, the SD of the LV cavity and remote myocardium was used as a reference for 
quantifying impaired myocardium. A region of interest of approximately 50 mm2 was drawn 
over each myocardial segments and LV cavity. A standardized SD was then calculated from 
the SD of the myocardium and the SD of the LV cavity according to the following formula:  
the SD of the myocardiumStandardized SD 100%
the SD of the LV cavity
 
The reduction in the percent SD between the myocardium surrounding a stenotic lesion and 
non-impaired myocardium away from a stenotic lesion was then defined as:  
standardized SD stenosis standardized SD no stenosis%SD x100%




In total, 48 patients had 70 atherosclerotic lesions (83 segments) detected by QCA: 35 
segments were categorized as a calcified plaque, and the other 48 segments were 
categorized as a non-calcified plaque. Forty-six segments were found to have more than 50% 
coronary stenosis by QCA. Diagnosis of significant stenosis by MSCT coronary angiography 
(segment-based analysis) had a sensitivity, specificity and accuracy for segments without 
calcified lesions of 92%, 100% and 99.7%, respectively, and 95.2%, 50%, and 77.1%, 
respectively, for calcified lesions. The standardized SD and %SD values in patients with a 
significant stenosis (more than 50% stenosis as determined by QCA) were significantly 
lower than those in patients without a stenosis. A similar trend was observed in patients 
with more than 75% stenosis. These values did not change during the early to late diastolic 
phase of the cardiac cycle. Taking into account the myocardial enhancement by calculating 
the decrease of the %SD, a sensitivity, specificity and accuracy of diagnosis of significant 
stenosis could be improved to 95.2%, 85.7% and 91.4%, respectively, for segments with 
calcified lesions. The analysis of the %SD reduction improved the diagnostic performance of 
MSCT for stenosis of coronaries with calcified plaques. The present study is a clinically 
essential investigation of first-pass myocardial enhancement by MSCT. Because the same 
image data that were used for MSCT coronary angiography were also used for the first-pass 
myocardial enhancement analysis, the patient was neither subjected to additional radiation 
exposure nor additional administration of contrast agent. 
Impaired myocardial blood flow and clinically unrecognized myocardial injuries could lead 
to reduced enhancement on MSCT images of the myocardium. First, the intra-myocardial 
coronary capillaries make up more than 90% of the microcirculation of the myocardium and 
the cross-connections serve to homogenize the myocardial pressure and flow distribution 
(Kassab et al., 1994, 1999). In myocardium supplied by healthy coronary arteries, increased 
capillary outlet pressure produces pressure dispersion and local flow reversal (Mittal et al., 
2005) during systole, whereas during diastole, the rapidly decreasing capillary outlet 
pressure promotes the washout of contrast agent. In contrast, stenotic epicardial coronary 
stenosis fails to supply optimal coronary blood flow (Gould et al., 1974) to the intra-
myocardial coronary capillary inlets and as a result, enhancement of CT images of the 
myocardium appears to be reduced. Impaired myocardial blood flow resulting from more 
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than 75% stenosis has already been visualized by myocardial contrast echocardiography 
with power Doppler imaging (Masugata et al., 2000). However, unrecognized myocardial 
injuries are also a possible cause for reduced myocardial enhancement, as has been shown 
by other studies in which myocardial injuries in patients with a clinical suspicion of CAD, 
but without known myocardial infarction, were detected by cardiac magnetic resonance 
imaging. We have shown that myocardial enhancement might be represented in the resting 
condition by the combination of reduced myocardial blood flow and unrecognized 
myocardial injuries. The advantage of MSCT imaging is that epicardial coronary stenosis 
can be analyzed concomitantly with an assessment of myocardial enhancement. It is 
important to note that an analysis of the degree of coronary stenosis and risk areas of the 
myocardium can be performed without additional radiation exposure or contrast injections. 
The introduction of myocardial assessment by first-pass scan protocols into clinical practice 
is easy without additional stress and cost, because of post-hoc analysis.  
3. Assessment of the atherosis and sclerosis in the aorta 
Atherosclerosis consists of two pathological processes: atherosis characterized by 
morphologic atheromatous lesions appearing in the intima, and sclerosis characterized by 
an increase in stiffness of the vessel walls. Aortic stiffness is known to increase with age 
(Tomochika et al., 1999), but it is also correlated with various diseases such as CAD 
(Herrington et al., 2003) and hypertension (Laurent et al., 2003), or hypercholesterolemia 
(Tomochika et al., 1999). So far, atherosis and sclerosis of the descending thoracic aorta 
(DTA) could be observed and analyzed during transesophageal echocardiography 
performed for other indications than CAD (Tomochika et al., 1999; Sugioka et al., 2002). 
Typical indications are cardiac embolism, valvular disease and atrial fibrillation, and 
transesophageal echocardiography is not performed for assessing aortic atherosclerosis in 
patients with CAD. A patient study with the latter aim would pose ethical problems, in 
particular since transesophageal echocardiography causes some discomfort. 
In contrast, for patients who already have an indication for coronary angiography by MSCT, 
which is non-invasive, it would be a clinically important advantage if the same MSCT data 
could be used to gain additional information about the CAD through the analysis of the 
aorta at multiple locations. A time-resolved, electrocardiographic (ECG)-gated CT technique 
to derive the aortic distensibility from cyclic cross-sectional area changes has already been 
validated in a phantom set-up with porcine aortic specimens (Ganten et al., 2005). Ganten et 
al reported the negative correlation between abdominal aortic distensibility and aging with 
the use of this method albeit 4- or 16-slice CT (Ganten et al., 2007). The distensibility 
however depends on the blood pressure, whereas the stiffness  is considered to be 
independent of the blood pressure (Hayashi et al., 1980; Hirai et al., 1989). 
Recently, we quantified atherosis and sclerosis of DTA and analyzed differences between 
patients with and without CAD using MSCT (Okuyama et al., 2008). The population 
contained 89 patients who underwent ECG-gated MSCT: 40 patients who were suspected of 
CAD by MSCT underwent invasive coronary angiography, and had documented significant 
stenoses (CAD group), 49 patients were found without significant stenoses (control group). 
We quantified atheromatous lesions and stiffness  of DTA. First, twenty cross-sectional 
images of DTA were reconstructed every 5% (0-95%) of the RR interval, and the largest and 
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short-axis images at 3 levels of the LV (basal, mid and apical), were analyzed. The SD in 
segments of the LV wall supplied by coronaries with and without stenosis was assessed. In 
this study, the SD of the LV cavity and remote myocardium was used as a reference for 
quantifying impaired myocardium. A region of interest of approximately 50 mm2 was drawn 
over each myocardial segments and LV cavity. A standardized SD was then calculated from 
the SD of the myocardium and the SD of the LV cavity according to the following formula:  
the SD of the myocardiumStandardized SD 100%
the SD of the LV cavity
 
The reduction in the percent SD between the myocardium surrounding a stenotic lesion and 
non-impaired myocardium away from a stenotic lesion was then defined as:  
standardized SD stenosis standardized SD no stenosis%SD x100%




In total, 48 patients had 70 atherosclerotic lesions (83 segments) detected by QCA: 35 
segments were categorized as a calcified plaque, and the other 48 segments were 
categorized as a non-calcified plaque. Forty-six segments were found to have more than 50% 
coronary stenosis by QCA. Diagnosis of significant stenosis by MSCT coronary angiography 
(segment-based analysis) had a sensitivity, specificity and accuracy for segments without 
calcified lesions of 92%, 100% and 99.7%, respectively, and 95.2%, 50%, and 77.1%, 
respectively, for calcified lesions. The standardized SD and %SD values in patients with a 
significant stenosis (more than 50% stenosis as determined by QCA) were significantly 
lower than those in patients without a stenosis. A similar trend was observed in patients 
with more than 75% stenosis. These values did not change during the early to late diastolic 
phase of the cardiac cycle. Taking into account the myocardial enhancement by calculating 
the decrease of the %SD, a sensitivity, specificity and accuracy of diagnosis of significant 
stenosis could be improved to 95.2%, 85.7% and 91.4%, respectively, for segments with 
calcified lesions. The analysis of the %SD reduction improved the diagnostic performance of 
MSCT for stenosis of coronaries with calcified plaques. The present study is a clinically 
essential investigation of first-pass myocardial enhancement by MSCT. Because the same 
image data that were used for MSCT coronary angiography were also used for the first-pass 
myocardial enhancement analysis, the patient was neither subjected to additional radiation 
exposure nor additional administration of contrast agent. 
Impaired myocardial blood flow and clinically unrecognized myocardial injuries could lead 
to reduced enhancement on MSCT images of the myocardium. First, the intra-myocardial 
coronary capillaries make up more than 90% of the microcirculation of the myocardium and 
the cross-connections serve to homogenize the myocardial pressure and flow distribution 
(Kassab et al., 1994, 1999). In myocardium supplied by healthy coronary arteries, increased 
capillary outlet pressure produces pressure dispersion and local flow reversal (Mittal et al., 
2005) during systole, whereas during diastole, the rapidly decreasing capillary outlet 
pressure promotes the washout of contrast agent. In contrast, stenotic epicardial coronary 
stenosis fails to supply optimal coronary blood flow (Gould et al., 1974) to the intra-
myocardial coronary capillary inlets and as a result, enhancement of CT images of the 
myocardium appears to be reduced. Impaired myocardial blood flow resulting from more 
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than 75% stenosis has already been visualized by myocardial contrast echocardiography 
with power Doppler imaging (Masugata et al., 2000). However, unrecognized myocardial 
injuries are also a possible cause for reduced myocardial enhancement, as has been shown 
by other studies in which myocardial injuries in patients with a clinical suspicion of CAD, 
but without known myocardial infarction, were detected by cardiac magnetic resonance 
imaging. We have shown that myocardial enhancement might be represented in the resting 
condition by the combination of reduced myocardial blood flow and unrecognized 
myocardial injuries. The advantage of MSCT imaging is that epicardial coronary stenosis 
can be analyzed concomitantly with an assessment of myocardial enhancement. It is 
important to note that an analysis of the degree of coronary stenosis and risk areas of the 
myocardium can be performed without additional radiation exposure or contrast injections. 
The introduction of myocardial assessment by first-pass scan protocols into clinical practice 
is easy without additional stress and cost, because of post-hoc analysis.  
3. Assessment of the atherosis and sclerosis in the aorta 
Atherosclerosis consists of two pathological processes: atherosis characterized by 
morphologic atheromatous lesions appearing in the intima, and sclerosis characterized by 
an increase in stiffness of the vessel walls. Aortic stiffness is known to increase with age 
(Tomochika et al., 1999), but it is also correlated with various diseases such as CAD 
(Herrington et al., 2003) and hypertension (Laurent et al., 2003), or hypercholesterolemia 
(Tomochika et al., 1999). So far, atherosis and sclerosis of the descending thoracic aorta 
(DTA) could be observed and analyzed during transesophageal echocardiography 
performed for other indications than CAD (Tomochika et al., 1999; Sugioka et al., 2002). 
Typical indications are cardiac embolism, valvular disease and atrial fibrillation, and 
transesophageal echocardiography is not performed for assessing aortic atherosclerosis in 
patients with CAD. A patient study with the latter aim would pose ethical problems, in 
particular since transesophageal echocardiography causes some discomfort. 
In contrast, for patients who already have an indication for coronary angiography by MSCT, 
which is non-invasive, it would be a clinically important advantage if the same MSCT data 
could be used to gain additional information about the CAD through the analysis of the 
aorta at multiple locations. A time-resolved, electrocardiographic (ECG)-gated CT technique 
to derive the aortic distensibility from cyclic cross-sectional area changes has already been 
validated in a phantom set-up with porcine aortic specimens (Ganten et al., 2005). Ganten et 
al reported the negative correlation between abdominal aortic distensibility and aging with 
the use of this method albeit 4- or 16-slice CT (Ganten et al., 2007). The distensibility 
however depends on the blood pressure, whereas the stiffness  is considered to be 
independent of the blood pressure (Hayashi et al., 1980; Hirai et al., 1989). 
Recently, we quantified atherosis and sclerosis of DTA and analyzed differences between 
patients with and without CAD using MSCT (Okuyama et al., 2008). The population 
contained 89 patients who underwent ECG-gated MSCT: 40 patients who were suspected of 
CAD by MSCT underwent invasive coronary angiography, and had documented significant 
stenoses (CAD group), 49 patients were found without significant stenoses (control group). 
We quantified atheromatous lesions and stiffness  of DTA. First, twenty cross-sectional 
images of DTA were reconstructed every 5% (0-95%) of the RR interval, and the largest and 
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smallest luminal areas were traced at 3 levels of the DTA avoiding sites of severe 
atheromatous lesion: at the pulmonary artery bifurcation (proximal DTA), below the heart 
(distal DTA), and in between (middle DTA). The maximum systolic (Dmax) and minimum 
diastolic (Dmin) lumen diameters were calculated from those areas with the assumption that 
the cross section was circular (diameter=2 [area/ ]1/ 2) (Nakatani et al., 1995). The aortic 
stiffness  was then calculated according to the formula  
=ln (BPsys/ BPdia)/ ([DmaxDmin]/ Dmin), where ln was the natural logarithm, BPsys was the 
systolic blood pressure, and BPdia was the diastolic blood pressure. Next, we assessed the 
grade of aortic atherosis for each patient. We divided the DTA into 3 segments of 5 cm 
length (2.5 cm proximal and 2.5 cm distal to each level described above), then continuously 
assessed the severity of atherosis in the transverse and longitudinal images of each area. We 
classified the aortic atheromatous lesions into 4 categories and scored each segment 
according to the severity of atherosis from 0 through 3, as described previously (Tomochika 
et al., 1999; Dávila-Román et al., 1994). An atheromatous score 0 indicated a normal aortic 
wall, score 1 indicated mild atherosis (intimal thickening <3.0 mm, without intimal 
irregularities), score 2 indicated moderate atherosis (intimal thickening 3.0 mm, with 
intimal irregularities) and score 3 indicated severe atherosis (significantly raised plaques, 
calcified plaques or raised plaques with ulcer formation) .   
In our study, the atheromatous score and stiffness  in the CAD group were significantly 
higher than those in controls. Multivariate analysis revealed that the average atheromatous 
score was an independent factor associated with CAD (p<0.005). Receiver-operating 
characteristic analyses were carried out on the average, maximum, and minimum 
atheromatous score and stiffness  for identifying patients with CAD. The areas under the 
curves for the average, maximum, and minimum atheromatous score were 0.82 (95% CI, 
0.73 to 0.91), 0.82 (95% CI, 0.73 to 0.91) and 0.75 (95% CI, 0.65 to 0.85), respectively. 
Regarding the average, maximum, and minimum stiffness , the areas under the curves 
were 0.75 (95% CI, 0.65 to 0.86), 0.74 (95% CI, 0.64 to 0.85) and 0.75 (95% CI, 0.65 to 0.85), 
respectively. A cut-off value 1.33 of the average atheromatous score (total atheromatous 
score 4) had a sensitivity of 73%, a specificity of 84%, a positive predictive value of 78%, 
and a negative predictive value of 79% for detection of CAD. In contrast, regarding the 
average stiffness , a cut-off value 14 had a sensitivity of 63%, a specificity of 65%, a 
positive predictive value of 60%, and a negative predictive value of 68%. Moreover, the 
combination of the average atheromatous score (1.33) and stiffness  (14) had a sensitivity 
of 48%, a specificity of 92%, a positive predictive value of 83%, and a negative predictive 
value of 68% for detection of CAD. In cases with image qualities unsatisfactory for 
interpretation of coronary stenoses, the additional assessment of atherosclerosis of DTA will 
be useful for identifying patients with CAD. 
4. Assessment of aortic valve area 
In industrialized countries the most frequent cause of aortic stenosis (AS) is degenerative 
changes of valve leaflets, such as the congenital bicuspid aortic valve (AV) and 
atherosclerotic valves. These changes frequently occur in elderly patients, who are also at 
risk for CAD. Severe AS (an AV area (AVA) of less than 1.0 cm2) accompanied by CAD 
presents problems for surgical decision-making in whether AV replacement should be 
performed with coronary artery bypass graft surgery. 
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Transthoracic echocardiography is an important and non-invasive method for assessing the 
significance of cardiac murmurs, which are derived from diseased heart valves. For 
diagnosing and evaluating the AVA by 2-dimensional echocardiography in patients with 
AS, the planimetric method without disturbed visualizations and the Doppler approach 
using an adequate angle of ultrasound beam are highly sensitive (Caidahl et al., 1998; Okura 
et al., 1997). The high spatial and temporal resolution of MSCT might allow for detailed 
images of the AV orifice and measurements of the AVA. 
We investigated whether the AVA in patients with AS assessed by MSCT corresponds to 
that by echocardiographic assessment and to evaluate simultaneously the clinical accuracy 
in detecting CAD with MSCT (Tanaka et al., 2007). The AVA of 29 consecutive AS patients 
with transthoracic echocardiography and MSCT were analyzed. The AVA was estimated by 
means of the continuity equation method in 2-dimensional echocardiography. Regarding 
AVA measurement method by MSCT, initially, one data set was reconstructed with the 
reconstruction window starting at 10% of the cardiac cycle. If motion artifacts were present 
in the AV, image reconstruction was repeated with the reconstruction window offset 2% 
toward the beginning and end of the systole until images without motion artifacts were 
obtained or until 20 data sets had been created, in which case the data set with the fewest 
motion artifacts was used for further evaluation for each coronary artery separately. The 
mid-systolic image data set, which was extracted with reference to the R wave of recorded 
ECG trace, was used to assess the AV orifice. The AV orifice images were reconstructed with 
a slice thickness of 2.0 mm in 1.5 mm intervals using the 2-step double-oblique method. The 
long axis of the transaxial image was obtained at mid-systole, and the next image was 
oblique at the line connecting the center of the ascending aorta and the AV orifice. Short-axis 
views of the aortic root were reconstructed as a first step. Further procedures were 
performed by inclining the short-axis image as a second step. AVA represented as planar 
images contained AV commissures. Finally, the calculations of the AVA were performed by 
planimetry. Concomitantly, the severty of the coronary artery stenosis was assessed by 
MSCT.
In our study, regression analysis showed that the AVA in patients with AS determined by 
MSCT correlated well w ith those determined by 2- dimensional echocardiography (r=0.96, 
p<0.001). Significant coronary stenosis of more than 50% diameter reduction was present in 
48% of the study population. The results of the present study are demonstrated by modern 
non-invasive technique of MSCT as follows: 1) the morphological appearance of AV orifice 
was clearly visualized; 2) the measurement of the AVA was accurately estimated to be the 
same as transthoracic echocardiography assessment; and 3) a moderate incidence of 
significant coronary stenosis was determined. Current guidelines recommend a diagnostic 
coronary angiography before surgery in symptomatic patients with AS. Analysis of the 
severity of AVA concomitant with CAD is important for patients with AS. Therefore, 
assessment for AS and CAD by MSCT is ideal for realization of these purposes. MSCT can 
investigate not only the degree of CAD and AS, but also the anatomical assessments of a 
calcified ascending aorta and patency of graft arteries, such as bilateral internal mammary 
arteries.
5. Assessment of coronary plaque 
Although CAD is the leading cause of death in the individuals with coronary risk factors, 
the majority of these individuals do not actually develop coronary symptoms before the 
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smallest luminal areas were traced at 3 levels of the DTA avoiding sites of severe 
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the cross section was circular (diameter=2 [area/ ]1/ 2) (Nakatani et al., 1995). The aortic 
stiffness  was then calculated according to the formula  
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systolic blood pressure, and BPdia was the diastolic blood pressure. Next, we assessed the 
grade of aortic atherosis for each patient. We divided the DTA into 3 segments of 5 cm 
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assessed the severity of atherosis in the transverse and longitudinal images of each area. We 
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irregularities), score 2 indicated moderate atherosis (intimal thickening 3.0 mm, with 
intimal irregularities) and score 3 indicated severe atherosis (significantly raised plaques, 
calcified plaques or raised plaques with ulcer formation) .   
In our study, the atheromatous score and stiffness  in the CAD group were significantly 
higher than those in controls. Multivariate analysis revealed that the average atheromatous 
score was an independent factor associated with CAD (p<0.005). Receiver-operating 
characteristic analyses were carried out on the average, maximum, and minimum 
atheromatous score and stiffness  for identifying patients with CAD. The areas under the 
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score 4) had a sensitivity of 73%, a specificity of 84%, a positive predictive value of 78%, 
and a negative predictive value of 79% for detection of CAD. In contrast, regarding the 
average stiffness , a cut-off value 14 had a sensitivity of 63%, a specificity of 65%, a 
positive predictive value of 60%, and a negative predictive value of 68%. Moreover, the 
combination of the average atheromatous score (1.33) and stiffness  (14) had a sensitivity 
of 48%, a specificity of 92%, a positive predictive value of 83%, and a negative predictive 
value of 68% for detection of CAD. In cases with image qualities unsatisfactory for 
interpretation of coronary stenoses, the additional assessment of atherosclerosis of DTA will 
be useful for identifying patients with CAD. 
4. Assessment of aortic valve area 
In industrialized countries the most frequent cause of aortic stenosis (AS) is degenerative 
changes of valve leaflets, such as the congenital bicuspid aortic valve (AV) and 
atherosclerotic valves. These changes frequently occur in elderly patients, who are also at 
risk for CAD. Severe AS (an AV area (AVA) of less than 1.0 cm2) accompanied by CAD 
presents problems for surgical decision-making in whether AV replacement should be 
performed with coronary artery bypass graft surgery. 
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in the AV, image reconstruction was repeated with the reconstruction window offset 2% 
toward the beginning and end of the systole until images without motion artifacts were 
obtained or until 20 data sets had been created, in which case the data set with the fewest 
motion artifacts was used for further evaluation for each coronary artery separately. The 
mid-systolic image data set, which was extracted with reference to the R wave of recorded 
ECG trace, was used to assess the AV orifice. The AV orifice images were reconstructed with 
a slice thickness of 2.0 mm in 1.5 mm intervals using the 2-step double-oblique method. The 
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performed by inclining the short-axis image as a second step. AVA represented as planar 
images contained AV commissures. Finally, the calculations of the AVA were performed by 
planimetry. Concomitantly, the severty of the coronary artery stenosis was assessed by 
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In our study, regression analysis showed that the AVA in patients with AS determined by 
MSCT correlated well w ith those determined by 2- dimensional echocardiography (r=0.96, 
p<0.001). Significant coronary stenosis of more than 50% diameter reduction was present in 
48% of the study population. The results of the present study are demonstrated by modern 
non-invasive technique of MSCT as follows: 1) the morphological appearance of AV orifice 
was clearly visualized; 2) the measurement of the AVA was accurately estimated to be the 
same as transthoracic echocardiography assessment; and 3) a moderate incidence of 
significant coronary stenosis was determined. Current guidelines recommend a diagnostic 
coronary angiography before surgery in symptomatic patients with AS. Analysis of the 
severity of AVA concomitant with CAD is important for patients with AS. Therefore, 
assessment for AS and CAD by MSCT is ideal for realization of these purposes. MSCT can 
investigate not only the degree of CAD and AS, but also the anatomical assessments of a 
calcified ascending aorta and patency of graft arteries, such as bilateral internal mammary 
arteries.
5. Assessment of coronary plaque 
Although CAD is the leading cause of death in the individuals with coronary risk factors, 
the majority of these individuals do not actually develop coronary symptoms before the 
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onset of acute myocardial infarction (AMI) or sudden death. In fact, AMI or sudden death 
frequently occurs as the first symptom of coronary diseases. Therefore, screening of the 
patients with unstable plaque is important for prevention of the onset of AMI or sudden 
cardiac death. Intracoronary thrombus, immediate result of plaque rupture plays key roles 
in the onset of acute coronary syndromes (ACS) (van der Wal et al., 1994; Moreno et al., 
1994). Ruptured plaques are histopathologically characterized by large lipid core and large 
plaque volumes that are covered by the thin fibrous cap often inflamed with macrophages 
and T lymphocytes infiltration. Moreover, in recent intravascular ultrasound (IVUS) studies, 
the term “ arterial remodeling”  was defined as a change in vessel size, using the ratio of the 
external elastic membrane area (vessel area) at the culprit lesion site to that at the minimally 
diseased reference site within the same vessel segment. Most of their studies demonstrate 
that the vessels are positively remodeled at the site of plaque rupture in patients with ACS 
(Schoenhagen et al., 2000; Ehara et al., 2004). Various diagnostic techniques have identified 
the imaging characteristics of vulnerable plaques and proposed that these characteristics 
may allow recognition of coronary lesions likely to result in ACS.   
Recently, MSCT has reached a spatial and temporal resolution high enough for assessment 
not only of coronary artery stenosis but also coronary atherosclerotic plaques. For the first 
time, Schroeder et al demonstrated that the IVUS-based coronary plaque configuration can 
be accurately identified by MSCT (Schroeder et al., 2001). They reported that IVUS-based 
soft plaques showed a mean density of 1426 HU, intermediated plaques of 9121 HU, and 
calcified plaques of 419194 HU.  Similarly, Motoyama et al showed that the corresponding 
values were 1112 HU, 7821 HU, and 516198 HU (Motoyama et al., 2007). Regarding 
arterial remodeling determined by MSCT, on the other hand, Achenbach et al reported that 
cross-sectional vessel areas and remodeling indices measured by 16-slice CT scanner 
correlated closely to IVUS (r = 0.88 and r = 0.91, respectively) (Achenbach et al., 2004). More 
recently, Leber et al provided comparative data of vessel areas, plaque areas, and lumen 
areas determined by IVUS and 64-slice CT, and reported that the correlation coefficients for 
these measurements were r = 0.88, r = 0.73, and r = 0.81, respectively (Leber et al., 2005). 
Based on these promising studies, the prospective MSCT study was designed by Motoyama 
et al (Motoyama et al., 2009) to evaluate the role of CT plaque characterization for predicting 
acute coronary events in 1059 subjects with established or suspected CAD who were 
followed up for an average of 27 months. They reported that of the 45 patients showing 
plaque with both positive remodeling and low-attenuation plaques (<30 HU), ACS 
developed in 10 (22.2%), compared with 1 (3.7%) of the 27 patients with plaques displaying 
either feature. In only 4 (0.5%) of the 820 patients with neither positive remodeling nor low-
attenuation plaques did ACS develop. None of the 167 patients with normal angiograms 
had acute coronary events. ACS was independently predicted by positive remodeling 
and/ or low-attenuation plaques. They concluded that the patients demonstrating positively 
remodeled coronary segments with low-attenuation plaques in CT angiography were at a 
higher risk of ACS developing over time when compared with patients having lesions 
without these characteristics. We also demonstrated that in patients with IVUS-based plaque 
rupture, the prevalence of an ulcer-like enhancement space, a ring-like sign was higher than 
those in patients without IVUS-based plaque rupture (Tanaka et al., 2008). Thus, MSCT 
might provide a useful and promising tool for the non-invasive detection of vulnerable 
plaques and vulnerable patients. 
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6. Conclusion 
The diagnostic accuracy of MSCT in the detection of coronary artery stenoses has been 
reported by many investigators, w ith a very high specificity and very high negative 
predictive values. However, most previous studies did not consist of consecutive patients 
and most studies excluded patient images w ith image qualities unsatisfactory for 
interpretation. MSCT scans of the coronary arteries are sti l l  associated w ith a relatively 
high radiation dose and administration of contrast agent, i t is therefore important to 
obtain as much relevant information as possible from the scan. The simultaneous 
assessment beyond angiography, which is often possible even in cases w ith unsatisfactory 
coronary image quality, could offer a way to increase the diagnostic usefulness of MSCT 
for CAD patients.  
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1. Introduction  
Coronary artery bypass graft (CABG) surgery is the standard care in the treatment of 
advanced coronary artery disease. Notwithstanding the clear benefits of bypass grafting, 
recurrent chest pain after myocardial revascularization surgery is a common postoperative 
presentation and the long-term clinical outcome after myocardial revascularization surgery 
is largely dependent on graft patency and the progression of coronary artery disease. 
Therefore, assessment of the status of the grafts and graft disease after CABG surgery is an 
important issue in cardiology. Although conventional coronary angiography is still standard 
method for assessment of the status of naïve and recipient vessels after CABG surgery, it is 
an invasive and costly procedure that is not risk-free. Recently, multidetector row computed 
tomography (MDCT) with retrospective electrocardiographic (ECG) gating has gained rapid 
acceptance as a diagnostic cardiac imaging modality, allowing assessment of coronary 
bypass graft patency with high spatial resolution. Initial assessment of bypass grafts was 
done with single-slice scanners and electron-beam CT. Subsequently, the addition of 
electrocardiographic ECG gating and the improved capabilities available with 4- or 16-slice 
MDCT scanners for rapid scanning of the area of interest led to promising results in the 
imaging of bypass grafts (Marano et al., 2005; Ueyama et al., 1999). Recently, the 
introduction of 64-slice MDCT permitted improved temporal resolution (94 to 200 msec) 
and spatial resolution (upto submillimeter) and reduction of both cardiac and respiratory 
motion, leading to improved assessment of graft stenosis and occlusion (Frazier et al., 2005; 
Lee et al., 2010). Moreover, 3-dimensional (3D) image processing and advanced volumetric 
visualization techniques now allow radiologists and cardiologists to evaluate coronary 
grafts in multiple planes using various projections. With the capability of acquiring 3D data 
volumes along with its tomographic nature, it shares many of the advantages of 
intravascular ultrasound and thus has the potential to enhance the practice of percutaneous 
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method for assessment of the status of naïve and recipient vessels after CABG surgery, it is 
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tomography (MDCT) with retrospective electrocardiographic (ECG) gating has gained rapid 
acceptance as a diagnostic cardiac imaging modality, allowing assessment of coronary 
bypass graft patency with high spatial resolution. Initial assessment of bypass grafts was 
done with single-slice scanners and electron-beam CT. Subsequently, the addition of 
electrocardiographic ECG gating and the improved capabilities available with 4- or 16-slice 
MDCT scanners for rapid scanning of the area of interest led to promising results in the 
imaging of bypass grafts (Marano et al., 2005; Ueyama et al., 1999). Recently, the 
introduction of 64-slice MDCT permitted improved temporal resolution (94 to 200 msec) 
and spatial resolution (upto submillimeter) and reduction of both cardiac and respiratory 
motion, leading to improved assessment of graft stenosis and occlusion (Frazier et al., 2005; 
Lee et al., 2010). Moreover, 3-dimensional (3D) image processing and advanced volumetric 
visualization techniques now allow radiologists and cardiologists to evaluate coronary 
grafts in multiple planes using various projections. With the capability of acquiring 3D data 
volumes along with its tomographic nature, it shares many of the advantages of 
intravascular ultrasound and thus has the potential to enhance the practice of percutaneous 
*Hyun Suk Yang, Joon Hyung Doh, Hong Jang, Gu Hyun Kang, Yong Hwan Park, Woo Jung Chun, Ju 
Hyeon Oh, Sung Min Ko and Hweung Kon Hwang 
Coronary Angiography 
– Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 162 
coronary intervention (PCI) in the catheterization laboratory by providing data which was 
difficult to obtain by invasive coronary angiography (Dikkers et al., 2007; Vembar et al., 
2003). Recent studies using 64-slice MDCT have reported sensitivity and specificity values of 
95% to 100% and 93% to 100%, respectively, for graft occlusion and high-grade stenosis with 
> 50% luminal narrowing (Table 1). Since naïve coronary arteries and coronary grafts are 
small vessels, 2 to 4 mm in diameter, and are characterized by both complex anatomy and 
continuous movements, high spatial and temporal resolutions are mandatory to visualize 
these vessels at MDCT. MDCT scanners characterized by submillimeter spatial resolution 
and a temporal resolution of 94 to 200 ms are now available and are increasingly used for 
cardiac imaging with promising results.  
 







Achenbach, et al., 1997 Electron-beam 25 56 100 100 
Engelmann, et al., 1997 Spiral 49 134 92 97 
Marano, et al., 2004 4-MDCT 57 122 89 95 
Ropers, et al., 2001 4-MDCT 65 182 92 95 
Anders, et al., 2006 16-MDCT 32 94 100 98 
Schlosser, et al., 2004 16-MDCT 48 131 96 95 
Dikkers, et al., 2007 64-MDCT 34 69 100 99 
Jabara, et al., 2007 64-MDCT 50 147 95 100 
Nazeri, et al., 2009 64-MDCT 89 287 98 97 
Ropers, et al., 2006 64-MDCT 50 138 100 94 
Tochii, et al., 2010 64-MDCT 19 90 100 93 
High-grade stenosis is defined as 50-99% stenosis 
Table 1. Results of studies of the use of MDCT to evaluate occlusion and high-grade stenosis 
of grafts  
2. Imaging acquisition 
2.1 Image protocol  
There are a variety of protocols for image acquisition in the evaluation of patients after 
CABG surgery. In many respects, the protocol is similar to that for coronary CT 
angiography (CTA). One important difference is that the scan should be extended superiorly 
to include the origins of the internal mammary arteries. Scanning is performed with the 
patient in the supine position, during breath-hold. After placement of the leads for ECG 
recording on the chest wall and a check of the heart rate, a noncontrast CT scan image is 
acquired through the entire thorax in order to define the volume of the subsequent CT 
angiography and to detect associated or unsuspected findings. Hence, MDCT angiography 
is performed during ECG recording, from the subclavian arteries to the cardiac base; in 
patients with venous grafts, a smaller scanning volume starting from the lower third of the 
ascending aorta is usually sufficient. On the contrary, when a right gastroepiploic artery 
(RGEA) has been used, the scanning volume should include the upper abdomen. Cardiac 
CTA technique requires rapid injection of nonionic, iodinated, low-osmolar intravenous 
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contrast. A bolus of 100 to 120 mL nonionic contrast material (high iodine concentration is 
recommended) is administered intravenously using an automatic injector at a flow rate of 3 
to 4 mL/s. A region of interest was placed in the descending aorta by using a preset 
threshold of 150 HU; a 10-second delay followed before scanning was begun to ensure 
filling of the distal vessels with contrast material. Since the left internal mammary artery 
(LIMA) is the most frequently used graft to the anterior cardiac wall, a right arm venous 
access is preferable in order to avoid streak artifacts from the left subclavian vein that may 
hamper a complete evaluation of LIMA course and takeoff. Axial images are reconstructed 
in the mid-to-late diastolic phase, using a fraction (percentage; relative delay) of the R-R 
interval of the cardiac cycle. Images are acquired with a heart rate < 70 beats per minute, if 
possible, and with breath-holding during mid-inspiration to prevent substantial inflow of 
unopacified blood into the right atrium, which may result in heterogeneity of contrast. Low 
heart rates (< 65 beats/min for 16-slice MDCT or < 70 beats/min for 64-slice MDCT) are 
recommended to obtain high-quality CT scans, and in the absence of contraindications 
(heart failure, systolic BP < 100 mm Hg, atrioventricular blockade greater than grade I, and 
referred adverse reaction), beta-blockers can be administered before CT acquisition (Frazier 
et al., 2005; Marano et al., 2005). Oral or intravenous beta-adrenergic blocking medications, 
specifically metoprolol (Lopressor; Novartis Pharmaceuticals Corp., East Hanover, NJ), are 
administered prior to scanning to prevent heart rate variability and tachycardia. 
Retrospective ECG-gated CTA is essential for optimal image acquisition and reconstruction 
of evenly spaced phases of the cardiac cycle. The images are acquired in a limited field of 
view with axial images centered on the heart. Using 60% to 80% of the R-R interval, with 0.6-
0.75 mm thick images reconstructed in 0.4-0.5 mm increments, axial source images, three-
dimensional (3D) volume-rendered images, and multiplanar reformatted (MPR) images are 
generated. Both 3D volume-rendering and MPR images are used to assess the bypass grafts, 
proximal and/or distal graft anastomoses, and the cardiac anatomy. In particular, curved 
multiplanar images with centerlines through the bypass grafts and native coronary arteries 
are obtained. To correctly assess graft patency and/or the presence of significant stenosis 
and occlusion, a thorough knowledge of CABG anatomy and its configuration on CTA is 
important for radiologists and cardiologists. There are 2 types of bypass grafts, arterial and 
venous. Venous grafts are generally larger in caliber than arterial grafts, and for this reason, 
jointly to the absence of surgical clips along their course, venous grafts are usually better 
assessable by noninvasive imaging techniques. In order of frequency of use, graft arteries 
include the internal mammary arteries (IMAs), radial arteries (RAs), right gastroepiploic 
artery (RGEA), and inferior epigastric artery (IEA). Although arterial grafts have better 
long-term outcomes, venous grafts, specifically saphenous vein grafts (SVGs), are more 
readily available. CTA following CABG surgery is done by first assessing the morphology 
and size of the ascending aorta and the origin of the in situ vessel such as the IMA. Then, 
graft patency is assessed for homogeneous, contrast-enhanced graft lumen and for regular 
shape and border of the graft wall. The graft is usually divided into 3 different segments: the 
origin or proximal anastomosis of the graft, the body of the graft, and the single (or 
sequential) distal anastomosis. During the CTA evaluation of bypass grafts, the proximal 
anastomosis is usually better visualized than the distal anastomosis. In cases in which the 
distal anastomosis is not well evaluated, the bypass graft is usually considered patent as 
long as contrast is evident within the graft lumen.  
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coronary intervention (PCI) in the catheterization laboratory by providing data which was 
difficult to obtain by invasive coronary angiography (Dikkers et al., 2007; Vembar et al., 
2003). Recent studies using 64-slice MDCT have reported sensitivity and specificity values of 
95% to 100% and 93% to 100%, respectively, for graft occlusion and high-grade stenosis with 
> 50% luminal narrowing (Table 1). Since naïve coronary arteries and coronary grafts are 
small vessels, 2 to 4 mm in diameter, and are characterized by both complex anatomy and 
continuous movements, high spatial and temporal resolutions are mandatory to visualize 
these vessels at MDCT. MDCT scanners characterized by submillimeter spatial resolution 
and a temporal resolution of 94 to 200 ms are now available and are increasingly used for 
cardiac imaging with promising results.  
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of grafts  
2. Imaging acquisition 
2.1 Image protocol  
There are a variety of protocols for image acquisition in the evaluation of patients after 
CABG surgery. In many respects, the protocol is similar to that for coronary CT 
angiography (CTA). One important difference is that the scan should be extended superiorly 
to include the origins of the internal mammary arteries. Scanning is performed with the 
patient in the supine position, during breath-hold. After placement of the leads for ECG 
recording on the chest wall and a check of the heart rate, a noncontrast CT scan image is 
acquired through the entire thorax in order to define the volume of the subsequent CT 
angiography and to detect associated or unsuspected findings. Hence, MDCT angiography 
is performed during ECG recording, from the subclavian arteries to the cardiac base; in 
patients with venous grafts, a smaller scanning volume starting from the lower third of the 
ascending aorta is usually sufficient. On the contrary, when a right gastroepiploic artery 
(RGEA) has been used, the scanning volume should include the upper abdomen. Cardiac 
CTA technique requires rapid injection of nonionic, iodinated, low-osmolar intravenous 
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contrast. A bolus of 100 to 120 mL nonionic contrast material (high iodine concentration is 
recommended) is administered intravenously using an automatic injector at a flow rate of 3 
to 4 mL/s. A region of interest was placed in the descending aorta by using a preset 
threshold of 150 HU; a 10-second delay followed before scanning was begun to ensure 
filling of the distal vessels with contrast material. Since the left internal mammary artery 
(LIMA) is the most frequently used graft to the anterior cardiac wall, a right arm venous 
access is preferable in order to avoid streak artifacts from the left subclavian vein that may 
hamper a complete evaluation of LIMA course and takeoff. Axial images are reconstructed 
in the mid-to-late diastolic phase, using a fraction (percentage; relative delay) of the R-R 
interval of the cardiac cycle. Images are acquired with a heart rate < 70 beats per minute, if 
possible, and with breath-holding during mid-inspiration to prevent substantial inflow of 
unopacified blood into the right atrium, which may result in heterogeneity of contrast. Low 
heart rates (< 65 beats/min for 16-slice MDCT or < 70 beats/min for 64-slice MDCT) are 
recommended to obtain high-quality CT scans, and in the absence of contraindications 
(heart failure, systolic BP < 100 mm Hg, atrioventricular blockade greater than grade I, and 
referred adverse reaction), beta-blockers can be administered before CT acquisition (Frazier 
et al., 2005; Marano et al., 2005). Oral or intravenous beta-adrenergic blocking medications, 
specifically metoprolol (Lopressor; Novartis Pharmaceuticals Corp., East Hanover, NJ), are 
administered prior to scanning to prevent heart rate variability and tachycardia. 
Retrospective ECG-gated CTA is essential for optimal image acquisition and reconstruction 
of evenly spaced phases of the cardiac cycle. The images are acquired in a limited field of 
view with axial images centered on the heart. Using 60% to 80% of the R-R interval, with 0.6-
0.75 mm thick images reconstructed in 0.4-0.5 mm increments, axial source images, three-
dimensional (3D) volume-rendered images, and multiplanar reformatted (MPR) images are 
generated. Both 3D volume-rendering and MPR images are used to assess the bypass grafts, 
proximal and/or distal graft anastomoses, and the cardiac anatomy. In particular, curved 
multiplanar images with centerlines through the bypass grafts and native coronary arteries 
are obtained. To correctly assess graft patency and/or the presence of significant stenosis 
and occlusion, a thorough knowledge of CABG anatomy and its configuration on CTA is 
important for radiologists and cardiologists. There are 2 types of bypass grafts, arterial and 
venous. Venous grafts are generally larger in caliber than arterial grafts, and for this reason, 
jointly to the absence of surgical clips along their course, venous grafts are usually better 
assessable by noninvasive imaging techniques. In order of frequency of use, graft arteries 
include the internal mammary arteries (IMAs), radial arteries (RAs), right gastroepiploic 
artery (RGEA), and inferior epigastric artery (IEA). Although arterial grafts have better 
long-term outcomes, venous grafts, specifically saphenous vein grafts (SVGs), are more 
readily available. CTA following CABG surgery is done by first assessing the morphology 
and size of the ascending aorta and the origin of the in situ vessel such as the IMA. Then, 
graft patency is assessed for homogeneous, contrast-enhanced graft lumen and for regular 
shape and border of the graft wall. The graft is usually divided into 3 different segments: the 
origin or proximal anastomosis of the graft, the body of the graft, and the single (or 
sequential) distal anastomosis. During the CTA evaluation of bypass grafts, the proximal 
anastomosis is usually better visualized than the distal anastomosis. In cases in which the 
distal anastomosis is not well evaluated, the bypass graft is usually considered patent as 
long as contrast is evident within the graft lumen.  
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2.2 Image noise  
The advantages of MDCT are the relatively rapid imaging time and high spatial resolution 
attributable to the multi-row detector system. Numerous studies dealing with MDCT 
coronary bypass angiography have reported cardiac and respiratory motion artifacts as the 
most significant limitations in the reliable assessment of graft patency and stenosis of 
recipient vessels. It is well known that heart rate greatly influences image quality and 
stenosis detection. The introduction of 64-slice MDCT scanners, with faster gantry rotation 
times and shorter breath-hold times, improved diagnostic image quality by reducing cardiac 
and respiratory motion artifacts. However, optimum performance was observed primarily 
in patients with heart rates below 70 beats per minute. Even with improved spatial and 
temporal resolution with 64-slice technology, routine administration of β-blockers is still 
required. If graft segment image quality is suboptimal due to motion artifacts, a potential 
remedy is to obtain additional image reconstructions in smaller increments throughout the 
cardiac cycle. The other limitations of MDCT are the presence of calcification and metal clip 
artifacts, which make assessment of graft patency difficult, and accurate evaluation of the 
degree of stenosis impossible. Nevertheless, the thinner slices of 64-slice MDCT give 
increased temporal resolution, and 3-dimentional reconstructions show consistent detail in 
every plane. Moreover, bypass grafts are characterized by minor calcification compared to 
naive vessels, allowing more accurate analysis in most cases. Coronary calcifications and 
metal clip artifacts still remain a challenging issue with 64-slice cardiac CT despite 
improvements with the use of sharper image filters, e.g. the B46 Kernel (Siemens Medical 
Solutions) (Seifarth et al., 2005). The another important limitation is the high radiation dose 
required for 64-slice MDCT, although electrocardiogram-dependent dose modulation can 
reduce this by 30%–50%. The minimization of radiation exposure as well as optimization of 
the diagnostic accuracy in calcified vessels remain the chief goals for future MDCT 
advances. 
3. Type of arterial or vein graft  
3.1 Saphenous Vein Graft (SVG)  
The SVG was first successfully used in a CABG operation by Sabiston in 1962. Both the 
benefits and limitations of SVG have been well documented in the literature (Bourassa et al., 
1985; Campeau et al., 1983). Saphenous veins are fairly simple to access and harvest from the 
lower extremities, and they are more versatile and widely available than arterial grafts. In 
addition, during the intra- and perioperative period, saphenous veins are resistant to spasm 
versus their arterial counterparts. However, the use of SVG is limited by distortion from 
varicose and sclerotic disease as well as a higher occurrence of intimal hyperplasia and 
atherosclerotic changes after exposure to systemic blood pressure, resulting in lower 
patency rates. Graft occlusion can also occur due to vascular damage during harvesting of 
the saphenous vein. In a large study, the SVG patency was 88% perioperatively, 81% at 1 
year, 75% at 5 years, and 50% at greater than or equal to 15 years (Fitzgibbon et al., 1996). 
The graft attrition rate between 1 and 6 years after CABG surgery is 1% to 2% per year, and 
between 6 and 10 years is 4% per year. The great saphenous vein is the vein routinely used 
for CABG surgery. The proximal anastomosis of the venous graft with the ascending aorta is 
usually performed cranial to the origin of coronary arteries and as distal as the proximal 
portion of the aortic arch. The SVG can be sutured directly to the anterior portion of the 
ascending aorta or attached with an anastomotic device, allowing faster, sutureless 
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attachment. The device, called the Symmetry Bypass System aortic connector (St Jude 
Medical, St Paul, Minn), alters the common appearance of the bypass graft by requiring the 
aortic connector to be anastomosed perpendicularly to the aorta (Mack et al., 2003; Poston et 
al., 2004). Recent reports have documented the development of significant stenosis and 
occlusion in 13.7%-15.5% of vein grafts attached with the aortic connector (Carrel et al., 2003; 
Wiklund et al., 2002). In order to support the course of the aortovenous anastomosis, the 
left-sided SVG is connected to the left side of the aorta, stabilizing the graft on top of the 
main pulmonary artery. A right-sided SVG is attached either to the lower aspect or right 
side of the ascending aorta, allowing the graft to traverse the right arterio-ventricular 
groove. SVGs tend to appear as large contrast-filled vessels (Fig.1).  
 
Fig. 1. Saphenous vein grafts. Three-dimensional volume-rendered images show the typical 
appearance of right (arrow) and left (arrowhead) saphenous vein grafts (SVGs) sutured to 
the anterior aorta. The left SVG is attached to the mid-portion of left anterior descending 
(LAD) artery and the right SVG is attached to the distal-portion of right coronary artery 
(RCA).    
An SVG to the right side is attached to the distal right coronary artery (RCA), posterior 
descending artery (PDA), or distal LAD artery. The distal anastomosis may lie on the 
phrenic wall of the heart. An SVG to the left side is attached distally to the LAD artery, 
diagonal artery, left circumflex (LCx) artery, or the obtuse marginal (OM) arteries, by 
traversing anteriorly and superiorly to the right ventricle outflow tract (RVOT) or main 
pulmonary artery (Fig. 2, 3, 4).  
SVG may present a horizontal or slightly oblique course on axial images, especially when 
the distal anastomosis is placed on the LCx or a diagonal branch to supply the left cardiac 
wall. In these cases, the graft can be recognized in the fatty tissue of mediastinum, posterior 
to the sternum and anterior to the RVOT. On occasion, the distal SVG is anastomosed 
sequentially to greater than or equal to 2 coronary vessels or in the same vessel, using side-
to-side and end-to-side anastomoses. The naive vessel distal to the anastamotic site should 
be assessed and is recognized by its position and smaller caliber compared with the SVG 
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The advantages of MDCT are the relatively rapid imaging time and high spatial resolution 
attributable to the multi-row detector system. Numerous studies dealing with MDCT 
coronary bypass angiography have reported cardiac and respiratory motion artifacts as the 
most significant limitations in the reliable assessment of graft patency and stenosis of 
recipient vessels. It is well known that heart rate greatly influences image quality and 
stenosis detection. The introduction of 64-slice MDCT scanners, with faster gantry rotation 
times and shorter breath-hold times, improved diagnostic image quality by reducing cardiac 
and respiratory motion artifacts. However, optimum performance was observed primarily 
in patients with heart rates below 70 beats per minute. Even with improved spatial and 
temporal resolution with 64-slice technology, routine administration of β-blockers is still 
required. If graft segment image quality is suboptimal due to motion artifacts, a potential 
remedy is to obtain additional image reconstructions in smaller increments throughout the 
cardiac cycle. The other limitations of MDCT are the presence of calcification and metal clip 
artifacts, which make assessment of graft patency difficult, and accurate evaluation of the 
degree of stenosis impossible. Nevertheless, the thinner slices of 64-slice MDCT give 
increased temporal resolution, and 3-dimentional reconstructions show consistent detail in 
every plane. Moreover, bypass grafts are characterized by minor calcification compared to 
naive vessels, allowing more accurate analysis in most cases. Coronary calcifications and 
metal clip artifacts still remain a challenging issue with 64-slice cardiac CT despite 
improvements with the use of sharper image filters, e.g. the B46 Kernel (Siemens Medical 
Solutions) (Seifarth et al., 2005). The another important limitation is the high radiation dose 
required for 64-slice MDCT, although electrocardiogram-dependent dose modulation can 
reduce this by 30%–50%. The minimization of radiation exposure as well as optimization of 
the diagnostic accuracy in calcified vessels remain the chief goals for future MDCT 
advances. 
3. Type of arterial or vein graft  
3.1 Saphenous Vein Graft (SVG)  
The SVG was first successfully used in a CABG operation by Sabiston in 1962. Both the 
benefits and limitations of SVG have been well documented in the literature (Bourassa et al., 
1985; Campeau et al., 1983). Saphenous veins are fairly simple to access and harvest from the 
lower extremities, and they are more versatile and widely available than arterial grafts. In 
addition, during the intra- and perioperative period, saphenous veins are resistant to spasm 
versus their arterial counterparts. However, the use of SVG is limited by distortion from 
varicose and sclerotic disease as well as a higher occurrence of intimal hyperplasia and 
atherosclerotic changes after exposure to systemic blood pressure, resulting in lower 
patency rates. Graft occlusion can also occur due to vascular damage during harvesting of 
the saphenous vein. In a large study, the SVG patency was 88% perioperatively, 81% at 1 
year, 75% at 5 years, and 50% at greater than or equal to 15 years (Fitzgibbon et al., 1996). 
The graft attrition rate between 1 and 6 years after CABG surgery is 1% to 2% per year, and 
between 6 and 10 years is 4% per year. The great saphenous vein is the vein routinely used 
for CABG surgery. The proximal anastomosis of the venous graft with the ascending aorta is 
usually performed cranial to the origin of coronary arteries and as distal as the proximal 
portion of the aortic arch. The SVG can be sutured directly to the anterior portion of the 
ascending aorta or attached with an anastomotic device, allowing faster, sutureless 
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attachment. The device, called the Symmetry Bypass System aortic connector (St Jude 
Medical, St Paul, Minn), alters the common appearance of the bypass graft by requiring the 
aortic connector to be anastomosed perpendicularly to the aorta (Mack et al., 2003; Poston et 
al., 2004). Recent reports have documented the development of significant stenosis and 
occlusion in 13.7%-15.5% of vein grafts attached with the aortic connector (Carrel et al., 2003; 
Wiklund et al., 2002). In order to support the course of the aortovenous anastomosis, the 
left-sided SVG is connected to the left side of the aorta, stabilizing the graft on top of the 
main pulmonary artery. A right-sided SVG is attached either to the lower aspect or right 
side of the ascending aorta, allowing the graft to traverse the right arterio-ventricular 
groove. SVGs tend to appear as large contrast-filled vessels (Fig.1).  
 
Fig. 1. Saphenous vein grafts. Three-dimensional volume-rendered images show the typical 
appearance of right (arrow) and left (arrowhead) saphenous vein grafts (SVGs) sutured to 
the anterior aorta. The left SVG is attached to the mid-portion of left anterior descending 
(LAD) artery and the right SVG is attached to the distal-portion of right coronary artery 
(RCA).    
An SVG to the right side is attached to the distal right coronary artery (RCA), posterior 
descending artery (PDA), or distal LAD artery. The distal anastomosis may lie on the 
phrenic wall of the heart. An SVG to the left side is attached distally to the LAD artery, 
diagonal artery, left circumflex (LCx) artery, or the obtuse marginal (OM) arteries, by 
traversing anteriorly and superiorly to the right ventricle outflow tract (RVOT) or main 
pulmonary artery (Fig. 2, 3, 4).  
SVG may present a horizontal or slightly oblique course on axial images, especially when 
the distal anastomosis is placed on the LCx or a diagonal branch to supply the left cardiac 
wall. In these cases, the graft can be recognized in the fatty tissue of mediastinum, posterior 
to the sternum and anterior to the RVOT. On occasion, the distal SVG is anastomosed 
sequentially to greater than or equal to 2 coronary vessels or in the same vessel, using side-
to-side and end-to-side anastomoses. The naive vessel distal to the anastamotic site should 
be assessed and is recognized by its position and smaller caliber compared with the SVG 
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(Fig. 3, 4). Typically, venous grafts are larger than arterial grafts and are not accompanied by 
surgical clips along their course. Sometimes a circumferential clip can be identified at the 
site of proximal anastomosis with the ascending aorta (Fig.1). 
 
 
Fig. 2. Saphenous vein grafts. Three-dimensional volume-rendered images show the typical 
appearance of right (arrow) and left (arrowhead) saphenous vein grafts (SVGs) sutured to 
the anterior aorta. The right SVG is attached to the mid-portion of left anterior descending 




Fig. 3. Saphenous vein graft. Three-dimensional volume-rendered images show the left 
saphenous vein graft (SVG) with its anastomosis with the left circumflex (LCx) artery.    
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Fig. 4. Saphenous vein graft. Three-dimensional volume-rendered images show the left 
saphenous vein graft (SVG), which is attached to the mid-portion of left anterior descending 
(LAD) artery.    
3.2 Internal Mammary Artery (IMA) 
The internal mammary artery (IMA) is characterized by unique resistance to atherosclerosis 
and extremely high long-term patency rates compared with the saphenous vein. The IMA 
has a nonfenestrated internal elastic lamina without vaso vasorum inside the vessel wall, 
which tends to protect against cellular migration and intimal hyperplasia. Moreover, the 
medial layer of IMA is thin and poor of muscle cells with poor vasoreactivity. In addition, 
the endothelium produces vasodilator (nitric oxide) and platelet inhibitor (prostacyclin). 
Glycosaminoglycan and lipid compositions of IMA result in being less atherogenetic in 
comparison with venous grafts. Therefore, use of the IMA decreases all postoperative 
cardiac events and mortality, and is associated with a long-term patency rate well >90% at 
10 years (Loop et al., 1986; Motwani & Topol, 1998).  
3.2.1 Left IMA 
The Left IMA (LIMA) is the vessel of choice for the surgical revascularization of the left 
anterior descending (LAD) artery for its biological and anatomical characteristiscs, being the 
conduit more proximal to the LAD artery and the easiest to harvest both in median 
sternotomy and mini-thoracotomy. Due to anatomical proximity to the LAD artery and 
favorable patency rates, the left IMA (LIMA) is most commonly used as an in situ graft to 
revascularize the LAD or diagonal artery, supplying the anterior or anterolateral cardiac 
wall. The LIMA extends from its origin at the subclavian artery and courses through the 
anterior mediastinum along the right ventricle outflow tract (RVOT) after being separated 
surgically from its original position in the left parasternal Region (Fig. 5). 
Infrequently, sequential distal anastomoses, with side-to-side and end-to-side anastomoses 
to the diagonal and LAD arteries, respectively, or involving separate sections of the LAD 
artery, are performed. On axial images, the LIMA is no longer visible in its usual site, on the 
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(Fig. 3, 4). Typically, venous grafts are larger than arterial grafts and are not accompanied by 
surgical clips along their course. Sometimes a circumferential clip can be identified at the 
site of proximal anastomosis with the ascending aorta (Fig.1). 
 
 
Fig. 2. Saphenous vein grafts. Three-dimensional volume-rendered images show the typical 
appearance of right (arrow) and left (arrowhead) saphenous vein grafts (SVGs) sutured to 
the anterior aorta. The right SVG is attached to the mid-portion of left anterior descending 




Fig. 3. Saphenous vein graft. Three-dimensional volume-rendered images show the left 
saphenous vein graft (SVG) with its anastomosis with the left circumflex (LCx) artery.    
Assessment of Coronary Artery Bypass Graft (CABG) Patency 
and Graft Disease Using Multidetector Computed Tomography (MDCT) 167 
Fig. 4. Saphenous vein graft. Three-dimensional volume-rendered images show the left 
saphenous vein graft (SVG), which is attached to the mid-portion of left anterior descending 
(LAD) artery.    
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sternotomy and mini-thoracotomy. Due to anatomical proximity to the LAD artery and 
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to the diagonal and LAD arteries, respectively, or involving separate sections of the LAD 
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Fig. 5. Left internal mammary artery (IMA) graft. Three-dimensional volume-rendered 
images show the left IMA graft from its origin at the left subclavian artery to its anastomosis 
with the left anterior descending (LAD) artery. There is also a left saphenous vein graft 
(SVG), which is attached to the obtuse marginal (OM) artery. Note the smaller diameter of 





Fig. 6. Left internal mammary artery (IMA) graft. Three-dimensional volume-rendered 
images show the left IMA graft from its origin at the left subclavian artery to its anastomosis 
with the left anterior descending (LAD) artery. There is also a right saphenous vein graft 
(SVG) sutured to the anterior aorta with its anastomosis with the posterior descending 
artery (PDA). The left saphenous vein grafts (SVG) are attached to diagonal artery and the 
obtuse marginal (OM) artery.  
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left side of the sternum, but courses as a small vessel in the anterior mediastinum along the 
right ventricle outflow tract (RVOT). Although in most cases LIMA grafts show a single 
distal anastomosis to the left anterior descending artery (LAD) or a diagonal branch, 
multiple sequential anastomoses to both the LAD and diagonal branches are sometimes 
performed. Surgical clips are routinely used to occlude collaterals and to avoid arterial 
bleeding and can be seen either adjacent to the graft or at the original site of the LIMA. As 
with other grafts, on CTA, the distal anastamosis is typically most difficult to visualize. 
Surgical clips are used routinely to occlude branch vessels of the IMA, and metallic artifact 
may limit assessment in some instances (Fig. 6).  
3.2.2 Right IMA 
The right IMA (RIMA) is used less frequently than the LIMA. The RIMA may be used in a 
variety of ways. As an in situ graft, The RIMA remains attached to the right subclavian 
artery proximally and anastomoses with the target coronary artery distally. However, it is 
more commonly used as “free” graft from the ascending aorta to the RCA or from the LIMA 
to the left circumflex artery (LCx) or obtuse marginal (OM) branches. In cases in which both 
in situ IMAs are necessary for revascularization of the left heart, either the RIMA is 
connected to the LCx artery or OM branches by extension through the transverse sinus of 
the pericardium and the LIMA is attached to the LAD artery or the RIMA is attached to the 
LAD artery and the LIMA is anastomosed to the LCx artery or other side branches (OM or 
diagnonal branches). Otherwise, the RIMA can be removed from the right subclavian artery 
and used as a composite or free graft. As a segment of a composite graft to perform an 
arterial "T" or "Y" graft, the RIMA is anastomosed proximally to LIMA, allowing total 
arterial revascularization instead of using a venous graft with LIMA. As a free graft, a RIMA 
is anastomosed to the anterior ascending aorta and used in the same way as an SVG. The 
CTA appearance of the RIMA is similar to that of the LIMA. As already described for LIMA 
grafts, surgical clips are used to occlude collaterals. Studies have shown that total arterial 
myocardial revascularzation has the advantages of decreased recurrent angina and superior 
patency rates at 1 year when compared with those of conventional coronary artery bypass 
surgery in which a LIMA graft is coupled with an SVG (Muneretto et al., 2003).  
3.3 Radial Artery (RA) 
The first use of the radial artery (RA) as arterial conduit for coronary revascularization has 
been de-scribed by Carpentier et al in 1971 (Carpentier et al., 1973). As a muscular artery 
from the forearm, the RA has a prominent medial layer and elevated vasoreactivity, which 
results in a lower patency rate than that of IMA grafts (Possati et al., 2003). The RA is 
usually harvested from the nondominant arm and is used as a third arterial graft, either as a 
free or composite graft or to avoid using a venous graft in case of unavailability of IMA 
grafts. The RA is often grafted to supply the left cardiac wall (LCx, OM). On CTA, the 
caliber of the RA is similar to the IMA, but it typically is visualized coursing from the 
ascending aorta to the naïve coronary artery (Fig. 7). In the early postoperative period, the 
RA may be reduced in caliber and may be difficult to identify because of vasospasm. In 
addition, because the RA is a muscular artery, the number of surgical clips used to close 
collaterals along the graft is usually higher than with IMA. This may represent a limit for 
noninvasive assessment of RA grafts with MDCT because of artifacts from surgical clips 
limiting a full CTA evaluation of an RA graft.  
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left side of the sternum, but courses as a small vessel in the anterior mediastinum along the 
right ventricle outflow tract (RVOT). Although in most cases LIMA grafts show a single 
distal anastomosis to the left anterior descending artery (LAD) or a diagonal branch, 
multiple sequential anastomoses to both the LAD and diagonal branches are sometimes 
performed. Surgical clips are routinely used to occlude collaterals and to avoid arterial 
bleeding and can be seen either adjacent to the graft or at the original site of the LIMA. As 
with other grafts, on CTA, the distal anastamosis is typically most difficult to visualize. 
Surgical clips are used routinely to occlude branch vessels of the IMA, and metallic artifact 
may limit assessment in some instances (Fig. 6).  
3.2.2 Right IMA 
The right IMA (RIMA) is used less frequently than the LIMA. The RIMA may be used in a 
variety of ways. As an in situ graft, The RIMA remains attached to the right subclavian 
artery proximally and anastomoses with the target coronary artery distally. However, it is 
more commonly used as “free” graft from the ascending aorta to the RCA or from the LIMA 
to the left circumflex artery (LCx) or obtuse marginal (OM) branches. In cases in which both 
in situ IMAs are necessary for revascularization of the left heart, either the RIMA is 
connected to the LCx artery or OM branches by extension through the transverse sinus of 
the pericardium and the LIMA is attached to the LAD artery or the RIMA is attached to the 
LAD artery and the LIMA is anastomosed to the LCx artery or other side branches (OM or 
diagnonal branches). Otherwise, the RIMA can be removed from the right subclavian artery 
and used as a composite or free graft. As a segment of a composite graft to perform an 
arterial "T" or "Y" graft, the RIMA is anastomosed proximally to LIMA, allowing total 
arterial revascularization instead of using a venous graft with LIMA. As a free graft, a RIMA 
is anastomosed to the anterior ascending aorta and used in the same way as an SVG. The 
CTA appearance of the RIMA is similar to that of the LIMA. As already described for LIMA 
grafts, surgical clips are used to occlude collaterals. Studies have shown that total arterial 
myocardial revascularzation has the advantages of decreased recurrent angina and superior 
patency rates at 1 year when compared with those of conventional coronary artery bypass 
surgery in which a LIMA graft is coupled with an SVG (Muneretto et al., 2003).  
3.3 Radial Artery (RA) 
The first use of the radial artery (RA) as arterial conduit for coronary revascularization has 
been de-scribed by Carpentier et al in 1971 (Carpentier et al., 1973). As a muscular artery 
from the forearm, the RA has a prominent medial layer and elevated vasoreactivity, which 
results in a lower patency rate than that of IMA grafts (Possati et al., 2003). The RA is 
usually harvested from the nondominant arm and is used as a third arterial graft, either as a 
free or composite graft or to avoid using a venous graft in case of unavailability of IMA 
grafts. The RA is often grafted to supply the left cardiac wall (LCx, OM). On CTA, the 
caliber of the RA is similar to the IMA, but it typically is visualized coursing from the 
ascending aorta to the naïve coronary artery (Fig. 7). In the early postoperative period, the 
RA may be reduced in caliber and may be difficult to identify because of vasospasm. In 
addition, because the RA is a muscular artery, the number of surgical clips used to close 
collaterals along the graft is usually higher than with IMA. This may represent a limit for 
noninvasive assessment of RA grafts with MDCT because of artifacts from surgical clips 
limiting a full CTA evaluation of an RA graft.  
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Fig. 7. Radial artery (RA) graft. (A) Three-dimensional volume-rendered image shows radial 
artery graft sutured to the anterior aorta with its anastomosis with diagonal artery. There 
are also left internal mammary artery (LIMA) graft from its origin at the left subclavian 
artery to its anastomosis with the left anterior descending (LAD) artery and right saphenous 
vein graft (SVG), which is attached to the distal right coronary artery (RCA). Note the 
diameter of the RA is similar to the IMA, but it typically is visualized coursing from the 
ascending aorta to the diagonal artery. (B) Curved multiplanar reformation image shows 
patent RA graft within the anterior mediastinum. The full extent of the graft is seen from the 
ascending aorta to diagonal artery.  
3.4 Right Gastroepiploic Artery (RGEA) and Inferior Epigastric Artery (IEA) 
The use of right gastroepiploic and inferior epigastric arteries in CABG procedures has been 
limited because of the need to extend the median sternotomy to expose the abdominal 
cavity (Buche et al., 1992; Manapat et al., 1994; Pym et al., 1987). Although the use of these 
arteries increases surgical time and technical difficulty of the surgery, these arteries can be 
used as a free graft to perform total arterial revascularization. The use of the RGEA was first 
described by Pym et al in June 1984 (Pym et al., 1987). Although it has been originally used 
in reoperation, in the absence of other suitable conduits, RGEA is now used as secondary, 
tertiary, or quaternary arterial conduit to provide all-arterial revascularization. The 
biological characteristics of RGEA are similar to IMA, but unclear benefits for third or fourth 
arterial grafts, the increment of surgery time, and the involvement of an additional body 
cavity are the main drawbacks limiting the widespread use of this conduit. Occasionally, the 
RGEA is used to supply the inferior cardiac wall and is anastomosed as an in situ graft to 
the posterior descending artery (PDA). In these cases, the mobilized artery is seen coursing 
anterior to the liver and through the diaphragm to reach the site of anastomosis. Small clips 
can be identified at the original site of the RGEA, near the small curvature of stomach. These 
instances require that the surgical history be conveyed to the radiologist so the CTA 
protocol can be modified to include the upper abdomen, because the gastroepiploic artery is 
freed to course anteriorly to the liver and through the diaphragm to reach the target vessel. 
The inferior epigastric artery (IEA) is an arterial branch of the abdominal wall, arising from 
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the external iliac artery and coursing inside the abdominal rectus muscle. Similar to the 
radial artery (RA), the IEA has a predominant muscular structure, while the limited length 
of the vessel with an adequate caliber is a constraint to using this vessel only as a lateral 
branch of a multiple arterial graft.  
4. Planning percutaneous intervention (PCI) or repeat surgery of bypass graft  
As medical and surgical treatments for coronary artery disease have improved, patients are 
living longer. Consequently, PCI or second CABG operations have become more common. 
Sometimes, because the proximal anastomosis of the bypass grafts with the aorta is 
occluded or severe stenotic, visualization of bypass grafts is difficult or impossible with 
invasive coronary angiography, and if it is possible, the radiation dose must be increased for 
visualization of the grafts and naive vessels. MDCT is emerging as a useful tool of mapping 
the course of bypass grafts before PCI (Dikkers et al., 2007; Hecht & Roubin, 2007; Song et 
al., 2010). Three-dimentional volume-rendered images with computer software delineate 
relationships between the aorta, naïve arteries, and bypass grafts. Figure 8 (Song et al., 2010) 
is an example of successful PCI for occluded coronary artery bypass grafts with the aid of 
MDCT. A 68-year-old man was admitted to our hospital with severe exertional chest pain of 
2 months duration. He had been diagnosed with unstable angina 2 years earlier. At that 
time, coronary angiography had revealed severe 3-vessel disease with diffuse 50% stenosis 
from the distal portion of the left main coronary artery to the left anterior descending 
coronary artery (LAD), diffuse 90% stenosis of the left circumflex artery, and total occlusion 
of the obtuse marginal (OM) branches and proximal right coronary artery. Subsequently, 
CABG had been performed using left internal mammary artery to the LAD, saphenous vein 
for aorta-diagonal-OM1-OM2 grafts, and free right internal mammary artery to the posterior 
descending coronary artery. In invasive coronary angiography, the left internal mammary 
artery-to-LAD graft was patent, but no aortic ostium could be seen despite repeated 
attempts with various catheters and aortography. Because conventional angiography failed 
to visualize the grafts, we examined the feasibility of a PCI using 64-slice MDCT. The aortic 
graft anastomosis was totally occluded, but there was no vessel wall calcification. All 
grafted vessels could be identified. Based on these findings, a successful second-stage PCI 
was performed. Injury to a preexisting left IMA graft at sternal reentry is a well-recognized 
risk in second CABG surgery (Fullerton et al., 1994; Gillinov et al., 1999). MDCT is emerging 
as a useful means of mapping the course of a left IMA graft before repeat surgery (Gilkeson 
et al., 2003; Ohtsuka et al., 2000). Three-dimensional volume-rendered images delineate 
relationships between the sternum, ribs, and bypass grafts, thereby minimizing the risk of 
injury to the graft vessel during surgical reentry. Understanding the sternal proximity of 
preexisting bypass grafts, as well as normal structures including the aorta, pulmonary 
artery, and naïve coronary arteries, allows the surgeon to plan an appropriate surgical 
approach. 
5. Complication
5.1 Graft failure 
Bypass graft failures are classified either as early or late following CABG surgery. During 
the early phase, usually within 1 month after CABG surgery, the most common cause of 
graft failure is thrombosis from platelet dysfunction at the site of focal endothelial damage 
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Fig. 7. Radial artery (RA) graft. (A) Three-dimensional volume-rendered image shows radial 
artery graft sutured to the anterior aorta with its anastomosis with diagonal artery. There 
are also left internal mammary artery (LIMA) graft from its origin at the left subclavian 
artery to its anastomosis with the left anterior descending (LAD) artery and right saphenous 
vein graft (SVG), which is attached to the distal right coronary artery (RCA). Note the 
diameter of the RA is similar to the IMA, but it typically is visualized coursing from the 
ascending aorta to the diagonal artery. (B) Curved multiplanar reformation image shows 
patent RA graft within the anterior mediastinum. The full extent of the graft is seen from the 
ascending aorta to diagonal artery.  
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limited because of the need to extend the median sternotomy to expose the abdominal 
cavity (Buche et al., 1992; Manapat et al., 1994; Pym et al., 1987). Although the use of these 
arteries increases surgical time and technical difficulty of the surgery, these arteries can be 
used as a free graft to perform total arterial revascularization. The use of the RGEA was first 
described by Pym et al in June 1984 (Pym et al., 1987). Although it has been originally used 
in reoperation, in the absence of other suitable conduits, RGEA is now used as secondary, 
tertiary, or quaternary arterial conduit to provide all-arterial revascularization. The 
biological characteristics of RGEA are similar to IMA, but unclear benefits for third or fourth 
arterial grafts, the increment of surgery time, and the involvement of an additional body 
cavity are the main drawbacks limiting the widespread use of this conduit. Occasionally, the 
RGEA is used to supply the inferior cardiac wall and is anastomosed as an in situ graft to 
the posterior descending artery (PDA). In these cases, the mobilized artery is seen coursing 
anterior to the liver and through the diaphragm to reach the site of anastomosis. Small clips 
can be identified at the original site of the RGEA, near the small curvature of stomach. These 
instances require that the surgical history be conveyed to the radiologist so the CTA 
protocol can be modified to include the upper abdomen, because the gastroepiploic artery is 
freed to course anteriorly to the liver and through the diaphragm to reach the target vessel. 
The inferior epigastric artery (IEA) is an arterial branch of the abdominal wall, arising from 
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the external iliac artery and coursing inside the abdominal rectus muscle. Similar to the 
radial artery (RA), the IEA has a predominant muscular structure, while the limited length 
of the vessel with an adequate caliber is a constraint to using this vessel only as a lateral 
branch of a multiple arterial graft.  
4. Planning percutaneous intervention (PCI) or repeat surgery of bypass graft  
As medical and surgical treatments for coronary artery disease have improved, patients are 
living longer. Consequently, PCI or second CABG operations have become more common. 
Sometimes, because the proximal anastomosis of the bypass grafts with the aorta is 
occluded or severe stenotic, visualization of bypass grafts is difficult or impossible with 
invasive coronary angiography, and if it is possible, the radiation dose must be increased for 
visualization of the grafts and naive vessels. MDCT is emerging as a useful tool of mapping 
the course of bypass grafts before PCI (Dikkers et al., 2007; Hecht & Roubin, 2007; Song et 
al., 2010). Three-dimentional volume-rendered images with computer software delineate 
relationships between the aorta, naïve arteries, and bypass grafts. Figure 8 (Song et al., 2010) 
is an example of successful PCI for occluded coronary artery bypass grafts with the aid of 
MDCT. A 68-year-old man was admitted to our hospital with severe exertional chest pain of 
2 months duration. He had been diagnosed with unstable angina 2 years earlier. At that 
time, coronary angiography had revealed severe 3-vessel disease with diffuse 50% stenosis 
from the distal portion of the left main coronary artery to the left anterior descending 
coronary artery (LAD), diffuse 90% stenosis of the left circumflex artery, and total occlusion 
of the obtuse marginal (OM) branches and proximal right coronary artery. Subsequently, 
CABG had been performed using left internal mammary artery to the LAD, saphenous vein 
for aorta-diagonal-OM1-OM2 grafts, and free right internal mammary artery to the posterior 
descending coronary artery. In invasive coronary angiography, the left internal mammary 
artery-to-LAD graft was patent, but no aortic ostium could be seen despite repeated 
attempts with various catheters and aortography. Because conventional angiography failed 
to visualize the grafts, we examined the feasibility of a PCI using 64-slice MDCT. The aortic 
graft anastomosis was totally occluded, but there was no vessel wall calcification. All 
grafted vessels could be identified. Based on these findings, a successful second-stage PCI 
was performed. Injury to a preexisting left IMA graft at sternal reentry is a well-recognized 
risk in second CABG surgery (Fullerton et al., 1994; Gillinov et al., 1999). MDCT is emerging 
as a useful means of mapping the course of a left IMA graft before repeat surgery (Gilkeson 
et al., 2003; Ohtsuka et al., 2000). Three-dimensional volume-rendered images delineate 
relationships between the sternum, ribs, and bypass grafts, thereby minimizing the risk of 
injury to the graft vessel during surgical reentry. Understanding the sternal proximity of 
preexisting bypass grafts, as well as normal structures including the aorta, pulmonary 
artery, and naïve coronary arteries, allows the surgeon to plan an appropriate surgical 
approach. 
5. Complication
5.1 Graft failure 
Bypass graft failures are classified either as early or late following CABG surgery. During 
the early phase, usually within 1 month after CABG surgery, the most common cause of 
graft failure is thrombosis from platelet dysfunction at the site of focal endothelial damage 
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Fig. 8. Coronary artery graft dilatation aided by multidector computed tomography. (A) In 
invasive coronary angiography, aortic ostium of saphenous vein graft (SVG) could not be 
seen despite repeated attempts with various catheters and aortography. (B) Curved 
multiplanar reformation image and three-dimensional volume-rendered image showed the 
aortic graft anastomosis of saphenous vein graft (SVG) was totally occluded. There was also 
a patent left internal mammary artery (LIMA) graft from its origin at the left subclavian 
artery to its anastomosis with the left anterior descending (LAD) artery. (C) Based on these 
64-MDCT findings, a second-stage percutaneous coronary intervention (PCI) was performed 
successfully. Note that 64-MDCT is a useful tool for visualizing bypass graft in a selected 
group of patients with failed angiography for graft assessment. 
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during surgical harvesting and anastomosis. Graft closure from thrombosis at 1 month is a 
recognized complication in 10-15% of cases (Fitzgibbon et al., 1996).  Perioperative venous 
graft failure after off-pump CABG procedures is chiefly determined by the two factors of 
graft endothelial damage and patient hypercoagulability. Early bypass graft failure can also 
be due to a malpositioned graft (Ricci et al., 2000). If the graft is too long, it may twist or 
kink. Technical factors associated with use of an aortic connector may predispose venous 
 
Fig. 9. Acute occlusion of saphenous vein graft (SVG). (A) Invasive coronary angiography 
showed the proximal-portion of saphenous vein graft (SVG) was severely occluded with 
thrombi. (B) After successful percutaneous coronary intervention (PCI), invasive coronary 
angiography showed the proximal-portion of saphenous vein graft (SVG) with stenting was 
patent. (C, D) At 6-month follow-up, three-dimensional volume-rendered image showed the 
proximal-portion of saphenous vein graft (SVG) with stenting was still patent. Note that the 
findings of invasive coronary angiography is similar to those of three-dimensional volume-
rendered images of 64-MDCT. The figures also demonstrate that 64-MDCT has a useful role 
to follow-up of patients who have undergone percutaneous intervention for bypass graft 
stenosis and occlusion.  
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Fig. 10. Chronic occlusion of left saphenous vein graft (SVG). (A, left panel) Immediate after 
CABG surgery, three-dimensional volume-rendered image showed that left saphenous vein 
graft (SVG) was patent with its anastomsis to the mid-portion of left anterior descending 
(LAD) artery. There was a patent right saphenous vein graft (SVG), which was attached to 
the distal-portion of right coronary artery (RCA). (A, right panel) At 8 months after CABG 
surgery, three-dimensional volume-rendered image showed severe stenosis at proximal-
portion of left saphenous vein graft (SVG), which was attached to the mid-portion of left 
anterior descending (LAD) artery. Right saphenous vein graft (SVG) was still patent despite 
the graft had diffuse mild narrowing from proximal anastomosis site to distal anastomosis 
site. (B) Invasive coronary angiography showed the proximal-portion of left saphenous vein 
graft (SVG) was severely occluded. (C) Percutaneous coronary intervention was performed 
successfully. Note that the findings of invasive coronary angiography is similar to those of 
three-dimensional volume-rendered images of 64-MDCT. 
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Fig. 11. Chronic occlusion of right saphenous vein graft (SVG). (A, B) Three-dimensional 
volume-rendered image showed severe stenosis at mid-portion of right saphenous vein 
(SVG) graft, which is attached to the distal right coronary artery artery (RCA). Radial artery 
(RA) and left internal mammary artery (LIMA) grafts were patent. (C) Invasive coronary 
angiography showed the mid-portion of right saphenous vein (SVG) graft was severely 
occluded. (D) Percutaneous coronary intervention was performed successfully. Note that 
the findings of invasive coronary angiography is similar to those of three-dimensional 
volume-rendered images of 64-MDCT. 
grafts to kinking (Traverse et al., 2003). Late-phase venous graft failure is due primarily to 
progressive changes related to systemic blood pressure exposure. One month after surgery, 
the venous graft starts to undergo neointimal hyperplasia. Although this process does not 
produce significant stenosis, it is the foundation for later development of graft atheroma. 
Beyond 1 year, atherosclerosis is the dominant process, resulting in graft stenosis and 
occlusion. On the other hand, arterial grafts, specifically IMA graft, are resistant to atheroma 
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Fig. 10. Chronic occlusion of left saphenous vein graft (SVG). (A, left panel) Immediate after 
CABG surgery, three-dimensional volume-rendered image showed that left saphenous vein 
graft (SVG) was patent with its anastomsis to the mid-portion of left anterior descending 
(LAD) artery. There was a patent right saphenous vein graft (SVG), which was attached to 
the distal-portion of right coronary artery (RCA). (A, right panel) At 8 months after CABG 
surgery, three-dimensional volume-rendered image showed severe stenosis at proximal-
portion of left saphenous vein graft (SVG), which was attached to the mid-portion of left 
anterior descending (LAD) artery. Right saphenous vein graft (SVG) was still patent despite 
the graft had diffuse mild narrowing from proximal anastomosis site to distal anastomosis 
site. (B) Invasive coronary angiography showed the proximal-portion of left saphenous vein 
graft (SVG) was severely occluded. (C) Percutaneous coronary intervention was performed 
successfully. Note that the findings of invasive coronary angiography is similar to those of 
three-dimensional volume-rendered images of 64-MDCT. 
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Fig. 11. Chronic occlusion of right saphenous vein graft (SVG). (A, B) Three-dimensional 
volume-rendered image showed severe stenosis at mid-portion of right saphenous vein 
(SVG) graft, which is attached to the distal right coronary artery artery (RCA). Radial artery 
(RA) and left internal mammary artery (LIMA) grafts were patent. (C) Invasive coronary 
angiography showed the mid-portion of right saphenous vein (SVG) graft was severely 
occluded. (D) Percutaneous coronary intervention was performed successfully. Note that 
the findings of invasive coronary angiography is similar to those of three-dimensional 
volume-rendered images of 64-MDCT. 
grafts to kinking (Traverse et al., 2003). Late-phase venous graft failure is due primarily to 
progressive changes related to systemic blood pressure exposure. One month after surgery, 
the venous graft starts to undergo neointimal hyperplasia. Although this process does not 
produce significant stenosis, it is the foundation for later development of graft atheroma. 
Beyond 1 year, atherosclerosis is the dominant process, resulting in graft stenosis and 
occlusion. On the other hand, arterial grafts, specifically IMA graft, are resistant to atheroma 
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development. Late IMA graft failure is more commonly due to progression of 
atherosclerotic disease in the native coronary artery distal to the graft anastomosis. CTA can 
delineate multiple findings associated with graft stenosis and occlusion. Calcified and 
noncalcified atherosclerotic plaque is readily identified, and the calculation of the extent of 
graft narrowing is straightforward. Occlusion can be determined by non-visualization of a 
vessel which is known to have been used for surgical grafting. In many instances, the most 
proximal part of an occluded aortocoronary graft fills with contrast, creating a small out-
pouching from the ascending aorta, allowing a diagnosis. Acute or chronic graft occlusion 
can sometimes be differentiated by the diameter of the bypass graft. In chronic occlusion, 
the diameter is usually reduced from scarring, as compared with acute occlusion in which 
the diameter is usually enlarged (Fig. 9, 10, 11). 
5.2 Graft vasospasm  
Radial artery (RA) grafts are susceptible to vasospasm because the RA is a muscular artery 
with elevated vasoreactivity. The appearance is similar to fixed graft stenosis, although the 
luminal narrowing is more extensive in length. Nevertheless, the administration of 
intraoperative alpha-adrenergic antagonist solution or posteroperative calcium channel 
blockers can overcome many cases of graft vasospasm postoperatively (Locker et al., 2002; 
Myers & Fremes, 2003).  
5.3 Graft aneurysm  
There are 2 types of bypass graft aneurysms: true aneurysms and pseudoaneurysms (Dubois 
& Vandervoort, 2001; Mohara et al., 1998). True aneuryms are usually found 5 to 7 years 
after CABG surgery and are related to atherosclerotic disease. On the other hand, 
pseudoaneuryms more commonly occur within 6 months after surgery, although they may 
also arise several years later. Pseudoaneurysms arise at either proximal or distal anastomotic 
sites. Pseudoaneurysm cases that are found earlier may be related to infection or tension at 
the anastomotic site, resulting in suture rupture. In late-onset pseudoaneurysms, similar to 
true aneurysms, atherosclerotic changes likely played a role. Currently, there is no clear 
guideline for surgery. Nevertheless, size >2 cm has been a cause for concern (Memon et al., 
2003). Graft aneurysms may lead to various complications, including compression and mass 
effect on adjacent structures, thrombosis and embolization of the bypass graft leading to an 
acute coronary event, formation of fistula to the right atrium and ventricle, sudden rupture 
leading to hemothorax, hemopericardium, or death. 
5.4 Pericardial and pleural effusions
Approximately 22%-85% of patients have postoperative pericardial effusions after CABG 
surgery (Meurin et al., 2004; Pepi et al., 1994). Although pericardial effusions are common, 
only 0.8%-6% of patients progress to cardiac temponade (Katara et al., 2003). Risk factors 
include postoperative coagulation abnormality or use of anticoagulation agents that are 
often related to the use of cardiopulmonary bypass. Nearly all significant pericardial 
effusions are diagnosed within 5 days postoperatively, peak in 10 days, and resolve within a 
month (Kuvin et al., 2002). Postoperative pleural effusions are even more numerous after 
surgery, a prevalence of 89% within 7 days after surgery (Hurlbut et al., 1990; Vargas et al., 
1994). These pleural effusions are usually unilateral, small, left-sided, and without clinical 
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significance. Only 1%-4% of CABG surgery patients proceed to develop clinically significant 
effusions that require thoracentesis (Peng et al., 1992).  
5.5 Sternal infection  
The sternal infection is an important complication of the CABG surgery, with a prevalence 
of 1% to 20% (Roy, 1998). Three different compartments may be affected: the presternal 
(cellulitis, sinus tracts, and abscess), sternal (osteomyelitis, and dehiscence), or retrosternal 
(mediastinitis, hematoma, and abscess) compartments (Li & Fishman, 2003). Risk factors 
include diabetes mellitus, obesity, current cigarette smoking, and steroid therapy. Surgical 
risk factors include complexity of surgery, type of bone saw used, type of sternal closure, 
length of surgical time, blood transfusions, and early reexploration to control hemorrhage. 
The CTA is important in revealing the extent and depth of infection, which, in turn, will 
help guide treatment planning. Usually, the preservation of mediastinal fat planes in CTA 
excludes surgical intervention. On the other hand, obliteration of mediastinal fat planes and 
diffuse soft tissue infiltration without or with gas collection, or low-density fluid collections 
within the mediastinum, are concerning for sternal infection. Recently published studies 
reported a 1-year mortality rate of approximately 22% (Loop et al., 1986; Sarr et al., 1984). 
5.6 Pulmonary embolism 
Clinical diagnosis of deep vein thrombosis and pulmonary embolism may be especially 
challenging because postoperative atelectasis, pleural effusion, or fluid overload may all 
contribute to the development of chest pain and dyspnea after CABG surgery. A recent 
report regarding pulmonary embolism in the post-CABG surgery population showed an 
overall prevalence of 23% for deep vein thrombosis by 1 week after surgery, with less than 
2% of these cases identified clinically (Shammas, 2000).  
5.7 Incidental findings  
Although the intent of CTA after CABG surgery is to assess bypass graft patency and 
surgical complications, incidental findings are also frequently detected. In a recent study, 
13.1% of patients in the immediate postoperative period had unsuspected noncardiac 
findings, including pulmonary embolism, pulmonary nodules, pneumonia, mucous 
plugging, and pneumothorax. (Mueller et al., 2007) Therefore, radiologists need to be aware 
of clinically significant findings with possible life-threatening consequences.  
6. Conclusions 
In recent years, MDCT with retrospective ECG gating has gained rapid acceptance as a 
diagnostic cardiac imaging modality, allowing assessment of coronary bypass graft patency 
with high spatial resolution. This tool could play an important role in patients with 
recurrence of chest pain or with unclear stress test results after myocardial revascularization 
surgery. Furthermore, the newest technological development of the CT scanner could 
strengthen the role of MDCT before percutaneous intervention of occluded or stenotic 
grafts, allowing the consensual assessment of occluded or stenotic bypass grafts which are 
difficult or impossible to be visualized with invasive coronary angiography. Therefore, it is 
crucial that cardiologists and radiologists understand CABG anatomy with knowledge of 
the type and number of bypass grafts used during myocardial revascularization surgery. 
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development. Late IMA graft failure is more commonly due to progression of 
atherosclerotic disease in the native coronary artery distal to the graft anastomosis. CTA can 
delineate multiple findings associated with graft stenosis and occlusion. Calcified and 
noncalcified atherosclerotic plaque is readily identified, and the calculation of the extent of 
graft narrowing is straightforward. Occlusion can be determined by non-visualization of a 
vessel which is known to have been used for surgical grafting. In many instances, the most 
proximal part of an occluded aortocoronary graft fills with contrast, creating a small out-
pouching from the ascending aorta, allowing a diagnosis. Acute or chronic graft occlusion 
can sometimes be differentiated by the diameter of the bypass graft. In chronic occlusion, 
the diameter is usually reduced from scarring, as compared with acute occlusion in which 
the diameter is usually enlarged (Fig. 9, 10, 11). 
5.2 Graft vasospasm  
Radial artery (RA) grafts are susceptible to vasospasm because the RA is a muscular artery 
with elevated vasoreactivity. The appearance is similar to fixed graft stenosis, although the 
luminal narrowing is more extensive in length. Nevertheless, the administration of 
intraoperative alpha-adrenergic antagonist solution or posteroperative calcium channel 
blockers can overcome many cases of graft vasospasm postoperatively (Locker et al., 2002; 
Myers & Fremes, 2003).  
5.3 Graft aneurysm  
There are 2 types of bypass graft aneurysms: true aneurysms and pseudoaneurysms (Dubois 
& Vandervoort, 2001; Mohara et al., 1998). True aneuryms are usually found 5 to 7 years 
after CABG surgery and are related to atherosclerotic disease. On the other hand, 
pseudoaneuryms more commonly occur within 6 months after surgery, although they may 
also arise several years later. Pseudoaneurysms arise at either proximal or distal anastomotic 
sites. Pseudoaneurysm cases that are found earlier may be related to infection or tension at 
the anastomotic site, resulting in suture rupture. In late-onset pseudoaneurysms, similar to 
true aneurysms, atherosclerotic changes likely played a role. Currently, there is no clear 
guideline for surgery. Nevertheless, size >2 cm has been a cause for concern (Memon et al., 
2003). Graft aneurysms may lead to various complications, including compression and mass 
effect on adjacent structures, thrombosis and embolization of the bypass graft leading to an 
acute coronary event, formation of fistula to the right atrium and ventricle, sudden rupture 
leading to hemothorax, hemopericardium, or death. 
5.4 Pericardial and pleural effusions
Approximately 22%-85% of patients have postoperative pericardial effusions after CABG 
surgery (Meurin et al., 2004; Pepi et al., 1994). Although pericardial effusions are common, 
only 0.8%-6% of patients progress to cardiac temponade (Katara et al., 2003). Risk factors 
include postoperative coagulation abnormality or use of anticoagulation agents that are 
often related to the use of cardiopulmonary bypass. Nearly all significant pericardial 
effusions are diagnosed within 5 days postoperatively, peak in 10 days, and resolve within a 
month (Kuvin et al., 2002). Postoperative pleural effusions are even more numerous after 
surgery, a prevalence of 89% within 7 days after surgery (Hurlbut et al., 1990; Vargas et al., 
1994). These pleural effusions are usually unilateral, small, left-sided, and without clinical 
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significance. Only 1%-4% of CABG surgery patients proceed to develop clinically significant 
effusions that require thoracentesis (Peng et al., 1992).  
5.5 Sternal infection  
The sternal infection is an important complication of the CABG surgery, with a prevalence 
of 1% to 20% (Roy, 1998). Three different compartments may be affected: the presternal 
(cellulitis, sinus tracts, and abscess), sternal (osteomyelitis, and dehiscence), or retrosternal 
(mediastinitis, hematoma, and abscess) compartments (Li & Fishman, 2003). Risk factors 
include diabetes mellitus, obesity, current cigarette smoking, and steroid therapy. Surgical 
risk factors include complexity of surgery, type of bone saw used, type of sternal closure, 
length of surgical time, blood transfusions, and early reexploration to control hemorrhage. 
The CTA is important in revealing the extent and depth of infection, which, in turn, will 
help guide treatment planning. Usually, the preservation of mediastinal fat planes in CTA 
excludes surgical intervention. On the other hand, obliteration of mediastinal fat planes and 
diffuse soft tissue infiltration without or with gas collection, or low-density fluid collections 
within the mediastinum, are concerning for sternal infection. Recently published studies 
reported a 1-year mortality rate of approximately 22% (Loop et al., 1986; Sarr et al., 1984). 
5.6 Pulmonary embolism 
Clinical diagnosis of deep vein thrombosis and pulmonary embolism may be especially 
challenging because postoperative atelectasis, pleural effusion, or fluid overload may all 
contribute to the development of chest pain and dyspnea after CABG surgery. A recent 
report regarding pulmonary embolism in the post-CABG surgery population showed an 
overall prevalence of 23% for deep vein thrombosis by 1 week after surgery, with less than 
2% of these cases identified clinically (Shammas, 2000).  
5.7 Incidental findings  
Although the intent of CTA after CABG surgery is to assess bypass graft patency and 
surgical complications, incidental findings are also frequently detected. In a recent study, 
13.1% of patients in the immediate postoperative period had unsuspected noncardiac 
findings, including pulmonary embolism, pulmonary nodules, pneumonia, mucous 
plugging, and pneumothorax. (Mueller et al., 2007) Therefore, radiologists need to be aware 
of clinically significant findings with possible life-threatening consequences.  
6. Conclusions 
In recent years, MDCT with retrospective ECG gating has gained rapid acceptance as a 
diagnostic cardiac imaging modality, allowing assessment of coronary bypass graft patency 
with high spatial resolution. This tool could play an important role in patients with 
recurrence of chest pain or with unclear stress test results after myocardial revascularization 
surgery. Furthermore, the newest technological development of the CT scanner could 
strengthen the role of MDCT before percutaneous intervention of occluded or stenotic 
grafts, allowing the consensual assessment of occluded or stenotic bypass grafts which are 
difficult or impossible to be visualized with invasive coronary angiography. Therefore, it is 
crucial that cardiologists and radiologists understand CABG anatomy with knowledge of 
the type and number of bypass grafts used during myocardial revascularization surgery. 
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1. Introduction 
Myocardial bridging(MB) is considered as a congenital condition. Usually, coronary artery 
runs through epicardially. Myocardial bridging occurs when a segment of a coronary artery 
or its major branch travels intramurally through the myocardium. The myocardium 
overlying the intramural segment of epicardial coronary artery is called a myocardial 
bridging, and the artery coursing within the myocardium is called a “tunneled artery”. It 
may dip into the myocardium for varying lengths. The mid portion of left anterior coronary 
artery has been reported as the most frequent site of myocardial bridges. This phenomenon 
was first described by Grainicianu in the early 1920s. In 1960, Portmann and Iwig first 
reported the radiological appearance of transient occlusion in a segment of the left anterior 
descending coronary artery during systole. A large discrepancy exists between pathological 
series, in which the incidence has varied from 15% to 85%, and angiographic series, in which 
it is reported as being between 0.51% and 2.5%. 
The clinical significance of MB is controversial. Myocardial bridging has been shown linking 
to clinical complications that include ischemia, acute coronary syndrome, coronary spasm, 
arrhythmia, and sudden death, although in the vast majority of cases, myocardial bridging 
remains clinically silent. 
Coronary angiography remains the current gold standard for diagnosing MB. Lower 
prevalence of myocardial bridging on coronary angiography may partly due to thin 
bridging. In addition, coronary angiography is an invasive technique with complications 
and risks. Until now, intravascular ultrasound (IVUS) is the most accurate method to 
diagnose MB. Intracoronary Doppler ultrasound (ICD) has also been used in the diagnosis 
of bridging. However, they are all invasive and expensive and not routinely used in 
clinical settings. Therefore, the need for a non-invasive technique for detection of bridging 
has emerged. While multi-detector computed tomography (MDCT) angiography is faster 
and more adequate, it has the ability to assess the course and the anatomic relationships 
of the coronary arteries. With the advent of high-resolution magnetic resonance imaging 
and shorter scan time, it will have a bright future for the reason of no contrast and 
radiation. 
In this paper, we will discuss the non-invasive method to detect myocardial bridging in 
comparison to invasive technique. 
Coronary Angiography 
– Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 182 
Song, B. G.; Choi, J. H.; Choi, S. M.; Park, J. H.; Park, Y. H. & Choe, Y. H. (2010). Coronary 
artery graft dilatation aided by multidetector computed tomography. Asian 
Cardiovascular and Thoracic Annals, Vol.18, No.2, (Feb 2010), pp. 177-179, ISSN 1816-
5370  
Tochii, M.; Takagi, Y.; Anno, H.; Hoshino, R.; Akita, K.; Kondo, H. & Ando, M. (2010). 
Accuracy of 64-slice multidetector computed tomography for diseased coronary 
artery graft detection. Annals of Thoracic Surgery, Vol.89, No.6, (Jun 2010), pp. 1906-
1911, ISSN 1552-6259  
Traverse, J. H.; Mooney, M. R.; Pedersen, W. R.; Madison, J. D.; Flavin, T. F.; Kshettry, V. R.; 
Henry, T. D.; Eales, F.; Joyce, L. D. & Emery, R. W. (2003). Clinical, angiographic, 
and interventional follow-up of patients with aortic-saphenous vein graft 
connectors. Circulation, Vol.108, No.4, (Jul 2003), pp. 452-456, ISSN 1524-4539  
Ueyama, K.; Ohashi, H.; Tsutsumi, Y.; Kawai, T.; Ueda, T. & Ohnaka, M. (1999). Evaluation 
of coronary artery bypass grafts using helical scan computed tomography. 
Catheterization and Cardiovascular Interventions, Vol.46, No.3, (Mar 1999), pp. 322-326, 
ISSN 1522-1946  
Vargas, F. S.; Cukier, A.; Hueb, W.; Teixeira, L. R. & Light, R. W. (1994). Relationship 
between pleural effusion and pericardial involvement after myocardial 
revascularization. Chest, Vol.105, No.6, (Jun 1994), pp. 1748-1752, ISSN 0012-3692  
Vembar, M.; Garcia, M. J.; Heuscher, D. J.; Haberl, R.; Matthews, D.; Bohme, G. E. & 
Greenberg, N. L. (2003). A dynamic approach to identifying desired physiological 
phases for cardiac imaging using multislice spiral CT. Medical Physics, Vol.30, No.7, 
(Jul 2003), pp. 1683-1693, ISSN 0094-2405 
Wiklund, L.; Bugge, M. & Berglin, E. (2002). Angiographic results after the use of a 
sutureless aortic connector for proximal vein graft anastomoses. Annals of Thoracic 
Surgery, Vol.73, No.6, (Jun 2002), pp. 1993-1994, ISSN 0003-4975  
10 
Detection Myocardial Bridging 
Using Non-Invasive Technique 
Junbo Ge and Jianying Ma 
Shanghai Institute of Cardiovascular Diseases 
Zhongshan Hospital, Fudan University 
China 
1. Introduction 
Myocardial bridging(MB) is considered as a congenital condition. Usually, coronary artery 
runs through epicardially. Myocardial bridging occurs when a segment of a coronary artery 
or its major branch travels intramurally through the myocardium. The myocardium 
overlying the intramural segment of epicardial coronary artery is called a myocardial 
bridging, and the artery coursing within the myocardium is called a “tunneled artery”. It 
may dip into the myocardium for varying lengths. The mid portion of left anterior coronary 
artery has been reported as the most frequent site of myocardial bridges. This phenomenon 
was first described by Grainicianu in the early 1920s. In 1960, Portmann and Iwig first 
reported the radiological appearance of transient occlusion in a segment of the left anterior 
descending coronary artery during systole. A large discrepancy exists between pathological 
series, in which the incidence has varied from 15% to 85%, and angiographic series, in which 
it is reported as being between 0.51% and 2.5%. 
The clinical significance of MB is controversial. Myocardial bridging has been shown linking 
to clinical complications that include ischemia, acute coronary syndrome, coronary spasm, 
arrhythmia, and sudden death, although in the vast majority of cases, myocardial bridging 
remains clinically silent. 
Coronary angiography remains the current gold standard for diagnosing MB. Lower 
prevalence of myocardial bridging on coronary angiography may partly due to thin 
bridging. In addition, coronary angiography is an invasive technique with complications 
and risks. Until now, intravascular ultrasound (IVUS) is the most accurate method to 
diagnose MB. Intracoronary Doppler ultrasound (ICD) has also been used in the diagnosis 
of bridging. However, they are all invasive and expensive and not routinely used in 
clinical settings. Therefore, the need for a non-invasive technique for detection of bridging 
has emerged. While multi-detector computed tomography (MDCT) angiography is faster 
and more adequate, it has the ability to assess the course and the anatomic relationships 
of the coronary arteries. With the advent of high-resolution magnetic resonance imaging 
and shorter scan time, it will have a bright future for the reason of no contrast and 
radiation. 
In this paper, we will discuss the non-invasive method to detect myocardial bridging in 
comparison to invasive technique. 
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The prevalence varies substantially among different studies. It was higher at autopsy 
studies than conventional coronary angiographical studies. The incidence of myocardial 
bridging among postmortem studies had been reported from 5% to 86%[1-11]. However, the 
prevalence of myocardial bridging among patients with conventional coronary angiography 
varied from 0.5% to 33%[12-27]. The discrepancy may be partly due to that the compression 
during systole is little and lack of provocation with nitroglycerin at the time of angiography. 
In a large cohort study of Chinese patients, myocardial bridging is up to 16.1% after 
intracoronary nitroglycerin [27]. It was reported that the incidence of myocardial bridging 
may be as high as 40% in patients with coronary angiography when positive inotropic 
medication but not nitroglycerin is used as prevocational agent[23]. Another reason may be 
partly due to that myocardial bridging does not always induce dynamic compression at 
conventional angiography. In that case, it is difficult to unmask the myocardial bridging at 
conventional angiography [28].  
 
 
Fig. 1. One case of myocardial bridging on conventional angiography. Compression of 
coronary artery during systolic occurs at the middle segment of left anterior descending 
artery(white arrow) and relaxation at diastolic phase. 
It was reported that myocardial bridging is higher in patients with heart transplant 
recipients. In 33% of 64 heart transplant patients, myocardial bridging is detected. The 
higher incidence might be related increased stiffness and hypertrophy of myocardium[20]. 
At the circumstance of myocardial hypertrophy, vigorous contraction facilities the detection 
of myocardial bridging. A higher prevalence of myocardial bridging had also been reported 
in patients with hypertrophy. Multiple sites of myocardial bridging may be occurred in 
patients with hypertrophic obstructive cardiomyopathy[29]. 
Most of myocardial bridging is occurred at the site of LAD. However, myocardial bridging 
of right coronary and left circumflex is reported not only at postmortem studies but also 
conventional angiographic studies[30]. The incidence of myocardial bridging at the site of 
LAD shows no difference at different age and sex[12]. 
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3. Classification of myocardial bridging 
At postmortem studies, Ferreira et al distinguished between two types of bridging: (1) 
superficial bridges (75% of cases) crossing the artery perpendicularly or at an acute angle 
toward the apex, and (2) muscle bundles arising from the right ventricular apical trabeculae 
(25% of cases) that cross the LAD transversely, obliquely, or helically before terminating in 
the interventricular septum[8]. 
Superficial or deep myocardial bridges form in utero at the time of cardiac development. In 
most individuals they do not cause symptoms but particularly in those with deep 
myocardial bridges, the anatomical relation of the myocardial fibers can distort the artery 
that can be identified angiographically. The possibility of myocardial bridges should be 
borne in mind in individuals with ischemia but no evidence of coronary atherosclerosis. 
Based on conventional angiography, myocardial bridging is classified as three groups 
according to the percentage of systolic compression of left anterior descending coronary 
artery. Systolic compression less than 50% was classified as group I. Systolic compression 
between 50% and 70% represented group II. Patients with systolic compression≥70% 
represented group III. [12]. 
Schwarz proposed a new MB classification for symptomatic patients with MB. Three types 
of myocardial bridging were divided. Type A indicates patients with MB with no objective 
signs of ischemia. MB was detected occasionally. Type B indicates patients with MB with 
objective signs of ischemia. Type C indicates patients with or without objective signs of 
ischemia and altered intracoronary hemodynamics (by QCA/CFR/intracoronary Doppler). 
The classification is of clinical importance since 5-year follow-up showed that type B 
responded well to beta-blockers or calcium channel antagonists [31]. 
Based on computed topography angiography(CTA), MB can be classified as three types. 
Type I is myocardial bridging with partial encasement as LAD being within the 
interventricular gorge and in direct contact with left ventricular myocardium. Type II is 
myocardial bridging with full encasement as LAD being surrounded by myocardium but  
 
 
Fig. 2. Schematic illustration of classification of MB at MDCT. At normal condition, coronary 
runs through the ventricular septal without contacting with myocardium(A). When the 
artery is closely contacting with septal myocardium without myocardium overlying it, it is 
classified as partial encasement(B). If there is myocardium overlying the artery, it is called 
full encasement(C and D, arrow indicates myocardium overlying coronary artery). The full 
encasement is further classified as overlying myocardium without measurable (less than 
0.7mm, C) and measurable type (D) [28]. 
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most individuals they do not cause symptoms but particularly in those with deep 
myocardial bridges, the anatomical relation of the myocardial fibers can distort the artery 
that can be identified angiographically. The possibility of myocardial bridges should be 
borne in mind in individuals with ischemia but no evidence of coronary atherosclerosis. 
Based on conventional angiography, myocardial bridging is classified as three groups 
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without measurable overlying myocardium. Type III is myocardial bridging with full 
encasement as LAD being surrounded by myocardium but with measurable overlying 
myocardium (>0.7mm) [28](Figure 2).  
4. Modern view of MB 
Usually, dynamic compression of myocardial bridging is caused by myocardium overlying 
tunneled artery. During systolic phase, contraction of myocardium induces stenosis of 
coronary artery, while coronary artery turns to normal because of the relaxation of 
myocardium during diastolic phase. However, recent study by Kim et al raised some new 
features on MB. They demonstrated that systolic compression does not always occur in 
segments with overlying muscle. Dynamic compression affects only one third of patients 
with overlying myocardium. The length of dynamic compression was longer than that of 
tunneled segment. It suggested that coronary artery entrapped within the interventricular 
gorge is the mechanism of dynamic compression [28].  
5. Mechanisms for atherosclerosis and ischemia 
Myocardial bridging is usually considered as a benign condition since coronary flow is 
maximal during diastole but not systole. However, frame by frame analysis of myocardial 
bridging at intrvascular ultrasound (IVUS), which half moon phenomenon is seen as new 
characteristic at IVUS, showed delayed relaxation during early diastole [32]. At the same time, 
studies with intracoronary Doppler in patients with myocardial bridging showed that a peak 
of high flow velocity was detected in early diastole [33-34]. The reason for this hemodynamic 
disturbance may be related to the pressure gradient between the proximal and distal segment 
of myocardial bridging. The lower shear stress may contribute to atherosclerosis at proximal 
segment of myocardial bridging, whereas higher shear stress may protect it from atherosclerosis 
at the tunneled segment of myocardial bridging, which is of interest to study [35].  
Also, those high pressure gradients ultimately increase local wall tension and subsequent 
endothelial dysfunction and atherosclerosis formation at the proximal segment. The extent 
of atherosclerosis is higher in the proximal segment of myocardial bridging than the 
tunneled segment is attributed to the higher expression of eNOS, ET-1 and ACE [36]. Recent 
study showed that properties of the MB enhance the development of atherosclerosis in the 
LAD proximal to the MB, resulting in MI[37]. Studies by MDCT showed that length and 
thickness of MB as well as MB location are associated with the formation of culprit lesions of 
LAD proximal to MB in MI. In myocardial infarction (MI) patients with culprit lesions in the 
LAD proximal to MB, MB length, MB thickness, and index of the length multiplied by 
thickness of MB were significantly greater than non-culprit group. The distance from the 
orifice of the left main trunk to MB entrance was anatomical significantly shorter [38]. It 
further supports the notion that anatomatical properties of MB are associated with 
atherosclerosis at proximal segment of MB.  
It demonstrated that coronary atherosclerosis is more pronounced and extended up toward 
to the coronary ostium. It suggests that myocardial bridging enhances the predisposition to 
coronary atherosclerosis and myocardial infarction. This novel anatomic risk factor for 
coronary atherosclerosis and myocardial infarction changes previous opinion that 
myocardial bridging is considered as a benign condition. Future studies must demonstrate 
not only the presence of bridging but also the disease stage and the presence of signs of 
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complicated lesions, which may be an even more pronounced hint of the anatomic risk 
factor for a acute coronary events.[39] 
Ischemia induced by myocardial bridging is related to several reasons. In addition to 
systolic compression and delayed diastolic relaxation, vasospasm of coronary artery may be 
another mechanism. The considerable delay in blood flow and reduced distal coronary 
pressure are presumed to impair coronary vasodilator reserve, which may induce ischemia 
in patients with myocardial bridging. Another reason for coronary ischemia may be related 
to coronary spasm, of which is stimulated by endothelial dysfunction of coronary artery. 
Coronary angina even myocardial infarction may occur in this situation.  
6. Detection of myocardial bridging using non-invasive method  
Multi-detector computed tomography (MDCT) 
Technique 
The heart is moving fast during computed tomography imaging. So it requires a higher 
temporal resolution and higher spatial resolution for visualization of coronary artery as well as 
myocardial bridging. Despite improvement of imaging acquisition of coronary artery, there is 
still some gap between coronary CT angiography and invasive coronary angiography. At 
normal condition, temporal resolution of MDCT((4-MDCT, 250 milliseconds; 16-MDCT, 183–
250 milliseconds; 64-MDCT, 165–210 milliseconds) is much more lower than that of invasive 
coronary angiography(<10 milliseconds). However, with dual source CT, the temporal 
resolution can be achieved less than 100 milliseconds, which eliminates the need for cardiac 
control before coronary CT angiography with beta-blockers. When beta-blockers is used before 
imaging acquisition, it may reduce the systole compression and decrease the detection rate of 
myocardial bridging. Furthermore, the use of dual source CT may manifest the milking effect, 
as shown in invasive coronary angiography. [40] 
7. Myocardial bridging on MDCT 
16-MDCT 
Although conventional coronary angiography is considered as golden standard for 
detecting myocardial bridging, other techniques are also used at clinical, including 
intravascular ultrasound and Doppler. However, they are all invasive method with much 
trauma and not cost-effectiveness. With the advance of multi-detector row spiral computed 
tomography(MDCT) and multiplanar reconstruction, coronary artery disease is possible to 
be visualized accurately and non-invasively.  
At the beginning, myocardial bridging is estimated about 22(3.5%) of the unselected 626 
patients with 16-MDCT scanners, 15(2.4%) at the middle segment of LAD, 5(0.8%) at the 
distal segment of LAD and 2(0.3%) at proximal segment of LAD. The length and depth of 
myocardial bridging is between 6 and 22 mm (mean, 17mm) and between 1.2 and 3.3 mm 
(mean, 2.5 mm). [41] In their study, they first examine axial resource and the multiplanar 
reconstructions for all patients. Myocardial bridging is diagnosed if coronary vessel 
coursing in the muscle or getting closer to the septum. By means of changing the window 
width and level, the muscle fibers overlying the coronary and the narrowing of the vessel at 
this area can be analyzed. Compared with detection of myocardial bridging with coronary 
angiography, MDCT does not require an experienced eye and deep style myocardial bridge. 
It is more easily to unveil the mask of bridging even a few muscles overlying the tunneled 
artery based on constructional 3D volume-rendering images. [41] 
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without measurable overlying myocardium. Type III is myocardial bridging with full 
encasement as LAD being surrounded by myocardium but with measurable overlying 
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thickness of MB were significantly greater than non-culprit group. The distance from the 
orifice of the left main trunk to MB entrance was anatomical significantly shorter [38]. It 
further supports the notion that anatomatical properties of MB are associated with 
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to the coronary ostium. It suggests that myocardial bridging enhances the predisposition to 
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coronary atherosclerosis and myocardial infarction changes previous opinion that 
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complicated lesions, which may be an even more pronounced hint of the anatomic risk 
factor for a acute coronary events.[39] 
Ischemia induced by myocardial bridging is related to several reasons. In addition to 
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another mechanism. The considerable delay in blood flow and reduced distal coronary 
pressure are presumed to impair coronary vasodilator reserve, which may induce ischemia 
in patients with myocardial bridging. Another reason for coronary ischemia may be related 
to coronary spasm, of which is stimulated by endothelial dysfunction of coronary artery. 
Coronary angina even myocardial infarction may occur in this situation.  
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Technique 
The heart is moving fast during computed tomography imaging. So it requires a higher 
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myocardial bridging. Despite improvement of imaging acquisition of coronary artery, there is 
still some gap between coronary CT angiography and invasive coronary angiography. At 
normal condition, temporal resolution of MDCT((4-MDCT, 250 milliseconds; 16-MDCT, 183–
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Although conventional coronary angiography is considered as golden standard for 
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intravascular ultrasound and Doppler. However, they are all invasive method with much 
trauma and not cost-effectiveness. With the advance of multi-detector row spiral computed 
tomography(MDCT) and multiplanar reconstruction, coronary artery disease is possible to 
be visualized accurately and non-invasively.  
At the beginning, myocardial bridging is estimated about 22(3.5%) of the unselected 626 
patients with 16-MDCT scanners, 15(2.4%) at the middle segment of LAD, 5(0.8%) at the 
distal segment of LAD and 2(0.3%) at proximal segment of LAD. The length and depth of 
myocardial bridging is between 6 and 22 mm (mean, 17mm) and between 1.2 and 3.3 mm 
(mean, 2.5 mm). [41] In their study, they first examine axial resource and the multiplanar 
reconstructions for all patients. Myocardial bridging is diagnosed if coronary vessel 
coursing in the muscle or getting closer to the septum. By means of changing the window 
width and level, the muscle fibers overlying the coronary and the narrowing of the vessel at 
this area can be analyzed. Compared with detection of myocardial bridging with coronary 
angiography, MDCT does not require an experienced eye and deep style myocardial bridge. 
It is more easily to unveil the mask of bridging even a few muscles overlying the tunneled 
artery based on constructional 3D volume-rendering images. [41] 
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In another study with 16-row MDCT of 148 patients with coronary heart disease，23 
patients (15.8%) with myocardial bridging is detected over 1.0 mm in thickness: 21 (87.5%) 
were located in LAD with a mean thickness and length of 1.80.7 and 20.08.6 mm. 
Moreover, although the tunneled segment beneath MB was always free of coronary wall 
lesions, 79.2% (19/24) of the segments proximal to MB demonstrated coronary wall lesions. 
Of special significance were three symptomatic MB patients without any atherosclerotic 
lesion throughout all the coronary arteries. [42] 
64-MDCT 
In a study, 277 patients studied with 64-slice MDCT for suspected or known coronary 
atherosclerosis were retrospectively reviewed for myocardial bridging. MB was presented in 
82 patients (30%). Bridges were of variable length (<1 cm 58%; 1-2 cm 32%; >2 cm 10%) 
depth (superficial 69%, intramyocardial 31%) and frequently localized in the mid-distal 
segment of the left anterior descending artery (95%). Coronary segments proximal to the 
bridge showed no atherosclerotic disease (33%), positive remodeling (27%), <50% stenosis 
(20%) or >50% stenosis (20%). In this study, 12 non-calcified, 32 mixed and 17 calcified 
plaques were identified. The distal segments were significantly less affected (p<0.0001). [43] 
 
 
Fig. 3. MB at 64-MDCT. It clearly demonstrates that coronary artery coursing through 
myocardium at the middle segment of LAD. 
128-MDCT 
Lazoura et al evaluates the prevalence, length, depth, and location of myocardial bridging of 
the coronary arteries using 128-MDCT. 875 patients were enrolled in this study. 184 subjects 
(21%) were found to a single myocardial bridge, including complete bridging in 161 patients 
(18.4%) and incomplete bridging in 23 patients (2.6%). Most of MB were at the middle 
segment of LAD(67.9%). The mean length and maximum myocardial thickness overlying 
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the complete bridging were 20.9 mm (range 8–32mm) and 2.6 mm (range 1.2–5.3 mm), 
respectively. The mean length of the incomplete bridging was 17 mm (range 9–2.3 mm). [44] 
Dual source MDCT 
Dual source MDCT has fewer imaging time and better resolution for detecting myocardial 
bridging and is not influenced by heart rate. The results by Hwang et al showed that 536 
patients of the 1,275 patients (42%) were found with MB in this study. Superficial MB was 
observed in 368 of 557 (66%) cases, and deep MB was seen in 189 of 557 (34%) cases. Superficial 
MB showed 2 types: complete (128 of 368, 35%) and incomplete (240 of 368, 65%).The mean 
length of a tunneled segment for superficial MB was 16.4 ± 8.6 mm. The mean length and 
depth of a tunneled segment for deep MB were 27.6 ±12.8 mm and 3.0 ± 1.4 mm, respectively. 
The incidence of atherosclerotic plaques in a 2-cm-long segment proximal to MB was 16%[45]. 
Studies evaluate MB using MDCT are illustrated in table 1 
 
Author (Refer.) Sample size Frequency (%) MDCT Comment  
Takamura et al 38 228 18.9 16 AMI patients 
Ou et al 46 2530 5.4 DSCT All patients 
Kim et al 47 607 6.42 64 All patients 
La Grutta et al43 277 30 64 Suspected or known coronary artery disease 
Lazoura et al44 875 21 128 All patients 
Bayrak et al48 990 22.5 64 All patients 
Liu et al 49 3011 5.8 64 Coronary heart disease 
De Rosa 50 235 48.7 16 Atypical chest pain 
Jacobs 51 506 10.4 64 All patients 
Atar 52 165 17 64 All patients 
Zeina 53 300 26 16(226),64(64) All patients 
Yang 54 900 18.6 64 Suspected coronary artery disease 
Kawawa55 148 15.8 16 Coronary heart disease 
Hwang 45 1275 46 DSCT All patients 
Chen 56 114 50 64 APH patients 
Koşar et al 57 700 37 64 Suspected or known coronary artery disease 
Chen58 276 8.7 16 All patients 
Kim 28 300 58 64 Suspected or known coronary artery disease 
Jodocy 59 221 23 64 All patients 
Lubarsky60 245 44 64 All patients 
Konen61 118 30.5 64 All patients 
DSCT indicates dual source computed tomography; APH: apical hypertrophic cardiomyopathy  
Table 1. Illustration of MB at different MDCT studies  
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Fig. 3. MB at 64-MDCT. It clearly demonstrates that coronary artery coursing through 
myocardium at the middle segment of LAD. 
128-MDCT 
Lazoura et al evaluates the prevalence, length, depth, and location of myocardial bridging of 
the coronary arteries using 128-MDCT. 875 patients were enrolled in this study. 184 subjects 
(21%) were found to a single myocardial bridge, including complete bridging in 161 patients 
(18.4%) and incomplete bridging in 23 patients (2.6%). Most of MB were at the middle 
segment of LAD(67.9%). The mean length and maximum myocardial thickness overlying 
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the complete bridging were 20.9 mm (range 8–32mm) and 2.6 mm (range 1.2–5.3 mm), 
respectively. The mean length of the incomplete bridging was 17 mm (range 9–2.3 mm). [44] 
Dual source MDCT 
Dual source MDCT has fewer imaging time and better resolution for detecting myocardial 
bridging and is not influenced by heart rate. The results by Hwang et al showed that 536 
patients of the 1,275 patients (42%) were found with MB in this study. Superficial MB was 
observed in 368 of 557 (66%) cases, and deep MB was seen in 189 of 557 (34%) cases. Superficial 
MB showed 2 types: complete (128 of 368, 35%) and incomplete (240 of 368, 65%).The mean 
length of a tunneled segment for superficial MB was 16.4 ± 8.6 mm. The mean length and 
depth of a tunneled segment for deep MB were 27.6 ±12.8 mm and 3.0 ± 1.4 mm, respectively. 
The incidence of atherosclerotic plaques in a 2-cm-long segment proximal to MB was 16%[45]. 
Studies evaluate MB using MDCT are illustrated in table 1 
 
Author (Refer.) Sample size Frequency (%) MDCT Comment  
Takamura et al 38 228 18.9 16 AMI patients 
Ou et al 46 2530 5.4 DSCT All patients 
Kim et al 47 607 6.42 64 All patients 
La Grutta et al43 277 30 64 Suspected or known coronary artery disease 
Lazoura et al44 875 21 128 All patients 
Bayrak et al48 990 22.5 64 All patients 
Liu et al 49 3011 5.8 64 Coronary heart disease 
De Rosa 50 235 48.7 16 Atypical chest pain 
Jacobs 51 506 10.4 64 All patients 
Atar 52 165 17 64 All patients 
Zeina 53 300 26 16(226),64(64) All patients 
Yang 54 900 18.6 64 Suspected coronary artery disease 
Kawawa55 148 15.8 16 Coronary heart disease 
Hwang 45 1275 46 DSCT All patients 
Chen 56 114 50 64 APH patients 
Koşar et al 57 700 37 64 Suspected or known coronary artery disease 
Chen58 276 8.7 16 All patients 
Kim 28 300 58 64 Suspected or known coronary artery disease 
Jodocy 59 221 23 64 All patients 
Lubarsky60 245 44 64 All patients 
Konen61 118 30.5 64 All patients 
DSCT indicates dual source computed tomography; APH: apical hypertrophic cardiomyopathy  
Table 1. Illustration of MB at different MDCT studies  
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8. Comparison of coronary CT angiography and invasive coronary 
angiography for detection of myocardial bridging 
Several studies have explored the effect of MDCT and invasive coronary angiography for 
detection of myocardial bridging. Leschka et al studied 100 patients (38 women, 62 men; 
mean age, 63.8 11.6 years) who underwent 64-section MDCT and conventional coronary 
angiography. They found that the depiction rate of MB is greater with 64-section MDCT 
coronary angiography than with conventional coronary angiography. MB was detected with 
MDCT in 26 (26%) of 100 patients and with conventional angiography in 12 patients (12%). 
In 14 patients in whom MB was found at MDCT but not at conventional angiography, 
length, depth, and systolic compression were significantly lower than in patients in whom 
both modalities depicted the anomaly. The degree of systolic compression of MB 
significantly correlates with tunneled segment depth but not length [62].  
In another study with 120 patients who underwent MDCT and coronary angiography, 30 
patients were observed with MB. The within-MB diameters on MDCT-CTA and coronary 
angiography showed a significant correlation during systolic and diastolic phases. In case of 
MB, segments with sufficient systolic compression (>50%), length of MBs on MDCT and 
coronary angiography correlated significantly not only at systolic phase but also at diastolic 
phase [63].  
Kim et al in a study with 300 patients who received 64 section MDCT showed that frequency 
of MB was 58% which partial encasement of 57 patients and full encasement of 117 paxents, 
while only 40 patients (13.3%; partial encasement in 1 patient and full encasement in 39) 
demonstrated dynamic compression at conventional angiography. The length of the 
dynamic compression was considerably longer than the respective tunneled segment in all 
patients. Total length correlated with the dynamic compression, but depth did not. The 
higher prevalence of MB on MDCT is considered to the inclusion of partial and full 
encasement on CTA, the use of short-axis images obtained perpendicular to the long axis of 
the LAD for all analysis and measurement, the consistently high image quality of CTA with 
64-section CT, observation of a single artery (LAD) with a specific purpose and the 
convenience of their system for reviewers[28].  
9. Comparison of myocardial bridging detection by MDCT with intravascular 
ultrasound 
The intravascular ultrasound has also been used to study MB. Instead of systolic 
compression, “half-moon” phenomenon has been demonstrated. It is specific for the 
existence of MB.[33,64]Invasive intravascular ultrasound (IVUS) is considered as the most 
accurate method for detecting MB under current situation. Data from our study showed that 
comparing with IVUS, the sensitivity of detection by MSCT was 93% and specificity was 
100%. Minimal and maximal diameters of MB derived from MSCT were significantly 
smaller than those from IVUS [65]. MSCT offers a reliable non-invasive method for MB in 
LAD and atherosclerosis diagnosis with diagnostic accuracy comparable with invasive 
IVUS. 
From studies above, it can be concluded that prevalence of MB on MDCT is relatively high 
than we have thought to. The specificity and sensitivity on MDCT is higher than that on 
conventional angiography and is nearly equal to IVUS, which is thought to be golden 
 
 




Fig. 4. MDCT,CAG and IVUS images in a patient with MB. MB at the middle segment of 
LAD is showed in MDCT image (A and B). Myocardium over tunneled artery is clearly 
demonstrated (arrows). The compression segment is much longer than the tunneled artery 
which suggests compression occurs not only at the segment with overlying myocardium. 
Coronary angiography clearly demonstrated the milking effect during systolic phase which 
is relaxed during diastolic phase (C and D). “Half moon” phenomenon is seen at IVUS both 
systole (E, arrows) and diastole (F, arrows)[65].  (Reprinted with permission of the author) 
standard. The lower rate of MB on coronary angiography may be due to less compression 
during systole, shorter length of MB, course of the tunnel segment. Not only MB can be 
assessed on MDCT, but also the atherosclerosis progress at the proximal segment of MB can 
be evaluated on MDCT during follow up. In the future, MDCT studies will need to evaluate 
the natural course of coronary atherosclerosis in those with and without myocardial 
bridging and to demonstrate whether the congenital variant is clearly a anatomic risk factor 
for myocardial infarction, possibly related to earlier onset and manifestation of coronary 
artery disease [39]. 
10. Detection of MB with magnetic resonance imaging (MR) 
Substantial progress has been made since first study of visualizing coronary arteries in the 
late 1980s. [66-67] 
The advantage of without contrast and radiation with MR makes it preferable for younger 
athletes and renal insufficient patients to identify possible coronary artery disease as well as 
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standard. The lower rate of MB on coronary angiography may be due to less compression 
during systole, shorter length of MB, course of the tunnel segment. Not only MB can be 
assessed on MDCT, but also the atherosclerosis progress at the proximal segment of MB can 
be evaluated on MDCT during follow up. In the future, MDCT studies will need to evaluate 
the natural course of coronary atherosclerosis in those with and without myocardial 
bridging and to demonstrate whether the congenital variant is clearly a anatomic risk factor 
for myocardial infarction, possibly related to earlier onset and manifestation of coronary 
artery disease [39]. 
10. Detection of MB with magnetic resonance imaging (MR) 
Substantial progress has been made since first study of visualizing coronary arteries in the 
late 1980s. [66-67] 
The advantage of without contrast and radiation with MR makes it preferable for younger 
athletes and renal insufficient patients to identify possible coronary artery disease as well as 
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MB.  In addition, calcified lesions at MDCT images show positive diagnosis or cannot be 
clearly demonstrated for the artifact from calcification in many cases.  Recent study by Liu et 
al showed that detection of calcified lesion of coronary artery by MR is better than that by 
MDCT [68]. 
At the beginning, a spoiled gradient-echo sequence at 3-dimensional coronary MR was used 
for detection of coronary artery disease [69]. Later, steady-state free precession (SSFP) 
imaging [70-71] was used to gain better image results. The major problems affecting 
coronary MR imaging are the long time scanning and artifacts induced by motion instability 
during long time scan. With the improvement in parallel processing, multichannel receiver 
coils and wide use of 3.0-T MR, it will be a promising method for assessing coronary artery 
disease as well as MB. However, artifact was much more common with the use of SSFP 
sequence when 3.0-T MR was applied to evaluate coronary artery. A spoiled gradient echo 
technique has gained much attention for better image quality and less artifacts.[72] 
Nowadays, the diagnostic accuracy of the coronary MRA technique to detect a patient with 
a 50% stenosis demonstrated a sensitivity of 88.7%, a specificity of 82.1%, a positive 
predictive value of 86.5%, and a negative predictive value of 92%.[73]  
Recent study showed that coronary artery with diameter larger than 1.5mm could be clearly 
assessed with 3.0 T MR, which in previous studies, only coronary artery with diameters 
larger than 2.0mm be clearly evaluated.[74] In this circumstance, MB at the proximal and 




Fig. 5. CAG, MDCT and MR images in a patient with MB. MB at the middle segment of LAD 
is showed in coronary angiography image. A milking effect is seen during systolic phase(B, 
arrows) which is relaxed during diastole (A, arrow). Myocardium overlying tunneled artery 
is not demonstrated at MDCT (C, arrow and D). The compression segment at coronary 
angiography is longer that tunneled artery at MDCT. MB at the middle segment of LAD and 
compression of MB are showed at MR image (E, arrow). A soft plaque was demonstrated at 
proximal segment of LAD at MDCT image (C).  
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However, until now, there is not a study to evaluate the prevalence of MB at coronary MR. 
It may be due to about one third of the patients can not complete the coronary MR imaging 
or the inability to evaluate all the coronary arteries in all patients [73]. In the further, more 
sensitive technique must be used in clinical for better image quality and shorter time scan. A 
pilot study should be prepared to assess the prevalence of MB and atherosclerosis progress 
induced by MB. 
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However, until now, there is not a study to evaluate the prevalence of MB at coronary MR. 
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1. Introduction 
Worldwide the health expenditures as a percentage of each national gross domestic product 
continue to rise. Cardiovascular diseases as part of the noncommunicable disease group, 
according to the World Health Organization and the most important scientific associations, 
are growing due to the aging of the population and the increase of cardiovascular risk 
factors, due to the epidemiologic as well as to the health transition, especially in the 
developing countries, which account for the majority of the population in the world (Lopez 
et al., 2006). 
In the last few decades we witnessed a proliferation of diagnostic tests to evaluate cardiac 
heart diseases and in particular coronary artery disease (CAD): exercise stress test, trans-
thoracic echocardiography, stress echocardiography, stress single photon emission 
computed tomography, myocardial perfusion imaging, magnetic resonance, fractional flow 
reserve, electron beam computed tomography.  
Each diagnostic test, which continuously evolves due to technological improvements, 
proved to have a high sensibility, specificity and good accuracy in identifying symptomatic 
as well asymptomatic CAD patients.  
All these tests are however unable to give us information about the anatomy of the coronary 
arteries, which is essential to provide a treatment that goes beyond the medical treatment 
and in particular when cardiac surgery is needed. 
In fact catheter angiography or invasive coronary angiography (ICA), since its introduction 
in the second half of last century, was the only test able to visualize, in vivo, the coronary 
tree and to provide images of the coronary artery anatomy upon which both cardiologists 
and surgeons decide if a patient should be revascularized or medically treated. 
With time ICA increased its performance due to the improvement in its software and 
hardware (quantitative coronary angiography, flat panel digital detectors), and due to the 
introduction of important tools which can be used routinely like intravascular coronary 
ultrasound, that for the first time visualized, in vivo, the presence of non calcified plaques 
and vessel's positive remodeling.  
There are other interesting tools that can be associated to ICA, but, for the moment, are the 
armamentarium of some specialized centers and mainly used for research purposes like 
elastography, spectroscopy, angioscopy, thermography and optical coherence thermography. 
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elastography, spectroscopy, angioscopy, thermography and optical coherence thermography. 
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All this data places ICA as the “reference” technique or “gold standard” technique to study 
the anatomy of coronary arteries.  
ICA has been widely employed to validate the results obtained with functional procedures, 
even though the anatomical findings of ICA are also judged by functional tests (Winchester 
et al., 2010).  
These interdependence of validation shows how a technique, even ICA, cannot be 
considered the unique “gold standard” technique to study CAD patients. In fact clinicians 
while studying their patients have to consider more than one question (diagnostic question, 
prognostic question, therapeutic question) and ICA alone is unable to give an exhaustive 
answer to all these questions (Mark et al., 2010).  
This is the reason why we are in search for technologies to evaluate CAD patients and in 
particular to study the anatomy of their coronary arteries keeping in mind that these new 
tests have to be feasible, able to compete with ICA in  providing accurate information and, 
last but not least, economically affordable.  
2. Cardiac computed tomography 
The introduction of multidetector row systems in the field of computed tomography have 
made imaging of the heart and in particular that of epicardial coronary arteries feasible. The 
first and most important force behind the rapid growth of cardiac computed tomography 
(CCT) imaging in less than a decade is the possibility to obtain information of the anatomy 
of coronary arteries (Mark et al., 2010).  
Since its introduction in the last years of the second millennium, CCT, for the moment, is the 
only real alternative to ICA able to visualize coronary arteries and most interestingly to 
obtain this information non-invasively.  
Both CCT and ICA visualize only the epicardial vessels, which are also the ones that are 
usually treated by surgical or percutaneous revascularization procedures. 
There are also other factors which may indicate the use of CCT instead of ICA.  
There is a significant number of patients who perform ICA (10-20% of the patients) who 
have normal coronary arteries. Moreover not all patients who have a diseased coronary 
artery at the ICA should undergo catheter based or surgical based revascularization 
procedures. For a significant number of patients in whom ICA demonstrates the presence of 
some degree of CAD it is enough to introduce or change the medical treatment associated 
with life-style modifications. For this wide group of patients having a non-invasive way to 
visualize coronary arteries would be preferable to the invasive one, and for them ICA 
cannot be considered the real “gold standard” technique. On the other side there is an 
unacceptable high percentage (2%-8%) of patients with acute coronary syndromes who are 
discharged from the emergency department without a correct diagnosis and who may 
benefit from a CCT examination (Hoffmann et al., 2006). 
There are also other disadvantages in ICA procedures that could be avoided if instead CCT 
is performed.  
The first group of disadvantages is related to the so called major adverse events that occur 
within the first 24 hours after selective coronary angiography procedures although they  
have a relatively low incidence, which ranges between 0.2 to 0.3% and is related to the 
invasiveness of the procedure itself. The catheter during its movement inside the 
cardiovascular system may cause the rupture of an atherosclerotic plaque and a 
dislodgment of an embolus to the heart, brain or abdomen causing respectively a 
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myocardial infarction, stroke or intestinal infarction. All these complications can be 
resolved, if correctly addressed, but sometimes may cause a severe morbidity and even the 
death of the patient.  
There are also the so called minor complications present in all the hemodinamic 
laboratories, although their incidence is higher in smaller laboratories and with less skilled 
operators. The incidence of the minor complications is relatively high, roughly between 1% 
to 2%. Most of these minor complications are related to problems with the peripheral vessels 
through which catheters are inserted like dissection of the femoral artery, arteriovenous 
fistulas, groin and retro-peritoneal haematomas which may lead to severe anaemization, 
prolonged morbidity and may require surgery to be solved (Bluemke et al., 2008).  
There are also other important limits that must be considered while using CCT, that the 
evolving technologies are trying to overcome. One of these limits, still present with the 
currently available 64 channel systems, is related to patient's heart rate which must be 
rhythmic and around or less than 60-64 beats per minute. Patients with atrial fibrillation or 
with a heart rate that can not be reduced pharmacologically with beta-blockers to the rate of 
60-64 beats per minute, for the moment, are not eligible to undergo this kind of examination. 
The introduction of some new tools like the “tube current modulation” and the “step and 
shoot” procedures and the 128, 256, 320 channel scanners will offer the possibility to study 
also patients with higher heart rates and with atrial fibrillation, making it possible to image 
the entire heart not only, as it is now, in a single breath hold, but in a single heartbeat. 
Moreover performing CCT in patients with high body mass index or with chronic 
obstructive pulmonary disease may add some additional technical problems (Mark et al., 
2010). 
Finally it is worth noting that both ICA and CCT use non-ionic contrast medium to visualize 
coronary artery lumen. For this reason particular attention must be given in allergic patients 
who may develop anaphylactoid reactions and especially in patients with a pre-existing 
renal impairment which is the major risk factor for the development of contrast medium-
induced nephropathy. Contrast medium-induced nephropathy is associated with adverse 
outcomes including higher mortality. For these reasons patients before CCT should be 
screened by noting their baseline serum creatinine, presence of comorbidities and by 
ensuring adequate hydration before and after contrast exposure (Mark et al., 2010).  
3. Cardiac computed tomography and patients with suspected coronary 
artery disease 
The most interesting indication for CCT to the public and physicians is the possibility to 
evaluate patients with suspected CAD who highly outnumber those who were already 
diagnosed to have CAD or those who underwent surgical or percutaneous revascularization 
procedures. The 64 or more channel CCT systems are currently considered adequate to 
study symptomatic as well as well asymptomatic patients suspected to have CAD (Taylor et 
al., 2010). 
In patients with suspected CAD, CCT non-invasively provides important information about 
coronary calcium scoring, left ventricular function and coronary artery anatomy. However 
while calcium scoring can be obtained also with electron beam computed tomography, left 
ventricular function can be assessed also with echocardiography, magnetic resonance and 
myocardial perfusion imaging, coronary artery anatomy, besides ICA, can be evaluated only 
with CCT. 
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myocardial infarction, stroke or intestinal infarction. All these complications can be 
resolved, if correctly addressed, but sometimes may cause a severe morbidity and even the 
death of the patient.  
There are also the so called minor complications present in all the hemodinamic 
laboratories, although their incidence is higher in smaller laboratories and with less skilled 
operators. The incidence of the minor complications is relatively high, roughly between 1% 
to 2%. Most of these minor complications are related to problems with the peripheral vessels 
through which catheters are inserted like dissection of the femoral artery, arteriovenous 
fistulas, groin and retro-peritoneal haematomas which may lead to severe anaemization, 
prolonged morbidity and may require surgery to be solved (Bluemke et al., 2008).  
There are also other important limits that must be considered while using CCT, that the 
evolving technologies are trying to overcome. One of these limits, still present with the 
currently available 64 channel systems, is related to patient's heart rate which must be 
rhythmic and around or less than 60-64 beats per minute. Patients with atrial fibrillation or 
with a heart rate that can not be reduced pharmacologically with beta-blockers to the rate of 
60-64 beats per minute, for the moment, are not eligible to undergo this kind of examination. 
The introduction of some new tools like the “tube current modulation” and the “step and 
shoot” procedures and the 128, 256, 320 channel scanners will offer the possibility to study 
also patients with higher heart rates and with atrial fibrillation, making it possible to image 
the entire heart not only, as it is now, in a single breath hold, but in a single heartbeat. 
Moreover performing CCT in patients with high body mass index or with chronic 
obstructive pulmonary disease may add some additional technical problems (Mark et al., 
2010). 
Finally it is worth noting that both ICA and CCT use non-ionic contrast medium to visualize 
coronary artery lumen. For this reason particular attention must be given in allergic patients 
who may develop anaphylactoid reactions and especially in patients with a pre-existing 
renal impairment which is the major risk factor for the development of contrast medium-
induced nephropathy. Contrast medium-induced nephropathy is associated with adverse 
outcomes including higher mortality. For these reasons patients before CCT should be 
screened by noting their baseline serum creatinine, presence of comorbidities and by 
ensuring adequate hydration before and after contrast exposure (Mark et al., 2010).  
3. Cardiac computed tomography and patients with suspected coronary 
artery disease 
The most interesting indication for CCT to the public and physicians is the possibility to 
evaluate patients with suspected CAD who highly outnumber those who were already 
diagnosed to have CAD or those who underwent surgical or percutaneous revascularization 
procedures. The 64 or more channel CCT systems are currently considered adequate to 
study symptomatic as well as well asymptomatic patients suspected to have CAD (Taylor et 
al., 2010). 
In patients with suspected CAD, CCT non-invasively provides important information about 
coronary calcium scoring, left ventricular function and coronary artery anatomy. However 
while calcium scoring can be obtained also with electron beam computed tomography, left 
ventricular function can be assessed also with echocardiography, magnetic resonance and 
myocardial perfusion imaging, coronary artery anatomy, besides ICA, can be evaluated only 
with CCT. 
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In a recent meta-analysis CCT compared to ICA had an average sensitivity and specificity of 
98% and 91% respectively, to detect/exclude significant stenosis on a patient basis (Abdulla 
et al., 2007).  
The majority of the studies performed with CCT has been done to determine its role in the 
assessment of patients with suspected CAD by comparing it with the “anatomic” test (ICA) 
or/and “functional” tests like stress echocardiography, single emission computed 
tomography, myocardial perfusion imaging or fractional flow reserve.  
Till now there are no large scale studies to evaluate the predictive value of the results 
obtained with CCT. Nevertheless while a negative CCT rules out significant CAD (negative 
predictive value between 98 and 100% in most studies) a positive CCT test does not have a 
similar high positive predictive value (93% with a range from 64% to 100%) due to the 
tendency of this test to overestimate disease severity in small, distal and calcified vessels. 
This is the reason why CCT is considered an “ideal test” to study patients who have a low or 
intermediate pre-test probability to have hemodynamically relevant coronary artery 
stenosis. In those with high pre-test probability to have significant coronary stenosis, the 
clinical benefit of CCT decreases with the increased probability to have a treatment through 
surgical or percutaneous revascularization procedures (Achenbach, 2006, Schuijf et al., 
2011).  
In the recent American Appropriate Use Criteria Task Force for CCT, the use of CCT in the 
detection of CAD in symptomatic as well as asymptomatic patients with low and 
intermediate pretest probability to have CAD, was pointed to be appropriate (i.e. the test is 
acceptable and considered a reasonable approach to study the disease and its expected 
incremental information, combined with clinical judgment exceeds the expected negative 
consequences by a sufficiently wide margin) with a quite high appropriateness score 
(between 7 and 8 out of the highest value of 9; an indication to be appropriate had to have a 
score from 7-9 ) (Taylor et al., 2010). 
3.1 Cardiac computed tomography and invasive coronary angiography 
The published literature in which CCT’s ability to evaluate coronary artery anatomy, 
compared to ICA, in patients suspected to have CAD, although applied in high quality 
studies in selected subjects and interpreted by experts, has a high diagnostic accuracy, but 
probably may not reflect its real use in the daily clinical practice. In most of the published 
papers CCT has an overall high sensitivity and specificity both on a per-patient and on a per 
vessel basis for the presence of more than 50% obstructive lesions. 
Invasive coronary angiography in evaluating coronary arteries is still considered the “gold 
standard” or “reference standard” technique mainly because in more than 50 years 
experience it provided an extensive evidence of its value in patient management and 
because it has, for the moment, the highest spatial (<0.16 mm vs approximately 0.4 mm of 
CCT) and temporal resolution (33 msec. vs 140 to 200 msec. of the recent cardiac computed 
systems or 83 msec. of the dual source system). It is however worth noting that ICA 
visualizes coronary arteries by creating only a limited number of 2D coronary luminograms, 
whereas CCT gives an unlimited number of 2D reformatted images as well as 3D volume-
rendered images from transverse reconstructions that can rule out eccentric lesions that are 
difficult to be studied by traditional invasive angiography (Mark et al., 2010) 
Invasive coronary angiography estimates the coronary artery severity as a percent diameter 
stenosis by comparing the narrowing of the lumen of the vessel with the adjacent segment, 
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which arbitrarily is considered normal, while it could have a non-visualized, non calcified, 
eccentric plaque. This visual procedure to estimate lesions has a high degree of intra and 
inter-observer variability that can be somehow reduced by a computer assisted 
interpretation (quantitative coronary angiography).  
Cardiac computed tomography on the other hand is, and in the future probably will be able 
to provide more information not currently available from ICA, and this may be the basis for 
its more extensive use in patients with suspected CAD. Invasive coronary angiography can 
visualize the first stages of the atherosclerotic process (vessel’s positive remodeling and the 
presence of non calcified plaques) only if it is performed using expensive and specialized 
tools like intravascular ultrasound and optical coherence thermography. All this 
information is already available with CCT and helps to understand the atherosclerotic 
burden of CAD patients “better” than with ICA.  
Although CCT provides images of the plaque both internal and external to the lumen 
helping in having a more precise evaluation of lumen narrowing, its ability in assessing the 
real vessel stenosis has still some technical limits. In fact in the presence of calcified lesions, 
especially in small and distal vessels, CCT tends to overestimate lesion severity because of 
the “blooming effect”, which is related to the X-rays not absorbed by the calcified lesion that 
during image reconstruction causes the lesion to seem bigger than it actually is (Ropers  et 
al., 2006a).  
Another important limit of CCT is related to the fact that less than or equal to 5% of patients 
have a non-valuable scans due to motion artefacts, because the patient cannot follow breathing 
commands, involuntary motion of the diaphragm or to arrhythmias occurring during the CCT 
scan. To study the coronary anatomy of these patients ICA must be performed.  
3.2 Cardiac computed tomography and functional tests 
Although CCT was introduced to provide information regarding the anatomy of coronary 
arteries as an alternative procedure to ICA, it is also possible to compare its results with 
those obtained with functional tests. The utility in performing such comparison is to 
evaluate if CCT has a similar or superior accuracy than functional tests in the 
characterization of patients with suspected CAD. In doing so it is however necessary to keep 
in mind that, as with ICA, functional tests are often not concordant with the results of CCT 
because they consider different parameters. Cardiac computed tomography allows the 
detection of atherosclerotic plaques, that may be hemodynamically non significant resulting 
in a negative functional test, while a positive functional test may be present in a patient with 
normal epicardial coronary arteries, but with diseased coronary microcirculation able to 
produce clinically significant ischemia.  
When CCT was compared to dobutamine stress echocardiography the positive and negative 
likelihood ratios for dobutamine stress echocardiography were 4.37 and 0.36 compared with 
3.5 and 0.11 for coronary computed tomography respectively (Nixdorff et al., 2008).   
Several studies have been performed comparing both CCT and stress myocardial perfusion 
imaging to ICA. Cardiac computed tomography proved to have a higher sensitivity and 
specificity than myocardial perfusion imaging (respectively 94% vs 81% and 96% vs 78%; 
Budoff et al., 2007). 
When CCT was compared to fractional flow reserve, which is considered the reference 
standard for hemodynamically significant obstructive disease, it was found that the 
sensitivity and specificity of CCT for fractional flow reserve-defined hemodynamically 
significant lesions were 94% and 40% respectively (Gaemperli et al., 2007). 
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which arbitrarily is considered normal, while it could have a non-visualized, non calcified, 
eccentric plaque. This visual procedure to estimate lesions has a high degree of intra and 
inter-observer variability that can be somehow reduced by a computer assisted 
interpretation (quantitative coronary angiography).  
Cardiac computed tomography on the other hand is, and in the future probably will be able 
to provide more information not currently available from ICA, and this may be the basis for 
its more extensive use in patients with suspected CAD. Invasive coronary angiography can 
visualize the first stages of the atherosclerotic process (vessel’s positive remodeling and the 
presence of non calcified plaques) only if it is performed using expensive and specialized 
tools like intravascular ultrasound and optical coherence thermography. All this 
information is already available with CCT and helps to understand the atherosclerotic 
burden of CAD patients “better” than with ICA.  
Although CCT provides images of the plaque both internal and external to the lumen 
helping in having a more precise evaluation of lumen narrowing, its ability in assessing the 
real vessel stenosis has still some technical limits. In fact in the presence of calcified lesions, 
especially in small and distal vessels, CCT tends to overestimate lesion severity because of 
the “blooming effect”, which is related to the X-rays not absorbed by the calcified lesion that 
during image reconstruction causes the lesion to seem bigger than it actually is (Ropers  et 
al., 2006a).  
Another important limit of CCT is related to the fact that less than or equal to 5% of patients 
have a non-valuable scans due to motion artefacts, because the patient cannot follow breathing 
commands, involuntary motion of the diaphragm or to arrhythmias occurring during the CCT 
scan. To study the coronary anatomy of these patients ICA must be performed.  
3.2 Cardiac computed tomography and functional tests 
Although CCT was introduced to provide information regarding the anatomy of coronary 
arteries as an alternative procedure to ICA, it is also possible to compare its results with 
those obtained with functional tests. The utility in performing such comparison is to 
evaluate if CCT has a similar or superior accuracy than functional tests in the 
characterization of patients with suspected CAD. In doing so it is however necessary to keep 
in mind that, as with ICA, functional tests are often not concordant with the results of CCT 
because they consider different parameters. Cardiac computed tomography allows the 
detection of atherosclerotic plaques, that may be hemodynamically non significant resulting 
in a negative functional test, while a positive functional test may be present in a patient with 
normal epicardial coronary arteries, but with diseased coronary microcirculation able to 
produce clinically significant ischemia.  
When CCT was compared to dobutamine stress echocardiography the positive and negative 
likelihood ratios for dobutamine stress echocardiography were 4.37 and 0.36 compared with 
3.5 and 0.11 for coronary computed tomography respectively (Nixdorff et al., 2008).   
Several studies have been performed comparing both CCT and stress myocardial perfusion 
imaging to ICA. Cardiac computed tomography proved to have a higher sensitivity and 
specificity than myocardial perfusion imaging (respectively 94% vs 81% and 96% vs 78%; 
Budoff et al., 2007). 
When CCT was compared to fractional flow reserve, which is considered the reference 
standard for hemodynamically significant obstructive disease, it was found that the 
sensitivity and specificity of CCT for fractional flow reserve-defined hemodynamically 
significant lesions were 94% and 40% respectively (Gaemperli et al., 2007). 
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3.3 Cardiac computed tomography and patients with acute chest pain 
The performance of CCT was also tested in specific environments such as the emergency 
department, comparing it with functional tests as well as combined clinical and marker 
data. The results obtained from these studies show that a negative CCT exam improves the 
diagnostic accuracy in ruling out subjects with a low risk to have acute coronary syndromes. 
Goldstein et al. (Goldstein et al., 2007) found that CCT compared to myocardial perfusion 
imaging in addition to standard care had a reduced diagnostic time (3.4 h vs 15.0 h; p<0.001) 
and lower costs ($1586 vs $1872; p<0.001) while no adverse cardiovascular events occurred 
in either group after 6 months of follow-up. On the other side according to Hadamitzky et 
al. finding an obstructive CAD on CCT at the emergency department is associated with an 
odd ratio of 17.3 to have severe cardiac events (cardiac death, myocardial infarction or 
unstable angina) while in patients without CAD at the CCT the rate of cardiac events is 
better predicted than with the Framingham risk score (Hadamitzky et al., 2009).  
4. Cardiac computed tomography and anomalous coronary arteries 
Invasive coronary angiography provides only a 2D view of the coronary arteries and 
sometimes fails to clearly visualize the relationship between coronary vessels and the 
surrounding structures. This issue becomes critical when anomalous coronary arteries must 
be visualized. Moreover, it is not always easy to selectively engage the anomalous coronary 
vessel, which may lead to the erroneous assumption that the coronary vessel is occluded. In 
addition, the declining use of pulmonary artery catheters during the routine invasive 
angiography procedures has made it more difficult to understand the course of the coronary 
vessels within the heart and discern the anterior versus the posterior direction of the 
anomalous vessels. 
Congenital coronary artery anomalies are rare and occur in 0.17% of the autopsy cases. The 
incidence of anomalous origin of the coronary vessels is higher in the population of patients 
referred for ICA (0.6–1.3%). Although anomalous coronary vessels lack clinical significance 
in the majority of patients, there are some ‘‘malignant’’ anomalies that may cause non-fatal 
or fatal acute myocardial infarction or sudden death, especially in young athletes without 
atherosclerotic CAD (Angelini et al, 2002). In older patients, both CAD and coronary vessel 
anomalies may be present and in these cases it is difficult to clarify the exact mechanism of 
myocardial ischemia. 
In the last few years, several studies showed the usefulness of the non-invasive modalities 
for the detection of coronary vessel anomalies such as magnetic resonance imaging and 
especially multidetector computed tomography. Magnetic resonance imaging, as it is free 
from X-radiations would be preferable to multidetector computed tomography, especially 
for younger patients in whom an anomalous artery origin is suspected, and in those who 
have a cardiac anomaly which may be associated with coronary vessel anomalies (i.e. 
tetralogy of Fallot) or in patients who have to be followed for the presence of coronary 
artery aneurysms like in the Kawasaki disease (Mark et al, 2010).  
Although there are multiple published series of patients who underwent comparison of 
coronary magnetic resonance angiography with ICA with a quite good accuracy, CCT due 
to its excellent spatial resolution, which allows an excellent detection of the origin of the 
coronary vessels and visualizes their course within the heart, is the real alternative to 
invasive angiography  (Cademartiri et al., 2007) and sometimes it can be considered the real 
“gold standard” technique in studying the anomalous coronary arteries. In fact in the recent 
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American Appropriate Use Criteria Task Force for CCT, the use of CCT in the “assessment 
of anomalies of coronary arterial and other thoracic arteriovenous vessels” was pointed to 
be the most appropriate indication (score 9 out of 9) (Taylor et al., 2010).  
5. Cardiac computed tomography and cardiac bypass surgery 
Another indication for CCT is to follow up patients who performed coronary artery by-pass 
grafting. This was indeed the first clinical application of CCT. In fact arterial as well venous 
by-passes are easier to be studied than epicardial coronary arteries because they are bigger 
vessels (typically 2 to 4 mm), have lower motion and usually not calcified.  
By-passes have been evaluated beginning with the 4 slice CCT with good results (Moore et 
al., 2005) and now with the latest generation of CCT systems their accuracy is very high 
(Stein et al., 2008).  
There are however several difficulties in the assessment of by-passes related to the presence of 
artifacts caused by metal clips, especially when they are at the level of the distal anastomotic 
site where there can be found also calcified lesions and the grafts have a greater motion. 
Cardiac computed tomography has a good accuracy in assessing graft occlusion; the 
sensitivity, specificity and accuracy of CCT for detection of bypass occlusion in studies 
performed with 16-slices computed tomography was respectively of 97%, 100% and 99% 
(Martuscelli et al., 2004) and in the most recent meta-analysis on the diagnostic accuracy of 
the 64-channel CCT the sensibility and specificity in the detection of graft occlusion 
calculated on a per-graft rather than a per-patient basis were respectively 97% and 100% 
(Stein et al., 2008). 
Cardiac computed tomography’s accuracy in assessing graft stenosis is however lower and 
reduces the overall specificity to 97% while the overall sensitivity remains almost 
unchanged (98%). The latest generation CCT systems have a positive likelihood ratio above 
10 and a negative likelihood ratio of 0.02 which leads to a very high positive predictive 
value and especially a very high negative predictive value compared with traditional ICA 
indicating that CCT can rule out or rule in graft disease with a very high accuracy (Stein et 
al., 2008).  
It is however important to consider that assessing the native coronary arteries downstream 
from the grafts and in the un-grafted segments in patients in whom in the meantime CAD 
may have progressed, can be very challenging since these vessels tend to be small and 
sometimes heavily calcified (sensitivity 86%, specificity 76% and accuracy 78%) (Ropers et 
al., 2006b). 
In the recent American Appropriate Use Criteria Task Force for CCT the use of CCT in the 
“evaluation of graft patency after cardiac surgery” was pointed to be appropriate with a 
high indication score (8 out of the highest value of 9) (Taylor et al., 2010). 
Another issue is related to the area that must be studied during CCT examination. While 
patients who did not perform a coronary bypass are studied from the level of the carina to 
the diaphragm, those who have performed a bypass surgery should be studied from the 
level of the aortic arch and sometimes even from the clavicle in case we want to study the 
origin of the internal mammary arteries. Nevertheless CCT is preferred by patients because 
it is considered “non-invasive”, even if it needs a greater amount of contrast medium and 
greater amount of radiation. In fact patients who performed bypass surgery have already 
experienced a pre-operative ICA, cardiac surgery and sometimes, after the cardiac bypass 
surgery, a second or third diagnostical and/or interventional ICA. 
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3.3 Cardiac computed tomography and patients with acute chest pain 
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American Appropriate Use Criteria Task Force for CCT, the use of CCT in the “assessment 
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There are some cases where CCT could be considered the “gold standard” technique to 
follow-up patients who underwent bypass surgery. These patients are those who underwent 
a gastroepiploic bypass to the posterior descending coronary artery. It is easier to study the 
gastroepiploic bypass with CCT rather than performing a challenging ICA, which may need 
a great amount of contrast medium and a great amount of radiation (Ropers et al., 2006b).  
Cardiac computed tomography can be also the “ideal technique” in planning the re-do 
cardiac bypass surgery patients as it provides the exact relationship between the intra-
thoracic organs and the chest wall (spatial relationship between grafts, epicardial coronary 
arteries, right ventricle and sternum) (Mark et al., 2010). 
Another filed in which CCT could be used is that of patients who have to undergo cardiac 
bypass surgery. Cardiac computed tomography, unlike ICA, does not explore the coronary 
circulation dynamically and is unable to provide information regarding the direction of the 
blood inside the vessel and, because of its limited spatial resolution, is unable to detect the 
presence of homo and/or hetero coronary collateral circulation, which is very  important to 
characterize patients with CAD and is useful in deciding their management. This 
information however is not always essential for the surgeon. In fact although CCT does not 
supply the surgeon with images showing the presence and direction of collateral circulation 
in most of the cases, it clearly indicates if the vessels after the stenosis or occlusion are 
pervious and could be grafted. Having preoperatively clear images of the diseased vessels 
for the presence of calcified or soft plaques is also useful for the surgeon to decide where to 
perform the anastomosis. Moreover, the study of the wall-thickness changes over the 
cardiac cycle obtained with CCT may guide both surgeons and interventional cardiologists 
to decide the real necessity for the revascularization and could help to avoid sudden 
decisions during ICA procedures for patients who may benefit more from cardiac bypass 
surgery rather than percutaneous interventions (Bamoshmoosh et al., 2008). 
Recently some published papers hypnotized that CCT could be  judged enough to decide if 
a patient can be directly sent to perform bypass cardiac surgery without confirming CCT 
results with traditional ICA. In fact the information obtained with CCT supplies the surgeon 
with a virtual 3D images showing the diseased vessel and help in pre-planning the length of 
the required conduit. This can be of great importance especially in off pump and in 
minimally invasive surgery.  
In a recent interesting prospective clinical trial, CCT was compared to conventional 
coronary angiography to evaluate if CCT alone was adequate for proceeding in cardiac 
bypass surgery without coronary angiography. In this study 50 patients with proven severe 
CAD underwent CCT and ICA prior to cardiac bypass surgery. CCT images were compared 
with those of ICA for the accuracy, sensitivity and specificity in detecting significant 
stenosis. An excellent correlation was found between ICA and CCT results. The overall 
sensitivity, specificity, positive and negative predictive values for quantitative assessment of 
stenosis > 70% by CCT compared to ICA were 98.5 %, 99.1 %, 82.3 % and 99.8%, 
respectively. The Authors conclude that the improved spatial and temporal resolution of the 
64 row scanners provided an excellent correlation of CCT with ICA, and in selected patients, 
they even recommend the consideration of CCT as a sole criteria for proceeding in cardiac 
bypass surgery without coronary angiography (Bedi et al., 2008). 
These interesting results that indicate a possible future use of CCT not only complementary 
but also as an alternative to ICA in the flow chart in the evaluation of CAD patients prior to 
cardiac bypass surgery needs however to be further analyzed in multi-centric 
interdisciplinary studies.  
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6. Cardiac computed tomography and prior coronary stenting 
The evaluation of coronary stents by CCT is challenging because there are important technical 
limitations related to the presence of the metal in the stent struts that cannot be completely 
bypassed by “convolution algorithms”. The metal present in the stent absorbs the lower-
energy portion of the X-ray beam leaving the not absorbed X-rays to reach the detector 
realising what is called the “blooming artefact”, that causes the stent struts to appear thicker 
than they actually are and to produce also the “partial volume averaging” which is an artefact 
that affects the voxels immediately adjacent to the stent struts. During the reconstruction of the 
images both the “blooming artefact” and the “partial volume averaging” produced by the 
stent, associated with the eventually "blooming artefact" of the calcified plaque beneath the 
stent, interfere with the ability to assess the presence of in-stent restenosis and in general to 
evaluate if and how much the vessel is diseased (Mark et al., 2010)  
All these data led the American Heart Association to consider in 2006 statement CCT non 
advisable to study patients with prior coronary stenting (class III with a level of evidence C) 
(Budoff et al., 2006).  
However stents are not to be considered as equivalent because they have different metal 
composition, different designs and more importantly different sizes. With the new 
generation CCT systems the indication changed and stents 3.5 mm or larger are now judged 
100% assessable. The ability to evaluate in stent restenosis reduces to 80% in the 3 mm stents 
and to 33% in the smaller stents (Sheth et al., 2007). Thus in a patient with a known large 
stent, like those in the left main, CCT could be considered a real alternative to ICA to rule 
out significant in-stent restenosis. In fact in the recent American Appropriate Use Criteria 
Task Force for CCT the use of CCT in the “risk assessment in asymptomatic patients with 
prior left main coronary stent with stent diameter ≥ 3 mm ” was pointed to be appropriate 
with a high indication score (7 out of the highest value of 9) (Taylor et al, 2010).  
Moreover as it is pointed by the writing group of the American Appropriate Use Criteria 
Task Force for CCT the 2010 appropriateness criteria reflect the actual most common clinical 
scenarios, keeping in mind that from the 2006 appropriateness criteria to those of 2010 some 
indications shifted up 1 category from either uncertain to appropriate and from 
inappropriate to uncertain (Taylor et al, 2010). The increasing amount of published papers 
with the most advanced computed tomography machines indicate the usefulness of CCT in 
the daily work to rule out or to rule in the presence of in-stent restenosis of CAD patients 
who may have performed several diagnostical and/or interventional coronary angiography 
procedures and ask for CCT instead of ICA (Sun & Almutairi, 2010). In the daily experience 
both patients and their physicians more and more frequently ask for an alternative to ICA at 
least at the time of the characterization of the CAD and want to have the opportunity to 
choose off-line the therapeutical decision. 
This is the reason why the writing group of the American Appropriate Use Criteria Task 
Force for CCT do not believe that an uncertain rating must be used as a reason to deny 
reimbursement for CCT imaging, but consider that in these cases additional documentations 
have to be presented to justify reimbursement (Taylor et al, 2010).  
7. Cardiac computed tomography and radiation dose 
Since the introduction of CCT in the clinical practice the dose of radiation delivered to 
patients during the exams is the most often discussed drawback, because it has been 
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considered a critical safety issue, especially when besides CCT, ICA and/or stress 
myocardial perfusion imaging have to be performed. In the commonly used CCT systems 
the amount of radiation, expressed as units of millisieverts (equivalent to millijoules per 
kilogram of tissue), absorbed by patients during the test is 2-4 folds that of ICA (Mark et 
al., 2010). The introduction of improvements in CCT technologies like the “ECG-
controlled tube-current modulation” and the ‘‘step and shoot’’ protocols, which use a 
prospective gating and predict when diastole will occur,  decrease x-ray tube current 
during systole leading to a significant reduction of the radiation dose from about 18 
millisieverts to less than 4 millisieverts, which is almost equal to that of traditional 
coronary angiography (Scheffel et al., 2008; Hausleiter et al., 2006). As with ICA patient 
radiation dose is directly correlated with cardiac tomography equipment, practice and 
experience of the center where the CCT is performed and patient related factors like 
patient weight and heart rate.  
If it is difficult to ascertain the developing of malignancy as a consequence of a biologic 
damage due to radiation in adults, the population most likely studied with CCT. 
Nevertheless as a consequence of a good clinical practice CCT must be performed only 
when its indication is appropriate (see the 2010 appropriateness criteria of the American 
Appropriate Use Criteria Task Force for CCT) and if patient’s diagnostic question cannot be 
adequately addressed by other investigations (Taylor et al., 2010).  
8. Illustrative case 
The patient is a 63-year-old man who was in treatment for arterial hypertension 
(Amlodipine 10 mg, Ramipril 10 mg and Furosemide 25 mg) and hyperlipidemias 
(Atorvastatin 10 mg). In 2000 he was operated for an adenoma of the adrenal cortex. In 2004 
for a “type A” aortic dissection, in extra-corporeal circulation, he underwent prosthesis  
implantation (26 mm).  
The patient was doing fine till June 2006 when he began to suffer of chest pain associated 
with dyspnoea. For this reason he performed a maximal treadmill stress test which was 
positive by electrocardiographic criteria (2.5 mm ST depression in lead V4-V6) and typical 
effort chest pain. 
The patient was sent to perform ICA. The test, which was performed through a femoral 
approach, was however unable to selectively catheterize the right coronary artery and a 
severe left main and left anterior descending CAD were suspected. The indication given to 
the patient by the interventional cardiologist was to undergo bypass surgery.  
However, in such a complex patient, the surgeon wanted to have a complete anatomical 
description of the coronary tree and the aorta to better pre-plan the surgical intervention 
and asked for a CCT test. 
Cardiac computed tomography was performed with 64-slice multidetector computed 
tomography Brilliance scanner (Philips, USA) by administering 100 ml of iodinated contrast 
medium (Iomeron 400 mg/dl, Bracco Imaging, Milano, Italia) at a rate of 5 ml/s through a 
18 gauge cannula placed in the antecubital vein. 
To reduce patient’s heart rate, 30 minutes before the test he was given 100 mg of Metoprolol 
per os. Cardiac computed tomography provided images which were judged of good quality 
and both right and left coronary arteries were correctly visualized (Fig. 1). 
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Fig. 1. 2D map in which in the middle segment of the right coronary artery (arrow n°1) there 
is a non calcified plaque (50% stenosis) and in the middle segment of the left anterior 
descending coronary artery (arrow n°2) a mixed plaque (50-75% stenosis).  
Right coronary artery was the dominant vessel; in the proximal segment there were small, 
mixed, non critical lesions; in the middle segment there was a non calcified plaque that 
produced a 50% stenosis; no lesions were seen in the distal segment and in the posterior 
descending coronary artery  (Fig. 2). 
 
 
Fig. 2. Multiplanar reconstructed image of the right coronary artery and posterior 
descending coronary artery: in the middle segment (arrow) there is a non calcified eccentric 
plaque (50% stenosis). 
The left main had a non calcified lesion which caused less than 20% stenosis. The left 
anterior descending coronary artery had in the proximal segment a non significant lesion 
followed in the middle segment by a mixed stenosis that caused a critical 50-75% stenosis; 
no lesions were seen in the distal segment and in the diagonal branches  (Fig. 3 A). No 
significant lesions were seen in the circumflex coronary artery (Fig. 3 B). 
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Fig. 3. Multiplanar reconstructed image of the left coronary artery. In A the left main (arrow 
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Fig. 4. Volume rendering image of the heart ad aorta (A) and lumen image of the aorta (B) 
where the aortic dissection with the true and false lumen are visible. 
In this case ICA was unable to visualize coronary arteries because the catheters during the 
exam were engaging the false lumen due to the presence of the aortic dissection. CCT on the 
other side was very useful as it was the only test that provided the correct anatomical view 
of the coronary tree. Moreover CCT indicated the presence of a severe aortic dissection in a 
patient already treated for “type A” aortic dissection. 
In this case CCT was also a very useful test for the surgeon to pre-plan the operation. In fact 
the patient underwent a second extra-corporeal circulation surgery for a radical aortic 
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replacement employing simultaneous modified Bentall and elephant trunk procedure and a 
coronary artery bypass surgery for the anterior descending coronary artery using the left 
internal mammary artery. At the 2 year follow up the patient was doing fine. 
9. Conclusion  
Invasive coronary angiography is an indispensable test to evaluate coronary arteries and in 
more than a half century experience it proved to be extremely  reliable in the diagnostical as 
well therapeutical processes of CAD patients. For this reason it is considered the “gold 
standard” or “reference standard” technique upon which we compare the results of the 
other cardiac exams. However ICA is not always the most appropriate test with which we 
can evaluate CAD patients. The introduction in the cardiac arena of CCT, that with very 
good accuracy investigates coronary arteries, provided us with a complementary and 
sometimes an alternative test to ICA. In particular settings that can range from quite simple 
cases (identification of a coronary artery with an anomalous origin) to very complex cases 
(need to pre-plan a re-do bypass surgery), or that of the patient of the illustrative case it can 
be even considered the “real gold” standard technique. However to better understand the 
real usefulness of CCT and correctly allocate it in the flow chart of the evaluation of CAD 
patients more experience must be gained by routine users, further multi-centric 
interdisciplinary studies must be performed till the production of approved clinical practice 
guidelines.  
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1. Introduction 
The prognostic power of angiographic coronary anatomy has been definitively established 
since the CASS registry (1), where the 12-year survival rate of medically treated patients 
with no significant coronary lesions was 91%, compared with 74, 59 and 50% for patients 
with one, two and three vessel disease. Survival rate is known to further decrease in the 
presence of a left main coronary artery disease, and of a severe proximal left anterior 
descending stenosis (2).    
However, several lines of evidence, obtained with different approaches, demonstrate that a 
physiologic risk assessment is superior to an angiographically oriented approach in 
prognostic stratification of patients with stable ischemic heart disease. In particular, in a 
recent study, Gimelli et al (3), in order to predict patient survival rate, analyzed a group of 
676 consecutive in-patients who underwent a complete diagnostic work-up that included 
gated single photon emission computed tomography (SPECT) and coronary arteriography 
for known or suspected ischemic heart disease. Patients with acute myocardial infarction 
(MI), previous coronary artery bypass surgery, overt hyperthyroidism or who were 
undergoing dialysis treatment were excluded. 
To predict patient survival rate, the Authors utilized an angiographic semi-quantitative 
score, that takes into account the number of stenotic coronary arteries, the location of 
coronary stenoses (proximal, middle, or distal), and the degree of luminal diameter 
reduction (using a 50 and a 70% coronary stenosis threshold). As expected, this score was an 
independent predictor of event-free survival. However, the prognostic impact of this score 
disappeared once gated SPECT variables were included into the model (3).  
The notion that the prognostic impact of functional risk assessment is superior to 
angiography is not novel. In patients with defined coronary artery disease, exercise 
variables primarily relating to the functional state are known to provide an incremental 
prognostic information over coronary anatomy (4). The treadmill score also adds 
independent prognostic information to that provided by clinical data, coronary 
arteriography and left ventricular (LV) ejection fraction (5). The predictive power of clinical 
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1. Introduction 
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independent predictor of event-free survival. However, the prognostic impact of this score 
disappeared once gated SPECT variables were included into the model (3).  
The notion that the prognostic impact of functional risk assessment is superior to 
angiography is not novel. In patients with defined coronary artery disease, exercise 
variables primarily relating to the functional state are known to provide an incremental 
prognostic information over coronary anatomy (4). The treadmill score also adds 
independent prognostic information to that provided by clinical data, coronary 
arteriography and left ventricular (LV) ejection fraction (5). The predictive power of clinical 
data is also strengthened by adding the results of dobutamine echocardiography (6); 
however, the power of the model was increased to a minor degree by the addition of 
coronary anatomy data. In a group of patients who underwent stress echocardiography with 
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either dipyridamole or dobutamine, and who also underwent coronary angiography within a 
year without an intervening procedure, coronary angiography parameters did not add 
significant predictive power to the model compared with stress echocardiographic variables 
(7). As to nuclear cardiology, the superiority of myocardial perfusion imaging over coronary 
angiography in risk stratification of patients with ischemic heart disease is also well known. In 
1992, Pollock et al. demonstrated that myocardial perfusion is superior to coronary 
angiography in risk stratification of ischemic heart disease patients (8); at variance with our 
study, these authors used Thallium-201 (Tl-201) and static planar imaging. In a series of 316 
medically treated patients, Iskandrian et al. (9) showed the independent and incremental 
prognostic information of exercise SPECT Tl-201 imaging even when catheterization data are 
available. All these evidences definitively underline the superiority of functional risk 
stratification over an approach based solely on angiographic coronary anatomy.  
These observations can be partly explained by the limitations of coronary angiography. First 
of all, coronary angiography has a limited sensitivity when compared to necropsy studies 
(10) and to intravascular ultrasound investigations (11). Furthermore, the identification of 
significant lesions may be confounded by coronary remodeling and by the extraluminal 
location of some plaques (12). Finally, coronary angiography does not allow to study 
coronary microcirculation, increasingly recognized as independent determinant of impaired 
blood flow, disease progression and adverse prognosis (13).  
2. The role of nuclear medicine as functional imaging 
The clinical use of radioisotopes in the evaluation of patients with ischemic heart disease is 
largely based on noninvasive methodology suitable for visualizing myocardial perfusion. 
A lthough contrast echocardiography and magnetic resonance imaging have been proposed 
recently for the same purpose, at present most of the noninvasive tests for assessing 
myocardial perfusion reside in nuclear cardiology. The most popular radioactive flow 
tracers are characterized by a rapid myocardial extraction followed by either a sequestration 
(for Technetium 99m labeled agents – Tc 99m) or a very slow washout (for Tl-201). These 
features make the tracer uptake proportional to blood flow in each myocardial region, even 
if, up to now, the quantitation of absolute flow is not possible with these techniques. Despite 
this limitation, myocardial perfusion can be imaged and underperfusion can be detected as 
a relative uptake defect compared with the better perfused myocardium. As “ significant”  
coronary stenosis regionally impairs flow reserve, myocardial perfusion imaging has 
become a common tool for the diagnosis of coronary artery disease and coronary 
angiography the gold standard for defining its sensitivity and specificity.
The main strength of radionuclide cardiac imaging in patients with coronary artery disease 
is to provide pathophysiologic and clinical information related to major objectives of 
assessment which include myocardial perfusion, viability and their relationship with left 
ventricular function. For these hypothesis, these data have additional value over anatomic 
information, provided by other imaging techniques, for patient management and outcome. 
3. Overview of imaging principles 
The two different approaches used to evaluate myocardial perfusion by nuclear imaging are 
SPECT and positron emission tomography (PET). SPECT gamma-emitting tracers include 
Tl-201, Tc-99m Sestamibi and Tetrofosmine. PET positron emitting tracers include O-15 
water, N-13 ammonia and rubidium-82, a generator produced readily available agent. 
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As potassium analogue, Tl-201 has high myocardium uptake and has been the most 
commonly used perfusion tracer during the past years (14). Tl-201 is distributed into the 
myocardium proportionally to the flow over a wide range of values. However, some 
limitations have recently reduced its use: the low photon energy is associated with a lower 
resolution and significant attenuation by overlying tissues; the prolonged physical half-life 
(73 hours) causes a significant radiation exposure to the patient.  
Tc-99m labeled tracers, having a shorter physical half life (6 hours) and better imaging 
capabilities, replaced Tl-201 in several indications for clinical SPECT (15). Tc-99m labeled 
tracers are readily available, the images obtained show higher spatial resolution and tissue 
attenuation is also less significant. Tc-99m Sestamibi and Tetrofosmine, the two most 
commonly used labeled tracers, distribute into the myocardium proportionally to the flow 
but their uptake is also dependent on normal mithocondrial function. After myocardial 
uptake, the retention of Tc-99 m labeled tracers in the myocardium is high so that two 
separate tracer injections are required to compare stress and resting perfusion.  
Up to now, one of the major advantages of PET over SPECT is the possibility to correct 
myocardial tissue radioactivity for attenuation of the surrounding organs so that, using 
appropriate models to describe the kinetics of the single tracer, it is possible to quantitate 
myocardial blood flow (MBF) in absolute terms (mL.g-1.min-1) (16-17). O-15 water is 
considered the gold standard for MBF quantitation because its kinetic in the heart is 
independent of myocardial metabolism (18). However, the tracer is freely diffusible and has 
a very short physical half-life (120 sec) so that images have not a high myocardial definition 
and approaches to correct for radioactivity in the vascular compartment are required for 
MBF quantitation (19).  
N-13 Ammonia is highly extracted and retained by the heart and has a relatively longer 
physical half-life than O-15 water (9.96 min) resulting in good to excellent images of the 
myocardium. However, the uptake and retention are dependent on myocardial metabolism 
(20), which may also cause regional differences in tracer accumulation (21). Rest and stress 
studies should be separated by 30 to 40 minutes to allow decay of the previously injected 
dose. There are a number of approaches for MBF quantitation with N-13 ammonia using 
one, two or three compartments models (22-24) and corrections for lower extraction at 
higher flows is used from empirical relationships obtained in experimental studies.  
Rubidium-82, is a potassium analog like Tl-201, allows good quality myocardial images and 
is available by a generator. The very short physical half-life (76 sec) allows to perform rest 
and stress studies with minimal time intervals but also introduces some challenges for the 
absolute quantitation of MBF (16).   
A typical myocardial perfusion imaging exam includes a rest-stress protocol where either a 
physical (bycicle or treadmill exercise in conjunction with SPECT) or a pharmacological 
(dipyridamole, adenosine or dobutamine in conjunction with SPECT or PET) stressor is 
applied. In general SPECT is finalized to the detection of relative regional differences in 
myocardial perfusion while PET adds the potential of measuring absolute regional MBF and 
MBF reserve. The development of ECG-gated SPECT and PET has also enabled accurate 
regional and global cardiac function measurements based on a true tomographic approach. 
The methods are relatively operator-independent and comprehensive software packages 
allow the evaluation of the extent and severity of regional LV dysfunction, in hypoperfused 
but viable myocardium, as well as of global LV ejection fraction, volumes, diastolic function 
and geometry (25-27). 
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4. Endothelial dysfunction and myocardial perfusion imaging  
Another confirmation that myocardial perfusion imaging remains one of the best predictor 
of prognosis in patients with ischemic heart disease comes from coronary microvascular 
alterations in various heart diseases.  
A specific alteration of coronary endothelial function has been found in patients with 
different diseases such as atherosclerosis (28), dilated cardiomyopathy (29) and arterial 
hypertension (30). However, the relevance of endothelial dysfunction to physiologic flow 
control has not been directly documented. Accordingly, coronary artery stenosis is still  
considered the only factor able to affect coronary blood flow regulation in a relevant fashion 
during daily life. Nevertheless, endothelium is an important factor in the integrated 
response of hyperemic flow, even to agents affecting vasomotor tone, through direct action 
on smooth muscle cells. In fact, the lack of the endothelial contribution might limit the effect 
of endothelium-independent agents on flow. 
Several studies have actually documented abnormal flow responses to dipyridamole or 
atrial pacing in the myocardium supplied by angiographically normal coronary arteries in 
patients with dilated cardiomyopathy (31) or arterial hypertension (32) and even in patients 
with single vessel disease on control coronary arteries (33). 
Thus far, the link between reduced vasodilator response and endothelial dysfunction has 
not been tested directly. However, the coincidence of both abnormalities in populations 
with various heart diseases suggests their possible association in the same patient and thus a 
potential pathophysiologic link between the two. With regard to myocardial perfusion 
imaging, the reduction in maximal flow capacity due to microvascular alterations causes a 
reduction in perfusion differences between territories perfused by angiographically normal 
and stenotic vessels during vasodilator stress, thus explaining the relative decrease in 
sensitivity of myocardial perfusion scintigraphy in the detection of single-vessel coronary 
artery disease (34). On the other side, microvascular dysfunction might produce regional flow 
abnormalities per se, thus hampering the postulated cause-effect relationship between 
epicardial stenosis and perfusion defect. 
In agreement with this concept, Zeiher et al (35) demonstrated that coronary microvascular 
endothelial dysfunction was associated with a high incidence of reversible perfusion defects at 
stress myocardial perfusion imaging despite the absence of coronary stenosis. According to the 
traditional criteria, the abnormal scan results of these patients are considered to be “ false 
positive” . In contrast, this feature might represent an actual stenosis-independent abnormality 
in blood flow distribution rather than the effect of technical artifacts such as attenuation or 
partial-volume effect. This concept seems of great relevance, as monitoring of microvascular 
function can also be used for assessing the efficacy of therapy. Gould (36) demonstrated that 
aggressive cholesterol lowering is able to reduce reversible perfusion defects induced by 
dipyridamole. Guethlin et al (37) showed that statin therapy improves myocardial blood flow 
response to adenosine independently of stenosis severity in the related vessel. The most 
striking feature of these findings is that the interventions thought to improve endothelial 
function actually improved the flow response to endothelial independent stimuli, underlining 
the relevance of the endothelium in the integrated tuning of vasomotor tone. 
5. Functional risk assessment vs. noninvasive coronary angiography 
The prognostic value of coronary artery calcium (CAC) has been consistently demonstrated 
in large series of patients (39-41). Current evidence also suggests that the use of CAC is 
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independently predictive of outcome over and above traditional cardiac risk factors. As to 
functional risk assessment, CAC scores are predictive of a higher likelihood of ischemia on 
PET myocardial perfusion imaging (42). More importantly, patients with and without 
ischemia on PET perfusion imaging exhibit a stepwise increase in their risk of cardiac events 
with increasing calcium scores. These findings suggest that imaging approaches that 
combine quantitative information on the anatomic burden of ischemic heart disease with its 
physiological consequences offer improved risk stratification over conventional approaches 
that use myocardial perfusion alone. However, an independent and incremental prognostic 
value of CAC over clinical, electrocardiographic, laboratory, echocardiographic and 
angiographic variables has not been demonstrated yet. 
A similar consideration applies to computed tomography (CT) of the coronary arteries. 
A lthough the presence of obstructive coronary lesions at 64-slice CT angiography was a 
predictor of an adverse outcome (death, nonfatal myocardial infarction, unstable angina, 
and coronary revascularization) as compared to the patients with normal coronary arteries 
(43), an independent and incremental prognostic value of CT angiography over clinical, 
electrocardiographic, echocardiographic and scintigraphic variables has not been 
demonstrated. Up to now, two studies have been designed to test the impact of a combined 
anatomic and functional non-invasive imaging for detection and characterization of 
ISCHEMIC HEART DISEASE: the EVINCI study in Europe and the SPARC trial in the 
United States of America. While we are waiting for the results of these two trials, patients 
outcome in stable ischemic heart disease should be estimated using the evidences so far 
collected. 
6. Myocardial perfusion imaging and revascularization 
No differences in the composite of death, acute myocardial infarction and stroke was found 
between patients with stable ischemic heart disease, objective evidence of ischemia and 
significant coronary stenoses randomized to optimal medical therapy with or without 
percutaneous coronary intervention in the COURAGE trial (44). The relationship between 
extent of myocardial ischemia at gated SPECT and coronary revascularization has been 
explored in a subset of patients enrolled in a nuclear substudy of the COURAGE trial (45). In 
these patients, the addition of percutaneous coronary intervention to optimal medical 
therapy resulted in more effective reduction of ischemia than optimal medical therapy 
alone. This greater reduction in ischemic burden was associated with improvements in 
angina class and less reliance on nitrate therapy for symptom relief. Moreover, patients with 
moderate to severe ischemia randomized to percutaneous coronary intervention plus 
optimal medical therapy more commonly experienced a significant reduction in ischemia at 
follow-up compared with those receiving optimal medical therapy (78% versus 52%). Thus, 
the results of the nuclear substudy suggest that gated SPECT could be utilized for the 
identification of patients who will benefit more from coronary revascularization.  
7. The proper diagnostic work-up 
In patients with stable ischemic heart disease, myocardial perfusion imaging may be 
sometimes regarded as an unnecessary, or even redundant investigation. The study of 
Gimelli and Colleagues shows that myocardial perfusion abnormalities at rest and after 
stress are still the best predictors of cardiac event-free survival, even when compared with 
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an extensive diagnostic work-up. Specifically, when gated SPECT data were added to the 
clinical, laboratory, electrocardiographic and echocardiographic variables, the prognostic 
stratification significantly improved; however, when coronary angiography was added to 
gated SPECT, prognostic stratification did not further improve (Figure 1, top panel). On the 
other hand, if the information provided by gated SPECT was made available after clinical, 
laboratory, electrocardiographic, echocardiographic and angiographic variables, the 
prognostic stratification still improved significantly (Figure 1, lower panel). Thus, gated 
Modified from Gimelli et al, J Nucl Med 2009;50:546-53 
Fig. 1. Incremental prognostic value during the diagnostic work-up.  In the upper panel, the 
information provided by stress/ rest gated SPECT is available after clinical examination, 
laboratory tests, electrocardiography and echocardiography but before coronary 
angiography. In the lower panel, the information provided by gated SPECT is available after 
coronary angiography.  
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SPECT adds a prognostic information that is greater than that provided by coronary 
angiography. This observation suggests that the indications for myocardial perfusion 
imaging in risk stratification of patients with known or suspected ischemic heart disease 
should be broadened. 
In current clinical practice, a functional risk assessment may conflict w ith a health care 
delivery policy oriented towards cost saving and direct reperfusion. In this respect, a recent 
survey of the European Society of Cardiology has shown that non-invasive functional tests 
are under-utilized, w ith wide variability between different countries (46), so that several 
patients without significant ischemic heart disease directly undergo invasive coronary 
angiography. On the other hand, coronary lesions detected by coronary angiography are 
often revascularized even without the evidence that either myocardial blood supply or 
mechanical function is altered (47). This “ anatomically oriented”  invasive approach may 
negatively affect patient management, w ith consequent suboptimal medical treatment, 
inappropriate revascularizations, additional risks and increased health costs.  
8. Conclusions 
Several lines of evidence, collected with different approaches, demonstrate that a 
physiologic risk assessment is superior to an angiographically oriented approach in 
prognostic stratification of patients with stable ischemic heart disease. On these basis, 
stress/ rest myocardial perfusion abnormalities should be known – whenever possible - 
before coronary angiography in order to guide decision making, provided that 
appropriateness and patient’s risk/ benefits ratio are correctly considered. 
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negatively affect patient management, w ith consequent suboptimal medical treatment, 
inappropriate revascularizations, additional risks and increased health costs.  
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1. Introduction  
Coronary artery disease (CAD) is a major cause of mortality and morbidity and its 
management consumes a large proportion of national healthcare budgets (Underwood et al., 
2004). It has been estimated that approximately twenty diseases account for over 80% of all 
the deaths in the world (Satra et al., 2011). Specifically, atherosclerosis which occurs in the 
coronary arteries as the underlying defect responsible for CAD accounts for nearly half of 
these deaths. Although CAD treatment protocols are improving, its prevalence has 
increased. New imaging technologies have added to the immediate costs of investigation 
but they also have the potential to reduce overall costs, by virtue of their greater diagnostic 
and prognostic accuracy. This allows a more informed selection of therapy, which in turn can 
lead to a better clinical outcome (Underwood et al., 2004). 
Myocardial perfusion scintigraphy (MPS) was developed in the 1970s and has been used 
increasingly in clinical cardiology since the 1980s (Underwood et al., 2004). Technical 
developments that have fuelled this recent increase are single-photon emission tomographic 
computed imaging (SPECT), pharmacological stress and ECG-gated imaging (Underwood et al., 
2004). Nowadays, MPS comprises the only widely available method of assessing myocardial 
perfusion directly and many previously published reports support its evidence in the 
diagnosis of myocardial ischaemia and necrosis (Satra et al., 2011). Moreover, the prognostic 
value of this method for patients’ risk stratification has already been extensively reported, 
with an incremental prognostic value after clinical assessment, exercise electrocardiography 
and even above coronary angiography (Satra et al., 2011). Thus, MPS is an established 
imaging technique that is already an integral part of the management of CAD  (diagnosis, 
prognostication, selection for revascularization and assessment of acute coronary syndromes) 
and is included in a number of professional guidelines (Underwood et al., 2004).  
2. SPECT myocardial perfusion imaging agents 
MPS involves intravenous injection of small amounts of a radioactive tracer, usually during 
some form of cardiovascular stress. The three commercially available tracers are thallium-
201 thallous chloride (Tl-201), technetium-99m (Tc-99m) 2-methoxy-isobutyl-isonitrile 
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1. Introduction  
Coronary artery disease (CAD) is a major cause of mortality and morbidity and its 
management consumes a large proportion of national healthcare budgets (Underwood et al., 
2004). It has been estimated that approximately twenty diseases account for over 80% of all 
the deaths in the world (Satra et al., 2011). Specifically, atherosclerosis which occurs in the 
coronary arteries as the underlying defect responsible for CAD accounts for nearly half of 
these deaths. Although CAD treatment protocols are improving, its prevalence has 
increased. New imaging technologies have added to the immediate costs of investigation 
but they also have the potential to reduce overall costs, by virtue of their greater diagnostic 
and prognostic accuracy. This allows a more informed selection of therapy, which in turn can 
lead to a better clinical outcome (Underwood et al., 2004). 
Myocardial perfusion scintigraphy (MPS) was developed in the 1970s and has been used 
increasingly in clinical cardiology since the 1980s (Underwood et al., 2004). Technical 
developments that have fuelled this recent increase are single-photon emission tomographic 
computed imaging (SPECT), pharmacological stress and ECG-gated imaging (Underwood et al., 
2004). Nowadays, MPS comprises the only widely available method of assessing myocardial 
perfusion directly and many previously published reports support its evidence in the 
diagnosis of myocardial ischaemia and necrosis (Satra et al., 2011). Moreover, the prognostic 
value of this method for patients’ risk stratification has already been extensively reported, 
with an incremental prognostic value after clinical assessment, exercise electrocardiography 
and even above coronary angiography (Satra et al., 2011). Thus, MPS is an established 
imaging technique that is already an integral part of the management of CAD  (diagnosis, 
prognostication, selection for revascularization and assessment of acute coronary syndromes) 
and is included in a number of professional guidelines (Underwood et al., 2004).  
2. SPECT myocardial perfusion imaging agents 
MPS involves intravenous injection of small amounts of a radioactive tracer, usually during 
some form of cardiovascular stress. The three commercially available tracers are thallium-
201 thallous chloride (Tl-201), technetium-99m (Tc-99m) 2-methoxy-isobutyl-isonitrile 
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(MIBI) and technetium-99m 1,2-bis[bis(2-ethoxyethyl) phosphino] ethane (tetrofosmin). 
These are avidly extracted by cardiac myocytes and hence their initial myocardial 
distribution reflects a combination of the distribution of myocytes and perfusion. 
Comparison of images following stress and rest injections of tracer (or following 
redistribution for thallium) allows myocardial viability and perfusion to be assessed 
independently (Underwood et al., 2004). Tl-201 is a good tracer of myocardial perfusion and it 
has been used clinically for more than two decades (Hesse et al., 2005). It is administered 
intravenously as thallous chloride and the usual activity is 80 MBq. It does, however, have 
limitations: 
i. Relatively long physical half-life: high radiation burden for the patient (80 MBq delivers 
an effective dose of approximately 18 mSv). 
ii. Relatively low injected activity: low signal-to-noise ratio; images can be suboptimal 
(obese patients) and low count levels impair high-quality ECG-gated SPECT studies. 
iii. Relatively low energy emission: low-resolution images and significant attenuation by 
soft tissue. 
Tc-99m compounds do not have these limitations, which has encouraged the development 
and increasing use of such tracers, even if the physiological properties (somewhat lower 
fractional myocardial tracer uptake, in particular during high coronary flow values) of both 
Tc-99m labeled tracers are inferior to those of Tl-201 (Hesse et al., 2005). Two Tc-99m labeled 
perfusion tracers are currently available commercially: Tc-2-methoxyisobutylisonitrile (ses-
tamibi) and Tc-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane (tetrofosmin). Tc-99m sestamibi 
is a cationic complex which diffuses passively through the capillary and cell membrane, al-
though less readily than Tl-201, resulting in lower immediate extraction. Within the cell it is 
localized in the mitochondria, where it is trapped (Li et al., 1990), and retention is based on 
intact mitochondria, reflecting viable myocytes. Elimination of the radiotracer occurs mostly 
through the kidneys and the hepatobiliary system. Tetrofosmin comprises an interesting 
alternative radiotracer for myocardial perfusion scanning, as it combines the exceptional 
physical properties of Tc-99m with easy and fast preparation. This compound is also cleared 
rapidly from the blood and its myocardial uptake is rather similar to that of sestamibi (Jain 
et al., 1993), with approximately 1.2% of the administered dose being taken up by the 
myocardium. The exact mechanism of uptake is unknown, but it is supposed to be similar to 
that of sestamibi. Elimination of the radiotracer occurs mostly through the kidneys and the 
hepatobiliary system, and the hepatic clearance is slightly more rapid than in the case of 
sestamibi (Münch et al., 1997). For both Tc-99m labeled tracers splanchnic uptake and 
excretion are markedly higher than for Tl-201, which may occasionally complicate 
interpretation of the inferior wall perfusion. The tracer molecules taken up by the cardiac 
myocytes remain within the cells: usually two visits on two different days are necessary to 
obtain optimal stress and rest images (Anagnostopoulos et al., 2003; Hesse et al., 2005). 
After intravenous injection, Tc-99m labeled radiopharmaceuticals are distributed within the 
myocardium according to myocardial perfusion and viability. Unlike Tl-201, they have little 
(sestamibi) or almost no redistribution (tetrofosmin) and so separate injections are required 
for stress and resting studies. The higher energy of Tc-99m generally leads to better quality 
images (because of less attenuation and scatter). Moreover, the short half-life of Tc-99m 
permits much higher activities to be administered, giving better counting statistics and thus 
allowing performance of left ventricular (LV) ECG gating or first-pass imaging, which 
provides additional functional information. The diagnostic reference level for tomography is 
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a total of 1000 MBq for a one-day protocol (normally divided as 250 MBq and 750 MBq), or 
400 MBq for each study of a two-day protocol. Higher activities can be considered on an 
individual basis by the practitioner, for instance in obese patients (Anagnostopoulos et al., 
2003; Hesse et al., 2005). 
3. Clinical evaluation of MPS 
Many studies have evaluated the diagnostic accuracy of MPS for the detection of coronary 
heart disease, but they are of variable size and quality. There is a wide range of values 
reported for sensitivity and specificity that tend to overlap between different tests, although 
there have been studies comparing these different protocols in a head-to-head fashion. In the 
largest single study of 2,560 patients randomized to each of the three tracers and using mainly 
adenosine stress (the ROBUST study), overall sensitivity in the subset of patients undergoing 
angiography was 91%, specificity 87% and normalcy rate 89%, with no significant difference 
between the three tracers (Kapur et al., 2002).  However, image quality was superior for the 
studies acquired with the Tc-99m-based agents, most likely due in part to the lower energy of Tl-
201. In contrast, there is generally good agreement between Tc-99m sestamibi and Tc-99m 
tetrofosmin in identifying myocardial ischaemia (Russell & Zaret, 2006). In one of our previous 
studies using Tc-99m tetrofosmin as the radiotracer, we have found a good segmental agreement 
between tetrofosmin scintigram and coronary angiography. The sensitivity, specificity, positive 
predictive value and negative predictive value ranged between 72.2-91.1%, 80.0-88.2%, 76.4-
88.5% and 83.3-85.7% respectively, depending on the obstructed vessel (Georgoulias et al., 1996). 
The power of myocardial perfusion imaging (MPI) for predicting future coronary events has 
been demonstrated in a large number of high-quality studies and in many thousands of pa-
tients. It is perhaps the area of nuclear cardiology where the evidence is most strong (Brown, 
1991, 1995, 1996). The most important variables that predict the likelihood of future events 
are the extent and severity of inducible ischaemia (Ladenheim et al., 1986) but other 
predictors are increased lung uptake of thallium (Gill et al., 1987), stress-induced ventricular 
dilatation (Weiss et al., 1987) and left ventricular ejection fraction (Gioia et al., 1996; Johnson 
et al., 1997). In general, markers of left ventricular dysfunction tend to predict cardiac 
mortality and inducible ischaemia predicts acute coronary syndromes (Hachamovitch et al., 
1998; Sharir et al., 2001). MPS has incremental prognostic value even after clinical 
assessment, exercise electrocardiography and coronary angiography (Iskandrian  et al., 1993; 
Sharir et al., 1999). In other words, patients who appear to be high risk after coronary 
angiography can be separated into higher and lower risk groups by MPS. In addition, 
several studies have indicated that a negative SPECT study confers an excellent prognosis 
with an annual cardiac event rate of <1% for the general population (Geleijnse  et al., 1996; 
Iskander & Iskandrian, 1998; Machecourt et al., 1994; Marie et al., 1995; Schinkel et al., 2005; 
Shaw et al., 2003). In the setting of a normal myocardial perfusion study in a low-risk 
patient, it takes 9 years for the risk of a cardiac event to reach 1%, suggesting that, in the 
absence of new symptoms, a repeat perfusion study may not be needed for 3 to 5 years 
(Russell & Zaret, 2006). However, this "warranty period" does not appear to be absolute and 
is affected by clinical and technical factors, including the presence of diabetes or CAD, 
increasing age and male gender, and the need to perform a pharmacologic stress test rather 
than an exercise perfusion imaging test, which can increase the annual cardiac event rate in 
patients with a normal perfusion scan to as high as 1.8% (Hachamovitch et al., 2003). In 
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a total of 1000 MBq for a one-day protocol (normally divided as 250 MBq and 750 MBq), or 
400 MBq for each study of a two-day protocol. Higher activities can be considered on an 
individual basis by the practitioner, for instance in obese patients (Anagnostopoulos et al., 
2003; Hesse et al., 2005). 
3. Clinical evaluation of MPS 
Many studies have evaluated the diagnostic accuracy of MPS for the detection of coronary 
heart disease, but they are of variable size and quality. There is a wide range of values 
reported for sensitivity and specificity that tend to overlap between different tests, although 
there have been studies comparing these different protocols in a head-to-head fashion. In the 
largest single study of 2,560 patients randomized to each of the three tracers and using mainly 
adenosine stress (the ROBUST study), overall sensitivity in the subset of patients undergoing 
angiography was 91%, specificity 87% and normalcy rate 89%, with no significant difference 
between the three tracers (Kapur et al., 2002).  However, image quality was superior for the 
studies acquired with the Tc-99m-based agents, most likely due in part to the lower energy of Tl-
201. In contrast, there is generally good agreement between Tc-99m sestamibi and Tc-99m 
tetrofosmin in identifying myocardial ischaemia (Russell & Zaret, 2006). In one of our previous 
studies using Tc-99m tetrofosmin as the radiotracer, we have found a good segmental agreement 
between tetrofosmin scintigram and coronary angiography. The sensitivity, specificity, positive 
predictive value and negative predictive value ranged between 72.2-91.1%, 80.0-88.2%, 76.4-
88.5% and 83.3-85.7% respectively, depending on the obstructed vessel (Georgoulias et al., 1996). 
The power of myocardial perfusion imaging (MPI) for predicting future coronary events has 
been demonstrated in a large number of high-quality studies and in many thousands of pa-
tients. It is perhaps the area of nuclear cardiology where the evidence is most strong (Brown, 
1991, 1995, 1996). The most important variables that predict the likelihood of future events 
are the extent and severity of inducible ischaemia (Ladenheim et al., 1986) but other 
predictors are increased lung uptake of thallium (Gill et al., 1987), stress-induced ventricular 
dilatation (Weiss et al., 1987) and left ventricular ejection fraction (Gioia et al., 1996; Johnson 
et al., 1997). In general, markers of left ventricular dysfunction tend to predict cardiac 
mortality and inducible ischaemia predicts acute coronary syndromes (Hachamovitch et al., 
1998; Sharir et al., 2001). MPS has incremental prognostic value even after clinical 
assessment, exercise electrocardiography and coronary angiography (Iskandrian  et al., 1993; 
Sharir et al., 1999). In other words, patients who appear to be high risk after coronary 
angiography can be separated into higher and lower risk groups by MPS. In addition, 
several studies have indicated that a negative SPECT study confers an excellent prognosis 
with an annual cardiac event rate of <1% for the general population (Geleijnse  et al., 1996; 
Iskander & Iskandrian, 1998; Machecourt et al., 1994; Marie et al., 1995; Schinkel et al., 2005; 
Shaw et al., 2003). In the setting of a normal myocardial perfusion study in a low-risk 
patient, it takes 9 years for the risk of a cardiac event to reach 1%, suggesting that, in the 
absence of new symptoms, a repeat perfusion study may not be needed for 3 to 5 years 
(Russell & Zaret, 2006). However, this "warranty period" does not appear to be absolute and 
is affected by clinical and technical factors, including the presence of diabetes or CAD, 
increasing age and male gender, and the need to perform a pharmacologic stress test rather 
than an exercise perfusion imaging test, which can increase the annual cardiac event rate in 
patients with a normal perfusion scan to as high as 1.8% (Hachamovitch et al., 2003). In 
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these high-risk patients with normal myocardial perfusion studies, it may be prudent to 
perform repeat perfusion imaging on a more frequent basis.  
Because of its prognostic power, MPS can be used as the gatekeeper to coronary 
angiography. Bateman and colleagues showed that referral to coronary angiography after 
normal, mild to moderately abnormal and severely abnormal perfusion scans was 3.5%, 9% 
and 60% respectively (Bateman et al., 1995). Importantly, a policy of selective referral to 
coronary angiography based upon high-risk findings is defensible, as patients with mild to 
moderate abnormalities when managed medically have outcomes comparable to those 
undergoing invasive evaluation and subsequent revascularization (Underwood et al., 2004). 
Besides, several reports underlie that such a policy can be also cost-effective even if it is 
more expensive than an alternative test such as the exercise ECG (Underwood et al., 2004). 
Furthermore, MPS can provide useful information about cardiac risk in patients requiring 
non-cardiac surgery although these patients are generally at low risk and the predictive 
value of a normal perfusion study is greater than that of an abnormal study, while the 
clinical value of MPS using Tc-99m labeled agents (MIBI, tetrofosmin) to assess patients 
with acute coronary syndrome has been well established (Underwood et al., 2004).  
MPS is of proven value to assess patients post revascularization. Information gained from 
post-intervention  myocardial SPECT is important to differentiate patients with angina from 
those with exo-cardiac chest pain syndromes, to assess peri-intervention myocardial 
damage/acute vessel closure, to predict-detect restenosis after PCI and graft 
occlusion/stenosis after CABG surgery, to detect CAD progression in non-revascularized 
vessels, to assess left ventricular function (gated-SPECT), to evaluate the effects of 
intervention if required for occupational reasons and to predict patients’ long-term 
prognosis. With respect to detect graft patency, MPS has a 80-96% sensitivity and 61-88% 
specificity, while regarding restenosis after PCI, sensitivity and specificity range between 74-
94% and 67-88%, respectively (Georgoulias et al., 1998, 2008, 2010b). Specifically, using Tc-
99m tetrofosmin as the radiotracer, we  have reported a sensitivity, specificity, positive and 
negative  predictive value of MPI in detecting restenosis of 81.3%, 88%, 81.3% and 88%, 
respectively, whereas for the detection of restenosis in specific vessel, the corresponding 
values were 81.3%, 90%, 76.5% and 89.7%, respectively (Georgoulias et al., 1998, 2008, 
2010b). 
4. Increased pulmonary uptake during MPI 
It is generally supported that increased pulmonary uptake of a myocardial perfusion 
radiotracer reflects increased pulmonary capillary wedge pressure. This finding may be 
attributed to either ischaemic or non-ischaemic causes (valvular heart disease, 
cardiomyopathy, and pulmonary disease). 
4.1 Tl-201 pulmonary uptake 
A significant number of studies have engaged with the clinical importance of increased 
thallium (Tl)-201 lung uptake during myocardial perfusion imaging (Gill et al., 1987; 
Homma et al., 1987; Hurwitz et al., 1992; Kaul et al., 1998; Kurata et al., 1991; Liu et al., 1985; 
Mahmood et al., 1992). The quantification of lung uptake is mostly estimated using the 
lung/heart ratio (LHR) of radioactivity (counts/pixel) in two regions of interest (ROIs), one 
in the lung (usually the left one) and another one over the myocardium of the left ventricle, 
delineated in the anterior images (Gill et al., 1987; Hurwitz et al., 1992; Kurata et al., 1991; 
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Mahmood et al., 1992). However, there is a general discrepancy in the reported LHR normal 
values, depended mainly on the method of calculation. For Tl-201, LHR upper normal limits 
range in the literature from approximately 0.37 to 0.55 (Georgoulias et al., 2010a). Increased 
exercise Tl-201 uptake is associated with decreased left ventricular function, the presence of 
multiple-vessel CAD, and poor patient prognosis (Brown, 1997; Chin et al., 1996; Daou et al., 
2000; Gill et al., 1987; Kurata et al., 1991; Morel et al., 1999). Kurata et al. have found that 
patients with abnormal Tl-201 lung uptake had more extensive multiple-vessel CAD, more 
severe left ventricular dysfunction, and more perfusion defects than did patients with normal Tl-
201 pulmonary activity (Kurata et al., 1991).  
Follow-up studies have shown that abnormal lung Tl-201 uptake is in general a significant 
predictor of subsequent adverse cardiac events for patients undergoing an MPI. Moreover, 
the Tl-201 LHR prognostic value has been reported in specific subgroups such as in patients 
treated with thrombolytic therapy during acute myocardial infarction, in patients with 
unstable angina and non-Q myocardial infarction, in patients after coronary artery bypass 
grafting, in patients with left ventricular apical aneurysm and in patients with severe post-
ischaemic left ventricular dysfunction or after heart transplantation (Dakik et al., 1996; Jain 
et al., 1997; Krawczynska et al., 1997; Marcassa et al., 2000; Sarda et al., 2001;  Wu et al., 
2005). Abnormal pulmonary Tl-201 uptake during stress (treadmill or pharmacologic test) 
imaging has similar clinical significance to that noted during exercise. Thus, high uptake of 
Tl-201 in the lungs has an important prognostic value (Brown, 1997; Chin et al., 1996; Daou 
et al., 2000; Gill et al., 1987; Morel et al., 1999). Moreover, published data present an 
incremental prognostic value of increased Tl-201 pulmonary uptake over clinical, stress 
testing and other imaging findings, providing clinically useful risk assessment (Marcassa et 
al., 2000). 
4.2 Tc-99m sestamibi pulmonary uptake 
Although technetium-based radiopharmaceuticals have been widely used for several years, 
their limited use in lung uptake assessment has been regarded as a potential drawback. The 
results of assessing Tc-99m  sestamibi pulmonary-to heart ratio of activity on conventional 
images obtained 30–60 min after stress are ambiguous, while a few studies have suggested 
that measuring lung uptake of Tc-99m sestamibi on immediate post-stress images may be 
more valuable (Bacher-Stier et al., 2000; Choy & Leslie, 2001; Giubbini et al., 1995; Hurwitz 
et al., 1993; Hurwitz et al., 1996; Hurwitz et al., 1998; Hurwitz, 2000; Patel et al., 2004; 
Romanens et al., 2001; Saha et al., 1994). In addition, the methodology for calculating LHR 
among investigators varies; for example, a large ROI that enclosed the entire left ventricle or 
most of the left ventricle respectively and a fixed-size ROI in the left lung (Choy & Leslie, 
2001; Patel et al., 2004). Other widely used methods are the following: a transmural segment 
of the myocardium is outlined containing the area of peak counts and a crescenting ROI 
placed over the left lung or alternatively, a fixed small rectangular ROI placed over maximal 
myocardial and left lung activity (Hurwitz et al., 1993; Hurwitz et al., 1996; Hurwitz et al., 
1998; Hurwitz, 2000; Romanens et al., 2001). Thus, the reported LHR normal values for Tc-
99m sestamibi vary significantly between 0.44 and 0.56, depended on the method of 
calculation and the time interval between radiotracer’s injection and the acquisition of the 
image for the LHR calculation, although early post-stress calculated values are generally 
higher than those calculated during the standard acquisition time (Georgoulias et al., 2010a).  
In addition, conflicting results have been reported about the relation between the values of 
LHR measured in the delayed images and the presence of extensive myocardial ischaemia 
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et al., 1997; Krawczynska et al., 1997; Marcassa et al., 2000; Sarda et al., 2001;  Wu et al., 
2005). Abnormal pulmonary Tl-201 uptake during stress (treadmill or pharmacologic test) 
imaging has similar clinical significance to that noted during exercise. Thus, high uptake of 
Tl-201 in the lungs has an important prognostic value (Brown, 1997; Chin et al., 1996; Daou 
et al., 2000; Gill et al., 1987; Morel et al., 1999). Moreover, published data present an 
incremental prognostic value of increased Tl-201 pulmonary uptake over clinical, stress 
testing and other imaging findings, providing clinically useful risk assessment (Marcassa et 
al., 2000). 
4.2 Tc-99m sestamibi pulmonary uptake 
Although technetium-based radiopharmaceuticals have been widely used for several years, 
their limited use in lung uptake assessment has been regarded as a potential drawback. The 
results of assessing Tc-99m  sestamibi pulmonary-to heart ratio of activity on conventional 
images obtained 30–60 min after stress are ambiguous, while a few studies have suggested 
that measuring lung uptake of Tc-99m sestamibi on immediate post-stress images may be 
more valuable (Bacher-Stier et al., 2000; Choy & Leslie, 2001; Giubbini et al., 1995; Hurwitz 
et al., 1993; Hurwitz et al., 1996; Hurwitz et al., 1998; Hurwitz, 2000; Patel et al., 2004; 
Romanens et al., 2001; Saha et al., 1994). In addition, the methodology for calculating LHR 
among investigators varies; for example, a large ROI that enclosed the entire left ventricle or 
most of the left ventricle respectively and a fixed-size ROI in the left lung (Choy & Leslie, 
2001; Patel et al., 2004). Other widely used methods are the following: a transmural segment 
of the myocardium is outlined containing the area of peak counts and a crescenting ROI 
placed over the left lung or alternatively, a fixed small rectangular ROI placed over maximal 
myocardial and left lung activity (Hurwitz et al., 1993; Hurwitz et al., 1996; Hurwitz et al., 
1998; Hurwitz, 2000; Romanens et al., 2001). Thus, the reported LHR normal values for Tc-
99m sestamibi vary significantly between 0.44 and 0.56, depended on the method of 
calculation and the time interval between radiotracer’s injection and the acquisition of the 
image for the LHR calculation, although early post-stress calculated values are generally 
higher than those calculated during the standard acquisition time (Georgoulias et al., 2010a).  
In addition, conflicting results have been reported about the relation between the values of 
LHR measured in the delayed images and the presence of extensive myocardial ischaemia 
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or severe CAD (Bacher-Stier et al., 2000; Choy & Leslie, 2001; Patel et al., 2004; Saha et al., 
1994). On the other hand, the clinical value of Tc-99m sestamibi LHR obtained almost 
immediately after stress (exercise or vasodilatation), has been reported in several studies 
(Flamen et al., 1995; Münch et al., 1997; Nakajima et al., 1993). They have found that 
increased pulmonary to myocardial ratio calculated on early post-stress images was 
associated with severe scintigraphic abnormalities and angiographic findings (mainly three-
vessel disease or stenoses in the left mainstem), in concordance to Tl-201 post-stress lung 
uptake (Hurwitz et al., 1993; Hurwitz et al., 1998; Hurwitz, 2000; Romanens et al., 2001). In 
addition, Leslie et al. have reported the prognostic value of lung sestamibi uptake in a 
cohort of 718 patients with known or suspected CAD, who underwent a Tc-99m sestamibi 
MPI (Leslie et al., 2005). 
4.3 Tc-99m tetrofosmin pulmonary uptake 
As we have already mentioned Tc-99m tetrofosmin is an interesting alternative 
radiopharmaceutical for MPS, as it combines the exceptional physical properties of Tc-99m 
with easy and fast preparation (Georgoulias et al., 1996; Heo et al., 1994; Nakajima et al., 
1993; Sridhara et al., 1993). The diagnostic and prognostic value of myocardial perfusion 
SPECT studies using this radiotracer has already been well established, although a few 
studies have utilized the usefulness of lung uptake as an ancillary parameter. 
We have mentioned above the significant variability of the applied techniques for 
calculating LHR using Tc-99m labeled tracers. For the quantification of Tc-99m tetrofosmin 
pulmonary uptake, in our Nuclear Medicine Laboratory we acquire early anterior planar 
images (1000 kcounts, matrix 256X256), 4–6 min after radiotracer injection at stress (early 
post-stress images), considering that Tc-99m tetrofosmin has a rapid clearance from the 
lungs. We then delineate two ROIs: one square, 15X15 pixels, placed over the left mid-lung 
area at the vicinity of the myocardium (at a distance of at least 3 pixels above the 
anterolateral wall – ‘lung ROI’) and the other, manually drown irregular ROI, including the 
whole myocardial activity of the left ventricle (‘myocardial ROI’) (Choy & Leslie, 2001; 
Georgoulias et al., 2006; Patel et al., 2004) (Fig. 1). The pulmonary/heart ratio was 
determined as the mean counts/pixel in the lung ROI divided by the mean counts/pixel in 
the myocardial ROI (Choy & Leslie, 2001; Giubbini et al., 1995; Homma et al., 1987; Hurwitz 
et al., 1992; Hurwitz et al., 1998; Kaul et al., 1998; Kurata et al., 1991; Liu et al., 1985; Patel et 
al., 2004; Tanigaki et al., 1998; Tsou et al., 2002). Our method for calculating Tc-99m 
tetrofosmin LHR is similar to that used by Choy & Leslie (Choy & Leslie, 2001) and Patel et 
al. (Patel et al., 2004). This approach may underestimate the counts from the heart, if severe 
defects are present, thus potentially overestimating the LHR value. On the other hand, this 
method avoids problems related to hot spots or other artefacts that could have erroneous 
effects on LHR. We believe that our method is more representative of pulmonary and heart 
radioactivity, especially in cases with regional myocardial ischemia. 
The mechanism of lung uptake with Tc-99m labeled myocardial perfusion tracers has not 
been directly established, but it is reasonable to consider that it shares similarities with Tl-
201 lung uptake. Our findings (presenting below) that CAD severity, scintigraphic 
ischaemic abnormalities and clinical-exercise data of myocardial ischaemia have a 
considerable correlation with stress LHR, support the role of ischaemic left ventricular 
dysfunction with subsequent pulmonary congestion-increased pulmonary vascular transit 
time as previously suggested for thallium (although additional factors may be also 
important) (Choy & Leslie, 2001; Georgoulias et al., 2006).  
 




RCA: right coronary artery; LCX: left circumflex artery; LAD: left anterior descending artery 
Fig. 1. (A) Normal early post-stress LHR value (0.402) in a 50-year-old woman without 
CAD. (B) Elevated early post-stress LHR value (0.693) in a 61-year-old man with 3-vessel 
disease (RCA 95%, LCX 95%, LAD 80%) (Reprinted from European Journal of Nuclear 
Medicine and Molecular Imaging, Vol. 37, Georgoulias, P., Tsougos, I., Valotassiou, V., 
Tzavara, C., Xaplanteris, P., & Demakopoulos, N., Long-term prognostic value of early 
poststress (99m)Tc-tetrofosmin lung uptake during exercise (SPECT) myocardial perfusion 
imaging, pp. 789-798, Fig. 1, 2010, with kind permission from Springer Science & Business 
Media B.V.). 
In 2006, we published our results of studying 158 consecutive patients who underwent a 
stress/rest Tc-99m tetrofosmin myocardial SPECT (rest scans were obtained as gated 
SPECT) and coronary angiography (Georgoulias et al., 2006). An early post-stress LHR 
value of 0.500 was defined as the upper normal limit, taking into consideration the early 
post-stress LHR values calculated in a normal group and using the formula ‘mean value ± 
2SD’. Patients with a normal early post-stress LHR value generally had a better performance 
in the treadmill testing than those with an abnormal value, had significantly better 
myocardial perfusion and function and better angiographic results (Georgoulias et al., 2006). 
We found a significant correlation (P <0.001) among early post stress LHR, summed stress 
score (SSS) and the number of stenosed vessels (Georgoulias et al., 2006). The associations 
between the values of early post-stress LHR and summed difference score (SDS), left 
ventricular ejection fraction (LVEF) were weaker (P= 0.031, P=0.017). The incidence of multi-
vessel CAD in the subgroup of patients with increased values of early post-stress LHR, was 
significantly higher than in the normal group (81% vs. 42%, P<0.001) (Georgoulias et al., 
2006). We also reported a significant difference (P<0.001) of the early post stress LHR value 
between patients with normal coronary arteries or one-vessel disease and patients with 
multi-vessel disease (Fig. 2). The above-mentioned data could be attributed to the influence 
of ischaemia on the early post-stress LHR value and are generally analogous with other 
published data, while other investigators did not find similar results using Tc-99m sestamibi 
as the radiotracer (Hurwitz et al., 1993; Hurwitz et al., 1998; Saha et al., 1994). 
Moreover, early post-stress LHR was an independent predictor of multi-vessel CAD 
(coefficient 1.85, SD 0.16, P<0.001), with an incremental value for its identification 
(Georgoulias et al., 2006). Similar results have been presented by Tsou et al., Tanigaki et al. 
and Okajima et al. who have also reported the incremental value of Tc-99m tetrofosmin 
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CAD. (B) Elevated early post-stress LHR value (0.693) in a 61-year-old man with 3-vessel 
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In 2006, we published our results of studying 158 consecutive patients who underwent a 
stress/rest Tc-99m tetrofosmin myocardial SPECT (rest scans were obtained as gated 
SPECT) and coronary angiography (Georgoulias et al., 2006). An early post-stress LHR 
value of 0.500 was defined as the upper normal limit, taking into consideration the early 
post-stress LHR values calculated in a normal group and using the formula ‘mean value ± 
2SD’. Patients with a normal early post-stress LHR value generally had a better performance 
in the treadmill testing than those with an abnormal value, had significantly better 
myocardial perfusion and function and better angiographic results (Georgoulias et al., 2006). 
We found a significant correlation (P <0.001) among early post stress LHR, summed stress 
score (SSS) and the number of stenosed vessels (Georgoulias et al., 2006). The associations 
between the values of early post-stress LHR and summed difference score (SDS), left 
ventricular ejection fraction (LVEF) were weaker (P= 0.031, P=0.017). The incidence of multi-
vessel CAD in the subgroup of patients with increased values of early post-stress LHR, was 
significantly higher than in the normal group (81% vs. 42%, P<0.001) (Georgoulias et al., 
2006). We also reported a significant difference (P<0.001) of the early post stress LHR value 
between patients with normal coronary arteries or one-vessel disease and patients with 
multi-vessel disease (Fig. 2). The above-mentioned data could be attributed to the influence 
of ischaemia on the early post-stress LHR value and are generally analogous with other 
published data, while other investigators did not find similar results using Tc-99m sestamibi 
as the radiotracer (Hurwitz et al., 1993; Hurwitz et al., 1998; Saha et al., 1994). 
Moreover, early post-stress LHR was an independent predictor of multi-vessel CAD 
(coefficient 1.85, SD 0.16, P<0.001), with an incremental value for its identification 
(Georgoulias et al., 2006). Similar results have been presented by Tsou et al., Tanigaki et al. 
and Okajima et al. who have also reported the incremental value of Tc-99m tetrofosmin 
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Fig. 2. Mean value (±SD) of early post-stress LHR, in patients with normal angiography, one-
vessel disease, two-vessel disease and three-vessel disease (Reprinted from Nuclear 
Medicine Communications, Vol. 27, Georgoulias, P., Demakopoulos, N., Kontos, A., 
Xaplanteris, P., Xydis, K., & Fezoylidis, I., Early post-stress pulmonary uptake of 99m Tc 
tetrofosmin during exercise (SPECT) myocardial perfusion imaging: correlation with 
haemodynamic, perfusion and function parameters, pp. 119-126, 2006, with kind permission 
from Wolters Kluwer Health). 
LHR, compared to conventional MPI, for the detection of multi-vessel disease (Okajima et 
al., 2004a; Tanigaki et al., 1998; Tsou et al., 2002). Specifically, the early post-stress LHR 
added incremental value to clinical, exercise testing, and myocardial perfusion and function 
data, for the identification of patients with multi-vessel CAD. In detail, if the cut-off point of 
early post-stress LHR value was set at 0.500, the sensitivity, positive and negative predictive 
value to detect multi-vessel CAD improved from 87%, 84% and 82% to 94%, 85% and 91%, 
respectively, while the specificity did not change considerably (78%) (Georgoulias et al., 
2006).  
On the other hand there are only few published data about the Tc-99m tetrofosmin LHR 
prognostic value (Casáns Tormo et al., 2001). In a previously published manuscript, we have 
evaluated the long-term prognostic value of early post-stress Tc-99m tetrofosmin LHR, in a 
cohort of 276 patients who were investigated with stress/rest Tc-99m tetrofosmin 
myocardial gated-SPECT (rest studies) and coronary angiography. During a mean follow-up 
period of 32.4 months (SD=9.6) hard cardiac events (cardiovascular death and non-fatal 
myocardial infarction) occurred in 28 (10.1%) patients and soft cardiac events 
(revascularization procedures) in 32 (11.6%) patients (Georgoulias et al., 2010a). Implying 
multiple Cox regression analysis with stepwise-forward approach, early post-stress LHR 
was found to be a significant independent predictor for both soft and hard cardiac events. 
The hazard ratio (for 0.1 unit increase) was 4.41 (95%CI: 1.52 - 12.73, p=0.006) for soft cardiac 
events and 4.22 (95%CI: 2.07 - 8.62, p<0.001) for hard cardiac events. The other significant 
prognostic factors were use of β-blockers, SSS and use of nitrates for soft events and exercise 
duration and SSS for hard cardiac events (Georgoulias et al., 2010a). 
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The cumulative soft event-free rates for one, two and five years were 100% (SE=0%), 99.2% 
(SE=0.8%) and 92.8% (SE=3.2%) for patients with early post-stress LHR value less than 0.500 
and 98.5% (SE=1.0%), 96.1% (SE=1.7%) and 63.5% (SE=5.8%) for patients with early post-
stress LHR value more than 0.500, respectively. Finally, the cumulative hard event-free rates 
for one, two and five years were 100% (SE=0%), 99.2% (SE=0.8%) and 89.8% (SE=3.7%) for 
patients with early post-stress LHR value less than 0.500 and 98.5% (SE=1.1%), 92.1% 
(SE=2.4%) and 75% (SE=5.0%) for patients with early post-stress LHR value more than 0.500, 
respectively (Fig. 3, 4). 
Furthermore, the incremental prognostic value of early post-stress LHR was evaluated by a 
statistically significant increase in the global chi-square of the Cox proportional-hazard 
model that included clinical, exercise, angiographic and scintigraphic variables (Valotassiou 
et al., 2009). Using ROC analysis, the optimal sensitivity and specificity of various early 
post-stress LHR cut-off values for the prediction of cardiac events, was determined. ROC 
curve analysis showed that the optimal cut-off of early post-stress LHR for the prediction of 
soft cardiac events was 0.527 with sensitivity equal to 78.1% and specificity equal to 80.7 
(Valotassiou et al., 2009). Similarly, the early post-stress LHR value of 0.530 represented the 
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Fig. 3. Kaplan-Meier estimates for soft cardiac events according to early post-stress LHR 
levels (Reprinted from European Journal of Nuclear Medicine and Molecular Imaging, Vol. 
37, Georgoulias, P., Tsougos, I., Valotassiou, V., Tzavara, C., Xaplanteris, P., & 
Demakopoulos, N.,  Long-term prognostic value of early poststress (99m)Tc-tetrofosmin 
lung uptake during exercise (SPECT) myocardial perfusion imaging, pp. 789-798, Fig. 2, 
2010, with kind permission from Springer Science & Business Media B.V.). 
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added incremental value to clinical, exercise testing, and myocardial perfusion and function 
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value to detect multi-vessel CAD improved from 87%, 84% and 82% to 94%, 85% and 91%, 
respectively, while the specificity did not change considerably (78%) (Georgoulias et al., 
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(revascularization procedures) in 32 (11.6%) patients (Georgoulias et al., 2010a). Implying 
multiple Cox regression analysis with stepwise-forward approach, early post-stress LHR 
was found to be a significant independent predictor for both soft and hard cardiac events. 
The hazard ratio (for 0.1 unit increase) was 4.41 (95%CI: 1.52 - 12.73, p=0.006) for soft cardiac 
events and 4.22 (95%CI: 2.07 - 8.62, p<0.001) for hard cardiac events. The other significant 
prognostic factors were use of β-blockers, SSS and use of nitrates for soft events and exercise 
duration and SSS for hard cardiac events (Georgoulias et al., 2010a). 
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and 98.5% (SE=1.0%), 96.1% (SE=1.7%) and 63.5% (SE=5.8%) for patients with early post-
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patients with early post-stress LHR value less than 0.500 and 98.5% (SE=1.1%), 92.1% 
(SE=2.4%) and 75% (SE=5.0%) for patients with early post-stress LHR value more than 0.500, 
respectively (Fig. 3, 4). 
Furthermore, the incremental prognostic value of early post-stress LHR was evaluated by a 
statistically significant increase in the global chi-square of the Cox proportional-hazard 
model that included clinical, exercise, angiographic and scintigraphic variables (Valotassiou 
et al., 2009). Using ROC analysis, the optimal sensitivity and specificity of various early 
post-stress LHR cut-off values for the prediction of cardiac events, was determined. ROC 
curve analysis showed that the optimal cut-off of early post-stress LHR for the prediction of 
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Fig. 3. Kaplan-Meier estimates for soft cardiac events according to early post-stress LHR 
levels (Reprinted from European Journal of Nuclear Medicine and Molecular Imaging, Vol. 
37, Georgoulias, P., Tsougos, I., Valotassiou, V., Tzavara, C., Xaplanteris, P., & 
Demakopoulos, N.,  Long-term prognostic value of early poststress (99m)Tc-tetrofosmin 
lung uptake during exercise (SPECT) myocardial perfusion imaging, pp. 789-798, Fig. 2, 
2010, with kind permission from Springer Science & Business Media B.V.). 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 
 
234 
78.6%). The area under the curve (AUC) was 0.80 (95% CI: 0.71 - 0.88) and 0.76 (95% CI: 0.66- 
0.86), for soft and hard cardiac events, respectively. The addition of early post-stress LHR in 
the Cox regression model, included clinical, exercise data and myocardial perfusion SSS, 
increased significantly the global chi-square for both soft and hard cardiac events (p<0.001) 
declaring the significant incremental value of early post-stress LHR. The adjusted hazard 
ratios for early post-stress LHR more than 0.53 were 9.44 and 7.51 (95% CI: 3.13 - 28.41, 
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Fig. 4. Kaplan-Meier estimates for hard cardiac events according to early post-stress LHR 
levels (Reprinted from European Journal of Nuclear Medicine and Molecular Imaging, Vol. 
37, Georgoulias, P., Tsougos, I., Valotassiou, V., Tzavara, C., Xaplanteris, P., & 
Demakopoulos, N.,  Long-term prognostic value of early poststress (99m)Tc-tetrofosmin 
lung uptake during exercise (SPECT) myocardial perfusion imaging, pp. 789-798, Fig.3, 
2010, with kind permission from Springer Science & Business Media B.V.). 
To summarize, early post-stress Tc-99m tetrofosmin LHR appeared to be a useful index of 
extensive myocardial ischaemia, heart dysfunction and multi-vessel CAD (Georgoulias et 
al., 2006). Moreover, our results suggest that early post-stress LHR is an independent and 
powerful predictor for both hard (death or myocardial infarction) and soft cardiac events 
(revascularization procedures), providing incremental prognostic information to that 
provided by clinical, exercise testing and scintigraphic data (Georgoulias et al., 2010a; 
Valotassiou et al., 2009). In addition, an early post-stress LHR value of 0.53 was the optimal-
cut off for the prediction of any cardiac event and could be useful in clinical practice, 
contributing to more accurate patient risk stratification with valuable influence on their 
therapy (Valotassiou et al., 2009). 
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5. Incidental pathologic extra-cardiac findings during MPI 
Extra-cardiac findings during acquisition of MPS (using Tl-201 or Tc-99m labeled  
radiotracers) can be visualized in the area being viewed, including mainly the thorax and 
the upper abdomen, depending on the patient body size and the camera field of view (Kim 
et al., 2002; Vijayakumar et al., 2005). These extra-cardiac uptake accumulations may be 
benign or malignant and require further investigation which might be life saving for the 
patient (Kim et al., 2002; Vijayakumar et al., 2005). After intravenous administration, normal 
uptake of Tc-99m tetrofosmin is seen in several organs, most commonly localized in the 
heart, lungs, breasts mainly during lactation and lymph nodes, while in the abdomen 
significant normal uptake can occur in the liver, gall bladder and bowel (Vijayakumar et al., 
2005). Elimination of the radiotracer occurs mostly through the kidneys and the 
hepatobiliary system (Hesse et al., 2005). 
Pathologic uptake of Tc-99m tetrofosmin can occur in benign or malignant tumors and also 
in infectious or non-infectious diseases (Vijayakumar et al., 2005). The mechanism of uptake 
of Tc-99m tetrofosmin in non-cardiac lesions is not completely understood, but the size of 
the lesion, its mitochondrial-rich cellularity and perfusion (factors) play a significant role 
(Kinuya et al., 2003; Sükan et al., 2004). Over-expression of P-glycoprotein or multi-drug 
resistance can decrease tumor uptake and are also associated with resistance to cancer 
treatment. Benign Tc-99m tetrofosmin incidental extra-cardiac uptake in the neck and chest 
has been reported in thyroid diseases, parathyroid adenomas, benign lymph node 
hyperplasia, esophagitis, neurofibroma, smoker’s lung, lung infections, sarcoidosis and 
scapular hibernoma (Bestetti et al., 1996; Kannan et al., 2007; Oller et al., 2001; Vijayakumar 
et al., 2005). Photopenia in the lung bases due to pleural effusions and abnormal right liver 
configuration caused by elevation of the right hemi-diaphragm has also been reported 
during Tc-99m tetrofosmin MPS (Shih et al., 2002). In neck and chest malignant diseases, 
extra-cardiac uptake has been reported in: thyroid cancer, neuroendocrine tumors, 
mediastinal tumors, lung cancer, breast cancer, esophageal carcinoma, lymphoma, Kaposi’s 
sarcoma, multiple myeloma and in nasopharyngeal cancer (Khairallah et al., 2002; Okajima 
et al., 2004b; Torreggiani et al., 1999; Vijayakumar et al., 2005). Moreover, Tc-99m 
tetrofosmin incidental uptake in abdominal abnormalities has been detected during cardiac 
acquisition, when the area being viewed includes the lower thorax and the upper abdomen, 
in abnormalities of the liver, gallbladder, kidneys, oesophagus, stomach, bowel and bone 
marrow (Shih et al., 2002). Hepatocellular carcinoma, melanoma, sarcomas and multiple 
myeloma have also been described in the abdomen, accumulating Tc-99m tetrofosmin in 
MPS (Fisher et al., 2000; Hadase et al., 2003; Vijayakumar et al., 2005; Yi & Jacobs, 2004). 
Others, reviewing the raw data cine images of 566 patients during Tl-201 dipyridamole Tc-
99m tetrofosmin rest-stress MPS, found 234 abnormalities (Shih et al., 2002; Shih et al., 2005) 
such as: bone marrow visualisation (39.7%), duodenogastric and enterogastric reflux 
(20.1%), non-visualisation of the gallbladder (13.2%), small-atrophic-scarred, vaguely seen 
or ectopic kidneys, splenomegaly, liver diseases like hepatomegaly and cirrhosis and breast 
attenuation causing photopenia in the liver. The authors suggested that Tc-99m tetrofosmin 
is accumulated in the red bone marrow due to high and/or expanded haematopoetic 
activity. It is obvious that all these coincidental abdominal abnormalities should alert the 
referring physician to suggest further investigation. In addition, duodenogastric and 
enterogastric refluxes, which represent approximately 20% of the abdominal abnormalities, 
may cause symptoms mimicking angina. Recently, Gratz et al. reported six patients with 
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Fig. 4. Kaplan-Meier estimates for hard cardiac events according to early post-stress LHR 
levels (Reprinted from European Journal of Nuclear Medicine and Molecular Imaging, Vol. 
37, Georgoulias, P., Tsougos, I., Valotassiou, V., Tzavara, C., Xaplanteris, P., & 
Demakopoulos, N.,  Long-term prognostic value of early poststress (99m)Tc-tetrofosmin 
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unexpected abnormal mediastinal and/or thoracic activities, out of 2155 who underwent  
Tc-99m tetrofosmin MPI. Subsequently, the patients underwent resection of a thymoma 
(n=2), nonsmall cell lung cancer (n=1) and breast cancer (n=3) (Gratz et al., 2008). 
We have previously published an unusual case of a 60 year-old woman with atypical 
precardiac symptoms who underwent Tc-99m tetrofosmin stress - rest SPECT imaging 
(Kotsalou et al., 2008). The MPI gated-study was normal. However, an incidental finding 
of intense extra-cardiac uptake of the radiotracer in the left paracardiac area was observed 
(Fig. 5).  
 
 
Fig. 5. Anterior (a) and left lateral (b) projections of the thorax, demonstrated intense Tc-99m 
tetrofosmin uptake in the left paracardiac area (arrows).  Myocardial perfusion SPET 
imaging was normal (c) (Reprinted from Hellenic Journal of Nuclear Medicine, Vol. 11, 
Kotsalou, I., Georgoulias, P., Fourlis, S., Zoumboulidis, A., Giaslakiotis, K., Androulaki, A., 
Chronopoulos, P., & Dimakopoulos, N.,  Incidental pathologic extracardiac uptake of 
99mTc-tetrofosmin in myocardial perfusion imaging, pp. 43-45, 2008, with kind permission 
from the Hellenic Society of Nuclear Medicine). 
The computerized tomography (CT) and magnetic resonance imaging (MRI) tests revealed a 
mass of 6 cm diameter in the left lower anterior mediastinal area (Fig. 6). The patient after a 
biopsy underwent surgical resection of the mass through medial sternotomy followed by 
adjuvant radiotherapy of the mediastinum, because of microscopic invasion of the capsule. 
The histologic-immunochistochemical examination established the diagnosis of a thymoma 
type AB and stage 2b (Masaoka II2 and TNM Pt2) (Fig. 7). 
 




Fig. 6. Computed tomography (a) and magnetic resonance imaging (b) revealed a solid mass 
located in the left lower anterior mediastinal area, in contact but not infiltrating 
pericardium, while signs of pressing the left lung were also noticed (arrows).  Thymoma 
was the possible diagnosis (Reprinted from Hellenic Journal of Nuclear Medicine, Vol. 11, 
Kotsalou, I., Georgoulias, P., Fourlis, S., Zoumboulidis, A., Giaslakiotis, K., Androulaki, A., 
Chronopoulos, P., & Dimakopoulos, N.,  Incidental pathologic extracardiac uptake of 
99mTc-tetrofosmin in myocardial perfusion imaging, pp. 43-45, 2008, with kind permission 
from the Hellenic Society of Nuclear Medicine). 
Other authors have also reported cases of incidental thymoma detection during MPS 
(Chadika et al., 2005; Douglas et al., 2000; Rebollo Aguirre et al., 2003; Sciagrà et al., 1998; 
Vijayakumar et al., 2004; Vijayakumar et al., 2005). Moreover, Douglas et al. reviewed three 
cases of incidental occult thymoma, detected during dual isotope Tl-201 and Tc-99m 
tetrofosmin SPECT imaging (Douglas et al., 2000). The authors suggested that solitary extra-
cardiac uptake on Tc-99m images without Tl-201 uptake, corresponds to well- differentiated 
tumors, while the opposite corresponds to poorly-differentiated thymoma (Douglas et al., 
2000). 
6. Conclusion 
In conclusion, early post-stress Tc-99m tetrofosmin LHR has a significant clinical value, as a 
useful index of extensive myocardial ischaemia, heart dysfunction and multi-vessel CAD. 
Moreover, early post-stress LHR appears as an independent and powerful predictor, 
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Fig. 7. Histologic and immunochistochemical examination confirmed the diagnosis of a 
mixed type AB thymoma, stage Masaoka II2 and TNM Pt2 (Reprinted from Hellenic Journal 
of Nuclear Medicine, Vol. 11, Kotsalou, I., Georgoulias, P., Fourlis, S., Zoumboulidis, A., 
Giaslakiotis, K., Androulaki, A., Chronopoulos, P., & Dimakopoulos, N.,  Incidental 
pathologic extracardiac uptake of 99mTc-tetrofosmin in myocardial perfusion imaging, pp. 
43-45, 2008, with kind permission from the Hellenic Society of Nuclear Medicine). 
assigning incremental prognostic information to that provided by clinical, exercise testing 
and scintigraphic data. In addition, an LHR value of 0.53 was the optimal-cut off for the 
prediction of any cardiac event and could be useful in clinical practice. It seems that the 
clinical value of routine pulmonary uptake measurements during Tc-99m tetrofosmin 
myocardial scintigram, in immediate post-stress images, as an ancillary scintigraphic sign, 
will maximize not only the information it provides for the assessment of the severity of 
myocardial ischaemia and CAD, but also the prognostic value of the study. In an era where 
a continuous effort is underway for deriving as many elements as possible from the 
examinations, the calculation of early post-stress LHR during myocardial perfusion imaging 
may contribute to a better (more accurate) patient risk stratification with valuable influence 
on their therapy. 
Additionally, careful inspection of projection images should be an integral part of 
interpreting MPI studies. According to the literature, during Tc-99m tetrofosmin MPI 
various incidental extra-cardiac neck, chest and abdominal abnormalities have been 
detected. Even though MPI is performed for cardiac evaluation, Nuclear Medicine 
physicians should be aware of non-cardiac uptake of the radiotracer which can play an 
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essential role in early tumor detection resulting in life-saving early therapy. Any extra-
cardiac focal uptake of Tc-99m tetrofosmin requires attention of the interpreting physician 
and has to be mentioned in the report, guiding the referring physician to request further 
investigation. The identification of these coincidental findings is significant for the early 
detection of the coexisting pathology and may prove to be essential in saving patient’s life. 
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1. Introduction 
Myocardial perfusion imaging (MPI) was developed in the 1970s and has been used 
increasingly in clinical cardiology since the 1980s (Underwood et al., 2004). Technical 
developments that have fuelled this recent increases are single-photon emission computed 
tomography (SPECT) imaging, pharmacological stress and ECG-gated SPECT imaging. MPI 
comprises the only widely available method of assessing myocardial perfusion directly and 
many previously published reports support its evidence in the diagnosis of myocardial 
ischemia and necrosis. Moreover, the prognostic value of this method for patients’ risk 
stratification has already been extensively reported, with an incremental prognostic value 
after clinical assessment, exercise electrocardiography and even above coronary 
angiography. Thus, MPI is an established imaging technique that is already an integral part of 
the management of coronary artery disease (CAD) (diagnosis, prognostication, selection for 
revascularization and assessment of acute coronary syndromes) and is included in a number of 
professional guidelines. (1, 2) 
In the past two decades, a great body of literature has established the use of nuclear imaging 
for risk stratification in patients with known or suspected CAD. Risk stratification is of 
crucial importance for the practice of contemporary medicine. Extending the paradigm of 
noninvasive cardiac testing beyond the detection of disease is especially important, may risk 
assessment permits patients who are identified as being at a high risk for subsequent cardiac 
events should receive aggressive management, possibly including cardiac catheterization for 
potential revascularization procedures that may improve their outcome. Conversely, the 
management focus in patients with low future event rate should be shifted toward risk 
factor modification and aggressive medical therapy, reserving invasive procedures for 
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patients who fail medical management. CAD is disease with a wide spectrum of severity 
and extent with outcome, such as nonfatal myocardial infarction (MI) or cardiac death being 
related to the severity of disease. Clinical trials have shown that patients with severe CAD 
as left main coronary artery disease, especially those with left ventricular dysfunction, can 
benefit from coronary artery bypass graft surgery (CABG) with significant reduction in their 
mortality rate (1, 2, 3). Whereas patients with single-vessel or with two-vessel disease 
(without proximal left anterior descending artery involvement) would have improved 
symptoms of angina following CABG  and percutaneous transluminal coronary angioplasty 
with or without stent implantation, without any effect on their mortality rate.  
Risk assessment based on clinical finding and resting ECG only is limited. Exercise testing 
can also help, especially when examining the patient's functional capacity. Exercise-induced 
ECG changes and risk indices also have substantial prognostic value. Unfortunately most 
patients (55%) with suspected CAD would fall in an intermediate-risk group, necessitating 
additional risk stratification.  
Coronary angiography, considered the “gold standard” for the diagnosis of CAD, often does 
not provide information about the physiologic significance of atherosclerotic lesions, 
especially in borderline lesions. More importantly, it does not provide a clear marker of risk 
of adverse events, especially in patients with moderate disease severity. Andreas Gruentzig 
said; “When coronary angiography founded coronary artery disease, I would like to have diagnostic 
procedure who will give me functional significance that lesion.”(2, 3, 4, 5)   
2. Risk based on nuclear imaging results 
Determination culprit lesion  
The current definition of culprit lesion; that is zone of ischemia under the coronary stenoses (what 
degree?) That is not quite good definition. Some autors offer degree of coronary stenoses ≤ 70 
%, some ≤ 75%, even < 80-85% ) but is not quite wright, because that is not definy two 
pathophysiologic aspects of ischemia; severity and extent. Ladenhaim et al. have also shown 
that the magnitude of ischemia (severity and extent) correlates well with cardiac events. 
Some other autors shown correlation between event rate (death, nofatal IM and 
revascularization) and extent of ischemia demonstrated by the number of ischemic segments 
on SPECT scan. Iskander and Iskadrian have also shown that defects reversibility is an 
important predictor of type of cardiac events, whereas reversible perfusion defects are 
associated with nonfatal MI. This is very important finding, since a reversible defect on the 
myocardial perfusion imaging (MPI) by single photon-emission computed tomography 
(SPECT) is the only available diagnostic tool that can independently predict the risk of 
nonfatal MI. Therefore, stress perfusion studies should be reported documenting defect 
severity (mild, moderate, severe), size (small, moderate, large) and reversibility to provide 
essential risk stratification (2, 4, 5, 6).  
The value of MPI comes from the ability to identify and quantify the degree of jeopardized 
myocardium during stress tests. The size and severity of the perfusion abnormality provide 
powerful prognostic information and has been shown to directly relate to outcome. SPECT 
perfusion imaging and determination of culprit lesion is more predicitble of cardiac events 
than coronary angiography. As SPECT imaging may identify those patients at high risk for 
subsequent cardiac events, perfusion imaging may be used to help guide further testing and 
revascularization procedures, and this obviously has important cost-effectiveness 
ramifications. 
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The primary objective of those study was to determinate and localizes culprit lesion by 
knew introduce parameters SRS (summary reversible score) and ISRS (index of summary 
reversible score), under the angiographically detected coronary narrowing ≥75% for the least 
one coronary artery (2, 14).  
A welt of literature supports the use of MPI for risk stratification in patients with known or 
suspected CAD. The ability of SPECT imaging to localize and define the culprit lesion 
(extent/severity) of disease predicts subsequent cardiac events such as MI or cardiac death. 
Furthermore, specific applications of these nuclear cardiology techniques, such as post 
infarction or in patients with unstable angina, have also successfully assessed risk of 
cardiovascular events. The prognostic applications of perfusion imaging are germane to all 
health care providers, as these methods may be used to guide subsequent tests and 
treatments. MPI has significantly impact on patient management decisions and the cost-
effective utilization of health care. 
The rapid rate of technical advances and improved operator expertise has enabled this 
technique to gain more widespread application. Despite the large number of PTCA 
performed yearly, preprocedure documentation of myocardial ischemia is uncommon, 
occurring in only 29% of patients. Despite the obvious value of nuclear cardiology to detect, 
localize, and define the extent of ischemia, this procedure appears underutilized before 
performance of percutaneous intervention. It is unclear whether this reflects an under 
utilization of noninvasive methods to objectively justify the performance of PTCA or 
whether the addition of such techniques is considered superfluous. 
Myocardial perfusion imaging provides information on the extent and location of 
myocardial ischemia. The assessment of jeopardized myocardium may be performed and 
provides a measure of the relative value of PTCA in terms of the amount of jeopardized 
myocardium. The location of the stenosis may dictate the area at risk: extent and severity of 
perfusion defects were significantly smaller in patients with proximal compared with distal 
coronary artery occlusions (2, 14).  
Before revascularization is performed, myocardial perfusion imaging may assist in 
management decisions by demonstrating the presence of myocardial ischemia, viability and 
delineating the severity and extent of coronary artery disease. The significance of equivocal 
lesions may be determined and culprit vessel may be successfully defined by SPECT 
imaging before angioplasty.  
The aim of this study was to determinate and localizes culprit lesion by myocardial 
perfusion imaging (MPI), under the angiographically detected coronary narrowing ≥75% for 
the least one coronary artery. One hundred thirty-two (132) patients with known coronary 
artery disease (CAD) were studied. In all of them angiographically detected significant 
coronary narrowing (≥75% luminal stenosis for the least one coronary artery). Al patients 
submitted MPI 99mTc-MIBI, with pharmacologic adenosine stress protocol with concomitant 
low level bicycle exercise 50W (AdenoEX). We were measured relative uptake 99mTc-MIBI 
for each myocardial segment using short-axis myocardial tomogram study. A 5-point 
scoring system was used to assess difference between uptake degree in stress and rest 
studies for the same segments, and we were created two index; Sum reversibility score 
(SRS), Index of sum reversibility score (ISRS). Results: A total of 396 vascular territories 
(2244 segments) were analyzed before elective percutaneous coronary intervention (ePCI). 
Overall sensivity, specificity, and accuracy using SS were 90.2%, 87.5%, 89.4%, with positive 
predictive value 94, 1%. Overall sensitivity, specificity, and accuracy using ISRS were 94.4%, 
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90.6%, 93, 2%, with positive predictive value 95, 7%. Conclusion: MPI with two created 
index SRS and ISRS significantly improves sensitivity, specificity, and accuracy for 
determination culprit lesion in patients undergoing PCI. Conclusion: AdenoEX MPI 
significantly improves sensitivity, specificity, and accuracy for determination and 
localization culprit lesion in patients undergoing ePCI. 
3. Coronary artery disease – exercise and pharmacologic stress test 
Coronary artery disease (CAD) is still single greatest cause of death of men and women. In 
the USA more than 9 million patients are referred yearly for diagnostic cardiac stress test 
with radionuclide imaging. Although an increasing number of patients undergo 
pharmacologic stress because they are unable to perform adequate physical stress, such as 
maximal workload, duration, hemodynamic response, exercise-induced symptoms, and 
electrocardiography (ECG) changes, provide invaluable additional information for assessing 
a patients condition not available with pharmacologic stress. Pharmacologic stress testing 
accounts for approximately 48% of stress myocardial perfusion studies done to detect CAD 
in the US. Exercise stress test is preferred for patients who can exercise and achieve 
adequate exercise endpoints. Pharmacologic stress testing is reserved for patients who have 
exercise limitations. It is estimated that at least 25% of patients and 50% of hospitalized 
patients cannot perform maximal exercise. Pharmacologic stress can be done with 
vasodilator agents (adenosine, dipyridamole, adenosine triphosphate, or selective adenosine 
A2a receptor agonist) or with inotropic and chronotropic agents (dobutamine or 
arbutamine). Patients with left bundle branch block (LBBB) or electronically paced rhythms 
may have anteroseptal perfusion defects with exercise or dobutamine perfusion imaging 
unrelated to stenosis of the left anterior descending artery and hence vasodilator stress 
testing is recommended in these patients (6, 7, 8, 9).  
Adenosine and dipyridamole stress have been used in combination with exercise especially 
in patients with limited exercise capacity. The reported benefits of the combination protocols 
include improvement in ischemia detection and image quality, and reduction in side effects. 
The addition of exercise to vasodilator stress might partly overcome the roll-off 
phenomenon observed with vasodilators alone resulting in more radiotracer extraction and 
better estimation of CAD. 
Simultaneous exercise in conjunction with adenosine stress was safe and significantly 
reduced adenosine side effects by 30%-40% and enhanced image quality. These benefits 
were similar with sub maximal or maximal exercise (6-9, 10)  
Similar to adenosine, patients who underwent dipyridamole-exercise had fewer noncardiac 
side effects, more ischemic ECG changes, higher HR and systolic BP, and better image 
qualities with increased heart to liver and heart to gut count ratios.   
One of the most powerful uses of MPI is the evaluation of the risk for future events in 
patients with suspected or known CAD. Over the years, MPI has evolved as an essential tool 
in the evaluation and assessment of patient prior to coronary revascularization. It has a dual 
role. Prior to coronary angiography, MPI is extremely useful in documenting ischemia and 
determining the functional impact of single or multiple lesions identified subsequently. MPI 
remains the test of choice for identifying the lesion responsible for the ischemic symptoms, 
or so called culprit lesion. That is extremely useful for further management decisions with 
respect to percutaneous interventions. In compare, the absence of reversible ischemia in 
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patients with known CAD is an excellent prognostic marker and predicts a low annual 
event rate. The current definition of culprit lesion that is zone of ischemia under the 
coronary stenoses is not quite right, because that is not defined two pathophysiologic 
aspects of ischemia; severity and extent. The primary objective of those study was to 
determinate and localizes culprit lesion by knew introduce parameters SRS (summary 
reversible score) and ISRS (index of summary reversible score), under the angiographically 
detected coronary narrowing ≥75% for the least one coronary artery (2, 14). 
4. Methods 
One hundred thirty-two (132) patients with known CAD were studied. In all of them 
angiographically detected significant coronary narrowing (≥75% luminal stenosis for the 
least one coronary artery). All patients were submitted to 2 iv injections of 99mTc-MIBI, one 
in a peak pharmacologic stress test with concomitant low level exercise stress test (50W) 
AdenoEx protocol; we administered adenosine (in the dose of 140 μg/kg/min) in 
combination with supine bicycle exercise low level 50W. We started infusion at the end of 
the 1st minute bicycle exercise, and finished in the 5th minute. Bicycle exercise was 
continuing one minute more until 6th minute. Radiopharmaceutical 99mTc-MIBI was 
administrated during the infusion at the end of 2nd minute. Imaging started 15 minutes 
after iv. 99mTc-MIBI 740 MBq and the other 370 MBq at rest 3 hour after in the rest study.  
Images of the heart were taken; 15 min after injections for the stress studies, and 30 minutes 
after injections for the rest study, using an Orbiter Siemens gamma camera, which was fitted 
with a low energy, all purpose collimator, and connected with a dedicated computer system. 
Briefly, 32 projections were obtained over a semicircular 1800 arch wich extended from the 
anterior 00 to the left posterior position 1800. In each patient, we were using Stirner 
quantification program (Euro menu) modificated and standardized myocardial 
segmentation and nomenclature for topographic imaging of the heart analyzed SPECT. 
Quantification regional 99mTc-MIBI uptake was performed using short-axis myocardial 
tomography that was divided on 16 segments + apex for each study (2, 11).  
The left anterior descedenting artery (LAD) vascular territory including; basal anterior, basal 
anteroseptal, mid anterior, mid anteroseptal, apical anterior, apical septal, and apex; Left 
circumflex artery (LCx); basal inferolateral, basal anterolateral, mid inferolateral, mid 
anterolateral, apical lateral; Right coronary artery (RCA); basal inferoseptal, basal inferior, 
mid inferoseptal, mid inferior, apical inferior.  
We were measured relative uptake, in area individual coronary artery vascular territory, 
from each segment and compare with the segment with the best uptake, and we founded in 
the AdenoEx study; Normal relative uptake (> 85%); Probably normal (75%-85%); Equivocal 
(65%-75%); Probably abnormal (50%-65%); Abnormal (< 50%). Rest study; Normal relative 
uptake (> 90%); probably normal (80%-90%); equivocal (70%-80%); probably abnormal 
(55%-75%); abnormal (< 55%). Different between relative uptake each segment we were 
scoring with a 5-point scoring system to ass’s difference between uptake degree in stress 
and rest studies for the same segments (1= normal, 2= mild ischemia, 3= moderate ischemia, 
4= reversibility, 5= severe reversibility).  
We were introduced two knew index score to determinate culprit lesion. Summary 
reversible score (SRS) ≥ 3 in the territory of stenoses coronary artery was determinate 
culprit lesion. At least two segments with score 5 (index of summary reversible score- 
ISRS) in the territory of stenoses coronary artery was determinate culprit lesion. 
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90.6%, 93, 2%, with positive predictive value 95, 7%. Conclusion: MPI with two created 
index SRS and ISRS significantly improves sensitivity, specificity, and accuracy for 
determination culprit lesion in patients undergoing PCI. Conclusion: AdenoEX MPI 
significantly improves sensitivity, specificity, and accuracy for determination and 
localization culprit lesion in patients undergoing ePCI. 
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accounts for approximately 48% of stress myocardial perfusion studies done to detect CAD 
in the US. Exercise stress test is preferred for patients who can exercise and achieve 
adequate exercise endpoints. Pharmacologic stress testing is reserved for patients who have 
exercise limitations. It is estimated that at least 25% of patients and 50% of hospitalized 
patients cannot perform maximal exercise. Pharmacologic stress can be done with 
vasodilator agents (adenosine, dipyridamole, adenosine triphosphate, or selective adenosine 
A2a receptor agonist) or with inotropic and chronotropic agents (dobutamine or 
arbutamine). Patients with left bundle branch block (LBBB) or electronically paced rhythms 
may have anteroseptal perfusion defects with exercise or dobutamine perfusion imaging 
unrelated to stenosis of the left anterior descending artery and hence vasodilator stress 
testing is recommended in these patients (6, 7, 8, 9).  
Adenosine and dipyridamole stress have been used in combination with exercise especially 
in patients with limited exercise capacity. The reported benefits of the combination protocols 
include improvement in ischemia detection and image quality, and reduction in side effects. 
The addition of exercise to vasodilator stress might partly overcome the roll-off 
phenomenon observed with vasodilators alone resulting in more radiotracer extraction and 
better estimation of CAD. 
Simultaneous exercise in conjunction with adenosine stress was safe and significantly 
reduced adenosine side effects by 30%-40% and enhanced image quality. These benefits 
were similar with sub maximal or maximal exercise (6-9, 10)  
Similar to adenosine, patients who underwent dipyridamole-exercise had fewer noncardiac 
side effects, more ischemic ECG changes, higher HR and systolic BP, and better image 
qualities with increased heart to liver and heart to gut count ratios.   
One of the most powerful uses of MPI is the evaluation of the risk for future events in 
patients with suspected or known CAD. Over the years, MPI has evolved as an essential tool 
in the evaluation and assessment of patient prior to coronary revascularization. It has a dual 
role. Prior to coronary angiography, MPI is extremely useful in documenting ischemia and 
determining the functional impact of single or multiple lesions identified subsequently. MPI 
remains the test of choice for identifying the lesion responsible for the ischemic symptoms, 
or so called culprit lesion. That is extremely useful for further management decisions with 
respect to percutaneous interventions. In compare, the absence of reversible ischemia in 
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patients with known CAD is an excellent prognostic marker and predicts a low annual 
event rate. The current definition of culprit lesion that is zone of ischemia under the 
coronary stenoses is not quite right, because that is not defined two pathophysiologic 
aspects of ischemia; severity and extent. The primary objective of those study was to 
determinate and localizes culprit lesion by knew introduce parameters SRS (summary 
reversible score) and ISRS (index of summary reversible score), under the angiographically 
detected coronary narrowing ≥75% for the least one coronary artery (2, 14). 
4. Methods 
One hundred thirty-two (132) patients with known CAD were studied. In all of them 
angiographically detected significant coronary narrowing (≥75% luminal stenosis for the 
least one coronary artery). All patients were submitted to 2 iv injections of 99mTc-MIBI, one 
in a peak pharmacologic stress test with concomitant low level exercise stress test (50W) 
AdenoEx protocol; we administered adenosine (in the dose of 140 μg/kg/min) in 
combination with supine bicycle exercise low level 50W. We started infusion at the end of 
the 1st minute bicycle exercise, and finished in the 5th minute. Bicycle exercise was 
continuing one minute more until 6th minute. Radiopharmaceutical 99mTc-MIBI was 
administrated during the infusion at the end of 2nd minute. Imaging started 15 minutes 
after iv. 99mTc-MIBI 740 MBq and the other 370 MBq at rest 3 hour after in the rest study.  
Images of the heart were taken; 15 min after injections for the stress studies, and 30 minutes 
after injections for the rest study, using an Orbiter Siemens gamma camera, which was fitted 
with a low energy, all purpose collimator, and connected with a dedicated computer system. 
Briefly, 32 projections were obtained over a semicircular 1800 arch wich extended from the 
anterior 00 to the left posterior position 1800. In each patient, we were using Stirner 
quantification program (Euro menu) modificated and standardized myocardial 
segmentation and nomenclature for topographic imaging of the heart analyzed SPECT. 
Quantification regional 99mTc-MIBI uptake was performed using short-axis myocardial 
tomography that was divided on 16 segments + apex for each study (2, 11).  
The left anterior descedenting artery (LAD) vascular territory including; basal anterior, basal 
anteroseptal, mid anterior, mid anteroseptal, apical anterior, apical septal, and apex; Left 
circumflex artery (LCx); basal inferolateral, basal anterolateral, mid inferolateral, mid 
anterolateral, apical lateral; Right coronary artery (RCA); basal inferoseptal, basal inferior, 
mid inferoseptal, mid inferior, apical inferior.  
We were measured relative uptake, in area individual coronary artery vascular territory, 
from each segment and compare with the segment with the best uptake, and we founded in 
the AdenoEx study; Normal relative uptake (> 85%); Probably normal (75%-85%); Equivocal 
(65%-75%); Probably abnormal (50%-65%); Abnormal (< 50%). Rest study; Normal relative 
uptake (> 90%); probably normal (80%-90%); equivocal (70%-80%); probably abnormal 
(55%-75%); abnormal (< 55%). Different between relative uptake each segment we were 
scoring with a 5-point scoring system to ass’s difference between uptake degree in stress 
and rest studies for the same segments (1= normal, 2= mild ischemia, 3= moderate ischemia, 
4= reversibility, 5= severe reversibility).  
We were introduced two knew index score to determinate culprit lesion. Summary 
reversible score (SRS) ≥ 3 in the territory of stenoses coronary artery was determinate 
culprit lesion. At least two segments with score 5 (index of summary reversible score- 
ISRS) in the territory of stenoses coronary artery was determinate culprit lesion. 
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Results: A total of 396 vascular territories (2244 segments) were analyzed before elective 
percutaneous coronary intervention (ePCI). Overall sensitivity, specificity, and accuracy 
using SS were 90.2%, 87.5%, 89.4%, with positive predictive value 94,1%. Overall sensitivity, 
specificity, and accuracy using ISRS were 94.4%, 90.6%, 93, 2%, with positive predictive 
value 95, 7%. Conclusion: MPI with two created index SRS and ISRS significantly improves 
sensitivity, specificity, and accuracy for determination culprit lesion in patients undergoing 
PCI. 
5. State of the art and future directions 
Since the introduction of myocardial perfusion imaging (MPI) into clinical medicine in late 
1970s, this technique has undergone considerable expansion and evolution. Initially, 
myocardial perfusion imaging was introduced as a noninvasive diagnostic tool in 
determining the presence or absence of coronary artery disease (CAD).  
The ability to distinguish patients at low risk from those at high risk for future cardiac 
events has become an essential adjunct for clinicians in the management of patients of 
CAD.  The power of myocardial perfusion imaging (MPI) for predicting future coronary 
events has been demonstrated in a large number of high-quality studies and in many 
thousands of patients. It is perhaps the area of nuclear cardiology where the evidence is 
most strong. The most important variables that predict the likelihood of future events are 
the extent and severity of inducible ischemia. In general, markers of left ventricular 
dysfunction tend to predict cardiac mortality and inducible ischemia predicts acute 
coronary syndromes. MPI has incremental prognostic value even after clinical assessment, 
exercise electrocardiography and coronary angiography. In other words, patients who 
appear to be high risk after coronary angiography can be separated into higher and lower 
risk groups by MPS. In addition, several studies have indicated that a negative SPECT 
study confers an excellent prognosis with an annual cardiac event rate of <1% for the 
general population. In the setting of a normal myocardial perfusion study in a low-risk 
patient, it takes 9 years for the risk of a cardiac event to reach 1%, suggesting that, in the 
absence of new symptoms, a repeat perfusion study may not be needed for 3 to 5 years 
(13, 14, 15). However, this "warranty period" does not appear to be absolute and is 
affected by clinical and technical factors, including the presence of diabetes or CAD, 
increasing age and male gender, and the need to perform a pharmacologic stress test 
rather than an exercise perfusion imaging test, which can increase the annual cardiac 
event rate in patients with a normal perfusion scan to as high as 1.8%. In these high-risk 
patients with normal myocardial perfusion studies, it may be prudent to perform repeat 
perfusion imaging on a more frequent basis.  
Because of its prognostic power, MPI can be used as the gatekeeper to coronary 
angiography. Bateman and colleagues showed that referral to coronary angiography after 
normal, mild to moderately abnormal and severely abnormal perfusion scans was 3.5%, 9% 
and 60% respectively. Importantly, a policy of selective referral to coronary angiography 
based upon high-risk findings is defensible, as patients with mild to moderate abnormalities 
when managed medically have outcomes comparable to those undergoing invasive 
evaluation and subsequent revascularization. Besides, several reports underlie that such a 
policy can be also cost-effective even if it is more expensive than an alternative test such as 
the exercise ECG. Furthermore, MPS can provide useful information about cardiac risk in 
patients requiring non-cardiac surgery although these patients are generally at low risk and 
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the predictive value of a normal perfusion study is greater than that of an abnormal study, 
while the clinical value of MPS to assess patients with acute coronary syndrome has been 
well established. 
MPS is of proven value to assess patients post revascularization. Information gained from 
post-intervention myocardial SPECT is important to differentiate patients with angina 
from those with echo-cardiac chest pain syndromes, to assess peri-intervention 
myocardial damage/acute vessel closure, to predict-detect restenosis after PCI and graft 
occlusion/stenosis after CABG surgery, to detect CAD progression in non-revascularized 
vessels, to evaluate the effects of intervention if required for occupational reasons and to 
predict patients’ long-term prognosis (16, 17).  
The assessment of patients’ prognosis is central to the clinical management of patients with 
CAD. Patients with CAD can be characterized along a continuum of risk for cardiac events. 
When the risk of cardiac events low, cardiologists generally employ conservative medical 
management. Conversely, when the risk of cardiac events is high, aggressive patient 
management, such as the performance of coronary bypass surgery or coronary angioplasty, 
tends to be favored. Between these extremes of risk, are a large number of patients who have 
an intermediate risk of cardiac events, which can be arbitrary and roughly defined as a 
likelihood of from 2% to 5% of major cardiac events over the ensuing year. Decision making 
to such patients is challenging, since the indication for conservative versus aggressive 
treatment is most uncertain in this group. Thus, the clinical often desires additional 
prognostic information about such patient to better define the likelihood of cardiac events. It 
is this group of patients in whom radionuclide stress testing finds its greatest prognostic 
benefit. The prognostic utility of radionuclide stress tests derives from their ability to 
quantify the magnitude of jeopardized myocardium during exercise or during 
pharmacologic stress testing with dipyridamole or adenosine. Specifically, MPI measures 
two indices of ischemia: ischemic extent and ischemic severity. Ischemic extent indices 
reflect the area of myocardial mass that became during stress. Ischemic severity indices 
correlate roughly with the number of stenosed coronary arteries. The number of reversible 
myocardial perfusions defects seen by MPI SPECT, constitutes a typical variable of ischemic 
extent. By contrast, ischemic severities indices reflect the magnitude of inducible ischemia 
within a given myocardial region. For instance, the severity of a perfusion defects reflects 
the severity of subtending coronary stenoses. Variables of ischemia extent and severity that 
can be assessed with stress myocardial perfusion SPECT are shown in the Table 1. 
Included in this list are two variables that may be assessed by obtaining an early anterior 
planar scintigram before SPECT imaging: a) the post-stress lung uptake of isotope, and b) 
the transient post-stress ischemic dilatation of the left ventricle. 
Because of its clinical importance, information about the extent and severity of jeopardized 
myocardium should be incorporated into the routine reporting of radionuclide stress test 
results. Conventional practice is to divide the short axis of the left ventricle into the three 
regions: apical, mid-ventricular and basal. The apex is assessed from the vertical long axis 
slices. Our approach is to assess the reduction in regional uptake of isotope in each of the 17 
myocardial segments. On a five-point scale, as follows: 1 = none, 2 = mild, 3 = moderate, 4 = 
severe and 5 = complete reduction in regional uptake. Comparison of the stress and rest scores 
provides the physician with a quantitative estimation of the degree of reversibility of each 
myocardial defect. From the location of defects, it can be estimated which coronary vessels are 
the most likely culprit lesions for the induction of myocardial ischemia (2, 10, 16, 17, 18).  
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Results: A total of 396 vascular territories (2244 segments) were analyzed before elective 
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The ability to distinguish patients at low risk from those at high risk for future cardiac 
events has become an essential adjunct for clinicians in the management of patients of 
CAD.  The power of myocardial perfusion imaging (MPI) for predicting future coronary 
events has been demonstrated in a large number of high-quality studies and in many 
thousands of patients. It is perhaps the area of nuclear cardiology where the evidence is 
most strong. The most important variables that predict the likelihood of future events are 
the extent and severity of inducible ischemia. In general, markers of left ventricular 
dysfunction tend to predict cardiac mortality and inducible ischemia predicts acute 
coronary syndromes. MPI has incremental prognostic value even after clinical assessment, 
exercise electrocardiography and coronary angiography. In other words, patients who 
appear to be high risk after coronary angiography can be separated into higher and lower 
risk groups by MPS. In addition, several studies have indicated that a negative SPECT 
study confers an excellent prognosis with an annual cardiac event rate of <1% for the 
general population. In the setting of a normal myocardial perfusion study in a low-risk 
patient, it takes 9 years for the risk of a cardiac event to reach 1%, suggesting that, in the 
absence of new symptoms, a repeat perfusion study may not be needed for 3 to 5 years 
(13, 14, 15). However, this "warranty period" does not appear to be absolute and is 
affected by clinical and technical factors, including the presence of diabetes or CAD, 
increasing age and male gender, and the need to perform a pharmacologic stress test 
rather than an exercise perfusion imaging test, which can increase the annual cardiac 
event rate in patients with a normal perfusion scan to as high as 1.8%. In these high-risk 
patients with normal myocardial perfusion studies, it may be prudent to perform repeat 
perfusion imaging on a more frequent basis.  
Because of its prognostic power, MPI can be used as the gatekeeper to coronary 
angiography. Bateman and colleagues showed that referral to coronary angiography after 
normal, mild to moderately abnormal and severely abnormal perfusion scans was 3.5%, 9% 
and 60% respectively. Importantly, a policy of selective referral to coronary angiography 
based upon high-risk findings is defensible, as patients with mild to moderate abnormalities 
when managed medically have outcomes comparable to those undergoing invasive 
evaluation and subsequent revascularization. Besides, several reports underlie that such a 
policy can be also cost-effective even if it is more expensive than an alternative test such as 
the exercise ECG. Furthermore, MPS can provide useful information about cardiac risk in 
patients requiring non-cardiac surgery although these patients are generally at low risk and 
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the predictive value of a normal perfusion study is greater than that of an abnormal study, 
while the clinical value of MPS to assess patients with acute coronary syndrome has been 
well established. 
MPS is of proven value to assess patients post revascularization. Information gained from 
post-intervention myocardial SPECT is important to differentiate patients with angina 
from those with echo-cardiac chest pain syndromes, to assess peri-intervention 
myocardial damage/acute vessel closure, to predict-detect restenosis after PCI and graft 
occlusion/stenosis after CABG surgery, to detect CAD progression in non-revascularized 
vessels, to evaluate the effects of intervention if required for occupational reasons and to 
predict patients’ long-term prognosis (16, 17).  
The assessment of patients’ prognosis is central to the clinical management of patients with 
CAD. Patients with CAD can be characterized along a continuum of risk for cardiac events. 
When the risk of cardiac events low, cardiologists generally employ conservative medical 
management. Conversely, when the risk of cardiac events is high, aggressive patient 
management, such as the performance of coronary bypass surgery or coronary angioplasty, 
tends to be favored. Between these extremes of risk, are a large number of patients who have 
an intermediate risk of cardiac events, which can be arbitrary and roughly defined as a 
likelihood of from 2% to 5% of major cardiac events over the ensuing year. Decision making 
to such patients is challenging, since the indication for conservative versus aggressive 
treatment is most uncertain in this group. Thus, the clinical often desires additional 
prognostic information about such patient to better define the likelihood of cardiac events. It 
is this group of patients in whom radionuclide stress testing finds its greatest prognostic 
benefit. The prognostic utility of radionuclide stress tests derives from their ability to 
quantify the magnitude of jeopardized myocardium during exercise or during 
pharmacologic stress testing with dipyridamole or adenosine. Specifically, MPI measures 
two indices of ischemia: ischemic extent and ischemic severity. Ischemic extent indices 
reflect the area of myocardial mass that became during stress. Ischemic severity indices 
correlate roughly with the number of stenosed coronary arteries. The number of reversible 
myocardial perfusions defects seen by MPI SPECT, constitutes a typical variable of ischemic 
extent. By contrast, ischemic severities indices reflect the magnitude of inducible ischemia 
within a given myocardial region. For instance, the severity of a perfusion defects reflects 
the severity of subtending coronary stenoses. Variables of ischemia extent and severity that 
can be assessed with stress myocardial perfusion SPECT are shown in the Table 1. 
Included in this list are two variables that may be assessed by obtaining an early anterior 
planar scintigram before SPECT imaging: a) the post-stress lung uptake of isotope, and b) 
the transient post-stress ischemic dilatation of the left ventricle. 
Because of its clinical importance, information about the extent and severity of jeopardized 
myocardium should be incorporated into the routine reporting of radionuclide stress test 
results. Conventional practice is to divide the short axis of the left ventricle into the three 
regions: apical, mid-ventricular and basal. The apex is assessed from the vertical long axis 
slices. Our approach is to assess the reduction in regional uptake of isotope in each of the 17 
myocardial segments. On a five-point scale, as follows: 1 = none, 2 = mild, 3 = moderate, 4 = 
severe and 5 = complete reduction in regional uptake. Comparison of the stress and rest scores 
provides the physician with a quantitative estimation of the degree of reversibility of each 
myocardial defect. From the location of defects, it can be estimated which coronary vessels are 
the most likely culprit lesions for the induction of myocardial ischemia (2, 10, 16, 17, 18).  
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Predictor Ischemia Extent Ischemia Severity 
- Number and/or location 
of reversible defections 
- Magnitude of defects 
- Delayed redistribution 
- Lung uptake of isotopeª 
- Transient LV dilatationª  
- Magnitude of WMA¹ 
- Number/location of 
WMA¹ 





















ªBest assessed by obtaining a 5-minute and 4-hour anterior planar scintigram before the initiation of 
SPECT imaging. 
¹Obtained from concomitant rest-exercise first-pass radionuclide ventriculography when employing 
99mTc-agents.  
LV left ventricle; WMA wall-motion abnormality; EF ejection fraction 
Table 1. Predictors of stress-induced ischemia extent and severity using SPECT and 
adjunctive scintigrams. 
The relationship between the magnitude of inducible myocardial ischemia and the 
likelihood of cardiac events is not linear. Previous investigation has shown that the 
magnitude of ischemia has an exponential relationship to the occurrence of subsequent 
cardiac events. Patients who demonstrate only mild ischemia at a peak stress have only a 
small, relatively flat increase in the likelihood of cardiac events as compared to patients who 
manifest no scintigraphic evidence of inducible ischemia. But, once ischemia progressed to a 
moderate magnitude, the likelihood of cardiac events begins to increase sharply. Ladenheim 
and colleagues performed a 1-year follow-up of 1.689 patients without prior myocardial 
infarction (MI) who underwent exercises planar MPI for diagnostic or prognostic purposes. 
The frequency of hard cardiac events (MI/cardiac death) and late (> 60 days) bypass 
surgery after testing were recorded as cardiac events. Ischemic extent and ischemic severity 
were exponentially related to the cardiac event rate (2, 17, 18).  
Based on the published prognostic literature, four points may be derived that can serve as 
general rules of thumb for the utilization of scintigraphic testing in clinical practice: 
6. Use of radionuclide stress testing in patient-management decision 
- Risk assessment in patients with a high likelihood of CAD 
- Selection of therapy in patients with angiographically documented CAD; 
- Selection between medical therapy versus revascularization. 
- Identification of culprit lesions prior to coronary intervention. 
- Evaluation of borderline coronary artery stenosis. 
- Risk stratification of post-MI patients 
- Predischarge exercise testing. 
- Predischarge pharmacological stress testing. 
- Evaluation of patients following thrombolysis. 
- Predischarge evaluation of patients with unstable angina 
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- Risk stratification of the elderly 
- Risk stratification of patients with congestive heart failure and/or left ventricular 
dysfunction 
- Evaluation of patients following treatment modalities for CAD 
- Percutaneous coronary intervention 
- Coronary artery by-pass surgery 
- Medical therapy 
- Risk stratification of patients prior to elective noncardiac surgery 
Substitution of pharmacological stress testing for risk stratification. In general, the 
performance of myocardial perfusion scintigraphy with exercise as opposed to 
pharmacological stress is preferable for prognosis purposes. Important prognostic variables 
associated with exercise ECG testing include exercise capacity, exercise-inducible chest pain 
or hypotension, and the ECG response to exercise, particularly the heart rate threshold and 
post-exercise duration of stress-induced ST-segment depression. These variables cannot be 
assessed when pharmacologic instead of exercise testing is employed. 
However, the performance of myocardial perfusion imaging in conjunction with 
pharmacologic stress testing, either with dipyridamole or with adenosine, has essentially the 
same sensitivity and specificity for detecting CAD as does exercise myocardial perfusion 
scintigraphy. Moreover, studies done with both modalities indicate that magnitude of 
ischemic defects induces by exercise is not underestimated by those induces by pharmacologic 
stress. A normal scintigraphic study in association with pharmacological stress is associated 
with a same low risk of cardiac events as is a normal exercise myocardial perfusion study. 
Dipyridamole or adenosine SPECT is commonly employed as the pharmacological stress 
agent, given its ease to use. Myocardial perfusion imaging (MPI) can also be performed in 
conjunction with dobutamine or arbutamine stress, but is generally reserved for patients with 
asthma or chronic lung disease. Despite the theoretical advantages of exercise in assessment 
prognosis, excellent risk stratification has been reported with adenosine SPECT imaging, with 
results similar to those observed with exercise. 
Based on the strongly documented prognostic efficacy, MPI has emerged as a key guide for 
major medical decisions involving patients with suspected or known CAD 
Myocardial perfusion imaging provides incremental prognostic value, particularly in 
patients and an intermediate or high pretest likelihood of CAD or patients with stable CAD 
and mild symptoms. Patients who exhibit normal myocardial perfusion and function on 
gated SPECT have an excellent prognosis and should be referred for non cardiac evaluation 
for determining etiology of the presenting symptoms. Conversely, patients with high-risk 
scans may benefit from an early invasive strategy with a view toward revascularization 
depending on coronary anatomical finding. A substantial number of patients undergoing 
SPECT perfusion imaging will have mild ischemia without a multivessel disease scan 
pattern. If patients with mild ischemia have good exercise tolerance, they should be 
considered as candidates for intense medical therapy with follow-up exercise SPECT 
imaging possibly at 1 year. Unpublished data from the Clinical Outcomes Utilizing 
Revascularization and Aggressive Drug Evaluations (COURAGE) trial seem to indicate that 
many ischemic defects may markedly improve with aggressive lowering of abnormal lipids 
an the other pharmacological interventions. Hachamovitch and colleagues reported patients 
with the mildly abnormal scan had a 0.8% annual cardiac death rate compared with 0.9% for 
those who underwent revascularization. The death rate in medically treated patients who 
had moderately abnormal scans was 2.3% versus 1.1% for such patients undergoing 
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Predictor Ischemia Extent Ischemia Severity 
- Number and/or location 
of reversible defections 
- Magnitude of defects 
- Delayed redistribution 
- Lung uptake of isotopeª 
- Transient LV dilatationª  
- Magnitude of WMA¹ 
- Number/location of 
WMA¹ 





















ªBest assessed by obtaining a 5-minute and 4-hour anterior planar scintigram before the initiation of 
SPECT imaging. 
¹Obtained from concomitant rest-exercise first-pass radionuclide ventriculography when employing 
99mTc-agents.  
LV left ventricle; WMA wall-motion abnormality; EF ejection fraction 
Table 1. Predictors of stress-induced ischemia extent and severity using SPECT and 
adjunctive scintigrams. 
The relationship between the magnitude of inducible myocardial ischemia and the 
likelihood of cardiac events is not linear. Previous investigation has shown that the 
magnitude of ischemia has an exponential relationship to the occurrence of subsequent 
cardiac events. Patients who demonstrate only mild ischemia at a peak stress have only a 
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infarction (MI) who underwent exercises planar MPI for diagnostic or prognostic purposes. 
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were exponentially related to the cardiac event rate (2, 17, 18).  
Based on the published prognostic literature, four points may be derived that can serve as 
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6. Use of radionuclide stress testing in patient-management decision 
- Risk assessment in patients with a high likelihood of CAD 
- Selection of therapy in patients with angiographically documented CAD; 
- Selection between medical therapy versus revascularization. 
- Identification of culprit lesions prior to coronary intervention. 
- Evaluation of borderline coronary artery stenosis. 
- Risk stratification of post-MI patients 
- Predischarge exercise testing. 
- Predischarge pharmacological stress testing. 
- Evaluation of patients following thrombolysis. 
- Predischarge evaluation of patients with unstable angina 
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- Risk stratification of the elderly 
- Risk stratification of patients with congestive heart failure and/or left ventricular 
dysfunction 
- Evaluation of patients following treatment modalities for CAD 
- Percutaneous coronary intervention 
- Coronary artery by-pass surgery 
- Medical therapy 
- Risk stratification of patients prior to elective noncardiac surgery 
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pattern. If patients with mild ischemia have good exercise tolerance, they should be 
considered as candidates for intense medical therapy with follow-up exercise SPECT 
imaging possibly at 1 year. Unpublished data from the Clinical Outcomes Utilizing 
Revascularization and Aggressive Drug Evaluations (COURAGE) trial seem to indicate that 
many ischemic defects may markedly improve with aggressive lowering of abnormal lipids 
an the other pharmacological interventions. Hachamovitch and colleagues reported patients 
with the mildly abnormal scan had a 0.8% annual cardiac death rate compared with 0.9% for 
those who underwent revascularization. The death rate in medically treated patients who 
had moderately abnormal scans was 2.3% versus 1.1% for such patients undergoing 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 
 
258 
revascularization. Finally, patients with a severely abnormal scan treated medically had an 
annual cardiac death rate of 4.6% versus 1.3% for such patients who were revascularized. In 
the second study, these investigators showed that medically treated patients who had 
greater than 20% of the total myocardium rendered ischemic had higher annual cardiac 
death rate (6.7%) compared with 2.0% for patients with this degree of extensive ischemia 
who underwent revascularization. For patients with 10% or less of the total myocardium 
rendered ischemic, there was no difference in outcome between medical therapy and 
revascularization (2, 12, 13, 17, 18).  
Exercise myocardial perfusion imaging is a valuable adjunct for separating high to low risk 
patients who present symptoms consistent with stable CAD, or in patients who have known 
disease and in whom further prognostication is warranted. Multiple high-risk nuclear 
imaging variables can be identified, and the greater the extent of exercise/induced ischemia, 
the greater the risk of cardiac events. Adjunctive variables, such as transient ischemic cavity 
dilatation and functional assessment with evaluation of regional wall thickening or wall 
motion and left ventricular ejection fraction greatly assist in the risk stratification process.  
Nuclear cardiology is uniquely placed to address all the major determinants of prognosis in 
CAD can be assessed by measurements of stress-induced perfusion or function. These 
measurements include the amount of infarcted myocardium, the amount of jeopardized 
myocardium (supplied by vessels with hemodynamically significant stenosis), and the degree 
of jeopardy (tightness of the individual coronary stenosis). Recent evidence in large patient 
cohorts has revealed that factor estimating the extent of left ventricular dysfunction (left 
ventricular ejection fraction, extent of infarcted myocardium, transient ischemic dilatation of 
the left ventricle and increasing lung uptake) are excellent predictors of cardiac mortality. 
However, measurements of inducible ischemia are the best predictors of the development of 
acute coronary syndromes. Several reports have shown that nuclear testing yields incremental 
prognostic value over clinical information with respect to cardiac death, or the combination of 
cardiac death and nonfatal myocardial infarction as isolated endpoints. Now it is possible to 
tailor therapeutic decision making for an individual patient based upon combination of clinical 
factors and nuclear scan results. Patients with severe perfusion abnormalities on their stress 
image may have a five- to ten-fold higher likelihood of cardiac death versus patient with a 
normal myocardial perfusion SPECT. If the defects perfusion determined as a culprit lesion, 
invasive therapy (PCI) is an optimized outcome for that patient (2). 
7. Clinical evaluation of MPS 
The power of myocardial perfusion imaging (MPI) for predicting future coronary events has 
been demonstrated in a large number of high-quality studies and in many thousands of pa-
tients. It is perhaps the area of nuclear cardiology where the evidence is most strong. The 
most important variables that predict the likelihood of future events are the extent and 
severity of inducible ischemia. In general, markers of left ventricular dysfunction tend to 
predict cardiac mortality and inducible ischemia predicts acute coronary syndromes. MPS 
has incremental prognostic value even after clinical assessment, exercise 
electrocardiography and coronary angiography. In other words, patients who appear to be 
high risk after coronary angiography can be separated into higher and lower risk groups by 
MPS. In addition, several studies have indicated that a negative SPECT study confers an 
excellent prognosis with an annual cardiac event rate of <1% for the general population. In 
the setting of a normal myocardial perfusion study in a low-risk patient, it takes 9 years for 
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the risk of a cardiac event to reach 1%, suggesting that, in the absence of new symptoms, a 
repeat perfusion study may not be needed for 3 to 5 years. However, this "warranty period" 
does not appear to be absolute and is affected by clinical and technical factors, including the 
presence of diabetes or CAD, increasing age and male gender, and the need to perform a 
pharmacologic stress test rather than an exercise perfusion imaging test, which can increase 
the annual cardiac event rate in patients with a normal perfusion scan to as high as 1.8%. In 
these high-risk patients with normal myocardial perfusion studies, it may be prudent to 
perform repeat perfusion imaging on a more frequent basis.  
Because of its prognostic power, MPS can be used as the gatekeeper to coronary angiography. 
Bateman and colleagues showed that referral to coronary angiography after normal, mild to 
moderately abnormal and severely abnormal perfusion scans was 3.5%, 9% and 60% re-
spectively. Importantly, a policy of selective referral to coronary angiography based upon 
high-risk findings is defensible, as patients with mild to moderate abnormalities when 
managed medically have outcomes comparable to those undergoing invasive evaluation and 
subsequent revascularization. Besides, several reports underlie that such a policy can be also 
cost-effective even if it is more expensive than an alternative test such as the exercise ECG. 
Furthermore, MPS can provide useful information about cardiac risk in patients requiring non-
cardiac surgery although these patients are generally at low risk and the predictive value of a 
normal perfusion study is greater than that of an abnormal study, while the clinical value of 
MPS to assess patients with acute coronary syndrome has been well established. 
MPS is of proven value to assess patients post revascularization. Information gained from 
post-intervention myocardial SPECT is important to differentiate patients with angina from 
those with echo-cardiac chest pain syndromes, to assess peri-intervention myocardial 
damage/acute vessel closure, to predict-detect restenosis after PCI and graft 
occlusion/stenosis after CABG surgery, to detect CAD progression in non-revascularized 
vessels, to evaluate the effects of intervention if required for occupational reasons and to 
predict patients’ long-term prognosis ( 2, 14, 16, 17, 18).  
 
 
Fig. 1. Culprit lesion on the lateral and inferior segments on the short axis after SPECT MPI 
with AdenoEx protocol. In the rest study (right side) we showed normal finding of 
perfusion in the same area. We indicated invasive strategy. 
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revascularization. Finally, patients with a severely abnormal scan treated medically had an 
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factors and nuclear scan results. Patients with severe perfusion abnormalities on their stress 
image may have a five- to ten-fold higher likelihood of cardiac death versus patient with a 
normal myocardial perfusion SPECT. If the defects perfusion determined as a culprit lesion, 
invasive therapy (PCI) is an optimized outcome for that patient (2). 
7. Clinical evaluation of MPS 
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most important variables that predict the likelihood of future events are the extent and 
severity of inducible ischemia. In general, markers of left ventricular dysfunction tend to 
predict cardiac mortality and inducible ischemia predicts acute coronary syndromes. MPS 
has incremental prognostic value even after clinical assessment, exercise 
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Fig. 2. Occlusion ACx, and subtotal stenosis RCA. In the same acts we perfiormed PCI with 
stent implantation  
 
 
Fig. 3. MPI nearly after PCI (two weeks) showed normal findinig  
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Fig. 4. Rest study showed normal MPI finding; stress two lines short axis below; culprit 
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Fig. 7. Two months after we performed MPI for assessment elective PCI theraphy. We fnded 
normal perfusion in the rest (up) and AdenoEx study (below two lines short axis)  
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Fig. 11. Nearly after elective PCI intervention we performed MPI with normal finding of 
perfusion 
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Myocardial perfusion imaging by SPECT, with pharmacologic stress test AdenoEX 
significantly improves sensitivity, specificity, and accuracy for determination and 
localization culprit lesion in patients undergoing elective percutaneous coronary 
intervention.  
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Turkey 
1. Introduction  
The early identification of susceptibility to adverse cardiovascular outcomes and risk 
stratification amongst asymptomatic individuals, as well as amongst those with overt 
disease continues to be one of the major priorities of clinically-orientated research in the 
field of atherothrombosis (Dotsenko et al., 2008). Conventional cardiovascular risk 
assessment is based on traditional risk factors such as serum cholesterol concentrations, 
blood pressure levels, smoking, and diabetes mellitus. However, available data from 
epidemiological studies indicate that these classic risk factors do not fully explain the 
distribution of risk in the general population. On the other hand, classic risk scores may 
provide variable results in different people groups  (Blankenberg et al., 2010). Besides, 
coronary  artery disease often occurs in the absence of traditional risk factors (Yilmaz  et al., 
2007).  Therefore, it is becoming increasingly clear that the newer laboratory  measures may 
be useful to refine risk estimates in the general population. The pressing need for the 
development and clinical implementation of new markers of atherothrombotic disease has 
fuelled rapidly expanding research into cardiac biomarkers  (Dotsenko et al., 2008; Le & 
Wilson, 2010) . 
Cardiovascular biomarkers have the potential to augment clinical risk stratification by 
aiding in screening, diagnosis and assessment of prognosis. However, most current 
biomarkers have only modest predictive value, and there is a need to identify additional 
biomarkers from new biological pathways (May & Wang, 2008). Biomarker research is 
actively developing new testing strategies trying to improve upon current approaches, but it 
is often unclear how to assess the incremental prognostic information that a new test 
provides (Wood & Greenland, 2009).  Some individual biomarkers such as
  
C-reactive 
protein (CRP) have demonstrated consistent associations
 
with incident cardiovascular 
events across multiple studies,
 
but the magnitude of these associations is modest, and only
 
small improvements in discrimination and reclassification are
 
seen. One attractive solution 
to the limitations of individual
 
biomarkers is to combine nonredundant biomarkers into 
panels
 
to enhance risk assessment. However, results of studies testing
 
multiple biomarkers 
for risk prediction in primary prevention
 
populations have not provided a clear picture, 
with some studies
 
showing qualified promise and others suggesting limited
 
value (de 
Lemos & Rohatgi, 2010). This chapter provides an overview
 
of the way of biomarker 
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disease continues to be one of the major priorities of clinically-orientated research in the 
field of atherothrombosis (Dotsenko et al., 2008). Conventional cardiovascular risk 
assessment is based on traditional risk factors such as serum cholesterol concentrations, 
blood pressure levels, smoking, and diabetes mellitus. However, available data from 
epidemiological studies indicate that these classic risk factors do not fully explain the 
distribution of risk in the general population. On the other hand, classic risk scores may 
provide variable results in different people groups  (Blankenberg et al., 2010). Besides, 
coronary  artery disease often occurs in the absence of traditional risk factors (Yilmaz  et al., 
2007).  Therefore, it is becoming increasingly clear that the newer laboratory  measures may 
be useful to refine risk estimates in the general population. The pressing need for the 
development and clinical implementation of new markers of atherothrombotic disease has 
fuelled rapidly expanding research into cardiac biomarkers  (Dotsenko et al., 2008; Le & 
Wilson, 2010) . 
Cardiovascular biomarkers have the potential to augment clinical risk stratification by 
aiding in screening, diagnosis and assessment of prognosis. However, most current 
biomarkers have only modest predictive value, and there is a need to identify additional 
biomarkers from new biological pathways (May & Wang, 2008). Biomarker research is 
actively developing new testing strategies trying to improve upon current approaches, but it 
is often unclear how to assess the incremental prognostic information that a new test 
provides (Wood & Greenland, 2009).  Some individual biomarkers such as
  
C-reactive 
protein (CRP) have demonstrated consistent associations
 
with incident cardiovascular 
events across multiple studies,
 
but the magnitude of these associations is modest, and only
 
small improvements in discrimination and reclassification are
 
seen. One attractive solution 
to the limitations of individual
 
biomarkers is to combine nonredundant biomarkers into 
panels
 
to enhance risk assessment. However, results of studies testing
 
multiple biomarkers 
for risk prediction in primary prevention
 
populations have not provided a clear picture, 
with some studies
 
showing qualified promise and others suggesting limited
 
value (de 
Lemos & Rohatgi, 2010). This chapter provides an overview
 
of the way of biomarker 
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discovery and selection for cardiovascular disease (CVD) and the practical considerations 
that are a prerequisite to
 
their clinical use . 
2. What is a biomarker and how do we find the best biomarkers for 
cardiovascular disease?  
Biomarkers are one such tool to better
 
identify high-risk individuals, to diagnose disease 
conditions
 
promptly and accurately, and to effectively prognosticate and 
 
treat patients with 
disease  (Dotsenko et al., 2008). The term biomarker (biological marker) was introduced in 
1989
 
as a Medical Subject Heading (MeSH) term and in 2001, a National Institutes of
 
Health 
(NIH) working group standardized the definition
 
of a biomarker as "a characteristic that is 
objectively measured
 
and evaluated as an indicator of normal biological processes,
 
pathogenic processes, or pharmacologic responses to a therapeutic
 
intervention" (Vasan,  
2006). (Table1).  
Ambiguity concerning decision limits frustrates clinicians and
 
negatively affects the clinical 
adoption of a biomarker. At
 
the time of clinical introduction, a new biomarker ideally 
should
 
have well-characterized decision limits that (a) are pragmatic
 
to apply, (b) have 
undergone validation in multiple studies,
 
(c) have been evaluated in the relevant 
population(s) and application(s),
 
and (d) have achieved synergy between available scientific 
data
 
and regulatory labeling (Morrow & Cook, 2011). 
 
Biological marker (biomarker): A characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention. 
Risk factor: A risk factor is associated with a disease because it is in the causal pathway 
leading to the disease. 
Risk marker: A risk marker is associated with the disease (statistically) but need not be 
causally linked; it may be a measure of the disease process itself. 
Clinical end point: A characteristic or variable that reflects how a patient feels, functions, 
or survives. 
Intermediate (nonultimate) end point: A true clinical end point (a symptom or measure of 
function, such as symptoms of angina frequency or exercise tolerance) but not the ultimate 
end point of the disease, such as survival or the rate of other serious and irreversible 
morbid events. 
Validation of a biomarker (assay or method validation): A process for assessing 
performance characteristics (ie, sensitivity, specificity, and reproducibility) of a biomarker 
measurement or an assay technique. 
Qualification of a biomarker (clinical validation): The evidentiary process linking a 
biomarker to disease biology or clinical outcome. 
Evaluation of a biomarker: A process of linking biomarkers to outcomes, often with a 
view to establish surrogate status. 
Adapted from Reference : Vasan, (2006). 
Table 1. Biomarkers: A basic glossary. 
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How do we find the best biomarkers for cardiovascular disease?  Cardiovascular risk 
estimation by novel biomarkers needs assessment in disease-free population cohorts, 
followed up for incident cardiovascular events, assaying the serum and plasma archived at 
baseline (Blankenberg et al., 2010). Composite end points are often used to increase the 
number of events in the comparison with persons who do not develop events. Such 
composite end points might include the development of acute coronary syndrome , cardiac 
failure, cerebrovascular disease, and intermittent claudication. When possible, it is probably 
best to focus the research  interest  on discrete events, such as the occurrence of a first 
coronary heart disease event (Le & Wilson, 2010); or perhaps research should be done 
considering the severity of the disease, namely the degree of coronary  stenosis evaluated by 
coronary  angiography.  Besides, diagnosing coronary artery disease (CAD) in  patients at 
risk can be challenging and typically requires coronary  angiography  as the gold standard 
(Rosenberg  et al, 2010).  
When a new biomarker X is evaluated, it is important to remember that the question of 
interest is not whether X is a better predictor of disease than a previously known biomarker 
Y. Rather, the pertinent question is whether X improves the predictive accuracy of the best 
available model (representing the standard of care for that disease) that incorporates several 
known predictors of disease including Y. Thus, the relative added values of new biomarkers 
is best evaluated by estimating the increment to the c statistic compared with that from a 
model that incorporates other previously known predictors (Vasan,  2006). The c statistic, or 
area under the receiver operating characteristic (ROC) curve, achieved popularity in 
diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant 
to discriminating diseased versus nondiseased patients (Cook, 2007). 
Although it is generally believed that new biomarkers should add to the c statistic to be 
useful, there are exceptions to this rule. Novel biomarkers (eg, homocysteine) that are not 
incremental to known risk factors may be measured in select clinical situations such as in 
the following: asymptomatic individuals without obviously elevated conventional risk 
factors but with very strong family history of vascular disease; patients with premature 
vascular disease but no obvious risk factors; and patients with aggressive recurrent vascular 
disease in the face of well-controlled levels of conventional risk factors  (Vasan,  2006). 
Most of the cardiovascular biomarker studies that test the  utility of a large number of 
laboratory tests are hypothesis-generating in nature, and validation of the results is 
important. Several validations of a new biomarker may be needed to demonstrate that the 
new test provides information that could help predict risk in the population or in specific 
subgroups of the population . When the usefulness of a new test for predicting disease is 
assessed, it is important to bear in mind whether the test adds or replaces information 
concerning risk or prognosis for a specific clinical or subclinical outcome.The test must also 
be reproducible, be standardized, have a high diagnostic sensitivity and specificity, and 
have a high predictive value (Le & Wilson, 2010). 
3. What are the new biomarkers for CVD?  
In recent years, a number of new candidate risk factors or markers have been proposed as 
significant predictors of atherosclerosis and its complications (Table 2) (Hackam & Anand,  
2003). In a contemporary publication of the MONICA (Monitoring of Trends and 
Determinants of Cardiovascular Disease) investigators, Blankenberg and colleagues 
evaluated the potential contribution  of 30 novel biomarkers to the 10-year cardiovascular 
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data
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pharmacological responses to a therapeutic intervention. 
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leading to the disease. 
Risk marker: A risk marker is associated with the disease (statistically) but need not be 
causally linked; it may be a measure of the disease process itself. 
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Intermediate (nonultimate) end point: A true clinical end point (a symptom or measure of 
function, such as symptoms of angina frequency or exercise tolerance) but not the ultimate 
end point of the disease, such as survival or the rate of other serious and irreversible 
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How do we find the best biomarkers for cardiovascular disease?  Cardiovascular risk 
estimation by novel biomarkers needs assessment in disease-free population cohorts, 
followed up for incident cardiovascular events, assaying the serum and plasma archived at 
baseline (Blankenberg et al., 2010). Composite end points are often used to increase the 
number of events in the comparison with persons who do not develop events. Such 
composite end points might include the development of acute coronary syndrome , cardiac 
failure, cerebrovascular disease, and intermittent claudication. When possible, it is probably 
best to focus the research  interest  on discrete events, such as the occurrence of a first 
coronary heart disease event (Le & Wilson, 2010); or perhaps research should be done 
considering the severity of the disease, namely the degree of coronary  stenosis evaluated by 
coronary  angiography.  Besides, diagnosing coronary artery disease (CAD) in  patients at 
risk can be challenging and typically requires coronary  angiography  as the gold standard 
(Rosenberg  et al, 2010).  
When a new biomarker X is evaluated, it is important to remember that the question of 
interest is not whether X is a better predictor of disease than a previously known biomarker 
Y. Rather, the pertinent question is whether X improves the predictive accuracy of the best 
available model (representing the standard of care for that disease) that incorporates several 
known predictors of disease including Y. Thus, the relative added values of new biomarkers 
is best evaluated by estimating the increment to the c statistic compared with that from a 
model that incorporates other previously known predictors (Vasan,  2006). The c statistic, or 
area under the receiver operating characteristic (ROC) curve, achieved popularity in 
diagnostic testing, in which the test characteristics of sensitivity and specificity are relevant 
to discriminating diseased versus nondiseased patients (Cook, 2007). 
Although it is generally believed that new biomarkers should add to the c statistic to be 
useful, there are exceptions to this rule. Novel biomarkers (eg, homocysteine) that are not 
incremental to known risk factors may be measured in select clinical situations such as in 
the following: asymptomatic individuals without obviously elevated conventional risk 
factors but with very strong family history of vascular disease; patients with premature 
vascular disease but no obvious risk factors; and patients with aggressive recurrent vascular 
disease in the face of well-controlled levels of conventional risk factors  (Vasan,  2006). 
Most of the cardiovascular biomarker studies that test the  utility of a large number of 
laboratory tests are hypothesis-generating in nature, and validation of the results is 
important. Several validations of a new biomarker may be needed to demonstrate that the 
new test provides information that could help predict risk in the population or in specific 
subgroups of the population . When the usefulness of a new test for predicting disease is 
assessed, it is important to bear in mind whether the test adds or replaces information 
concerning risk or prognosis for a specific clinical or subclinical outcome.The test must also 
be reproducible, be standardized, have a high diagnostic sensitivity and specificity, and 
have a high predictive value (Le & Wilson, 2010). 
3. What are the new biomarkers for CVD?  
In recent years, a number of new candidate risk factors or markers have been proposed as 
significant predictors of atherosclerosis and its complications (Table 2) (Hackam & Anand,  
2003). In a contemporary publication of the MONICA (Monitoring of Trends and 
Determinants of Cardiovascular Disease) investigators, Blankenberg and colleagues 
evaluated the potential contribution  of 30 novel biomarkers to the 10-year cardiovascular 
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disease risk in 2 population cohorts (Blankenberg et al., 2010). These biomarkers were part 
of the MORGAM (MONICA, Risk, Genetics, Archiving, and Monograph) Biomarker Project 
(Evans et al.,2005) and were representative of 9 distinct metabolic processes linked to 
atherosclerosis . They  include (a) lipid-related  biomarkers, (b) renal function markers, (c) 
metabolic markers representing glucose and obesity pathways, (d) markers of vascular 
function and neurohumoral activity, (e) inflammation markers, (f) markers of oxidative 
stress and antioxidants, (g) coagulation markers, (h) angiogenesis markers, and (i) necrosis 
markers ; classified similar to the risk factors in Table 2 (Blankenberg et al., 2010). 
In recent years, the importance of inflammation and increased reactive oxygen species (ROS) 
for the pathogenesis of atherosclerosis is well recognized (Kaneto et al, 2010; Mayer, 2000; 
Tabit et al, 2010). Consequently, “non-traditional factors” such as high-sensitive C-reactive 
protein (hs-CRP), total homocysteine (t-Hcy), as well as oxidative stress, have been 
proposed as risk factors for the development and progression of atherosclerosis and 
atherothrombotic cardiovascular disease (Djoussé et al,2001; Eren et al,2002; Lee  et al,2003; 
Pence et al, 2003). Therefore, this chapter will focus on total-homocystein,  hs-CRP and the 
underlying oxidative stress mechanism of CVD or atherosclerosis.  
 
Inflammatory Markers Lipid-Related Factors 
C-reactive protein 
Interleukins (eg, IL-6) 
Serum amyloid A 
Vascular and cellular adhesion molecules 
Soluble CD40 ligand 
Leukocyte count 
Small dense low-density lipoprotein (LDL) 
Lipoprotein(a) 
Remnant lipoproteins 
Apolipoproteins A1 and B 
High-density lipoprotein subtypes 
Oxidized LDL 
Hemostasis/Thrombosis Markers Other Factors 
Fibrinogen 
von Willebrand factor antigen 
Plasminogen activator inhibitor 1 (PAI-1) 
Tissue-plasminogen activator 
Factors V, VII, and VIII 
D-dimer 
Fibrinopeptide A 
Prothrombin fragment 1+2 
Homocysteine 




Angiotensin-converting enzyme genotype 
ApoE genotype 
Infectious agents: Cytomegalovirus, 
Chlamydia pneumonia, Helicobacter pylori, 





Platelet size and volume 
 
Table 2. Novel risk factors for atherosclerotic vascular disease (Hackam & Anand,  2003). 
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4. Diagnostic values of homocysteine, C-reactive protein and bilirubin for 
coronary artery disease.   
C-reactive protein (CRP) is a circulating acute-phase reactant that is increased many-fold 
during the inflammatory response to tissue injury or infection (Pepys & Baltz, 1983). This 
protein has received substantial attention in recent years as a promising biological predictor 
of atherosclerotic disease (Pearson et al., 2003). On the other hand, it has been postulated 
that mild to moderate elevations of homocysteine in the general population predispose to 
atherosclerosis in a manner akin to the classic risk factors (Hackam & Anand,  2003). 
Additionally, the adaptive and protective responses of arterial vasculature against oxidative 
stress are  important in the prevention of atherosclerosis (Hoekstra et al, 2004). 
4.1 CRP or hs-CRP 
An evolving body of work suggests that even small increases  in CRP within the normal 
range are predictive of future vascular events in apparently healthy, asymptomatic 
individuals (Ridker et al, 2002).  Danesh et al reported a meta-analysis of 14 prospective 
long-term studies of CRP and the risk of nonfatal myocardial infarction or death from 
coronary heart disease (Danesh et al., 2000). The attention in this protein stems in part from 
a recent shift in thinking about the pathogenesis of CVD, an entity once  primarily 
considered to be a bland lipid storage disease. Inflammation is now widely accepted as 
central to every aspect of the atherosclerotic process, from its initiation to its progression to 
plaque rupture, the latter being the essential event underlying the acute coronary 
syndromes  (Hackam & Anand,  2003). Debate exists about the utility of CRP as a marker of 
cardiovascular risk, given its role as an acute-phase reactant and hence its elevation in the 
presence of any inflammatory focus or injury. This has been countered somewhat by the 
development in recent times of an ultrasensitive assay, which has been shown to have a 
degree of measurement stability similar to that of total cholesterol (Davison & Davis, 2003). 
In other words, the guidelines identify CRP (as measured by a high-sensitivity [hs] assay--
hence the name hs-CRP) as the inflammatory marker of choice for cardiovascular risk 
stratification. Although a number of other inflammatory markers such as serum amyloid A, 
white blood cell count, and fibrinogen have been investigated, the “hs-CRP” level has the 
most stability, assay precision, accuracy, and availability (Shishehbor et al, 2003). 
4.2 Homocysteine 
Interest in homocysteine as a causal factor was spurred by the observation that more than 
50% of children with the genetic disorder homocystinuria die of premature vascular disease 
and strategies that reduce homocysteine levels in these children have been shown to 
decrease  vascular event rates (Humphrey  et al, 2008).  Mechanistic studies have 
demonstrated that homocysteine  might induce vascular damage by promoting platelet 
activation, oxidative stress, endothelial dysfunction, hypercoagulability, vascular smooth 
muscle cell proliferation, and endoplasmic reticulum stress (De Bree et al., 2002;  Mangoni & 
Jackson, 2002). In their meta-analysis, Humphrey et al evaluated homocysteine levels as a 
predictor of new CAD events in persons without known CAD. Their review showed an 
association between elevated homocysteine levels and CAD that was independent of 
Framingham risk factors. In the overall analysis, the risk of any CAD event increased 
approximately 20% for each increase of 5 μmol/L of homocysteine. Consequently, elevated 
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disease risk in 2 population cohorts (Blankenberg et al., 2010). These biomarkers were part 
of the MORGAM (MONICA, Risk, Genetics, Archiving, and Monograph) Biomarker Project 
(Evans et al.,2005) and were representative of 9 distinct metabolic processes linked to 
atherosclerosis . They  include (a) lipid-related  biomarkers, (b) renal function markers, (c) 
metabolic markers representing glucose and obesity pathways, (d) markers of vascular 
function and neurohumoral activity, (e) inflammation markers, (f) markers of oxidative 
stress and antioxidants, (g) coagulation markers, (h) angiogenesis markers, and (i) necrosis 
markers ; classified similar to the risk factors in Table 2 (Blankenberg et al., 2010). 
In recent years, the importance of inflammation and increased reactive oxygen species (ROS) 
for the pathogenesis of atherosclerosis is well recognized (Kaneto et al, 2010; Mayer, 2000; 
Tabit et al, 2010). Consequently, “non-traditional factors” such as high-sensitive C-reactive 
protein (hs-CRP), total homocysteine (t-Hcy), as well as oxidative stress, have been 
proposed as risk factors for the development and progression of atherosclerosis and 
atherothrombotic cardiovascular disease (Djoussé et al,2001; Eren et al,2002; Lee  et al,2003; 
Pence et al, 2003). Therefore, this chapter will focus on total-homocystein,  hs-CRP and the 
underlying oxidative stress mechanism of CVD or atherosclerosis.  
 
Inflammatory Markers Lipid-Related Factors 
C-reactive protein 
Interleukins (eg, IL-6) 
Serum amyloid A 
Vascular and cellular adhesion molecules 
Soluble CD40 ligand 
Leukocyte count 
Small dense low-density lipoprotein (LDL) 
Lipoprotein(a) 
Remnant lipoproteins 
Apolipoproteins A1 and B 
High-density lipoprotein subtypes 
Oxidized LDL 
Hemostasis/Thrombosis Markers Other Factors 
Fibrinogen 
von Willebrand factor antigen 
Plasminogen activator inhibitor 1 (PAI-1) 
Tissue-plasminogen activator 
Factors V, VII, and VIII 
D-dimer 
Fibrinopeptide A 
Prothrombin fragment 1+2 
Homocysteine 




Angiotensin-converting enzyme genotype 
ApoE genotype 
Infectious agents: Cytomegalovirus, 
Chlamydia pneumonia, Helicobacter pylori, 





Platelet size and volume 
 
Table 2. Novel risk factors for atherosclerotic vascular disease (Hackam & Anand,  2003). 
New Noninvasive Modalities in Coronary 
Angiography - Diagnostic Values of New Biomarkers for Cardiovascular Disease 
 
271 
4. Diagnostic values of homocysteine, C-reactive protein and bilirubin for 
coronary artery disease.   
C-reactive protein (CRP) is a circulating acute-phase reactant that is increased many-fold 
during the inflammatory response to tissue injury or infection (Pepys & Baltz, 1983). This 
protein has received substantial attention in recent years as a promising biological predictor 
of atherosclerotic disease (Pearson et al., 2003). On the other hand, it has been postulated 
that mild to moderate elevations of homocysteine in the general population predispose to 
atherosclerosis in a manner akin to the classic risk factors (Hackam & Anand,  2003). 
Additionally, the adaptive and protective responses of arterial vasculature against oxidative 
stress are  important in the prevention of atherosclerosis (Hoekstra et al, 2004). 
4.1 CRP or hs-CRP 
An evolving body of work suggests that even small increases  in CRP within the normal 
range are predictive of future vascular events in apparently healthy, asymptomatic 
individuals (Ridker et al, 2002).  Danesh et al reported a meta-analysis of 14 prospective 
long-term studies of CRP and the risk of nonfatal myocardial infarction or death from 
coronary heart disease (Danesh et al., 2000). The attention in this protein stems in part from 
a recent shift in thinking about the pathogenesis of CVD, an entity once  primarily 
considered to be a bland lipid storage disease. Inflammation is now widely accepted as 
central to every aspect of the atherosclerotic process, from its initiation to its progression to 
plaque rupture, the latter being the essential event underlying the acute coronary 
syndromes  (Hackam & Anand,  2003). Debate exists about the utility of CRP as a marker of 
cardiovascular risk, given its role as an acute-phase reactant and hence its elevation in the 
presence of any inflammatory focus or injury. This has been countered somewhat by the 
development in recent times of an ultrasensitive assay, which has been shown to have a 
degree of measurement stability similar to that of total cholesterol (Davison & Davis, 2003). 
In other words, the guidelines identify CRP (as measured by a high-sensitivity [hs] assay--
hence the name hs-CRP) as the inflammatory marker of choice for cardiovascular risk 
stratification. Although a number of other inflammatory markers such as serum amyloid A, 
white blood cell count, and fibrinogen have been investigated, the “hs-CRP” level has the 
most stability, assay precision, accuracy, and availability (Shishehbor et al, 2003). 
4.2 Homocysteine 
Interest in homocysteine as a causal factor was spurred by the observation that more than 
50% of children with the genetic disorder homocystinuria die of premature vascular disease 
and strategies that reduce homocysteine levels in these children have been shown to 
decrease  vascular event rates (Humphrey  et al, 2008).  Mechanistic studies have 
demonstrated that homocysteine  might induce vascular damage by promoting platelet 
activation, oxidative stress, endothelial dysfunction, hypercoagulability, vascular smooth 
muscle cell proliferation, and endoplasmic reticulum stress (De Bree et al., 2002;  Mangoni & 
Jackson, 2002). In their meta-analysis, Humphrey et al evaluated homocysteine levels as a 
predictor of new CAD events in persons without known CAD. Their review showed an 
association between elevated homocysteine levels and CAD that was independent of 
Framingham risk factors. In the overall analysis, the risk of any CAD event increased 
approximately 20% for each increase of 5 μmol/L of homocysteine. Consequently, elevated 
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homocysteine levels independently and moderately increased the risk of developing CAD 
either in a causal manner or as a risk marker by approximately 20% (Humphrey  et al, 2008). 
4.3 Oxidative stress and bilirubin 
Imbalances in the redox status in which excess oxidation occurs or reducing power cannot 
be maintained (e.g. in inflammation, age, smoking, high lipid content and oxidation) creates 
a state  in which molecular and tissue modifications progress rapidly, leading to 
development of lesions and full-blown atherogenesis. Oxidative stress  does  not replace the 
recognized role of lipids and cholesterol in atherosclerosis, but rather underline that role. 
Indeed, quantifying redox processes may well elucidate some molecular mechanisms by 
which lipids mediate atherogenesis (Gamkrelidze et al., 2008). Bilirubin has been considered 
an antioxidant, with capacity to remove reactive species of oxygen. Recent data advocates 
the idea that an increased bilirubin level promotes protection against atherosclerosis  (Ghem 
et al., 2010). 
The heme oxygenase responsible for the degradation of heme grouping of hemoglobin is a 
stress  inducible enzyme with antioxidative properties . The products of its reaction 
(bilirubine, carbon monoxide and iron) develop a potential protective role against 
atherosclerosis (Hoekstra et al, 2004). Studies have suggested that different circulating forms 
of bilirubin have the capacity to remove  a variety of reactive species of oxygen, and inhibit 
the oxidation of LDL particles and the chemotaxis of monocytes, all of which are crucial 
steps in atherogenesis (Ghem et al., 2010). 
In a study we have  done , we assessed the diagnostic performance and relationship of 
bilirubin with hs-CRP and t-Hcy  for cardiovascular disease in men and women in an 
angiographically documented design. The study demonstrated that patients with 
angiographically confirmed coronary artery disease (CAD) had significantly higher serum 
hs-CRP and t-Hcy levels than non-stenotic patients (patients with normal angiogram) and 
the apparently healthy control group.Optimal cut-off levels and the associated diagnostic 
performances (sensitivity, specificity and diagnostic value) of serum bilirubin, hs-CRP, t-
Hcy, based on ROC analysis, are given in Table3. Optimal cut-off levels for bilirubin, hs-
CRP and t-Hcy providing the maximum efficiency found in patients (n = 319) with CAD 
were 0.59 mg/dL, 1.09 mg/dL and 12.1 µmol/L respectively. 
 








Bilirubin 0.59 mg/dL 70.9 40.4 0.507 1.19 0.72 
High-sensitivity 
C-reactive protein 
      
1.09 mg/dL 50.0 80.7 0.648 2.59 0.62 
Total homocysteine 121 ^mol/L 76.8 70.2 0.781 2.67 0.29 
+LR = positive likelihood ratio 
-LR = negative likelihood ratio 
Table 3. Optimal cut-off levels and associated specificity, sensitivity and diagnostic value of 
concentrations of biomarkers for the diagnosis of angiographically documented coronary 
artery disease 
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These data strongly suggest that serum t-Hcy helps to identify individuals at risk of 
atherosclerosis (AUC value 0.781), especially among those with elevated hs-CRP and 
decreased bilirubin levels. t-Hcy showed the highest AUC value (0.781) compared to hs-CRP 
(0.648) and bilirubin (0.507). Area under the curve (AUC) values in receiving operating 
characteristics (ROC) curve (as a measure of discriminating efficacy) were used for 
comparison of the diagnostic values of different analyses (including only the CAD and non-
CAD groups, using angiography as the gold standard). ROC curve-based sensitivities of 
bilirubin, hs-CRP and t-Hcy levels were 70.9%, 50.0%, 76.8% respectively. The specificities of 
bilirubin, hs-CRP and t-Hcy were 40.4%, 80.7% and 70.2% respectively (data of ROC curves 








Fig. 2. ROC curve for hs-CRP. 
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homocysteine levels independently and moderately increased the risk of developing CAD 
either in a causal manner or as a risk marker by approximately 20% (Humphrey  et al, 2008). 
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recognized role of lipids and cholesterol in atherosclerosis, but rather underline that role. 
Indeed, quantifying redox processes may well elucidate some molecular mechanisms by 
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an antioxidant, with capacity to remove reactive species of oxygen. Recent data advocates 
the idea that an increased bilirubin level promotes protection against atherosclerosis  (Ghem 
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The heme oxygenase responsible for the degradation of heme grouping of hemoglobin is a 
stress  inducible enzyme with antioxidative properties . The products of its reaction 
(bilirubine, carbon monoxide and iron) develop a potential protective role against 
atherosclerosis (Hoekstra et al, 2004). Studies have suggested that different circulating forms 
of bilirubin have the capacity to remove  a variety of reactive species of oxygen, and inhibit 
the oxidation of LDL particles and the chemotaxis of monocytes, all of which are crucial 
steps in atherogenesis (Ghem et al., 2010). 
In a study we have  done , we assessed the diagnostic performance and relationship of 
bilirubin with hs-CRP and t-Hcy  for cardiovascular disease in men and women in an 
angiographically documented design. The study demonstrated that patients with 
angiographically confirmed coronary artery disease (CAD) had significantly higher serum 
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CRP and t-Hcy providing the maximum efficiency found in patients (n = 319) with CAD 
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Bilirubin 0.59 mg/dL 70.9 40.4 0.507 1.19 0.72 
High-sensitivity 
C-reactive protein 
      
1.09 mg/dL 50.0 80.7 0.648 2.59 0.62 
Total homocysteine 121 ^mol/L 76.8 70.2 0.781 2.67 0.29 
+LR = positive likelihood ratio 
-LR = negative likelihood ratio 
Table 3. Optimal cut-off levels and associated specificity, sensitivity and diagnostic value of 
concentrations of biomarkers for the diagnosis of angiographically documented coronary 
artery disease 
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These data strongly suggest that serum t-Hcy helps to identify individuals at risk of 
atherosclerosis (AUC value 0.781), especially among those with elevated hs-CRP and 
decreased bilirubin levels. t-Hcy showed the highest AUC value (0.781) compared to hs-CRP 
(0.648) and bilirubin (0.507). Area under the curve (AUC) values in receiving operating 
characteristics (ROC) curve (as a measure of discriminating efficacy) were used for 
comparison of the diagnostic values of different analyses (including only the CAD and non-
CAD groups, using angiography as the gold standard). ROC curve-based sensitivities of 
bilirubin, hs-CRP and t-Hcy levels were 70.9%, 50.0%, 76.8% respectively. The specificities of 
bilirubin, hs-CRP and t-Hcy were 40.4%, 80.7% and 70.2% respectively (data of ROC curves 








Fig. 2. ROC curve for hs-CRP. 
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Fig. 3. ROC curve for bilirubin. 
In agreement with previous reports, we found that the bilirubin levels in serum were 
significantly lower in the patients with CAD than in age- and sex-matched controls 
(Madhavan  et al., 1997; Schwertner  et al., 1994;  Vitek et al., 2002).  We found that a serum 
bilirubin concentration of 10.0 µmol/L (0.58 mg/dL) discriminated between high and low 
cardiovascular risks . 
Additionally, we found that the number of stenotic coronary arteries was significantly 
associated with elevated serum t-Hcy and hs-CRP concentrations. Several researchers have 
investigated the risk of myocardial infection in individuals with the UGT1A1*28 allele ( 
Bosma et al., 2003; Schwertner, 2003).  According to the “oxidative modification hypothesis”, 
which suggests atherogenesis is initiated by oxidization of low-density lipoprotein particles, 
it has been suggested that increased physiological concentrations of serum bilirubin may 
reduce atherogenic risk by reducing oxidation. An involvement of bilirubin in immune 
reactions and inflammatory processes has also been documented (Delores  et al., 2000; 
Kronenberg  et al., 2002; Lin et al., 2003).  
Earlier studies have reported differences in the levels of t-Hcy, ranging between 13.9–20.1 
µmol/L in persons with CAD (Yu et al., 2000; Zylberstein et al., 2004). We found a mean t-Hcy 
level of 19.4 (SD 8.73) µmol/L in the CAD group, 10.7 (SD 5.14) µmol/L in the healthy group 
and 13.0 (SD 8.61) µmol/L in the non-CAD group. Some differences between reported serum 
t-Hcy levels may be related to analytical methods and ethnic differences. A study in 19 centres 
in Europe reported high homocysteine levels and increased risk of CAD in smokers  (Graham  
et al., 1997). We found that the t-Hcy levels tended to increase in the presence of more 
cardiovascular risk factors, i.e. male gender, older age, diabetes mellitus, hyperlipidaemia and 
certain chronic diseases. As expected, traditional coronary risk factors were more prevalent 
among those participants with elevated levels of t-Hcy and hs-CRP in our study, as in other 
studies  (Abdemouttaleb  et al., 2000; Sesso  et al., 2003; Siri  et al., 1998).    
5. What is new about hyperhomocysteinemia?  
Homocysteine is an accepted independent risk factor for several major pathologies 
including cardiovascular disease, birth defects, osteoporosis, Alzheimer’s disease, and renal 
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failure. Interestingly, many of the pathologies associated with homocysteine are also linked 
to oxidative stress (Suszynska et al., 2010). Evidence indicates that hyperhomocysteinemia, 
which occurs in 5–7% of the general population is a risk factor for CVD, but how? 
(Jakubowski, 2004). Hyperhomocysteinemia is accused of being responsible for elevating 
oxidative stress as a result of formation of Hcy- thiolactone or Hcy-thiyl radical, which may 
lead to impairment of cell signaling and cause pathology (Doshi et al., 2001; Lang et al., 
2000). Many researchers, and especially Jakubowski, suggested that metabolic conversion of  
Hcy to Hcy-thiolactone followed by subsequent spontaneous protein N-homocysteinylation 
by Hcy-thiolactone might contribute to Hcy toxicity in humans. (Jakubowski, 2002). Hcy-
thiolactone is a reactive intermediate that causes protein N-homocysteinylation through the 
formation of amide bonds with ɛ-amino groups of protein lysine residues; in the event,  
homocysteinylated proteins  may lose their biological activities (Jakubowski, 2003). 
Whereas epidemiological data indicate that elevation of plasma homocysteine is not 
associated with a significant change in plasma total cholesterol, some studies have reported 
a negative correlation with HDL concentrations  (Ciaccio & Bellia, 2010; Domagała  et al., 
2006; Williams  & Schalinske, 2010). Because low plasma HDL concentration sometimes is 
associated with increased risk of  CVD, whereas other conditions with low plasma HDL 
concentration are associated with improved prognosis, it seems that it is not only the 
concentration per se but also the function of the HDL particles that is important for its 
antiatherogenic effects (Bełtowski, 2005; Mikael et al.,2006).  HDL particles are susceptible to 
structural modifications mediated by various mechanisms, including oxidation, glycation, 
or enzymatic degradation, affecting their functional properties .Moreover, in vitro studies 
have shown that homocysteinylation of HDL may reduce the activity of the enzyme 
Paraoxonase (PON), which is associated with human HDL, thus rendering the HDL particle 
more susceptible to oxidative damage.  Formation of inflammatory HDL has been suggested 
to correlate with decreases  in the activities of various HDL associated enzymes, such as 
PON, a multifunctional enzyme with antioxidant capacity, and the ability to detoxify the 
homocysteine metabolite homocysteine thiolactone  (Bełtowski, 2005; Liao  et al., 2007)  . 
Paraoxonase is thought to influence serum homocysteine concentrations, at least in part, due 
to its homocysteine thiolactonase activity and to play a role in atherosclerosis. (Yang  et al, 
2006).  Hcy- thiolactonase activity is influenced by both PON1 and MTHFR genotypes and 
there is a direct relation between Hcy and Hcy- thiolactone levels. In relation to this matter, 
Jakubowski et al. hypothesized that high thiolactonase associated PON1  R and L alleles 
should confer significant cardiovascular protection in subjects with high Hcy levels  
(Jakubowski et al., 2001). 
6. Conclusion  
The availability of well-validated decision limits is vital to optimal integration of a new 
biomarker into clinical practice. Approaches to internal validation and data-mining methods 
lead to overfitting and overestimation of risk relationships and are generally not sufficient 
for selecting final clinical cutpoints. Such methods, when applied correctly, can be 
reasonable for suggesting cutpoints for external validation. Biomarkers that have monotonic 
linear relationships with risk are best handled as continuous variables when incorporated 
into comprehensive risk models. As consistently demonstrated in clinical practice and 
professional society guidelines, however, practitioners will almost always seek thresholds to 
provide structure for clinical decision-making, such as those existing for cholesterol. 
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failure. Interestingly, many of the pathologies associated with homocysteine are also linked 
to oxidative stress (Suszynska et al., 2010). Evidence indicates that hyperhomocysteinemia, 
which occurs in 5–7% of the general population is a risk factor for CVD, but how? 
(Jakubowski, 2004). Hyperhomocysteinemia is accused of being responsible for elevating 
oxidative stress as a result of formation of Hcy- thiolactone or Hcy-thiyl radical, which may 
lead to impairment of cell signaling and cause pathology (Doshi et al., 2001; Lang et al., 
2000). Many researchers, and especially Jakubowski, suggested that metabolic conversion of  
Hcy to Hcy-thiolactone followed by subsequent spontaneous protein N-homocysteinylation 
by Hcy-thiolactone might contribute to Hcy toxicity in humans. (Jakubowski, 2002). Hcy-
thiolactone is a reactive intermediate that causes protein N-homocysteinylation through the 
formation of amide bonds with ɛ-amino groups of protein lysine residues; in the event,  
homocysteinylated proteins  may lose their biological activities (Jakubowski, 2003). 
Whereas epidemiological data indicate that elevation of plasma homocysteine is not 
associated with a significant change in plasma total cholesterol, some studies have reported 
a negative correlation with HDL concentrations  (Ciaccio & Bellia, 2010; Domagała  et al., 
2006; Williams  & Schalinske, 2010). Because low plasma HDL concentration sometimes is 
associated with increased risk of  CVD, whereas other conditions with low plasma HDL 
concentration are associated with improved prognosis, it seems that it is not only the 
concentration per se but also the function of the HDL particles that is important for its 
antiatherogenic effects (Bełtowski, 2005; Mikael et al.,2006).  HDL particles are susceptible to 
structural modifications mediated by various mechanisms, including oxidation, glycation, 
or enzymatic degradation, affecting their functional properties .Moreover, in vitro studies 
have shown that homocysteinylation of HDL may reduce the activity of the enzyme 
Paraoxonase (PON), which is associated with human HDL, thus rendering the HDL particle 
more susceptible to oxidative damage.  Formation of inflammatory HDL has been suggested 
to correlate with decreases  in the activities of various HDL associated enzymes, such as 
PON, a multifunctional enzyme with antioxidant capacity, and the ability to detoxify the 
homocysteine metabolite homocysteine thiolactone  (Bełtowski, 2005; Liao  et al., 2007)  . 
Paraoxonase is thought to influence serum homocysteine concentrations, at least in part, due 
to its homocysteine thiolactonase activity and to play a role in atherosclerosis. (Yang  et al, 
2006).  Hcy- thiolactonase activity is influenced by both PON1 and MTHFR genotypes and 
there is a direct relation between Hcy and Hcy- thiolactone levels. In relation to this matter, 
Jakubowski et al. hypothesized that high thiolactonase associated PON1  R and L alleles 
should confer significant cardiovascular protection in subjects with high Hcy levels  
(Jakubowski et al., 2001). 
6. Conclusion  
The availability of well-validated decision limits is vital to optimal integration of a new 
biomarker into clinical practice. Approaches to internal validation and data-mining methods 
lead to overfitting and overestimation of risk relationships and are generally not sufficient 
for selecting final clinical cutpoints. Such methods, when applied correctly, can be 
reasonable for suggesting cutpoints for external validation. Biomarkers that have monotonic 
linear relationships with risk are best handled as continuous variables when incorporated 
into comprehensive risk models. As consistently demonstrated in clinical practice and 
professional society guidelines, however, practitioners will almost always seek thresholds to 
provide structure for clinical decision-making, such as those existing for cholesterol. 
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Therefore, such cutpoints warrant development and validation. Although the approach is 
demanding, we recommend assessment of clinical decision limits by external validation in 2 
or more data sets that are appropriate to each of the proposed clinical application(s), with 
attention paid to the possibility of differences in risk relationships in clinically relevant 
subpopulations (Morrow & Cook, 2011). 
To conclude, there is little evidence of an association between the serum concentration of 
bilirubin and atherosclerosis. In contrast, the concentration of novel (t-Hcy and hs-CRP) and 
traditional risk markers may be stronger markers for atherosclerosis in CAD patients. 
Additional studies are still necessary to confirm and demonstrate the association of these 
findings with clinical outcomes. 
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1. Introduction  
Coronary artery disease (CAD) is the world’s leading cause of illness and death. In 2005, 
approximately 7.6 million deaths were attributed to coronary artery disease, accounting for 
almost 13% of the total deaths (WHO, 2011). From a pathophysiological point of view the 
disease could be considered as a severe clinical manifestation of atherosclerosis (Mallat & 
Tedgui, 2001). The disruption of an atherosclerotic plaque with superimposed thrombosis 
had been identified as the main cause of acute coronary syndromes, including acute 
myocardial infarction (AMI), and sudden death (Gensini & Dilaghi, 2002; Shah, 2003).  
The initially silent progression of arterial plaque, prompted by classic risk factors (including 
hypertension, diabetes mellitus, dyslipidaemia, age, stress, physical inactivity, dietary habits 
and cigarette smoking), is followed by a phase of acute or chronic progression toward an 
increasing degree of stenosis that eventually causes thrombosis (Gensini & Dilaghi, 2002; 
Fuster et al., 2005). Plaque disruption and/or endothelial activation represent the main 
trigger event for AMI, through exposure of plaque thrombogenic components to platelets 
and to clotting components of flowing blood. In this phase, haemostasis related risk factors 
and platelet status play a crucial role. However, current research supports the view of 
atherosclerosis as an inflammatory process that initiates and promotes lesion development 
to the point of acute thrombotic complications and clinical events. Thus, the time has come 
to embrace inflammation as a common pathway for atherogenic risk factors and for 
providing new opportunities for therapeutic intervention (Libby, 2003). 
Acute myocardial infarction is a critical clinical presentation of coronary artery disease in 
many asymptomatic patients and often the event is fatal. Establishing the presence of 
coronary lesions either in asymptomatic patients or in symptomatic patients with acute or 
chronic chest pain can be a challenging task. Consequently, major clinical research efforts 
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have been dedicated to the identification of patients at higher risk and to the diagnosis of 
coronary artery disease. 
Angiography remains the undisputed standard in interventional cardiology. Succeeding 
breakthroughs for cardiac imaging from every branch of radiology technology offer 
remarkable views and are providing new insights into coronary pathology. Although 
angiography is a first-line test for coronary artery disease, particularly for screening 
symptomatic patients, the evaluation of asymptomatic individuals currently relies on the 
identification of risk factors (e.g., hypertension, dyslipidaemia, diabetes mellitus, stress and 
smoking habits) (Conroya et al., 2003; Kotecha et al., 2010). However, neither the absence of 
high-grade stenosis provided by imaging modalities such as angiography assure the lack of 
future cardiac events, nor the cardiovascular events are readily explained by cardiovascular 
risk factors (Fisher et al., 2000; Kern, 2000; Hadamitzky et al., 2009; Marwan et al., 2009). The 
understanding of the cellular biology of the unstable plaque remains poorly known, and the 
crucial question is still the identification of the factor(s) that play a significant role in the 
plaque disruption. 
Rupture of atherosclerotic plaque has been identified as the proximate event in the majority 
of cases of acute ischemic syndromes. Plaque rupture exposes thrombogenic components of 
the plaque, activating the clotting cascade and promoting thrombus formation. Future 
culprit lesions are difficult to identify, however, and angiographic assessment of stenosis 
severity is prone to underestimation. Compared with plaques that cause severe luminal 
stenosis, vulnerable plaques may cause relatively minor stenosis, although they account for 
more cases of rupture and thrombosis. Such unstable, vulnerable plaques may be associated 
with outward remodeling of the vessel. Because severely stenotic plaques are more likely to 
stimulate collateral circulation to the post-stenotic segment, plaque rupture and thrombosis 
at such sites may be clinically silent. Characteristic histomorphologic features of vulnerable 
plaques include a high lipid content, increased number of inflammatory cells, and extensive 
adventitial and intimal neovascularity. These cells are mostly monocyte-macrophages and 
they are probably recruited into the atherosclerotic plaques by adhesion molecules, 
especially intracellular adhesion molecule (ICAM)-1 and P-selectin, and chemokines such as 
monocyte chemoattractant protein (MCP)-1. Another potential avenue for the entry and 
recruitment of inflammatory cells inside the atherosclerotic lesion may be through the 
adventitial neovasculature, which is enhanced in atherosclerosis. In addition, other factors 
that may contribute to the recruitment of inflammatory cells and their activation in 
atherosclerosis include oxidized lipids, cytokines such as tumor necrosis factor alpha (TNF-
), increased angiotensin II activity, elevated arterial pressure, diabetes, chronic infections 
remote from the arterial wall, possible infectious organisms in the vessel wall and activation 
of the immune system (Shah, 2003). In addition, interaction between inflammatory cells, 
vascular smooth muscle cells, endothelial cells and extracellular matrix may contribute to 
the development of plaque and its rupture. TNF-, mainly secreted by macrophages, 
influences many aspects of atherosclerosis by increasing the permeability of endothelial 
cells, promoting monocyte adhesion, inducing macrophage differentiation and probably 
promoting vascular calcification (Trion & van der Laarse, 2004). The calcification of arteries 
resembles the bone formation (Trion & van der Laarse, 2004). Activated monocytes produce 
TNF- and other osteoinductive factors that stimulate the differentiation and mineralization 
of cardiovascular cells (Trion & van der Laarse, 2004). 
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New approaches claim that measurements of carotid intima-media thickness or coronary 
artery calcium obtained by non-invasive techniques can be used to identify vulnerable 
patients at a time when risk factor modification can slow or stop the atherosclerotic process. 
Nevertheless, the uncertainty about the functional significance of these markers in the 
unstable plaque context has not yet been overcome. The crucial questions still are the 
identification and characterization of the vulnerable plaque in hopes of identifying 
morphologic and physiological features that predict plaque rupture.  
An increase body of literature associates plaque rupture with inflammatory mediators, such 
as tissue factors, cell adhesion molecules and cytokines, expressed by vascular and immune 
cells (Shah, 2003; Fuster et al., 2005; Mauriello et al., 2005; Armstrong et al., 2006a).  
White blood-cell count (WBC), the most widely available and inexpensive measure of 
systemic inflammation has been associated with cardiovascular mortality both in primary 
and secondary prevention settings. In apparently healthy individuals, a high white blood-
cell count has been associated with increased cardiovascular mortality and incidence of 
cardiovascular disease, independently of traditional atherosclerotic risk factors (Folsom et 
al., 1999; Margolis et al., 2005; Shankar et al., 2007). In a study of patients with acute coronary 
syndromes, higher baseline white blood-cell counts were associated with greater extent of 
coronary artery disease, lower thrombolysis in myocardial infarction (TIMI) flow and 
myocardial perfusion grades during coronary angiography in addition to a higher 6-month 
mortality independently of other risk factors including ST-segment deviation and troponin 
levels (Sabatine et al., 2002a). A high neutrophil count and a low lymphocyte count may 
carry most of this increased risk, as reported for patients assessed for coronary artery 
disease by coronary angiography (Horne et al., 2005).  
Thus, for prognostic purposes, clinicians have focused on white blood-cell, neutrophils or 
downstream products such as C-reactive protein (CRP). Neutrophils, however, live only for 
hours and generate no memory of their engagement, which is carried out through inherited 
receptors that are similar in all hosts, while lymphocytes are long-lived cells that can survive 
for decades, and the lymphocyte repertoire is tailored for each individual. When mobilized 
in immune responses, lymphocytes undergo clonal burst, differentiate into distinct types of 
effector cells, and memorize information about the antigen (Bodi et al, 2008). Little is known 
regarding the role of lymphocytes, which play an important role in the control of the 
inflammatory system and in the pathophysiology of coronary disease (Bodi et al, 2008). 
Several studies had demonstrated that the adaptative immunity plays an important role in 
the pathogenesis of coronary artery disease (Blum & Yeganeh, 2003; Methe et al., 2005; Han 
et al., 2007; Packard et al., 2009; Hansson, 2009). In the culprit lesions of patients with acute 
coronary syndromes the percentage of activated T lymphocytes is significantly increased, 
and experimental results (Caligiuri et al., 2000) suggest the existence of antigenic stimuli in 
these lesions. These findings lead to the paradigm that the transition from a stable to an 
unstable plaque includes immunological activation and may be T cell-dependent (Steppich 
et al., 2007). 
The interactions between leucocytes, activated platelets and activated endothelial cells, 
mediated by P-selectin, E-selectin and ICAM-1 whose soluble forms can be released in 
circulation, associate with the initiation of arterial thrombus (Price & Loscalzo, 1999). The 
expression of ICAM-1 in activated endothelial cells and of P-selectin in activated platelets, 
seems to have key roles in binding and rolling of leukocytes along the activated 
endothelium, and in platelet aggregation and platelet-leukocyte adhesion.  
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remarkable views and are providing new insights into coronary pathology. Although 
angiography is a first-line test for coronary artery disease, particularly for screening 
symptomatic patients, the evaluation of asymptomatic individuals currently relies on the 
identification of risk factors (e.g., hypertension, dyslipidaemia, diabetes mellitus, stress and 
smoking habits) (Conroya et al., 2003; Kotecha et al., 2010). However, neither the absence of 
high-grade stenosis provided by imaging modalities such as angiography assure the lack of 
future cardiac events, nor the cardiovascular events are readily explained by cardiovascular 
risk factors (Fisher et al., 2000; Kern, 2000; Hadamitzky et al., 2009; Marwan et al., 2009). The 
understanding of the cellular biology of the unstable plaque remains poorly known, and the 
crucial question is still the identification of the factor(s) that play a significant role in the 
plaque disruption. 
Rupture of atherosclerotic plaque has been identified as the proximate event in the majority 
of cases of acute ischemic syndromes. Plaque rupture exposes thrombogenic components of 
the plaque, activating the clotting cascade and promoting thrombus formation. Future 
culprit lesions are difficult to identify, however, and angiographic assessment of stenosis 
severity is prone to underestimation. Compared with plaques that cause severe luminal 
stenosis, vulnerable plaques may cause relatively minor stenosis, although they account for 
more cases of rupture and thrombosis. Such unstable, vulnerable plaques may be associated 
with outward remodeling of the vessel. Because severely stenotic plaques are more likely to 
stimulate collateral circulation to the post-stenotic segment, plaque rupture and thrombosis 
at such sites may be clinically silent. Characteristic histomorphologic features of vulnerable 
plaques include a high lipid content, increased number of inflammatory cells, and extensive 
adventitial and intimal neovascularity. These cells are mostly monocyte-macrophages and 
they are probably recruited into the atherosclerotic plaques by adhesion molecules, 
especially intracellular adhesion molecule (ICAM)-1 and P-selectin, and chemokines such as 
monocyte chemoattractant protein (MCP)-1. Another potential avenue for the entry and 
recruitment of inflammatory cells inside the atherosclerotic lesion may be through the 
adventitial neovasculature, which is enhanced in atherosclerosis. In addition, other factors 
that may contribute to the recruitment of inflammatory cells and their activation in 
atherosclerosis include oxidized lipids, cytokines such as tumor necrosis factor alpha (TNF-
), increased angiotensin II activity, elevated arterial pressure, diabetes, chronic infections 
remote from the arterial wall, possible infectious organisms in the vessel wall and activation 
of the immune system (Shah, 2003). In addition, interaction between inflammatory cells, 
vascular smooth muscle cells, endothelial cells and extracellular matrix may contribute to 
the development of plaque and its rupture. TNF-, mainly secreted by macrophages, 
influences many aspects of atherosclerosis by increasing the permeability of endothelial 
cells, promoting monocyte adhesion, inducing macrophage differentiation and probably 
promoting vascular calcification (Trion & van der Laarse, 2004). The calcification of arteries 
resembles the bone formation (Trion & van der Laarse, 2004). Activated monocytes produce 
TNF- and other osteoinductive factors that stimulate the differentiation and mineralization 
of cardiovascular cells (Trion & van der Laarse, 2004). 
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New approaches claim that measurements of carotid intima-media thickness or coronary 
artery calcium obtained by non-invasive techniques can be used to identify vulnerable 
patients at a time when risk factor modification can slow or stop the atherosclerotic process. 
Nevertheless, the uncertainty about the functional significance of these markers in the 
unstable plaque context has not yet been overcome. The crucial questions still are the 
identification and characterization of the vulnerable plaque in hopes of identifying 
morphologic and physiological features that predict plaque rupture.  
An increase body of literature associates plaque rupture with inflammatory mediators, such 
as tissue factors, cell adhesion molecules and cytokines, expressed by vascular and immune 
cells (Shah, 2003; Fuster et al., 2005; Mauriello et al., 2005; Armstrong et al., 2006a).  
White blood-cell count (WBC), the most widely available and inexpensive measure of 
systemic inflammation has been associated with cardiovascular mortality both in primary 
and secondary prevention settings. In apparently healthy individuals, a high white blood-
cell count has been associated with increased cardiovascular mortality and incidence of 
cardiovascular disease, independently of traditional atherosclerotic risk factors (Folsom et 
al., 1999; Margolis et al., 2005; Shankar et al., 2007). In a study of patients with acute coronary 
syndromes, higher baseline white blood-cell counts were associated with greater extent of 
coronary artery disease, lower thrombolysis in myocardial infarction (TIMI) flow and 
myocardial perfusion grades during coronary angiography in addition to a higher 6-month 
mortality independently of other risk factors including ST-segment deviation and troponin 
levels (Sabatine et al., 2002a). A high neutrophil count and a low lymphocyte count may 
carry most of this increased risk, as reported for patients assessed for coronary artery 
disease by coronary angiography (Horne et al., 2005).  
Thus, for prognostic purposes, clinicians have focused on white blood-cell, neutrophils or 
downstream products such as C-reactive protein (CRP). Neutrophils, however, live only for 
hours and generate no memory of their engagement, which is carried out through inherited 
receptors that are similar in all hosts, while lymphocytes are long-lived cells that can survive 
for decades, and the lymphocyte repertoire is tailored for each individual. When mobilized 
in immune responses, lymphocytes undergo clonal burst, differentiate into distinct types of 
effector cells, and memorize information about the antigen (Bodi et al, 2008). Little is known 
regarding the role of lymphocytes, which play an important role in the control of the 
inflammatory system and in the pathophysiology of coronary disease (Bodi et al, 2008). 
Several studies had demonstrated that the adaptative immunity plays an important role in 
the pathogenesis of coronary artery disease (Blum & Yeganeh, 2003; Methe et al., 2005; Han 
et al., 2007; Packard et al., 2009; Hansson, 2009). In the culprit lesions of patients with acute 
coronary syndromes the percentage of activated T lymphocytes is significantly increased, 
and experimental results (Caligiuri et al., 2000) suggest the existence of antigenic stimuli in 
these lesions. These findings lead to the paradigm that the transition from a stable to an 
unstable plaque includes immunological activation and may be T cell-dependent (Steppich 
et al., 2007). 
The interactions between leucocytes, activated platelets and activated endothelial cells, 
mediated by P-selectin, E-selectin and ICAM-1 whose soluble forms can be released in 
circulation, associate with the initiation of arterial thrombus (Price & Loscalzo, 1999). The 
expression of ICAM-1 in activated endothelial cells and of P-selectin in activated platelets, 
seems to have key roles in binding and rolling of leukocytes along the activated 
endothelium, and in platelet aggregation and platelet-leukocyte adhesion.  
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The majority of soluble P-selectin appears to be derived from activated platelets, as its levels 
are correlated with other established platelet markers but not with endothelial markers 
(Price & Loscalzo, 1999). Stimulated platelets and immune cells express membrane proteins, 
such as integrins, CD40 and its ligand (CD40L) (Henn et al., 2001), and eventually secrete 
products with pro-inflammatory properties, such as TNF-, and also soluble forms of 
adhesion molecules. Clinical data relating soluble P-selectin, ICAM-1 and TNF- to 
coronary disease are limited and have been derived primarily from randomized clinical 
trials, cross-sectional or retrospective studies in patients with acute coronary syndromes. 
While, increased levels of soluble P-selectin have been consistently associated with acute 
coronary syndromes (Ridker et al., 2001), the measurement of sICAM-1 is not consensual. 
Prolonged high levels of sICAM-1 were associated with unstable angina and acute 
myocardial infarction (Mulvihill et al., 2000), although a stronger predictive information for 
sICAM-1 could not be found (Haim et al., 2002; Hartford et al., 2006). Increases in TNF- and 
in some of its soluble receptors were related to primary cardiovascular events and to 
mortality in heart failure subsequent to myocardial infarction (Ponthieux et al., 2004; 
Valgimigli et al., 2005). 
C-reactive protein is a down-stream marker of inflammation produced in the liver. Its 
production appears to be regulated, during the acute phase response, by several cytokines, 
including TNF- (Calabrò et al., 2009). Though it was originally proposed as a nonspecific 
marker of inflammation, several reports suggest that CRP may play a direct 
pathophysiological role in the development and progression of atherosclerosis. Proposed 
mechanisms include induction of endothelial dysfunction, promotion of foam cell 
formation, inhibition of endothelial progenitor cell survival and differentiation, and 
activation of complement in atherosclerotic plaque intima and ischemic myocardium 
(Armstrong et al., 2006b). CRP is a robust clinical marker because of its stability, 
reproducible results, and ease of assay (Armstrong et al., 2006b). An increasing variety of 
literature has been propose CRP as a major cardiovascular risk factor. Elevated baseline 
concentrations of this acute phase-protein are associated with the risk of atherosclerotic 
events in general populations (Calabrò et al., 2009) and show a predictor value in terms of 
cardiovascular risk associated with both primary and secondary prevention of coronary 
artery disease (Ikonomidis et al., 2008).  
Although a great pool of information concerning systemic inflammation markers has been 
so far collected in different cardiovascular conditions, the evolution of coronary syndromes 
is not well depicted.  
An approach with multiple inflammatory markers might be of interest since different 
markers may enhance or initiate different and not always overlapping inflammatory 
pathways, leading to atherosclerosis and cardiac events and may indicate different stages of 
disease (Ikonomidis et al., 2008). Therefore, the relationship of inflammatory molecules and 
cells with the coronary disease severity and extension, and with the physiological response 
of the cardiovascular system may evidence the underlying mechanisms of inflammation 
responsible for plaque instability.  
The main objective of this study was to investigate several inflammatory markers in 
coronary artery disease. The circulating levels of CRP, sP-selectin, sICAM-1, TNF-, and 
inflammatory blood cells were assessed as they express cell adhesion, cell activation and 
inflammation processes which are crucial in thrombosis and secondary tissue remodelling 
as the cause of ischemia and necrosis.  
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This combined evaluation in a well-defined group of patients that had undergone 
angiography to precisely define coronary artery phenotype, may reveal the relevant roles of 
those markers in coronary disease and in the processes involved in lesion vulnerability.  
2. Materials and methods 
2.1 Study groups 
To achieve the proposed objective it is necessary to unveil the effect of coronary occlusion, 
ischemia, and necrosis. Therefore, patients with different stages of coronary artery disease 
were included in the study.  
A total of 177 subjects (53 women and 124 men) were recruited at the Cardiology Service in 
Santa Marta Hospital (Lisbon, Portugal). 
Among them, 65 patients with acute myocardial infarction constituted the acute myocardial 
infarction (AMI) group. Those patients were diagnosed with ST-elevation myocardial 
infarction (ST-element changes and creatine kinase >3 times normal; n=56) or non-ST-
elevation myocardial infarction (creatine kinase >3 times normal and without ST-element 
changes; n=9). All AMI patients were enrolled in the first 24 hours of hospital admission, 
and were submitted to primary percutaneous transluminal coronary angioplasty as 
reperfusion therapy. The time period from the onset of chest pain to the intervention was 
less than 9 hours for the majority of AMI patients.  
Fifty-five patients with angiographically confirmed coronary artery disease suffering from 
chest discomfort, were also enrolled in the study and constituted the CAD group.   
A coronary control group (CC) was established. This group was constituted by twenty-nine 
age-matched patients with chest discomfort complain but without coronary artery disease 
confirmed by coronary angiography.  
A reference group (REF) of 26 healthy non-smoking volunteers was also established to help 
on inflammation baseline interpretation. Inclusion criteria for reference controls was absence 
of any history of coronary disease, dyslipidaemia or hypertension, any mobility limiting 
conditions, life threatening diseases, or any other disease or condition that would impair 
compliance. These 26 volunteers were not submitted to coronary angiography.  
Informed consent was obtained for all subjects enrolled, and the study was approved by the 
local Ethical Committee. 
2.2 Criteria used for patient’s selection 
Exclusion criteria were age above 85, significant co-morbidities as peripheral artery disease 
or carotid artery disease, known antecedents of malignance or infectious diseases, chronic 
renal insufficiency and previous myocardial infarction in the last 5 years. Concurrent 
inflammatory disorders, malignant neoplasm or infection were also excluded.  
All patients were clinically and biochemically characterized, by a battery of systemic 
indicators. 
The patients’ characterization was accomplished with anthropometric data (body mass 
index, waist perimeter and blood pressure) and biochemical data consisting of a battery of 
systemic indicators, such as glucose, haematocrit, albumin, triglycerides, total cholesterol, 
cholesterol of LDL and HDL. The cardiac function enzymes creatinine kinase and cardiac 
troponin T (cTnT) were also determined, and ventricle electrolytic regulation assessed by 
the determination of N-terminal pro B type natriuretic peptide (NT-proBNP).  
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The majority of soluble P-selectin appears to be derived from activated platelets, as its levels 
are correlated with other established platelet markers but not with endothelial markers 
(Price & Loscalzo, 1999). Stimulated platelets and immune cells express membrane proteins, 
such as integrins, CD40 and its ligand (CD40L) (Henn et al., 2001), and eventually secrete 
products with pro-inflammatory properties, such as TNF-, and also soluble forms of 
adhesion molecules. Clinical data relating soluble P-selectin, ICAM-1 and TNF- to 
coronary disease are limited and have been derived primarily from randomized clinical 
trials, cross-sectional or retrospective studies in patients with acute coronary syndromes. 
While, increased levels of soluble P-selectin have been consistently associated with acute 
coronary syndromes (Ridker et al., 2001), the measurement of sICAM-1 is not consensual. 
Prolonged high levels of sICAM-1 were associated with unstable angina and acute 
myocardial infarction (Mulvihill et al., 2000), although a stronger predictive information for 
sICAM-1 could not be found (Haim et al., 2002; Hartford et al., 2006). Increases in TNF- and 
in some of its soluble receptors were related to primary cardiovascular events and to 
mortality in heart failure subsequent to myocardial infarction (Ponthieux et al., 2004; 
Valgimigli et al., 2005). 
C-reactive protein is a down-stream marker of inflammation produced in the liver. Its 
production appears to be regulated, during the acute phase response, by several cytokines, 
including TNF- (Calabrò et al., 2009). Though it was originally proposed as a nonspecific 
marker of inflammation, several reports suggest that CRP may play a direct 
pathophysiological role in the development and progression of atherosclerosis. Proposed 
mechanisms include induction of endothelial dysfunction, promotion of foam cell 
formation, inhibition of endothelial progenitor cell survival and differentiation, and 
activation of complement in atherosclerotic plaque intima and ischemic myocardium 
(Armstrong et al., 2006b). CRP is a robust clinical marker because of its stability, 
reproducible results, and ease of assay (Armstrong et al., 2006b). An increasing variety of 
literature has been propose CRP as a major cardiovascular risk factor. Elevated baseline 
concentrations of this acute phase-protein are associated with the risk of atherosclerotic 
events in general populations (Calabrò et al., 2009) and show a predictor value in terms of 
cardiovascular risk associated with both primary and secondary prevention of coronary 
artery disease (Ikonomidis et al., 2008).  
Although a great pool of information concerning systemic inflammation markers has been 
so far collected in different cardiovascular conditions, the evolution of coronary syndromes 
is not well depicted.  
An approach with multiple inflammatory markers might be of interest since different 
markers may enhance or initiate different and not always overlapping inflammatory 
pathways, leading to atherosclerosis and cardiac events and may indicate different stages of 
disease (Ikonomidis et al., 2008). Therefore, the relationship of inflammatory molecules and 
cells with the coronary disease severity and extension, and with the physiological response 
of the cardiovascular system may evidence the underlying mechanisms of inflammation 
responsible for plaque instability.  
The main objective of this study was to investigate several inflammatory markers in 
coronary artery disease. The circulating levels of CRP, sP-selectin, sICAM-1, TNF-, and 
inflammatory blood cells were assessed as they express cell adhesion, cell activation and 
inflammation processes which are crucial in thrombosis and secondary tissue remodelling 
as the cause of ischemia and necrosis.  
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This combined evaluation in a well-defined group of patients that had undergone 
angiography to precisely define coronary artery phenotype, may reveal the relevant roles of 
those markers in coronary disease and in the processes involved in lesion vulnerability.  
2. Materials and methods 
2.1 Study groups 
To achieve the proposed objective it is necessary to unveil the effect of coronary occlusion, 
ischemia, and necrosis. Therefore, patients with different stages of coronary artery disease 
were included in the study.  
A total of 177 subjects (53 women and 124 men) were recruited at the Cardiology Service in 
Santa Marta Hospital (Lisbon, Portugal). 
Among them, 65 patients with acute myocardial infarction constituted the acute myocardial 
infarction (AMI) group. Those patients were diagnosed with ST-elevation myocardial 
infarction (ST-element changes and creatine kinase >3 times normal; n=56) or non-ST-
elevation myocardial infarction (creatine kinase >3 times normal and without ST-element 
changes; n=9). All AMI patients were enrolled in the first 24 hours of hospital admission, 
and were submitted to primary percutaneous transluminal coronary angioplasty as 
reperfusion therapy. The time period from the onset of chest pain to the intervention was 
less than 9 hours for the majority of AMI patients.  
Fifty-five patients with angiographically confirmed coronary artery disease suffering from 
chest discomfort, were also enrolled in the study and constituted the CAD group.   
A coronary control group (CC) was established. This group was constituted by twenty-nine 
age-matched patients with chest discomfort complain but without coronary artery disease 
confirmed by coronary angiography.  
A reference group (REF) of 26 healthy non-smoking volunteers was also established to help 
on inflammation baseline interpretation. Inclusion criteria for reference controls was absence 
of any history of coronary disease, dyslipidaemia or hypertension, any mobility limiting 
conditions, life threatening diseases, or any other disease or condition that would impair 
compliance. These 26 volunteers were not submitted to coronary angiography.  
Informed consent was obtained for all subjects enrolled, and the study was approved by the 
local Ethical Committee. 
2.2 Criteria used for patient’s selection 
Exclusion criteria were age above 85, significant co-morbidities as peripheral artery disease 
or carotid artery disease, known antecedents of malignance or infectious diseases, chronic 
renal insufficiency and previous myocardial infarction in the last 5 years. Concurrent 
inflammatory disorders, malignant neoplasm or infection were also excluded.  
All patients were clinically and biochemically characterized, by a battery of systemic 
indicators. 
The patients’ characterization was accomplished with anthropometric data (body mass 
index, waist perimeter and blood pressure) and biochemical data consisting of a battery of 
systemic indicators, such as glucose, haematocrit, albumin, triglycerides, total cholesterol, 
cholesterol of LDL and HDL. The cardiac function enzymes creatinine kinase and cardiac 
troponin T (cTnT) were also determined, and ventricle electrolytic regulation assessed by 
the determination of N-terminal pro B type natriuretic peptide (NT-proBNP).  
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Furthermore, detailed in-hospital data was registered, including: demographic (such as age 
and sex), and coronary risk factors data (such as, smoking, previous diagnostic of diabetes 
mellitus, hypertension and hyperlipidaemia) and personal history and family history of 
coronary artery disease. Current, in-hospital and after angioplasty medication was also 
recorded: insulin or other anti-diabetic drugs; antiplatelet and anti-aggregant drugs, such as 
aspirin, clopidrogel or glycoprotein IIb/IIIa receptor antagonists; -blockers; ACE inhibitors 
and statins.  
2.2.1 Definition of risk factors, clinical signs and syndromes 
Diabetes was diagnosed on the basis of fasting plasma glucose concentration ≥7.0 mmol/l 
(126 mg/dl) or 2–h plasma glucose ≥11.1 mmol/l (200 mg/dl) or confirmed as clinically 
known and treated diabetes mellitus. Subjects were diagnosed hypertensive if they were 
documented to have systolic blood pressure 140 mmHg and/or diastolic blood pressure 
90 mmHg or were already on anti-hypertensive therapy. Dyslipidaemia was identified in 
subjects who had been given lipid-lowering medication or having total serum cholesterol 
level 190 mg/dl or serum triglycerides 180 mg/dl.  
Smoking was defined as the inhaled use of cigarettes, cigars or pipes in any quantity. 
Subjects who smoked within the previous 1 year were also defined as smokers. 
Several inflammatory markers such as white blood-cell count, CRP and TNF- levels have 
been extensively associated with cardiovascular disease risk (Ikonomidis et al., 2008). In fact, 
several studies established cut-off values associated with cardiovascular risk and to the 
occurrence of adverse cardiovascular events for these biomarkers (Sabatine et al., 2002a; 
Sabatine et al., 2002b; Grau et al., 2004; Ridker & Cook, 2004; Ikonomidis et al., 2005; Ridker et 
al., 2005).  
Based on these documented limits values, we establish risk classes for white blood-cell 
count, CRP and TNF- levels. For the white blood-cell counts the cut-off value (low/high 
risk) considered was >10.1x109/l (Sabatine et al., 2002a; Grau et al., 2004). The classes of 
cardiovascular risk associated to CRP were considered as low and high risk based on the 
cut-off value of ≥3 mg/dl (Sabatine et al., 2002b; Ridker & Cook, 2004; Ridker et al., 2005). 
Finally, for the TNF- concentrations the cut-off value considered for low/high risk was 
≥3.61 pg/ml (Ikonomidis et al., 2005). 
2.2.2 Angiographic data 
AMI and CAD patients were clinically characterized for the extension of coronary artery 
disease through the characterization of lesion morphology data to define the coronary stenosis, 
the number of diseased vessels, flow characteristics of responsible vessel such as the 
thrombolysis in myocardial infarction (TIMI) risk score (from 0-3 referring to the levels of 
coronary blood flow assessed during coronary angiography), lesion length and the presence of 
calcium and/or thrombi in the lesions. The number and type of stents (bare metal or drug 
eluting stent) positioned in patients undergoing coronary angiography were also recorded. 
A coronary stenosis was considered clinically significant (high-grade) above 70% narrowing 
in the luminal diameter. Multivessel disease was defined when more than one major 
coronary artery presented high-grade stenosis. Patients were classified according to the class 
of stenosis based on TIMI risk score: TIMI 3 – patients having normal flow and complete 
perfusion; and TIMI < 3 – patients with some degree of occlusion. In the later the TIMI 
scores considered were TIMI 2 for flow partial perfusion and TIMI 0 for no perfusion. 
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Additionally, patients were divided into 2 subgroups according to the lesion length using a 
cut-off of 15 mm. Small lesions were considered ≤15 mm and large lesions >15 mm. 
2.3 Study protocol 
A longitudinal study was carried out in the AMI patients. Patients were assessed at hospital 
admission before the administration of IIb/IIIa inhibitors and coronary angioplasty 
intervention, 2 and 40 days after the initial intervention. At these three time-points 
biochemical parameters and circulating inflammatory markers were measured. CAD and 
CC patients were only assessed at hospital admission before percutaneous intervention. 
2.4 Blood sampling and laboratory assays 
Blood samples were drawn from all patients into pyrogen-free blood collection tubes 
without additives and immediately centrifuged (2500 rpm for 10 minutes). The serum was 
collected after centrifugation and aliquots were stored at -80ºC until analysis. Sample 
storage period did not exceed 6 months. Samples were thawed only once. 
Lipid profile, glucose levels, albumin, creatinine kinase, troponin T, NT-proBNP, blood cells 
count and levels of high-sensitivity CRP were routinely measured on hospital.  
Soluble concentrations of ICAM-1 and P-selectin were measured by enzyme-linked 
immunosorbent assays (ELISA) commercial kits (R&D Systems, Minneapolis, USA). The 
concentrations of TNF- were assessed using a commercial available high sensitivity ELISA 
(R&D Systems, Minneapolis, USA). All the assays were performed on serum according to 
the manufacturer’s recommendations. Each sample was measured in duplicate; the intra-
assay variation among the duplicates for all samples was <10%. 
2.5 Statistical analysis 
Data were summarized as mean and standard deviation (SD) or median and quartiles for 
continuous variables and as proportions for categorical variables. Non-continuous variables 
were analysed using a 2x2 table and 2 test. Differences between the four study groups were 
compared using a general linear model analysis of variance (ANOVA) followed by post hoc 
procedures (Tukey and Scheffé tests) to identify differences. ANOVA adequacy was 
weighted by checking the variance homogeneity using Levene’s test and by verifying the 
significance of F distribution with the Welch statistics. For the variables white blood-cell, 
neutrophils, lymphocytes and monocyte counts, sP-selectin, sICAM-1, CRP, total 
cholesterol, LDL-cholesterol, triglycerides, glucose, troponin T and NT-proBNP the 
homogeneity of variance was not reached, thus variables were logarithmic transformed 
before performing ANOVA analysis.  
Associations between inflammatory mediators, and with risk factors, co-morbidities and 
angiographic data were evaluated using non-parametric Spearman correlations. 
The study of the repeated measures of inflammatory parameters in AMI patients through 
time requires specific statistical methods as common analysis of variance or non-parametric 
correlations are inappropriate. The inflammatory parameters and mediators, CRP, sP-
selectin, sICAM-1, TNF-, and blood cell counts, were measured in day 0 at hospital 
admission before percutaneous transluminal coronary angioplasty, and repeated at day 2 
and day 40 after the initial percutaneous transluminal coronary angioplasty in the same 
patient. Consequently, the observations are inter-correlated and classical statistical 
techniques do not account for this type of variability. For that reason, a non-linear regression 
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Furthermore, detailed in-hospital data was registered, including: demographic (such as age 
and sex), and coronary risk factors data (such as, smoking, previous diagnostic of diabetes 
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coronary artery disease. Current, in-hospital and after angioplasty medication was also 
recorded: insulin or other anti-diabetic drugs; antiplatelet and anti-aggregant drugs, such as 
aspirin, clopidrogel or glycoprotein IIb/IIIa receptor antagonists; -blockers; ACE inhibitors 
and statins.  
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(126 mg/dl) or 2–h plasma glucose ≥11.1 mmol/l (200 mg/dl) or confirmed as clinically 
known and treated diabetes mellitus. Subjects were diagnosed hypertensive if they were 
documented to have systolic blood pressure 140 mmHg and/or diastolic blood pressure 
90 mmHg or were already on anti-hypertensive therapy. Dyslipidaemia was identified in 
subjects who had been given lipid-lowering medication or having total serum cholesterol 
level 190 mg/dl or serum triglycerides 180 mg/dl.  
Smoking was defined as the inhaled use of cigarettes, cigars or pipes in any quantity. 
Subjects who smoked within the previous 1 year were also defined as smokers. 
Several inflammatory markers such as white blood-cell count, CRP and TNF- levels have 
been extensively associated with cardiovascular disease risk (Ikonomidis et al., 2008). In fact, 
several studies established cut-off values associated with cardiovascular risk and to the 
occurrence of adverse cardiovascular events for these biomarkers (Sabatine et al., 2002a; 
Sabatine et al., 2002b; Grau et al., 2004; Ridker & Cook, 2004; Ikonomidis et al., 2005; Ridker et 
al., 2005).  
Based on these documented limits values, we establish risk classes for white blood-cell 
count, CRP and TNF- levels. For the white blood-cell counts the cut-off value (low/high 
risk) considered was >10.1x109/l (Sabatine et al., 2002a; Grau et al., 2004). The classes of 
cardiovascular risk associated to CRP were considered as low and high risk based on the 
cut-off value of ≥3 mg/dl (Sabatine et al., 2002b; Ridker & Cook, 2004; Ridker et al., 2005). 
Finally, for the TNF- concentrations the cut-off value considered for low/high risk was 
≥3.61 pg/ml (Ikonomidis et al., 2005). 
2.2.2 Angiographic data 
AMI and CAD patients were clinically characterized for the extension of coronary artery 
disease through the characterization of lesion morphology data to define the coronary stenosis, 
the number of diseased vessels, flow characteristics of responsible vessel such as the 
thrombolysis in myocardial infarction (TIMI) risk score (from 0-3 referring to the levels of 
coronary blood flow assessed during coronary angiography), lesion length and the presence of 
calcium and/or thrombi in the lesions. The number and type of stents (bare metal or drug 
eluting stent) positioned in patients undergoing coronary angiography were also recorded. 
A coronary stenosis was considered clinically significant (high-grade) above 70% narrowing 
in the luminal diameter. Multivessel disease was defined when more than one major 
coronary artery presented high-grade stenosis. Patients were classified according to the class 
of stenosis based on TIMI risk score: TIMI 3 – patients having normal flow and complete 
perfusion; and TIMI < 3 – patients with some degree of occlusion. In the later the TIMI 
scores considered were TIMI 2 for flow partial perfusion and TIMI 0 for no perfusion. 
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Additionally, patients were divided into 2 subgroups according to the lesion length using a 
cut-off of 15 mm. Small lesions were considered ≤15 mm and large lesions >15 mm. 
2.3 Study protocol 
A longitudinal study was carried out in the AMI patients. Patients were assessed at hospital 
admission before the administration of IIb/IIIa inhibitors and coronary angioplasty 
intervention, 2 and 40 days after the initial intervention. At these three time-points 
biochemical parameters and circulating inflammatory markers were measured. CAD and 
CC patients were only assessed at hospital admission before percutaneous intervention. 
2.4 Blood sampling and laboratory assays 
Blood samples were drawn from all patients into pyrogen-free blood collection tubes 
without additives and immediately centrifuged (2500 rpm for 10 minutes). The serum was 
collected after centrifugation and aliquots were stored at -80ºC until analysis. Sample 
storage period did not exceed 6 months. Samples were thawed only once. 
Lipid profile, glucose levels, albumin, creatinine kinase, troponin T, NT-proBNP, blood cells 
count and levels of high-sensitivity CRP were routinely measured on hospital.  
Soluble concentrations of ICAM-1 and P-selectin were measured by enzyme-linked 
immunosorbent assays (ELISA) commercial kits (R&D Systems, Minneapolis, USA). The 
concentrations of TNF- were assessed using a commercial available high sensitivity ELISA 
(R&D Systems, Minneapolis, USA). All the assays were performed on serum according to 
the manufacturer’s recommendations. Each sample was measured in duplicate; the intra-
assay variation among the duplicates for all samples was <10%. 
2.5 Statistical analysis 
Data were summarized as mean and standard deviation (SD) or median and quartiles for 
continuous variables and as proportions for categorical variables. Non-continuous variables 
were analysed using a 2x2 table and 2 test. Differences between the four study groups were 
compared using a general linear model analysis of variance (ANOVA) followed by post hoc 
procedures (Tukey and Scheffé tests) to identify differences. ANOVA adequacy was 
weighted by checking the variance homogeneity using Levene’s test and by verifying the 
significance of F distribution with the Welch statistics. For the variables white blood-cell, 
neutrophils, lymphocytes and monocyte counts, sP-selectin, sICAM-1, CRP, total 
cholesterol, LDL-cholesterol, triglycerides, glucose, troponin T and NT-proBNP the 
homogeneity of variance was not reached, thus variables were logarithmic transformed 
before performing ANOVA analysis.  
Associations between inflammatory mediators, and with risk factors, co-morbidities and 
angiographic data were evaluated using non-parametric Spearman correlations. 
The study of the repeated measures of inflammatory parameters in AMI patients through 
time requires specific statistical methods as common analysis of variance or non-parametric 
correlations are inappropriate. The inflammatory parameters and mediators, CRP, sP-
selectin, sICAM-1, TNF-, and blood cell counts, were measured in day 0 at hospital 
admission before percutaneous transluminal coronary angioplasty, and repeated at day 2 
and day 40 after the initial percutaneous transluminal coronary angioplasty in the same 
patient. Consequently, the observations are inter-correlated and classical statistical 
techniques do not account for this type of variability. For that reason, a non-linear regression 
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algorithm that accounts for the effect of repeated measures was applied, the linear mixed 
effects model. The procedure of lineal mixed effects models the concentrations of the 
inflammatory markers measured through time considering that measures for each patient 
were not independent (Twisk, 2006). Using this algorithm the concentrations of the 
inflammatory parameters CRP, sP-selectin, sICAM-1, TNF-) and blood cell counts can be 
modelled as a response variable on time. This statistical model describes the longitudinal 
variations of each patient for each variable by calculating slopes and averages of the 
variables in each time point. Therefore, it allows to estimate the differences in average slopes 
between baseline (day 0) and the other time points, giving a measure of the variation of each 
blood marker over time. In order to apply the lineal mixed effects model, variables should 
comply with normality distribution.  A logarithm transformation was used for the variables 
CRP, sICAM-1, white blood-cell, neutrophil and lymphocyte counts, while a square root 
transformation was used for monocyte counts, sP-selectin and TNF-.  
Values of p<0.05 (two-tailed) were considered statistical significant.  
The calculations were performed using SPSS (version 19.0) and R (version 2.11.1) software.   
3. Results 
3.1 Demographic and clinical characteristics of the study groups 
The demographic characteristics and clinical features of the study groups including risk 
factors, co-morbidities and previous-event medication intake are summarized in Table 1.  
The age of subjects enrolled ranged between 27 and 81 years, having the three groups 
matching ages. There were no significant differences between AMI, CAD and CC subjects in 
body mass index (BMI), waist perimeter and blood pressure, except for sex ratio. As can be 
inferred from Table 1, AMI patients were mostly men (80%), while in CAD and CC groups 
the percentage of the masculine gender decreased (70% and 60%, respectively).  The three 
groups also had similar prevalence of risk factors as diabetes, dyslipidaemia and 
hypertension, however smoking was more frequent in AMI patients.  
Since coronary disease risk factors and co-morbidities were exclusion criteria in REF group 
selection, these subjects were not considered in this comparison. 
 





Sex, f/m 13/16 18/37 15/50 
Age (y) 60±9 64±9 61±15 
Body mass index (kg/m2) 29±6 27±3 27±4 
Waist perimeter (cm) 100±13 98±9 94±17 
Systolic blood pressure (mm Hg) 140±20 152±23 125±22 
Diastolic blood pressure (mm Hg) 77±10 78±10 73±15 
Risk factors and co-morbidity    
Hypertension, n (%) 19 (66) 35 (63) 42 (64) 
Smoking, n (%) 3 (10) 6 (11) 33 (50) a,b 
Dyslipidaemia, n (%) 21 (72) 34 (61) 38 (58) 
Diabetes, n (%) 7 (24) 16 (24) 12 (21) 
Family history of CAD, n (%) 1 (3) 12 (21) 9 (14) 
Table 1. Clinical characteristics of the studied groups. 
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Values are expressed as mean±SD, except otherwise indicated. a p<0.05 vs CTR group; b 
p<0.05 vs CAD group. 
Medication intake in AMI group had also into account the medication before hospital 
admission and the in-hospital and follow-up treatments. There were no significant 
differences in the use of pre-event medication in AMI patients and patients with CAD or CC 
subjects (Table 2).  
 





Previous-event medication    
Aspirin, n (%) 9 (31) 23 (41) 20 (30) 
ACE-inhibitor, n (%) 9 (31) 20 (36) 23 (35) 
-blockers, n (%) 7 (24) 15 (27) 11 (17) 
Statins, n (%) 13 (45) 17 (48) 19 (29) 
Table 2. Pre-event medication in the studied groups.   
After admission, in-hospital medication for the AMI patients included aspirin (59%), -
blockers (52%), angiotensin-converting enzyme (ACE)-inhibitors (55%), statins (12%) and 
antiplatelet inhibitors (79%). During follow-up 80% of patients took antiplatelet inhibitors 
(clopidogrel and aspirin) in addition to the previous medication referred above. 
Furthermore, in the course of the angioplasty, stents were implanted in 86% of the patients, 
being 29% drug-eluting stents. 
 





Total cholesterol (mg/dl) * 165 (148 – 200) 
158 
(133 – 205) 
191 
(158 – 230) 
LDL-cholesterol (mg/dl) * 111 (85.8 – 136) 
102 
(82.0 – 129) 
128 
(103 – 149) 
HDL-cholesterol (mg/dl) * 40 (312 – 50) 
42 
(35 – 50) 
38 
(31 – 47) 
Triglycerides (mg/dl) * 104 (65 – 137) 
104 
(68 – 130) 
122 
(59 – 154) 
Haematocrit (%) 40 (36 – 43) 
39 
(36 – 42) 
40 
(37 – 44) 
Glucose (mg/dl) * 111 (95 – 128) 
115 
(94 – 134) 
139 
(116 – 202) 
Albumin (g/dl) 3.70 (3.40 – 3.90) 
3.6 0 
(3.20 – 4.00) 
3.40 
(3.10 – 3.70) 
Troponin T (ng/ml) <0.01 ** <0.01 ** 0.34 
a,b 
(0.08 – 1.74) 
NT-proBNP (pg/ml) 71 (40 – 126) 
102 
(52 – 235) 
275 a,b 
(137 – 1030) 
Data are expressed as median and quartiles (lower quartile-upper quartile). * not compared (see text); ** 
values below detection limit; a p<0.05 vs CC group; b p<0.05 vs CAD group. 
Table 3. Biochemical data of the studied groups. 
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algorithm that accounts for the effect of repeated measures was applied, the linear mixed 
effects model. The procedure of lineal mixed effects models the concentrations of the 
inflammatory markers measured through time considering that measures for each patient 
were not independent (Twisk, 2006). Using this algorithm the concentrations of the 
inflammatory parameters CRP, sP-selectin, sICAM-1, TNF-) and blood cell counts can be 
modelled as a response variable on time. This statistical model describes the longitudinal 
variations of each patient for each variable by calculating slopes and averages of the 
variables in each time point. Therefore, it allows to estimate the differences in average slopes 
between baseline (day 0) and the other time points, giving a measure of the variation of each 
blood marker over time. In order to apply the lineal mixed effects model, variables should 
comply with normality distribution.  A logarithm transformation was used for the variables 
CRP, sICAM-1, white blood-cell, neutrophil and lymphocyte counts, while a square root 
transformation was used for monocyte counts, sP-selectin and TNF-.  
Values of p<0.05 (two-tailed) were considered statistical significant.  
The calculations were performed using SPSS (version 19.0) and R (version 2.11.1) software.   
3. Results 
3.1 Demographic and clinical characteristics of the study groups 
The demographic characteristics and clinical features of the study groups including risk 
factors, co-morbidities and previous-event medication intake are summarized in Table 1.  
The age of subjects enrolled ranged between 27 and 81 years, having the three groups 
matching ages. There were no significant differences between AMI, CAD and CC subjects in 
body mass index (BMI), waist perimeter and blood pressure, except for sex ratio. As can be 
inferred from Table 1, AMI patients were mostly men (80%), while in CAD and CC groups 
the percentage of the masculine gender decreased (70% and 60%, respectively).  The three 
groups also had similar prevalence of risk factors as diabetes, dyslipidaemia and 
hypertension, however smoking was more frequent in AMI patients.  
Since coronary disease risk factors and co-morbidities were exclusion criteria in REF group 
selection, these subjects were not considered in this comparison. 
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Risk factors and co-morbidity    
Hypertension, n (%) 19 (66) 35 (63) 42 (64) 
Smoking, n (%) 3 (10) 6 (11) 33 (50) a,b 
Dyslipidaemia, n (%) 21 (72) 34 (61) 38 (58) 
Diabetes, n (%) 7 (24) 16 (24) 12 (21) 
Family history of CAD, n (%) 1 (3) 12 (21) 9 (14) 
Table 1. Clinical characteristics of the studied groups. 
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Values are expressed as mean±SD, except otherwise indicated. a p<0.05 vs CTR group; b 
p<0.05 vs CAD group. 
Medication intake in AMI group had also into account the medication before hospital 
admission and the in-hospital and follow-up treatments. There were no significant 
differences in the use of pre-event medication in AMI patients and patients with CAD or CC 
subjects (Table 2).  
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-blockers, n (%) 7 (24) 15 (27) 11 (17) 
Statins, n (%) 13 (45) 17 (48) 19 (29) 
Table 2. Pre-event medication in the studied groups.   
After admission, in-hospital medication for the AMI patients included aspirin (59%), -
blockers (52%), angiotensin-converting enzyme (ACE)-inhibitors (55%), statins (12%) and 
antiplatelet inhibitors (79%). During follow-up 80% of patients took antiplatelet inhibitors 
(clopidogrel and aspirin) in addition to the previous medication referred above. 
Furthermore, in the course of the angioplasty, stents were implanted in 86% of the patients, 
being 29% drug-eluting stents. 
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Table 3. Biochemical data of the studied groups. 
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Concerning biochemical data (as listed in Table 3) AMI patients at admission had high levels 
of troponin T and NT-proBNP. Lipid and glucose data obtained could not be directly 
compared as fasting-blood tests were only performed for REF individuals.  
3.2 Angiographic features 
Of the 151 subjects submitted to angiography (CC, CAD and AMI groups), 29 subjects (19%) 
had at least one episode of chest pain previous to the coronary angiography, whereas 122 
(81%) were asymptomatic.  
Lesion morphology data, based on angiography, in AMI and CAD patients was obtained for 
94 patients (77%), for the remaining patients those data were not possible to be obtained 
from the hospital registries.  
Multivessel disease was found in a total of 42 patients (45%). Analysis of angiographic 
complexity of the diseased vessels showed impaired flow (TIMI <3) in 44 patients (54%), 
and large lesions (>15 mm) also in 44 patients.  
From all the patients analysed, it was possible to detect the presence of calcium within the 
lesions in 14 patients (13%) and the presence of thrombi in 25 patients (24%). 
The resume of the angiographic data for the CAD and AMI patients is listed in Table 4. 
Comparing the morphologic data of patients from the CAD and AMI groups, it is possible 
to verify that an impaired flow (TIMI <3) is more frequent in AMI patients than in CAD 
patients. Furthermore, AMI patients had more often thrombi in the lesions than the CAD 
patients (Table 4). 
 
 
 CAD AMI 
Multivessel disease, n (%) 15 (42) 27 (47) 
TIMI   
TIMI 0, n (%) 2 (8) 32 (58) 
TIMI 1, n (%) 2 (8) 3 (5) 
TIMI 2, n (%) 1 (4) 4 (7) 
TIMI 3, n (%) 21 (81) 16 (29) 
Impaired flux TIMI <3, n (%) 5 (19) 39 (71) a 
Lesion length   
Small lesions, n (%) 11 (44) 18 (56) 
Large lesion, n (%) 14 (38) 30 (63) 
Lesions with calcium, n (%) 9 (20) 5 (8) 
Lesions with thrombi, n (%) 2 (5) 23 (38) a 
Data are expressed as number and percentages. a p<0.05 vs CAD group. 
Table 4. Angiographic data of the patients studied. 
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3.3 Inflammatory mediators 
The blood cell counts and concentration level of inflammatory mediators for the studied 
groups are presented in Table 5.  
 











(5.06 – 6.26) 
6.81 
(5.74 – 8.56) 
6.32 
(5.39 – 7.88) 
11.3 a,b,c 
(7.69 – 13.9) 
Neutrophils (x109/l) 3.00 (2.49 – 3.59 
3.54 
(3.20 – 4.19) 
4.08 a 
(2.94 – 4.95) 
8.34 a,b,c 
(5.61 – 11.2) 
Lymphocytes (x109/l) 2.02 (1.71 – 2.26) 
2.03 
(1.69 – 3.32) 
1.77 
(1.38 – 2.30) 
1.54 
(1.24 – 2.24) 
Monocytes (x109/l) 0.37 (0.28 – 0.51) 
0.42 
(0.28 – 0.58) 
0.50 
(0.34 – 0.67) 
0.60 a,b,c 
(0.42 – 0.81) 
Inflammatory markers     
CRP (mg/dl) <0.32 ** 0.66 (0.31 – 0.74) 
0.43 
(0.18 – 1.29) 
0.69 a 
(0.34 – 1.39) 
TNF- (pg/ml) 0.37 (0.12 – 1.14) 
1.17 




(0.57 – 2.47) 
sP-selectin (ng/ml) 84 (93 – 119) 
68 a 
(41 – 83) 
53 a 
(42 – 82) 
83 
(54 – 116) 
sICAM-1 (ng/ml) 214 (190 – 246) 
247 
(204 – 316) 
220 
(200 – 237) 
248 
(218 – 258) 
Data are expressed as median and quartiles (lower quartile-upper quartile). ** values below detection 
limit; a p<0.05 vs REF group; b p<0.05 vs CC group; c p<0.05 vs CAD group. 
Table 5. Inflammatory mediators in the four study groups. 
The results revealed that the circulating counts of white blood-cells and neutrophils in AMI 
patients at hospital admission were increased relative to the other groups (REF, CC and 
CAD). Monocyte counts were also increased in AMI patients relative to a normal baseline 
situation (REF group). The circulating levels of CRP and TNF- also showed the same trend 
(Table 5). Furthermore, in CAD patients the neutrophils counts and the TNF- 
concentrations were also increased in comparison to REF subjects (Table 5). 
Opposite, the concentrations of sP-selectin were significantly decreased in CAD and CC 
subjects in comparison to the REF subjects (Table 5). 
The relationships of white blood-cells, neutrophils, monocytes, lymphocytes counts, 
inflammatory mediators (CRP, TNF-, sP-selectin and sICAM-1) and cardiac markers (NT-
proBNP and troponin T) concentrations, were assessed using non-parametric Spearman 
correlations. Several significant associations were found. 
Relevant positive correlations were verified between CRP and ICAM-1(r=0.415, p<0.001), 
neutrophil (r=0.378, p<0.001) and monocyte counts (r=0.437, p<0.001). sICAM-1 also showed 
positive associations with white blood-cell counts (r=0.342, p=0.004) and TNF- 
concentrations (r=0.415, p<0.001).  
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Concerning biochemical data (as listed in Table 3) AMI patients at admission had high levels 
of troponin T and NT-proBNP. Lipid and glucose data obtained could not be directly 
compared as fasting-blood tests were only performed for REF individuals.  
3.2 Angiographic features 
Of the 151 subjects submitted to angiography (CC, CAD and AMI groups), 29 subjects (19%) 
had at least one episode of chest pain previous to the coronary angiography, whereas 122 
(81%) were asymptomatic.  
Lesion morphology data, based on angiography, in AMI and CAD patients was obtained for 
94 patients (77%), for the remaining patients those data were not possible to be obtained 
from the hospital registries.  
Multivessel disease was found in a total of 42 patients (45%). Analysis of angiographic 
complexity of the diseased vessels showed impaired flow (TIMI <3) in 44 patients (54%), 
and large lesions (>15 mm) also in 44 patients.  
From all the patients analysed, it was possible to detect the presence of calcium within the 
lesions in 14 patients (13%) and the presence of thrombi in 25 patients (24%). 
The resume of the angiographic data for the CAD and AMI patients is listed in Table 4. 
Comparing the morphologic data of patients from the CAD and AMI groups, it is possible 
to verify that an impaired flow (TIMI <3) is more frequent in AMI patients than in CAD 
patients. Furthermore, AMI patients had more often thrombi in the lesions than the CAD 
patients (Table 4). 
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TIMI   
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TIMI 1, n (%) 2 (8) 3 (5) 
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3.3 Inflammatory mediators 
The blood cell counts and concentration level of inflammatory mediators for the studied 
groups are presented in Table 5.  
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The results revealed that the circulating counts of white blood-cells and neutrophils in AMI 
patients at hospital admission were increased relative to the other groups (REF, CC and 
CAD). Monocyte counts were also increased in AMI patients relative to a normal baseline 
situation (REF group). The circulating levels of CRP and TNF- also showed the same trend 
(Table 5). Furthermore, in CAD patients the neutrophils counts and the TNF- 
concentrations were also increased in comparison to REF subjects (Table 5). 
Opposite, the concentrations of sP-selectin were significantly decreased in CAD and CC 
subjects in comparison to the REF subjects (Table 5). 
The relationships of white blood-cells, neutrophils, monocytes, lymphocytes counts, 
inflammatory mediators (CRP, TNF-, sP-selectin and sICAM-1) and cardiac markers (NT-
proBNP and troponin T) concentrations, were assessed using non-parametric Spearman 
correlations. Several significant associations were found. 
Relevant positive correlations were verified between CRP and ICAM-1(r=0.415, p<0.001), 
neutrophil (r=0.378, p<0.001) and monocyte counts (r=0.437, p<0.001). sICAM-1 also showed 
positive associations with white blood-cell counts (r=0.342, p=0.004) and TNF- 
concentrations (r=0.415, p<0.001).  
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Apart from the relationship between the number of neutrophils and monocytes in blood 
(r=0.464, p<0.001), neutrophils and monocytes were also associated to the levels of cardiac 
function markers troponin T and NT-proBNP (r=0.526 and r=0.315, p<0.001, respectively for 
neutrophils; and r=0.438 and r=0.356, p<0.001, respectively for monocytes). CRP was also 
significantly associated to the levels of troponin T and NT-proBNP (r=0.626 and r=0.470, 
p<0.001, respectively). 
Given the importance of risk factors and co-morbidities in the disease evolution, 
hypertension, dyslipidaemia, smoking habits and diabetes were also tested for Spearman 
correlations with inflammatory markers. Relevant correlations were only verified for sP-
selectin and sICAM-1 with cardiovascular risk factors. sP-selectin showed a negative 
correlation with hypertension (r=-0.379, p<0.001) and a positive correlation with smoking 
(r=0.381, p<0.001). Furthermore, sICAM-1 was also positively associated to smoking 
(r=0.373, r<0.001). 
Importantly, levels of P-selectin were also negatively associated with age (r=-0.399, p<0.001). 
In fact, subjects with age above 65 had lower levels of sP-selectin (55 ng/ml) compared to 
younger (65 years) subjects (78 ng/ml).  
As mentioned previously the enrolled subjects were classified in risk classes white blood-
cell count, CRP and TNF- levels. The frequency of each class in the studied population is 
resumed in Table 6.  
 
 CC CAD AMI Total Population 
WBC risk score     
Low risk (≤10.1x109/l), n (%) 28 (97) 50 (89) 24 (36) 127 (72) 
High risk (>10.1x109/l), n (%) 1 (3) 1 (2) 33 (50) 35 (20) 
CRP risk score     
Low risk (<3 mg/dl), n (%) 22 (76) 38 (68) 51 (77) 135 (76) 
High risk (≥3 mg/dl), n (%) 1 (3) 3 (5) 5 (8) 9 (5) 
TNF- risk score     
Low risk (>3.61 pg/ml), n (%) 19 (66) 20 (36) 35 (53) 89 (72) 
High risk (≥3.61 pg/ml), n (%) 3 (10) 2 (4) a 4 (6) 9 (5) a 
Data are expressed as number and percentages.  
Table 6. Distribution of the enrolled subjects in the white blood-cell (WBC), CRP and TNF- 
risk classes. 
3.3.1 Longitudinal variations 
The blood cell counts, the concentrations of inflammatory mediators and other biochemical 
markers, in AMI patients assessed at hospital admission, 2 and 40 days after percutaneous 
transluminal coronary angioplasty intervention are presented in Table 7.  
In the overall an increasing trend of the measured concentrations of sICAM-1 and TNF- 
through time was observed, while a decreasing one was observed for white blood-cell and 
neutrophil counts. Monocyte counts and CRP concentration showed an initial increase. To 
assess the significance of these changes through time a regression model (linear mixed 
effects model) was applied. As mentioned before (see section 2.5 Statistical analysis), 
appropriate transformations of variables had to be applied. Therefore, the results from the 
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 AMI patients 
 Day 0 Day 2 Day 40 
Biochemical characterization    
Total cholesterol (mg/dl) 191 (158 – 230) 
162 
(136 – 192) 
141 a 
(127 – 180) 
LDL-cholesterol (mg/dl) 128 (103 – 149) 
105 
(78 – 122) 
81 a 
(70 – 106) 
HDL-cholesterol (mg/dl) 38 (31 – 47) 
38 
(27 – 47) 
35 a 
(29 – 41) 
Triglyceride (mg/dl) 122 (59 – 154) 
95 
(90 – 110) 
112 a 
(79 – 175) 
Haematocrit (%) 40 (37 – 44) 
39 a 
(34 – 42) 
42 c 
(39 – 45) 
Glucose (mg/dl) 139 (116 – 202) 
121 
(102 – 151) 
102 a 
(93 – 135) 
Albumin (g/dl) 3.40 (3.10 – 3.70) 
3.19 a,b,c 
(3.00 – 3.50) 
3.90 
(3.60 – 4.20) 
Troponin T (ng/ml) 0.34 
b,c 
(0.08 – 1.74) 
2.40 a,b,c 
(1.70 – 4.10) <0.01 ** 
NT-proBNP (pg/ml) 275 
b,c 
(137 – 1030) 
1324 a,b,c 
(519 – 2955) 
611 a,b,c 
(354 – 1009) 
Blood cell counts    
White blood-cells (x109/l) 11.3 
a,b,c 
(7.69 – 13.9) 
8.48 a,c 
(6.31 – 10.3) 
6.68 
(5.37 – 7.33) 
Neutrophils (x109/l) 8.34 
a,b,c 
(5.61 – 11.2) 
5.32 a,b,c 
(4.05 – 6.37) 
3.82 a 
(3.12 – 4.85) 
Lymphocytes (x109/l) 1.54 (1.24 – 2.24) 
1.79 
(1.25 – 2.51) 
1.93 
(1.54 – 2.23) 
Monocytes (x109/l) 0.60 
a,b,c 
(0.42 – 0.81) 
0.74 a,b,c 
(0.62 – 0.91) 
0.48 
(0.40 – 0.58) 
Inflammatory markers    
CRP (mg/dl) 0.69 
a 
(0.34 – 1.39) 
3.49 a,b,c 
(1.52 – 6.92) 
0.34 
(0.32 – 0.70) 
TNF- (pg/ml) 1.57 
a 
(0.57 – 2.47) 
1.57 
(0.75 – 2.24) 
2.10 
(1.06 – 3.15) 
sP-selectin (ng/ml) 83 (54 – 116) 
67 
(48 – 79) 
70 
(62 – 103) 
sICAM-1 (ng/ml) 248 (218 – 258) 
281 
(238 – 309) 
298 
(224 – 400) 
Data are expressed as median and quartiles (lower quartile-upper quartile). ** values below detection limit; 
a p<0.05 vs REF group; b p<0.05 vs CC group; c p<0.05 vs CAD group (for comparison see Table 5). 
Table 7. Biochemical characterization and inflammatory mediators in the AMI patients at the 
three time-points: hospital admission (Day 0), two (Day 2) and 40 days (Day 40) after 
percutaneous transluminal coronary angioplasty intervention. 
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Apart from the relationship between the number of neutrophils and monocytes in blood 
(r=0.464, p<0.001), neutrophils and monocytes were also associated to the levels of cardiac 
function markers troponin T and NT-proBNP (r=0.526 and r=0.315, p<0.001, respectively for 
neutrophils; and r=0.438 and r=0.356, p<0.001, respectively for monocytes). CRP was also 
significantly associated to the levels of troponin T and NT-proBNP (r=0.626 and r=0.470, 
p<0.001, respectively). 
Given the importance of risk factors and co-morbidities in the disease evolution, 
hypertension, dyslipidaemia, smoking habits and diabetes were also tested for Spearman 
correlations with inflammatory markers. Relevant correlations were only verified for sP-
selectin and sICAM-1 with cardiovascular risk factors. sP-selectin showed a negative 
correlation with hypertension (r=-0.379, p<0.001) and a positive correlation with smoking 
(r=0.381, p<0.001). Furthermore, sICAM-1 was also positively associated to smoking 
(r=0.373, r<0.001). 
Importantly, levels of P-selectin were also negatively associated with age (r=-0.399, p<0.001). 
In fact, subjects with age above 65 had lower levels of sP-selectin (55 ng/ml) compared to 
younger (65 years) subjects (78 ng/ml).  
As mentioned previously the enrolled subjects were classified in risk classes white blood-
cell count, CRP and TNF- levels. The frequency of each class in the studied population is 
resumed in Table 6.  
 
 CC CAD AMI Total Population 
WBC risk score     
Low risk (≤10.1x109/l), n (%) 28 (97) 50 (89) 24 (36) 127 (72) 
High risk (>10.1x109/l), n (%) 1 (3) 1 (2) 33 (50) 35 (20) 
CRP risk score     
Low risk (<3 mg/dl), n (%) 22 (76) 38 (68) 51 (77) 135 (76) 
High risk (≥3 mg/dl), n (%) 1 (3) 3 (5) 5 (8) 9 (5) 
TNF- risk score     
Low risk (>3.61 pg/ml), n (%) 19 (66) 20 (36) 35 (53) 89 (72) 
High risk (≥3.61 pg/ml), n (%) 3 (10) 2 (4) a 4 (6) 9 (5) a 
Data are expressed as number and percentages.  
Table 6. Distribution of the enrolled subjects in the white blood-cell (WBC), CRP and TNF- 
risk classes. 
3.3.1 Longitudinal variations 
The blood cell counts, the concentrations of inflammatory mediators and other biochemical 
markers, in AMI patients assessed at hospital admission, 2 and 40 days after percutaneous 
transluminal coronary angioplasty intervention are presented in Table 7.  
In the overall an increasing trend of the measured concentrations of sICAM-1 and TNF- 
through time was observed, while a decreasing one was observed for white blood-cell and 
neutrophil counts. Monocyte counts and CRP concentration showed an initial increase. To 
assess the significance of these changes through time a regression model (linear mixed 
effects model) was applied. As mentioned before (see section 2.5 Statistical analysis), 
appropriate transformations of variables had to be applied. Therefore, the results from the 
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 AMI patients 
 Day 0 Day 2 Day 40 
Biochemical characterization    
Total cholesterol (mg/dl) 191 (158 – 230) 
162 
(136 – 192) 
141 a 
(127 – 180) 
LDL-cholesterol (mg/dl) 128 (103 – 149) 
105 
(78 – 122) 
81 a 
(70 – 106) 
HDL-cholesterol (mg/dl) 38 (31 – 47) 
38 
(27 – 47) 
35 a 
(29 – 41) 
Triglyceride (mg/dl) 122 (59 – 154) 
95 
(90 – 110) 
112 a 
(79 – 175) 
Haematocrit (%) 40 (37 – 44) 
39 a 
(34 – 42) 
42 c 
(39 – 45) 
Glucose (mg/dl) 139 (116 – 202) 
121 
(102 – 151) 
102 a 
(93 – 135) 
Albumin (g/dl) 3.40 (3.10 – 3.70) 
3.19 a,b,c 
(3.00 – 3.50) 
3.90 
(3.60 – 4.20) 
Troponin T (ng/ml) 0.34 
b,c 
(0.08 – 1.74) 
2.40 a,b,c 
(1.70 – 4.10) <0.01 ** 
NT-proBNP (pg/ml) 275 
b,c 
(137 – 1030) 
1324 a,b,c 
(519 – 2955) 
611 a,b,c 
(354 – 1009) 
Blood cell counts    
White blood-cells (x109/l) 11.3 
a,b,c 
(7.69 – 13.9) 
8.48 a,c 
(6.31 – 10.3) 
6.68 
(5.37 – 7.33) 
Neutrophils (x109/l) 8.34 
a,b,c 
(5.61 – 11.2) 
5.32 a,b,c 
(4.05 – 6.37) 
3.82 a 
(3.12 – 4.85) 
Lymphocytes (x109/l) 1.54 (1.24 – 2.24) 
1.79 
(1.25 – 2.51) 
1.93 
(1.54 – 2.23) 
Monocytes (x109/l) 0.60 
a,b,c 
(0.42 – 0.81) 
0.74 a,b,c 
(0.62 – 0.91) 
0.48 
(0.40 – 0.58) 
Inflammatory markers    
CRP (mg/dl) 0.69 
a 
(0.34 – 1.39) 
3.49 a,b,c 
(1.52 – 6.92) 
0.34 
(0.32 – 0.70) 
TNF- (pg/ml) 1.57 
a 
(0.57 – 2.47) 
1.57 
(0.75 – 2.24) 
2.10 
(1.06 – 3.15) 
sP-selectin (ng/ml) 83 (54 – 116) 
67 
(48 – 79) 
70 
(62 – 103) 
sICAM-1 (ng/ml) 248 (218 – 258) 
281 
(238 – 309) 
298 
(224 – 400) 
Data are expressed as median and quartiles (lower quartile-upper quartile). ** values below detection limit; 
a p<0.05 vs REF group; b p<0.05 vs CC group; c p<0.05 vs CAD group (for comparison see Table 5). 
Table 7. Biochemical characterization and inflammatory mediators in the AMI patients at the 
three time-points: hospital admission (Day 0), two (Day 2) and 40 days (Day 40) after 
percutaneous transluminal coronary angioplasty intervention. 
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obtained longitudinal models had into account these transformations (as can be observed in 
Figures 1 and 2). However, for results considerations purposes those transformations will 
not be further mentioned in the text.  
The association between white blood-cells, neutrophils, monocytes and lymphocytes and 
time were significant (p<0.05) (see Figure 1). 
Higher white blood-cell, neutrophil and monocyte counts were observed in the acute phase 
of AMI (Table 5). The high white blood-cell and neutrophil counts at admission significantly 
decrease in the following weeks (Figure 1A and 1B), reaching values similar to those 
observed in CAD patients and in control subjects (Tables 5 and 7).  
By the contrary, slightly low lymphocyte counts were observed in the acute phase of 
myocardial infarction, although that difference was not significant (Table 5). Those low 
levels were maintained after percutaneous transluminal coronary angioplasty (day 2) and 
increased with patient’s stabilization (Figure 1C and Table 7).  
Monocyte counts reach the highest value at day 2 (Figure 1D), decreasing in the following 
days (Day 40). At that time-point, the monocyte counts were similar to the counts verified in 
CAD, CC and REF groups (Tables 5 and 7).  
 
 
Fig. 1. Longitudinal variations of inflammatory cell counts, white blood-cell (WBC; A), 
neutrophils (B), lymphocytes (C) and monocytes (D) in AMI patients at hospital admission, 
two (Day 2) and 40 days (Day 40) after percutaneous transluminal coronary angioplasty 
intervention. * p<0.05 vs AMI patients at Day 0. 
The levels of sP-selectin in AMI patients were characterized by a decrease after PCTA 
followed by an increase to day 40 (Figure 2A). The association between sP-selectin and time 
was significant (p=0.003). Serum levels of this soluble adhesion molecule at inclusion were 
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remarkably elevated than 48 h later (p=0.001). After that abrupt decrease, sP-selectin levels 
seem to slightly increase, reverting to the levels observed at hospital admission.  
An increasing trend of sICAM-1 to day 40 was observed (Table 7) but the association of 
sICAM-1 with time was not significant (p=0.085; see Figure 2B).  
The levels of CRP were increased in AMI at admission (Table 5), and further increase at day 
2 reverting to significantly low levels after 40 days (p<0.05), as verified in Figure 2C. Those 
concentration levels were not significantly different from those verified in a normal non-
inflammatory situation – REF group (Tables 5 and 7). 
The serum levels of TNF- increased from day 0 to day 40 (Figure 2D). TNF- levels were 
remarkably elevated through time (p<0.001). TNF- concentrations were higher at day 2 
than at admission (day 0) and continue to increase until day 40 (p<0.001 relative to day 0). 
 
 
Fig. 2. Longitudinal variations of systemic concentrations of sP-selectin (A), sICAM-1 (B), 
CRP (C) and TNF- (D) in AMI patients at hospital admission, two (Day 2) and 40 days 
(Day 40) after percutaneous transluminal coronary angioplasty intervention. * p<0.05 vs AMI 
patients at Day 0. 
3.3.2 Medication influence 
To assess the influence of previous-event medication on inflammatory mediators, subjects 
that did not take medication before enrolment were compared to the remaining patients that 
had prescribed medication. Only sP-selectin and sICAM-1 concentrations were significantly 
affected by the previous-event drug intake (p=0.002 and p=0.014, respectively). Subjects 
without pre-event medication had higher levels of these molecules (94±32 ng/ml and 
280±96 ng/ml, respectively) than those with prescribed aspirin, ACE-inhibitors, -blockers 
or statins (61±22 ng/ml and 235±58 ng/ml, respectively). 
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remarkably elevated than 48 h later (p=0.001). After that abrupt decrease, sP-selectin levels 
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The serum levels of TNF- increased from day 0 to day 40 (Figure 2D). TNF- levels were 
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(Day 40) after percutaneous transluminal coronary angioplasty intervention. * p<0.05 vs AMI 
patients at Day 0. 
3.3.2 Medication influence 
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that did not take medication before enrolment were compared to the remaining patients that 
had prescribed medication. Only sP-selectin and sICAM-1 concentrations were significantly 
affected by the previous-event drug intake (p=0.002 and p=0.014, respectively). Subjects 
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or statins (61±22 ng/ml and 235±58 ng/ml, respectively). 
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To further evaluate the possible influence of drug therapy in serial changes of the 
inflammatory markers, the pre-event, in-hospital and follow-up medication data were 
categorized to type (antiplatelet inhibitors, ACE-inibitors, -blockers and statins) and added 
to the linear mixed effects models as co-variables. None of the drugs administered to the 
patients before or after admission significantly influenced the neutrophil and monocyte 
counts, and the CRP, TNF- or sICAM-1 concentrations (data not shown). However, the sP-
selectin variations over time were significantly influenced by pre-event ACE-inibitors 
(p<0.001) and -blockers (p=0.019) intake. Patients that received -blockers or ACE-inibitors 
showed minor serial changes and low levels of sP-selectin opposite to those that were not 
taking those drugs. The same trend was verified for the white blood-cell and lymphocytes 
counts longitudinal variations with the pre-event and -blockers (p=0.024 and p=0.25, 
respectively) intake. AMI patients that received -blockers showed minor serial changes and 
low levels of white blood-cell and lymphocytes counts compared to those that were not 
taking those drugs. 
3.4 Relationships between angiographic features and inflammatory mediators 
The existence of associations or variations between the levels of inflammatory mediators 
and the characterization of lesion morphology was also tested, including the number of 
diseased vessels (single versus multivessel disease), lesion length (small ≤15 mm versus 
large >15 mm lesions), TIMI risk score and the presence of calcium and thrombi.  
 
 
Fig. 3. Variations of white blood-cell (WBC) and neutrophil counts in the two classes of 
stenosis based on TIMI risk score (TIMI 3 and TIMI <3). * p<0.05 vs normal flux TIMI 3. 
The neutrophil counts were negatively correlated to the TIMI risk score classes (r=-0.503, 
p<0.001) and positively with the presence of thrombi in lesions (r=0.424, p<0.001). In fact, 
higher counts of neutrophils (and also white blood-cell) were observed in patients with 
impaired coronary flux (TIMI <3) than in patients with normal flux (Figure 3). The same 
tendency of increased levels was verified in patients with thrombi in lesions (Figure 4). 
The concentrations of sP-selectin were negatively correlated to the TIMI score (r=-0.554, 
p=0.041). No further correlations of inflammatory markers and angiographic features were 
observed, except for the AMI patients’ longitudinal variations. 
Considering the presence of calcium in lesions, the lymphocyte counts were lower in 
calcified lesions than in lesions without calcium (Figure 5). 
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Fig. 4. Variations of white blood-cell (WBC) and neutrophil counts in the presence or 
absence of thrombi in the lesions. * p<0.05 vs lesions without thrombi. 
 
 
Fig. 5. Variations of lymphocytes counts in the presence or absence of calcium in the lesions. 
* p<0.05 vs lesions without calcium. 
 
 
Fig. 6. Distribution of subjects with impaired flux (TIMI <3) through the white blood-cell 
(WBC) risk classes of cardiovascular events (low/high risk based on the cut-off level of 
>10.1x109/l). 
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Examining the longitudinal variations of inflammatory mediators and the angiographic 
features, no associations were verified for serial changes of white blood-cells, neutrophils, 
sP-selectin and sICAM-1 (p>0.05; data not shown). 
In what concerns the disease extension, the concentrations of CRP over time were positively 
correlated with multivessel disease (p=0.026). While, the monocyte counts and TNF- serial 
changes were correlated to the lesion length (p=0.043 and p=0.38, respectively).  
The risk classes of cardiovascular events based on white blood-cell and TNF- cut-off levels 
were also tested for possible associations to the lesion morphology data. 
No correlations were found to the CRP risk class with the lesion morphology data.  
By the contrary, the white blood-cell risk class was negatively correlated with the TIMI score 
classes (r=-0,439, p<0.001) and positively with the presence of thrombi in lesions (r=0.460, 
p<0.001). The distribution of patients within the TIMI score classes differs in the low versus 
high white blood-cell risk classes. As can be observed in Figure 6, among patients with 
impaired flux (TIMI <3), there were a higher number of patients with high WBC risk 
(>10.1x109/l) than patients with low WBC risk (p<0.001). The same tendency is verified for 
the presence of thrombi in lesions (p<0.001; see Figure 7).  
 
 
Fig. 7. Distribution of subjects with thrombi in lesions through the white blood-cell (WBC) 
risk classes of cardiovascular events (low/high risk based on the cut-off level of 
>10.1x109/l). 
Furthermore, among patients with calcified lesions there is also a higher frequency of 
patients with high TNF- risk (≥3.61 pg/ml) than patients with low TNF- risk (see Figure 
8), although the difference did not reach significance (p=0.08).  
 
 
Fig. 8. Distribution of subjects with thrombi in lesions through the TNF- risk classes of 
cardiovascular events (low/high risk based on the cut-off level of (≥3.61 pg/ml). 
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4. Discussion 
It is now widely recognized that inflammation plays a critical role in plaque destabilization 
and vulnerability and that is a key-event in coronary artery disease (Alam et al., 2004). In the 
last decades, important information about the pathophysiology and mechanism of coronary 
artery disease and acute myocardial infarction had been extensively studied (Davies, 2000; 
Frangogiannis et al., 2002; Libby, 2003; VanWijik et al., 2003; Alam et al., 2004; Fichtlscherer et 
al., 2004; Kumar et al., 2004; Wiviott et al., 2004; Jefferson et al., 2005; Armstrong et al., 2006a; 
Armstrong et al., 2006b; Libby, 2008; Skyschally et al., 2008). However, the understanding of 
the interactions between inflammatory markers and between the different cell types 
involved in those processes remains relatively unexplored, especially in human populations. 
Angiography is a first-line test for coronary artery disease, particularly for screening 
symptomatic patients. The evaluation of asymptomatic individuals relies on the 
identification of risk factors. However, neither the absence of stenosis provided by 
angiography assure the lack of future cardiac events, nor the cardiovascular events are 
readily explained by cardiovascular risk factors (Fisher et al., 2000; Kern, 2000; Hadamitzky 
et al., 2009; Marwan et al., 2009). Therefore, non-invasive estimation of coronary disease risk 
is important to screening both symptomatic and asymptomatic patients. Furthermore, the 
understanding of the cellular biology of the unstable plaque remains poorly known, and the 
crucial question is still the identification of the factor(s) that play a significant role in the 
plaque vulnerability. 
A multi-parameter approach was used in the present study, which allowed a better 
understanding of the complex relationships between the studied markers that meant to 
capture different stages of the inflammatory response involved in the different phases of 
coronary artery disease evolution and lesion progression.  
4.1 Inflammatory markers in CAD 
White blood-cell count, the most widely available and inexpensive measure of systemic 
inflammation has been associated with cardiovascular mortality both in primary and 
secondary prevention settings. In apparently healthy individuals, a high white blood-cell 
count has been associated with increased cardiovascular mortality and incidence of coronary 
artery disease, independently of traditional atherosclerotic risk factors (Ikonomidis et al., 2008). 
In acute myocardial infarction two different inflammatory processes can be considered: the 
coronary arterial inflammation that leads to the pathogenesis of acute myocardial infarction; 
and the myocardium inflammation after the acute phase that leads to ventricular remodeling 
and cardiac repair (Cheng et al., 2005). The immune cells can be related to both processes. 
The increase in total white blood-cells occurring in AMI patients is considered as an 
expression of acute-phase reaction (Dragu et al., 2008; Bodi et al., 2008), reflecting the 
infiltration of leukocytes into the necrotic tissue in response to ischemia and reperfusion. 
Neutrophils are the first leukocytes to be found in damaged myocardial area (Yu et al., 
2009). The prognostic role of leucocytes is supported by observations from thrombolysis 
trials that identified leukocyte count as a predictor of short- and long-term adverse clinical 
outcomes, whereas elevated neutrophil count is significantly associated with myocardial 
infarct extension and the early development of congestive heart failure  (Yu et al., 2009). 
Monocytes infiltrate the infarct zone where they appear to orchestrate the cardiac repair and 
remodeling process through a complex cascade involving cytokines and growth factors 
secretion (Dragu et al., 2008). Their number is reported (Bodi et al., 2008) to increase 2 to 3 
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Examining the longitudinal variations of inflammatory mediators and the angiographic 
features, no associations were verified for serial changes of white blood-cells, neutrophils, 
sP-selectin and sICAM-1 (p>0.05; data not shown). 
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Fig. 7. Distribution of subjects with thrombi in lesions through the white blood-cell (WBC) 
risk classes of cardiovascular events (low/high risk based on the cut-off level of 
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Furthermore, among patients with calcified lesions there is also a higher frequency of 
patients with high TNF- risk (≥3.61 pg/ml) than patients with low TNF- risk (see Figure 
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Fig. 8. Distribution of subjects with thrombi in lesions through the TNF- risk classes of 
cardiovascular events (low/high risk based on the cut-off level of (≥3.61 pg/ml). 
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4. Discussion 
It is now widely recognized that inflammation plays a critical role in plaque destabilization 
and vulnerability and that is a key-event in coronary artery disease (Alam et al., 2004). In the 
last decades, important information about the pathophysiology and mechanism of coronary 
artery disease and acute myocardial infarction had been extensively studied (Davies, 2000; 
Frangogiannis et al., 2002; Libby, 2003; VanWijik et al., 2003; Alam et al., 2004; Fichtlscherer et 
al., 2004; Kumar et al., 2004; Wiviott et al., 2004; Jefferson et al., 2005; Armstrong et al., 2006a; 
Armstrong et al., 2006b; Libby, 2008; Skyschally et al., 2008). However, the understanding of 
the interactions between inflammatory markers and between the different cell types 
involved in those processes remains relatively unexplored, especially in human populations. 
Angiography is a first-line test for coronary artery disease, particularly for screening 
symptomatic patients. The evaluation of asymptomatic individuals relies on the 
identification of risk factors. However, neither the absence of stenosis provided by 
angiography assure the lack of future cardiac events, nor the cardiovascular events are 
readily explained by cardiovascular risk factors (Fisher et al., 2000; Kern, 2000; Hadamitzky 
et al., 2009; Marwan et al., 2009). Therefore, non-invasive estimation of coronary disease risk 
is important to screening both symptomatic and asymptomatic patients. Furthermore, the 
understanding of the cellular biology of the unstable plaque remains poorly known, and the 
crucial question is still the identification of the factor(s) that play a significant role in the 
plaque vulnerability. 
A multi-parameter approach was used in the present study, which allowed a better 
understanding of the complex relationships between the studied markers that meant to 
capture different stages of the inflammatory response involved in the different phases of 
coronary artery disease evolution and lesion progression.  
4.1 Inflammatory markers in CAD 
White blood-cell count, the most widely available and inexpensive measure of systemic 
inflammation has been associated with cardiovascular mortality both in primary and 
secondary prevention settings. In apparently healthy individuals, a high white blood-cell 
count has been associated with increased cardiovascular mortality and incidence of coronary 
artery disease, independently of traditional atherosclerotic risk factors (Ikonomidis et al., 2008). 
In acute myocardial infarction two different inflammatory processes can be considered: the 
coronary arterial inflammation that leads to the pathogenesis of acute myocardial infarction; 
and the myocardium inflammation after the acute phase that leads to ventricular remodeling 
and cardiac repair (Cheng et al., 2005). The immune cells can be related to both processes. 
The increase in total white blood-cells occurring in AMI patients is considered as an 
expression of acute-phase reaction (Dragu et al., 2008; Bodi et al., 2008), reflecting the 
infiltration of leukocytes into the necrotic tissue in response to ischemia and reperfusion. 
Neutrophils are the first leukocytes to be found in damaged myocardial area (Yu et al., 
2009). The prognostic role of leucocytes is supported by observations from thrombolysis 
trials that identified leukocyte count as a predictor of short- and long-term adverse clinical 
outcomes, whereas elevated neutrophil count is significantly associated with myocardial 
infarct extension and the early development of congestive heart failure  (Yu et al., 2009). 
Monocytes infiltrate the infarct zone where they appear to orchestrate the cardiac repair and 
remodeling process through a complex cascade involving cytokines and growth factors 
secretion (Dragu et al., 2008). Their number is reported (Bodi et al., 2008) to increase 2 to 3 
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days after the acute episode. The elapsed time between neutrophils and monocytes 
responses was observed in the present study, as monocyte count peak was only reached at 
day 2 in AMI patients.  
No significant variations were observed in lymphocytes count in the four groups studied. 
However, in AMI patients the slight decrease in lymphocytes number at the onset of the 
acute event was emphasized in the longitudinal study where their number significantly 
increased to 40 days. Lymphopenia was previously described in the literature (Bodi et al., 
2008). The reason for the fall in T lymphocytes numbers and activity is not yet completely 
understood (Takeshita et al., 1997), but several authors proposed that could result from a 
self-protective response in face of an overshoot of pro-inflammatory cytokines and other 
products with tissue-damage potential (Steppich et al., 2007; Elenkov et al., 2005). A massive 
lymphocyte apoptosis is proposed as the underlying mechanism (Bodi et al., 2008). This 
theory gained more attention since hyper-inflammation was disregarded as the body 
primary response in acute stress situations, such as sepsis (Hotchkiss & Karl, 2003). Severe 
lymphopenia occurs in the initial stages of sepsis, but as the acute stress conditions evolves 
the lymphocyte counts return to normal levels (Bodi et al., 2008).  
During the acute event important feedback mechanism may be triggered to protect the 
organism from an “overshoot” of systemic pro-inflammatory cytokines and other products 
with tissue-damage potential by activated macrophages (Elenkov et al., 2005). As a 
consequence of those feedback mechanisms no systemic T lymphocytes activation would 
happen (Steppich et al., 2007), which could partially explain the low counts of lymphocytes 
verified at AMI onset. After acute myocardial infarction, myocardial necrosis releases or 
exposes normally sequestered antigenic constituents that may cause activation and 
proliferation of lymphocytes (Cheng et al., 2005), returning to the normal levels as verified in 
our study.  
After ischemia/reperfusion injury, leukocyte sequestration and the release of cytokines, 
such as TNF-α, may occur. Injured myocardium (Dawn et al., 2004), several extra-cardiac 
tissues and immune system activation (Chiu et al., 2005), proved contributing to circulating 
TNF- levels. Increasing levels of this pro-inflammatory cytokine after infarct, as measured 
in AMI patients, has been reported previously (Bauriedel et al., 2003; Barbaux et al., 2001; 
Blancke et al., 2005). This increasing suggests a continuous systemic inflammatory 
stimulation that can trigger and/or amplify local inflammatory responses related to 
ischemia/reperfusion injury (Barbaux et al., 2001). Though a cytoprotective role for TNF- 
has also been suggested (Blancke et al., 2005; Zirlik et al., 2007). The reported influence of 
TNF- in the upregulation of adhesion molecules is evidenced by its positive association 
with sICAM-1.  
No significant changes were verified in sICAM-1 levels in CAD and CC patients relative to 
healthy volunteers (REF group). Also, the levels of this adhesion molecule remained 
unchanged in AMI patients over 40 days after the acute event. Previous medication intake 
was found to exert no influence on sICAM-1 levels at admission. Also, in-hospital and 
follow-up medication had no influence on serial changes of this adhesion molecule. 
However, sICAM-1 levels were positively correlated with white blood-cell counts, 
suggesting ongoing inflammatory response in coronary artery disease patients that may 
favor the adhesion of inflammatory cells at injured site of lesions (Mulvihill et al., 2000; 
O’Malley et al., 2001). Some of the reported data demonstrated increases in circulating 
sICAM-1 for the first month after the acute event (O’Malley et al., 2001; Haim et al., 2002; 
Hartford et al., 2006), plausibly reflecting in specific conditions ICAM-1 expression at the 
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endothelial surface (Mulvihill et al., 2000). Although a stronger predictive information for 
sICAM-1 could not yet be found (Haim et al., 2002; Hartford et al., 2006). 
Similar values of sP-selectin between coronary artery disease patients and controls, as 
verified in the present study, had already been reported in literature (Barbaux et al., 2001; 
Blancke et al., 2005; Khare et al., 2005).  
In this study, a negative association between soluble P-selectin levels and age was observed, 
similar to that referred by Barbaux et al. (2001). Those authors called the attention for a 
complex relation between P-selectin and coronary artery disease dependent on age, which 
could be related to the different effects of P-selectin according to the stage of progression of 
atherosclerosis. The soluble form of P-selectin could bind to leukocytes via PSGL-1 without 
triggering their subsequent recruitment on the vascular surface, which limits the excessive 
activation and extravasation of leukocytes. Therefore, high levels of sP-selectin may be 
beneficial in some situations by protecting against inflammatory reactions (Barbaux et al., 
2001). This may explain the unexpectedly higher levels of sP-selectin found in REF group 
similar to the levels of AMI patients and higher than the levels observed in CAD patients. In 
fact, subjects from REF group were younger than those in AMI and CAD groups, 40% of 
which had more than 65 years old. Similar sP-selectin values between coronary artery 
disease patients and controls had already been described in literature (Barbaux et al., 2001; 
Khare et al., 2005). 
Furthermore, during the myocardial infarction, sP-selectin levels may be influenced by an 
intricate network of processes involving inflammatory stimulus of injured myocardium and 
vascular wall, and administrated medication. The serial changes of sP-selectin shortly after 
AMI clearly evidenced the fall of activated platelets in consequence of massive anti-platelet 
and anti-thrombotic therapeutic measures during intervention. The results of the changes of 
sP-selectin over time evidence a significant influence of medication. Shimomura et al. (1998) 
reported sP-selectin changes in AMI patients at admission and after reperfusion therapy 
similar to ours. Currently used therapies, such as ACE-inhibitors and β-blockers effectively 
counteract heightened platelet activation and aggregability (Bauriedel et al., 2003) resulting 
in decreased circulating levels of P-selectin (Cha et al., 2004; Xiao et al., 2004) as observed in 
this work. In fact, decreased sP-selectin levels were also found in CAD patients and CC 
subjects, which had a long-term therapy history. 
C-reactive protein (CRP) is considered by many authors as one of the most suitable 
candidates as nontradicional risk factors, since it meets most of the criteria to be a useful 
indicator in cardiovascular diseases (Calabrò et al., 2009). Elevated baseline concentrations of 
CRP are associated with the risk of atherosclerotic events in general populations and show a 
predictive value in terms of secondary prevention, both in patients with chronic stable 
angina and acute coronary syndromes (Calabrò et al., 2009). The prognostic significance of 
CRP has also been shown in apparently healthy adults without cardiovascular disease 
(Ridker et al., 2003; Dansesh et al., 2004; Ridker & Cook 2004). Our results are therefore 
consistent with previous variations of this acute-phase reactant described in literature (Fang 
et al., 2004; Li et al., 2005; Hartford et al., 2006).  
Leukocytes and released cytokines may contribute to ischemia/reperfusion injury by 
interacting with endothelial cells (Xu et al., 2006), linking the thrombotic and inflammatory 
responses (Libby & Simon, 2001). Thus, temporal and sequential association of events 
orchestrated by both inflammatory cells, e.g. white blood-cells, monocytes, neutrophils and 
lymphocytes, and inflammatory markers, such as TNF-, CRP, sICAM-1, and sP-selectin seem 
to be crucial in the initiation of inflammatory responses after ischemia/reperfusion injury. 
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sICAM-1 could not yet be found (Haim et al., 2002; Hartford et al., 2006). 
Similar values of sP-selectin between coronary artery disease patients and controls, as 
verified in the present study, had already been reported in literature (Barbaux et al., 2001; 
Blancke et al., 2005; Khare et al., 2005).  
In this study, a negative association between soluble P-selectin levels and age was observed, 
similar to that referred by Barbaux et al. (2001). Those authors called the attention for a 
complex relation between P-selectin and coronary artery disease dependent on age, which 
could be related to the different effects of P-selectin according to the stage of progression of 
atherosclerosis. The soluble form of P-selectin could bind to leukocytes via PSGL-1 without 
triggering their subsequent recruitment on the vascular surface, which limits the excessive 
activation and extravasation of leukocytes. Therefore, high levels of sP-selectin may be 
beneficial in some situations by protecting against inflammatory reactions (Barbaux et al., 
2001). This may explain the unexpectedly higher levels of sP-selectin found in REF group 
similar to the levels of AMI patients and higher than the levels observed in CAD patients. In 
fact, subjects from REF group were younger than those in AMI and CAD groups, 40% of 
which had more than 65 years old. Similar sP-selectin values between coronary artery 
disease patients and controls had already been described in literature (Barbaux et al., 2001; 
Khare et al., 2005). 
Furthermore, during the myocardial infarction, sP-selectin levels may be influenced by an 
intricate network of processes involving inflammatory stimulus of injured myocardium and 
vascular wall, and administrated medication. The serial changes of sP-selectin shortly after 
AMI clearly evidenced the fall of activated platelets in consequence of massive anti-platelet 
and anti-thrombotic therapeutic measures during intervention. The results of the changes of 
sP-selectin over time evidence a significant influence of medication. Shimomura et al. (1998) 
reported sP-selectin changes in AMI patients at admission and after reperfusion therapy 
similar to ours. Currently used therapies, such as ACE-inhibitors and β-blockers effectively 
counteract heightened platelet activation and aggregability (Bauriedel et al., 2003) resulting 
in decreased circulating levels of P-selectin (Cha et al., 2004; Xiao et al., 2004) as observed in 
this work. In fact, decreased sP-selectin levels were also found in CAD patients and CC 
subjects, which had a long-term therapy history. 
C-reactive protein (CRP) is considered by many authors as one of the most suitable 
candidates as nontradicional risk factors, since it meets most of the criteria to be a useful 
indicator in cardiovascular diseases (Calabrò et al., 2009). Elevated baseline concentrations of 
CRP are associated with the risk of atherosclerotic events in general populations and show a 
predictive value in terms of secondary prevention, both in patients with chronic stable 
angina and acute coronary syndromes (Calabrò et al., 2009). The prognostic significance of 
CRP has also been shown in apparently healthy adults without cardiovascular disease 
(Ridker et al., 2003; Dansesh et al., 2004; Ridker & Cook 2004). Our results are therefore 
consistent with previous variations of this acute-phase reactant described in literature (Fang 
et al., 2004; Li et al., 2005; Hartford et al., 2006).  
Leukocytes and released cytokines may contribute to ischemia/reperfusion injury by 
interacting with endothelial cells (Xu et al., 2006), linking the thrombotic and inflammatory 
responses (Libby & Simon, 2001). Thus, temporal and sequential association of events 
orchestrated by both inflammatory cells, e.g. white blood-cells, monocytes, neutrophils and 
lymphocytes, and inflammatory markers, such as TNF-, CRP, sICAM-1, and sP-selectin seem 
to be crucial in the initiation of inflammatory responses after ischemia/reperfusion injury. 
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4.2 Inflammatory markers and angiographic features 
There is a substantial interest in research and in clinical practice in the development and 
application of new biomarkers for risk stratification in patients with acute coronary 
syndromes. 
In particular, strategies combining multiple biomarkers that may reflect diverse 
pathophysiological contributors to the onset and complications of acute events are 
appealing as an approach to improve risk assessment and effective therapy. Numerous 
studies have demonstrated independent associations between levels of various 
inflammatory markers and the presence of angiographically documented coronary artery 
disease (Sabatine et al., 2002a). Evidences have been established for improved risk 
stratification using white blood-cells, B-type natriuretic peptide, high-sensitivity CRP, and 
troponin T, to mention a few, alone or in combination (Cavusoglu et al., 2006; Sanchis et al., 
2004; James et al., 2006). However, the relative importance of the various inflammatory 
markers with coronary disease is still scarce. Comparative evaluation of newer markers is 
necessary to assess these candidates for integration into present strategies concerning the 
evaluation of the strongest candidates in order to guide further development as well as 
potential clinical application. 
Acute phase proteins, adhesion molecules and cytokines have appeared among the potential 
candidate biomarkers of inflammation based upon prognostic performance in studies in 
patients with coronary artery disease (Armstrong et al., 2006a; Armstrong et al., 2006b; 
Armstrong et al., 2006c). 
In our study various clinical, biochemical and inflammatory markers were correlated with 
angiographic findings and risk scores.  White blood-cells, neutrophils, sP-selectin, sICAM-1, 
CRP and TNF-, were found to be associated either with risk scores for stenosis and TIMI or 
with the presence of calcium and thrombi in lesions. It was also found that high neutrophil 
and white blood-cell counts were correlated to high-grade stenosis and to the presence of 
thrombi. In addition, increased risk score based on white blood-cells counts was strongly 
correlated with high-risk TIMI score.  
White blood-cells counts have been associated with the lesion coverage and magnitude of 
coronary artery disease (Cavusoglu et al., 2006), lower TIMI flow and myocardial perfusion 
grades during coronary angiography (Sabatine et al., 2002a). Furthermore, white blood-cell 
count was strongly associated to multivessel coronary artery disease (Cavusoglu, et al. 2006). 
In unstable angina patients the baseline of white blood-cells count proved to be predictive of 
unfavorable clinical outcomes being highly significant for death within 30 days to six 
months (Sabatine et al., 2002a). In addition, establishing levels of white blood-cells counts, 
contributed to improved risk stratification. In patients with low white blood cell counts the 
predictive of mortality ranged from 1.5% (25th percentile) to 3.6% among patients with an 
intermediate white blood-cells count (25th to 75th percentiles), to 5.1% among patients with 
a high white blood-cell count (75th percentile). So far, no association between white blood 
cells count and new or recurrent myocardial infarction or rehospitalization for acute 
coronary syndromes could be established. 
High neutrophil counts were also associated to high cardiovascular risk (Horne et al., 2005). 
In the current study, the correlation of neutrophils with acute event manifestations, 
especially occlusive stenosis and the presence of thrombi in lesions, suggest their 
involvement in the coagulation management. Neutrophils are large cells that may 
accumulate in microvasculature after myocardial infarction. They can produce dramatic 
pathological anomalies as they adhere to capillary endothelium preventing reperfusion 
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(Bodi et al., 2008). Neutrophils that are recruited to the thrombosis region may be trapped in 
cloth releasing, during degranulation, myeloperoxidase. Myeloperoxidase is in fact an 
abundant leukocyte lysosomal enzyme. It was found to be elevated in culprit lesions that 
have fissured or ruptured in patients with sudden death from cardiac causes. Numerous 
lines of evidence suggest mechanistic links between myeloperoxidase and both 
inflammation and cardiovascular disease, therefore linking neutrophils to acute coronary 
syndromes and highlighting its potential and usefulness for risk stratification among 
patients with chest pain (Brennan et al., 2004). 
Our concurrent results also evidence the ability of white blood-cells and neutrophils as 
inflammatory entities to predict the presence of angiographic coronary disease and in 
particular the acute event. The negative correlation of sP-selectin with the class of TIMI 
(flow from 0 to 3) reinforced the value of combining multiple pathophysiological 
contributors in the evaluation of angiographic coronary disease. High values of s-Pselectin 
are linked to limitations in flow. The sP-selectin is an adhesion molecule involved in cell-
platelet aggregation and adhesion (Blann et al., 2003; Armstrong et al., 2006c). The verified 
synchronized rise of sP-selectin, white blood-cells and neutrophils count may be useful to 
further improve patients’ evaluation and prognosis.  
Also high CRP levels were associated to stenosis. Inflammation, atherosclerotic plaque 
rupture or myocardial necrosis, are mechanisms responsible for elevated CRP levels in the 
circulation. The potential use of CRP in patients’ diagnosis and in risk stratification of 
patients with coronary disease has been largely studied. Although the use of CRP as a 
prognostic marker still remains controversial (Packard & Libby, 2008). In fact, our results 
indicated an inverse association of CRP levels with stenosis what may suggest that CRP 
increases may be governed by other mechanisms. Results may also express the non-
relevance of CRP levels immediately after the acute event. Actually, the delay of 
approximately 48-h after the acute event for CRP increases is well documented in the 
literature (Fang et al., 2004; Hartford et al., 2006). Biomarkers studied in our work were 
measured at patient’s admission, what for myocardial infarction patients correspond to a 
maximum of 6-h after acute event. Our findings also pointed out for a positive correlation of 
high-risk CRP score with sICAM-1, suggesting that endothelial activation may influence 
CRP expression rather than coronary stenosis.  
On the other hand, the presence of calcium in the culprit lesion was associated to higher 
lymphocytes count, indicating that these cells may express the activity of the atherosclerotic 
plaque, as mineralized lesions usually indicate more stabilized plaques (Fischer et al., 2000). 
As referred previously the moderate and non-significant decrease of lymphocytes at the 
acute phase of myocardial infarction is expressed in the longitudinal study carried out in 
our work. Lymphocytes are long-lived cells that memorize specialized information about 
the antigen pool at the individual level (Bodi et al., 2008). Therefore, lymphocytes may keep 
information about the plaque composition and consequently be associated with the 
mechanisms of plaque formation during the life span of the individual. These findings are in 
line with current knowledge on coronary atherosclerotic plaque burden. Plaque burden, and 
not stenosis severity, was a more important marker of disease. Also, the prognosis of 
coronary artery disease is more closely related to atherosclerosis plaque stability than the 
extent of a particular stenosis. The lesion vulnerability is thought to be associated to the 
plaque composition (Fischer et al., 2000). Lesions contain a lipid core intertwined by fibrous 
tissue that contributes to the disarrangement of intimal structure. In addition to the presence 
of macrophages and smooth muscle cells, lymphocytes and monocytes have been identified 
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particular the acute event. The negative correlation of sP-selectin with the class of TIMI 
(flow from 0 to 3) reinforced the value of combining multiple pathophysiological 
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circulation. The potential use of CRP in patients’ diagnosis and in risk stratification of 
patients with coronary disease has been largely studied. Although the use of CRP as a 
prognostic marker still remains controversial (Packard & Libby, 2008). In fact, our results 
indicated an inverse association of CRP levels with stenosis what may suggest that CRP 
increases may be governed by other mechanisms. Results may also express the non-
relevance of CRP levels immediately after the acute event. Actually, the delay of 
approximately 48-h after the acute event for CRP increases is well documented in the 
literature (Fang et al., 2004; Hartford et al., 2006). Biomarkers studied in our work were 
measured at patient’s admission, what for myocardial infarction patients correspond to a 
maximum of 6-h after acute event. Our findings also pointed out for a positive correlation of 
high-risk CRP score with sICAM-1, suggesting that endothelial activation may influence 
CRP expression rather than coronary stenosis.  
On the other hand, the presence of calcium in the culprit lesion was associated to higher 
lymphocytes count, indicating that these cells may express the activity of the atherosclerotic 
plaque, as mineralized lesions usually indicate more stabilized plaques (Fischer et al., 2000). 
As referred previously the moderate and non-significant decrease of lymphocytes at the 
acute phase of myocardial infarction is expressed in the longitudinal study carried out in 
our work. Lymphocytes are long-lived cells that memorize specialized information about 
the antigen pool at the individual level (Bodi et al., 2008). Therefore, lymphocytes may keep 
information about the plaque composition and consequently be associated with the 
mechanisms of plaque formation during the life span of the individual. These findings are in 
line with current knowledge on coronary atherosclerotic plaque burden. Plaque burden, and 
not stenosis severity, was a more important marker of disease. Also, the prognosis of 
coronary artery disease is more closely related to atherosclerosis plaque stability than the 
extent of a particular stenosis. The lesion vulnerability is thought to be associated to the 
plaque composition (Fischer et al., 2000). Lesions contain a lipid core intertwined by fibrous 
tissue that contributes to the disarrangement of intimal structure. In addition to the presence 
of macrophages and smooth muscle cells, lymphocytes and monocytes have been identified 
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in the sub-endothelial region close to the lipid core. The continuous accumulation of 
extracellular lipids and cell debris promote the atheroma growth with prominent fibrous 
connective tissue and intimal thickening. Eventually the lipid core or other areas of the 
arterial wall may calcify and the lesions may present fissures, hematomas and thrombi. 
Lesions with high fibrotic content are usually more occlusive and ultimately may progress 
to complete occlusion without participation of acute plaque rupture. Therefore, the 
susceptibility to rupture is not strictly linked to significant stenosis. Also, the acute coronary 
syndromes are associated with plaque disruption and associated flow-limiting thrombus 
that may not be caused by of a non-obstructive plaque.  
The extent of coronary atherosclerosis, rather than the severity of stenosis, may be the most 
important predictor of death due to acute myocardial infarction or sudden cardiac death 
(Schmermund et al., 1997). The quantification of atherosclerotic burden has become vital to 
proper risk stratification, especially in the intermediate risk population (Mieres et al., 2005). 
Established noninvasive methods of evaluating CAD, such as stress testing, generally 
identify only patients with advanced atherosclerotic disease leading to a flow-limiting 
coronary stenosis and myocardial ischemia (Greenland & Gaziano 2003; Rumberger et al., 
2005). More recently published studies demonstrate a high sensitivity of coronary artery 
calcium for the presence of coronary artery disease but a lower specificity for obstructive 
coronary artery calcium depending on the magnitude of the coronary artery calcium (Budoff 
& Gul, 2008). Coronary calcification is a marker of atherosclerosis that can be quantified 
with the use of cardiac coronary tomography and it is proportional to the extent and 
severity of atherosclerotic disease. Coronary artery calcium was found to be a stronger 
independent predictor of future events than a sum of all of the conventional risk factors 
combined (Kennedy et al., 1998). Based on multiple observational studies, patients with 
increased plaque burdens (increased coronary artery calcium) are approximately ten times 
more likely to suffer a cardiac event over the next 3–5 years (Budoff & Gul, 2008). Opposite, 
Bauer and coworkers (Bauer et al., 2009) combining angiographic findings of calcified and 
non-calcified plaque burden and stenosis severity and the myocardial perfusion imaging 
finding of ischemia proposed that non-calcified plaque burden is a better predictor of the 
finding of myocardial ischemia at stress myocardial perfusion imaging than are calcium 
score and degree of stenosis. 
A variety of inflammatory factors including the actions of inflammatory cells are thought to 
play an important role in plaque stability and calcification (Morrow et al., 2008). Vascular 
calcification is a prominent feature of atherosclerosis but the mechanisms underlying 
calcification are still unclear. Vascular smooth muscle cells are currently considered to be 
responsible for the formation of vascular calcifications. Cytokines play an important role in 
regulation of vascular smooth muscle cells growth and differentiation.  
In fact, in our work a strong positive association of TNF- with lesion length was found. In 
addition high TNF- levels (≥3.16 pg/ml) were associated with high calcium percentage in 
plaques. TNF- was also found to be augmented at patients’ admission (coronary artery 
disease and myocardial infarction) and progressively increase to 40 days in the infarction 
evolution. These findings suggest a dual role of TNF- in coronary artery disease. On one 
hand TNF- was associated with vascular calcification, possibly expressing a role in the 
stabilization of the plaque, and on the other hand TNF- was related to the inflammatory 
process after myocardial infarction.   
This pleiotropic nature of TNF- is documented in literature (Trion & Laarse, 2004; Lencel et 
al., 2010). TNF- influences many aspects of atherosclerosis by increasing the permeability 
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of endothelial cells, promoting monocyte adhesion, inducing macrophage differentiation, 
and promoting foam cell formation. TNF- is also a regulator of bone formation. In both 
intima and media, calcification resembles bone formation. This cytokine has indeed been 
shown to stimulate in vitro the expression by vascular smooth muscle cells key enzymes of 
the mineralization process inducing the calcification of collagen fibrils. TNF- can also 
trigger the differentiation of vascular smooth muscle cells and/or mesenchymal stem cells 
into osteoblast-like cells, by expressing specific transcription factors, eventually leading to 
formation of a bone-like tissue (Lencel et al., 2010). 
5. Conclusion 
Reported results support the concept of a differential response of inflammatory markers in 
coronary artery disease. In acute events the inflammatory response and the interactions 
between the inflammatory markers observed influenced both the clinical outcome and the 
vascular remodeling that persist after clinical stabilization as given by the interplay of the 
studied inflammatory mediators.  
The inflammatory multimarker approach used and the differential response observed can 
contribute to a better assessment of the disease evolution and therapeutic plans. 
Only the simultaneous assessment of several markers, as innovatively done in the present 
study, can give a valuable contribution to the understanding of their importance in coronary 
artery disease and in the evolution of acute myocardial infarction.  
This study was useful both in research and clinical practice approaches. Combining 
inflammation assessment together with angiographic findings helped unravelling non-
invasive markers for the disease. 
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important predictor of death due to acute myocardial infarction or sudden cardiac death 
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Established noninvasive methods of evaluating CAD, such as stress testing, generally 
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disease and myocardial infarction) and progressively increase to 40 days in the infarction 
evolution. These findings suggest a dual role of TNF- in coronary artery disease. On one 
hand TNF- was associated with vascular calcification, possibly expressing a role in the 
stabilization of the plaque, and on the other hand TNF- was related to the inflammatory 
process after myocardial infarction.   
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intima and media, calcification resembles bone formation. This cytokine has indeed been 
shown to stimulate in vitro the expression by vascular smooth muscle cells key enzymes of 
the mineralization process inducing the calcification of collagen fibrils. TNF- can also 
trigger the differentiation of vascular smooth muscle cells and/or mesenchymal stem cells 
into osteoblast-like cells, by expressing specific transcription factors, eventually leading to 
formation of a bone-like tissue (Lencel et al., 2010). 
5. Conclusion 
Reported results support the concept of a differential response of inflammatory markers in 
coronary artery disease. In acute events the inflammatory response and the interactions 
between the inflammatory markers observed influenced both the clinical outcome and the 
vascular remodeling that persist after clinical stabilization as given by the interplay of the 
studied inflammatory mediators.  
The inflammatory multimarker approach used and the differential response observed can 
contribute to a better assessment of the disease evolution and therapeutic plans. 
Only the simultaneous assessment of several markers, as innovatively done in the present 
study, can give a valuable contribution to the understanding of their importance in coronary 
artery disease and in the evolution of acute myocardial infarction.  
This study was useful both in research and clinical practice approaches. Combining 
inflammation assessment together with angiographic findings helped unravelling non-
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1. Introduction 
This work was born from the need to verify an intuition: could platelets’ fatty acids, rather 
than the fatty acids of other cellular elements, in some way, be potential markers of Ischemic 
Cardiovascular Disease and Major Depression? For this reason a research work has been set 
up that, besides the aid of the most advanced statistical methods, has also made use of the 
Artificial Neural Networks (ANN), in the shape and form of a Self-Organizing Map (SOM). 
The aim was to compare a group of apparently healthy subjects with two groups of subjects 
with different clinical diagnoses, one of depression and the other of ischemic heart disease. 
From the statistical evidence of the numerous parameters affected, we thought it would be 
appropriate to develop the SOM. The field of investigation has been narrowed down by 
reducing it to three of the fatty acids characterizing the two diseases and the pathological 
subjects (depressed and ischemic) and the normal ones have been placed onto the map 
obtained by the SOM, clearly distinguishing one from the other. 
Naturally conjectures, hypotheses and convictions accrued from long examinations and 
discussions of the data.  
Having at our disposal two neural networks that had proven to be effective in classifying 
the two pathologies, we were naturally curious to see how the two groups would behave at 
the moment when their data were fed into the networks, but crossing them (the ones of the 
ischemic patients in the depression network and those of the depressive patients in the 
ischemic network).   
The result was found to more or less uniformly corroborate the literature data, even if, of 
course, we are aware of the fact that it will be crucial to recruit from the field significant 
samples of patients affected by both clinically verified ischemia and depression. Also, we 
must not forget that in order to get an optimum recruitment, significant samples of normal 
subjects will also have to be selected, non-cardiopathic depressives and non-depressive 
heart disease patients. The four groups will obviously have to be balanced for age and sex.  
Caution, therefore, but accompanied by the evidence, by the concordances that are 
constantly observed in the SOM and that will have to be repeatedly examined in the light of 
new and increasingly more consistent testing, that, even seems to justify the interpretative 
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samples of patients affected by both clinically verified ischemia and depression. Also, we 
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possibilities of the connections between depressive illness and ischemic cardiovascular 
disease.  
The fact remains that the markers identified are the expression of the pathology of reference 
and that anyone who finds himself in the position of the network corresponding to the 
disease can be recognized to be at high risk. This could be stated much sooner than the 
moment when the clinical evidence becomes available.  
We have been comforted in this evaluation by what has been shown by some patients added 
to the test for their correspondence between clinical evidence and placing of input vectors of 
the patients’ data in the network.  
The investigations performed on other subjects, for example, children, young sportspeople, 
subjects with morphea, scleroderma etc., have shown unthinkable matches with the 
literature data relating to the risk of the diseases investigated.  
For children, in particular, an absolutely original result has been found. In other words, the 
fact that the platelet stearic acid is practically double if compared with that of all the other 
subjects, and this point, takes on great importance, precisely in the safeguarding of the child 
in respect to ischemic cardiopathy and, probably, other possible pathological phenomena. 
The child loses this condition when he or she becomes a young adult.  
To conclude, we can say that Major Depression and Cardiovascular Ischemic Disease benefit 
from an unequivocal biochemical typification that can be recognised through the 
identification of fatty acids markers of the platelets and by measuring its concentration. The 
platelets bring with them all those elements that mime the neuron and that can alternate the 
physiological hemocoagulative response, thereby actually becoming the great mediators 
between the brain and the heart.  
Before the new results, it becomes almost maniacal to search for bibliographical references 
that, for better or for worse, are (but may also not be) comforting for the statements and/or 
concepts expressed by the researcher.  
This is because novelties are always the subject of diffidence. 
Before going to press, we have detected, following a very difficult search, some working 
hypotheses in some way capable of conceptually motivating all of the work performed, 
which we report hereunder:  
- L. S. Schneider, Principles and Practice of Geriatric Psychiatry (Second Edition), 2002: 
It is important to consider that major depression is characterized and defined by descriptive - not 
biological - criteria, making it unlikely that a neurochemical finding could adequately 
characterize the disorder. Major depression is heterogeneous in its expression, possessing various 
phenomenology, family history, and course. In the elderly, a neurochemical characteristic of 
depression would have to be specific enough to distinguish from dementia, or from secondary 
depression. In addition, neurochemical differences would be expected between late-onset and 
early-onset depression, or delusional and non-delusional depression, thus helping to validate 
these putative subtypes. 
- Steven J. Garlow, M.D., Ph.D., Charles B. Nemeroff, M.D., PhD., Emory University, 
General Clinical Research Center, Period: 10/30/74 - 11/01/02, NIH:  
Platelets from depressed patients are produced in a "unregulated" state, with increased amounts 
of a number of transcripts that encode platelet specific, the result being the platelets are more 
reactive and prone to thrombus formation, 2) the platelet serotonergic system, in particular the 
5-HT2A receptor, is altered in depression which in turn contributes to the increased platelet 
reactivity observed in depression, and the relevant alteration may occur in the megakaryocytes 
and 3) alterations in the concentration of one or more humoral factors (interleukins, cytokines, 
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stress hormones) orchestrate the alterations in platelet reactivity and serotonergic functioning 
observed in depression.  
- Steven J. Garlow, M.D., Ph.D., Emory University, General Clinical Research Center, 
Period: 10/30/74 - 11/01/02, NIH:  
We hypothesize that platelet function is altered in depression resulting in platelets that are 
excessively prone to enter the clotting cascade and hence increase risk of heart disease. We have 
identified a series of megakaryocytic cell lines that express a number of platelet markers and the 
5-HT2A receptor and SERT. We have demonstrated a direct regulatory interaction between the 
5-HT2A receptor and the expression of a number of important platelet genes. Gene expression in 
megakaryocytes is regulated by a series of cytokines and growth factors including IL-3, IL-6, IL-
11, TPO, and SCF. These factors are being tested for their ability to regulate the transcription of 
the 5-HT2A and SERT genes in megakaryocytes. 
We think that we have identified, to a reasonable degree of certainty, the biochemical rules 
that govern the platelets in the diagnostic determination of Major Depression and Ischemic 
Cardiovascular Disease. Obviously, we are convinced that the disease, in this specific case 
Major Depression and Ischemic Cardiovascular Disease, is never linked just to biological 
factors but it  is always the synthesis of biology and culture, as every medical anthropology 
teaches.  
2. Medical-anthropology remarks 
“Another, not less important, goal could be that of easing the pain in mental disorders. Outside the 
medical field, the problem of the suffering due to personal and social conflicts seems to find no 
solutions. Today we tend to make no distinction and to adopt the medical modus operandi to eliminate 
every kind of inconvenience. The supporters of this trend can make use of the following fascinating 
observation: if a rise in the levels of serotonin can, for example, not only treat depression but also 
reduce aggressiveness, making the subject less shy and more confident, why don’t we try to make the 
most out of it? One could say that only a self-righteous spoilsport could deny another fellow human 
being the benefits of these miraculous medicines… 
But obviously the problem is that the choice is not clear for many different reasons. Firstly, we don’t 
know the deeper biological effects of the drugs. Secondly, the possible consequences of a drug large-
scale use are still unknown. As a third and perhaps most important point it could be argued that the 
suggested solution for the problem of personal and social suffering must tackle the causes, the origin, 
of personal and social conflicts if it is to work effectively in the long-run. Otherwise this solution will 
work for symptoms but it won’t get to the roots of the malaise.” (1)  (This passage has been 
independently translated into English from the Italian Edition: A. Damasio, L’errore di Cartesio. 
Emozioni, ragione e cervello umano, Adelphi, Milano 1995. For the official English version, see the 
English edition in the bibliography: 1).  
This dense passage by Damasio leads to two final reflections:  
- the roots of the malaise should never be considered either merely biological or merely 
psychological, but rather human, deeply human. If you approach the human pain with 
an auto-referential knowledge or with knowledge displayed as pure, it becomes 
impossible, ab origine, to understand it (in this sense, the pure biomedicine is due to 
fail);  
- the understanding of each and every human experience, especially painful experiences 
in all their polychrome, iridescent images, means understanding the meaning, that is to 
say understanding those biological, existential, ethical, cultural, spiritual dynamics 
embodied in every single way we live our lives. And yet, the assumption that it is 
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possibilities of the connections between depressive illness and ischemic cardiovascular 
disease.  
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to the test for their correspondence between clinical evidence and placing of input vectors of 
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The investigations performed on other subjects, for example, children, young sportspeople, 
subjects with morphea, scleroderma etc., have shown unthinkable matches with the 
literature data relating to the risk of the diseases investigated.  
For children, in particular, an absolutely original result has been found. In other words, the 
fact that the platelet stearic acid is practically double if compared with that of all the other 
subjects, and this point, takes on great importance, precisely in the safeguarding of the child 
in respect to ischemic cardiopathy and, probably, other possible pathological phenomena. 
The child loses this condition when he or she becomes a young adult.  
To conclude, we can say that Major Depression and Cardiovascular Ischemic Disease benefit 
from an unequivocal biochemical typification that can be recognised through the 
identification of fatty acids markers of the platelets and by measuring its concentration. The 
platelets bring with them all those elements that mime the neuron and that can alternate the 
physiological hemocoagulative response, thereby actually becoming the great mediators 
between the brain and the heart.  
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that, for better or for worse, are (but may also not be) comforting for the statements and/or 
concepts expressed by the researcher.  
This is because novelties are always the subject of diffidence. 
Before going to press, we have detected, following a very difficult search, some working 
hypotheses in some way capable of conceptually motivating all of the work performed, 
which we report hereunder:  
- L. S. Schneider, Principles and Practice of Geriatric Psychiatry (Second Edition), 2002: 
It is important to consider that major depression is characterized and defined by descriptive - not 
biological - criteria, making it unlikely that a neurochemical finding could adequately 
characterize the disorder. Major depression is heterogeneous in its expression, possessing various 
phenomenology, family history, and course. In the elderly, a neurochemical characteristic of 
depression would have to be specific enough to distinguish from dementia, or from secondary 
depression. In addition, neurochemical differences would be expected between late-onset and 
early-onset depression, or delusional and non-delusional depression, thus helping to validate 
these putative subtypes. 
- Steven J. Garlow, M.D., Ph.D., Charles B. Nemeroff, M.D., PhD., Emory University, 
General Clinical Research Center, Period: 10/30/74 - 11/01/02, NIH:  
Platelets from depressed patients are produced in a "unregulated" state, with increased amounts 
of a number of transcripts that encode platelet specific, the result being the platelets are more 
reactive and prone to thrombus formation, 2) the platelet serotonergic system, in particular the 
5-HT2A receptor, is altered in depression which in turn contributes to the increased platelet 
reactivity observed in depression, and the relevant alteration may occur in the megakaryocytes 
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stress hormones) orchestrate the alterations in platelet reactivity and serotonergic functioning 
observed in depression.  
- Steven J. Garlow, M.D., Ph.D., Emory University, General Clinical Research Center, 
Period: 10/30/74 - 11/01/02, NIH:  
We hypothesize that platelet function is altered in depression resulting in platelets that are 
excessively prone to enter the clotting cascade and hence increase risk of heart disease. We have 
identified a series of megakaryocytic cell lines that express a number of platelet markers and the 
5-HT2A receptor and SERT. We have demonstrated a direct regulatory interaction between the 
5-HT2A receptor and the expression of a number of important platelet genes. Gene expression in 
megakaryocytes is regulated by a series of cytokines and growth factors including IL-3, IL-6, IL-
11, TPO, and SCF. These factors are being tested for their ability to regulate the transcription of 
the 5-HT2A and SERT genes in megakaryocytes. 
We think that we have identified, to a reasonable degree of certainty, the biochemical rules 
that govern the platelets in the diagnostic determination of Major Depression and Ischemic 
Cardiovascular Disease. Obviously, we are convinced that the disease, in this specific case 
Major Depression and Ischemic Cardiovascular Disease, is never linked just to biological 
factors but it  is always the synthesis of biology and culture, as every medical anthropology 
teaches.  
2. Medical-anthropology remarks 
“Another, not less important, goal could be that of easing the pain in mental disorders. Outside the 
medical field, the problem of the suffering due to personal and social conflicts seems to find no 
solutions. Today we tend to make no distinction and to adopt the medical modus operandi to eliminate 
every kind of inconvenience. The supporters of this trend can make use of the following fascinating 
observation: if a rise in the levels of serotonin can, for example, not only treat depression but also 
reduce aggressiveness, making the subject less shy and more confident, why don’t we try to make the 
most out of it? One could say that only a self-righteous spoilsport could deny another fellow human 
being the benefits of these miraculous medicines… 
But obviously the problem is that the choice is not clear for many different reasons. Firstly, we don’t 
know the deeper biological effects of the drugs. Secondly, the possible consequences of a drug large-
scale use are still unknown. As a third and perhaps most important point it could be argued that the 
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Emozioni, ragione e cervello umano, Adelphi, Milano 1995. For the official English version, see the 
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This dense passage by Damasio leads to two final reflections:  
- the roots of the malaise should never be considered either merely biological or merely 
psychological, but rather human, deeply human. If you approach the human pain with 
an auto-referential knowledge or with knowledge displayed as pure, it becomes 
impossible, ab origine, to understand it (in this sense, the pure biomedicine is due to 
fail);  
- the understanding of each and every human experience, especially painful experiences 
in all their polychrome, iridescent images, means understanding the meaning, that is to 
say understanding those biological, existential, ethical, cultural, spiritual dynamics 
embodied in every single way we live our lives. And yet, the assumption that it is 
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mainly up to philosophy (because of its very nature), to the arts in all their declensions, 
to theology and to religion to understand the meaning, doesn’t preclude the possibility 
of science having a say in the matter. Indeed, as the man is one, the science is one, too, 
and we are talking about human science, with its wide range of meanings: from a 
biological and chemical meaning to a spiritual one, following epistemological paths that 
cross and enrich each other, just because the man is biology and soulology, 
neurophysiology and  psychology, flesh and soul, blood and essence. So, philosophical, 
ethical or theological meanings do exist, just in the same way as biological, chemical or 
biochemical meanings exist. The biologist or the chemist who’s running tests on, for 
example, the platelet membrane fatty acids is perfectly aware, or should be aware, that 
all his work can’t be separated from the man considered as a bundle of meanings, and 
that in lab he can grasp, of all these meanings, only the biological one. The same goes 
for the philosopher or the theologian who is perfectly aware, or should be aware, that 
the theoretical, the existential or the spiritual analysis takes shape in the biological 
dimension, whose progressive cognitive exploration, in turn, enriches the spiritual 
research. But now, after this important remark, let’s come back to the biochemical 
discours. 
Platelets, Fatty Acids, Major Depression, Ischemic Cardiovascular Disease 
Numerous epidemiological and clinical data suggest that variations in the fatty acid 
composition of erythrocyte cellular membranes can be correlated with major depression. In 
particular, an alteration in the Arachidonic Acid (AA)/ Eicosapentaenoic Acid (EPA) ratio 
has been reported. The fatty acid composition of the cellular membranes determines its 
fluidity. The physical properties of the receptors and the enzymes, such as adenylate 
cyclases and the phospholipases, are influenced by the fluidity of the cellular membranes 
and these effects have a certain relevance in depression, in that the final responses to the 
neurotransmittor stimulation depends on the membrane’s equilibrium. In fact, by virtue of 
the presence of double bonds in their molecule, omega-3 fatty acids have a folded over 
structure, they occupy a higher volume and they make the membranes, apparently more 
fluid (in fact, omega 3 fatty acids are less fluidizing of omega 6 by the saturated chain length 
from the first double bond). That aspect explains, in literature, why these compounds are 
thought to be effective as anti-depressives and mood stabilizers (2, 3, 4, 5, 6). The debate is 
still open and probably the antidepressant function of omega 3 fatty acids may be attributed 
to other reasons. 
This fact is also connected to the neurochemical theories of depressive disease that see the 
involvement of various neurotransmittor systems; the new research could highlight the fact 
that the imbalance involves the receptor functions and some secondary intracellular 
messengers (7). Other authors (8) have found negative correlations between the erythrocyte 
level of EPA, positive correlations between the AA/EPA ratio in the membranes and the 
score of the Hamilton Rating Scale, which measures the severity of the depressive 
symptoms. A high proportion of AA and a low one of EPA in the erythrocyte cellular 
membranes can bring about a hyperproduction of eicosanoids that derive from the PUFA 
n6, such as the prostacyclines, leukotrienes and the inflammation mediators with an 
increase in the oxidative stress (9). 
Some further food for thought is the problem of the depression at the outset in advanced 
age. Depression has a lifetime prevalence of about 15% and most of all it affects the age-
range between 18 and 29 years. Henderson et al. (10), using the ICD10 criteria, found a 3.3% 
prevalence in the population aged over 70 years. Depression is ten times more frequent in 
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the elderly bearers of organic diseases than in the healthy ones, although specific biological 
bonds were not evidenced between the diseases. The internal diseases that are most 
frequently complicated with the outset of depressive symptoms are hypo- and 
hyperthyroidism, Cushing’s syndrome, viral infections, lymphomas, carcinomas of the 
pancreas. Even some drugs can trigger a depressive episode (reserpine, alpha-methyl-dopa, 
clonidine, propanolol, digitalis, steroids, levo-dopa, and some anti-tumor drugs). The high 
prevalence of depression during other neurological diseases such as Alzheimer’s also stands 
out (between 15% and 20% of the patients with AD diagnosis present a major depressive 
picture, up to 50% present less serious depressive symptoms), and vascular dementia, 
Parkinson’s (40%-50% of patients affected by PD present an accompanying depression that 
is not in relation to the seriousness of the motor impairment). From a symptomatological 
standpoint, the depression that occurs in advanced age is prevalently characterized by 
somatic or anxiety symptoms, rather than by a marked drop in the humoral moral tone, by a 
marked apathy, obsessive ruminations, sleep disorders. Often the symptoms of a depression 
at the outset in advanced age mimic the cognitive deterioration typical of dementia (to the 
extent that we speak of pseudo-depressive dementia), posing large problems of differential 
diagnosis (11). Although the biological bases of depression in the elderly person are not yet 
known, it is possible to hypothesize, given the symptomatic confusion with the dementia 
picture and the high incidence of major depression in the   neuro-degenerative diseases, that 
it is a question of a particular nosographic entity in relation to depression in adult age and 
that cerebral aging constitutes a factor of vulnerability (if not indeed an etiological factor). 
The new frontiers of research take into consideration the addition of omega-3 and other anti-
oxidant substances in the diet for the treatment of depression. It has been hypothesized that 
the omega 3 fatty acids have mood stabilizing properties with a mechanism akin to that of 
lithium and valproic acid, reducing the turnover of the arachidonic acid and modifying the 
transduction pathways of the neuronal signal. In their action on bipolar disorders, the 
omega-3 fatty acids largely resemble lamotrigin, that is, they seem to have stabilizing and 
anti-depressant properties (12). Biochemical studies have shown that a high-dose oral 
administration of omega-3 leads to their membrane incorporation. The increase in the  
concentration of omega-3 in the membranes seems to suppress the transduction pathways of 
the signal associated to the production of inoxitol-3-phosphate, which is the second 
messenger associated to numerous neurotransmittor systems, such as the serotoninergic one 
(rec, 5HT2). Another mechanism proposed is that of the calcium-antagonist, by means of the 
calcium channel block. Studies on this effect derive from the cardiological literature.  
Extrapolating the data on the cardiac mechanism to the SNC, an increased activity of the 
brain phospholipases can be supposed during the maniacal phases, with an increased 
release of fatty acids as second messengers, which triggers a cascade of events culminating 
in the release of calcium from the cell deposits (and the consequent activation of protein 
kinase, which in turn activate various enzymes, amongst which those dedicated to the gene 
transcription). The blocking of the calcium channels by the omega-3 could reduce a process 
of hyper-activated signal transduction (anti-kindling?). The omega-3 fatty acids also produce 
a direct inhibition of the protein kinase C (PKC), with an action akin to that of the valproate. 
Lastly, the omega-3 fatty acids inhibit the production of pro-inflammatory cytokines. The 
concomitant intake of antioxidant vitamins (Vitamins C and E) would optimize the effect of 
the omega-3, preventing their oxidation (13). Vitamin E has been used at high 
pharmacological doses in the treatment of disorders such as Parkinson’s, Alzheimer’s and 
retarded dyscinesia. Clinical studies have shown that the use of vitamin E brings benefits in 
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the theoretical, the existential or the spiritual analysis takes shape in the biological 
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picture and the high incidence of major depression in the   neuro-degenerative diseases, that 
it is a question of a particular nosographic entity in relation to depression in adult age and 
that cerebral aging constitutes a factor of vulnerability (if not indeed an etiological factor). 
The new frontiers of research take into consideration the addition of omega-3 and other anti-
oxidant substances in the diet for the treatment of depression. It has been hypothesized that 
the omega 3 fatty acids have mood stabilizing properties with a mechanism akin to that of 
lithium and valproic acid, reducing the turnover of the arachidonic acid and modifying the 
transduction pathways of the neuronal signal. In their action on bipolar disorders, the 
omega-3 fatty acids largely resemble lamotrigin, that is, they seem to have stabilizing and 
anti-depressant properties (12). Biochemical studies have shown that a high-dose oral 
administration of omega-3 leads to their membrane incorporation. The increase in the  
concentration of omega-3 in the membranes seems to suppress the transduction pathways of 
the signal associated to the production of inoxitol-3-phosphate, which is the second 
messenger associated to numerous neurotransmittor systems, such as the serotoninergic one 
(rec, 5HT2). Another mechanism proposed is that of the calcium-antagonist, by means of the 
calcium channel block. Studies on this effect derive from the cardiological literature.  
Extrapolating the data on the cardiac mechanism to the SNC, an increased activity of the 
brain phospholipases can be supposed during the maniacal phases, with an increased 
release of fatty acids as second messengers, which triggers a cascade of events culminating 
in the release of calcium from the cell deposits (and the consequent activation of protein 
kinase, which in turn activate various enzymes, amongst which those dedicated to the gene 
transcription). The blocking of the calcium channels by the omega-3 could reduce a process 
of hyper-activated signal transduction (anti-kindling?). The omega-3 fatty acids also produce 
a direct inhibition of the protein kinase C (PKC), with an action akin to that of the valproate. 
Lastly, the omega-3 fatty acids inhibit the production of pro-inflammatory cytokines. The 
concomitant intake of antioxidant vitamins (Vitamins C and E) would optimize the effect of 
the omega-3, preventing their oxidation (13). Vitamin E has been used at high 
pharmacological doses in the treatment of disorders such as Parkinson’s, Alzheimer’s and 
retarded dyscinesia. Clinical studies have shown that the use of vitamin E brings benefits in 
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the treatment of AD, but that it does not have effects in retarding the progression of 
Parkinson’s and retarded dyscinesia (14). 
Melatonin also seems to have a ‘scavenger’ activity vis-à-vis the hydroxylic radicals besides 
its known properties of gonad function and biological rhythm regulation. This fact suggests 
that the melatonin could interfere with the neurodegenerative processes that affect the 
formation of free radicals and the release of amino-acid exciters (15). 
Depression and the cardiac arrhythmias are linked to the autonomous nervous system as 
has been seen in the measurement of heart beat variability.  
The transport protein of serotonin and the areas promoting the transport of serotonin 
ligands are shared by the platelets and the cerebral neurons so that central as well as 
peripheral effects may be expected.  
Platelet activation is significantly higher among the depressed patients both in the presence 
and the absence of heart disease.  
All of this shows the existence of a common path to the ischemic event both at the cerebral 
and the cardiac level by which the depression, more by the cerebral way than mental-
behavioural, increases mortality. Although the routine screening for depression in the 
conditions of primary intervention is controversial, the incidence and the effects of 
depression among the heart patients and the stroke survivors are persuasive arguments for 
performing a screening among these groups. 
While the post-MI depression has been well documented, depression as a risk factor for 
CHD remains controversial. Some studies have found a positive correlation between 
depression and the development of CHD in women alone, but other studies have found that 
depression was associated to an increase in the CHD risk in men. Confluent variables such 
as physical functions, hostility, anxiety and somatization involve evidence of a possible 
relationship between cause and effect. The parameters, the depression symptoms such as 
fatigue, the lack of interest in activities, the increase or loss of appetite, the psychomotor 
retardation or agitation, concentration disorders, low self-esteem, a depressed mood, and 
recurrent suicide attempts, can themselves be the precursors to CHD.   
Vast as well as exhaustive scientific research has been performed on the relationship 
between depression and ischemic cardiovascular disease (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26, 27, 28), and it has also dealt with the study of the fatty acids evaluated in several bio-
humoral fractions of the human organism (plasma phospholipids, cholesterol esters, 
erythrocytes, etc.) in order to identify the involvement of the different acidic components, in 
particular the saturated ones, on the determinism of the atherogenetic phenomenon and of 
those aspects of hemocoagulation that induce a thrombogenetic risk (29, 30, 31, 32, 33, 34, 35, 
36, 37, 38, 39, 40). 
3. Biological plausibility of the platelet role between depression and 
cardiovascular disease - fragments from the scientific literature 
…It is well known that platelets possess metabolic capacities for fatty acid synthesis and that 
they possess the neurotransmittor receptors. These characteristics make the platelets, in the 
view of many researchers, an element akin to the neuron. With scientific simplification, a 
“fragment of circulating brain” and they differ substantially from the erythrocytes … (41) 
…The platelets perform an important role not only in the hemostasis but also in the 
physiopathology of the ischemic coronary disease. Recent results suggest that the platelets 
are affected by different stress agents including the psychological ones and that the platelets 
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offer an important advantage in the understanding of the neurophysiology of the various 
psychiatric disorders.  
Research is described relating to the use of platelets as a ground for investigating the 
relations between stress and cardiovascular disease, apart from psychopharmacological 
research. There is evidence to propose circulating platelets as a model for bioaminergic 
neurons. There are many similarities between platelets and neurons relating to the 
metabolism of serotonin, and it is possible to extend this research model to other 
neurotransmitters such as dopamine, GABA, glutamate, etc. The reason for such similarities 
can be traced back to the common embryogenetic origin of the two different cells. Some 
modifications of the platelet functions have been observed in the psychiatric syndromes and 
the bond between coronary pathology, stress and platelet function is of interest for future 
research. Other studies might look to the thrombotic events such as stroke and vascular 
dementia and their association with stress agents using the platelets as search means or 
examine the association of certain risk factors of ischemic cardiopathy, with certain 
personality traits, using platelets as the variable key… (42).  
…The comparison with the properties of human platelets and the serotoninergic 
synaptosomes may be useful as a model in the study of the transport, the metabolism and 
the release of serotonin by the serotoninergic neurons of the central nervous system (43).  
…A marked reduction in the levels of serotonin has been found in patients with major 
depressive disorder but not in the dystimic disorders. These modifications may represent 
biochemical modifications suggesting major depressive disorders and cannot be attributed 
to chronic anti-depressive treatment … (44). 
The reduction in the serotonin levels in depressive patients could be traced back to their 
psychobiological distinction, which involves an abnormal metabolism of the biogenic 
amines in the brain… (45). The identification of the peripheral markers for the psychiatric 
illnesses is important if we want to implement an improvement in the diagnosis and the 
treatment of the diseases. The response of platelet intracellular calcium consequent to the 
neurotransmitter stimulation has been used as a peripheral marker of psychiatric illness. 
There is evidence of the appropriateness of extending the use of the platelets as a peripheral 
marker. The depressed patients show a rise in the basal platelet activation as compared with 
normal subjects and an elevated susceptibility to platelet activation could be the mechanism 
that makes depression a significant risk factor for cardiovascular and cerebrovascular 
disease… (46, 47).  
…Fatty acids other than the omega 3 can interact with the metabolism of the eicosanoids 
and influence the platelet function. For example, there is evidence that diets rich in 
unsaturated fatty acids such as linoleic and oleic acid can reduce the trend to thrombosis 
replacing the Arachidonic acid in the platelet phospholipids, diminishing the in vitro 
production of the A2 thromboxanes and the platelet aggregation. Nevertheless, there is little 
evidence that the platelet function, in vivo, is affected by these diets…(48)  
There are results that show that the linoleic acid of the diet does not increase the level of 
arachidonic acid in the plasma and in the platelets besides not contributing in a persistent 
way to the prostaglandin biosynthesis that is increased by the intake of arachidonic acid 
with the Western diet… (49). An elevated intake of linoleic acid can be thought to be 
protective against ischemic stroke, possibly through a potential mechanism reducing arterial 
pressure, reducing platelet aggregation and increasing erythrocyte deformability… (50).  
… Oleic acid has been shown to be a powerful inhibitor of induced PAF platelet aggregation 
and serotonin secretion. Consequently, in order to understand the molecular action 
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the treatment of AD, but that it does not have effects in retarding the progression of 
Parkinson’s and retarded dyscinesia (14). 
Melatonin also seems to have a ‘scavenger’ activity vis-à-vis the hydroxylic radicals besides 
its known properties of gonad function and biological rhythm regulation. This fact suggests 
that the melatonin could interfere with the neurodegenerative processes that affect the 
formation of free radicals and the release of amino-acid exciters (15). 
Depression and the cardiac arrhythmias are linked to the autonomous nervous system as 
has been seen in the measurement of heart beat variability.  
The transport protein of serotonin and the areas promoting the transport of serotonin 
ligands are shared by the platelets and the cerebral neurons so that central as well as 
peripheral effects may be expected.  
Platelet activation is significantly higher among the depressed patients both in the presence 
and the absence of heart disease.  
All of this shows the existence of a common path to the ischemic event both at the cerebral 
and the cardiac level by which the depression, more by the cerebral way than mental-
behavioural, increases mortality. Although the routine screening for depression in the 
conditions of primary intervention is controversial, the incidence and the effects of 
depression among the heart patients and the stroke survivors are persuasive arguments for 
performing a screening among these groups. 
While the post-MI depression has been well documented, depression as a risk factor for 
CHD remains controversial. Some studies have found a positive correlation between 
depression and the development of CHD in women alone, but other studies have found that 
depression was associated to an increase in the CHD risk in men. Confluent variables such 
as physical functions, hostility, anxiety and somatization involve evidence of a possible 
relationship between cause and effect. The parameters, the depression symptoms such as 
fatigue, the lack of interest in activities, the increase or loss of appetite, the psychomotor 
retardation or agitation, concentration disorders, low self-esteem, a depressed mood, and 
recurrent suicide attempts, can themselves be the precursors to CHD.   
Vast as well as exhaustive scientific research has been performed on the relationship 
between depression and ischemic cardiovascular disease (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26, 27, 28), and it has also dealt with the study of the fatty acids evaluated in several bio-
humoral fractions of the human organism (plasma phospholipids, cholesterol esters, 
erythrocytes, etc.) in order to identify the involvement of the different acidic components, in 
particular the saturated ones, on the determinism of the atherogenetic phenomenon and of 
those aspects of hemocoagulation that induce a thrombogenetic risk (29, 30, 31, 32, 33, 34, 35, 
36, 37, 38, 39, 40). 
3. Biological plausibility of the platelet role between depression and 
cardiovascular disease - fragments from the scientific literature 
…It is well known that platelets possess metabolic capacities for fatty acid synthesis and that 
they possess the neurotransmittor receptors. These characteristics make the platelets, in the 
view of many researchers, an element akin to the neuron. With scientific simplification, a 
“fragment of circulating brain” and they differ substantially from the erythrocytes … (41) 
…The platelets perform an important role not only in the hemostasis but also in the 
physiopathology of the ischemic coronary disease. Recent results suggest that the platelets 
are affected by different stress agents including the psychological ones and that the platelets 
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offer an important advantage in the understanding of the neurophysiology of the various 
psychiatric disorders.  
Research is described relating to the use of platelets as a ground for investigating the 
relations between stress and cardiovascular disease, apart from psychopharmacological 
research. There is evidence to propose circulating platelets as a model for bioaminergic 
neurons. There are many similarities between platelets and neurons relating to the 
metabolism of serotonin, and it is possible to extend this research model to other 
neurotransmitters such as dopamine, GABA, glutamate, etc. The reason for such similarities 
can be traced back to the common embryogenetic origin of the two different cells. Some 
modifications of the platelet functions have been observed in the psychiatric syndromes and 
the bond between coronary pathology, stress and platelet function is of interest for future 
research. Other studies might look to the thrombotic events such as stroke and vascular 
dementia and their association with stress agents using the platelets as search means or 
examine the association of certain risk factors of ischemic cardiopathy, with certain 
personality traits, using platelets as the variable key… (42).  
…The comparison with the properties of human platelets and the serotoninergic 
synaptosomes may be useful as a model in the study of the transport, the metabolism and 
the release of serotonin by the serotoninergic neurons of the central nervous system (43).  
…A marked reduction in the levels of serotonin has been found in patients with major 
depressive disorder but not in the dystimic disorders. These modifications may represent 
biochemical modifications suggesting major depressive disorders and cannot be attributed 
to chronic anti-depressive treatment … (44). 
The reduction in the serotonin levels in depressive patients could be traced back to their 
psychobiological distinction, which involves an abnormal metabolism of the biogenic 
amines in the brain… (45). The identification of the peripheral markers for the psychiatric 
illnesses is important if we want to implement an improvement in the diagnosis and the 
treatment of the diseases. The response of platelet intracellular calcium consequent to the 
neurotransmitter stimulation has been used as a peripheral marker of psychiatric illness. 
There is evidence of the appropriateness of extending the use of the platelets as a peripheral 
marker. The depressed patients show a rise in the basal platelet activation as compared with 
normal subjects and an elevated susceptibility to platelet activation could be the mechanism 
that makes depression a significant risk factor for cardiovascular and cerebrovascular 
disease… (46, 47).  
…Fatty acids other than the omega 3 can interact with the metabolism of the eicosanoids 
and influence the platelet function. For example, there is evidence that diets rich in 
unsaturated fatty acids such as linoleic and oleic acid can reduce the trend to thrombosis 
replacing the Arachidonic acid in the platelet phospholipids, diminishing the in vitro 
production of the A2 thromboxanes and the platelet aggregation. Nevertheless, there is little 
evidence that the platelet function, in vivo, is affected by these diets…(48)  
There are results that show that the linoleic acid of the diet does not increase the level of 
arachidonic acid in the plasma and in the platelets besides not contributing in a persistent 
way to the prostaglandin biosynthesis that is increased by the intake of arachidonic acid 
with the Western diet… (49). An elevated intake of linoleic acid can be thought to be 
protective against ischemic stroke, possibly through a potential mechanism reducing arterial 
pressure, reducing platelet aggregation and increasing erythrocyte deformability… (50).  
… Oleic acid has been shown to be a powerful inhibitor of induced PAF platelet aggregation 
and serotonin secretion. Consequently, in order to understand the molecular action 
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mechanism of the oleic acid, the effects of this free fatty acid have been sought for in many 
biochemical events associated with the platelet aggregation induced by the PAF. 
… The decrease in the level of [32P] PIP and [32P] PIP2 determined by the oleic acid has 
been associated with an inhibition in the platelet aggregation induced by the PAF. These 
results suggest that the inhibition of the PAF response by the oleic acid may be one of the 
steps in signal transduction … 
…Many literature reports suggest that olive oil can inhibit platelet function. This possible 
effect is of interest for two reasons: it can contribute to the apparently anti-atherogenetic role 
of olive oil and can invalidate the use of olive oil as an inert placebo in the studies on 
platelet function … (51). 
…After the supplementation with olive oil the platelet aggregation and the release of A2 
thromboxane were diminished, the content of oleic acid was considerably increased, and the 
content of arachidonic acid was significantly diminished. These data suggest that an excess 
of oleic acid displaces the incorporation of the arachidonic acid in the platelet 
phospholipids. … it is concluded that the olive oil supplement exerts an inhibitor effect on 
the various aspects of platelet function, “an effect that can reduce the risk of heart disease, 
although fish intake can also exert a protective effect…” (52).  
…There is relevance in the negative effect low plasma levels of linoleic acid in the long-term 
prognosis after myocardial infarction … (53). 
…The polyunsaturated fatty acids and principally linoleic acid can have a substantially 
cardioprotective effect that is reflected in mortality. The quality of the dietary lipids seems 
more important than the quantity of the reduction in cardiovascular mortality in man… (54, 
55).  
4. The experimental design 
Not believing the research performed on the omega 3 fatty acids to be exhaustive in the 
various experimental conditions of the literature, we have oriented our research towards a 
complex tissue and in particular that of the platelets, which, for their structural and 
functional characteristics, seemed to us to better fulfil the working hypotheses of a 
mediation role between cerebral and cardiac phenomena.  
For the experimental aim of providing better knowledge on the fatty acid-depression and 
ischemic cardiovascular disease, we recruited:  
1. 84 subjects (51 females and 33 males, with mean age: 60, 21, SD ± 12.27) with clinical 
diagnosis of Major Depression. All the patients were interviewed to confirm the 
diagnosis of Major Depression; the instruments used were: Clinical Global Impression 
(CGI), Symptoms Check List-90 (SCL-90), Medical and Pharmacological history, BMI, 
Structured Clinical Interview DSM-IV-SCID-IV (American Psychiatric Association 
2000), and Hamilton Rating Scale of Depression (HRSD). 
The severity of the depressive symptoms in the group of patients was determined by 
the Hamilton Rating Scale of Depression 21 items version (HRSD-21), Hamilton 
(1960).  
2. 50 subjects (17 females and 33 males, mean age: 68, 00, SD: ± 9.50) with diagnosis of 
Ischemic Cardiovascular Disease confirmed in the hemodynamic diagnostic phase.  
3. 60 subjects (38 males and 22 females, with mean age: 33.97, SD: ± 12, 40), apparently 
healthy, with no known or referred history of depression or cardiovascular disease. 
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5. Results of the study 
The results, regarding the platelet’s fatty acid composition, after the statistical analysis, are 
expressed in Table 1 and 2. 
All the ANNs tested gave essentially the same result. However, one type of ANN, known as 
Self-Organizing Map (SOM), gave superior information by allowing the results to be 
described in a two-dimensional plane with potentially informative border areas. A series of 
repeated and independent SOM simulations, with the input parameters being changed each 
time, led to the finding that the best discriminant map was that obtained by inclusion of the 
following three fatty acids: Linoleic Acid (C18:2 n-6), Arachidonic Acid (C20:4 n-6) and 
Palmitic Acid (C16:0) for the depressive condition and Oleic Acid (C18:1), Linoleic Acid 
(C18:2 n-6) and Arachidonic Acid (C20:4 n-6) for the ischemic condition (56, 57, 58, 59, 60). 
The SOM is an unsupervised competitive-learning network algorithm, which was invented 
by Teuvo Kohonen in 1981–82. According to Kohonen et al. (61, 62, 63) the central property 
of the SOM is that it forms a nonlinear projection of a high-dimensional data manifold on a 
regular, low-dimensional (usually 2D) grid. In the display, the clustering of the data space as 
well as the metric-topological relations of the data items is clearly visible. If the data items 
are vectors, the components of which are variables with a definite meaning such as the 
descriptors of statistical data, or measurements that describe a process, the SOM grid can be 
used as a groundwork on which each of the variables can be displayed separately using 
greylevel or pseudocolor coding. This kind of combined display has been found very useful 
for the understanding of the mutual dependencies between the variables, as well as of the 
structures of the data set. In the context of this definition, a manifold refers to a topological 
space with welldefined mathematical properties. A particular strength of the SOM map 
displays lies in enabling relevant information to be 'found' rather than 'searched for'. 
The fatty acids values of the 3 groups, administered to the SOM, mixing healthy and 
pathological individuals and hiding the information on to their own pathological condition, 
 





C 14:0 0.87±0.59 1.03±0.706 N.S. 
C 16:0 20.68±2.15 17.92±4.462 < .01 
C 16:1 1.48±0.71 2.02±1.571 < .05 
C 17:1 0.80±0.540 0.45±0.267 < .01 
C 18:0 11.22±3.00 12.7±3.016 < .01 
C 18:1 n9 22.19±2.08 21.14±4.134 N.S. 
C 18:1 n7 1.82±0.64 1.89±0.870 N.S. 
C 18:2 n6 19.40±2.69 16.71±3.359 < .01 
C18:3  n3 0.48±0.17 0.73±1.554 N.S. 
C 20:3 n3 2.11±0.76 2.29±0.773 N.S. 
C 20:4 n6 14.06±2.41 19.03±3.839 < .01 
C 22:4 1.62±0.704 1.60±0.820 N.S. 
C 22:5 1.16±0.615 0.98±0.564 N.S. 
C 22:6 n3 2.09±0.80 1.49±0.802 < .01 
Table 1. Platelet fatty acids in MD 
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mechanism of the oleic acid, the effects of this free fatty acid have been sought for in many 
biochemical events associated with the platelet aggregation induced by the PAF. 
… The decrease in the level of [32P] PIP and [32P] PIP2 determined by the oleic acid has 
been associated with an inhibition in the platelet aggregation induced by the PAF. These 
results suggest that the inhibition of the PAF response by the oleic acid may be one of the 
steps in signal transduction … 
…Many literature reports suggest that olive oil can inhibit platelet function. This possible 
effect is of interest for two reasons: it can contribute to the apparently anti-atherogenetic role 
of olive oil and can invalidate the use of olive oil as an inert placebo in the studies on 
platelet function … (51). 
…After the supplementation with olive oil the platelet aggregation and the release of A2 
thromboxane were diminished, the content of oleic acid was considerably increased, and the 
content of arachidonic acid was significantly diminished. These data suggest that an excess 
of oleic acid displaces the incorporation of the arachidonic acid in the platelet 
phospholipids. … it is concluded that the olive oil supplement exerts an inhibitor effect on 
the various aspects of platelet function, “an effect that can reduce the risk of heart disease, 
although fish intake can also exert a protective effect…” (52).  
…There is relevance in the negative effect low plasma levels of linoleic acid in the long-term 
prognosis after myocardial infarction … (53). 
…The polyunsaturated fatty acids and principally linoleic acid can have a substantially 
cardioprotective effect that is reflected in mortality. The quality of the dietary lipids seems 
more important than the quantity of the reduction in cardiovascular mortality in man… (54, 
55).  
4. The experimental design 
Not believing the research performed on the omega 3 fatty acids to be exhaustive in the 
various experimental conditions of the literature, we have oriented our research towards a 
complex tissue and in particular that of the platelets, which, for their structural and 
functional characteristics, seemed to us to better fulfil the working hypotheses of a 
mediation role between cerebral and cardiac phenomena.  
For the experimental aim of providing better knowledge on the fatty acid-depression and 
ischemic cardiovascular disease, we recruited:  
1. 84 subjects (51 females and 33 males, with mean age: 60, 21, SD ± 12.27) with clinical 
diagnosis of Major Depression. All the patients were interviewed to confirm the 
diagnosis of Major Depression; the instruments used were: Clinical Global Impression 
(CGI), Symptoms Check List-90 (SCL-90), Medical and Pharmacological history, BMI, 
Structured Clinical Interview DSM-IV-SCID-IV (American Psychiatric Association 
2000), and Hamilton Rating Scale of Depression (HRSD). 
The severity of the depressive symptoms in the group of patients was determined by 
the Hamilton Rating Scale of Depression 21 items version (HRSD-21), Hamilton 
(1960).  
2. 50 subjects (17 females and 33 males, mean age: 68, 00, SD: ± 9.50) with diagnosis of 
Ischemic Cardiovascular Disease confirmed in the hemodynamic diagnostic phase.  
3. 60 subjects (38 males and 22 females, with mean age: 33.97, SD: ± 12, 40), apparently 
healthy, with no known or referred history of depression or cardiovascular disease. 
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5. Results of the study 
The results, regarding the platelet’s fatty acid composition, after the statistical analysis, are 
expressed in Table 1 and 2. 
All the ANNs tested gave essentially the same result. However, one type of ANN, known as 
Self-Organizing Map (SOM), gave superior information by allowing the results to be 
described in a two-dimensional plane with potentially informative border areas. A series of 
repeated and independent SOM simulations, with the input parameters being changed each 
time, led to the finding that the best discriminant map was that obtained by inclusion of the 
following three fatty acids: Linoleic Acid (C18:2 n-6), Arachidonic Acid (C20:4 n-6) and 
Palmitic Acid (C16:0) for the depressive condition and Oleic Acid (C18:1), Linoleic Acid 
(C18:2 n-6) and Arachidonic Acid (C20:4 n-6) for the ischemic condition (56, 57, 58, 59, 60). 
The SOM is an unsupervised competitive-learning network algorithm, which was invented 
by Teuvo Kohonen in 1981–82. According to Kohonen et al. (61, 62, 63) the central property 
of the SOM is that it forms a nonlinear projection of a high-dimensional data manifold on a 
regular, low-dimensional (usually 2D) grid. In the display, the clustering of the data space as 
well as the metric-topological relations of the data items is clearly visible. If the data items 
are vectors, the components of which are variables with a definite meaning such as the 
descriptors of statistical data, or measurements that describe a process, the SOM grid can be 
used as a groundwork on which each of the variables can be displayed separately using 
greylevel or pseudocolor coding. This kind of combined display has been found very useful 
for the understanding of the mutual dependencies between the variables, as well as of the 
structures of the data set. In the context of this definition, a manifold refers to a topological 
space with welldefined mathematical properties. A particular strength of the SOM map 
displays lies in enabling relevant information to be 'found' rather than 'searched for'. 
The fatty acids values of the 3 groups, administered to the SOM, mixing healthy and 
pathological individuals and hiding the information on to their own pathological condition, 
 





C 14:0 0.87±0.59 1.03±0.706 N.S. 
C 16:0 20.68±2.15 17.92±4.462 < .01 
C 16:1 1.48±0.71 2.02±1.571 < .05 
C 17:1 0.80±0.540 0.45±0.267 < .01 
C 18:0 11.22±3.00 12.7±3.016 < .01 
C 18:1 n9 22.19±2.08 21.14±4.134 N.S. 
C 18:1 n7 1.82±0.64 1.89±0.870 N.S. 
C 18:2 n6 19.40±2.69 16.71±3.359 < .01 
C18:3  n3 0.48±0.17 0.73±1.554 N.S. 
C 20:3 n3 2.11±0.76 2.29±0.773 N.S. 
C 20:4 n6 14.06±2.41 19.03±3.839 < .01 
C 22:4 1.62±0.704 1.60±0.820 N.S. 
C 22:5 1.16±0.615 0.98±0.564 N.S. 
C 22:6 n3 2.09±0.80 1.49±0.802 < .01 
Table 1. Platelet fatty acids in MD 
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C14:0 0.87±0.59 0.34±0.26 < 0.01 
C16:0 20.68±2.15 23.32±3.17 < 0.01 
C16:1 1.48±0.71 0.74±0.54 < 0.01 
C18:0 11.23±3.00 17.65±2.50 < 0.01 
C18:1 n9 22.19±2.08 17.48±2.14 < 0.01 
C18:1 n7 1.82±0.64 1.04±0.46 < 0.01 
C18:2 n6 19.41±2.69 10.51±3.44 < 0.01 
C18:3 n3 0.48±0.17 0.59±0.30 < 0.05 
C20:3 n3 2.11±0.76 0.73±0.42 < 0.01 
C20:4 n6 14.06±2.41 15.17±3.01 < 0.05 
C22:6 n3 2.09±0.80 1.87±0.70 N.S. 
Table 2. Platelet fatty acids in IHD 
gave, as a result, the separation of the different groups, respectively, Depressive vs. Normal 
and Ischemic vs. Normal, recognizing as similar those belonging to the same population 
and, in the meanwhile, different those belonging to one population from the other ones. 
An objective, clear and extremely economic diagnostic tool has been built, which beyond the 
simple healthy / diseased information, offers a range of intensity, starting from a simple 
blood test. 
When this type of situation has been noted, we thought of putting together in a SOM the 
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Platelet, Fatty Acids, Membrane Viscosity, Depression 




Fig. 2. Classification of the Ischemic Subjects 
 
 
Fig. 3. Simultaneous classification of the three groups and, highlighted, the mixed area 
depressed and ischemic subjects 
The distribution of the 144 subjects affected by the SOM for depression has allowed us to 
identify four areas: two specific ones (exclusively normal and exclusively pathological) and 
two mixed ones with different concentrations of pathological subjects and apparently 
normal subjects of the sample. The two intermediate areas (yellow and orange) have initially 
been interpreted as different possible levels of staging of the depressive disease and a 
pathological condition not diagnosed in the normal subjects, as described in the literature, 
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moreover. The capacity of this mathematical instrument to express the pathology according 
to a different scale of intensity soon appeared clear. As regards the hypothesis that the 
positioning of the cases was also the expression of a different chemico-physical condition of 
the membrane, we addressed our attention towards the possibility of identifying such a 
condition by only considering the Arachidonic, Linoleic and Palmitic acids. Among the 
different characteristics observed in these fatty acids there emerged a significant correlation 
(r = 0.66, p < 0.001) between the sum of the 2 unsaturated acids (AA+AL) as compared with 
the saturate (AP). In other words, the sum of the three fatty acids can be considered, to a fair 
degree of approximation, constant and equal to 53.33 ± 3.43 (average±SD). 
Further analysis has led us to identify an effective index (B2) that relates the saturation 
characteristics of the set of the three fatty acids (57). 
That index has been identified in the following way: 
 
 
Fig. 4. Distribution of the B2 index on the map 
That coefficient was calculated for all the 144 subjects studied. This has allowed us to further 
classify the subjects on the grounds of this index with statistical significance (comparison 
between the indices of the normal and the pathological subjects). 
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1 Palmitic Acid C 16:0
2 Linoleic Acid C 18:2
3 Arachidonic Acid C 20:4
Where: 
Ai = percentage of i-th  Fatty Acid 
mwi = molecular weight of  i-th  Fatty Acid 
mpi = melting point of  i-th  Fatty Acid 
We then asked the SOM to express the B2 expected at every point of the map.  
6. Cardiovascular ischemic disease 
As the fatty acids identified by the network do not represent the majority of all the fatty 
acids of the acidic spectrum, we tried to identify an index that could express the saturation 
level that could most significantly be traced back to the CAIN logic (Coronary Artery 
Ischemic Neural network).  
The search for such an index has been performed by assessing the various ratio 
combinations between saturated fatty and unsaturated acids defining the result with the 
reported initials (SI = Saturation Index Total and Classic), B2, B4, Btot. Some of these are 
already known of in the literature, others are defined by the Authors. 
In this way we can define: 
 SITOT = (C14:0 + C16:0 + C18:0) / (C16:1 + C18:1n9 + C18:1n7 + C18:2 + C18:3 +C20:3 + C20:4 
+ C22:6).  
 SICLASSIC = C18:0 / C18:1 n9  
 B2= f (C16:0, C18:2, C20:4) 
 B4= f (C16:0, C18:0, C18:1, C20:4) 
 BTOT= f (C14:0, C16:0, C18:0, C16:1, C18:1n9, C18:2, C18:3, C20:4, C22:6)  
As can be observed in Table 3, all the parameters that express the saturation level are 
significantly and strongly correlated to each other. For the sake of simplicity of calculation 
and use, we therefore decided to use the SI Classic (hereinafter SI).  
This index, akin to the case of depression with the B2, has been put into the CAIN and, as 
can be seen (figure 5), it has cadenced the membership of the two groups in the pathological 
and normal quadrant in a way corresponding to the classification effected by the RNA. For 
that purpose, the cut-off value proposed for the SI is 0.80. 
This SI trend is distributed growingly (from the bottom to the top of the map) and is 
coherent with CAIN. While the area of the disease is observed with a very gradual 
distribution, the area of normality appears to be more non-homogeneous. That condition 
can probably be traced back to three pieces of evidence:   
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Table 3. Correlation of the identified saturation index. 
 
 
Fig. 5. Distribution of the saturation index (SI Classic) on the CAIN map colouring in red the 
subjects with SI > 0.80 and in green those with SI <= 0.80 
1. The oleic level, in any case distributed in the area of normality, is the guarantee of the 
same, nonetheless having in the lowest cut-off values; 
2. The levels of oleic acid in the area of normality must in any case take account of the 
distribution of the other fatty acids, CAIN markers. This supports the configuration 
assumed.  
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3. In the pathology area, the gradual distribution seems to suggest the position of strength 
of the oleic acid that leaves aside the value assumed by the other AG.  
It is still interesting to see how the characterisation of the oleic acid is also conditioned by a 
relationship with a fatty acid (stearic) not considered by the conventional statistical 
methods, neither by the RNA. 
7. CAIN and Framingham (The Framingham score) 
The Framingham score (61) is one of the best known diagnostic instruments suited to 
quantifying the presence of the cardiopathy risk. Constructed on a statistical basis, it is made 
up of 5 items relating to: 
a. Subject age; 
b. Total cholesterol; 
c. Smoke; 
d. HDL level; 
e. Systolic Blood Pressure; 
For each item a score is assigned, according to the value relating to the subject being 
studied, taking account of the sex (Fig. 6). 
 
 
Fig. 6. The Framingham Score 
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The total score obtained (Figure 7) is converted, by means of a Table (Table 4) into a risk 
percentage over 10 years. 
 
 
Fig. 7. The conversion of the Framingham score to a 10-year risk percentage. 
The 10-year risk percentage thus obtained can be further classified, according to what has 
been suggested by Anderson et al. (64) following the Table reported below. 
 
0 to 5% low risk 
5 to 10% moderate risk 
10 to 20% average risk 
20 to 40% high risk 
> 40% very high risk 
Table 4. Ten-year risk classification 
Now, let’s suppose we have to examine an ideal, hypothetical subject, who is in excellent 
condition: a non-smoker, perfect levels of Total Cholesterol, HDL, systolic pressure, etc. 
Although his/her health conditions are excellent, according to Framingham, he/she 
nonetheless has a risk factor: age! In other words, the fact of ageing, irrespective of 
conditions of health, in itself constitutes a risk factor. The graph of the Framingham score in 
relation to age of the ideal subject is represented in Fig. 8 (in blue). It should be pointed out 
that, as the score is different depending on the sex, the graph has been constructed using the 
mean value. Moreover, for the sake of illustration’s clarity, the linear interpolation of the 
curve has been made to overlap with that of the extrapolated curve (in red in Fig. 8). 
Let’s now consider the high risk and the very high risk levels according to Anderson’s 
classification. They are described for a ten-year risk over 20% (see Table 4). That percentage 
risk, in Framingham’s conversion table, read retrospectively, corresponds to a value of 22.5 
Framingham points, for the female population. It should be point out that we have chosen 
the female population because it is characterised by higher scores. It is worth underlining 
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Fig. 8. Graph with the age in the y-axis and the Framingham score in the x-axis. In blue: ideal 
trend of the Framingham score for a  ypothetical subject with a single risk factor: age. In red: 
the linear interpolation of the mentioned curve. 
that, in any case, by choosing the male population as reference or the mean value of the two 
sexes, the reasoning that follows does not vary quantitatively and leads to the same 
conclusion. By reporting the Framingham risk according to age, the high risk threshold and 
thus highlighting the risk area, we obtain the graph reported in Figure 9.  
 
 
Fig. 9. Graph of the Framingham score by age. In the y-axis: age of the subject; in the x-axis: 
the Framingham score. Colour gradation highlighting (orange up to red) the risk areas 
according to Anderson’s classification. 
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8. Saturation Index and CAIN 
In order to find a good index to describe synthetically the classification effected by CAIN, 
several paths have been tried. The most effective one has turned out to be that of the saturation 
indices, as reported above. In particular, the literature (65, 66) has suggested the Saturation 
Index (SI) particularly used in the oncology field, which is defined in the following way: 
 
It is possible to express the SI levels corresponding to each point of the CAIN map and 
describe then by means of a graph for level curves. In this way it is simpler to intuit the 
dynamics of SI in CAIN (Fig. 10). It should be remembered that CAIN is constructed using 
Oleic, Linoleic and Arachidonic Acid while the SI value is calculated by using Oleic Acid 
and Stearic Acid.  
 
 
CAIN Map    SI position in CAIN 
Fig. 10. On the left, the clustering of CAIN in the two areas: pathological (at the top) and 
non-pathological (at the bottom). On the right of the graph for level curves relating to the SI 
in the CAIN map. Notice how the separation curve of the clusters can be intuitively 
overlapped in the left-hand map towards the level curve of similar coordinates.  
By trying to evaluate the SI trend in CAIN (Fig. 11) we can see that it takes on minimum 
values in the lower part, corresponding to the “Normal” cluster of CAIN. From the bottom 
upwards, the value grows gradually until it reaches the maximum values in the upper part 
of the map, corresponding to the area of pathology, according to the CAIN clustering.  
9. The SI of some populations 
We have evaluated the mean values of SI in some subject populations. The first two were: 
a. “YOUNG”: Young sports people, supposedly healthy [n= 45; males = 35, females = 10; 
age = 22.7 ± 3.7 (m±SD)] 
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Fig. 11. The SI dynamic in CAIN. 
b. “ADULT”: Adults, supposedly healthy [n= 60; males = 38, females = 22; age = 34.0 ± 
12.4 (m±SD)] 
By building a graph whose y-axis had the age and whose x-axis the SI value, we obtained, 
for the two populations cited, the curve reported in Fig.12.  
 
 
Fig. 12. Graph of the SI values for 2 supposedly healthy populations of different mean ages 
Then, a third population was added: 
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c. “DEPRESSIVE”: Subjects with clinical diagnosis of Major Depression [n=84; males = 33, 
females = 51; age = 60.2 ± 12.3 (m±SD)] 
In Figures 13 and 14 the resultant graph is shown. 
 
 




Fig. 14. In red: interpolation (prolonging) of the segment “Young”-“Adult”. The 
interpolation and the curve obtained in Fig. 13 can be overlapped. 
The subjects of the third group are positioned in a perfectly overlapping way with the 
interpolation (prolonging) of the segment that unites the “Young” and the “Adult” 
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population (Fig. 12). In other words, the means of the three populations are positioned (to a 
good degree of approximation) on the same line. It should be borne in mind that, while the 
“Young” and “Adult” populations are healthy subjects, the “Depressive” population is 
composed of subjects with the Major Depression syndrome, characterised, however, by 
being non-pathological from the cardiovascular standpoint. Hence, a fourth population was 
added: 
d) “Ischemic”: Subjects with diagnosis of ischemia [n= 50; males = 33, females = 17; age = 
68.0 ± 9.5 (m ± SD)]. Figure 15 reports the resulting graph. It appears evident that the 
“Ischemic” population does not result to be in line with the other populations examined 
being characterised by a far superior SI value. 
 
 
Fig. 15. Curve of the mean values of SI of the four populations: “Young”, “Normal”, 
“Depressive” and “Ischemic” 
10. SI, CAIN and the Framingham Score 
By comparing the graph constructed on the grounds of the Framingham score as opposed to 
the one relating to the SI, looking at the Figures 16 and 17 we can see some curious 
congruities. 
In fact, we can see that, by matching the curve by age obtained in the SI graph to the age 
curve obtained in the Framingham, the “Ischemic” population coincides with the “Very 
high risk” area of the Framingham score. The two graphs seem to let transpire a certain, as 
yet not well defined, similitude. 
But what is the cut-off between healthy and pathological (from the cardiopathological point 
of view) in the SI graph? 
To answer this question it is necessary to ask CAIN for help. It is important to evaluate 
which SI value corresponds to the subdivision line between the 2 clusters (“Ischemia” and 
“Normal”) that CAIN has formed (Figure 18).  
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Fig. 16. Framingham score graph 
 
 
Fig. 17. SI graph  
By overlapping the CAIN clustering with the SI level curve graph (Figure 19) we can see that 
the SI value corresponding to the separation line of the two CAIN areas is indeed SI = 0.8. 
Now it is sufficient to report on the SI graph undergoing construction, the SI value 
corresponding to 0.8. This will be the cut-off of the SI values that subdivides the 
pathological and non-pathological subjects according to CAIN. Indeed, Figure  19 clearly 
shows that values lower than 0.8 in CAIN characterise healthy subjects, as opposed to those 
superior to 0.8 which, on the contrary , identify pathological subjects. 
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Fig. 18. Evaluation of the SI value corresponding to the clustered subdivision line (“normal” 
and “Ischemia”) of CAIN. By subdivision it is observed that the line corresponds to the level 





Fig. 19. SI and CAIN graph 
Once the areas of pathology and non-pathology are identified in the SI graph, it is 
juxtaposed with the one obtained from the Framingham (Figure 20). The match is certain. 
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Once the areas of pathology and non-pathology are identified in the SI graph, it is 
juxtaposed with the one obtained from the Framingham (Figure 20). The match is certain. 
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Fig. 20. The Framingham score graph (on the left) and the SI graph (on the right). 
In order to better appreciate the overlap between the two graphs we propose (Figure 21) the 
overlapping obtained by coinciding the two cut-off lines. The two curves submitted overlap 
in an absolutely coherent way.  
 
 
Fig. 21. Overlap of the Framingham Score and the SI graph. On the y-axis the age, on the left 
x-axis the Framingham score values, with related curve in red; on the right x-axis the SI 
values with related curve in green. 
By overlapping the two graphs, so that the SI cut-off value matches that of the Framingham 
Score, we obtain a match of the two underlying curves (red and green).  
The following figure sums up all the positions of the individuals investigated. 
Platelet, Fatty Acids, Membrane Viscosity, Depression 




Fig. 22. The Figure represents all the positions of the subjects studied; it can be seen how the 
swine and the children (SI) occupy an absolutely different position from the adults and even 
more detached from the ischemic patients.  
11. Conclusions 
What has been illustrated shows, at least as a first approximation, that the results obtained 
by CAIN 3 are absolutely compatible with the Framingham Score. Apart from corroborating 
the results obtained with CAIN even more, this obliges us to make a comparison between 
the two methods.  
The Framingham score, constructed on a statistical basis, offers as a result a pure number 
that quantifies a risk. Actually, it is one-dimensional. On the other hand, CAIN shows the 
result on a two-dimensional map, obviously capable of giving more information. In actual 
fact, for CAIN we have to speak of multidimensionality because once the position of a 
subject has been identified, there is a great deal of information available. Without citing it 
all, suffice it to think that it is possible to know if any ischemic pathology is characterised by 
the low level of oleic or linoleic acid. It is possible to know its SI value straight away and, at 
least at a first approximation, the Framingham value. In other words, once the coordinates 
of the subject have been identified, it is possible to decide on which plane to observe it: the 
SI plane, the fatty acid plane, for example of arachidonic acid, etc. In any case, what is 
certain is that CAIN offers much more information than the Framingham. Suffice it to think, 
for example, that for a CAIN value one can go back to its Framingham value (albeit 
approximate). If, on the contrary, we have the Framingham score we can, in no way, 
position the subject in CAIN. 
These reasons raise a question up: is it plausible to think of CAIN as a new Framingham? 
Novel markers for ischemic heart disease are under investigation by the scientific 
community at international level. 
Our work focuses on a specific platelet membrane fatty acid condition of viscosity which is 
linked to molecular aspects such as serotonin and G proteins, factors involved in vascular 
biology. 
A suggestive hypothesis is considered about the possibility to use platelet membrane viscosity, 
in relation to serotonin or, indirectly, the fatty acid profile, as indicator of ischemic risk. 
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Fig. 22. The Figure represents all the positions of the subjects studied; it can be seen how the 
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What has been illustrated shows, at least as a first approximation, that the results obtained 
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the results obtained with CAIN even more, this obliges us to make a comparison between 
the two methods.  
The Framingham score, constructed on a statistical basis, offers as a result a pure number 
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fact, for CAIN we have to speak of multidimensionality because once the position of a 
subject has been identified, there is a great deal of information available. Without citing it 
all, suffice it to think that it is possible to know if any ischemic pathology is characterised by 
the low level of oleic or linoleic acid. It is possible to know its SI value straight away and, at 
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of the subject have been identified, it is possible to decide on which plane to observe it: the 
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certain is that CAIN offers much more information than the Framingham. Suffice it to think, 
for example, that for a CAIN value one can go back to its Framingham value (albeit 
approximate). If, on the contrary, we have the Framingham score we can, in no way, 
position the subject in CAIN. 
These reasons raise a question up: is it plausible to think of CAIN as a new Framingham? 
Novel markers for ischemic heart disease are under investigation by the scientific 
community at international level. 
Our work focuses on a specific platelet membrane fatty acid condition of viscosity which is 
linked to molecular aspects such as serotonin and G proteins, factors involved in vascular 
biology. 
A suggestive hypothesis is considered about the possibility to use platelet membrane viscosity, 
in relation to serotonin or, indirectly, the fatty acid profile, as indicator of ischemic risk. 
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In the case of biological membranes we use the terms of “fluidity”, “stiffness,” permeability 
“functionality”, and “stickiness”, related or connected with biological effects of considerable 
importance. 
Fluidity and viscosity are two terms used in physics with specific meaning: the viscosity is a 
dynamic property of matter and is defined as the skid resistance of two fluid layers between 
them, in a real system treated as a package of fluid layers superimposed (in slow linear 
motion), which can vary with temperature for the same molecules, while the fluidity is the 
opposite. 
Rigidity, permeability and function are, however, characteristics of the membrane and are 
terms used to describe a physical and biological membrane behavior on the physiology of 
the cell. The viscosity of the membrane, of course, is related to the composition of fatty acids 
constituting the lipid bilayer (membrane folds). With reference to the membrane folds, they 
are usually very close and the distance may be very small in the case of saturated fatty acids, 
distance which tends to increase, replacing these with unsaturated fatty acids, much more as 
they are unsaturated. 
It has been demonstrated that the membrane viscosity is a peculiar characteristic in 
depressive subjects (67, 68) and that regulates serotonin receptors uptake [69]. 
Among all its function serotonin is also involved in some aspects of cardiac events such as 
coronary artery disease, in aggregation and vasoconstriction [70, 71]. 
Platelet takes up serotonin from plasma by the serotonin transporters and it is, then, secreted 
by the platelet dense granules during platelet activation, playing a role in platelet aggregation 
and vasoconstriction of surrounding blood vessels. Recent studies suggest that intracellular 
serotonin may also play a role in platelet activation through covalent linkage to small G 
proteins, activating G protein signaling pathways and stimulating platelet aggregation [72]. 
Total serotonin levels and the number of platelets have been found significantly higher 
among patients whith coronary artery disease [70]. 
Independently of the SOM results, among all the fatty acid profiles we have investigated 
(about 350 subjects), three fatty acids (Palmitic, Linoleic and Arachidonic), unexpectedly, 
had a constant total amount (53. 33 ± 3.43) representing the larger amount of platelet 
membrane fatty acids in all cases studied. 
If we consider this fatty acid triplet instead of that one which has allowed the classification 
of the ischemic subjects we can do a further consideration. 
It means that we can, also for the ischemic subjects, calculate a new index (B3) according to 

















C 16:0 0.246 20.68±2.15 5.089 17.92±4.462 4.408 23.32±3.17 5.737 
C 18:2 
n6 -0.018 19.40±2.69 -0.348 16.71±3.359 -0,301 10.51±3.44 -0.189 
C 20:4 
n6 -0.164 14.06±2.41 -2.306 19.03±3.839 -3.121 15.17±3.01 -2.488 
   2,434  0.986  3.060 
Table 5. Value of the B3 index in the subjects studied 
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As a result we obtained an index that expresses, on the basis of fatty acids detected, a 
coefficient of viscosity.  
The result is consistent with the knowledge that relates to the membrane viscosity, 
especially platelets, in the conditions investigated (normal, ischemic and depressive). 
This could lead to the hypothesis of the possibility to evaluate the ischemic risk considering 
each fatty acid concentration, within the same, identical quantity. 
As shown in table 1 the B3 index is significantly higher (about 30%) in ischemic than in 
normal subjects and 3 times higer than in depressive subjects. 
For the properties that link membrane viscosity to the platelet serotonin receptor uptake and 
for the role of serotonin in coronary artery disease, the evaluation of the chemical-physical 
characteristic should be utilized to forecast the ischemic risk, in agreement with the 
experimental result obtained in an Ischemic Heart Disease group of subjects through the 
SOM use. 
The Issue of Neural Networks 
(Discussion with Kary B. Mullis Nobel Prize), September 21, 2007 
Let’s try this one more time, Massimo, because somewhere there must be a disconnect in our 
dialogue on this business of an un-trained neural network being able to spot the likelihood 
of coronary heart disease in a set of patients, where the only information given to the 
network, is the concentration of three lipids on their platelets, let’s just call the lipids 1, 2  
and 3. 
What I understand is that you are demonstrating that in the absence of a “training set” your 
program can pick the patients who have a high probability for a coronary problem just from 
these values.  
By a training set I mean that the values for 1, 2 and 3, paired with an independent diagnosis 
of a coronary artery problem are presented to the computer for a certain number of your 
initial group. You are claiming that a “training set” is not necessary. 
How, I ask, could that possibly work? 
Now I do realize that lipid composition on platelets could easily have something to do with 
coronary artery problems, (and clinical depression). I don’t disbelieve that they could. 
Nobody I ever heard of predicted that, but when you told me it was true, I accepted it. But 
when you explained to me that your program had discovered this relationship with no 
reference to some external standard, no training set, I was incredulous and still am.  
I simply claim that without some additional data, like a training set of data points wherein 
the lipid variables were paired with clinical outcomes or some similar KNOWN variable 
relevant to coronary artery problems, (or a super-exceptional knowledge of physiology), the 
neuronal net, which is a mathematical object, not an oracle, could know anything except 1, 2, 
and 3 (the inputs) about the patients.  
In my experience, usually, the inputs to neuronal networks, trained with known data, are 
based on something like a thousand RNA concentrations from 100 patients, such that 
humans would have trouble seeing the connections, thus the need for the computer in the 
first place. In fact if the relationship that they discover is as simple as some mathematical 
expression among three numbers, then everyone is surprised but the computer program is 
no longer necessary. The purpose of the computer was to find those particular three 
parameters out of the thousand available. The analysis of a particular clinical finding in that 
case can, thereafter, be done by a calculator. Something like this happened at a company I 
was consulting for in Savannah, wherein a very uncomplicated solution appeared from a 
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coronary artery disease, in aggregation and vasoconstriction [70, 71]. 
Platelet takes up serotonin from plasma by the serotonin transporters and it is, then, secreted 
by the platelet dense granules during platelet activation, playing a role in platelet aggregation 
and vasoconstriction of surrounding blood vessels. Recent studies suggest that intracellular 
serotonin may also play a role in platelet activation through covalent linkage to small G 
proteins, activating G protein signaling pathways and stimulating platelet aggregation [72]. 
Total serotonin levels and the number of platelets have been found significantly higher 
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As a result we obtained an index that expresses, on the basis of fatty acids detected, a 
coefficient of viscosity.  
The result is consistent with the knowledge that relates to the membrane viscosity, 
especially platelets, in the conditions investigated (normal, ischemic and depressive). 
This could lead to the hypothesis of the possibility to evaluate the ischemic risk considering 
each fatty acid concentration, within the same, identical quantity. 
As shown in table 1 the B3 index is significantly higher (about 30%) in ischemic than in 
normal subjects and 3 times higer than in depressive subjects. 
For the properties that link membrane viscosity to the platelet serotonin receptor uptake and 
for the role of serotonin in coronary artery disease, the evaluation of the chemical-physical 
characteristic should be utilized to forecast the ischemic risk, in agreement with the 
experimental result obtained in an Ischemic Heart Disease group of subjects through the 
SOM use. 
The Issue of Neural Networks 
(Discussion with Kary B. Mullis Nobel Prize), September 21, 2007 
Let’s try this one more time, Massimo, because somewhere there must be a disconnect in our 
dialogue on this business of an un-trained neural network being able to spot the likelihood 
of coronary heart disease in a set of patients, where the only information given to the 
network, is the concentration of three lipids on their platelets, let’s just call the lipids 1, 2  
and 3. 
What I understand is that you are demonstrating that in the absence of a “training set” your 
program can pick the patients who have a high probability for a coronary problem just from 
these values.  
By a training set I mean that the values for 1, 2 and 3, paired with an independent diagnosis 
of a coronary artery problem are presented to the computer for a certain number of your 
initial group. You are claiming that a “training set” is not necessary. 
How, I ask, could that possibly work? 
Now I do realize that lipid composition on platelets could easily have something to do with 
coronary artery problems, (and clinical depression). I don’t disbelieve that they could. 
Nobody I ever heard of predicted that, but when you told me it was true, I accepted it. But 
when you explained to me that your program had discovered this relationship with no 
reference to some external standard, no training set, I was incredulous and still am.  
I simply claim that without some additional data, like a training set of data points wherein 
the lipid variables were paired with clinical outcomes or some similar KNOWN variable 
relevant to coronary artery problems, (or a super-exceptional knowledge of physiology), the 
neuronal net, which is a mathematical object, not an oracle, could know anything except 1, 2, 
and 3 (the inputs) about the patients.  
In my experience, usually, the inputs to neuronal networks, trained with known data, are 
based on something like a thousand RNA concentrations from 100 patients, such that 
humans would have trouble seeing the connections, thus the need for the computer in the 
first place. In fact if the relationship that they discover is as simple as some mathematical 
expression among three numbers, then everyone is surprised but the computer program is 
no longer necessary. The purpose of the computer was to find those particular three 
parameters out of the thousand available. The analysis of a particular clinical finding in that 
case can, thereafter, be done by a calculator. Something like this happened at a company I 
was consulting for in Savannah, wherein a very uncomplicated solution appeared from a 
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computer program called a support vector machine regarding the differential diagnosis of 
acute lymphocytic leukemia and chronic myelogenous leukemia. The input had consisted of 
several thousands of RNA levels from several hundred patients. After the result had 
appeared it did not require a computer to make the diagnosis. A human could look at just 
two relevant RNA levels, and make the call. 
Until then, which two, or whether there were only two RNA levels that held the critical data 
was not known. The support vector machine was instructed (trained) by clinical data, not 
simply the RNA levels. That’s why it worked. 
Computers are patient and capable of tedious calculations, but they are not capable, of ever 
telling you something that given great time and near-infinite patience, you could not have 
worked out yourself on a calculator. There is no discontinuity between classical 
mathematics and what is referred to as Turing Machine-like universal calculators. They are 
just fast, very fast, but not infinitely fast, or perhaps more importantly here, wise. What this 
means is that we understand how they work. There’s no mystery, only speed. 
So, if your program can always predict coronary artery conditions from three numbers 
representing the composition of three different lipids on platelets, without ever having 
being trained on a set of these variables paired with some clinical indicators, there is no way 
that a philosopher of science could legitimately say that you had not discovered something 
that was unexplainable, but clearly useful. However, its validity is purely based on 
induction, that is, it keeps working, unless Lucio can explain how it happened, and the 
process can be adapted to other applications. Most scientists, on the other hand, and I have 
to admit in this case that I fall into the latter category, would say you are damned lucky or 
you are missing something important. 
What you are doing isn’t in the commonly accepted sense, scientific. It is lacking in the 
essential quality of being largely explainable as a consequence, however subtle, of known 
facts, and therefore serving as a guide for other scientists to develop similar methods.  
If Lucio has discovered a new principle of neural nets that allows them, independently of a 
training set, to distinguish healthy coronary arteries from unhealthy coronary arteries on the 
basis of three numbers, which to a non-biologically informed computer, are only numbers, 
that principle overshadows this particular use of it by a revolutionary leap, and deserves to 
be published not only in the appropriate medical journal, but in a computer science journal 
as well. 
Given that this is the case: some new principle of neural network programming has been 
discovered and it has found ratios of three lipids that can be used to predict future 
cardiovascular problems, then congratulations are in order, BUT even in that case, I  don’t 
understand why the program is still necessary to make the diagnosis. 
In the case I mentioned earlier regarding leukemia, once the relevant genes had been 
identified, the computer program was no longer necessary.    
There is one explanation that I can imagine to account for the facts, but it brings into 
question your judgement and that of Lucio. Since there were only three variables being 
considered, it is not impossible that the relationship between them, which correlates with 
coronary heart disease, is simple enough that it could have been discovered empirically 
without the use either in the beginning or especially later of a neural net. In fact, how 
complicated can be the relationship between three numbers?  What is the computer doing?  
Why didn’t you compare by eye the three numbers in light of who was a coronary artery 
risk patient (which as you explained to me from the Framingham data was mostly just the 
age of the patients.) 
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Was something preventing you from knowing their potential coronary artery status prior to 
the computer study, which is not now preventing you from knowing that, and if not, then 
how do you evaluate your present results?  Either you know now the coronary artery risk 
and can compare it to what your computer says, or you don’t. If you do know it now then 
you can use it to validate your result. If you know it now, when did you learn it?  Were you 




Dear Dr. Mullis, 
How are you? And what about Linda and Nancy? Everybody is ok, here in Italy.  
Well, let’s come to the point. Now I clearly understand (I hope) the misunderstandings 
between you and Massimo. I’ll try to explain. 
You wrote: 
“Let’s try this one more time, Massimo, because somewhere there must be a disconnect in our 
dialogue on this business of an un-trained neural network being able to spot the likelihood of 
coronary heart disease in a set of patients, where the only information given to the network, is the 
concentration of three lipids on their platelets, let’s just call the lipids 1, 2 and 3. 
What I understand is that you are demonstrating that in the absence of a “training set” your 
program can pick the patients who have a high probability for a coronary problem just from these 
values. By a training set I mean that the values for 1, 2 and 3, paired with an independent diagnosis 
of a coronary artery problem are presented to the computer for a certain number of your initial group. 
You are claiming that a “training set” is not necessary. 
How, I ask, could that possibly work? 
Now I do realize that lipid composition on platelets could easily have something to do with coronary 
artery problems, (and clinical depression). I don’t disbelieve that they could. Nobody I ever heard of 
predicted that, but when you told me it was true, I accepted it. But when you explained to me that 
your program had discovered this relationship with no reference to some external standard, no 
training set, I was incredulous and still am.  
I simply claim that without some additional data, like a training set of data points wherein the lipid 
variables were paired with clinical outcomes or some similar KNOWN variable relevant to coronary 
artery problems, (or a super-exceptional knowledge of physiology), the neuronal net, which is a 
mathematical object, not an oracle, could know anything except 1, 2, and 3 (the inputs) about the 
patients. “  
Kary, you are right, we had to start from a “training set”. Maybe this is the main point of the 
misunderstanding. It’s simply a problem of words, I believe. Make the call. 
Of course we started from a “training set”. About Ischemia, it is made up by 60 healthy 
subjects versus 50 patients with definite diagnosis of Ischemia. So, we had a data base of 110 
subjects. For each Subject, we had his Fatty Acids pattern (11 variables) paired with “an 
external variable”: his healthy status related to Ischemia, I mean, if the subject is pathologic 
or healthy. 
So, we absolutely started from a “Training Set”. 
I think the misunderstanding occurred when we talked about the mathematical method, the 
training process, in particular. 
Many mathematical methods, ANNs in particular, are classified into 2 big families: 
Supervised ANNs and Unsupervised ANNs, according to the training process they use. 
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mathematics and what is referred to as Turing Machine-like universal calculators. They are 
just fast, very fast, but not infinitely fast, or perhaps more importantly here, wise. What this 
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So, if your program can always predict coronary artery conditions from three numbers 
representing the composition of three different lipids on platelets, without ever having 
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that principle overshadows this particular use of it by a revolutionary leap, and deserves to 
be published not only in the appropriate medical journal, but in a computer science journal 
as well. 
Given that this is the case: some new principle of neural network programming has been 
discovered and it has found ratios of three lipids that can be used to predict future 
cardiovascular problems, then congratulations are in order, BUT even in that case, I  don’t 
understand why the program is still necessary to make the diagnosis. 
In the case I mentioned earlier regarding leukemia, once the relevant genes had been 
identified, the computer program was no longer necessary.    
There is one explanation that I can imagine to account for the facts, but it brings into 
question your judgement and that of Lucio. Since there were only three variables being 
considered, it is not impossible that the relationship between them, which correlates with 
coronary heart disease, is simple enough that it could have been discovered empirically 
without the use either in the beginning or especially later of a neural net. In fact, how 
complicated can be the relationship between three numbers?  What is the computer doing?  
Why didn’t you compare by eye the three numbers in light of who was a coronary artery 
risk patient (which as you explained to me from the Framingham data was mostly just the 
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Was something preventing you from knowing their potential coronary artery status prior to 
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Dear Dr. Mullis, 
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You wrote: 
“Let’s try this one more time, Massimo, because somewhere there must be a disconnect in our 
dialogue on this business of an un-trained neural network being able to spot the likelihood of 
coronary heart disease in a set of patients, where the only information given to the network, is the 
concentration of three lipids on their platelets, let’s just call the lipids 1, 2 and 3. 
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of a coronary artery problem are presented to the computer for a certain number of your initial group. 
You are claiming that a “training set” is not necessary. 
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artery problems, (and clinical depression). I don’t disbelieve that they could. Nobody I ever heard of 
predicted that, but when you told me it was true, I accepted it. But when you explained to me that 
your program had discovered this relationship with no reference to some external standard, no 
training set, I was incredulous and still am.  
I simply claim that without some additional data, like a training set of data points wherein the lipid 
variables were paired with clinical outcomes or some similar KNOWN variable relevant to coronary 
artery problems, (or a super-exceptional knowledge of physiology), the neuronal net, which is a 
mathematical object, not an oracle, could know anything except 1, 2, and 3 (the inputs) about the 
patients. “  
Kary, you are right, we had to start from a “training set”. Maybe this is the main point of the 
misunderstanding. It’s simply a problem of words, I believe. Make the call. 
Of course we started from a “training set”. About Ischemia, it is made up by 60 healthy 
subjects versus 50 patients with definite diagnosis of Ischemia. So, we had a data base of 110 
subjects. For each Subject, we had his Fatty Acids pattern (11 variables) paired with “an 
external variable”: his healthy status related to Ischemia, I mean, if the subject is pathologic 
or healthy. 
So, we absolutely started from a “Training Set”. 
I think the misunderstanding occurred when we talked about the mathematical method, the 
training process, in particular. 
Many mathematical methods, ANNs in particular, are classified into 2 big families: 
Supervised ANNs and Unsupervised ANNs, according to the training process they use. 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 
 
344 
1) ANNs, using a supervised training process, need the complete training set, that is, all 
variables plus the “external variable”. For example, the Multi-Layered Perceptron (usually 
using the Back propagation algorithm) is a supervised ANN, probably the most common. It 
studies the Data Base, “learning” the features of each subject, according to his “external 
variable”, which it knows. Mathematically, it builds an n-dimensional error surface linking 
all variables involved to the “external variable”. It’s called “supervised” because it corrects 
itself reducing, in an iterative way, the global error knowing the correct result, as if “a 
teacher” would correct it, at each time. 
2) ANNs using an unsupervised training process, such as the Self Organizing Map (SOM), 
just need all variables, without the “external” one.  
This is because they use a different approach: they are not trained to find the feature of the 
different “external” value. They just look at the data and try to put together similar subjects 
without considering the “external variable” (pay attention, SOMs are different from the 
common “cluster analysis”).  
A SOM is able to do so, comparing, in a particular way, all the subjects of the data base (if 
you are interested, I attach an appendix to this paper where I try to explain how a SOM 
works, but , please, read all this paper before).  
I think it could be clearer following this example. 
Suppose you want to build up a system able to recognize handwritten characters. You 
probably start from a Data Base made of characters written by different humans (of course 
with different handwritings). In this case, the “external variable” is the real alphabetical 
letter the handwritten character represents. 
You could build this system using statistical “supervised” method. But you can also use a 
SOM. In this case, you have to show to the SOM the different handwritten characters, 
MIXED AND WITHOUT TELLING WHICH ONES RAPRESENT “A”, “B”, “C” AND SO 
ON. You just hope the Net will set different characters in different areas, putting the 
handwritten characters of “A” near to each other, and far from the handwritten characters of 
“B”, “C”, and so on. If (as usually happens), once the SOM is trained, all “A” are near, all 
“B” are near and so on, the SOM is ready: it mathematically realizes that all handwritten 
“A” are similar and puts them near to each other. The SOM realizes  that “A” are different 
from “B” and put all handwritten ”B” far form “A” but, again, near to each other. I mean: 
the “external” variable in this case is the alphabetic letter, linked to any different 
handwritten character. The SOM did not know this, when it was training, and when it was 
producing the final map. Just once the map is done, an external human observes that all 
handwritten characters, linked to the alphabetic letter “A” are together! And it’s the same 
with all other letters. Just now, the human divides the map into clusters, one for each letter 
(usually using a well known mathematical method such as the “Voronoi clusterization”). 
Once the SOM is trained, if we give it a new handwritten character, it will be mapped near 
to the similar characters, very probably in the correct cluster. 
So the whole training set, at the end, is absolutely necessary. It is not, for the SOM training. 
By the way, common commercial OCR (Optical Character Recognizer) software, usually use 
really this method. Actually, a lot of common commercial software use this kind of ANN 
even for many other purposes. 
Let’s return to Ischemia. 
We had a Training set of 110 subjects. We give to a SOM the 110 subject Data Base, without 
saying who was pathologic and who was not (exactly as done with handwritten characters). 
We just told the SOM the 3 fatty acids values. 
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Once the SOM gave us the result (I mean the map), we just observed that pathological 
subjects were all mapped on the top while healthy subjects were all mapped on the bottom. 
But we observe it, not the SOM, which does not know their pathological status. I mean: just 
once the net drew its answer, I mean the map, we colour healthy with green and pathologic 
with red, and realize the result. Since, all pathologic subjects are into a cluster, while other 
are opposite, we can say that: 
all pathologic subjects are similar to each other, and different from normal, at least from 
the 3 fatty acids involved point of view. (statement 1) 
This last statement is absolutely scientific. In fact: 
- The SOM is a very common neural network, deeply known and widely used even in 
common commercial software. It appeared to the scientific community more than 20 
years ago (T. Kohonen, 1981). Actually, in the biomedical field, SOMs are widely used 
since 10 years at least, and of course, they are absolutely accepted. 
So, the protocol used, is not a mystery, nothing unexplainable, but well known and 
accepted from years. 
Maybe it’s not so popular as a logistic regression but, at least here in Italy, more popular 
than Support Vector Machines. 
- If anyone, everywhere and whenever he wants, builds up a SOM or buys it (there are 
hundreds of commercial software developing SOMs) and trains it with our training set 
(of course, without the information about the pathological status), he will find that 
pathologic subjects go to a side and healthy, opposite. Probably, he will not find exactly 
our map, but the same result for sure. In fact, a SOM, like almost all ANNs, depends on 
random starting weight and on some other parameters: as you know, being familiar 
with ANNs, each training process is always different from another! In any case, if 
someone gives the same SOM parameters we used (to tell you the truth, they are those 
suggested by the literature, so they are the first that a computer scientist would try…) 
he will have exactly the same map.  
As a result of the statement 1, we can add that the 3 fatty acids of the pathologic population 
are, in some ways, different from those of the healthy population.  
Another result is, like in the handwriting character example, that we can map a new subject, 
whose status is unknown and, according to his position on the map, according to the cluster 
he reaches, we can think that he can be considered healthy or pathologic. I E: if his position 
into the map is in the middle of all other pathologic subjects, he can be suspected to be 
pathologic, or at least it’s very probable. 
Now, another point: 
“In my experience, usually, the inputs to neuronal networks, trained with known data, are based 
on something like a thousand RNA concentrations from 100 patients, such that humans would have 
trouble seeing the connections, thus the need for the computer in the first place. In fact if the 
relationship that they discover is as simple as some mathematical expression among three numbers, 
then everyone is surprised but the computer program is no longer necessary. The purpose of the 
computer was to find those particular three parameters out of the thousand available. The analysis of 
a particular clinical finding in that case can, thereafter, be done by a calculator.”   
Well, this is not our case. In our situation we had 110 subjects, and only 11 variables 
(coupled with the pathological status, 12th variable). So our main problem wasn’t to find 
those particular parameters out of only 11 variables. Talking about Ischemia (things are 
quite different about Depression), we identified the 3 fatty acids, quite easily, by means of 
common conventional statistics (Discriminant Analysis, ANOVA and so on). 
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with red, and realize the result. Since, all pathologic subjects are into a cluster, while other 
are opposite, we can say that: 
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So, the protocol used, is not a mystery, nothing unexplainable, but well known and 
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Maybe it’s not so popular as a logistic regression but, at least here in Italy, more popular 
than Support Vector Machines. 
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(of course, without the information about the pathological status), he will find that 
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Once we found those 3 parameters, we wanted to study their dynamics, we wanted more 
information, a deeper knowledge of the problem and, a diagnostic tool. So we tried to use 
different mathematical tools such as “Cluster analysis”, Classification Trees, and so on, but 
in our opinion, the best one has been the SOM.  
In fact, it quickly led us to a lot of important (according to us) results. We do not use “a 
thousand RNA concentrations” but just a simple SOM. Maybe in our case, the need for the 
computer is not in the first place, maybe we could reach same results “by eye” but, as you 
say, the main feature of a calculator is speed and our main interest is the result, secondly the 
method. In any case, by eyes we can’t evaluate the 3 parameters in the same time, with the 
same speed and precision of the SOM. 
Many people are scared by the name “artificial neural network”. But ANNs are not strange 
objects at all! They are not difficult; they are accepted as useful tools from years and 
commonly used even in everyday life application. Maybe, the only trouble is the different 
approach they use, a bit different from conventional statistics. But the problem, if it exists, is 
just in our way of thinking. And, I’m sure, Kary, you have not this kind of problems at all!!!  
One more question: 
“There is one explanation that I can imagine to account for the facts, but it brings into question your 
judgement and that of Lucio. Since there were only three variables being considered, it is not 
impossible that the relationship between them, which correlates with coronary heart disease, is simple 
enough that it could have been discovered empirically without the use either in the beginning or 
especially later of a neural net. In fact, how complicated can be the relationship between three 
numbers?  What is the computer doing?  Why didn’t you compare by eye the three numbers 
in light of who was a coronary artery risk patient (which as you explained to me from the 
Framingham data was mostly just the age of the patients.)” 
Well, a computer is not necessary to guess a handwritten character!  
How complicated can be recognizing a handwritten letter? 
But I ask you: can you explain the mathematical rules in order to classify a handwritten 
character, in an easy way? Or better: a digitized character could be expressed, for example, 
with a 8x4 matrix of pixels = 32 pixels. We certainly could give a formula with 32 variables 
in order to classify a character, but all computer scientists find it more comfortable to use a 
SOM instead of a formula. And I agree with them.  
 
Well, in our problem, there are only 3 numbers, it’s true. But, when we found the SOM map, 
we just understood that using the 3 fatty acid, we could classify a patient but we absolutely 
did not know the correct rules in order to do that, yet. We realized soon that it was not a so 
simple problem. 
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Some examples of handwritten “A” in an 8x4 matrix of pixel 
I try to explain. When Massimo and I studied the “rules”, we observed that a subject was 
pathologic if parameter 1 was low while parameter 2 was medium and parameter 3 was 
high. If parameter 3 decreases, the subject is no more pathologic unless parameter 2 
increases too, but just up to a certain value, and so on. I mean that there are a lot of possible 
configurations, combinations. We agree that we could express them with pencil and paper 
but we simply find it more comfortable and clearer using a 2 dimensional map. In our 
opinion, it’s just more simple, easy and clear. 
For example, let’s think about the Body Mass Index (BMI) and its application. It’s one of the 
simplest formulas all over the world. You just have to calculate Height/Weight2 and than 
check the result in a reference table. Well, every doctor simply has stupid soft wares that do 
it. I’m sure this could be done by eye but it’s faster and maybe easier to use a computer that 
shows a graph. Of course, we translated all our results into rules, and we are using them in 
order to continue our research. But when we have to check the healthy status of a new 
subject, we find it more comfortable to use the SOM, mainly when a subject falls in our 
border-line area. 
So Kary, as you have seen, there’s no mystery, nothing is unexplainable. Everything is, in the 
commonly accepted sense, scientific. I have not discovered a new principle of neural nets 
(warning: until now!), unfortunately, because the net we used has been existing since 1981.  
Maybe the reason of this misunderstanding between you and Massimo, between you and 
us, is me. I feel really guilty and apologize, because I was not clear in my explanations with 
you. You always had to talk of mathematical questions with Massimo, who is neither a 
mathematician nor a computer scientist! I remember that, even if we didn’t have so many 
occasions to talk together in private discussions, you came to me many times, for questions, 
remarks and so on. I apologize but my main problem is that it’s very difficult to talk with 
you: I’m neither a “researcher”, and I should talk with a Nobel laureate. I know, you were 
present when I did my first lecture, and year by year you saw me grow.  
I am really sorry, Dr. Mullis, but you are considered one of the best minds all over the 
world, and I feel so small, in front of you… sorry. 
Thank you for your time, 
Sincerely, Lucio. 
Dec 17, 2007 
 
Dear Massimo, 
Lucio has clarified the situation for me. 
I now understand your work with Lucio and agree that it is a contribution to the field of 
diagnostics in cardiology which is worth pursuing. There was a communication problem. 
I did not understand that after the self-organizing map program had operated in an 
unsupervised manner on all the data from healthy and at-risk patients, sorting each 
individual set of the values for oleic, linoleic and arachadonic acid into one of 400 bins, 
according to the similarity of the relations between their components, then you, knowing 
which sets were (from independent considerations) at-risk, “colored” the 400 squares 
according to “healthy” or “at-risk.”  That input from you  took the place of informing the 
overall procedure as to which of the patterns it had found originated in healthy and not-so-
healthy patients, and logical induction allows you to assume that whenever future values 
fall into one of those categories it will be defined. 
Certainly now by examining the program statements that assign the three fatty acid 
concentrations to particular cells in your program, you could replace the program with a 
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healthy patients, and logical induction allows you to assume that whenever future values 
fall into one of those categories it will be defined. 
Certainly now by examining the program statements that assign the three fatty acid 
concentrations to particular cells in your program, you could replace the program with a 
Coronary Angiography 
 – Advances in Noninvasive Imaging Approach for Evaluation of Coronary Artery Disease 
 
348 
series of “if then” statements, but I understand that computers are ubiquitous and cheap. 
Why bother. In addition, by continuing to add more data, which you know is from healthy 
or unhealthy patients you might refine your colouring pattern if that is called for. 
So the mystery is solved.  
I’m sorry to have been so much trouble. I think if scientists still refused to talk to each other 
except in Latin, such misunderstandings might not happen. But then we would all have to 
learn Latin (even Italians) and agree on how to interpret it. 
Give Lucio my best and assure him that I understand now what you are doing as a result of 
his explanation. 
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1. Introduction 
The current definition of biomarkers includes “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Biomarkers Definitions Working 
Group, 2001)”. Accordingly, biomarkers are usually used for detection and establishing the 
magnitude of a physiological derangement as well as to monitor a treatment.  
The role for imaging techniques and biomarkers in the diagnosis and treatment of 
myocardial infarction (MI) after percutaneous coronary intervention is well-established. 
Many candidate biomarkers emerging from genomics and proteomics research have the 
potential to serve as predictive indexes for guiding the development of interventional 
cardiology (Gerhardt  et al. 1991; Katus et al., 1991; Lindpaintner, 1997; Kong et al., 1997). 
Among them the undisputed role still play cardiac proteins like troponins or creatine 
kinase-myocardial band (CK-MB) (Alcock et al., 2010; Lim et al., 2011). Less established, 
however, is the employment of biomarkers to determine long-term, progressive, or dynamic 
risk over time in patients with advanced coronary artery disease (CAD). Biomarkers offer a 
means to track differential exposure as well as impact of exposure. As such, they reflect 
individual vulnerability, ongoing person-environment interaction, and unmeasured 
environmental factors that mediate the effect of exposures (Fig. 1). Essential to a vision of 
synergistic diagnostics is a focus on the mechanisms of diseases. Understanding what is 
happening on a molecular and cellular level, how disease actually begins, how cells begin to 
express certain proteins, influence other cells and trigger processes (atherosclerosis, 
thrombosis, calcification) will allow to develop in vitro diagnostics and imaging techniques 
to distinguish these processes. By characterizing a comprehensive set of measurable 
processes that capture diverse pathogenic aspects of CAD, a real-time systems view of 
disease activity can be generated to improve decision making. 
This chapter summarize a current view on the development of new biomarkers as a 
prognostic platform among patients at risk of CAD and upcoming complications. 
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express certain proteins, influence other cells and trigger processes (atherosclerosis, 
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to distinguish these processes. By characterizing a comprehensive set of measurable 
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disease activity can be generated to improve decision making. 
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Fig. 1. Model showing relationship of a biomarker with internal and external factors which 
have an impact on measurable and unmeasurable features of biomarker. 
2. Bone remodelling biomarkers 
About 10 years ago, the hypothesis that bone remodelling biomarkers might be involved in 
the progression of coronary artery calcification seemed to be tricky and beyond any 
reasonable expectation. However, in 1995 Boström et al. first time proposed the possible 
mechanisms for bone formation in artery walls involving retention of pluripotent cells or 
osteoblastic immigration coupled with embryonic-like osteogenic program (Boström et al. 
1995). The main reason for understanding the regulatory mechanisms of vascular 
calcification was firstly related to therapeutic approaches to prevent and possibly reverse 
vascular mineralization (Demer , 1997;  Parhami  et al. 1997). The data from clinical studies 
regularly report an association between bone remodeling biomarkers and the presence, 
severity and progression of a broad range of cardiovascular diseases. Whether they are 
biomarkers or rather play a causal role in mediating or protecting against vascular injury is 
not clear. The mechanisms underlying the postulated role of bone remodelling biomarkers 
in atherosclerosis probably involve inflammation and calcification processes. 
This section will focus on the prognostic significance of plasma bone remodelling 
biomarkers levels in stable and unstable CAD. 
2.1 Biology of bone remodelling of biomarkers 
Vascular biomineralization in an atherosclerotic plaque results from an  imbalance in 
osteoblast- and osteoclast-like cells and the induction of vascular or immune cells 
differentiation into osteogenic cells (Demer & Tintut, 2008). Osteobalsts, osteoclasts and 
inflammatory cells are firmly involved in bone remodelling (Fig. 2). 
Acceleration of New Biomarkers Development and 




Fig. 2. Bone remodelling osteoblasts and osteoclasts differentiation. Figure was produced 
using Servier Medical Art. 
 
 
Fig. 3. The role of osteoprotegerin (OPG) in pre-osteoclast differentiation. OPG trap and 
neutralize a soluble receptor activator of nuclear factor kappa-B ligand (RANKL) which 
activates osteoclasts by its receptor (RANK). Figure was produced using Servier Medical Art. 
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Mesenchymal stem cells are precursors for pre-osteoblasts. Osteoblasts activity leads to 
bone formation and mineralization, their differentiation and activity is mostly regulated by  
RANKL (receptor activator of nuclear factor kappa-B ligand) inducers, such as:  vitamin D 
(1,25[OH]2D), glucocorticosteroids, parathormone (PTH), prostaglandins (PGE2), 
lipopolysaccharides (LPS), histamine and pro-inflammatory cytokines: interleukins (IL-1 
and IL-11), tumor necrosisi factor alfa (TNF-α) and others (Eriksen, 2010). RANKL is a 
surface-bound molecule (also known as CD254). It is found on osteoblasts and serves to 
stimulate osteoclasts by RANK (receptor activator of nuclear factor kappa-B) activation and 
RANK/RANKL axis has a core regulatory role in osteoblasts and osteoclasts signalling (Fig. 
3) (Caidahl et al., 2010). 
2.2 Osteoprotegerin and osteopontin as risk factors of coronary artery disease 
Several studies suggest the involvement of bone remodeling biomarkers  in coronary artery 
disease and related atherosclerotic disorders (Van Campenhout & Golledge, 2009; Venuraju 
et al. 2010). Prime regulators of bone remodelling, such as osteoprotegerin (OPG) and 
osteopontin (OPN), are significantly and independently associated with inflammatory 
processes and arterial hypertension and may exert substantial influence on the severity of 
cardiovascular disease. (Stępień et al., 2011) 
OPG is a soluble glycoprotein widely expressed in most human tissues including the bone 
(osteoblasts) and the vasculature (endothelial and vascular smooth muscle cells, VSMC) 
(Collin-Osdoby, 2004; Schoppet et al., 2002) that is implicated in the regulation of bone and 
vascular calcification. OPG is a member of the tumor necrosis factor (TNF)-related family 
and a part of the OPG/RANKL/RANK triad. OPG acts as a soluble secreted decay receptor 
for a receptor activator of nuclear factor kappa-B ligand (RANKL) and neutralize this 
essential cytokine required for the osteoclasts differentiation (Hsu et al., 1999) (Fig. 3).  
RANKL expressed on osteoblastic, stromal and T cells binds to RANK (osteoclast 
differentiation factor) on the surface of osteoclasts, monocytic and dendritic cells and 
mediates a cell-to-cell signal responsible for osteoclastogenesis (Yasuda et al. 1998). 
Additional roles in immunological responses include the RANK-RANKL binding between 
dendritic and T cells which enhances the immunostimulatory capacity of dendritic cells and 
T cell proliferation (Green & Flavel 1999). 
It was observed that opg-knockout mice (OPG -/-) develop early onset osteoporosis and 
arterial calcification (Bucay et al., 1998) and the restoration of the gene prevented osteoporosis 
progression and arterial calcification (Min et al., 2000). Increased OPG level has been observed 
in men with advanced CAD and plasma OPG level has proved to be an independent predictor 
of myocardial ischemia in asymptomatic diabetic patients (Avignon, 2007; Schoppet et al., 
2003). Moreover, increased OPG has been related to the number and vulnerability  of plaques 
as well as in carotid artery (Kadoglou et al., 2008; Vik et al. 2010) or coronary vessels 
(Palazzuoli at al., 2008), which suggests its involvement in the coronary disease progression 
(Mikami et al., 2008; Pedersen et al., 2010). Elevated OPG in plasma is univariable predictors of 
coronary artery calcification (CAC) progression (Anand et al., 2007). The sensitivity of OPG for 
detecting of CAC score higher than 200 Agatston units was 80% in patients with predialysis 
diabetic nephropathy (Schoppet et al., 2003).  However, in the large Norwegian study by 
Pederesen et al. (Pedersen et al., 2010), adjustment for conventional risk factors attenuated the 
risk estimates for OPG levels. Only the subgroup of patients with stable angina pectoris (SA) 
with levels above the 90th percentile was at risk all-cause mortality: 1.94 (1.18, 3.18), p=0.01; 
CAD mortality: 2.29 (1.16, 4.49), p=0.02; and MI: 1.76 (1.02, 3.06), p=0.04.  
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In patients with acute coronary syndromes (ACS) the baseline OPG concentrations were 
strongly associated with increased long-term mortality (hazard ratio [HR] for log 
transformed OPG level 1.7 [range 1.5 to 1.9] p<0.0001) and heart failure hospitalizations (HR 
2.0 [range 1.6 to 2.5]; p < 0.0001) but weaker with recurrent MI (HR 1.3 [range 1.0 to 1.5]; p = 
0.02) and not with stroke (HR 1.2 [range 0.9 to 1.6]; p = 0.35). The association remained 
significant after adjustment for conventional risk markers (Omland et al., 2008). In 
apparently healthy individuals (the European Prospective Investigation into Cancer in 
Norfolk – EPIC Norfolk cohort) high serum concentrations of OPG and soluble RANKL 
were associated with an increased risk of future CAD (Semb et al., 2009). OPG showed a 
significant association with the risk of future coronary events in both sexes. This association 
remained statistically significant after adjustment for traditional cardiovascular risk factors 
(i.e. age, diabetes, systolic blood pressure, smoking, total cholesterol and HDL cholesterol). 
OPN is secreted as a calcium-binding glycophosphoprotein that has been implicated in bone 
remodeling and inflammation as well. Similarly to OPG, osteopontin is widely distributed 
in different human cells including osteoblasts, lymphocytes, macrophages, endothelial cells 
and vascular smooth muscle cells (Brown et al., 1992).  
OPN is a cytokine and has the ability to stimulate migration of macrophages and osteoclasts 
(Giachelli et al, 1998; Suzuki et al., 2002) and proliferation of osteoclasts and vascular 
smooth muscle cells (Giachelli et al, 1998; Liaw et al., 1994). A growing body of experimental 
evidence suggests that OPN overexpression plays an essential role in modulating 
compensatory cardiac fibrosis and hypertrophy (Xie et al., 2004; Singh et al. 2010). OPN acts 
through different integrins and thus has a great potential to regulate populations of different 
cells on the molecular and cellular levels (Bazzichi et al., 2009; Burke et al.,  2009). OPN 
plays a pivotal role in inflammation and atherosclerotic plaque formation in an animal 
model (Scatena et al., 2007). Recent data has indicated a high predictive value of OPN for 
secondary manifestations of atherosclerotic disease (e.g. cardiovascular death, myocardial 
infarction, stroke, and endovascular interventions) in a 3-year follow-up of patients 
undergoing carotid surgery (de Kleijn et al., 2010). 
Baseline levels of OPN are independent predictors of future adverse cardiac events in 
patients with chronic coronary syndrome (CCS), and may be useful for risk stratification 
(Minoretti et al., 2006). Recent data have indicated a high predictive value of OPN for 
secondary manifestations of atherosclerotic disease (e.g. cardiovascular death, MI, stroke 
and endovascular interventions) in a 3-year follow-up of patients undergoing carotid 
surgery. In a prospective study by Gogo et al. (Gogo et al., 2006), the association between 
angiographically quantified coronary artery calcification and OPG was not found. Detection 
of coronary calcification by coronary angiography may underestimate the calcification 
burden, thus synergistic diagnostics of coronary calcification should utilize more sensitive 
techniques of MSCT (Willemsen et al., 2009). However, in patients with CAD undergoing 
percutaneous coronary intervention (PCI) the highest OPN levels were associated with both 
plaque progression and restenosis in a stent (p=0.003). In addition, OPN, IL-6, and CRP 
were higher in patients with ACS than in those with CCS (analysis of variance: p<0.001, 
p<0.05 and p<0.05, respectively) (Mazzone et al, 2011). 
A question arises as to whether peripheral vascular function (calcification markers) matches 
the coronary arteries (calcification) and thus, whether it may serve as a surrogate marker to 
identify individuals with increased hazard of  CAD and mortality (de Kleijn et al., 2010; Lieb 
et al., 2010; Scatena et al., 2007). Therefore bone-matrix proteins combined with 
cardiovascular imaging  could be potential markers for vulnerable coronary artery  plaques. 
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Mesenchymal stem cells are precursors for pre-osteoblasts. Osteoblasts activity leads to 
bone formation and mineralization, their differentiation and activity is mostly regulated by  
RANKL (receptor activator of nuclear factor kappa-B ligand) inducers, such as:  vitamin D 
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Pederesen et al. (Pedersen et al., 2010), adjustment for conventional risk factors attenuated the 
risk estimates for OPG levels. Only the subgroup of patients with stable angina pectoris (SA) 
with levels above the 90th percentile was at risk all-cause mortality: 1.94 (1.18, 3.18), p=0.01; 
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Microparticles (MP) are sub-micron sized cell membrane/cytoplasmic fragments that are 
released from the cell surface. There are two well-known cellular processes that can lead to 
the formation of MPs: chemical and physical cell activation (by agonists or shear stress, 
respectively), and apoptosis (Jimenez et al., 2003). However, the mechanisms that take place 
during MP formation are still not revealed. It seems that, the flopping of phosphatidylserine 
(PS) to the outer layer of the plasma membrane is pivotal. Finally, this process  leads to the 
formation and shedding of MPs from activated or apoptotic cells. In resting condition the 
membrane asymmetry is maintained by an aminophospholipid translocase with flippase 
activity. Bilayer asymmetry is disrupted in the consequence of the inhibition of flippase 
activity by calcium influx. Increased calcium ions concentrations activate calcium-
dependent calpains, which disturb cytoskeleton, promote the shedding of MPs (Morel et al., 
2011) and stimulate scramblase and floppase activities, which lead to the collapse of the 
membrane asymmetry (Freyssinet & Toti, 2010). 
MPs are qualitatively and quantitatively diverse and vary in diameter between 0.1 and 1.5 
µm and may harbor a number of cell surface proteins (Fig. 4). MPs are released from various 
cell types such as circulating blood cells (platelets, lymphocytes T and B, monocytes and 




Fig. 4. A platelet microparticle is carrying not only specific membrane adhesion proteins (P-
selectin, integrins – e. i. GPIIbIIIa, ), but also may harbour and transfer tissue factor (TF) 
which has its procoagulant potential and other functional effectors (E-selectin, von 
Willebrand factor, arachidonic acid, thromboxane A2), that can regulate aggregation, 
adhesion molecule expression, cell proliferation, apoptosis and endothelial migration. MPs 
may capsule messenger molecules (miRNA, DNA ?), cytokines, growth factors and calpains. 
Figure was produced using Servier Medical Art. 
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MPs from numerous cellular sources have been described in human plasma. They have 
received increasing attention as potential biomarkers of cell damage and activation or 
biovectors in blood coagulation, inflammation and cancer (Benameur et al., 2009;  Hoyer et 
al., 2010). In several pathological states like dilated cardiomyopathy, chronic renal failure or 
cerebrovascular disease, MPs were used as biomarkers to identify a disease or to detect 
complications linked to a given disease (Bulut et al. 2011; Faure et al., 2006; Jung et al., 2009). 
Numerous clinical studies have evaluated their usefulness in the stratification of patients at 
risk for vascular disorders and to monitor response to treatment. Circulating MPs may serve 
as a marker for cardiovascular events in CAD patients or as a predictor of acute allograft 
rejection after heart transplantation (Morel et al., 2008; Sinning et al., 2010). 
3.1 Microparticles discrimination and enumeration 
The high level of microparticles’ diversity may create a problem with compatible 
masurement of MPs using different analytical methods. The number of microparticles 
depend on the detection technique and a wide range of pre-analytical variables, i.e. blood 
collecting and handling, plasma preparation and storage conditions. Therefore, optimization 
and standardization of detection methods are important to define microparticles correctly 
and to avoid falsely high or low quantification. Even minor protocol changes significantly 
affected MP levels (Ayers et al., 2011). 
3.1.1 Flow cytometry in MP analysis 
Several research have evaluated the impact of these different parameters to propose a pre-
analytical protocol for MP analysis. Three ISTH Scientific and Standardization 
Subcommittees (SSC Vascular Biology, DIC, and Haemostasis &Malignancy) have initiated 
a project aimed at standardizing the enumeration of cellular MPs by means of flow 
cytometry method (FCM). The first collaborative workshop was set to establish the 
resolution and a threshold levels of the flow cytometers currently used in laboratories. 
Additionally, the interinstrument reproducibility of platelet MP enumeration in human 
plasma was analyzed (Lacroix et al., 2010).  The study included 40 laboratories and 59 flow 
instruments were validated according to the protocol based on Megamix beads calibration 
to discriminate microparticles between 0.5 μm and 0.9 μm using the forward scatter (FS) 
channeling (FSC) parameter (FS/FSC). After that, selected laboratories received PFP 
samples prepared as frozen aliquots by the core laboratory, to avoid any preanalytic-linked 
variability. The authors found high discrepancy among Becton Dickinson instruments, as 
well within low, medium and high values of MP: coefficients of variation were 78%, 60% 
and 91%, respectively. Whereas interlaboratory reproducibilities were 30% ,15% and 17% for 
low, medium and high values among Beckmann Coulter instruments. These data indicate 
that standardization of platelet MPs enumeration by FCM dependents on intrinsic 
characteristics of instruments. Moreover, standardization by calibrated beads such is useful 
tool for MP enumeration, however, calibrated beads do not reflect real condition of MPs in 
human plasma.  
3.1.2 Indirect methods for MP enumeration 
Alternative methods for MP enumeration based on TF-activity/antigen or platelet 
glycoprotein GPIb-integrin have been already described (Huise et al, 2009; Kuriyama et al., 
2010). The activity of tissue factor is evaluated using a chromogenic substrate for factor Xa, 
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Numerous clinical studies have evaluated their usefulness in the stratification of patients at 
risk for vascular disorders and to monitor response to treatment. Circulating MPs may serve 
as a marker for cardiovascular events in CAD patients or as a predictor of acute allograft 
rejection after heart transplantation (Morel et al., 2008; Sinning et al., 2010). 
3.1 Microparticles discrimination and enumeration 
The high level of microparticles’ diversity may create a problem with compatible 
masurement of MPs using different analytical methods. The number of microparticles 
depend on the detection technique and a wide range of pre-analytical variables, i.e. blood 
collecting and handling, plasma preparation and storage conditions. Therefore, optimization 
and standardization of detection methods are important to define microparticles correctly 
and to avoid falsely high or low quantification. Even minor protocol changes significantly 
affected MP levels (Ayers et al., 2011). 
3.1.1 Flow cytometry in MP analysis 
Several research have evaluated the impact of these different parameters to propose a pre-
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instruments were validated according to the protocol based on Megamix beads calibration 
to discriminate microparticles between 0.5 μm and 0.9 μm using the forward scatter (FS) 
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well within low, medium and high values of MP: coefficients of variation were 78%, 60% 
and 91%, respectively. Whereas interlaboratory reproducibilities were 30% ,15% and 17% for 
low, medium and high values among Beckmann Coulter instruments. These data indicate 
that standardization of platelet MPs enumeration by FCM dependents on intrinsic 
characteristics of instruments. Moreover, standardization by calibrated beads such is useful 
tool for MP enumeration, however, calibrated beads do not reflect real condition of MPs in 
human plasma.  
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thus the ability of MPs to promote factor X activation in the presence of factor VII using a 
chromogenic activity assay is utilized (Huise et al, 2009). Alternatively, TF antigen or 
activity can be measured in plasma or whole blood (Key NS & Mackman N, 2010). 
However, determination of microparticle size is not possible by such approaches. 
3.1.3 Pre-analytical variability in MP determination 
The analysis of different protocols used in MP preparation showed that washing, 
centrifugation, filtration of buffer and long-term freezing influenced significantly the MP 
quantification (Ayers et al., 2011; Dey-Hazra et al., 2010). Freezing samples at -80°C decreased 
MP levels (Ayers et al., 2011; Shah et al., 2009). The second collaborative workshop was 
dedicated to propose a common pre-analytical protocol useful for standardization of pre-
analytical variables in determination of MPs (Scientific and Standardization Committee 2010). 
3.1.4 Specific antigens in MP discrimination 
There are two main features of native MPs: the small size and the anionic phospholipid - PS 
on the outer leaflet of their membrane. In addition, MPs carry surface membrane antigens 
reflecting their cell of origin, including those induced by cellular activation, cell injury or 
apoptosis. These properties permit detection of specific subpopulations, such as endothelial, 
leucocyte or platelet-derived MPs (Diamant et al., 2004). 
PS is specifically bound to annexin V and is recommended as a distinguish marker for MP 
enumeration (Bulut et al., 2009; Shah et al. 2009). However, a number of evidence suggests 
that some vesicles derived from endothelial cells are PS-negative by annexin-V labelling 
(Jimenez et al., 2003; Sekuła et al., 2011). In platelet-poor plasma obtained from healthy 
donors, 80% of platelet-derived MPs failed to bind annexin V (Connor et al., 2010). In this 
case, a phalloidin-staining of actin filaments could be helpful in discrimination of MPs and 
other cell fragments (Mobarrez et al., 2010). Washing samples as well as double 
centrifugation result in decreased annexin-V (Ayers et al. 2011). 
3.1.4.1 Platelet MPs 
Platelets constitute the main source of circulating procoagulant MPs under many 
physiological and pathophysiological situations (Geiser, et al., 1998; Huise et al, 2009; 
Kuriyama et al., 2010). Procoagulant platelet derived MPs are enriched in P-selectin 
(CD62P), cell surface protein (CD63), integrins: GPIIbIIIa (α2bβ3), GPIIb (α2b, CD41), GPIIIa 
(β3, CD61) and GPIb (CD42b), tissue factor (CD142, TF) or calpains (Figure 4).  
Patients with unstable angina (UA) and AMI had a significantly increased number of 
procoagulant MPs: GPIIbIIIa-positive, CD62P-positive and CD41-positive (Huisse et al., 
2009; Morel et al., 2004; Stankiewicz et al., 2007; van der Zee et al. 2006). The total number of 
platelet-derived MPs were numerically higher in patients with no recanalisation compared 
to patients with recanalisation (Huisse et al., 2009). However, we observed paradoxically 
lower  number of CD62P-positive platelets in whole blood obtained from patients with ACS, 
than from SA patients, but the level of soluble P-selectin in plasma was significantly higher 
than in those with ACS (Figure 5). We may suspect that soluble P-selectin  levels are 
derivatives of platelet origin MPs (Chung et.al., 2009). 
3.1.4.2 Tissue factor-bearing MPs 
It was shown by cell sorting with the specific marker CD42b that under resting conditions, 
blood-borne TF was mainly harbored by platelet-derived MPs (Müller et al, 2003). In acute 
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coronary syndromes, TF triggers the formation of intracoronary thrombi following endothelial 
injury, activation of macrophages and apoptotosis of smooth muscle cells (SMCs) and 
macrophages (Morel et al, 2006). Apoptotic (annexin V-positive) MPs support a number of TF-
positive MPs from different origin. Apoptotic macrophages and SMCs are the main source of 
membrane-bound TF and they contribute to TF accumulation. Formation of TF triggering MPs 
rich in PS provides a suitable anionic phospholipid surface for assembly of the tenase and 
prothrombinase complexes and thrombin activation (Del Conde et al., 2005). 
 
 
Fig. 5. Platelet activation measured as a percentage of surface P-selectin-positive (CD62+) 
platelet (PLT), and by monocyte/platelet aggregates (MO/CD61+) and neutrophil/platelet 
aggregates (N/CD61+) in peripheral blood from patients with stable angina (SA) and acute 
myocardial infarction (AMI), and by levels of soluble P-selectin in patients with stable 
angina (SA), and acute myocardial infarction (AMI). Data are expressed as medians. 
*p<0.05,***p<0.00001 for the comparison. 
Additionally, an increased number of TF-positive (CD142-positive) MPs in patients with 
ACS was observed (Figure 6) (Huisse et al., 2009; Steppich et al., 2005). Moreover, elevated 
levels of different origin TF-bearing MPs were significantly higher within the occluded 
coronary artery than in peripheral blood samples (Morel et al. 2009). It suggests their 
contrubution in coronary atherothrombosis and in situ formation of procoagulat MPs. 
3.1.4.3 Endothelial microparticles 
Endothelial microparticles (EMPs) are an emerging marker of endothelial cell (EC) 
activation and dysfunction  and their circulating numbers are elevated in a number of 
pathologic states including cardiovascular disease. Many studies suggest that endothelial 
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coronary syndromes, TF triggers the formation of intracoronary thrombi following endothelial 
injury, activation of macrophages and apoptotosis of smooth muscle cells (SMCs) and 
macrophages (Morel et al, 2006). Apoptotic (annexin V-positive) MPs support a number of TF-
positive MPs from different origin. Apoptotic macrophages and SMCs are the main source of 
membrane-bound TF and they contribute to TF accumulation. Formation of TF triggering MPs 
rich in PS provides a suitable anionic phospholipid surface for assembly of the tenase and 
prothrombinase complexes and thrombin activation (Del Conde et al., 2005). 
 
 
Fig. 5. Platelet activation measured as a percentage of surface P-selectin-positive (CD62+) 
platelet (PLT), and by monocyte/platelet aggregates (MO/CD61+) and neutrophil/platelet 
aggregates (N/CD61+) in peripheral blood from patients with stable angina (SA) and acute 
myocardial infarction (AMI), and by levels of soluble P-selectin in patients with stable 
angina (SA), and acute myocardial infarction (AMI). Data are expressed as medians. 
*p<0.05,***p<0.00001 for the comparison. 
Additionally, an increased number of TF-positive (CD142-positive) MPs in patients with 
ACS was observed (Figure 6) (Huisse et al., 2009; Steppich et al., 2005). Moreover, elevated 
levels of different origin TF-bearing MPs were significantly higher within the occluded 
coronary artery than in peripheral blood samples (Morel et al. 2009). It suggests their 
contrubution in coronary atherothrombosis and in situ formation of procoagulat MPs. 
3.1.4.3 Endothelial microparticles 
Endothelial microparticles (EMPs) are an emerging marker of endothelial cell (EC) 
activation and dysfunction  and their circulating numbers are elevated in a number of 
pathologic states including cardiovascular disease. Many studies suggest that endothelial 
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cell-derived MPs have a paracrine role and contribute to the development of endothelial 
dysfunction in most cardiovascular diseases: CAD, ACS, MI, hypertension and congestive 
heart failure. Moreover, diabetes, end-stage renal failure and pulmonary or venous 
embolism are strong factors bringing about EMP shedding [Bal et al., 2010; Chirinos et. al., 
2005; Faure et al., 2006; Morel et al., 2004a]. In this case patients have marked activation of 
endothelial, platelet, and leukocyte MPs.  
Endothelial-derived microparticles (EMPs) may carry different endothelial originating 
coagulation factors, for example TF, which contribute to the clot formation and lysis (Chou 
et al., 2004; Stępień et al., 2007b). Patients with AMI displayed higher levels of all MPs than 
patients with SA and CD31-positive EMPs appeared the main source of procoagulant MPs 
(Morel et al., 2004b). In patients with ACS significant correlations between both the total 
 
 
Fig. 6. Representative dot plot of circulating microparticles (MPs) in a patient with acute 
coronary syndrome (ACS) and in a control voluntary. A, C - flow cytometry gating logic, 
MPs were initially gated by forward (FCS-H) and side scatter (SSC-H) in logarithmic scale; 
B, D - fluorescence plots show MPs binding of annexin V-FITC (FL1-H) and anti-CD142-PE 
(FL2-H) monoclonal antibody. 
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number as well as the level of CD34, CD51 and CD142 were observed (Stankiewicz et al., 
2007). Moreover, increased number of EMPs (E-cadherin/CD144-positive MPs) was an 
independent predictor of future cardiovascular events (HR 2.42 [range 1.03 to 5.68), p=0.04), 
but not for all-cause mortality (HR 2.10 [range 0.83 to 5.32] p=0.12) in patients with heart 
failure (Nozaki et al., 2010) and the assessment of EMPs improved prediction of future 
cardiovascular events in patients with CAD (Nozaki et al., 2009).  
4. Clotting 
Clotting is a rapid and highly dynamic process,  which involves both platelets and 
coagulation factors. To monitor the clotting process a lot of instrumentations and methods 
are engaged: i) clotting times: the activated partial thromboplastin time (aPTT) and the 
prothrombin time (PT); ii) thromboelastography; iii) assessment of thrombin generation 
markers and thrombin inhibitors; iv) the real-time monitoring of thrombin generation. This 
section will focus on the prognostic significance of thrombin generation markers in stable 
and unstable CAD. 
4.1 Markers of thrombin generation in CAD patients 
Antithrombin (AT) appears to be the most important stoichiometric inhibitor which forms 
equimolar complexes with thrombin molecules – TAT (thrombin-antithrombin) complexes. 
A concentration of TAT complexes measured in peripheral venous blood and in blood 
collected at the site of microvascular injury reflect thrombin generation. TAT complexes are 
expressed during clot formation and there are (alike fibrinopeptide A and F 1+2 fragments) 
markers of thrombin activation (Pelzer et al., 1988; Pelzer et al., 1991). These markers are 
elevated in pro-thrombotic conditions In patients with cardiovascular disease, the detection 
of a prothrombotic state may have two major implications: i) to extend the duration and ii) 
to monitor the dose of anticoagulation after cardiac intervention. The thrombin plasma 
activity is very firmly associated with CAD. 
The potential coagulation activity in plasma can be evaluated by the rate of thrombin 
formation and the total amount of formed thrombin is measured by means of chromogenic 
or fluorescence methods (Devreese et al., 2007; Hemker et al., 2002). This thrombin potential 
in plasma can be assessed by different methods and the Calibrated Automated 
Thrombogram (CAT) applies a fluorogenic substrate. A chromogenic substrate is used in 
Behring Coagulation System (BCS). In both methods thrombin generation is activated by 
diluted recombinant tissue factor (TF), but in the BCS method a non-defined fibrin 
aggregation inhibitor is present. Both methods are applied in diagnostics. In CAT a 
calibration factor is measured in a plasma sample identical to that in which thrombin 
generation is being determined and the course of the calibration factor is assessed during 
the entire measurement (Figure 7). Thrombin generation assays seem to be useful in  
endogenous TF assessment (Ollivier et al. 2010; Stępień et al., 2007a).  
4.2 Blood sampling for coagulation markers assessment 
The most important think in coagulation diagnostics is to apply a reliably sampling method. 
To ensure accurate measurement samples must be collected in the circumstances under 
which false elevations of molecular markers of hemostatic and fibrinolytic activation will 
not occur. Thus, atraumatic antecubital venipuncture into vacutainer containing buffered 
sodium citrate is essential and the contamination with calcium or magnesium should be 
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avoided (van den Besselaar et al., 2007; Stegmar et al., 2007). To avoid activation of 
coagulation by tissue thromboplastin, each collection of citrated plasma should be preceded 
by a serum tube. Duration of needle puncture, rather than duration of tourniquet use, 
produced the greatest elevation in plasma levels of TAT and F1+2 (Omote et al., 2008). 
 
 
Fig. 7. The rate of thrombin formation is presented as the thrombin concentration against  
time curve. Three parameters are presented: lag time (Tlag),  peak height (Cmax) and 
endogenous thrombin potential (ETP). 
4.3 Prognostic value of thrombin generation in cardiac events 
Increased circulating levels of thrombin and its markers characterize ACS (Ardissino et al., 
2003; Takano et al., 1991). Plasma F1+2, normally about 1 nM, is roughly 1.5-2-fold higher 
than observed in SA patients, reaching maximum values in AMI (Ardissino et al., 2001). U-
shaped relationship between plasma prothrombin fragment 1+2 levels and the risk of 
developing cardiac death or renewed myocardial infarction was observed. Intermediate 
levels (1.5-1.9 nM) were associated with the lowest risk, whereas both higher (>1.9 nM) and 
lower (< 1.5 nM) values were associated with an increased risk (RR 1.56 [range 1.25 to 2.28] 
and RR 1.35 [range 1.11 to 1.86], respectively) (Ardissino et al., 2003). Hypercoagulable state 
measured as thrombin-antithrombin complexes (TAT) levels and as calibrated automated 
thrombogram reflects vascular impairment in CAD patients (Stępień et al., 2007a). It was 
observed that high TAT levels may predict mortality in chronic heart disease group after 
adjustment for classic risk factors (Marcucci et al., 2006). In empirical reconstruction, 
simulated maximum thrombin levels (p<0.01) and rates (p<0.01) were 50% higher with ACS 
while the initiation phases of thrombin generation were shorter than in patients with stable 
CAD (Brummel-Ziedins et al., 2008). Elevated levels of thrombin derivatives are associated 
with clinical risk factors for stroke (Lane et al., 1983; Takano et al., 1991). Elevated thrombin 
concentration reflects hypercoagulable state in patients with hypertension (Hoeper et al, 
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1998; Kłoczko et al., 1996), hyperglycaemia (Undas et al., 2008) and hypercholesterolemia 
(Wada et al., 1992; Sanguigni  et al., 2005; Undas et al., 2005).  
5. Conclusion 
Endothelial and platelets activation leading to cardiovascular complications can be 
evaluated quantitatively by measurement of plasma levels of circulating MPs. Moreover, a 
multiple biomarkers strategy that includes bone remodeling  biomarkers (OPG, OPN) and 
clotting properties can provide better risk stratification of cardiovascular events.  
Development and discovery of new biomarkers may improve clinical assessment of patients  
who might benefit more from treatment. Synergistic strategies in diagnostics seem to be 
more advantageous than routine method in prognosis and patients’ management. 
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1. Introduction  
Coronary artery disease (CAD) is one of the leading causes of death worldwide and it is 
expected that the rate of CAD will accelerate in the next decade due to overall aging of 
population and increases in the prevalence of cardiovascular risk factors (type 2 diabetes, 
obesity, metabolic syndrome) in younger generations (Amborsioni et al., 2003). The 
mortality associated with atherosclerotic disease is mainly related to the acute coronary 
syndromes (ACS), including acute myocardial infarction (AMI), unstable angina (UA) 
pectoris and sudden cardiac death. Inflammation plays a central role throughout the entire 
disease progression, and it lies at the root of atherosclerosis initiation, progression and its 
complications (Bonow et al., 2002).  
However, recent data support the notion that plaques within the coronary circulation 
become “more severe” or at “high-risk” (vulnerable plaque) in response to a wide array of 
local and systemic influences, both inflammatory and non-inflammatory (Alsheikh-Ali et al., 
2010; Finn AV et al., 2010). Indeed, plaques may have similar structural features and 
morphologic assessment, but may differ in their biology, their activity, and thus their 
likelihood of advancing toward clinical complications. Advances in the understanding of 
the pathogenesis of coronary atheroslcerosis have stimulated development of novel 
biomarkers, and expanded their role in the different spectra of their underlying 
pathophysiology (Hochholzer et al., 2010). In this regard, an emerging approach is 
represented by the assessment of plaque burden, morphology, and remodeling with in vivo 
atherosclerosis imaging and its correlation to novel biomarkers (Prati & Zimarino, 2010). 
In the past, invasive coronary angiography (CAG) has been the only diagnostic procedure 
for identifying coronary atherosclerosis. However, newer intracoronary imaging modalities 
have been developed allowing a more accurate and precise evaluation of coronary 
atherosclerotic lesions, with regard to specific morphologic criteria, especially concerning 
vulnerability. Intravascular ultrasound (IVUS) is a catheter-based technology that allows for 
assessment of vessel wall thickness and structure while coronary angioscopy also allows to 
visualize the vessel lumen (Kaneda et al., 2010). More recently, optical coherence 
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tomography (OCT) has been introduced as an invasive technique that provides images of 
vessel wall morphology and plaque characteristics (Prati et al., 2009; Bezerra et al., 2009).  
By using these novel techniques, an array of biomarkers assessing plaque growth and 
destabilization, myocardial stress and ischemia, along with inflammatory processes, has 
been developed, including cellular adhesion molecules, cytokines, and proatherogenic 
enzymes. Importantly, different biomarkers may look at different phases of coronary 
atherosclerotic disease and CAG, along with IVUS, angioscopy and OCT, may be of great 
clinical utility in assessing the role of these new biomarkers in coronary atherosclerosis 
pathophysiology  (Libby & Theroux, 2005; Hansson, 2005). 
The present chapter will summarize our current understanding of inflammatory and non-
inflammatory biomarkers, validated with intracoronary imaging modalities, their presumed 
pathophysiological role in coronary atherosclerosis and the clinical evidence that supports 
their prognostic importance.  
2. Soluble biomarkers  
A dynamic inflammation model has supplanted the previously held view of atherosclerosis 
as a passive deposition of debris in the arterial wall (Libby, 1995a, 1995b; 2001; 2002; Libby & 
Theroux, 2005). Numerous mediators contribute to atherogenesis, including chemokines, 
cytokines, growth factors, proteases, adhesion molecules, hemostasis regulators, and 
receptors, and their interactions may regulate plaque progression and instability (Blake & 
Ridker, 2002;).  
A biomarker is defined as a characteristic that is objectively measured and evaluated as an 
indicator  of normal biologic processes or pathogenic processes or as a physiologic response 
to a therapeutic intervention. In clinical medicine, biomarkers are routinely used in disease 
diagnosis, prognosis, ongoing clinical decision-making, and follow-up to assess effects of 
therapy. A framework for the validation of biomarkers was proposed by Boissel et al. 
(Boisell et al., 1992) and subsequently adapted by Espeland et al. (Espeland et al., 2005) in a 
discussion of the usefulness of carotid ultrasound to measure the clinical efficacy of lipid-
lowering medications. Espeland et al. (Espeland et al., 2005), in modifying the terminology 
of Boissel et al. (Boisell et al., 1992), described clinical and statistical characteristics that a 
biomarker should have to be considered a surrogate marker of efficacy in atherosclerotic 
disease. Importantly, the clinical criteria outlined for validating surrogate markers are 
efficiency, linkage, and congruence. Taken together, these data suggest that four main 
factors are related to the development of effective biomarkers (Fry, 2010): 1. Analytical 
validity: the accuracy and precision with which a particular biomarker is identified by the 
Proposed test; 2. Clinical validity: the accuracy with which a test identifies or predicts a 
patient’s clinical status; 3. Clinical utility: assessment of the risks and benefits, such as cost 
or patient outcome, resulting from the test; 4. Ethical, legal or social implications. 
Several inflammatory and non-inflammatory soluble biomarkers have been widely 
investigated during the last two decades in the setting of CAD, including both stable and 
unstable pattern of clinical presentation. On the one hand, many of these biomarkers have 
been associated with the presence of CAD; on the other hand, they have been associated 
with the presence of “vulnerable” plaque, thus with an increased risk of cardiac death and 
non-fatal AMI, eventually stressing both their diagnostic and prognostic role. In this regard, 
intracoronary imaging modalities may help to understand the pathological role exerted by 
soluble biomarkers in the pathogenesis of CAD. 
Biomarkers and Coronary Atherosclerotic Burden and Activity as 




Recent research has shown that inflammation plays a key role in CAD and other 
manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their 
effector molecules accelerate progression of the lesions, and activation of inflammation can 
elicit ACS. 
3.1 C-reactive protein 
C-reactive protein (CRP) was identified more than five decades ago as an acute-phase 
reactant that was capable of activating the complement system (Tillet & Francis, 1930; 
Abernathy & Avery, 1941). It was subsequently noted to be one of a number of acute-phase 
biomarkers, along with the erythrocyte sedimentation rate and complement, which was 
elevated in AMI (Boltax & Fischel, 1956). After the development of more sensitive, reliable, 
and readily available assays for CRP, a number of epidemiologic studies were conducted to 
assess the value of CRP in predicting cardiovascular risk (Ridker et al., 1997, 2001, 2002, 
2005a, 2005b; Danesh et al., 2004; Koenig et al., 2004; Cushman et al., 2005). In a post-mortem 
study of 302 autopsies of men and women with atherosclerosis, median CRP levels were 
higher with acute plaque rupture than in stable plaques or controls (Burke et al., 2002). The 
levels correlated with the staining intensity for CRP in macrophages and the lipid core of 
plaques, and it increased with the number of thin cap atheromas found in coronary arteries. 
Moreover, plasma CRP levels at the upper end of the reference range in apparently healthy 
men and women, in the absence of other sources of inflammation, has been previously 
correlated with increased risk of future cardiovascular events, including MI, peripheral 
vascular disease with intermittent claudication and stroke (Ridker, 2001). These data 
support the view that systemic CRP accurately reflects the number of vulnerable 
atherosclerotic plaques. Liuzzo et al. (Liuzzo et al., 1994) reported that patients with UA 
and elevated levels of CRP (>3 mg/dl) had higher rates of death, AMI and need for 
revascularization compared to patients without elevated levels. Of note, this increased risk 
may be evident as early as 14 days after presentation (Morrow et al., 1998). Importantly, 
the U.S. Centers for Disease Control and Prevention and the American Heart Association 
have both advocated the use of CRP as an adjunct to global risk prediction among those at 
intermediate risk for CAD (Pearson et al., 2003). Thus, among non-specific markers of 
inflammation, CRP is the most investigated and has widely been associated with an 
increased risk of future cardiovascular events both in primary and secondary prevention 
studies (Willerson et al., 2004; Ridker et al., 1997, 2001, 2005a, 2005b; Haverkate et al., 
1997). However, the association of CRP levels with angiographic coronary atherosclerotic 
burden is controversial, whereas its association with coronary instability has consistently 
been reported in several studies. 
More than 15 years ago, Mori et al. (Mori et al., 1995) reported that baseline CRP levels were 
associated with the severity of CAD, as determined by the Gensini score and this association 
remained significant even after adjustment for body-mass index, smoking history, 
hypertension, and total cholesterol. Subsequently, Tataru et al. (Tataru et al., 2000) found a 
correlation between CRP levels and the number of diseased vessels in patients with a 
previous history of MI. Zebrack et al. (Zebrack et al., 2002) enrolled 2.554 patients with 
angina but without AMI who underwent CAG (1.848 patients had CAD and 706 patients 
did not). CAD was quantified in 5 ways and combined for a CAD score and CRP was 
measured in all patients who were followed for up to 5 years for death or MI. Interestingly, 
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CRP correlated with the extent of CAD, but correlation coefficients were low (0.02 to 0.08). 
Of angiographic measures, the CAD score best predicted future events. CRP retained 
predictive value within each quintile of CAD score. CRP and CAD independently and 
additively contributed to the risk prediction: low CRP and lowest CAD score were 
associated with lowest risk, and high CRP and highest CAD score were associated with the 
highest risk, with a 10-fold difference between extremes (2.5% vs. 24%). In conclusion, they 
demonstrated that CRP correlated with extent of CAD, but the degree of correlation was 
low, however, both severity/extent of CAD and CRP were independent and additive 
predictors of risk. Azar et al. measured CRP levels in 98 patients with stable angina or an 
abnormal stress test who were referred for diagnostic CAG. They showed that the CRP level 
did not correlate with the extent and severity of coronary narrowing measured by 
angiography (Azar et al., 2000). In the acute setting of CAD, Niccoli et al. (Niccoli et al., 
2008)  studied 97 consecutive patients with UA undergoing CAG and CRP was measured by 
an ultrasensitive nephelometric method. Atherosclerotic disease severity and extent were 
assessed by angiography using the Bogaty score. No significant correlation was found 
between baseline CRP serum levels and angiographic measures of atherosclerotic disease 
severity and extent. In this study, the authors demonstrated that in patients with UA, CRP 
serum levels and coronary atherosclerosis are not correlated, but they were both 
independently associated with a worse outcome at 6-month follow-up. In UA patients, the 
association between atherosclerotic background and CRP may be altered by the increase in 
CRP associated with the acute phase response. On the other hand, in vitro studies suggest 
that the proatherogenic role of CRP is associated with very high levels of serum CRP (up to 
50 mg/L), much higher than that observed in patients with CAD or ACS (Devaraj et al., 
2003).  
Erren et al. (Erren et al., 1999) previously evaluated 147 patients undergoing semiquantitative 
CAG and they measured CRP, serum amyloid A (SAA), and the proinflammatory cytokine IL-
6; the active and total fractions of the anti-inflammatory cytokine transforming growth factor-
b (TGF-b); the macrophage activation marker neopterin; and the infection marker 
procalcitonin. Compared with 62 patients without either CAD or peripheral artery disease, 
57 patients with CAD but no peripheral artery disease showed greater median CRP and IL-6 
levels and a lower level of active-TGF-b. Moreover, CRP, IL-6, and neopterin levels showed 
a positive and the active TGF-b level a negative correlation with the extent of coronary 
atherosclerosis. Compared with these 57 patients with CAD alone, 15 patients with 
peripheral artery disease and CAD had higher median levels of SAA, IL-6, neopterin, and 
total TGF-b. However, these strong univariate associations of markers of inflammation and 
atherosclerosis were lost in multivariate analysis once age, sex, and HDL cholesterol or 
fibrinogen were taken into account. Taken together, these data suggest that increased 
plasma levels of CRP, SAA, IL-6, TGF-b, neopterin, and procalcitonin constitute an 
inflammatory signature of advanced atherosclerosis and are correlated with the extent of 
disease but do not provide discriminatory diagnostic power over and above established risk 
factors. Indeed, as previously mentioned, Lee et al. (Lee et al., 2006) reported on the 
associations between 3 plasma markers of low-gade inflammation, such as CRP, IL-6 and 
SAA protein and total homocysteine with CAD and death in a Canadian angiography 
cohort of 1.117 patients followed for 8.5 years. They found no significant association 
between elevated levels of these biomarkers and CAD (defined as the presence of any lesion 
with stenosis greater than 10%), but they did find significant independent associations of 
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elevated IL-6 (a key pro-inflammatory cytokine) and homocysteine levels with both CAD-
related and all-cause death. These findings do not support the hypotheses that these 
biomarkers play a causal role in atherogenesis. The importance of this study is that no 
previous studies have examined such associations in a large, prospective angiographic 
cohort in which CAD was defined using sensitive criteria. However, it is worth noting that 
when Lee et al. used the definition of CAD as the presence of any lesion of 50% stenosis 
(which was developed for assessing suitability for cardiac surgery or angioplasty), they 
observed significantly higher CRP and IL-6 levels in the CAD group (Lowe et al., 2005). 
On the other hand, several data suggest that CRP may be a marker of plaque activity 
(Liuzzo et al., 1994). In a previous report, Arroyo-Espliguero et al (Arroyo-Espliguero et al., 
2004) sought to assess whether CRP was an independent predictor of future cardiovascular 
events after adjustment for CAD severity and whether CRP levels correlate with number of 
angiographically complex coronary artery stenosis. They studied 825 consecutive anginal 
patients (700 with chronic stable angina and 125 with ACS without ST-segment elevation). 
The composite endpoint of non-fatal AMI, hospital admission with class IIIb UA and cardiac 
death was assessed at 1 year follow-up. CRP levels were higher in chronic stable angina 
patients with the combined end-point (p=0.03) after adjustment for number of diseased 
coronary arteries. CRP was also significantly higher in patients with ACS compared to 
stable patients (p=0.004) and correlated with number of complex angiographic stenoses 
(p=0.01). Interestingly, in this report, CRP levels predicted future cardiovascular events 
independently of CAD severity and correlated with number of angiographically complex 
coronary artery stenosis in patients with ACS, thus suggesting that CRP levels may be a 
marker of atheromatous plaque vulnerability and CAD activity. This concept was endorsed 
by studies showing that CRP levels correlate with cardiovascular risk in ACS patients, thus 
giving further support to the increasingly accepted hypothesis that CRP is not merely a 
marker of systemic inflammation but may also be a pathogenic mechanism in ACS (Yeh et 
al., 2001; Pasceri et al., 2000; Zwaka et al., 2001). Additionally, the relation of serum CRP 
concentrations with adverse cardiovascular events during follow-up in patients with stable 
angina also suggests that clinical “stability” does not always indicate atheromatous plaque 
stability (van der Wal et al., 1999). Geluk et al. (Geluk et al., 2008) recently evaluated the 
population based on the Prevention of Renal and Vascular Endstage Disease (PREVEND) 
study. Of note, 8.139 subjects without previous documented CAD were followed for the 
incidence of CAD and coronary events from 1997 to 2003. In the prospective PREVEND 
study of subjects without previous documented CAD, CRP levels at baseline were 
associated with angiographic characteristics and clinical consequences of plaque instability 
during follow-up. Because CRP was weakly correlated with angiographic plaque burden, it 
was suggested that CRP is stimulated not only by the extent of atherosclerosis but, 
importantly, by other factors. Indeed, they postulated that CRP is a measure of inflammed, 
unstable atherosclerotic plaque (both angiographically visible and occult), whereas 
angiography indicates the extent of visible stable and unstable occlusive plaque. The value 
of CRP in predicting future death or MI was apparent in all ranges of CAD severity. Those 
with extensive CAD were at relatively high risk of death or MI regardless of CRP levels. 
However, in the presence of a low to moderate risk angiogram (or even a normal 
angiogram), CRP became particularly useful in distinguishing patients at substantially 
lower versus higher risk for death or MI. A particularly high risk was observed in subjects 
with lower CAD scores but highly elevated CRP despite a lower prevalence of all traditional 
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CRP correlated with the extent of CAD, but correlation coefficients were low (0.02 to 0.08). 
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severity and extent. In this study, the authors demonstrated that in patients with UA, CRP 
serum levels and coronary atherosclerosis are not correlated, but they were both 
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association between atherosclerotic background and CRP may be altered by the increase in 
CRP associated with the acute phase response. On the other hand, in vitro studies suggest 
that the proatherogenic role of CRP is associated with very high levels of serum CRP (up to 
50 mg/L), much higher than that observed in patients with CAD or ACS (Devaraj et al., 
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6; the active and total fractions of the anti-inflammatory cytokine transforming growth factor-
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procalcitonin. Compared with 62 patients without either CAD or peripheral artery disease, 
57 patients with CAD but no peripheral artery disease showed greater median CRP and IL-6 
levels and a lower level of active-TGF-b. Moreover, CRP, IL-6, and neopterin levels showed 
a positive and the active TGF-b level a negative correlation with the extent of coronary 
atherosclerosis. Compared with these 57 patients with CAD alone, 15 patients with 
peripheral artery disease and CAD had higher median levels of SAA, IL-6, neopterin, and 
total TGF-b. However, these strong univariate associations of markers of inflammation and 
atherosclerosis were lost in multivariate analysis once age, sex, and HDL cholesterol or 
fibrinogen were taken into account. Taken together, these data suggest that increased 
plasma levels of CRP, SAA, IL-6, TGF-b, neopterin, and procalcitonin constitute an 
inflammatory signature of advanced atherosclerosis and are correlated with the extent of 
disease but do not provide discriminatory diagnostic power over and above established risk 
factors. Indeed, as previously mentioned, Lee et al. (Lee et al., 2006) reported on the 
associations between 3 plasma markers of low-gade inflammation, such as CRP, IL-6 and 
SAA protein and total homocysteine with CAD and death in a Canadian angiography 
cohort of 1.117 patients followed for 8.5 years. They found no significant association 
between elevated levels of these biomarkers and CAD (defined as the presence of any lesion 
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elevated IL-6 (a key pro-inflammatory cytokine) and homocysteine levels with both CAD-
related and all-cause death. These findings do not support the hypotheses that these 
biomarkers play a causal role in atherogenesis. The importance of this study is that no 
previous studies have examined such associations in a large, prospective angiographic 
cohort in which CAD was defined using sensitive criteria. However, it is worth noting that 
when Lee et al. used the definition of CAD as the presence of any lesion of 50% stenosis 
(which was developed for assessing suitability for cardiac surgery or angioplasty), they 
observed significantly higher CRP and IL-6 levels in the CAD group (Lowe et al., 2005). 
On the other hand, several data suggest that CRP may be a marker of plaque activity 
(Liuzzo et al., 1994). In a previous report, Arroyo-Espliguero et al (Arroyo-Espliguero et al., 
2004) sought to assess whether CRP was an independent predictor of future cardiovascular 
events after adjustment for CAD severity and whether CRP levels correlate with number of 
angiographically complex coronary artery stenosis. They studied 825 consecutive anginal 
patients (700 with chronic stable angina and 125 with ACS without ST-segment elevation). 
The composite endpoint of non-fatal AMI, hospital admission with class IIIb UA and cardiac 
death was assessed at 1 year follow-up. CRP levels were higher in chronic stable angina 
patients with the combined end-point (p=0.03) after adjustment for number of diseased 
coronary arteries. CRP was also significantly higher in patients with ACS compared to 
stable patients (p=0.004) and correlated with number of complex angiographic stenoses 
(p=0.01). Interestingly, in this report, CRP levels predicted future cardiovascular events 
independently of CAD severity and correlated with number of angiographically complex 
coronary artery stenosis in patients with ACS, thus suggesting that CRP levels may be a 
marker of atheromatous plaque vulnerability and CAD activity. This concept was endorsed 
by studies showing that CRP levels correlate with cardiovascular risk in ACS patients, thus 
giving further support to the increasingly accepted hypothesis that CRP is not merely a 
marker of systemic inflammation but may also be a pathogenic mechanism in ACS (Yeh et 
al., 2001; Pasceri et al., 2000; Zwaka et al., 2001). Additionally, the relation of serum CRP 
concentrations with adverse cardiovascular events during follow-up in patients with stable 
angina also suggests that clinical “stability” does not always indicate atheromatous plaque 
stability (van der Wal et al., 1999). Geluk et al. (Geluk et al., 2008) recently evaluated the 
population based on the Prevention of Renal and Vascular Endstage Disease (PREVEND) 
study. Of note, 8.139 subjects without previous documented CAD were followed for the 
incidence of CAD and coronary events from 1997 to 2003. In the prospective PREVEND 
study of subjects without previous documented CAD, CRP levels at baseline were 
associated with angiographic characteristics and clinical consequences of plaque instability 
during follow-up. Because CRP was weakly correlated with angiographic plaque burden, it 
was suggested that CRP is stimulated not only by the extent of atherosclerosis but, 
importantly, by other factors. Indeed, they postulated that CRP is a measure of inflammed, 
unstable atherosclerotic plaque (both angiographically visible and occult), whereas 
angiography indicates the extent of visible stable and unstable occlusive plaque. The value 
of CRP in predicting future death or MI was apparent in all ranges of CAD severity. Those 
with extensive CAD were at relatively high risk of death or MI regardless of CRP levels. 
However, in the presence of a low to moderate risk angiogram (or even a normal 
angiogram), CRP became particularly useful in distinguishing patients at substantially 
lower versus higher risk for death or MI. A particularly high risk was observed in subjects 
with lower CAD scores but highly elevated CRP despite a lower prevalence of all traditional 
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risk factors in these patients with low/moderate CAD scores (i.e., lower cholesterol levels, 
absence of diabetes, hypertension). Because these patients may be considered to have 
insignificant CAD and hence to be at low risk for MI, less aggressive medical therapy may 
be offered to them in comparison to patients with more extensive CAD, thus possibly 
underestimating their cardiovascular risk (Pearson et al., 2003; Lowe, 2005; Beaglehole & 
Magnus, 2002; Greenland & O’Malley, 2005). 
With the introduction of IVUS, new important data regarding CRP levels and CAD burden 
and, especially, plaque morphology have been provided, shedding some lights on CRP 
diagnostic and prognostic role in CAD patients. Sano et al. (Sano et al., 2003) investigated 
the relation between lesion morphology as seen under pre-intervention IVUS and CRP in 90 
consecutive patients presenting with AMI. Patients were divided into an elevated CRP 
group (3 mg/L) or a normal CRP group on the basis of serum CRP levels. There were no 
differences in patient characteristics or angiographic findings. Interestingly, they observed 
significantly more plaque rupture in the elevated CRP group than in the normal CRP group 
(70% versus 43%, p=0.01). A multivariate logistic regression model revealed that the 
presence of ruptured plaque alone correlated with elevation of serum CRP (p=0.02; odds 
ratio, 3.35; 95% CI, 1.22 to 9.18). These data further suggest that in the setting of AMI, 
elevated CRP levels may reflect the inflammatory activity of a ruptured plaque. 
Additionally, Sano et al. (Sano et al., 2003) found that in the normal CRP group, 44% of 
analyzed lesions were non–rupture-type lesions. Indeed, several pathological reports 
showed that AMI may be caused not only by plaque rupture but also by plaque erosion, 
which is a major substrate for coronary thrombosis in AMI (van der Wal et al., 1994; Farb et 
al., 1996; Arbustini et al., 1999). A more recent IVUS study (Otake et al., 2008) investigated 
the relation between plasma CRP and adiponectin and coronary plaque components in 
patients with ACS. Ninety-three culprit plaques (ACS n=50, non-ACS n=43) and 56 
nonculprit plaques (ACS n=28, non-ACS n=28) were analyzed using virtual histology (VH)-
IVUS to examine relations among plasma CRP, adiponectin, and ratios of each coronary 
plaque component. Plasma adiponectin was significantly lower and plasma CRP was 
significantly higher in patients with than without ACS. Notably, culprit plaques in patients 
with ACS had greater amounts of necrotic core plaque than those in patients without ACS. 
There was an inverse relation between CRP and adiponectin with regard to necrotic core 
ratio in both culprit and nonculprit lesions in patients with ACS, but not those without ACS. 
Thus, once again, increased plasma CRP levels might be related to the progression of ACS. 
Zhang et al. (Zhang et al., 2006) performed IVUS examination in 152 patients with 
confirmed CAD before percutaneous coronary intervention and measured CRP levels in all 
patients. Unstable and ruptured plaque were found more frequently in patients with AMI 
and UA. The levels of plasma CRP were higher in ruptured plaque group. CRP >8.94 mg/L 
was used to predict ruptured plaque with a ROC curve area of 0.76 (95% confidence 
interval, 67.0%-85.8%), sensitivity of 71.8%, specificity of 77.0% and accuracy of 69.2% 
(p<0.01). Chen et al. (Chen et al., 2007) aimed at investigating whether combined IVUS and 
measurements of serum inflammatory biomarkers could predict coronary plaque ruptures 
in patients with angina pectoris. The study population consisted of 20 patients with stable 
angina and 40 patients with UA. IVUS was performed in the 2 groups to measure intima-
media thickness, the plaque acoustic density of the common carotid arteries, and the flow-
mediated dilation of the brachial arteries. Serum lipid profile and inflammatory biomarkers 
were measured in all patients. Of 139 coronary artery plaques identified by IVUS, 48 
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plaques (9 in stable angina and 39 in UA) developed ruptures. Among measured 
parameters, they found that the values of carotid intima-media thickness, coronary external 
elastic membrane area, plaque area, plaque burden, plaque eccentric index and remodeling 
index, and serum CRP were significantly higher in UA patients than in stable angina 
patients (p<0.05 to 0.01). Additionally, they found that soluble intercellular adhesion 
molecule-1, and soluble vascular cell adhesion molecule-1 were significantly higher in UA 
patients (p<0.05). However, of these parameters, carotid intima-media thickness, serum 
CRP, and the coronary remodeling index, only, were found to be significant predictors of 
coronary plaque rupture, with odds ratios of 9.51 (95% confidence interval 1.29 to 21.81), 
3.02 (95% confidence interval 1.01 to 7.65), and 0.01 (95% confidence interval 0.00 to 0.34), 
respectively. Taken together, these data suggest the intriguing possibility that the 
association between CRP and risk of cardiovascular events is mediated by unstable plaque 
phenotype, raising the possibility that CRP is not only a marker of vascular inflammation 
but also of plaque disruption. However, Park et al. (Park et al., 2010) recently enrolled 188 
patients who underwent 3-vessel VH-IVUS with peripheral blood sampling, including CRP 
levels measurements. VH-TCFA was defined as a necrotic core >10% of plaque area in the 
presence of >40% plaque burden. There were 38 patients with ruptured plaque and 150 
patients without (107 patients with VH-TCFA, 43 patients without VH-TCFA) in culprit/target 
lesions. In the present study there were no significant differences in the CRP level between 
patients with and without VH-TCFA in the culprit/target lesions. However, it is worth 
mentioning that when lesions are analyzed post-rupture, after the necrotic core may have 
embolized, they most often appear “dark-green” and will be classified as fibrotic plaque rather 
than necrotic core in VH-IVUS analysis, and have a reduced calculated relative size of the 
necrotic core. Therefore, when the relationships between each plaque characteristic and 
plasma biomarker levels, including CRP, were evaluated in the study performed by Park et al. 
(Park et al., 2010), ruptured plaques were excluded to avoid the possibility of incorrect VH-
IVUS interpretation and this may partially explain the different results between studies. 
Takano et al. (Takano et al., 2005) have evaluated, using coronary angioscopy, changes of 
ruptured plaques in non culprit lesions in living patients and ability of CRP to predict 
disease activity of the plaque ruptures, also shown in other previous studies (Ishibashi et al., 
2002). They have identified by angioscopy 48 thrombi in 50 ruptured coronary plaques in 
nonculprit lesions in 30 patients with mean angioscopic follow-up period was 13 +/- 9 
months. They have shown that ruptured plaques in nonculprit lesions tend to heal slowly 
with a progression of angiographic stenosis and the serum CRP level in patients with healed 
plaques was lower than that in those without healed plaques, although  in patients with 
healed plaques did not significantly decrease from baseline to follow-up. Of note, at 
univariate logistic regression, serum CRP levels at follow-up were predictors of healing in 
nonculprit ruptured plaques, while, a multivariate logistic regression analysis, the authors 
showed that serum CRP levels at follow-up were not independent predictors of plaque 
healing. Thus, the power of serum levels of CRP in predicting disease activity should also be 
confirmed. Furthermore, the same authors have previously reported that statin therapy 
reduces the serum CRP level and angioscopic complexity of the plaques (the existence of 
the thrombus and the irregularity of the plaque) in nonculprit lesions (Takano et al., 2003). 
In this study, data  from univariate logistic regression analyses indicated that both statin 
therapy and serum CRP level at follow-up are considered predictors of healing in 
nonculprit ruptured plaques. However, a multivariate logistic regression analysis showed 
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risk factors in these patients with low/moderate CAD scores (i.e., lower cholesterol levels, 
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patients. Unstable and ruptured plaque were found more frequently in patients with AMI 
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(p<0.01). Chen et al. (Chen et al., 2007) aimed at investigating whether combined IVUS and 
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plaques (9 in stable angina and 39 in UA) developed ruptures. Among measured 
parameters, they found that the values of carotid intima-media thickness, coronary external 
elastic membrane area, plaque area, plaque burden, plaque eccentric index and remodeling 
index, and serum CRP were significantly higher in UA patients than in stable angina 
patients (p<0.05 to 0.01). Additionally, they found that soluble intercellular adhesion 
molecule-1, and soluble vascular cell adhesion molecule-1 were significantly higher in UA 
patients (p<0.05). However, of these parameters, carotid intima-media thickness, serum 
CRP, and the coronary remodeling index, only, were found to be significant predictors of 
coronary plaque rupture, with odds ratios of 9.51 (95% confidence interval 1.29 to 21.81), 
3.02 (95% confidence interval 1.01 to 7.65), and 0.01 (95% confidence interval 0.00 to 0.34), 
respectively. Taken together, these data suggest the intriguing possibility that the 
association between CRP and risk of cardiovascular events is mediated by unstable plaque 
phenotype, raising the possibility that CRP is not only a marker of vascular inflammation 
but also of plaque disruption. However, Park et al. (Park et al., 2010) recently enrolled 188 
patients who underwent 3-vessel VH-IVUS with peripheral blood sampling, including CRP 
levels measurements. VH-TCFA was defined as a necrotic core >10% of plaque area in the 
presence of >40% plaque burden. There were 38 patients with ruptured plaque and 150 
patients without (107 patients with VH-TCFA, 43 patients without VH-TCFA) in culprit/target 
lesions. In the present study there were no significant differences in the CRP level between 
patients with and without VH-TCFA in the culprit/target lesions. However, it is worth 
mentioning that when lesions are analyzed post-rupture, after the necrotic core may have 
embolized, they most often appear “dark-green” and will be classified as fibrotic plaque rather 
than necrotic core in VH-IVUS analysis, and have a reduced calculated relative size of the 
necrotic core. Therefore, when the relationships between each plaque characteristic and 
plasma biomarker levels, including CRP, were evaluated in the study performed by Park et al. 
(Park et al., 2010), ruptured plaques were excluded to avoid the possibility of incorrect VH-
IVUS interpretation and this may partially explain the different results between studies. 
Takano et al. (Takano et al., 2005) have evaluated, using coronary angioscopy, changes of 
ruptured plaques in non culprit lesions in living patients and ability of CRP to predict 
disease activity of the plaque ruptures, also shown in other previous studies (Ishibashi et al., 
2002). They have identified by angioscopy 48 thrombi in 50 ruptured coronary plaques in 
nonculprit lesions in 30 patients with mean angioscopic follow-up period was 13 +/- 9 
months. They have shown that ruptured plaques in nonculprit lesions tend to heal slowly 
with a progression of angiographic stenosis and the serum CRP level in patients with healed 
plaques was lower than that in those without healed plaques, although  in patients with 
healed plaques did not significantly decrease from baseline to follow-up. Of note, at 
univariate logistic regression, serum CRP levels at follow-up were predictors of healing in 
nonculprit ruptured plaques, while, a multivariate logistic regression analysis, the authors 
showed that serum CRP levels at follow-up were not independent predictors of plaque 
healing. Thus, the power of serum levels of CRP in predicting disease activity should also be 
confirmed. Furthermore, the same authors have previously reported that statin therapy 
reduces the serum CRP level and angioscopic complexity of the plaques (the existence of 
the thrombus and the irregularity of the plaque) in nonculprit lesions (Takano et al., 2003). 
In this study, data  from univariate logistic regression analyses indicated that both statin 
therapy and serum CRP level at follow-up are considered predictors of healing in 
nonculprit ruptured plaques. However, a multivariate logistic regression analysis showed 
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that neither statin therapy nor serum CRP level at follow-up is an independent predictor of 
plaque healing. These findings, however, should be confirmed in larger study populations. 
A study by Tanaka et al. (Tanaka et al., 2008) enrolled 43 consecutive ACS patients (with 
or without ST-segment elevation) undergoing OCT assessment and presenting with a 
ruptured plaque at the culprit site. Patients were divided into a rest group and an exertion 
group on the basis of their activities at the onset of ACS. Of interest, the thickness of the 
broken fibrous cap correlated positively with activity at the onset of ACS. The culprit 
plaque ruptured at the shoulder more frequently in the exertion group than in the rest 
group (rest 57% versus exertion 93%, p=0.014). The thickness of the broken fibrous cap in 
the exertion group was significantly higher than in the rest-onset group (rest onset: 50 µm 
[interquartile median 15 µm]; exertion: 90 µm [interquartile median 65 µm], p<0.01). These 
data suggest a thin-cap fibroatheroma (TCFA) is a lesion predisposed to rupture both at 
rest and during the patient’s day-to day activity, and some plaque rupture may occur in 
thick fibrous caps depending on exertion levels. Moreover, this study demonstrated also 
an inverse relationship between fibrous cap thickness and serum levels of CRP (r=-0.31, 
p<0.01). Li et al. (Li et al., 2010) investigated in stable and unstable patients the relationship 
between plaque morphology assessed by OCT and serum levels of several inflammatory 
biomarkers, such as CRP, IL-18, TNF-α, white blood cell count.  This study demonstrated 
that the plasma levels of inflammatory factors and white blood cell count were correlated 
inversely with fibrous cap thickness (r=0.775 for CRP, r=-0.593 for IL-18, r=-0.60 for TNF-α, 
and r=-0.356 for white blood cell count). Patients with TCFA (cap thickness less than 65 
micron) had higher plasma levels of inflammatory factors as well as WBC counts than those 
with thicker fibrous caps. ROC curves for CRP, IL-18, TNF-α and white blood cell count, 
which displayed the capability of prediction about TCFA, showed the area under the curves 
were 0.95, 0.86, 0.79 and 0.70 (p<0.05), respectively. Meanwhile, in multivariate logistic 
regression analysis, CRP was the only significant independent predictor of TCFA. Therefore, 
although IL-18, TNF-α and white blood cell count could also show similar characteristics, 
their predictive value was weak compared with CRP. 
Kashiwagi et al. (Kashiwagi et al., 2009) evaluated the relationship between coronary 
arterial remodelling assessed by IVUS, fibrous cap thickness assessed by OCT and CRP 
concentrations in patients with ACS. Positive remodelling was defined as 
remodelling>1.05, intermediate remodelling as remodelling=0.95–1.05, and negative 
remodelling as remodelling<0.95. On the basis of the IVUS findings, patients were 
divided into 2 groups (positive remodelling group, intermediate remodelling/negative 
remodelling group). Lipid-rich plaques and TCFA were more frequent in the positive 
remodelling group than in the other group and intermediate remodelling inversely 
correlated with the thickness of fibrous cap. Levels of CRP were higher in the positive 
remodelling group than in the other group and were higher in patients with a thin fibrous 
cap, suggesting that the inflammatory process may simultaneously contribute to both 
plaque growth and plaque instability.  
Kitabata et al. (Kitabata et al., 2010) investigated in stable and ACS patients the relationship 
between the presence of microchannels in coronary plaque  assessed by OCT and serum 
CRP levels. Microchannel was defined as a no-signal tubuloluminal structure on the cross-
sectional OCT image. Microchannels were found in 24 (38%) of the 63 enrolled patients and 
patients were divided into 2 groups according to the presence or absence of microchannels. 
The frequency of plaque rupture tended to be greater in the microchannel group (50% vs 
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28%, p=0.11). The thickness of the fibrous cap (median 60 vs 100 micron, p=0.001) was 
significantly lower in the patients with microchannels, and significant differences were 
found in the frequency of thin-cap fibroatheroma (54% vs 21%, p=0.012) and positive 
remodeling (67% vs 36%, p=0.02) between the 2 groups. CRP levels in the microchannel 
group were significantly greater than those in the no-microchannel group (median 0.27 vs 
0.13 mg/dl, p=0.015). Moreover, increased microchannel counts were associated with 
greater high-sensitivity CRP levels (p=0.01). Takarada et al. (Takarada et al., 2010) enrolled 
82 Non-ST-elevation-ACS patients undergoing OCT assessment of culprit lesion at baseline 
and after 9 months, evaluating morphological changes of coronary plaque and changes in 
serum levels of CRP. Of interest, the change in fibrous cap thickness had a significant 
positive correlation with changes in CRP levels (r=0.44, p<0.01). A recently published study 
by Ferrante et al. (Ferrante et al., 2010) enrolled 25 consecutive ACS patients undergoing 
percutaneous coronary intervention and OCT assessment, evaluating the relationship 
between plaque morphology and serum levels of myeloperoxidase (MPO) and CRP. OCT 
classified the culprit lesion as ruptured in 18 (72%) or eroded in 7 patients (28%) and 
detected intraluminal thrombus in 89% of ruptured plaques and 100% of eroded plaques. 
CRP levels did not differ significantly between patients with an eroded plaque and those 
with a ruptured plaque (median, 11.3 mg/L; 25th to 75th percentile, 1.3 to 28.5 versus 
median, 3.9 mg/L; 25th to 75th percentile, 1.3 to 17.8; p=0.76, respectively). On the contrary, 
a study by Bouki et al. (Bouki et al., 2010)  showed that higher levels of serum CRP and IL-18 
were found in patients with plaque rupture vs. those with no plaque rupture (median value: 
19.2mg/L vs. 1.6mg/L, p<0.001 and 219.5pg/ml versus 127.5pg/ml, p=0.001 respectively), 
and TCFA versus those without TCFA (median value: 15.2mg/L versus 1.6mg/L, p=0.004 
and 209.0pg/ml versus 153.2pg/ml, p=0.03, respectively). Moreover, serum CRP was the 
only independent predictor of plaque rupture (p=0.02, odds ratio 1.1, 95% confidence 
interval 1.0 to 1.2), and a cut-off value of CRP>4.5mg/L could detect ruptured plaque with a 
sensitivity of 91.7% and a specificity of 77.8%. Taken together, these data show that the 
association of CRP levels with coronary atherosclerotic burden is still controversial, whereas 
its association with coronary instability has consistently been reported in several studies, by 
using different intracoronary imaging modalities. Although initially considered only a 
marker of inflammation, CRP itself has been shown to possess proinflammatory and pro-
atherogenic properties. It stimulates endothelial cells to express adhesion molecules and 
secrete cytokines (Pasceri et al., 2000, 2001) and it decreases the expression of endothelial 
nitric oxide synthase (Verma et al., 2002; Venugopal et al, 2002). CRP accumulates in 
macrophage-rich regions of nascent atherosclerotic lesions and activates the macrophages to 
express cytokines and tissue factor, while enhancing macrophage uptake of LDL (Zwaka et 
al., 2001). It also amplifies pro-inflammatory effects of several other mediators including 
endotoxin (Nakogomi et al., 2000; Burke et al., 2002). These biological properties exerted by 
CRP may be held responsible for the detrimental role of this acute-phase reactant which 
may participate in the unstable patter of CAD. 
To date, there are no widely accepted and established markers of inflammation for 
cardiovascular disease and no known therapeutic measures to modulate coronary 
inflammation. CRP is currently the best marker of inflammation, and in addition to weight 
loss, exercise, and smoking cessation, statins are the best therapeutic option to modulate 
inflammation. New avenues for diagnosing and treating coronary inflammation should be 
investigated in larger and randomized trials. 
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plaque healing. These findings, however, should be confirmed in larger study populations. 
A study by Tanaka et al. (Tanaka et al., 2008) enrolled 43 consecutive ACS patients (with 
or without ST-segment elevation) undergoing OCT assessment and presenting with a 
ruptured plaque at the culprit site. Patients were divided into a rest group and an exertion 
group on the basis of their activities at the onset of ACS. Of interest, the thickness of the 
broken fibrous cap correlated positively with activity at the onset of ACS. The culprit 
plaque ruptured at the shoulder more frequently in the exertion group than in the rest 
group (rest 57% versus exertion 93%, p=0.014). The thickness of the broken fibrous cap in 
the exertion group was significantly higher than in the rest-onset group (rest onset: 50 µm 
[interquartile median 15 µm]; exertion: 90 µm [interquartile median 65 µm], p<0.01). These 
data suggest a thin-cap fibroatheroma (TCFA) is a lesion predisposed to rupture both at 
rest and during the patient’s day-to day activity, and some plaque rupture may occur in 
thick fibrous caps depending on exertion levels. Moreover, this study demonstrated also 
an inverse relationship between fibrous cap thickness and serum levels of CRP (r=-0.31, 
p<0.01). Li et al. (Li et al., 2010) investigated in stable and unstable patients the relationship 
between plaque morphology assessed by OCT and serum levels of several inflammatory 
biomarkers, such as CRP, IL-18, TNF-α, white blood cell count.  This study demonstrated 
that the plasma levels of inflammatory factors and white blood cell count were correlated 
inversely with fibrous cap thickness (r=0.775 for CRP, r=-0.593 for IL-18, r=-0.60 for TNF-α, 
and r=-0.356 for white blood cell count). Patients with TCFA (cap thickness less than 65 
micron) had higher plasma levels of inflammatory factors as well as WBC counts than those 
with thicker fibrous caps. ROC curves for CRP, IL-18, TNF-α and white blood cell count, 
which displayed the capability of prediction about TCFA, showed the area under the curves 
were 0.95, 0.86, 0.79 and 0.70 (p<0.05), respectively. Meanwhile, in multivariate logistic 
regression analysis, CRP was the only significant independent predictor of TCFA. Therefore, 
although IL-18, TNF-α and white blood cell count could also show similar characteristics, 
their predictive value was weak compared with CRP. 
Kashiwagi et al. (Kashiwagi et al., 2009) evaluated the relationship between coronary 
arterial remodelling assessed by IVUS, fibrous cap thickness assessed by OCT and CRP 
concentrations in patients with ACS. Positive remodelling was defined as 
remodelling>1.05, intermediate remodelling as remodelling=0.95–1.05, and negative 
remodelling as remodelling<0.95. On the basis of the IVUS findings, patients were 
divided into 2 groups (positive remodelling group, intermediate remodelling/negative 
remodelling group). Lipid-rich plaques and TCFA were more frequent in the positive 
remodelling group than in the other group and intermediate remodelling inversely 
correlated with the thickness of fibrous cap. Levels of CRP were higher in the positive 
remodelling group than in the other group and were higher in patients with a thin fibrous 
cap, suggesting that the inflammatory process may simultaneously contribute to both 
plaque growth and plaque instability.  
Kitabata et al. (Kitabata et al., 2010) investigated in stable and ACS patients the relationship 
between the presence of microchannels in coronary plaque  assessed by OCT and serum 
CRP levels. Microchannel was defined as a no-signal tubuloluminal structure on the cross-
sectional OCT image. Microchannels were found in 24 (38%) of the 63 enrolled patients and 
patients were divided into 2 groups according to the presence or absence of microchannels. 
The frequency of plaque rupture tended to be greater in the microchannel group (50% vs 
Biomarkers and Coronary Atherosclerotic Burden and Activity as 
Assessed by Coronary Angiography and Intra-Coronary Imaging Modalities 
 
383 
28%, p=0.11). The thickness of the fibrous cap (median 60 vs 100 micron, p=0.001) was 
significantly lower in the patients with microchannels, and significant differences were 
found in the frequency of thin-cap fibroatheroma (54% vs 21%, p=0.012) and positive 
remodeling (67% vs 36%, p=0.02) between the 2 groups. CRP levels in the microchannel 
group were significantly greater than those in the no-microchannel group (median 0.27 vs 
0.13 mg/dl, p=0.015). Moreover, increased microchannel counts were associated with 
greater high-sensitivity CRP levels (p=0.01). Takarada et al. (Takarada et al., 2010) enrolled 
82 Non-ST-elevation-ACS patients undergoing OCT assessment of culprit lesion at baseline 
and after 9 months, evaluating morphological changes of coronary plaque and changes in 
serum levels of CRP. Of interest, the change in fibrous cap thickness had a significant 
positive correlation with changes in CRP levels (r=0.44, p<0.01). A recently published study 
by Ferrante et al. (Ferrante et al., 2010) enrolled 25 consecutive ACS patients undergoing 
percutaneous coronary intervention and OCT assessment, evaluating the relationship 
between plaque morphology and serum levels of myeloperoxidase (MPO) and CRP. OCT 
classified the culprit lesion as ruptured in 18 (72%) or eroded in 7 patients (28%) and 
detected intraluminal thrombus in 89% of ruptured plaques and 100% of eroded plaques. 
CRP levels did not differ significantly between patients with an eroded plaque and those 
with a ruptured plaque (median, 11.3 mg/L; 25th to 75th percentile, 1.3 to 28.5 versus 
median, 3.9 mg/L; 25th to 75th percentile, 1.3 to 17.8; p=0.76, respectively). On the contrary, 
a study by Bouki et al. (Bouki et al., 2010)  showed that higher levels of serum CRP and IL-18 
were found in patients with plaque rupture vs. those with no plaque rupture (median value: 
19.2mg/L vs. 1.6mg/L, p<0.001 and 219.5pg/ml versus 127.5pg/ml, p=0.001 respectively), 
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using different intracoronary imaging modalities. Although initially considered only a 
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inflammation. CRP is currently the best marker of inflammation, and in addition to weight 
loss, exercise, and smoking cessation, statins are the best therapeutic option to modulate 
inflammation. New avenues for diagnosing and treating coronary inflammation should be 
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With improved understanding of the critical role of inflammation in atherothrombosis, 
attention has been focused on the circulating markers of inflammation, including fibrinogen 
(Ross, 1993; 1999; Lind, 2003). Evidence has been accumulated from several prospective 
studies that showed that high levels of fibrinogen were associated with an increased risk of 
coronary, cerebral and peripheral disease (Maresca et al., 1999; Danesh et al., 2004; Tamam 
et al., 2005). In a prospective study, Espinola-Klein et al. (Espinola-Klein et al. 2007) enrolled 
720 patients preceding CAG. Patients were compared with regard to atherosclerotic burden 
and classified as follows: no clinically significant stenosis (n=57, 7.9%), CAD only (n=362, 
50.3%), CAD with peripheral atherosclerosis (=multi-vascular atherosclerosis, n=301, 41.8%). 
They found a significant association between elevation of CRP and atherosclerotic burden 
(control: 2.6 (1.4–6.8) mg/l; CAD: 4.5 (2.1–12.1) mg/l; multi-vascular: 5.2 (2.0–15.6) mg/l, 
p<0.001). Results were similar with regard to IL-6 according to the extent of atherosclerosis 
(control: 7.8 (4.0–13.2) ng/ml; CAD: 11.4 (5.2–22.8) ng/ml; multi-vascular: 12.5 (5.8–
24.5) ng/ml, p<0.001). The strongest association was registered, indeed, between elevation 
of fibrinogen and extent of atherosclerosis (control: 296.0 (256.0–326.5) mg/dl; CAD: 329.0 
(281.8–399.3) mg/dl; multi-vascular: 351.0 (289.5–434.5) mg/dl, p<0.0001). Additionally, 
follow-up data after a median of 6.5 years were available in 719 patients (99.9%), and 75 
patients (10.4%) died from cardiovascular causes. Presence of multi-vascular atherosclerosis, 
elevation of IL-18 and elevation of fibrinogen were independently related to cardiovascular 
death in a fully adjusted model Hazard ratio (95% confidence interval) 2.0 (1.2-3.5) for 
presence of multi-vascular atherosclerosis (p<0.01), 2.2 (1.2-3.9) for high fibrinogen (p<0.01) 
and 2.8 (1.6-4.9) for high IL-18 (p<0.0001). Fibrinogen was achieved as independent 
predictor for both, mortality and atherosclerotic burden, whereas IL-18 was not related to 
atherosclerotic burden. These data suggest that fibrinogen was the only inflammatory 
marker with an independent association to the extent of atherosclerosis in the arterial vessel 
three. Previous investigations found also a strong interdependence between high serum 
fibrinogen levels and severe peripheral occlusive disease, indicating advanced 
atherosclerosis (Wattanakit et al., 2005). Presumably, the predictive value of high fibrinogen 
level is caused by the association to high atherosclerotic burden which is predictive for a 
worse prognosis itself.  Concordantly, Hoffmeister et al. (Hoffmeister et al., 2001) previously 
conducted a case-control study to assess the association between various markers of 
inflammation and the presence and severity of chronic stable CAD. They included 312 
clinically stable patients with angiographically documented CAD, and the severity of CAD 
was evaluated by 3 coronary scoring systems: the clinical 1- to 3-vessel disease score, the 
American Heart Association extension score (1 to 15 segments), and the Gensini score. 
Fibrinogen levels were highly significantly elevated (p<0.005) in patients with stable CAD 
compared with controls. After multivariable adjustment by means of logistic regression 
analysis, the association between CAD and fibrinogen remained substantial. However, no 
association between fibrinogen levels and any of the coronary scores applied was found. 
Finally, Memon et al. (Memon et al., 2006) measured plasma fibrinogen levels in 138 patients 
with angiographically assessed CAD and in 183 healthy subjects matched according to age 
and gender. According to the number of significantly stenosed (>or=50%) vessels, the 
patients were classified in four groups: those without stenosis (0-vessel disease) and those 
with 1, 2 or 3-vessel disease. Fibrinogen levels were significantly higher in patients than in 
controls (p<0.001). Although fibrinogen levels tended to increase with the number of 
stenotic vessels, the differences were not statistical significant.  
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Taken together these data suggest that fibrinogen can be discussed as a serological marker 
of high atherosclerotic burden within arterial vessel tree and may be a screening marker to 
identify patients that should be evaluated carefully for atherosclerotic manifestations. 
3.3 Eosinophil cationic protein 
Leukocyte recruitment and expression of proinflammatory cytokines characterize all steps 
of atherothrombosis (Libby & Theroux, 2005). Recent observations suggest that eosinophils 
may play a role in coronary atherosclerosis. Indeed, prospective studies have consistently 
shown an association between eosinophil count and increased risk for future cardiovascular 
events (Prentice  et al., 1982; Lee et al., 2001). Furthermore, eotaxin, an eosinophil-specific 
chemoattractant, is overexpressed in human atherosclerotic lesions (Haley et al., 2000) and 
patients with CAD show higher circulating levels of eotaxin as compared to healthy controls 
(Economou et al., 2001; Emanuele et al., 2006). Accordingly, a nonconservative 
polymorphism in the eotaxin gene (Zee et al., 2004) together with sequence variants 
affecting eosinophil count (Gudbjartsson et al., 2009) have recently been associated with an 
increased risk of myocardial infarction. Eosinophil cationic protein (ECP) is a zinc-
containing, highly cationic protein, stored in the peroxidase-positive and negative 
eosinophil granules which is secreted through priming by various triggers, such as 
immunoglobulins and complement components (Venge et al., 1999). Several studies have 
shown that the measurement of ECP in most biological fluids may be used as a marker of 
eosinophil activity and turnover, and that increased ECP serum levels are related to the 
presence, activity and severity of asthma, atopic disorders, and other immune diseases, such 
as rheumatoid arthritis, psoriasis, and adult celiac disease (Hällgren et al., 1991). In this 
regard, the role of ECP in CAD has been recently assessed (Niccoli et al., 2010). One-
hundred and ninety-eight consecutive anginal patients with angiographic evidence of CAD 
(stable angina or non-ST-elevation-ACS), or with angiographically normal coronary arteries 
were enrolled. The severity of CAD was graded according to Bogaty’s score and coronary 
lesion morphology was defined as smooth or complex. Baseline ECP and high sensitivity 
CRP were measured in all patients. ECP levels were significantly higher in stable angina 
patients (p<0.001) and non-ST elevation-ACS (p=0.016) compared to patients with normal 
coronary arteries, without significant difference between stable and unstable patients 
(p=0.45). Additionally, CRP levels were significantly higher in unstable patients compared 
to stable patients (p=0.03) and normal coronary arteries patients (p<0.001), without 
significant difference between stable and normal coronary arteries patients (p=0.20). The 
addition of ECP to main cardiovascular risk factors improved the area under the curve from 
0.88 to 0.92, p=0.007 for the angiographic diagnosis of CAD; further addition of CRP 
increased the area to 0.94, p=0.014. At multiple linear regression analysis, ECP levels 
independently predicted CAD severity (p=0.001), whereas CRP levels independently 
predicted lesion complexity (p=0.01). Taken together, these data suggest that ECP is a 
marker of CAD and that different inflammatory biomarkers reflect different phases of 
atherosclerotic plaque evolution (Niccoli et al., 2010). Further studies should address the 
role of ECP in CAD on larger study populations. 
3.4 Myeloperoxidase  
MPO is a member of the peroxidise superfamily that is predominantly found in neutrophils, 
monocytes and tissue macrophages and is released upon their activation as a response to 
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various stimuli (Nicholls et al., 2005). The enzyme is part of an innate host defence that acts 
on its substrate hydrogen peroxide of various sources augmenting its oxidative potential by 
producing potent oxidative species capable of modifying various cellular components by 
chlorination, nitration and cross-linking (Podrez et al., 2000; Heinecke et al., 2003). 
Demonstrations that MPO and its oxidation products are enriched within human atheroma 
(Daugherty et al., 2004) has increased interest in this enzyme in directions such as its 
participation in the promotion of atherosclerosis (Hazen et al., 1997), destabilization of 
atherosclerotic plaque (Sugiyama et al., 2001, 2004; Naruko et al., 2002) and in the possibility 
that MPO can serve as a biomarker to predict future adverse events in patients with CAD 
(Baldus et al., 2003; Brennan et al., 2003). Clinical studies have shown that plasma levels of 
MPO are increased in patients with stable CAD (Zhang et al., 2001) , ACS (Baldus et al., 
2003; Brennan et al., 2003), and ST-segment elevation AMI (Mocatta et al., 2007; Khan et al., 
2007). Other studies have proven that neutrophils, the main source of MPO release, are 
activated in ACS; however, their activation has not been linked with ischaemia/reperfusion 
per se (Biasucci et al., 1996). Furthermore, some observational studies have shown that 
baseline MPO plasma levels are predictive of future adverse coronary events in patients 
with acute chest pain (Brennan et al., 2003) or ACS (Baldus et al., 2003; Cavusoglu et al., 
2007) regardless of troponin levels.  
Ndrepepa et al. (Ndrepepa et al., 2008) recently conducted a case–control study in which 874 
patients with angiographically proven CAD were included. Cases included 680 patients 
with CAD (382 patients with stable CAD, 107 patients with non-ST-segment elevation-ACS 
and 191 patients with ST-segment elevation AMI), while controls included 194 subjects with 
normal coronary angiograms. MPO was measured using an enzyme immunoassay before 
angiography and heparin administration. MPO levels were significantly higher in cases as 
compared to controls (p<0.001). MPO levels were significantly higher in patients with AMI 
as compared to patients with stable CAD and with non-ST-segment elevation-ACS 
(p<0.0001). Elevated MPO level was associated with ACS with an area under receiver 
operating characteristic curve of 0.731 (95% confidence interval 0.692–0.770; p<0.001). 
Independent correlates of MPO level were ACS (p<0.001), CRP (p=0.007), creatinine 
(p=0.026), left ventricular ejection fraction (p=0.027, negative association) and smoking 
(p=0.028). Taken together, these data suggest that MPO level is elevated in patients with 
CAD and higher levels of MPO may be found with progression of CAD from stable CAD to 
non-ST-segment elevation ACS and to AMI. In a recent study, Wainstein et al. (Wainstein et 
al., 2010) have demonstrated that, in stable CAD, there was no association between MPO 
polymorphism and CAD severity, although a relationship was observed between plasma 
MPO levels and extent of CAD. de Azevedo et al. (de Azevedo et al., 2011) recently tested 
the hypothesis that MPO levels are higher in ACS patients with a greater extent of 
angiographic coronary involvement, by performing a cross-sectional study, examining high 
risk ACS patients who underwent CAG within 72 hours of the onset of symptoms and 
measuring their plasma MPO levels after sheath insertion. Gensini score was used to 
evaluate angiographic severity of CAD in 48 patients. Spearman’s correlation coefficient did 
not show a significant association between MPO levels and Gensini scores (r=0.2; p=0.177). 
There was no correlation between MPO and age, hypertension, diabetes, leukocyte count, 
troponin I, CK-MB, TIMI risk score C4 and Gensini score in the multivariate analysis. These 
findings indicate that MPO expression may not be associated with anatomical severity of 
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coronary lesions in ACS. However, in a previous study (Düzgünçinar et al., 2008), 48 stable 
CAD patients with angiographically documented coronary lesions were enrolled and the 
authors demonstrated a weak, but statistically significant association between MPO levels 
and Gensini score (r=0.228; p=0.04). Of note, they found a stronger association between 
MPO levels and calcium scores by multislice computed tomography in 30 patients (p=0.02). 
In another study, MPO levels were considered independent predictors of multivessel 
disease in 389 unselected stable and unstable patients referred for CAG (Cavusoglu et al., 
2006). On the other hand, Kubala et al. (Kubala et al., 2008) evaluated 557 clinically stable 
patients submitted to CAG and did not find a significant difference in MPO levels between 
patients with documented CAD (at least 1 vessel with 50% stenosis) and patients without 
CAD. Finally, in a recently published cross-sectional study, after evaluating 118 stable CAD 
patients, a lack of association between MPO promoter polymorphism and angiographic 
severity of coronary atherosclerosis was observed (Wainstein et al., 2010). Nevertheless, as a 
secondary objective, that study revealed a trend toward greater angiographic severity of 
CAD among patients with plasma MPO levels in the upper range (Wainstein et al., 2010). 
The lack of association might be attributed to the fact that angiography-based Gensini scores 
provide information on anatomical severity, hindering a functional and morphological 
analysis of the atherosclerotic plaque. A recently published study by Ferrante et al. (Ferrante 
et al., 2010) enrolled 25 consecutive ACS patients undergoing PCI and OCT assessment, 
evaluating the relationship between plaque morphology and serum levels of 
myeloperoxidase (MPO) and CRP. OCT classified the culprit lesion as ruptured in 18 (72%) 
or eroded in 7 patients (28%) and detected intraluminal thrombus in 89% of ruptured 
plaques and 100% of eroded plaques. Baseline systemic levels of serum MPO were 
significantly higher in patients with an eroded plaque than in those with a ruptured plaque 
(median, 2500 ng/mL; 25th to 75th percentile, 1415 to 2920 versus median, 707 ng/mL; 25th 
to 75th percentile, 312 to 943; p=0.001), whereas CRP levels did not differ significantly 
(median, 11.3 mg/L; 25th to 75th percentile, 1.3 to 28.5 versus median, 3.9 mg/L; 25th to 
75th percentile, 1.3 to 17.8; p=0.76, respectively). In addition, the same study  showed that 
the density of MPO-positive cells within thrombi overlying plaques in postmortem coronary 
specimens retrieved from sudden coronary death victims was significantly higher in lesions 
with erosion (n=11) than ruptures (n=11) (median, 1584; 25th to 75th percentile, 1088 to 2135 
cells/mm2 versus median, 579; 25th to 75th percentile, 442 to 760 cells/mm2; p=0.0012). Of 
importance, this study supports the concept that elevations in specific inflammatory 
biomarkers reflect different morphologies of complications of coronary atherosclerosis and 
highlights the heterogeneity of coronary mechanisms of ACS.  
Taken together, these data suggest a controversial role of MPO for CAD burden, while an 
involvement in disease activity seems to be clear. However, this issue should be investigated 
in larger studies and, again, IVUS and OCT may play a crucial role in the accurate 
assessment of plaque vulnerability. 
3.5 Matrix metalloproteinases 
In human atherosclerosis, unstable atherosclerotic plaque is an important event that 
triggers ACS. Plaque rupture frequently correlates with loss of the extracellular matrix at 
certain locations, often in the shoulder areas of the plaque. Focal destruction of the 
extracellular matrix renders the plaque less resistant to mechanical stresses imposed 
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cells/mm2 versus median, 579; 25th to 75th percentile, 442 to 760 cells/mm2; p=0.0012). Of 
importance, this study supports the concept that elevations in specific inflammatory 
biomarkers reflect different morphologies of complications of coronary atherosclerosis and 
highlights the heterogeneity of coronary mechanisms of ACS.  
Taken together, these data suggest a controversial role of MPO for CAD burden, while an 
involvement in disease activity seems to be clear. However, this issue should be investigated 
in larger studies and, again, IVUS and OCT may play a crucial role in the accurate 
assessment of plaque vulnerability. 
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triggers ACS. Plaque rupture frequently correlates with loss of the extracellular matrix at 
certain locations, often in the shoulder areas of the plaque. Focal destruction of the 
extracellular matrix renders the plaque less resistant to mechanical stresses imposed 
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during systole and therefore vulnerable to rupture. Recent findings have revealed 
enhanced expression of matrix metalloproteinases (MMPs) in the vulnerable region of 
plaques and this contributes to the weakening of plaque caps by degrading the 
extracellular matrix. 
MMPs are a family of zinc-containing endoproteinases that share structural domains but 
differ in substrate specificity, cellular sources, and inducibility. The list of MMPs has grown 
rapidly in the past several years, and by now >20 mammalian members have been cloned 
and identified. The members of the MMP family can degrade all of the components of the 
blood vessel wall and therefore play a major role in both physiologic and pathologic events 
that involve the degradation of extracellular matrix components. 
In recent studies using knockout mice, electrical injury of femoral arteries in mice which 
stimulates intimal thickening, caused enhanced expression of MMP-2 and MMP-9 (Lijnen et 
al., 1998). In TIMP-1-deficient mice intimal thickening was significantly higher compared 
with that in wild-type controls (Lijnen et al., 1999) Together, these observations support a 
role for MMP involvement in intimal thickening, particularly in migration of vascular 
smooth muscle cells. Previous studies demonstrated that lipid-laden macrophages from 
human atherosclerotic plaque elaborate MMP-1 and MMP-3 (Galis et al., 1995) and culture 
of macrophages with fibrous caps of human atherosclerotic plaque induces MMP-
dependent collagen breakdown (Shah et al., 1995). Other researchers have also detected the 
expression of several other MMPs including MMP-1, MMP-2, MMP-7, MMP-9, and MMP-12 
in the shoulder areas of plaque (Shu et al., 1998). Brown et al. (Brown et al., 1995) reported 
that MMP-9 was commonly expressed in coronary atherectomy specimens from patients 
with recent plaque rupture. Kai et al. (Kai et al., 1998) reported that circulating MMP-2 and 
MMP-9 levels on admission were elevated in patients with AMI and UA. Inokubo et al. 
(Inokubo et al., 2001) also reported that plasma levels of MMP-9 were significantly increased 
in the coronary circulation in patients with AMI and UA compared with those in control 
subjects, suggesting a process of active plaque rupture in ACS. Hirohata et al. (Hirohata et 
al., 1997) also observed increased plasma MMP-1 and MMP-2 levels, respectively, in 
patients with AMI. Thus, increased MMP expression may modulate vascular and 
ventricular remodeling in ACS. 
Wang et al. (Wang et al., 2008) evaluated the vulnerability of coronary artery plaque with 
CAG, IVUS and the levels of plasma inflammatory markers in 58 consecutive patients with 
lesion of a single blood vessel demonstrated by CAG. Patients were randomly divided into 3 
groups based on the angiographic morphology of the lesions: type I lesion group (n=16), 
type II lesion group (n=25), type III lesion group (n=17). A control group of stable angina 
(n=17) was established. A subgroup of 28 patients (including 18 ACS patients and 10 stable 
angina control patients) who underwent IVUS study were analyzed. Then the plasma levels 
of MMP, including MMP-2 and MMP-9, CD40L and PAPP-A were measured with ELISA, 
along with CRP levels. The plasma levels of MMP-2, MMP-9 and PAPP-A in type II lesion 
group were significantly higher than the other groups (p< 0.05, 0.05, 0.001, respectively). In 
type II lesion group, linear correlation analysis manifested significantly positive correlation 
between levels of CRP and MMP-2 (r=0.508); MMP-2 and MMP-9, CD40L, PAPP-A (r=0.647, 
0.704, 0.751, respectively); MMP-9 and CD40L, PAPP-A (r=0.491, 0.639, respectively); CD40L 
and PAPP-A (r=0.896). IVUS subgroup analysis showed that the area of plaques and 
plaques burden in culprit lesion, the incidence of high-risk plaques, remodeling index and 
positive remodeling percentage in ACS patients were significantly greater than those in the 
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control group (p=0.0001, 0.037, 0.028, 0.015, 0.040, respectively). Compared with the control 
group, the plasma levels of CRP, MMP-2, MMP-9 and PAPP-A were markedly elevated 
(p=0.033, 0.0001, 0.0001, 0.027, respectively). 
Park et al. (Park et al., 2010) recently enrolled 188 patients who underwent 3-vessel VH-
IVUS with peripheral blood sampling, including plasma levels of MMP-2,-9, tissue inhibitor 
of metalloproteinase-1, adiponectin, macrophage migration inhibitory factor, along with 
CRP levels measurements. Among the biomarkers, only the MMP-9 level was significantly 
higher in patients with ruptured plaque (p=0.002). In the subgroup without ruptured 
plaque, significant differences in the levels of several biomarkers were not observed 
between patients with and without VH-TCFA. In both culprit/target and nonculprit/non-
target vessels, the MMP-9 level showed a weak correlation with the total number of 
ruptured plaques (r=0.231, p=0.002). Among the biomarkers tested in this study, the MMP-9 
level was significantly higher in patients with ruptured plaque. However, measurement of 
several biomarkers, including MMP-9, was incapable of predicting the presence of VH-
TCFA. This 3-vessel VH-IVUS study of 188 patients showed that the plasma level of MMP-9 
might increase in patients with multiple ruptured plaques, as well as in patients with 
ruptured plaque in the culprit/target lesions. Both acute coronary syndrome and the MMP-
9 level were independent predictors of ruptured plaque in the culprit/target lesions. 
However, the presence of VH-TCFA in the culprit/target lesions or multiple VH-TCFAs 
detected by 3-vessel VH-IVUS study were not be predictive with the use of several 
biomarker assays, including MMP-9, in this study. The clinical presentation of ACS, not the 
level of the biomarkers, was the only independent predictor of VH-TCFA in the 
culprit/target lesions. MMPs belong to a family of multidomain zinc-dependent 
endopeptidases that promote degradation of all protein and  proteoglycan–core-protein 
components of the extracellular matrix (Galis et al., 2002). Among the family of MMPs, 
MMP-2 and MMP-9 are found in the macrophages and smooth muscle cells covering the 
shoulder region of atherosclerotic plaque (Galis et al., 1994). MMP-9 and MMP-2 are highly 
expressed in the vulnerable regions of atherosclerotic plaque and it has been suggested that 
they are causally involved in plaque rupture (Lijnen et al., 2003). Other studies have shown 
that the level of MMP-2 activity is higher in stable lesions of carotid artery plaque (Sluijter et 
al., 2006) and that the level of MMP-9 is increased in more unstable plaque (Sluijter et al., 
2006, Lotus et al., 2000). Blakenberg and collegues reported that a higher level of plasma 
MMP-9 was a predictor of cardiovascular mortality: the patients in the highest quartile of 
MMP-9 level (>72 ng/ml) had the highest probability of cardiovascular death (Blankenberg 
et al., 2003). Taken together, these data suggest that MMP-9 has a more significant role in 
plaque vulnerability than MMP-2, but more clinical studies are required to evaluate the 
exact role of MMP-2 in plaque vulnerability. Thus, CAG and IVUS combined with the study 
on plasma levels of inflammation mediators were helpful in judging the vulnerability of 
coronary artery plaques.  
Matrix metalloproteinases play a crucial role in initiating ACS by degrading extracellular 
matrix components, which leads to vulnerability of the plaque as well as formation of 
atherosclerotic lesions. Although the use of MMP inhibitors may have unforeseen adverse 
effects if used in the wrong setting, development of therapeutic drugs specifically targeted 
against MMPs may be useful in the prevention of atherosclerotic lesion development and 
cardiac events. 
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Inflammation, neovascularisation, imbalance between coagulation and anticoagulation 
system are interesting aspects (Ross  et al.,1993; Katagiri et al., 2007; Glass  et al., 2001), but 
another one is that of lipid system and coronary plaque.  
4.1 Lipid profile 
One of the major predisposing factors to atherosclerosis is an abnormal lipoprotein 
metabolism and it may be present in over 70% of patients with premature CAD (Genest et 
al., 2005).  
The association between CAD and levels of total cholesterol, LDL and low HDL has been 
proven and widely accepted in diagnostic practice. As a consequence the National 
Cholesterol Education Program III (NCEP III) recommended the analysis of Tc in 
combination with LDL and HDL-c as a basis for the screening and treatment of patients with 
CAD. High concentration of LDL cholesterol and lipoprotein (a) or low levels of HDL 
cholesterol are able to promote atheroma formation and are recognised as particularly 
important risk factors for atherosclerosis and CAD (Rosenson, 1996; . Grundy et al., 1989; 
LaRosa et al., 1990; v et al., 1994). Of note, randomised trials showed that LDL reduction 
decreases mortality and coronary events both in a primary and in a secondary prevention 
(Shepherd et al., 1995, Sacks et al., 1996). It was found that the reduction in non-fatal MI and 
CAD death was strongly correlated with the small incremented serum HDL-cholesterol 
level (Robins et al., 2001). An independent association of triglycerides (TG) with 
atherosclerosis and/or CAD remains uncertain. Some studies suggest that TG level does not 
influence the CAD risk whereas others provide some proofs that it does (Avins & Neuhaus, 
2000). Ten years ago it was suggested that there is an inverse association between HDL level 
and the number of diseased coronary vessels (Romm et al., 1991). However, some other 
studies manifested that there is no association of CAD severity with lipid concentration 
(Lekakis et al., 2000; Cerne et al., 2000). This conflicting data persuaded Tarchalski et al.  
(Tarchalski et al., 2003) to perform a prospective study for evaluation of the relationship 
between serum lipid levels and the extent of atherosclerosis within coronary arteries in 
patients with suspected CAD and no previous MI, and who were not treated with lipids 
lowering therapy before entering the study. The study was conducted in 141 patients (53.6 ± 
7.8 years old; 32 female) who underwent a routine CAG for CAD diagnosis. A modified 
angiographic Gensini Score was used to reflect the extent of coronary atherosclerosis. 
Fasting serum lipid concentrations were determined using cholesterol esterase/peroxidase 
(CHOD/PAP) enzymatic method for total cholesterol and its fractions and lipase glycerol 
kinase (GPO/PAP) enzymatic method TG evaluation. Gensini score was positively 
correlated with total cholesterol (r=0.404; p<0.001), LDL cholesterol (r=0.484; p<0.001) and 
TG (r=0.235; p=0.005). There was a negative correlation between Gensini Score and HDL 
cholesterol (r=–0.396; p<0.001). This study clearly showed that in angina pectoris patients 
with no previous MI, the extent of coronary atherosclerosis is positively correlated with pro-
atherogenic lipids, i.e. total cholesterol, LDL cholesterol and TG and negatively correlated 
with antiatherogenic HDL cholesterol. Cabin and Roberts (Cabin & Roberts, 1982) 
previously assessed the amount of cross-sectional area narrowing by atherosclerotic plaques 
histologically in each 5 mm segment of the entire lengths of the right, left main, left anterior 
descending, and left circumflex coronary arteries in 40 patients with fatal CAD and known 
fasting serum total cholesterol and TG levels. The number of 5 mm segments of coronary 
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artery narrowed severely (76 to 100% in cross-sectional area) by atherosclerotic plaques in 
each group was as follows: 172 of 505 (34%) 5 mm segments from group I; 242 of 353 (69%) 
segments from group II; 120 of 295 (41%) from group III and 425 of 884 (48%) segments from 
group IV. The mean percentage of 5 mm segments narrowed severely was significantly 
greater in group II than in group I (p<0.005) or group III (p<0.01). Additionally, the mean 
number of four coronary arteries per subject severely narrowed and the number of subjects 
with severe narrowing of the left main coronary artery were significantly greater in groups 
II and III than in group I. The percentages of 5 mm segments narrowed severely correlated 
significantly with the serum triglyceride level (p<0.03). Although it correlated with the 
number of severely narrowed coronary arteries per subject, the serum total cholesterol level, 
however, did not correlate with the percentage of 5 mm segments of coronary artery with 
severe narrowing. In 1994, Ladeia et al. (Ladeia et al., 1994) correlated lipid profile with 
CAD. One hundred patients with symptoms of CAD were studied by CAG. Coronary artery 
stenotic and normal proximal lumen were measured with a pachymeter, and the percent 
degree of obstruction calculated. CAD was documented in 74 patients, (56-75.6% men), with 
> or = 50% stenosis in 67 (90.5%), 54 (79.1%) men. The lesions were univessel in 24 (33.4%), 
bivessel in 29 (39.7%), and trivessel in 20 (27.4%). Seventy patients had total cholesterol > or 
=200 mg/dl, 29 (41.4%) > or =240 mg/dl); 69 (71.9%) LDL > or =130 mg/dl, 37 (38.5%) > or 
=160 mg/dl; 35 (36.5%) HDL <35 mg/dl and 10 TG > or =200 mg/dl. CAD patients had 
lower HDL values (38.8 +/- 10 mg/dl vs 48.2 +/- 13.6 mg/dl, p=0.01) and higher Castelli 
risk indexes (total cholesterol/HDL =5.9 +/- 1.7 vs 5.1 +/- 1.4 and LDL/HDL =4.1 +/- 1.5 vs 
3.4 +/- 1.2, p=0.04). Patients with > or =50% stenosis and multivessel disease showed higher 
Castelli risk indexes (p=0.01 and p=0.04 for total cholesterol/HDL, and p=0.01 and p=0.02 
for LDL/HDL, respectively). Twenty one (70%) of the 30 patients with total cholesterol<200 
mg/dl had CAD (28% of the patients with CAD), in whom there was a high frequency of 
patients with a low HDL level (11/21, 52.4% vs 3/9, 33%, p=0.06). Thus, lower HDL and 
higher Castelli risk indexes values were associated with more severe and intensive CAD. 
Additionally, total cholesterol <200 mg/dl is compatible with CAD, especially if there is a 
low HDL level. These findings further strengthen the need of HDL measurement for CAD 
risk assessment. 
Several mechanisms may explain these associations. The observed positive association of the 
extent of coronary atherosclerosis with total cholesterol seems to be caused by cholesterol 
present in LDL particles. Circulating LDL can enter cells via apo B/E receptors or through 
an unregulated scavenger receptor (Brown & Goldstein, 1986). The latest mechanism, 
present in smooth muscle cells and macrophages, can result in excess accumulation of 
intracellular cholesterol and the formation of foam cells. The unregulated scavenger 
receptors are able to uptake both native and modified LDL particles. The most common 
form of LDL modification is its oxidation, which can occur in any of the cells within the 
artery, including the endothelial cells, T lymphocytes, smooth muscle cells and 
macrophages (Hiltunen et al., 1998; Kloiche et al., 2000). Foam cells can rupture leading to 
the release of oxidized LDL, proteolytic enzymes and toxic oxygen derivatives that can 
altogether damage the vessel wall (Hiltunen et al., 1998; Kloiche et al., 2000, Dimmeler et al., 
1997). Oxidized (Oxy) LDL particles can promote atherosclerotic changes by several 
mechanisms, such as acting as a monocyte chemoattractant, inducing endothelial cells 
dysfunction and apoptosis, and reducing nitric oxide release and endothelium-dependent 
vasodilatation (Li & Mehta, 2000; Mathew et al., 1997; Anderson et al., 1996). Oxy LDL may 
increase platelet aggregation and thromboxane release what causes vasoconstriction and 
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altogether damage the vessel wall (Hiltunen et al., 1998; Kloiche et al., 2000, Dimmeler et al., 
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thrombus formation (Chen et al., 1996). Cytokines released from activated platelets and 
injured endothelial cells can stimulate smooth muscle proliferation and the formation of 
atherosclerotic plaque (Ross, 1993). Thus, the increased LDL cholesterol is related to the 
development of atherosclerotic changes within arteries. The inverse association of Gensini 
score with HDL cholesterol observed in the study performed by Tarchalski et al. (Tarchalski 
et al., 2003) can be explained by antiatherogenic properties of HDL particles. HDL is 
engaged in reverse cholesterol transport from cells and atherosclerotic plaques into the liver 
or to other tissues (Tall, 1990). The uptake of cellular cholesterol by HDL is controlled by 
apolipoprotein A-I and cholesterol efflux regulatory protein. Apolipoprotein A-I serves as a 
signal transduction protein to mobilize cholesterol esters from intracellular pools and also 
activates lecithin-cholesterol acyltransferase dependent cholesterol esterification. 
Cholesterol efflux regulatory protein promotes the transfer of intracellular cholesterol to the 
cell membrane and surface (Marcil et al., 1999). Further, cholesterol is removed from HDL 
particles by direct liver uptake or it is transferred to apolipoprotein B-containing 
lipoproteins, i.e. very low density lipoprotein, intermediate density lipoproteins and LDL 
(Tall, 1990; Marcil et al, 1989). In addition to reverse cholesterol transport, HDL has a variety 
of vascular actions that can counteract atherogenesis. HDL contains paraoxonase, an 
enzyme that protects lipoproteins from oxidative modification and it is able to destroy 
oxidized lipids present in oxy-LDL and to hydrolyze lipid peroxides in human 
atherosclerotic lesions. It was observed that lower serum paraoxonase is linked to more 
severe CAD (Aviram et al., 2000;  James et al., 2000; Shih et al., 1998). HDL is thought to 
maintain endothelial function and a low blood viscosity through a permissive action on red 
cell deformability (Kuhn et al., 1991; Epand et al., 1994). It is speculated that HDL may 
downregulate thrombin generation and in this way limit its influence on atherosclerosis 
(Griffin et al., 1999). As regards TG serum levels and CAD burden, according to literature it 
remains uncertain if there is an independent association of TG with coronary 
atherosclerosis. Lipoproteins rich in TG, i.e. very-low density lipoprotein and intermediate 
density lipoprotein (lipoprotein remnants) have been identified in human atherosclerotic 
plaques (Rosenson, 2001). Moreover, hypertriglyceridemia is associated with other 
abnormalities predisposing to the development of atherosclerosis.  
Taken together, these data suggest the role of lipid prophile both in coronary initiation, 
progression and instability. 
4.2 Adiponectin 
Obesity is one of the most common causes of cardiovascular morbidity and mortality 
(Matsuzawa et al., 1995). Abdominal visceral fat accumulation is accompanied by impaired 
glucose tolerance, dyslipidemia, and hypertension, and finally leads to atherosclerotic 
vascular disease. As important molecules linking these diseases and the inflammatory 
response, previous studies have shown the dynamic function of adipose tissue as an 
endocrine organ, releasing various cytokines, adipokines and inflammatory markers, which 
are involved in the development of atherosclerosis (Fortuno et al., 2003).  Notably, adipose 
tissue secretes a variety of bioactive molecules that directly contribute to the development of 
cardiovascular disease (Matsuzawa et al., 1999). Adiponectin is an adipose-specific plasma 
protein, with antiatherogenic and anti-inflammatory properties (Ouchi et al., 1999; 2001). 
and low plasma adiponectin was observed in patients with CAD (Ouchi et al. 2001).  
Additionally, several reports showed an inverse relation between serum CRP and 
adiponectin (Engeli et al., 2003; Yudkin et al., 1999). Otake et al. (Otake et al., 2008) 
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investigated the relation between plasma adiponectin and CRP and coronary plaque 
components in 93 patients with ACS, using VH-IVUS to examine relations among plasma 
CRP, adiponectin, and ratios of each coronary plaque component. They interestingly found 
that plasma adiponectin was significantly lower and plasma CRP was significantly higher in 
patients with than without ACS. There was an inverse relation between serum CRP and 
adiponectin with regard to necrotic core ratio in both culprit and nonculprit lesions in 
patients with ACS. The authors concluded that increased plasma CRP and 
hypoadiponectinemia might be related to the progression of ACS. Additionally, Sawada et 
al. (Sawada et al., 2010) enrolled 50 patients with stable CAD, showing that patients with 
TCFA had significantly lower plasma adiponectin levels than patients without TCFA 
(p<0.0001). Furthermore, the plasma adiponectin levels in patients with multi-vessel TCFA 
were significantly lower than those in patients with single-vessel TCFA (p=0.049). 
Multivariate logistic regression analysis revealed that plasma adiponectin was the strongest 
predictive factor of the presence of TCFA (p=0.0007). Of importance, these data suggest that 
in patients with stable CAD, adiponectin may be a useful biomarker to stratify “vulnerable 
patients” into risk categories. These findings suggest that adiponectin affected plaque 
components, and low plasma adiponectin, a well-known independent risk factor for CAD, 
might enhance the vulnerability of atherosclerotic plaques and vessels, which could lead to 
ACS. 
5. Coagulative/fibrinolysis state  
Coronary thrombosis occurs in most patients with AMI (De Wood et al., 1980) and there is 
also epidemiological evidence indicating the pathogenetic importance of haemostatic 
function in CAD (Meade et al., 1986). The precise role of haemostatic factors in the presence 
of coronary atherosclerosis, however, has not been fully elicited yet. 
5.1 Platelets 
Platelets are actively involved in the inflammatory cascade leading to vascular 
atherosclerosis (Libby & Simon, 2001;; Davi & Patrono, 2007). Platelets are enucleate cells of 
1-2 m length with average life span of 7–8 days, generated by bone-marrow derived 
megakaryocytes after cytoplasmic fragmentation, and play a pivotal role in the process of 
atherosclerosis. Large interest has been directed towards an improved understanding of 
platelet physiology, the assessment of platelet function and the development of improved 
antiplatelet treatment with faster and stronger activity. Patients with stable CAD have 
increased platelet reactivity and circulating monocyte-platelet aggregates (Furman et al., 
1998), which also have been demonstrated early markers of AMI (Furmam et al, 2001). In 
addition, platelet reactivity is progressively increased as a function of the number of 
vascular districts involved by atherosclerosis (cerebral, cardiac, peripheral) (Keating et al., 
2004). Although the platelet count does not appear to predict cardiovascular outcomes 
(Pizzulli et al., 1998) and a larger platelet size may correlate with CAD (Pizzulli et al., 1998) 
and MI. It has been observed a large variability in baseline platelet reactivity and effects of 
antiplatelet therapies, that may potentially due to the variability in platelet size. In fact, 
larger platelets have a greater mass and are both metabolically and enzymatically more 
active than smaller platelets. Indeed, they have a greater prothrombotic potential, with 
higher levels of intracellular thromboxane A2, and TG levels, as well as increased levels of 
procoagulant surface proteins (e.g. P selectin, GpIIb/IIIa). Hemostatically reactive platelets, 
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thrombus formation (Chen et al., 1996). Cytokines released from activated platelets and 
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enzyme that protects lipoproteins from oxidative modification and it is able to destroy 
oxidized lipids present in oxy-LDL and to hydrolyze lipid peroxides in human 
atherosclerotic lesions. It was observed that lower serum paraoxonase is linked to more 
severe CAD (Aviram et al., 2000;  James et al., 2000; Shih et al., 1998). HDL is thought to 
maintain endothelial function and a low blood viscosity through a permissive action on red 
cell deformability (Kuhn et al., 1991; Epand et al., 1994). It is speculated that HDL may 
downregulate thrombin generation and in this way limit its influence on atherosclerosis 
(Griffin et al., 1999). As regards TG serum levels and CAD burden, according to literature it 
remains uncertain if there is an independent association of TG with coronary 
atherosclerosis. Lipoproteins rich in TG, i.e. very-low density lipoprotein and intermediate 
density lipoprotein (lipoprotein remnants) have been identified in human atherosclerotic 
plaques (Rosenson, 2001). Moreover, hypertriglyceridemia is associated with other 
abnormalities predisposing to the development of atherosclerosis.  
Taken together, these data suggest the role of lipid prophile both in coronary initiation, 
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Obesity is one of the most common causes of cardiovascular morbidity and mortality 
(Matsuzawa et al., 1995). Abdominal visceral fat accumulation is accompanied by impaired 
glucose tolerance, dyslipidemia, and hypertension, and finally leads to atherosclerotic 
vascular disease. As important molecules linking these diseases and the inflammatory 
response, previous studies have shown the dynamic function of adipose tissue as an 
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are involved in the development of atherosclerosis (Fortuno et al., 2003).  Notably, adipose 
tissue secretes a variety of bioactive molecules that directly contribute to the development of 
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2004). Although the platelet count does not appear to predict cardiovascular outcomes 
(Pizzulli et al., 1998) and a larger platelet size may correlate with CAD (Pizzulli et al., 1998) 
and MI. It has been observed a large variability in baseline platelet reactivity and effects of 
antiplatelet therapies, that may potentially due to the variability in platelet size. In fact, 
larger platelets have a greater mass and are both metabolically and enzymatically more 
active than smaller platelets. Indeed, they have a greater prothrombotic potential, with 
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larger platelets, have more granules and adhesion receptors that have resulted in decreased 
bleeding time showing increased activation. Indeed, platelet aggregability has been directly 
related with systemic atherosclerotic disease (Keating et al., 2004). In addition, the most 
detrimental manifestation of coronary atherosclerotic disease (i.e., myocardial infarction)  is 
mediated by platelet activation (Fitzgerald  et al., 1986). On this basis, numerous therapeutic 
options, targeting platelet aggregability, have been proposed. 
5.1.1 Mean platelet volume 
Mean platelet volume (MPV) has been shown to be an indicator of platelet activation, that 
plays a pivotal role in the pathophysiology of atherosclerotic disease (Tsiara et al., 2003; 
Broadley et al., 2003). It has been reported that elevated values of MPV are associated with 
cardiovascular diseases (Pizzulli et al., 1998; Jagroop & Mikhailidis, 2003). Few and small 
reports have investigated so far the relationship between MPV and the extent of CAD, with 
contrasting results. Also an increase in MPV may be due to the usage of small platelets 
during acute ischemia (Pizzulli et al., 1998). On these grounds, MPV could be accepted as a 
parameter of platelet activity and has become a prognostic factor in CAD. Confirming the 
importance of MPV, several additional reports have demonstrated that MPV was associated 
with impaired myocardial perfusion and clinical outcome after primary angioplasty. De 
Luca et al. (De Luca et al., 2009) measured MPV in 1411 consecutive patients undergoing 
coronary angiography. Significant CAD was defined as stenosis >50% in at least 1 coronary 
vessel. They additionally measured carotid intima-media thickness in 359 patients. The 
relationship between MPV and platelet aggregation was valuated by PFA-100 in 50 
consecutive patients who were not taken any antiplatelet therapy, and in a cohort of patients 
who were on aspirin by PFA-100 (n=161) and Multiplate (n=94). Patients were divided into 
three groups according to tertiles of MPV. Patients with higher MPV were slightly older 
(p=0.038), with larger prevalence of diabetes (p<0.0001), hypertension (p=0.008), previous 
CAD (p=0.041), less often with stable angina (p=0.043) and family history of CAD (p=0.011), 
more often on statins (p=0.012), and diuretics (p=0.007). MPV was associated with baseline 
glycaemia (p<0.0001) and red blood cell count (p=0.056), but inversely related to platelet 
count (p<0.0001). MPV was not associated with the extent of coronary artery disease 
(p=0.71) and carotid intima-media thickness (p=0.9). No relationship was found between 
MPV and platelet aggregation. This study showed that MPV was not related to platelet 
aggregation, the extent of CAD and carotid intima-media thickness. Thus, according to this 
study (De Luca et al., 2009) this parameter cannot be considered as a marker of platelet 
reactivity or a risk factor for CAD. This is the largest study so far conducted to investigate 
the relationship between MPV and CAD.  
Several factors may contribute to explain these findings. The increase in MPV may be a 
process driven by increased production of bone-marrow derived larger circulating 
reticulated platelets within the blood stream (26). Indeed, the MPV has been shown to 
correlate with both megakaryocyte ploidy and with the percentage of circulating reticulated 
platelets (Smith et al., 2002). Furthermore, a positive correlation between thrombopoietin (a 
key thrombopoietic hormone) levels and MPV values has been demonstrated in CAD 
(Senaran et al., 2001).  Thus, larger MPV may not imply higher platelet reactivity, that has 
been shown to be related to the extent and complexity of CAD (Korovesis S, et al., 2000) but 
may be associated with even reduced aggregation since larger platelets may be precursor 
and not fully mature platelets. In fact, De Luca et al. (De Luca et al., 2009) did not observe 
any impact of MPV on platelet aggregation or aspirin resistance. Supporting these data, van 
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der Planken et al. (van der Planken et al., 2000) did not find any relationship between 
platelet prothrombinase activity, a final pathway platelet procoagulant activity of type 1 
diabetic platelets, and MPV. Furthermore, as shown by previous reports, MPV may be 
associated with other prognostic factors, such as smoking, diabetes, obesity, hypertension, 
that may primarily affect the extent of CAD and clinical outcome.  
5.2 Coagulative and fibrinolysis markers 
Previously clinical data support the proposition that activation of the coagulation and the 
platelet system is closely associated with myocardial ischaemia there is little information on 
the relation between the development of coronary atherosclerosis and the haemostatic 
system. 
Nichols et al. (Nichols et al., 1982) did not detect increased concentrations of platelet factor 4, 
B thromboglobulin, and fibrinopeptide A in a group of patients with abnormal coronary 
angiograms without previous MI. Furthermore, Schmitz-Huebner et al. (Schmitz-Huebner et 
al., 1988) analysed blood samples for haemostatic assessment from 225 patients with angina 
pectoris who were admitted to hospital for CAG. Thromboglobulin, platelet factor 3, platelet 
factor 4, factor VII:C, factor VIII:C, von Willebrand factor antigen, activated partial 
thromboplastin time, fibrinogen, antithrombin III, protein C:Ag, plasminogen, and 
antiplasmin were measured before angiography. Of note, patients who had had a MI in the 
two months before the investigation were excluded from the study. Multiple linear 
regression analysis showed that none of the haemostatic variables contributed 
independently to the prediction of an angiographic score that indicated the extent of 
coronary atherosclerosis. There were some significant correlations between haemostatic 
variables and conventional risk factors for CAD. However, the importance of the 
coagulation/fibrinolytic system is highlighted by several autopsic studies that show a high 
prevalence of old plaque disruptions without infarctions. A transient shift in the coagulation 
and anticoagulation balance is likely to result in an acute event. The prolonged presence of 
residual thrombus over a disrupted or eroded plaque will induce smooth muscle migration 
and produce new intima, leading to plaque expansion (Hoffmesister et al., 1995). Autopsic 
studies show that plaque growth is induced by episodic plaque disruption and thrombus 
formation (Holvoet et al., 1997).  Therefore, an active fibrinolytic system may be able to 
prevent luminal thrombosis in some cases of plaque disruption (Hoffmeister et al, 1999). t-
PA, as a crucial factor in fibrinolytic system, plays an important role in the balance between 
coagulative system and fibrinolytic system, which is mainly responsible for the dissolution 
of fibrin clots in the circulation, by converting inactive plasminogen to active plasmin. A 
rapid decline in release of active t-PA is associated with an increasing plaque burden and 
vulnerability. The reduction in acute fibrinolytic capacity reflects impairment of acute t-PA 
release that is likely to involve endothelial cell injury (Munkvad et al., 1990; Gyongyosi et 
al., 2004; Hoffmeister et al., 1998). In the study performed by Wang et al. (Wang et al., 2008), 
the authors aimed at assessing the association between vulnerability of plaque assessed with 
IVUS and plasma levels of fibrinolytic biomarkers in patients with ACS. Eighty-nine 
patients with ACS were enrolled in the study. Blood was collected to measure t-PA levels by 
liquid phase bead flow cytometry. Eighty-nine non-bifurcated lesions (identified by 
coronary angiography) were investigated using IVUS before catheterization. The areas of 
plaque and media were calculated and lesions were classified into two groups: VH-IVUS 
derived VH-TCFA and non-VH-TCFA plaque. Plasma t-PA level in patients with TCFA was 
significantly lower than that with non-TCFA (1489 ± 715) pg/ml vs (2163 ± 1004) pg/ml). 
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Decreased plasma levels of t-PA were associated with plaque vulnerability. Plasma levels of 
t-PA correlated negatively with plaque plus media and necrotic core in plaque in patients 
with acute coronary syndrome. Thus, t-PA may be considered an independent risk factor 
and a powerful predictor of vulnerable plaques. Decreased levels of t-PA may reflect 
instability of atherosclerotic plaques and might therefore serve as noninvasive determinants 
of those at high risk for consequent adverse events. Furthermore, in order to elucidate the 
causes of coronary instability in patients without systemic evidence of inflammation, Niccoli 
et al. (Niccoli et al., 2007) compared rate of episodic production of markers of thrombin 
generation [thrombin–antithrombin complexes (TAT)], of fibrinolysis [plasmin–antiplasmin 
complexes (PAP)], and angiographic severity and extent of coronary atherosclerosis in 
patients with severe UA and high or low systemic levels of CRP. They enrolled 40 
consecutive patients (age 59.7±8.7, 76% males) admitted to coronary care unit with severe 
UA (Braunwald class IIIB. The authors assayed TAT and PAP using commercially available 
ELISA assays and CRP with high sensitivity nephelometry. The evaluation of atherosclerotic 
disease severity and extent was performed according to Bogaty’s score. Patients were 
divided in two groups according to CRP levels: G1=CRP>3 mg/L and G2=CRP<3 mg/L. 
Number of diseased vessels and number of stenoses plus occlusion were similar between 
the two groups (1.8±0.9 in G1 vs 2.2±0.9 in G2, p=NS and 2.6±1.9 in G1 vs 2.7±1.3 in G2, 
p=NS, respectively), as well as extent score and index (8.4±4.5 in G1 vs 9.2±3.1 in G2, p=NS 
and 0.6±0.3 in G1 vs 0.6±0.27 in G2, p=NS, respectively). Episodic activation of thrombin 
generation, as assessed by TAT was more frequent in G1 than in G2 (85% vs 47%, p=0.03). 
Episodic activation of the fibrinolysis was more frequent in G1 than in G2 (80% vs 40%, 
p=0.01). This study demonstrated that patients with severe UA Who have on admission 
high serum levels of CRP are more prone to thrombin generation and fibrinolysis activation 
compared to patients with low admission CRP levels. Severity and extent of CAD was 
similar between patients with high or low CRP levels on admission. Furthermore, in this 
study performed by Niccoli et al. (Niccoli et al., 2007), in patients with systemic evidence of 
inflammation at baseline, episodes of thrombin and plasmin generation were observed more 
frequently than in patients without systemic evidence of inflammation. This is in keeping 
with results of studies (Levi et al., 2006) in the septic patients showing that severe systemic 
inflammation triggers blood coagulation. However, the authors (Niccoli et al., 2007) failed to 
find evidence of a hypercoagulable state or of a more severe coronary atherosclerosis in 
unstable patients without systemic evidence of inflammation. Future studies are warranted 
to investigate other mechanisms of destabilization in patients without systemic evidence of 
inflammation as for instance, mechanical rupture of a thin fibrous cap caused by greater 
mechanical stress. 
5.3 Tissue factor 
Atherosclerotic plaque rupture or fissuring is a key event in the pathogenesis of UA and MI 
(Fuster et al., 1992a,b). The exposure of blood to a procoagulant surface triggers thrombin 
generation, platelet aggregation, and fibrin deposition and leads to thrombus formation that 
can precipitate an acute coronary event. However, atherosclerotic plaques may rupture 
without triggering thrombosis. Necropsy data show that between 9% and 16% of people 
who die suddenly of non-cardiac causes have fissured plaques without thrombosis in their 
coronary arteries, but patients who die of cardiac causes have both thrombosed and non-
thrombosed ruptured plaques (Falk, 1985; Davies et al., 1989). The reasons why some 
ruptured plaques develop thrombosis and others do not are still not known. Tissue factor is 
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a small transmembrane cell surface receptor that mediates cellular initiation of the 
coagulation serine protease cascades (Edgington et al., 1991). In vitro studies have shown 
that tissue factor expression was observed on various cultured and stimulated cell types 
such as monocytes (Jude et al., 1994; Leatham et al., 1995; Barstad et al., 1995). smooth 
muscle cells (Taubman et al., 1993; Maynard et al., 1977), endothelial cells and fibroblasts 
(Green et al., 1971). Tissue factor in the media or the adventitial layer of human normal 
arteries is localized to aid the body in the prevention of blood loss as an initiator of blood 
coagulation (Weiss et al., 1989; Drake et al., 1989; Fleck et al., 1990; Wilcox et al., 1989) Tissue 
factor has recently been shown to be expressed in human coronary atherosclerotic plaque 
from directional atherectomy specimens from patients with stable and unstable coronary 
syndromes (Annex et al., 1995). Therefore, when tissue factor expressed in the coronary 
atherosclerotic plaques is exposed to the blood by the plaque disruption, it may lead to the 
thrombus formation and the occlusion of the related coronary artery. The plaque rupture is 
closely associated with the soft extracellular lipids (Berliner et al., 1995), macrophages (van 
der Wal et al., 1994) matrix-degrading proteases (Libby, 1995) such as interstitial collagenase 
(MMP-1), which degrades two major plaque structural proteins, type I and III collagen, and 
activated mast cells in the shoulder region of the atherosclerotic plaques. Of note, Van der 
Wal et al. (van der Wal et al., 1994) have reported that the macrophages were the 
predominant cells at the immediate site of either rupture or superficial erosion of the fibrous 
cap that contained few smooth muscle cells. However, it is not clear whether the 
macrophages express tissue factor in vulnerable human coronary atherosclerotic plaques in 
patients with unstable angina.  
Kaikita et al. (Kaikita et al., 1997) determined whether macrophages express tissue factor in 
human coronary atherosclerotic plaques. They examined directional coronary atherectomy 
specimens from 24 patients with UA and 23 with stable exertional angina. In these 
specimens, macrophages were detected in 22 (92%) of 24 patients with unstable angina 
versus 12 (52%) of 23 with stable exertional angina (p=0.003). The percentage of macrophage 
infiltration area was significantly larger in patients with unstable angina than in those with 
stable exertional angina (17±3% versus 6±2%, p=0.008). The immunohistochemical double 
staining revealed the expression of tissue factor on macrophages in 18 (75%) of 24 patients 
with unstable angina versus 3 (13%) of 23 with stable exertional angina (p<0.0001). 
Thrombus was identified in 20 (83%) of 24 patients with unstable angina versus 12 (52%) of 
23 with stable exertional angina (p=0.02). Fibrin deposition was mainly observed around 
macrophages expressing tissue factor in the patients with unstable angina. Thus, in this 
study, the authors demonstrated that tissue factor expression on macrophages was more 
frequent in coronary atherosclerotic plaques in patients with UA. Tissue factor expressed on 
macrophages may play an important role in the thrombogenicity in coronary atherosclerotic 
plaques of these patients.  
6. Conclusions and future perspectives  
Cardiovascular disease remains one of the leading causes of morbidity and mortality in the 
developed countries, thus the development of novel therapeutic strategies to reduce 
cardiovascular burden and  risk further than is currently possible is mandatory. Early 
detection of CAD is of paramount importance for initiating aggressive control of risk factors 
(smoking cessation, lipid lowering therapy, weight reduction therapy, aggressive therapy 
for hypertension) and establishing of pharmacologic therapy in order to reduce occurrence 
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of life threatening acute cardiovascular events (anti platelet agents, statins). The use of 
vascular imaging, combined with soluble molecular markers of disease burden, progression 
and activity, can provide crucial information that may help developing new pharmaceutical 
approaches. It is evident from the discussions now ongoing between  industry, government 
regulators, and academia that there is a shared recognition of the need for the application of 
new tools in drug development. This general philosophy, applied to atherosclerosis 
treatment, is critical to addressing the epidemic of CAD. In this regard, the association 
between plaque burden, morphology and activity, as assessed by imaging modalities, and 
levels of circulating biomarkers, assessing lipid metabolism, inflammation, platelets and 
white blood cells activation, and endothelial activation, is an intriguing field. New imaging 
modalities in combination with the development of new biomarkers (bioimaging) may 
significantly improve our understanding and management of patients at risk of coronary 
artery disease and its harmful complications, proving valuable insights into atherosclerotic 
disease progression and the relation to disease activity. In the last decades, an ongoing and 
intense research by different groups and investigators trying to delineate the role of 
different biologically active substances in the pathogenesis of progression of atherosclerotic 
CAD has provided data of paramount importance. Indeed, cardiovascular biomarker 
research efforts have resulted in the identification of new risk factors and novel drug targets, 
as well as the establishment of treatment guidelines, thus recognizing the importance of 
biomarkers in advancing therapies. However, given the complex pathophysiology of 
cardiovascular disease, no single biomarker will likely prove able to provide a universal 
surrogate whereby change observed independently predicts benefit, increased risk, or no 
effect across all drugs and mechanistic targets but the integration of different biomarkers 
looking at different phases of the coronary atherosclerotic disease should be the way 
forward. 
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of life threatening acute cardiovascular events (anti platelet agents, statins). The use of 
vascular imaging, combined with soluble molecular markers of disease burden, progression 
and activity, can provide crucial information that may help developing new pharmaceutical 
approaches. It is evident from the discussions now ongoing between  industry, government 
regulators, and academia that there is a shared recognition of the need for the application of 
new tools in drug development. This general philosophy, applied to atherosclerosis 
treatment, is critical to addressing the epidemic of CAD. In this regard, the association 
between plaque burden, morphology and activity, as assessed by imaging modalities, and 
levels of circulating biomarkers, assessing lipid metabolism, inflammation, platelets and 
white blood cells activation, and endothelial activation, is an intriguing field. New imaging 
modalities in combination with the development of new biomarkers (bioimaging) may 
significantly improve our understanding and management of patients at risk of coronary 
artery disease and its harmful complications, proving valuable insights into atherosclerotic 
disease progression and the relation to disease activity. In the last decades, an ongoing and 
intense research by different groups and investigators trying to delineate the role of 
different biologically active substances in the pathogenesis of progression of atherosclerotic 
CAD has provided data of paramount importance. Indeed, cardiovascular biomarker 
research efforts have resulted in the identification of new risk factors and novel drug targets, 
as well as the establishment of treatment guidelines, thus recognizing the importance of 
biomarkers in advancing therapies. However, given the complex pathophysiology of 
cardiovascular disease, no single biomarker will likely prove able to provide a universal 
surrogate whereby change observed independently predicts benefit, increased risk, or no 
effect across all drugs and mechanistic targets but the integration of different biomarkers 
looking at different phases of the coronary atherosclerotic disease should be the way 
forward. 
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In the intervening 10 years tremendous advances in the field of cardiac computed 
tomography have occurred. We now can legitimately claim that computed tomography 
angiography (CTA) of the coronary arteries is available. In the evaluation of patients 
with suspected coronary artery disease (CAD), many guidelines today consider CTA 
an alternative to stress testing. The use of CTA in primary prevention patients is 
more controversial in considering diagnostic test interpretation in populations with 
a low prevalence to disease. However the nuclear technique most frequently used by 
cardiologists is myocardial perfusion imaging (MPI). The combination of a nuclear 
camera with CTA allows for the attainment of coronary anatomic, cardiac function 
and MPI from one piece of equipment. PET/SPECT cameras can now assess perfusion, 
function, and metabolism. Assessing cardiac viability is now fairly routine with these 
enhancements to cardiac imaging. This issue is full of important information that 
every cardiologist needs to now.









pproach for Evaluation of C
oronary A
rtery D
isease
ISBN 978-953-51-648 2
